AU2014280939B2 - Uracil or thymine derivative for treating hepatitis C - Google Patents

Abstract

URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C Present application relates to the compounds of formula I useful to treat hepatitis C (HCV) infections. In the structure of the disclosed compounds is the uracil or thymine derivative linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2,4-dioxo-3,4 dihydropyrimidin-1(2H)-yl)-2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E)-N (4(3-t-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxy-styryl phenyl)methanesulfonamide.

Description

2014280939 24 Dec 2014

URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C CROSS-REFERENCE TO RELATED PATENT APPLICATIONS [00011 This patent application claims priority to U.S. Provisional Patent Application No. 60/972,877 (filed September 17,2007) and U.S. Provisional Patent Application No. 61/096,791 (filed September 13, 2008). The entire text of those applications is incorporated by reference into this application.

FIELD OF THE INVENTION (0002] This invention is directed to: (a) compounds and salts thereof that, inter alia, are useful as hepatitis C virus (HCV) inhibitors; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (0 kits comprising such compounds, salts, and compositions.

BACKGROUND OF THE INVENTION |0003] Hepatitis C is a blood-borne, infectious, viral disease that is caused by a hepatotropic virus called HCV. At least six different HCV genotypes (with several subtypes within each genotype) are known to date. In North America, HCV genotype la predominates, followed by HCV genotypes lb, 2a, 2b, and 3a. In the United States, HCV genotypes 1, 2, and 3 are the most common, with about 80% of the hepatitis C patients having HCV genotype 1. In Europe, HCV genotype lb is predominant, followed by HCV genotypes 2a, 2b, 2c, and 3a. HCV genotypes 4 and 5 are found almost exclusively in Africa. As discussed below, the patient’s HCV genotype is clinically important in determining the patient’s potential response to therapy and the required duration of such therapy. (0004] An HCV infection can cause liver inflammation (hepatitis) that is often asymptomatic, but ensuing chronic hepatitis can result in cirrhosis of the liver (fibrotic scarring of the liver), liver cancer, and/or liver failure. The World Health Organization estimates that about 170 million persons worldwide are chronically infected with HCV, and from about three to about four million persons are newly infected globally each year. According to the Centers for Disease Control and Prevention, about four million people in the United States are infected with HCV. Co-infection with the human immunodeficiency virus (HIV) is common, and rates of HCV infection among HIV positive populations are higher. |0005| There is a small chance of clearing the virus spontaneously, but the majority of patients with chronic hepatitis C will not clear it without treatment. Indications for treatment typically include proven HCV infection and persistent abnormal liver function tests. There are two treatment regimens that are primarily used to treat hepatitis C: monotherapy (using an interferon agent - either a “conventional” or longer-acting pegylated interferon) and combination therapy (using an interferon agent and ribavirin). Interferon, which is injected into the bloodstream, works by bolstering the immune response to HCV; and l 2014280939 24 Dec 2014 ribavirin, which is taken orally, is believed to work by preventing HCV replication. Taken alone, ribavirin does not effectively suppress HCV levels, but an interferon/ribavirin combination is more effective than interferon alone. Typically, hepatitis C is treated with a combination of pegylated interferon alpha and ribavirin for a period of 24 or 48 weeks, depending on the HCV genotype.

[0006] The goal of treatment is sustained viral response -- meaning that HCV is not measurable in the blood after therapy is completed. Following treatment with a combination of pegylated interferon alpha and ribavirin, sustained cure rates (sustained viral response) of about 75% or better occur in people with HCV genotypes 2 and 3 in 24 weeks of treatment, about 50% in those with HCV genotype 1 with 48 weeks of treatment, and about 65% in those with HCV genotype 4 in 48 weeks of treatment.

[0007] Treatment may be physically demanding, particularly for those with prior history of drug or alcohol abuse, because both interferon and ribavirin have numerous side effects. Common interferon-associated side effects include flu-like symptoms, extreme fatigue, nausea, loss of appetite, thyroid problems, high blood sugar, hair loss, and skin reactions at the injection site. Possible serious interferon-associated side effects include psychoses (e.g., suicidal behavior), heart problems (e.g., heart attack, low blood pressure), other internal organ damage, blood problems (e.g., blood counts falling dangerously low), and new or worsening autoimmune disease (e.g., rheumatoid arthritis). Ribavirin-associated side effects include anemia, fatigue, irritability, skin rash, nasal stuffiness, sinusitis, and cough. Ribavirin can also cause birth defects, so pregnancy in female patients and female partners of male patients must be avoided during treatment and for six months afterward.

[0008] Some patients do not complete treatment because of the serious side effects discussed above; other patients (non-responders) continue to have measurable HCV levels despite treatment; and yet other patients (relapsers) “clear” the virus during therapy, but the virus returns sometime after completion of the treatment regimen. Thus, there continues to be a need for alternative compounds, compositions, and methods of treatment (used either in combination with or in lieu of an interferon agent and/or ribavirin) to alleviate the symptoms of hepatitis C, thereby providing partial or complete relief. This invention provides compounds (including salts thereof), compositions, and methods of treatment that generally address such a need. 2 3 2014280939 27 Sep 2016

SUMMARY OF THE INVENTION

[0008a] A first aspect of the invention provides N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin- l(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide or a solvate or hydrate thereof. 5 [0008b] A second aspect of the invention provides crystalline N-(6-(3-tert-butyl-5-(2,4- dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl) naphthalen-2- yl)methanesulfonamide.

[0008c] A third aspect of the invention provides crystalline solvate of N-(6-(3-tert-butyl- 5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl) naphthalen-2- 10 yl)methanesulfonamide.

[0008d] A fourth aspect of the invention provides crystalline hydrate of N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl) naphthalen-2-yl)methanesulfonamide.

[0008e] A fifth aspect of the invention provides a salt of N-(6-(3-tert-butyl-5-(2,4-dioxo-15 3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl) naphthalen-2-yl)methanesulfonamide or a solvate or hydrate thereof.

[0008f] A sixth aspect of the invention provides crystalline salt of N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl) naphthalen-2- yl)methanesulfonamide. 20 [0008g] A seventh aspect of the invention provides N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4- dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide, monosodium salt.

[0008h] An eighth aspect of the invention provides crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy- phenyl)naphthalen-2- 25 yl)methanesulfonamide monosodium salt.

[0008i] A ninth aspect of the invention provides the crystalline pattern B N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide monosodium salt of the eighth aspect of the invention, wherein the salt has an X-ray powder diffraction pattern comprising at least three peaks selected 30 from the group consisting of 5.4+0.2, 10.8+0.2, 14.4+0.2, 16.3+0.2, 17.0+0.2, 18.8+0.2, 19.2+0.2, 19.6+0.2, 21.6iD.2, 22.1+0.2, 23.7+0.2, 28.8+0.2, 29.1+0.2, and 31.8+0.2 degrees 2Θ.

(11787880,1):KZA 3a 2014280939 27 Sep 2016 [0008j] A tenth aspect of the invention provides a pharmaceutical composition comprising the compound, or forms thereof, of the first to ninth aspects of the invention; and one or more excipients.

[0008k] An eleventh aspect of the invention provides a product comprising the 5 compound, or forms thereof, of the first to ninth aspects of the invention, and one or more additional therapeutic agents selected from the group consisting of interferon agents, ribavirin, HCV inhibitors, and anti-HIV agents for simultaneous, sequential or both simultaneous and sequential use in inhibiting replication of a ribonucleic acid (RNA) virus. 10 [00081] A twelfth aspect of the invention provides a product comprising the compound, or forms thereof, of the first to ninth aspects of the invention, and one or more additional therapeutic agents selected from the group consisting of interferon agents, ribavirin, HCV inhibitors, and anti-HIV agents for simultaneous, sequential or both simultaneous and sequential use in treating hepatitis C in a mammal in need of such treatment. 15 [0008m] A thirteenth aspect of the invention provides a composition comprising a first therapeutic agent and one or more second therapeutic agent, wherein the first therapeutic agent comprises the compound, or forms thereof, of the first to ninth aspect of the invention, and the second therapeutic agent is selected from the group consisting of ribavirin, HCV inhibitor, HCV protease inhibitor, and HIV inhibitor. 20 [0008n] A fourteenth aspect of the invention provides use of the compound, or forms thereof, of the first to ninth aspects of the invention in the manufacture of a medicament for inhibiting HCV polymerase.

[0008o] A fifteenth aspect of the invention provides a method of inhibiting HCV polymerase, said method comprising administering a therapeutically effective amount of 25 the compound, or forms thereof, of the first to ninth aspects of the invention, to a subject in need thereof.

[0008p] A sixteenth aspect of the invention provides use of the compound, or forms thereof, of the first to ninth aspects of the invention in the manufacture of a medicament for inhibiting replication of HCV.

(11787880_1):KZA 2014280939 27 Sep 2016 10 3b [0008q] A seventeenth aspect of the invention provides a method of inhibiting replication of HCV, said method comprising administering a therapeutically effective amount of the compound, or forms thereof, of the first to ninth aspects of the invention, to a subject in need thereof.

[0008r] An eighteenth aspect of the invention provides use of the compound, or forms thereof, of the first to ninth aspects of the invention in the manufacture of a medicament for treating hepatitis C in a subject.

[0008s] A nineteenth aspect of the invention provides a method of treating hepatitis C, said method comprising administering a therapeutically effective amount of the compound, or forms thereof, of the first to ninth aspects of the invention, to a subject in need thereof.

[0009] Disclosed herein are compounds that correspond in structure to formula 1:

[0010] In formula 1: 15 —*— is selected from the group consisting of single carbon-carbon bond and double carbon-carbon bond; R1 is selected from the group consisting of hydrogen, methyl, and nitrogen-protecting group; 20 R2 is selected from the group consisting of hydrogen, halo, hydroxy, methyl, cyclopropyl, and cyclobutyl; R3 is selected from the group consisting of hydrogen, halo, oxo, and methyl; R4 is selected from the group consisting of halo, alkyl, alkenyl, alkynyl, nitro, cyano, azido, alkyloxy, alkenyloxy, alkynyloxy, amino, aminocarbonyl, aminosulfonyl, alkylsulfonyl, carbocyclyl, and heterocyclyl, wherein: (a) the amino, aminocarbonyl, and aminosulfonyl optionally are substituted with: (1) one or two substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, and alkylsulfonyl, or

(11787880_1):KZA 3c 2014280939 27 Sep 2016 (2) two substituents that, together with the amino nitrogen, form a singlering heterocyclyl, and (b) the alkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy, alkynyloxy, and alkylsulfonyl, optionally are substituted with one or more substituents 5 independently selected from the group consisting of halo, oxo, nitro, cyano, azido, hydroxy, amino, alkyloxy, trimethylsilyl, carbocyclyl, and heterocyclyl, wherein: the amino optionally is substituted with: (1) one or two substituents independently selected from the ίο group consisting of alkyl, alkenyl, alkynyl, alkylcarbonyl, alkylsulfonyl, alkyloxycarbonyl, carbocyclyl, heterocyclyl, carbocyclylalkyl, and heterocyclylalkyl, or (2) two substituents that, together with the amino nitrogen, form a single- 15

(11787880_1):KZA 2014280939 24 Dec 2014 ring heterocyclyl, and (c) the carbocyclyl and heterocyclyl optionally are substituted with up to three substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, halo, oxo, nitro, cyano, azido, hydroxy, amino, alkyloxy, trimethylsilyl, carbocyclyl, and heterocyclyl, wherein: the amino optionally is substituted with: (1) one or two substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkylcarbonyl, alkylsulfonyl, alkyloxycarbonyl, carbocyclyl, heterocyclyl, carbocyclylalkyl, and heterocyclylalkyl, or (2) two substituents that, together with the amino nitrogen, form a singlering heterocyclyl; R5 is selected from the group consisting of hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy, alkynyloxy, alkylsulfonyloxy, carbocyclylsulfonyloxy, haloalkylsulfonyloxy, and halo; L is selected from the group consisting of bond, C(RA)=C(RB), C=C, C(0)N(Rc), NtR^ClO), Ci-Q-alkylene, C(H)20, OC(H)2, cyclopropyl-1,2-ene, C(H)2N(RL), N(RM)C(H)2, C(0)CH2, and CH2C(0);

Ra, Rb, Rl, and RM are independently selected from the group consisting of hydrogen, Ci-C6-alkyl, CrC6-alkyloxy, C3-C8-cycloalkyl, and halo, wherein: the C|-C6-alkyl optionally is substituted with one or more substituents independently selected from the group consisting of carboxy, halo, hydroxy, nitro, oxo, amino, cyano, alkyloxycarbonyl, alkylcarbonyloxy, alkyloxy, carbocyclyl, and heterocyclyl;

Rc is selected from the group consisting of hydrogen and alkyl; RD is selected from the group consisting of hydrogen and alkyl; R6 is selected from the group consisting of C5-CVcarbocyclyl, 5-6-membered heterocyclyl, fused 2-ring heterocyclyl, and fused 2-ring carbocyclyl, wherein each such substituent optionally is substituted with one or more substituents independently selected from the group consisting of RE, RF, Rc, R11, R1, RJ, and RK; each RK is independently selected from the group consisting of halo, nitro, hydroxy, oxo, carboxy, cyano, amino, imino, azido, and aldehydo, wherein: the amino optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, and alkynyl; each Rf is independently selected from the group consisting of alkyl, alkenyl, and alkynyl, wherein: 4 2014280939 24 Dec 2014 each such substituent optionally is substituted with one or more substituents independently selected from the group consisting of carboxy, hydroxy, halo, amino, imino, nitro, azido, oxo, aminosulfonyl, alkylsulfonyl, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, alkyloxy, alkenyloxy, alkynyloxy, carbocyclyl, heterocyclyl, cyano, and aminocarbonyl, wherein: the amino, imino, aminosulfonyl, aminocarbonyl, carbocyclyl, and heterocyclyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, alkylsulfonylamino, hydroxy, and alkyloxy, wherein: amino portion of the alkylsulfonylamino optionally is substituted with a substituent selected from the group consisting of alkyl, alkenyl, and alkynyl; each R<: is independently selected from the group consisting of carbocyclyl and heterocyclyl, wherein: each such substituent optionally is substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, carboxy, hydroxy, halo, amino, nitro, azido, oxo, aminosulfonyl, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, alkyloxy, alkenyloxy, alkynyloxy, carbocyclyl, heterocyclyl, cyano, and aminocarbonyl, wherein: the amino, aminosulfonyl, and aminocarbonyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkylsulfonyl, alkenylsulfonyl, and alkynylsulfonyl; each R11 is independently selected from the group consisting of alkyloxy, alkenyloxy, alkynyloxy, alkylsulfonyloxy, alkenylsulfonyloxy, and alkynylsulfonyloxy, wherein: each such substituent optionally is substituted with one or more substituents independently selected from the group consisting of carboxy, hydroxy, halo, amino, nitro, azido, oxo, aminosulfonyl, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, alkyloxy, alkenyloxy, alkynyloxy, carbocyclyl, heterocyclyl, cyano, and aminocarbonyl, wherein: the amino, aminosulfonyl, and aminocarbonyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkylsulfonyl, alkenylsulfonyl, and alkynylsulfonyl; each R1 is independently selected from the group consisting of alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, aminocarbonyl, alkyloxycarbonyl, carbocyclylcarbonyl, and heterocyclylcarbonyl, 5 2014280939 24 Dec 2014 wherein: (a) the alkylearbonyl, alkenylcarbonyl, and alkynylcarbonyl optionally are substituted with one or more substituents independently selected from the group consisting of carboxy, hydroxy, halo, amino, nitro, azido, oxo, aminosulfonyl, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, alkyloxy, alkenyloxy, alkynyloxy, carbocyclyl, heterocyclyl, cyano, and aminocarbonyl, and (b) the aminocarbonyl optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkyloxyalkyl, carbocyclyl, heterocyclyl, alkylsulfonyl, and alkylsulfonylamino, wherein: the carbocyclyl and heterocyclyl optionally are substituted with one or two substituents independently selected from the group consisting of halo, alkyl, and oxo; each RJ is independently selected from the group consisting of carbocyclylsulfonylamino, heterocyclylsulfonylamino, alkylearbonyl amino, alkenylcarbonylamino, alkynylcarbonylamino, alkyloxycarbonylamino, alkenyloxycarbonylamino, alkynyloxycarbonylamino, alkylsulfonylamino, alkenylsulfonylamino, alkynylsulfonylamino, aminocarbonylamino, alkyloxycarbonylaminoimino, alkylsulfonylaminoimino, alkenylsulfonylaminoimino, and alkynylsulfonylaminoimino, wherein: (a) the amino portion of such substituents optionally is substituted with a substituent independently selected from the group consisting of carbocyclylalkyl, heterocyclylalkyl, alkylcarbonyloxy, aminocarbonylalkyl, alkyl, alkenyl, alkynyl, alkylearbonyl, alkenylcarbonyl, alkynylcarbonyl, alkyloxycarbonyl, alkyloxyalkyloxycarbonyl, alkylcarbonyloxyalkyl, and alkylsulfonyl, wherein: (1) the carbocyclyl portion of the carbocyclylalkyl and the heterocyclyl portion of the heterocyclylalkyl optionally are substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, carboxy, hydroxy, alkyloxy, alkenyloxy, alkynyloxy, halo, nitro, cyano, azido, oxo, and amino, and (2) the amino portion of the aminocarbonylalkyl optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, and alkynyl, (b) the alkyl, alkenyl, and alkynyl portion of such substituents optionally is substituted with one or more substituents independently selected from the group consisting of carboxy, halo, oxo, amino, alkyloxycarbonyl, alkylcarbonyloxy, hydroxy, alkyloxy, carbocyclyl, heterocyclyl, and cyano, wherein: the amino optionally is substituted with one or two substituents independently 6 2014280939 24 Dec 2014 selected from the group consisting of alkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy, and alkynyloxy, wherein: the alkyl optionally is substituted with one or more hydroxy; (c) the carbocyclyl and heterocyclyl portions of such substituents optionally are substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, carboxy, hydroxy, alkyloxy, alkenyloxy, alkynyloxy, halo, nitro, cyano, azido, and amino, wherein: the amino optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, and alkynyl; and each RK is independently selected from the group consisting of aminosulfonyl, alkylsulfonyl, alkenylsulfonyl, and alkynylsulfonyl, wherein: (a) the alkylsulfonyl, alkenylsulfonyl, and alkynylsulfonyl optionally are substituted with one or more substituents independently selected from the group consisting of carboxy, hydroxy, halo, amino, nitro, azido, oxo, aminosulfonyl, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyioxy, alkyloxy, alkenyloxy, alkynyloxy, carbocyclyl, heterocyclyl, cyano, and aminocarbonyl, wherein: the amino, aminosulfonyl, and aminocarbonyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, and alkynyl; and (b) the aminosulfonyl optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, and alkynyl.

[0011] This invention also is directed to the salts (including pharmaceutically acceptable salts) of the compounds of the invention.

[0012] This invention also is directed to compositions (including pharmaceutical compositions) that comprise one or more compounds and/or salts of the invention, and, optionally, one or more additional therapeutic agents.

[0013] This invention also is directed to kits that comprise one or more compounds and/or salts of the invention, and, optionally, one or more additional therapeutic agents.

[0014] This invention also is directed to methods of use of the compounds, salts, compositions, and/or kits of the invention to, for example, inhibit replication of an RNA virus (including HCV), treat a disease treatable by inhibiting HCV ribonucleic acid (RNA) polymerase (including hepatitis C).

[0015] This invention also is directed to a use of one or more compounds and/or salts of the invention to prepare a medicament. The medicament optionally can comprise one or more additional therapeutic agents. In some embodiments, the medicament is useful for treating hepatitis C. 7 2014280939 24 Dec 2014 [0016] Further benefits of Applicants’ invention will be apparent to one skilled in the art from reading this patent application.

BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 shows an illustrative PXRD pattern for the ethanol solvate of compound IB-LO-2.3.

[0018] Figure 2 shows an illustrative TGA profile of the ethanol solvate of compound IB-LO-2.3.

[0019] Figure 3 shows an illustrative PXRD pattern for the acetonitrile solvate of compound IB-LO-2.3.

[0020] Figure 4 shows an illustrative PXRD pattern for the ethyl acetate solvate of compound IB-LO-2.3.

[0021] Figure 5 shows an illustrative PXRD pattern for the 2-propanol solvate of compound IB-LO-2.3.

[0022] Figure 6 shows an illustrative PXRD pattern for the methanol solvate of compound IB-LO-2.3.

[0023] Figure 7 shows an illustrative PXRD pattern for the 1 -propanol solvate of compound IB-LO-2.3.

[0024] Figure 8 shows an illustrative PXRD pattern for the solvent free crystalline compound IB-LO-2.3.

[0025] Figure 9 shows an illustrative PXRD pattern for the hydrate of compound IB-LO-2.3, [0026] Figure 10 shows an illustrative PXRD pattern for the pattern A monosodium salt of compound IB-LO-2.3.

[0027] Figure 11 shows an illustrative TGA profile of the pattern A monosodium salt of compound IB-L0-2.3. |0028] Figure 12 shows an illustrative PXRD pattern for the pattern B monosodium salt of compound IB-LO-2.3.

[0029] Figure 13 shows an illustrative TGA profile of the pattern B monosodium salt of compound IB-L0-2.3.

[0030] Figure 14 shows an illustrative PXRD pattern for the pattern C monosodium salt of compound IB-LO-2.3.

[0031] Figure 15 shows an illustrative PXRD pattern for the disodium salt of compound IB-LO-2.3.

[0032] Figure 16 shows an illustrative TGA profile of the disodium salt of compound IB-LO-2.3.

[0033] Figure 17 shows an illustrative PXRD pattern for the monopotassium salt of compound IB-LO-2.3.

[0034] Figure 18 shows an illustrative TGA profile of the monopotassium salt of compound IB-LO-2.3.

[0035] Figure 19 shows an illustrative PXRD pattern for the pattern A monocholine salt of compound IB-LO-2.3.

[0036] Figure 20 shows an illustrative TGA profile of the pattern A monocholine salt of compound IB-L0-2.3.

[0037] Figure 21 shows an illustrative PXRD pattern for the pattern B monocholine salt of compound IB-LO-2.3.

[0038] Figure 22 shows an illustrative TGA profile of the pattern B monocholine salt of compound IB- 8 2014280939 24 Dec 2014 LO-2.3.

[0039] Figure 23 shows an illustrative PXRD pattern for the dicholine salt of compound IB-LO-2.3.

[0040] Figure 24 shows an illustrative PXRD pattern for the disodium salt nonahydrate of compound IB-Ll-1.1.

[0041] Figure 25 shows an illustrative PXRD pattern for the disodium salt tetrahydrate of compound IB-Ll-1.1.

[0042] Figure 26 shows an illustrative TGA profile of the disodium salt tetrahydrate of compound IB-Ll-1.1.

[0043] Figure 27 shows an illustrative PXRD pattern for the dipotassium salt tetrahydrate of compound IB-L1-1.1.

[0044] Figure 28 show's an illustrative PXRD pattern for the monopotassium salt trihydrate of compound IB-L1-1.1.

[0045] Figure 29 shows an illustrative PXRD pattern for the monopotassium salt dihydrate of compound IB-L1-1.1, [0046] Figure 30 shows an illustrative TGA profile of the monopotassium salt dihydrate of compound IB-L1-1.1.

[0047] Figure 31 shows an illustrative PXRD pattern for the 1/7 potassium salt of compound IB-L1-1.1.

[0048] Figure 32 shows an illustrative PXRD pattern for the monodiethylamine salt tetrahydrate of compound IB-L1-1.1.

[0049] Figure 33 shows an illustrative TGA profile of the monodiethylamine salt tetrahydrate of compound IB-L1-1.1.

[0050] Figure 34 shows an illustrative PXRD pattern for the pattern A polymorph of compound IB-L1-1.1.

[0051] Figure 35 shows an illustrative DSC profile of the pattern A polymorph of compound IB-L1-1.1.

[0052] Figure 36 shows an illustrative PXRD pattern for the pattern B polymorph of compound IB-L1- 1.1.

[0053] Figure 37 shows an illustrative PXRD pattern for the pattern C polymorph of compound IB-L1-1.1.

[0054] Figure 38 shows an illustrative PXRD pattern for the pattern D polymorph of compound IB-L1- 1.1.

[0055] Figure 39 shows an illustrative PXRD pattern for the pattern A hydrate of compound IB-L1-1.1.

[0056] Figure 40 shows an illustrative TGA profile of the pattern A hydrate of compound IB-L1-1.1.

[0057] Figure 41 shows an illustrative PXRD pattern for the pattern B hydrate of compound IB-L1-1.1.

[0058] Figure 42 shows an illustrative TGA profile of the pattern B hydrate of compound IB-L1-1.1. 9 2014280939 24 Dec 2014 [0059] Figure 43 shows an illustrative PXRD pattern for the pattern C hydrate of compound IB-L1-1.1.

[0060] Figure 44 shows an illustrative TGA profile of the pattern € hydrate of compound IB-L1-1.1.

[0061] Figure 45 shows an illustrative PXRD pattern for the pattern D hydrate of compound IB-L1-1.1.

[0062] Figure 46 shows an illustrative PXRD pattern for the pattern E hydrate of compound 1B-L1-1.1.

DETAILED DESCRIPTION OF THE INVENTION

[0063] This detailed description is intended only to acquaint others skilled in the art with Applicants’ invention, its principles, and its practical application so that others skilled in the art may adapt and apply the invention in its numerous forms, as they may be best suited to the requirements of a particular use. This description and its specific examples are intended for purposes of illustration only. This invention, therefore, is not limited to the embodiments described in this patent application, and may be variously modified, A. Definitions.

[0064] The term "alkyl" (alone or in combination with another term(s)) means a straight-or branched-chain saturated hydrocarbyl substituent typically containing from 1 to about 20 carbon atoms, more typically from 1 to about 8 carbon atoms, and even more typically from 1 to about 6 carbon atoms. Examples of such substituents include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, and hexyl. As in this definition, throughout this detailed description Applicants have provided illustrative examples. The provision of such illustrative examples should not be interpreted as if the provided illustrative examples are the only options available to one skilled in the art.

[0065] The term "alkenyl" (alone or in combination with another term(s)) means a straight- or branched-chain hydrocarbyl substituent containing one or more double bonds and typically from 2 to about 20 carbon atoms, more typically from about 2 to about 8 carbon atoms, and even more typically from about 2 to about 6 carbon atoms. Examples of such substituents include ethenyl (vinyl), 2-propenyl, 3-propenyl, 1,4-pentadienyl, 1,4-butadienyl, 1-butenyl, 2-butenyl, and 3-butenyl.

[0066] The term "alkynyl" (alone or in combination with another term(s)) means a straight- or branched-chain hydrocarbyl substituent containing one or more triple bonds and typically from 2 to about 20 carbon atoms, more typically from about 2 to about 8 carbon atoms, and even more typically from about 2 to about 6 carbon atoms. Examples of such substituents include ethynyl, 2-propynyl, 3-propynyl, 2-butynyl, and 3-butynyl.

[0067] The term "carbocyclyl" (alone or in combination with another term(s)) means a saturated cyclic (,i.e., "cycloalkyl"), partially saturated cyclic {i.e., "cycloalkenyl"), or completely unsaturated (i.e., "aryl") hydrocarbyl substituent containing from 3 to 14 carbon ring atoms ("ring atoms" are the atoms bound together to form the ring or rings of a cyclic substituent). A carbocyclyl may be a single ring, which typically contains from 3 to 6 ring atoms. Examples of such single-ring carbocyclyls include cyclopropyl 10 2014280939 24 Dec 2014 (cyclopropanyl), cyclobutyl (cyclobutanyl), cyclopentyl (cyclopentanyl), cyclopentenyl, cyclopentadienyl, cyclohexyl (cyclohexanyl), cyclohexenyl, cyclohexadienyl, and phenyl. A carbocyclyl alternatively may be 2 or 3 rings fused together, such as naphthalenyl, tetrahydronaphthalenyl (tetralinyl), indenyl, indanyl (dihydroindenyl), anthracenyl, phenanthrenyl, and decalinyl.

[0068] The term "cycloalkyl" (alone or in combination with another term(s)) means a saturated cyclic hydrocarbyl substituent containing from 3 to 14 carbon ring atoms. A cycloalkyl may be a single carbon ring, which typically contains from 3 to 6 carbon ring atoms. Examples of single-ring cycloalkyls include cyclopropyl, cyclobutyl, cyclopcntyl, and cyclohexyl. A cycloalkyl alternatively may be 2 or 3 carbon rings fused together, such as, decalinyl.

[0069] The term "aryl" (alone or in combination with another term(s)) means an aromatic carbocyclyl containing from 6 to 14 carbon ring atoms. Examples of aryls include phenyl, naphthalenyl, and indenyl.

[0070] In some instances, the number of carbon atoms in a hydrocarbyl substituent (e.g., alkyl, alkenyl, alkynyl, or cycloalkyl) is indicated by the prefix "Cx-Cy-", wherein x is the minimum and y is the maximum number of carbon atoms in the substituent. Thus, for example, "CrC6-alkyl" refers to an alkyl substituent containing from 1 to 6 carbon atoms. Illustrating further, C3-C6-cycloalkyl means a saturated hydrocarbyl ring containing from 3 to 6 carbon ring atoms.

[0071] The term "hydrogen" (alone or in combination with another term(s)) means a hydrogen radical, and may be depicted as -H.

[0072] The term "hydroxy" (alone or in combination with another term(s)) means -OH.

[0073] The term "nitro" (alone or in combination with another term(s)) means -N02.

[0074] The term "cyano" (alone or in combination with another term(s)) means -CN, which also may be depicted as -C=N.

[0075] The term "keto" (alone or in combination with another term(s)) means an oxo radical, and may be depicted as =0.

[0076] The term "carboxy" (alone or in combination with another term(s)) means -C(0)-OH.

[0077] The term "amino" (alone or in combination with another term(s)) means -NH2.

[0078] The term "imino" (alone or in combination with another term(s)) means =NH.

[0079] The term "aminoimino" (alone or in combination with another term(s)) means =NNH2.

[0080] The term "halogen" or "halo" (alone or in combination with another term(s)) means a fluorine radical (which may be depicted as -F), chlorine radical (which may be depicted as -Cl), bromine radical (which may be depicted as -Br), or iodine radical (which may be depicted as -I).

[0081] A substituent is "substitutable" if it comprises at least one carbon or nitrogen atom that is bonded to one or more hydrogen atoms. Thus, for example, hydrogen, halogen, and cyano do not fall within this definition. In addition, a sulfur atom in a heterocyclyl containing such atom is substitutable with one or 11 2014280939 24 Dec 2014 two oxo substituents.

[0082] If a substituent is described as being "substituted", a non-hydrogen radical is in the place of hydrogen radical on a carbon or nitrogen of the substituent. Thus, for example, a substituted alkyl substituent is an alkyl substituent in which at least one non-hydrogen radical is in the place of a hydrogen radical on the alkyl substituent. To illustrate, monofluoroalkyl is alkyl substituted with a fluoro radical, and difluoroalkyl is alkyl substituted with two fluoro radicals. It should be recognized that if there are more than one substitution on a substituent, each non-hydrogen radical may be identical or different (unless otherwise stated).

[0083] If a substituent is described as being "optionally substituted", the substituent may be either (1) not substituted or (2) substituted. If a substituent is described as being optionally substituted with up to a particular number of non-hydrogen radicals, that substituent may be either (1) not substituted; or (2) substituted by up to that particular number of non-hydrogen radicals or by up to the maximum number of substitutable positions on the substituent, whichever is less. Thus, for example, if a substituent is described as a heteroaryl optionally substituted with up to 3 non-hydrogen radicals, then any heteroaryl with less than 3 substitutable positions would be optionally substituted by up to only as many nonhydrogen radicals as the heteroaryl has substitutable positions. To illustrate, tetrazolyl (which has only one substitutable position) would be optionally substituted with up to one non-hydrogen radical. To illustrate further, if an amino nitrogen is described as being optionally substituted with up to 2 nonhydrogen radicals, then a primary amino nitrogen will be optionally substituted with up to 2 nonhydrogen radicals, whereas a secondary amino nitrogen will be optionally substituted with up to only 1 non-hydrogen radical.

[0084] This patent application uses the terms "substituent" and "radical" interchangeably.

[0085] The prefix "halo" indicates that the substituent to which the prefix is attached is substituted with one or more independently selected halogen radicals. For example, haloalkyl means an alkyl substituent in which at least one hydrogen radical is replaced with a halogen radical. Examples of haloalkyls include chloromethyl, 1-bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl, and 1,1,1-trifluoroethyl. It should be recognized that if a substituent is substituted by more than one halogen radical, those halogen radicals may be identical or different (unless otherwise stated).

[0086] The prefix "perhalo" indicates that every hydrogen radical on the substituent to which the prefix is attached is replaced with independently selected halogen radicals, i.e., each hydrogen radical on the substituent is replaced with a halogen radical. If all the halogen radicals are identical, the prefix typically will identify the halogen radical. Thus, for example, the term "perfluoro" means that every hydrogen radical on the substituent to which the prefix is attached is substituted with a fluorine radical. To illustrate, the term "perfluoroalkyl" means an alkyl substituent wherein a fluorine radical is in the place of 12 2014280939 24 Dec 2014 each hydrogen radical.

[0087] The term "carbonyl" (alone or in combination with another term(s)) means -C(O)-.

[0088] The term "aminocarbonyl" (alone or in combination with another term(s)) means -C(0)-NH2.

[0089] The term "oxy" (alone or in combination with another term(s)) means an ether substituent, and may be depicted as -O-.

[0090] The term "alkoxy" (alone or in combination with another term(s)) means an alkylether substituent, i.e., -O-alkyl. Examples of such a substituent include methoxy (-O-CH3), ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, and tert-butoxy.

[0091] The term "alkylcarbonyl" (alone or in combination with another term(s)) means -C(0)-alkyl.

[0092] The term "aminoalkylcarbonyl" (alone or in combination with another term(s)) means -C(O)-alkyl-NH2.

[0093] The term "alkoxycarbonyl" (alone or in combination with another term(s)) means -C(0)-0-alkyl.

[0094] The term "carbocyclylcarbonyl" (alone or in combination with another term(s)) means -C(0)-carbocyclyl.

[0095] Similarly, the term "heterocyclylcarbonyl" (alone or in combination with another term(s)) means -C(0)-heterocyclyl.

[0096] The term "carbocyclylalkylcarbonyl" (alone or in combination with another term(s)) means -C(())-alkyl-carbocyclyl.

[0097] Similarly, the term "heterocyclylalkylcarbonyl" (alone or in combination with another term(s)) means -C(0)-alkyl-heterocyclyl. ]0098] The term "carbocyclyloxycarbonyl" (alone or in combination with another term(s)) means -C(O)-O-carbocyclyl.

[0099] The term "carbocyclylalkoxycarbonyl" (alone or in combination with another term(s)) means -C(0)-0-alkyl-carbocyclyl, fOOlOO] The term "thio" or "thia" (alone or in combination with another term(s)) means athiaether substituent, i.e., an ether substituent wherein a divalent sulfur atom is in the place of the ether oxygen atom. Such a substituent may be depicted as -S-. This, for example, "alkyl-thio-alkyl" means alkyl-S-alkyl (alkyl-sulfanyl-alkyl).

[00101] The term "thiol" or "sulfhydryl" (alone or in combination with another term(s)) means a sulfhydryl substituent, and may be depicted as -SH.

[00102] The term "(thiocarbonyl)" (alone or in combination with another term(s)) means a carbonyl wherein the oxygen atom has been replaced with a sulfur. Such a substituent may be depicted as -C(S)-, [00103] The term "sulfonyl" (alone or in combination with another term(s)) means -S(0)2-.

[00104] The term "aminosulfonyl" (alone or in combination with another term(s)) means -S(0)2-NH2. 13 2014280939 24 Dec 2014 [00105] The term "sulfmyl" or "sulfoxido" (alone or in combination with another term(s)) means -S(O)-.

[00106] The term "heterocyclyl" (alone or in combination with another term(s)) means a saturated (,i.e., "heterocycloalkyl"), partially saturated (i.e., "heterocycloalkenyl"), or completely unsaturated (i.e., "heteroaryl") ring structure containing a total of 3 to 14 ring atoms. At least one of the ring atoms is a heteroatom (i.e., oxygen, nitrogen, or sulfur), with the remaining ring atoms being independently selected from the group consisting of carbon, oxygen, nitrogen, and sulfur.

[00107] A heterocyclyl may be a single ring, which typically contains from 3 to 7 ring atoms, more typically from 3 to 6 ring atoms, and even more typically 5 to 6 ring atoms. Examples of single-ring heterocyclyls include furanyl, dihydrofuranyl, tetrahydrofuranyl, thiophenyl (thiofuranyl), dihydrothiophenyl, tetrahydrothiophenyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, triazolyl, tetrazolyl, oxazolyl, oxazolidinyl, isoxazolidinyl, isoxazolyl, thiazolyl, isothiazolyl, thiazolinyl, isothiazolinyl, thiazolidinyl, isothiazolidinyl, thiodiazolyl, oxadiazolyl (including 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl (furazanyl), or 1,3,4-oxadiazolyl), oxatriazolyl (including 1,2,3,4-oxatriazolyl or 1,2,3,5-oxatriazolyl), dioxazolyl (including 1,2,3-dioxazolyl, 1,2,4-dioxazolyl, 1,3,2-dioxazolyl, or 1,3,4-dioxazolyl), oxathiazolyl, oxathiolyl, oxathiolanyl, pyranyl, dihydropyranyl, thiopyranyl, tetrahydrothiopyranyl, pyridinyl (azinyl), piperidinyl, diazinyl (including pyridazinyl (1,2-diazinyl), pyrimidinyl (1,3-diazinyl), or pyrazinyl (1,4-diazinyl)), piperazinyl, triazinyl (including 1,3,5-triazinyl, 1,2,4-triazinyl, and 1,2,3-triazinyl)), oxazinyl (including 1,2-oxazinyl, 1,3-oxazinyl, or 1,4-oxazinyl)), oxathiazinyl (including 1,2,3-oxathiazinyl, 1,2,4-oxathiazinyl, 1,2,5-oxathiazinyl, or 1,2,6-oxathiazinyl)), oxadiazinyl (including 1,2,3-oxadiazinyl, 1,2,4-oxadiazinyl, 1,4,2-oxadiazinyl, or 1,3,5-oxadiazinyl)), morpholinyl, azepinyl, oxepinyl, thiepinyl, and diazepinyl.

[00108] A heterocyclyl alternatively may be 2 or 3 rings fused together, such as, for example, indolizinyl, pyranopyrrolyl, 4H-quinolizinyl, purinyl, naphthyridinyl, pyridopyridinyl (including pyrido[3,4-b]-pyridinyl, pyrido[3,2-b]-pyridinyl, or pyrido[4,3-b]-pyridinyl), and pteridinyl. Other examples of fused-ring heterocyclyls include benzo-fused heterocyclyls, such as indolyl, isoindolyl (isobenzazolyl, pseudoisoindolyl), indoleninyl (pseudoindolyl), isoindazolyl (benzpyrazolyl), benzazinyl (including quinolinyl (1-benzazinyl) or isoquinolinyl (2-benzazinyl)), phthalazinyl, quinoxalinyl, quinazolinyl, benzodiazinyl (including cinnolinyl (1,2-benzodiazinyl) or quinazolinyl (1,3-benzodiazinyl)), benzopyranyl (including chromanyl or isochromanyl), benzoxazinyl (including 1,3,2-benzoxazinyl, 1,4,2-benzoxazinyl, 2,3,1-benzoxazinyl, or 3,1,4-benzoxazinyl), and benzisoxazinyl (including 1,2-benzisoxazinyl or 1,4-benzisoxazinyl).

[00109] The term "2-fused ring" heterocyclyl (alone or in combination with another term(s)) means a saturated, partially saturated, or aryl heterocyclyl containing 2 fused rings. Examples of 2-fused-ring 14 2014280939 24 Dec 2014 heterocyclyls include indolizinyl, quinolizinyl, purinyl, naphthyridinyl, pteridinyl, indolyl, isoindolyl, indoleninyl, isoindazolyl, phthalazinyl, quinoxalinyl, quinazolinyl, benzodiazinyl, benzopyranyl, benzothiopyranyl, benzoxazolyl, anthranilyl, benzodioxolyl, benzodioxanyl, benzoxadiazolyl, benzofuranyl, iso benzofuranyl, benzothiazolyl, benzothiadiazolyl, benzimidazolyl, benzotriazolyl, benzoxazinyl, and tetrahydroisoquinolinyl.

[00110] The term "heteroaryl" (alone or in combination with another term(s)) means an aromatic heterocyclyl containing from 5 to 14 ring atoms, A heteroaryl may be a single ring or 2 or 3 fused rings. Examples of heteroaryl substituents include 6-membered ring substituents such as pyridyl, pyrazyl, pyrimidinyl, pyridazinyl, and 1,3,5-, 1,2,4- or 1,2,3-triazinyl; 5-membered ring substituents such as imidazyl, furanyl, thiophenyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, 1,2,3-, 1,2,4-, 1,2,5-, or 1,3,4-oxadiazolyl and isothiazolyl; 6/5-membered fused ring substituents such as benzothiofuranyl, benzisoxazolyl, benzoxazolyl, purinyl, and anthranilyl; and 6/6-membered fused rings such as benzopyranyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, and benzoxazinyl.

[00111] A prefix attached to a multi-component substituent only applies to the first component. To illustrate, the term "alkylcycloalkyl" contains two components; alkyl and cycloalkyl. Thus, the CrC6-prefix on Ci-C6-alkylcycloalkyl means that the alkyl component of the alkylcycloalkyl contains from 1 to 6 carbon atoms; the Ci-Q-prefix does not describe the cycloalkyl component. To illustrate further, the prefix "halo" on haloalkoxyalkyl indicates that only the alkoxy component of the alkoxyalkyl substituent is substituted with one or more halogen radicals. If halogen substitution may alternatively or additionally occur on the alkyl component, the substituent would instead be described as "halogen-substituted alkoxyalkyl" rather than "haloalkoxyalkyl." And finally, if the halogen substitution may only occur on the alkyl component, the substituent would instead be described as "alkoxyhaloalkyl." [00112] If substituents are described as being "independently selected" from a group, each substituent is selected independent of the other. Each substituent therefore may be identical to or different from the other substituent(s).

[00113] When words are used to describe a substituent, the rightmost-described component of the substituent is the component that has the free valence.

[00114] When a chemical formula is used to describe a substituent, the dash on the left side of the formula indicates the portion of the substituent that has the free valence.

[00115] When a chemical formula is used to describe a linking element between two other elements of a depicted chemical structure, the leftmost dash of the substituent indicates the portion of the substituent that is bound to the left element in the depicted structure. The rightmost dash, on the other hand, indicates the portion of the substituent that is bound to the right element in the depicted structure. To illustrate, if the depicted chemical structure is X-L-Y and L is described as -C(0)-N(H)-, then the chemical would be 15 2014280939 24 Dec 2014 X-C(0)-N(H)-Y.

[00116] With reference to the use of the words "comprise" or "comprises" or "comprising" in this patent application (including the claims), Applicants note that unless the context requires otherwise, those words are used on the basis and clear understanding that they are to be interpreted inclusively, rather than exclusively, and that Applicants intend each of those words to be so interpreted in construing this patent application, including the claims below.

[00117] ChemDraw software has been used to generate the compound names in this patent application.

[00118] The term "amorphous" as applied to a compound refers to a solid-state in which the compound molecules are present in a disordered arrangement and do not form a distinguishable crystal lattice or unit cell. When subjected to X-ray powder diffraction, an amorphous compound does not produce any characteristic crystalline peaks.

[00119] The term "crystalline form" as applied to a compound refers to a solid-state in which the compound molecules are arranged to form a distinguishable crystal lattice (i) comprising distinguishable unit cells, and (ii) yielding diffraction pattern peaks when subjected to X-ray radiation.

[00120] The term "purity", unless otherwise qualified, means the chemical purity of a compound according to conventional HPLC assay.

[00121] The term "phase purity" means the solid-state purity of a compound with regard to a particular crystalline or amorphous form of the compound as determined by X-ray powder diffraction analytical methods.

[00122] The term "phase pure" refers to purity with respect to other solid-state forms of the compound, and does not necessarily imply a high degree of chemical purity with respect to other compounds.

[00123] The term "PXRD" means X-ray powder diffraction.

[00124] The term "TGA" means thermo gravimetric analysis.

[00125] The term "DSC" means differential scanning calorimetry. B. Compounds.

[00126] This invention is directed, in part, to compounds that are phenyl-uracil derivatives that correspond in structure to formula I:

16 2014280939 24 Dec 2014 [00127] In these compounds, =^=-=^ is selected from the group consisting of single carbon-carbon bond and double carbon-carbon bond.

[00128] In some embodiments, ^=-= is a single carbon-carbon bond. In these embodiments, the compounds of formula I correspond in structure to the following formula (/. e., formula IA): R1

I

[00129] In other embodiments, is a double carbon-carbon bond. In these embodiments, the compounds of formula I correspond in structure to the following formula (/. e., formula IB): R1

L \ R6 R5

Bl. Substituent R1.

[001301R1 is selected from the group consisting of hydrogen, methyl, and nitrogen-protecting group.

[00131] In some embodiments, R1 is hydrogen.

[00132] In some embodiments, R1 is methyl.

[00133] In some embodiments, R1 is selected from the group consisting of hydrogen and methyl.

[00134] In some embodiments, R1 is a nitrogen-protecting group. In these embodiments, the compounds are useful as intermediates for the preparation of compounds of formula I. Nitrogen-protecting groups suitable for preparing compounds of formula I are known to those skilled in the art. B2. Substituent R2.

[00135] R2 is selected from the group consisting of hydrogen, halo, hydroxy, methyl, cyclopropyl, and cyclobutyl.

[00136] In some embodiments, R2 is hydrogen.

[00137] In some embodiments, R2 is halo. In some such embodiments, R2 is selected from the group 17 2014280939 24 Dec 2014 consisting of fluoro and chloro. In other such embodiments, R2 is fluoro. In yet other such embodiments, R2 is chloro. In yet other such embodiments, R2 is bromo. In further such embodiments, R2 is iodo.

[00138] In some embodiments, R2 is hydroxy.

[00139] In some embodiments, R2 is methyl.

[00140] In some embodiments, R2 is cyclopropyl.

[00141] In some embodiments, R2 is cyclobutyl.

[00142] In some embodiments, R2 is selected from the group consisting of hydrogen, methyl, hydroxy, and halo. In some such embodiments, R2 is selected from the group consisting of hydrogen, methyl, hydroxy, fluoro, and chloro. In other such embodiments, R2 is selected from the group consisting of hydrogen, methyl, hydroxy, and fluoro. In yet other such embodiments, R2 is selected from the group consisting of hydrogen, methyl, hydroxy, and chloro. In yet other such embodiments, R2 is selected from the group consisting of hydrogen, methyl, hydroxy, and bromo. In further such embodiments, R2 is selected from the group consisting of hydrogen, methyl, hydroxy, and iodo.

[00143] In some embodiments, R2 is selected from the group consisting of hydrogen, methyl, and halo. In some such embodiments, R2 is selected from the group consisting of hydrogen, methyl, fluoro, and chloro. In other such embodiments, R2 is selected from the group consisting of hydrogen, methyl, and fluoro. In yet other such embodiments, R2 is selected from the group consisting of hydrogen, methyl, and chloro. In yet other such embodiments, R2 is selected from the group consisting of hydrogen, methyl, and bromo. In further such embodiments, R2 is selected from the group consisting of hydrogen, methyl, and iodo.

[00144] In some embodiments, R2 is selected from the group consisting of hydrogen and halo. In some such embodiments, R2 is selected from the group consisting of hydrogen, fluoro, and chloro. In other such embodiments, R2 is selected from the group consisting of hydrogen and fluoro. In yet other such embodiments, R2 is selected from the group consisting of hydrogen and chloro. In yet other such embodiments, R2 is selected from the group consisting of hydrogen and bromo. In further such embodiments, R2 is selected from the group consisting of hydrogen and iodo. B3. Substituent R3.

[00145] R3 is selected from the group consisting of hydrogen, halo, oxo, and methyl. In some such embodiments, R3 is selected from the group consisting of hydrogen, fluoro, oxo, and methyl. In other such embodiments, R3 is selected from the group consisting of hydrogen, chloro, oxo, and methyl. In yet other such embodiments, R3 is selected from the group consisting of hydrogen, bromo, oxo, and methyl. In yet other such embodiments, R3 is selected from the group consisting of hydrogen, iodo, oxo, and methyl.

[00146] In some embodiments, R3 is selected from the group consisting of hydrogen, halo, and oxo. In 18 2014280939 24 Dec 2014 some such embodiments, R3 is selected from the group consisting of hydrogen, fluoro, and oxo. In other such embodiments, R3 is selected from the group consisting of hydrogen, chloro, and oxo. In yet other such embodiments, R3 is selected from the group consisting of hydrogen, bromo, and oxo. In yet other such embodiments, R3 is selected from the group consisting of hydrogen, iodo, and oxo.

[00147] In some embodiments, R3 is selected from the group consisting of hydrogen and methyl.

[00148] In some embodiments, R3 is hydrogen.

[00149] In some embodiments, R3 is methyl.

[00150] In some embodiments, R3 is oxo.

[00151] In some embodiments, R3 is halo. In some such embodiments, R3 is fluoro. In other such embodiments, R3 is chloro. In yet other such embodiments, R3 is bromo. In further such embodiments, R3 is iodo. B4. SubstituentR4.

[00152] R4 is selected from the group consisting of halo, alkyl, alkenyl, alkynyl, nitro, cyano, azido, alkyloxy, alkenyloxy, alkynyloxy, amino, aminocarbonyl, aminosulfonyl, alkylsulfonyl, carbocyclyl, and heterocyclyl, wherein: (a) the amino, aminocarbonyl, and aminosulfonyl optionally are substituted with: (1) one or two substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, and alkylsulfonyl, or (2) two substituents that, together with the amino nitrogen, form a singlering heterocyclyl, (b) the alkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy, alkynyloxy, and alkylsulfonyl, optionally are substituted with one or more substituents independently selected from the group consisting of halo, oxo, nitro, cyano, azido, hydroxy, amino, alkyloxy, trimethylsilyl, carbocyclyl, and heterocyclyl, wherein: the amino optionally is substituted with: (1) one or two substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkylcarbonyl, alkylsulfonyl, alkyloxycarbonyl, carbocyclyl, heterocyclyl, carbocyclylalkyl, and heterocyclylalkyl, or (2) two substituents that, together with the amino nitrogen, form a singlering heterocyclyl, and (c) the carbocyclyl and heterocyclyl optionally are substituted with up to three substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, halo, oxo, nitro, cyano, azido, hydroxy, amino, alkyloxy, trimethylsilyl, carbocyclyl, and heterocyclyl, 19 2014280939 24 Dec 2014 wherein: the amino optionally is substituted with: (1) one or two substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkylearbonyl, alkylsulfonyl, alkyloxycarbonyl, carbocyclyl, heterocyclyl, carbocyclylalkyl, and heterocyclylalkyl, or (2) two substituents that, together with the amino nitrogen, form a singlering heterocyclyl.

[00153] In some embodiments, R4 is selected from the group consisting of halo, alkyl, alkenyl, alkynyl, nitro, cyano, azido, alkyloxy, alkenyloxy, alkynyloxy, amino, aminocarbonyl, aminosulfonyl, alkylsulfonyl, carbocyclyl, and heterocyclyl, wherein: the amino, aminocarbonyl, and aminosulfonyl optionally are substituted with: (1) one or two substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, and alkylsulfonyl, or (2) two substituents that, together with the amino nitrogen, form a singlering heterocyclyl.

[00154] In some embodiments, R4 is selected from the group consisting of halo, alkyl, alkenyl, alkynyl, nitro, cyano, azido, alkyloxy, alkenyloxy, alkynyloxy, amino, aminocarbonyl, aminosulfonyl, alkylsulfonyl, carbocyclyl, and heterocyclyl, wherein: the alkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy, alkynyloxy, and alkylsulfonyl, optionally are substituted with one or more substituents independently selected from the group consisting of halo, oxo, nitro, cyano, azido, hydroxy, amino, alkyloxy, trimethylsilyl, carbocyclyl, and heterocyclyl, wherein: the amino optionally is substituted with: (1) one or two substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkylearbonyl, alkylsulfonyl, alkyloxycarbonyl, carbocyclyl, heterocyclyl, carbocyclylalkyl, and heterocyclylalkyl, or (2) two substituents that, together with the amino nitrogen, form a singlering heterocyclyl.

[00155] In some embodiments. R4 is selected from the group consisting of halo, alkyl, alkenyl, alkynyl, nitro, cyano, azido, alkyloxy, alkenyloxy, alkynyloxy, amino, aminocarbonyl, aminosulfonyl, alkylsulfonyl, carbocyclyl, and heterocyclyl, wherein: the carbocyclyl and heterocyclyl optionally are substituted with up to three substituents 20 2014280939 24 Dec 2014 independently selected from the group consisting of alkyl, alkenyl, alkynyl, halo, oxo, nitro, cyano, azido, hydroxy, amino, alkyloxy, trimethylsilyl, carbocyclyl, and heterocyclyl, wherein: the amino optionally is substituted with: (1) one or two substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkylcarbonyl, alkylsulfonyl, alkyloxycarbonyl, carbocyclyl, heterocyclyl, carbocyclylalkyl, and heterocyclylalkyl, or (2) two substituents that, together with the amino nitrogen, form a singlering heterocyclyl.

[00156] In some embodiments, R4 is selected from the group consisting of halo, alkyl, alkenyl, alkynyl, nitro, cyano, azido, alkyloxy, alkenyloxy, alkynyloxy, amino, aminocarbonyl, aminosulfonyl, alkylsulfonyl, carbocyclyl, and heterocyclyl, wherein: (a) the amino, aminocarbonyl, and aminosulfonyl optionally are substituted with: (1) one or two substituents independently selected from the group consisting of alkyl, alkenyl, and alkynyl, or, (2) two substituents that, together with the amino nitrogen, form a single-ring heterocyclyl; and (b) the alkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy, alkynyloxy, alkylsulfonyl, carbocyclyl, and heterocyclyl optionally are substituted with up to three substituents independently selected from the group consisting of halo, oxo, nitro, cyano, azido, hydroxy, amino, alkyloxy, carbocyclyl, and heterocyclyl, wherein the amino optionally is substituted with: (1) one or two substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkylcarbonyl, alkylsulfonyl, alkyloxycarbonyl, carbocyclyl, heterocyclyl, carbocyclylalkyl, and heterocyclylalkyl, or, (2) two substituents that, together with the amino nitrogen, form a single-ring heterocyclyl.

[00157] In some embodiments, R4 is selected from the group consisting of halo, alkyl, alkenyl, alkynyl, nitro, cyano, azido, alkyloxy, alkenyloxy, alkynyloxy, amino, aminocarbonyl, aminosulfonyl, alkylsulfonyl, carbocyclyl, and heterocyclyl, wherein: the amino, aminocarbonyl, and aminosulfonyl optionally are substituted with: (1) one or two substituents independently selected from the group consisting of alkyl, alkenyl, and alkynyl, or, (2) tw'O substituents that, together with the amino nitrogen, form a single-ring heterocyclyl. 21 2014280939 24 Dec 2014 [00158] In some embodiments, R4 is selected from the group consisting of halo, alkyl, alkenyl, alkynyl, nitro, cyano, azido, alkyloxy, alkenyloxy, alkynyloxy, amino, aminocarbonyl, aminosulfonyl, alkylsulfonyl, carbocyclyl, and heterocyclyl, wherein: the alkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy, alkynyloxy, alkylsulfonyl, carbocyclyl, and heterocyclyl optionally are substituted with up to three substituents independently selected from the group consisting of halo, oxo, nitro, cyano, azido, hydroxy, amino, alkyloxy, carbocyclyl, and heterocyclyl, wherein the amino optionally is substituted with: (1) one or two substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkylcarbonyl, alkylsulfonyl, alkyloxycarbonyl, carbocyclyl, heterocyclyl, carbocyclylalkyl, and heterocyclylalkyl, or, (2) two substituents that, together with the amino nitrogen, form a single-ring heterocyclyl.

[00159] In some embodiments, R4 is selected from the group consisting of halo, CrC4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, amino, C|-C4-alkylsulfonyl, C3-C6-carbocyclyl, and 5-6-membered heterocyclyl, wherein: (a) the amino optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, and alkylsulfonyl, (b) the CrC4-alkyl, C2-C4-alkenyl, and C2-C4-alkynyl optionally are substituted with one or more substituents independently selected from the group consisting of halo, oxo, hydroxy, alkyloxy, and trimethylsilyl, and (c) the C3-C6-carbocyclyl and 5-6-membered heterocyclyl optionally are substituted with up to three substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, halo, and amino, wherein: the amino optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, and alkylsulfonyl.

[00160] In some embodiments, R4 is selected from the group consisting of CrQ-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, amino, CrC4-alkylsulfonyl, C3-C6-carbocyclyl, and 5-6-membered heterocyclyl, wherein: (a) the amino optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, and alkylsulfonyl, (b) the Ci-C4-alkyl, C2-C4-alkenyl, and C2-C4-alkynyl optionally are substituted with one or more substituents independently selected from the group consisting of halo, oxo, hydroxy, alkyloxy, and trimethylsilyl, and (c) the C3-C6-carbocyclyl and 5-6-membered heterocyclyl optionally are substituted with up to three substituents independently selected from the group consisting of alkyl, alkenyl, 22 2014280939 24 Dec 2014 alkynyl, halo, and amino, wherein: the amino optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, and alkylsulfonyl.

[00161] In some embodiments, R4 is selected from the group consisting of halo, C,-C4-alkyl, C3-C6-carbocyclyl, and 5-6-membered heterocyclyl, wherein: (a) the Ci-C4-alkyl optionally is substituted with up to three substituents independently selected from the group consisting of halo, oxo, hydroxy, alkyloxy, and trimethylsilyl, and (b) the C3-C6-carbocyclyl and 5-6-membered heterocyclyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, halo, and alkylsulfonylamino.

[00162] In some embodiments, R4 is selected from the group consisting of halo, CrQ-alkyl, C3-CV,-carbocyclyl, and 5-6-membered heterocyclyl, wherein: (a) the C;-C.;-alkyl optionally is substituted with one or two substituents independently selected from the group consisting of halo, oxo, hydroxy, alkyloxy, and trimethylsilyl, and (b) the C i-Q-carbocyclyl and 5-6-membered heterocyclyl optionally are substituted with a substituent selected from the group consisting of alkyl, halo, and alkylsulfonylamino.

[00163] In some embodiments, R4 is selected from the group consisting of CrC4-alkyl, C3-C6-carbocyclyl, and 5-6-membered heterocyclyl, wherein: (a) the Ci-C4-alkyl optionally is substituted with up to three substituents independently selected from the group consisting of halo, oxo, hydroxy, alkyloxy, and trimethylsilyl, and (b) the CrCe-carbocyclyl and 5-6-membered heterocyclyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, halo, and alkylsulfonylamino.

[00164] In some embodiments, R4 is selected from the group consisting of halo, tert-butyl, C3-C6-carbocyclyl, and 5-6-membered heterocyclyl, wherein: the Q-Ce-carboeyclyl and 5-6-membered heterocyclyl optionally are substituted with a substituent selected from the group consisting of alkyl, halo, and alkylsulfonylamino.

[00165] In some embodiments, R4 is selected from the group consisting of tert-butyl, Q-Cé-carbocyclyl, and 5-6-membered heterocyclyl, wherein: the C3-C6-carbocyclyl and 5-6-membered heterocyclyl optionally are substituted with a substituent selected from the group consisting of alkyl, halo, and alkylsulfonylamino.

[00166] In some embodiments, R4 is selected from the group consisting of halo, alkyl, haloalkyl, carboxyalkyl, hydroxyalkyl, alkyloxyalkyl, trimethylsilylalkynyl, alkyicarbocyclyl, carbocyclyl, alkylheterocyclyl, heterocyclyl, haloearbocyclyl, alkylsulfonylamino, and alkylsulfonyl. 23 2014280939 24 Dec 2014 [00167] In some embodiments, R4 is selected from the group consisting of halo, alkyl, alkenyl, alkynyl, nitro, cyano, azido, alkyloxy, alkenyloxy, alkynyloxy, amino, aminocarbonyl, aminosulfonyl, alkylsulfonyl, carbocyclyl, and heterocyclyl.

[00168] In some embodiments, R4 is selected from the group consisting of halo, Ci-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, amino, CrC4-alkylsulfonyl, C3-C6-carbocyclyl, and 5-6-membered heterocyclyl. In some such embodiment, R4 is selected from the group consisting of halo, C,-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, amino, Ci-C4-alkylsulfonyl, C6-carbocyclyl, and 5-6-membered heterocyclyl. In other such embodiment, R4 is selected from the group consisting of halo, CrC4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, amino, Ci-C4-alkylsulfonyl, phenyl, and 5-6-membered heteroaryl.

[00169] In some embodiments, R4 is selected from the group consisting of CrC4-alkyl, C2-C4-alkenyl, C2-C4-alkyny], amino, Ci-C4-alkylsulfonyl, C3-C6-carbocyclyl, and 5-6-membered heterocyclyl. In some such embodiment, R4 is selected from the group consisting of Ci-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, amino, C1-C4-alkylsulfonyl, C6-carbocyclyl, and 5-6-membered heterocyclyl. In other such embodiment, R4 is selected from the group consisting of C]-C4-alkyl, Cj-Q-alkenyl, C2-C4-alkynyl, amino, C]-C4-alkylsulfonyl, phenyl, and 5-6-membered heteroaryl.

[00170] In some embodiments, R4 is selected from the group consisting of halo, CrC4-alkyl. C3-C6-carbocyclyl, and 5-6-membered heterocyclyl. In some such embodiments, R4 is selected from the group consisting of halo, Ci-C4-alkyl, C6-carbocyclyl, and 5-6-membered heterocyclyl. In other such embodiments, R4 is selected from the group consisting of halo, CrC4-alkyl, phenyl, and 5-6-membered heteroaryl.

[00171] In some embodiments, R4 is selected from the group consisting of Q-Q-alkyl, C3-Cs-carbocyclyl, and 5-6-membered heterocyclyl. In some such embodiments, R4 is selected from the group consisting of CrC4-alkyl, C6-carbocyclyl, and 5-6-membered heterocyclyl. In other such embodiments, R4 is selected from the group consisting of Ci-C4-alkyl, phenyl, and 5-6-membered heteroaryl.

[00172] In some embodiments, R4 is selected from the group consisting of halo, tert-butyl, C3-C6-carbocyclyl, and 5-6-membered heterocyclyl. In some such embodiments, R4 is selected from the group consisting of halo, tert-butyl, C6-carbocyclyl, and 5-6-membered heterocyclyl. In other such embodiments, R4 is selected from the group consisting of halo, tert-butyl, phenyl, and 5-6-membered heteroaryl.

[00173] In some embodiments, R4 is selected from the group consisting of tert-butyl, C3-C6-carbocyclyl, and 5-6-membered heterocyclyl. In some such embodiments, R4 is selected from the group consisting of tert-butyl, Cé-carbocyclyl, and 5-6-membered heterocyclyl. In other such embodiments, R4 is selected from the group consisting of tert-butyl, phenyl, and 5-6-membered heteroaryl.

[00174] In some embodiments, R4 is selected from the group consisting of C3-C6-carbocyclyl and 5-6-24 2014280939 24 Dec 2014 membered heterocyclyl. In some such embodiments, R4 is selected from the group consisting of CV carbocyclyl, and 5-6-membered heterocyclyl. In other such embodiments, R4 is selected from the group consisting of phenyl and 5-6-membered heteroaryl.

[00175] Suitable carbocyclyls for the above embodiments include, for example, cyclopropyl and phenyl.

[00176] Suitable heterocyclyls for the above embodiments include, for example, furanyl, thienyl, and pyridinyl.

[00177] In some embodiments, R4 is selected from the group consisting of halo, alky'l, and alkyloxy.

[00178] In some embodiments, R4 is alkyl.

[00179] In some embodiments, R4 is tert-butyl. B5. Substituent Rs.

[00180] Rs is selected from the group consisting of hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy, alkynyloxy, alkylsulfonyloxy, carbocyclylsulfonyloxy, haloalkylsulfonyloxy, and halo.

[00181] In some embodiments, R5 is selected from the group consisting of hydrogen, hydroxy, alkyloxy, and halo. In some such embodiments, R5 is selected from the group consisting of hydrogen, hydroxy, alkyloxy, and fluoro. In other such embodiments, R5 is selected from the group consisting of hydrogen, hydroxy, alkyloxy, and fluoro. In yet other such embodiments, R5 is selected from the group consisting of hydrogen, hydroxy, alkyloxy, and chloro. In yet other such embodiments, Rs is selected from the group consisting of hydrogen, hydroxy, alkyloxy, and bromo. In further such embodiments, R5 is selected from the group consisting of hydrogen, hydroxy, alkyloxy, and iodo.

[00182] In some embodiments, R5 is selected from the group consisting of hydrogen, hydroxy, methoxy, and halo. In some such embodiments, R5 is selected from the group consisting of hydrogen, hydroxy, methoxy, and fluoro. In other such embodiments, R5 is selected from the group consisting of hydrogen, hydroxy, methoxy, and chloro. In yet other such embodiments, R5 is selected from the group consisting of hydrogen, hydroxy, methoxy, and bromo. In further such embodiments, R5 is selected from the group consisting of hydrogen, hydroxy, methoxy, and iodo.

[00183] In some embodiments, R5 is selected from the group consisting of hydrogen, hydroxy, and alkyloxy. In some such embodiments, R5 is selected from the group consisting of hydrogen, hydroxy, methoxy, and ethoxy.

[00184] In some embodiments, R5 is s hydrogen.

[00185] In some embodiments, R5 is hydroxy.

[00186] In some embodiments, R5 is alkyloxy.

[00187] In some embodiments, R5 is methoxy.

[00188] In some embodiments, R5 is ethoxy. 25 2014280939 24 Dec 2014 B6. Substituent L.

[00189] L is selected from the group consisting of bond, C(RA)=C(RB), C=C, C(0)N(Rc), N(RD)C(0), C,-C2-alkylene, C(H)20, OC(H)2, cyclopropyl- 1,2-ene, C(H)2N(RL), N(RM)C(H)2, C(0)CH2, and CH2C(0), wherein RA, RB, Rc, RD, RL, and RM are as discussed below.

[00190] In some embodiments, L is selected from the group consisting of bond, C(RA)=C(RB), C=C, C(0)N(Rc), N(Rd)C(0), CrC2-alkylene, C(H)20, OC(H)2, cyclopropyl-1,2-ene, C(H)2N(RL), and N(RM)C(H)2.

[00191] In some embodiments, L is selected from the group consisting of C(RA)=C(RB), ethylene, and cyclopropyl-1,2-ene.

[00192] In some embodiments, L is selected from the group consisting of C(RA)=C(RB), C=C, C(0)N(Rc), N(R”)C(0), C,-C2-alkylene, C(H)20, OC(H)2, cyclopropyl-1,2-ene, C(H)2N(RL), N(Rm)C(H)2, C(0)CH2, and CH2C(0).

[00193] In some embodiments, L is selected from the group consisting of C=C, C(0)N(Rc), N(RD)C(0), C(H)20, OC(H)2, C(H)2N(Rl), andN(RM)C(H)2.

[00194] In some embodiments, L is a bond. In these embodiments, the compounds of formula I correspond in structure to formula I-L0:

(I-L0) [00195] In some such embodiments, the compounds correspond in structure to the following formula (i.e. formula IA-L0):

(IA-L0) R4 [00196]In other such embodiments, the compounds correspond in structure to the following formula (i.e. formula IB-L0): 26 R1

I

R6 R5 2014280939 24 Dec 2014 [00197] In some embodiments, L is C(RA)=C(RB), wherein RA and RD are as discussed below. In these embodiments, the compounds of formula I correspond in structure to formula I-Ll: r!

I

R6 [00198] In some such embodiments, the compounds correspond in structure to formula IA-L1:

R1 I

[00199] In other such embodiments, the compounds correspond in structure to formula ÏB-L1: R1

[00200] Typically, the compounds of formula I-Ll are more potent if R° and the phenyl-uracil are on opposite sides of the double bond (i.e., in trans configuration in relation to the double bond).

[00201] In some embodiments, L is C=C. In these embodiments, the compounds of formula I correspond in structure to formula I-L2: 27 R'

R6 2014280939 24 Dec 2014 [00202] In some such embodiments, the compounds correspond in structure to IA-L2: R'

R6 [00203] In other such embodiments, the compounds correspond in structure to formula IB-L2·, R1

R6 [00204] In some embodiments, L is C(0)N(Rc), wherein Rc is as discussed below. In these embodiments, the compounds of formula I correspond in structure to formula I-L3: R1

, R6 N I Rc [00205] In some such embodiments, the compounds correspond in structure to formula IA-L3: 28 2014280939 24 Dec 2014 R1

[00206] In other such embodiments, the compounds correspond in structure to formula IB-L3: R1

x· R6 N I rc [00207] In some embodiments, L is N(RD)C(0), wherein Ru is as discussed below. In these embodiments, the compounds of formula I correspond in structure to formula I-L4: R1

[00208] In some such embodiments, the compounds correspond in structure to formula IA-L4:

[00209] In other such embodiments, the compounds correspond in structure to formula IB-L4: 29 2014280939 24 Dec 2014

[00210] In some embodiments, L is Ci-C2-alkylene. In these embodiments, the compounds of formula I correspond in structure to formula 1-L5-1 (if L is methylene) or I-L5-2 (if L is ethylene):

[00211] In some such embodiments, compounds correspond in structure to formula IA-L5-1 (if L is methylene) or IA-L5-2 (if L is ethylene): R1 R1

! I

[00212] In other such embodiments, the compounds correspond in structure to formula IB-L5-1 (if L is methylene) or IB-L5-2 (if L is ethylene):

[00213J In some embodiments, L is C(H)20. In these embodiments, the compounds of formula I 30 2014280939 24 Dec 2014 correspond in structure to formula I-L6: R1

[00214] In some such embodiments, the compounds correspond in structure to formula IA-L6: R1

[00215] In other such embodiments, the compounds correspond in structure to formula IB-L6: R!

[00216] In some embodiments, L is OC(H)2. In these embodiments, the compounds of formula I correspond in structure to formula I-L7: R1

[00217] In some such embodiments, the compounds correspond in structure to formula IA-L7: 31 2014280939 24 Dec 2014 R'

CR ^R6 R5 [00218) In other such embodiments, the compounds correspond in structure to formula IB-L7: R1

[00219] In some embodiments, L is cyclopropyl-1,2-ene. In these embodiments, the compounds of formula I correspond in structure to formula I-L8: R’

-R6 [00220] In some such embodiments, the compounds correspond in structure to formula IA-L8: R>

R6 [00221] In other such embodiments, the compounds correspond in structure to formula IB-L8: 32 2014280939 24 Dec 2014 R1

R6

R1 I

N I RL

[00224] In some such embodiments, the compounds correspond in structure to formula IA-L9: R1

N I rl [00225]In other such embodiments, the compounds correspond in structure to formula IB-L9: R1

N I rl [00222] In some embodiments, L is selected from the group consisting of C=C, ethylene, and cyclopropyl-1,2-ene.

[00223] In some embodiments, L is C(H)2N(R' ). In these embodiments, the compounds of formula I correspond in structure to formula I-L9: .R6 ,R6 ,R6 33 2014280939 24 Dec 2014

Ri

rm I R5 [00226] In some embodiments, L is N(RM)C(H)2- In these embodiments, the compounds of formula I correspond in structure to formula I-L10: . R6 [00227] In some such embodiments, the compounds correspond in structure to formula IA-L10: R1

rm N' ^R6 R5 [00228] In other such embodiments, the compounds correspond in structure to formula IB-L10: R1

rM

I NL ^R6 R5 [00229] In some embodiments, L is C(0)C(H)2. In these embodiments, the compounds of formula I correspond in structure to formula I-Lll:

Rt I

34 2014280939 24 Dec 2014 [00230] In some such embodiments, the compounds correspond in structure to formula IA-LI1: R.

R6 [00231] In other such embodiments, the compounds correspond in structure to formula 1B-L11: R,

R6 [00232] In some embodiments, L is C(H)2C(0). In these embodiments, the compounds of formula I correspond in structure to formula I-L12:

R1 I

R6 [0Ö233] In some such embodiments, the compounds correspond in structure to formula IA-L12:

R6 [00234] In other such embodiments, the compounds correspond in structure to formula IB-L12: 35 *1

I

2014280939 24 Dec 2014 B7. Substituents R4 andRB.

[00235] RA and RB are independently selected from the group consisting of hydrogen, Ci-C6-alkyl, Cr C6-alkyloxy, C3-C8-cycloalkyl, and halo, wherein: the CrC6-alkyl optionally is substituted with one or more substituents independently selected from the group consisting of carboxy, halo, hydroxy, nitro, oxo, amino, cyano, al kyloxycarbonyl, alkylcarbonyloxy, alkyloxy, carbocyclyl, and heterocyclyl.

[00236] In some embodiments, one of RA and R® is hydrogen, and the other is selected from the group consisting of Ci-C6-alkyl, Ci-C6-alkyloxy, C3-C8-cycloalkyl, and halo, wherein: the CpQ-alkyl optionally is substituted with one or more substituents independently selected from the group consisting of carboxy, halo, hydroxy, nitro, oxo, amino, cyano, alkyloxycarbonyl, alkylcarbonyloxy, alkyloxy, carbocyclyl, and heterocyclyl, [00237] In some embodiments, RA and RB are independently selected from the group consisting of hydrogen, CrC6-alkyl, CrC6-alkyloxy, C3-Cs-cycloalkyl, and halo.

[00238] In some of the above embodiments, RA is hydrogen. In other of the above embodiments, R0 is hydrogen.

[00239] In some embodiment, one of RA and RB is hydrogen, and the other is selected from the group consisting of hydrogen, methyl, methoxy, and halo.

[00240] In some embodiments, RA is hydrogen, and RB is selected from the group consisting of methyl, methoxy, and halo. In some such embodiments, RB is selected from the group consisting of methyl, methoxy, and fluoro. In other such embodiments, R0 is selected from the group consisting of methyl, methoxy, and chloro. In yet other such embodiments, R0 is selected from the group consisting of methyl, methoxy, and bromo. In further such embodiments, R8 is selected from the group consisting of methyl, methoxy, and iodo. In yet further such embodiments, RB is selected from the group consisting of methyl, methoxy, chloro, and fluoro.

[00241] In some embod iments, R0 is hydrogen, and RA is selected from the group consisting of methyl, methoxy, and halo. In some such embodiments, RA is selected from the group consisting of methyl, methoxy, and fluoro. In other such embodiments, RA is selected from the group consisting of methyl, 36 2014280939 24 Dec 2014 methoxy, and chloro. In yet other such embodiments, RA is selected from the group consisting of methyl, methoxy, and bromo. In further such embodiments, RA is selected from the group consisting of methyl, methoxy, and iodo. In yet further such embodiments, RA is selected from the group consisting of methyl, methoxy, chloro, and fluoro.

[00242] In some embodiments, RA is hydrogen, and RB is hydrogen. B8. Substituent Rc.

[00243] Rc is selected from the group consisting of hydrogen and alkyl. In some such embodiments, Rc is selected from the group consisting of hydrogen and methyl.

[00244] In some embodiments, Rc is hydrogen.

[00245] hi some embodiments, Rc is alkyl. In some such embodiments, Rc is methyl. B9. Substituent R°.

[00246] Rd is selected from the group consisting of hydrogen and alkyl. In some such embodiments, RD is selected from the group consisting of hydrogen and methyl.

[00247] In some embodiments, RD is hydrogen.

[00248] In some embodiments, RD is alkyl. In some such embodiments, RD is methyl. B10. Substituent RL.

[00249] Rl is selected from the group consisting of hydrogen, Ci-C6-alkyl, CrC6-alkyloxy, C3-C8-cycloalkyl, and halo, wherein: the Ci-Cf,-alkyl optionally is substituted with one or more substituents independently selected from the group consisting of carboxy, halo, hydroxy, nitro, oxo, amino, cyano, alkyloxycarbonyl, alkylcarbonyloxy, alkyloxy, carbocyclyl, and heterocyclyl.

[00250] In some embodiments, Rl is selected from the group consisting of hydrogen, Ci-C6-alkyl, Cj-Ce-alkyloxy, C3-C8-cycloalkyl, and halo.

[00251] In some embodiments, RL is selected from the group consisting of hydrogen, Ci-Cé-alkyl, CrC6-alkyloxy, and halo, wherein: the Ci-C6-alkyl optionally is substituted with one or more substituents independently selected from the group consisting of carboxy, halo, hydroxy, nitro, oxo, amino, cyano, alkyloxycarbonyl, alkylcarbonyloxy, alkyloxy, carbocyclyl, and heterocyclyl.

[00252] In some embodiments, RL is selected from the group consisting of hydrogen, CrC6-aikyl, CrCV alkyloxy, and halo.

[00253] In some of the above embodiments, RL is halo. In some such embodiments, the halo is fluoro. In other such embodiments, the halo is chloro. In yet other such embodiments, the halo is bromo. In further such embodiments, the halo is iodo. 37 2014280939 24 Dec 2014 [00254] In some of the above embodiments, RL is hydrogen.

[00255] In some of the above embodiments, RL is Ci-Cg-alkyl.

[00256] In some of the above embodiments, RL is C|-C6-alkyloxy.

Bll. Substituent RM.

[00257] Rm is selected from the group consisting of hydrogen, Ci-Có-alkyl, CrC(,-alkyloxy, C3-Cs-cycloalkyl, and halo, wherein: the Ci-C6-alkyl optionally is substituted with one or more substituents independently selected from the group consisting of carboxy, halo, hydroxy, nitro, oxo, amino, cyano, alkyloxycarbonyl, alkylcarbonyloxy, alkyloxy, carbocyclyl, and heterocyclyl.

[00258] In some embodiments, RM is selected from the group consisting of hydrogen, CrQ-alkyl, Ci-Ce-alkyloxy, C3-C8-cycloalkyl, and halo.

[00259] In some embodiments, RM is selected from the group consisting of hydrogen, Ci-Cö-alkyl, CrQ-alkyloxy, and halo, wherein: the Ci-C6-alkyl optionally is substituted with one or more substituents independently selected from the group consisting of carboxy, halo, hydroxy, nitro, oxo, amino, cyano, alkyloxycarbonyl, alkylcarbonyloxy, alkyloxy, carbocyclyl, and heterocyclyl.

[00260] In some embodiments, RM is selected from the group consisting of hydrogen, CrC6-alkyl, CpCe-alkyloxy, and halo.

[00261] In some of the above embodiments, RM is halo. In some such embodiments, the halo is fluoro.

In other such embodiments, the halo is chloro. In yet other such embodiments, the halo is bromo. In further such embodiments, the halo is iodo.

[00262] In some of the above embodiments, RM is hydrogen.

[00263] In some of the above embodiments, RM is Cj-Q-alkyl.

[00264] In some of the above embodiments, RM is Ci-C6-alkyloxy. B12. Substituent R6.

[00265] R6 is selected from the group consisting of C5-C6-carbocyclyl, 5-6-membered heterocyclyl, fused 2-ring carbocyclyl, and fused 2-ring heterocyclyl, wherein each such substituent optionally is substituted with one or more substituents independently selected from the group consisting of RE, RF, RG, RH, R1, RJ, and RK, wherein RE, RF, RG, RH, R1, RJ, and RK are as described below. In some such embodiments, the C5-C6-carbocyclyl, 5-6-membered heterocyclyl, fused 2-ring carbocyclyl, and fused 2-ring heterocyclyl are not substituted. In other such embodiments, the C5-C6-carbocyclyl, 5-6-membered heterocyclyl, fused 2-ring carbocyclyl, and fused 2-ring heterocyclyl are substituted with a substituent selected from the group consisting of RE, RF, RG, R51. R1, RJ, and RK. In other such embodiments, the 38 2014280939 24 Dec 2014 C5-C6-carbocyclyl, 5-6-membered heterocyclyl, fused 2-ring carbocyclyl, and fused 2-ring heterocyclyl are substituted with a substituent selected from the group consisting of RE, RF, R1, RJ, and RK. In other such embodiments, the C5-C6-carbocyclyl, 5-6-membered heterocyclyl, fused 2-ring carbocyclyl, and fused 2-ring heterocyclyl are substituted with a substituent selected from the group consisting of RE, RF, and RJ. In other such embodiments, the C5-C6-carbocyclyl, 5-6-membered heterocyclyl, fused 2-ring carbocyclyl, and fused 2-ring heterocyclyl are substituted with a substituent selected from the group consisting of Rr and RJ. In other such embodiments, the Cs-C6-carbocyclyl, 5-6-membered heterocyclyl, fused 2-ring carbocyclyl, and fused 2-ring heterocyclyl are substituted with RJ. In yet other such embodiments, the Cs-Q-carbocyclyl, 5-6-membered heterocyclyl, fused 2-ring carbocyclyl, and fused 2-ring heterocyclyl are substituted with two substituents independently selected from the group consisting of Re, Rf, Rg, Rh, R(. Rj, and RK. In yet other such embodiments, the Cs-Ce-carbocycIyl, 5-6-membered heterocyclyl, fused 2-ring carbocyclyl, and fused 2-ring heterocyclyl are substituted with two substituents independently selected from the group consisting of RE, RF, R1, RJ, and RK In yet other such embodiments, the C5-C6-carbocyclyl, 5-6-membered heterocyclyl, fused 2-ring carbocyclyl, and fused 2-ring heterocyclyl are substituted with two substituents independently selected from the group consisting of Re, Rf, and RJ, In yet other such embodiments, the C5-C6-carbocyclyl, 5-6-membered heterocyclyl, fused 2-ring carbocyclyl, and fused 2-ring heterocyclyl are substituted with two substituents independently selected from the group consisting of Rf and RJ. In further such embodiments, the C5-C6-carbocyclyl, 5-6-membered heterocyclyl, fused 2-ring carbocyclyl, and fused 2-ring heterocyclyl are substituted with three substituents independently selected from the group consisting of RE, RF, Rc, RfI, R1, RJ, and RK. In further such embodiments, the C5-C6-carbocyclyl, 5-6-membered heterocyclyl, fused 2-ring carbocyclyl, and fused 2-ring heterocyclyl are substituted with three substituents independently selected from the group consisting of RE, RF, R1, RJ, and RK. In further such embodiments, the Cs-C6-carbocyclyl, 5-6-membered heterocyclyl, fused 2-ring carbocyclyl, and fused 2-ring heterocyclyl are substituted with three substituents independently selected from the group consisting of RE, RF, and RJ. In further such embodiments, the C5-C6-carbocyclyl, 5-6-membered heterocyclyl, fused 2-ring carbocyclyl, and fused 2-ring heterocyclyl are substituted with three substituents independently selected from the group consisting of R1' and RJ. In further such embodiments, the C5-C6-carbocyclyl, 5-6-membered heterocyclyl, fused 2-ring carbocyclyl, and fused 2-ring heterocyclyl are substituted with one, two, or three substituents independently selected from the group consisting of RE, RF, RG, RH, R1, RJ, and RK In further such embodiments, the Cs-Ce-carbocyclyl, 5-6-membered heterocyclyl, fused 2-ring carbocyclyl, and fused 2-ring heterocyclyl are substituted with one, two, or three substituents independently selected from the group consisting of RE, RF, R1, RJ, and RK. In further such embodiments, the C5-C6-carbocyclyl, 5-6-membered heterocyclyl, fused 2-ring carbocyclyl, and fused 2-ring heterocyclyl are 39 2014280939 24 Dec 2014 substituted with one, two, or three substituents independently selected from the group consisting of RE,

Rf, and RJ. In further such embodiments, the C5-C6-carbocyclyl, 5-6-membered heterocyclyl, fused 2-ring carbocyclyl, and fused 2-ring heterocyclyl are substituted with one, two, or three substituents independently selected from the group consisting of RF and RJ.

[00266] In some embodiments, R6 is selected from the group consisting of C5-C6~carbocyclyl and 5-6-membered heterocyclyl, wherein each such substituent optionally is substituted with one or more substituents independently selected from the group consisting of RE, R1', RG, Rn, R1, RJ, and RK. In some such embodiments, the Cs-C6-carbocyclyl and 5-6-membered heterocyclyl are not substituted. In other such embodiments, the Cs-C6-carbocyc]yi and 5-6-membered heterocyclyl are substituted with a substituent selected from the group consisting of RE, RF, Rt:, RH, R1, RJ, and RK. In yet other such embodiments, the C5-C6-carbocyclyl and 5-6-membered heterocyclyl are substituted with two substituents independently selected from the group consisting of RE, R1, RG, RH, R1, RJ, and RK. In further such embodiments, the C5-C6-carbocyclyI and 5-6-membered heterocyclyl are substituted with three substituents independently selected from the group consisting of RE, RF, RG, RH, R1, RJ, and RK. In further such embodiments, the C5-C6-carbocyclyl and 5-6-membered heterocyclyl are substituted with one, two, or three substituents independently selected from the group consisting of RE, R1, RG, RH, R1, RJ, and RK.

[00267] In some embodiments, R' is C5-C6-carbocyclyl optionally substituted with one or more substituents independently selected from the group consisting of RE, RF, RG, RH, R1, R1, and RK. In some such embodiments, the C5-C6-carbocyclyl is not substituted. In other such embodiments, the C5-C6-carbocyclyl is substituted with a substituent selected from the group consisting of R1 RF, RG, RH, R1, RJ, and RK. In yet other such embodiments, the C5-C6-carbocyclyl is substituted with two substituents independently selected from the group consisting of RE, RF, RG, R11, R!, RJ, and RK. In further such embodiments, the C5-C6-carbocyclyl is substituted with three substituents independently selected from the group consisting of RE, Rr, RG, RH, R1, RJ, and RK. In further such embodiments, the C5-C6-carbocyclyl is substituted with one, two, or three substituents independently selected from the group consisting of RE, Rf, Rg, Rh, R1, R’, and RK.

[00268] In some embodiments, Re is 5-6-membered heterocyclyl optionally substituted with one or more substituents independently selected from the group consisting of RE, RF, Rc, RH, R1, RJ, and RK. In some such embodiments, the 5-6-membered heterocyclyl is not substituted. In other such embodiments, the 5-6-membered heterocyclyl is substituted with a substituent selected from the group consisting of RE, Rf, Rg, Rh, R1, Rj, and RK. In yet other such embodiments, the 5-6-membered heterocyclyl is substituted with two substituents independently selected from the group consisting of RE, RF, RG, R11, R1, RJ, and RK. In further such embodiments, the 5-6-membered heterocyclyl is substituted with three 40 2014280939 24 Dec 2014 substituents independently selected from the group consisting of RE, Rr, RG, RH, R1, R1, and RK. In further such embodiments, the 5-6-membered heterocyclyl is substituted with one, two, or three substituents independently selected from the group consisting of RE, RF, RG, RH, R1, RJ, and RK.

[00269] In some embodiments, R6 is selected from the group consisting of fused 2-ring carbocyclyl and fused 2-ring heterocyclyl, wherein each such substituent optionally is substituted with one or more substituents independently selected from the group consisting of RE, RF, Rc, RH, R1, RJ, and RK. In some such embodiments, the fused 2-ring carbocyclyl and fused 2-ring heterocyclyl are not substituted.

In other such embodiments, the fused 2-ring carbocyclyl and fused 2-ring heterocyclyl are substituted with a substituent selected from the group consisting of RE, RF, Rc, RH, R1, RJ, and RK. In yet other such embodiments, the fused 2-ring carbocyclyl and fused 2-ring heterocyclyl are substituted with two substituents independently selected from the group consisting of RE, RF, RG, RH, R1, RJ, and RK. In further such embodiments, the fused 2-ring carbocyclyl and fused 2-ring heterocyclyl are substituted with three substituents independently selected from the group consisting of RE, RF, RG, RH, R1, RJ, and RK. In further such embodiments, the fused 2-ring carbocyclyl and fused 2-ring heterocyclyl are substituted with one, two, or three substituents independently selected from the group consisting of RE, RF, RG, R11, R1, RJ, and RK.

[00270] In some embodiments, R6 is fused 2-ring carbocyclyl optionally substituted with one or more substituents independently selected from the group consisting of RE, RF, Rc, RH, R1, RJ, and RK. In some such embodiments, the fused 2-ring carbocyclyl is not substituted. In other such embodiments, the fused 2-ring carbocyclyl is substituted with a substituent selected from the group consisting of RE, RF,

Rg, Rh, R1, Rj, and RK. In yet other such embodiments, the fused 2-ring carbocyclyl is substituted with two substituents independently selected from the group consisting of Rr, R' RG, RH, R1, RJ, and RK. In further such embodiments, the fused 2-ring carbocyclyl is substituted with three substituents independently selected from the group consisting of RF', RF, RG, R11, R1, RJ, and RK. In further such embodiments, the fused 2-ring carbocyclyl is substituted with one, two, or three substituents independently selected from the group consisting of RE, RF, RG, RH, R1, RJ, and RK.

[00271] In some embodiments, R6 is fused 2-ring heterocyclyl optionally substituted with one or more substituents independently selected from the group consisting of RE, RF, RG, RH, R1, RJ, and RK. In some such embodiments, the fused 2-ring heterocyclyl is not substituted. In other such embodiments, the fused 2-ring heterocyclyl is substituted with a substituent selected from the group consisting of RE, RF, Rg, Rh, R1, Rj, and RK. In yet other such embodiments, the fused 2-ring heterocyclyl is substituted with two substituents independently selected from the group consisting of RE, RF, RG, RH, R1, R1, and RK. In further such embodiments, the fused 2-ring heterocyclyl is substituted with three substituents independently selected from the group consisting of RE, RF, RG, R11, R1, RJ, and RK. In further such 41 2014280939 24 Dec 2014 embodiments, the fused 2-ring heterocyclyl is substituted with one, two, or three substituents independently selected from the group consisting of RE, RF, RG, RH, R1, RJ, and RK.

[00272] In some of the above embodiments, the optionally substituted Cs-Q-carbocyclyl is selected from the group consisting of cyclopentyl, cyclopentenyl, cyclopentadienyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, and phenyl. In some such embodiments, the optionally substituted C5-C6-carbocyclyl is phenyl.

[00273] In some of the above embodiments, the optionally substituted C5-C6-carbocyclyl is C5-carbocyclyl. Examples of C5-carbocyclyls include cyclopentyl, cyclopentenyl, and cyclopentadienyl.

[00274] In other of the above embodiments, the optionally substituted C5-C<s-carbocyclyl is C6-carbocyclyl. Examples of C6-carbocyclyls include cyclohexyl, cyclohexenyl, cyclohexadienyl, and phenyl.

[00275] In some of the above embodiments, the optionally substituted 5-6-membered-heterocyclyl is selected from the group consisting of furanyl, dihydrofuranyl, tetrahydrofiiranyl, thiophenyl (thiofuranyl), dihydrothiopheny 1, tetrahydrothiophenyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, oxazolyl, dihydrooxazolyl, isoxazolyl, dihydroisoxazolyl, oxazolidinyl, isoxazolidinyl, thiazolyl, isothiazolyl, thiazolinyl, isothiazolinyl, thiazolidinyl, isothiazolidinyl, imidazolyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, oxathiolyl, oxathiolanyl, triazolyl, oxadiazolyl, furazanyl, tetrazolyl, oxatriazolyl, dioxazolyl, oxathiazolyl, oxathiazolidinyl, dihydrooxadiazolyl, dioxazolidinyl, pyranyl, dihydropyranyl, tetrahydropyranyl, pyridinyl, dihydropyridinyl, tetrahydropyridinyl, piperidinyl, diazinyl, pyrazinyl, pyridazinyl, pyrimidinyl, dihydropyrazinyl, tetrahydropyrazinyl, piperazinyl, triazinyl, dihydrotriazinyl, tetrahydrotriazinyl, triazinanyl, oxazinyl, dihydrooxazinyl, morpholinyl, oxathiazinyl, dihydrooxathiazinyl, oxathiazinanyl, oxadiazinyl, dihydrooxadiazinyl, oxadiazinanyl, thiopyranyl, dihydrothiopyranyl, and tetrahydrothiopyranyl.

[00276] In some of the above embodiments, the optionally substituted 5-6-membered-heterocyclyl is 5-membered heterocyclyl. Examples of such 5-membered heterocyclyl include furanyl, dihydrofuranyl, tetrahydrofuranyl, thiophenyl (thiofuranyl), dihydrothiophenyl, tetrahydrothiophenyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, oxazolyl, dihydrooxazolyl, isoxazolyl, dihydroisoxazolyl, oxazolidinyl, isoxazolidinyl, thiazolyl, isothiazolyl, thiazolinyl, isothiazolinyl, thiazolidinyl, isothiazolidinyl, imidazolyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, oxathiolyl, oxathiolanyl, triazolyl, oxadiazolyl, furazanyl, tetrazolyl, oxatriazolyl, dioxazolyl, oxathiazolyl, oxathiazolidinyl, dihydrooxadiazolyl, and dioxazolidinyl.

[00277] In other of the above embodiments, the optionally substituted 5-6-membered-heterocyclyl is 6-membered heterocyclyl. Examples of 6-membered heterocyclyls include pyranyl, dihydropyranyl, tetrahydropyranyl, pyridinyl, dihydropyridinyl, tetrahydropyridinyl, piperidinyl, diazinyl, pyrazinyl, 42 2014280939 24 Dec 2014 pyridazinyl, pyrimidinyl, dihydropyrazinyl, tetrahydropyrazinyl, piperazinyl, triazinyl, dihydrotriazinyl, tetrahydrotriazinyl, triazinanyl, oxazinyl, dihydrooxazinyl, morpholinyl, oxathiazinyl, dihydrooxathiazinyl, oxathiazinanyl, oxadiazinyl, dihydrooxadiazinyl, oxadiazinanyl, thiopyranyl, dihydrothiopyranyl, and tetrahydrothiopyranyl.

[00278] In some of the above embodiments, the optionally substituted fused 2-ring carbocyclyl is selected from the group consisting of naphthalenyl, dihydronaphthalenyl, tetrahydronaphthalenyl, hexahydronaphthalenyl, octahydronaphthalenyl, decahydronaphthalenyl, indenyl, dihydroindenyl, hexahydroindenyl, octahydroindenyl, pentalenyl, octahydropentalenyl, and hexahydropentalenyl. In some such embodiments, the optionally substituted fused 2-ring carbocyclyl is selected from the group consisting of naphthalenyl and dihydroindenyl. In some such embodiments, the optionally substituted fused 2-ring carbocyclyl is naphthalenyl. In other such embodiments, the optionally substituted fused 2-ring carbocyclyl is dihydroindenyl. In further such embodiments, the optionally substituted fused 2-ring carbocyclyl is indenyl.

[00279] In some of the above embodiments, the optionally substituted fused 2-ring heterocyclyl is selected from the group consisting of

43 2014280939 24 Dec 2014

X1, X2, and X3 are independently selected from the group consisting of N and C(H); X4 is selected from the group consisting of N(H), O, and S;

Xs, X6, and X7 are independently selected from the group consisting of N and C(H);

Xs is selected from the group consisting of N(H), O, and S; X9 is selected from the group consisting of N(H), O, and S; X10, Xn, X12, and X13 are independently selected from the group consisting of N and C(H); X14 is selected from the group consisting of N(H), O, and S; X15, X16, X17, and X18 are independently selected from the group consisting of N and C(H); one or more of X19, X20, and X21 is N, and the remaining one(s) is/are C(H); one or more of X22, X23, X24, and X25 is N, and the remaining one(s) is/are C(H); one or more of X2S, X27, and X2S is N, and the remaining one(s) is/are C(H); one or more of X29, X3n, X31, and X32 is N, and the remaining one(s) is/are C(H); one or more of X33, X34, and X35 is N, and the remaining one(s) is/are C(H); one or more of X36, X37, X3S, and X39 is N, and the remaining one(s) is/are C(H); X40, X41, and X42 are independently selected from the group consisting of N and C(H); one of X43, X44, and X4S is selected from the group consisting of N(H), O, and S, and the 44 2014280939 24 Dec 2014 remaining two are 0(1¾ one of X46 and X47 is selected from the group consisting ofN(H), O, and S, and the other one is C(H)2; X48, X49, Xs0, and X51 are independently selected from the group consisting of N and C(H); X52, X53, and X54 are independently selected from the group consisting of N and C(H);

Xs5 is selected from the group consisting of N(H), O, and S; X56, X57, and X58 are independently selected from the group consisting of N and C(H); X59 is selected from the group consisting of N(H), O, and S; X60 is selected from the group consisting of N(H), O, and S; X61, X62, X63, and X64 are independently selected from the group consisting of N and C(H); χ65 is selected from the group consisting of N(H), O, and S; X66, X67, X68, and X69 are independently selected from the group consisting of N and C(H); one or more of X70, X71, and X72 is N, and the remaining one(s) is/are C(H); one or more of X73, X74, X7S, and X76 is N, and the remaining one(s) is/are C(H); and one of X77 and X78 is N(H), and the remaining one is C(H)2.

[00280] In some of the above embodiments, the optionally substituted fused 2-ring heterocyclyl is selected from the group consisting of

45 2014280939 24 Dec 2014

(Hl 2) 9

[00281] In some of the above embodiments, the optionally substituted fused 2-ring heterocyclyl is selected from the group consisting of:

(H20) 46 2014280939 24 Dec 2014 [00282] In some of the above embodiments, X1, X2, and X3 are C(H), [00283] In some of the above embodiments, Xs, X6, and X7 are C(H).

[00284] In some of the above embodiments, X10, Xn, X12, and X13 are C(H).

[00285] In some of the above embodiments, X15, X16, X17, and X18 are C(H).

[00286] In some of the above embodiments, one of X19, X20, and X21 is N.

[00287] In some of the above embodiments, one of X22, X23, X24, and X25 is N.

[00288] In some of the above embodiments, one of X26, X27, and X28 is N, and one of X29, X30, X31, and X32 is N.

[00289] In some of the above embodiments, X40, X41, and X42 are C(H).

[00290] In some of the above embodiments, X48, X49, X50, and X51 are C(H).

[00291] In some of the above embodiments, X52, Xs3, and X54 are C(H). 100292] In some of the above embodiments, X56, X57, and X58 are C(H).

[00293] In some of the above embodiments, X61, X62, X63, and X64 are C(H).

[00294] In some of the above embodiments, X66, X67, X68, and X69 are C(H).

[00295] In some of the above embodiments, one or more of X7ft, X71, and X72 is N, and the remaining one(s) is/are C(H).

[00296] In some of the above embodiments, one or more of X73, X74, X75, and X76 is N, and the remaining one(s) is/are C(H). B13. Substituent Re.

[00297] Each RE is independently selected from the group consisting of halo, nitro, hydroxy, oxo, carboxy, cyano, amino, imino, azido, and aldehydo, wherein the amino optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, and alkynyl.

[00298] In some embodiment, each RE is independently selected from the group consisting of halo, nitro, hydroxy, oxo, carboxy, amino, imino, and aldehydo, wherein the amino optionally is substituted with one or two independently selected alkyl.

[00299] In some embodiment, each RE is independently selected from the group consisting of halo, nitro, hydroxy, oxo, carboxy, amino, imino, aldehydo, and alkylamino.

[00300] In some embodiment, each RE is independently selected from the group consisting of chloro, fluoro, nitro, hydroxy, oxo, carboxy, amino, imino, aldehydo, and alkylamino.

[00301] In some embodiment, each RE is independently selected from the group consisting of halo, nitro, hydroxy, oxo, carboxy, cyano, amino, imino, and azido. In some such embodiments, each RE is halo. In other such embodiments, each RE is nitro. In yet other such embodiments, each RE is hydroxy. In yet other such embodiments, each RE is oxo. In yet other such embodiments, each RE is carboxy. In yet other such embodiments, each RE is cyano. In yet other such embodiments, each RE is amino. In further 47 2014280939 24 Dec 2014 such embodiments, each RE is imino. In yet further such embodiments, each RE is and azido.

[00302] In some embodiments, each RE is independently selected from the group consisting of halo, nitro, hydroxy, oxo, carboxy, cyano, amino, and imino. B14, Substituent RF.

[00303] Each RF is independently selected from the group consisting of alkyl, alkenyl, and alkynyl, wherein: each such substituent optionally is substituted with one or more substituents independently selected from the group consisting of carboxy, hydroxy, halo, amino, imino, nitro, azido, oxo, aminosulfonyl, alkylsulfonyl, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, alkyloxy, alkenyloxy, alkynyloxy, carbocyclyl, heterocyclyl, cyano, and ami nocarbonyl, wherein: the amino, imino, aminosulfonyl, aminocarbonyl, carbocyclyl, and heterocyclyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, alkylsulfonylamino, hydroxy, and alkyloxy, wherein: amino portion of the alkylsulfonylamino optionally is substituted with a substituent selected from the group consisting of alkyl, alkenyl, and alkynyl.

[00304] In some embodiment, each RF is independently selected from the group consisting of alkyl, alkenyl, and alkynyl, wherein: each such substituent optionally is substituted with one or more substituents independently selected from the group consisting of carboxy, hydroxy, halo, amino, imino, nitro, azido, oxo, aminosulfonyl, alkylsulfonyl, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, alkyloxy, alkenyloxy, alkynyloxy, carbocyclyl, heterocyclyl, cyano, and aminocarbonyl, wherein: the amino, imino, aminosulfonyl, and aminocarbonyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, and alkylsulfonylamino, wherein: amino portion of the alkylsulfonylamino optionally is substituted with a substituent selected from the group consisting of alkyl, alkenyl, and alkynyl.

[00305] In some of the above embodiments, each RF is independently selected from the group consisting of the alkyl, alkynyl, and alkynyl, wherein such substituents are not substituted.

[00306] In some embodiments, each RF is independently selected from the group consisting of alkyl, 48 2014280939 24 Dec 2014 alkenyl, and alkynyl, wherein: each such substituent optionally is substituted with one or two substituents independently selected from the group consisting of carboxy, hydroxy, halo, amino, imino, nitro, oxo, aminosulfonyl, alkylsulfonyl, alkyloxycarbonyl, alkylcarbonyloxy, alkyloxy, carbocyclyl, heterocyclyl, cyano, and aminocarbonyl, wherein: the amino, imino, aminosulfonyl, and aminocarbonyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, alkylsulfonyl, and alkylsulfonylamino, wherein: amino portion of the alkylsulfonylamino optionally is substituted with alkyl.

[00307] In some embodiments, each RF is an independently selected alkyl optionally substituted with a substituent selected from the group consisting of carboxy, hydroxy, halo, amino, imino, nitro, oxo, aminosulfonyl, alkylsulfonyl, alkyloxycarbonyl, alkylcarbonyloxy, alkyloxy, carbocyclyl, heterocyclyl, cyano, and aminocarbonyl, wherein: the amino, imino, aminosulfonyl, and aminocarbonyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, alkylsulfonyl, and alkylsulfonylamino, wherein: amino portion of the alkylsulfonylamino optionally is substituted with alkyl.

[00308] In some embodiments, each RF is an independently selected alkyl optionally substituted with a substituent selected from the group consisting of carboxy, halo, amino, imino, and aminosulfonyl, wherein: the amino, imino, and aminosulfonyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, alkylsulfonyl, and alkylsulfonylamino.

[00309] In some embodiments, each RF is an independently selected alkyl optionally substituted with amino, wherein the amino optionally is substituted with alkylsulfonyl.

[00310] In some embodiments, each RF is an independently selected alkyl substituted with amino, wherein the amino is substituted with alkylsulfonyl. In some such embodiments, each RF is methylsulfonylaminomethyl.

[00311] In some embodiments, each RF is independently selected from the group consisting of alkyl, alkenyl, and alkynyl, wherein: each such substituent optionally is substituted with one, two, or three substituents independently selected from the group consisting of carboxy, hydroxy, halo, amino, imino, nitro, 49 2014280939 24 Dec 2014 azido, oxo, aminosulfonyl, alkylsulfonyl, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, alkyloxy, alkenyloxy, alkynyloxy, carbocyclyl, heterocyclyl, cyano, and aminocarbonyl.

[00312] In some embodiments, each RF is independently selected alkyl substituted with one or more substituents independently selected from the group consisting of carboxy, hydroxy, halo, amino, imino, nitro, azido, oxo, aminosulfonyl, alkylsulfonyl, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, alkyloxy, alkenyloxy, alkynyloxy, carbocyclyl, heterocyclyl, cyano, and aminocarbonyl. B15. Substituent Rc.

[00313] Each RG is independently selected from the group consisting of carbocyclyl and heterocyclyl, wherein: each such substituent optionally is substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, carboxy, hydroxy, halo, amino, nitro, azido, oxo, aminosulfonyl, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, alkyloxy, alkenyloxy, alkynyloxy, carbocyclyl, heterocyclyl, cyano, and aminocarbonyl, wherein: the amino, aminosulfonyl, and aminocarbonyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkylsulfonyl, alkenylsulfonyl, and alkynylsulfonyl.

[00314] In some of the above embodiments, each RG is independently selected from the group consisting of carbocyclyl and heterocyclyl, wherein such substituents are not substituted.

[00315] In some embodiments, each Rc is independently selected from the group consisting of carbocyclyl and heterocyclyl, wherein: each such substituent optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, carboxy, hydroxy, halo, amino, nitro, oxo, aminosulfonyl, alkyloxycarbonyl, alkylcarbonyloxy, alkyloxy, carbocyclyl, heterocyclyl, cyano, and aminocarbonyl, wherein: the amino, aminosulfonyl, and aminocarbonyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl and alkylsulfonyl.

[00316] In some of the above embodiments, the carbocyclyl is C3-C6-carbocyclyl.

[00317] In some of the above embodiments, the heterocyclyl is 5-6-membered heterocyclyl. 50 2014280939 24 Dec 2014 BI6. Substituent RH.

[00318J Each RH is independently selected from the group consisting of alkyloxy, alkenyloxy, alkynyloxy, alkylsulfonyloxy, alkenylsulfonyloxy, and alkynylsulfonyloxy, wherein: each such substituent optionally is substituted with one or more substituents independently selected from the group consisting of carboxy, hydroxy, halo, amino, nitro, azido, oxo, aminosulfonyl, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxyearbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, alkyloxy, alkenyloxy, alkynyloxy', carbocyclyl, heterocyclyl, cyano, and aminocarbonyl, wherein: the amino, aminosulfonyl, and aminocarbonyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkylsulfonyl, alkenylsulfonyl, and alkynylsulfonyl.

[00319] In some of the above embodiments, each RH is independently selected from the group consisting of alkyloxy, alkenyloxy, alkynyloxy, alkylsulfonyloxy, alkenylsulfonyloxy, and alkynylsulfonyloxy, wherein such substituents are not substituted.

[00320] In some embodiments, each RH is independently selected from the group consisting of alkyloxy and alkylsulfonyloxy, wherein: each such substituent optionally is substituted with one or two substituents independently selected from the group consisting of carboxy, hydroxy, halo, amino, nitro, oxo, aminosulfonyl, alkyloxycarbonyl, alkylcarbonyloxy, alkyloxy, carbocyclyl, heterocyclyl, cyano, and aminocarbonyl, wherein: the amino, aminosulfonyl, and aminocarbonyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl and alkylsulfonyl.

[00321] In some embodiments, each RH is independently selected from the group consisting of alkyloxy and alkylsulfonyloxy, wherein: each such substituent optionally is substituted with one or two substituents independently selected from the group consisting of carboxy, hydroxy, halo, amino, nitro, oxo, aminosulfonyl, alkyloxycarbonyl, alkylcarbonyloxy, alkyloxy, cyano, and aminocarbonyl, wherein: the amino, aminosulfonyl, and aminocarbonyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl and alkylsulfonyl.

[00322] In some embodiments, each RH is independently selected from the group consisting of alkyloxy and alkylsulfonyloxy, wherein: each such substituent optionally is substituted with one or two substituents 51 2014280939 24 Dec 2014 independently selected from the group consisting of carboxy, hydroxy, halo, amino, nitro, oxo, aminosulfonyl, alkyloxyearbonyl, alkylcarbonyloxy, alkyloxy, cyano, and aminocarbonyl.

[00323] In some embodiments, each R11 is independently selected alkyloxy.

[00324] In some embodiments, each RH is independently selected alkylsulfonyloxy. BI7. Substituent R1 [00325] Each R1 is independently selected from the group consisting of alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, aminocarbonyl, alkyloxyearbonyl, carbocyclylcarbonyl, and heterocyclylcarbonyl, wherein: (a) the alkylcarbonyl, alkenylcarbonyl, and alkynylcarbonyl optionally are substituted with one or more substituents independently selected from the group consisting of carboxy, hydroxy, halo, amino, nitro, azido, oxo, aminosulfonyl, alkyloxyearbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, alkyloxy, alkenyloxy, alkynyloxy, carbocyclyl, heterocyclyl, cyano, and aminocarbonyl, and (b) the aminocarbonyl optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkyloxyalkyl, carbocyclyl, heterocyclyl, alkylsulfonyl, and alkylsulfonylamino, wherein: the carbocyclyl and heterocyclyl optionally are substituted with one or two substituents independently selected from the group consisting of halo, alkyl, and oxo.

[00326] In some embodiments, each R1 is independently selected from the group consisting of alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, aminocarbonyl, alkyloxyearbonyl, carbocyclylcarbonyl, and heterocyclylcarbonyl, wherein such substituents are not substituted.

[00327] In some embodiments, each R1 is independently selected from the group consisting of alkylcarbonyl, aminocarbonyl, alkyloxyearbonyl, carbocyclylcarbonyl, and heterocyclylcarbonyl, wherein: (a) the alkylcarbonyl optionally is substituted with a substituent selected from the group consisting of carboxy, hydroxy, halo, amino, nitro, oxo, aminosulfonyl, alkyloxyearbonyl, alkylcarbonyloxy, alkyloxy, and aminocarbonyl, and (b) the aminocarbonyl optionally is substituted with a substituent selected from the group consisting of alkyl, alkyloxyalkyl, alkylsulfonyl, and alkylsulfonylamino.

[00328] In some embodiments, each R1 is independently selected from the group consisting of alkylcarbonyl and aminocarbonyl, wherein: the aminocarbonyl optionally is substituted with a substituent selected from the group consisting of alkyl, alkyloxyalkyl, alkylsulfonyl, and alkylsulfonylamino. 52 2014280939 24 Dec 2014 [00329] In some embodiment, each R1 is independently selected from the group consisting of alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, and aminocarbonyl, wherein: (a) the alkylcarbonyl, alkenylcarbonyl, and alkynylcarbonyl optionally are substituted with one or more substituents independently selected trom the group consisting of carboxy, hydroxy, halo, amino, nitro, azido, oxo, aminosulfonyl, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, alkyloxy, alkenyloxy, alkynyloxy, carbocyclyl, heterocyclyl, cyano, and aminocarbonyl, and (b) the aminocarbonyl optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, and alkylsulfonylamino.

[00330] In some of the above embodiments, each R1 is independently selected from the group consisting of alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, and aminocarbonyl, wherein such substituents are not substituted.

[00331] In some embodiments, each R1 is independently selected from the group consisting of alkylcarbonyl and aminocarbonyl, wherein: (a) the alkylcarbonyl optionally is substituted with one or two substituents independently selected from the group consisting of carboxy, hydroxy, halo, amino, nitro, azido, oxo, aminosulfonyl, alkyloxycarbonyl, alkylcarbonyloxy, alkyloxy, carbocyclyl, heterocyclyl, cyano, and aminocarbonyl, and (b) the aminocarbonyl optionally is substituted with one or two substituents independently selected from the group consisting of alkyl and alkylsulfonylamino.

[00332] In some embodiments, each R1 is independently selected from the group consisting of alkylcarbonyl and aminocarbonyl, wherein: (a) the alkylcarbonyl optionally is substituted with one or two substituents independently selected from the group consisting of carboxy, hydroxy, halo, amino, nitro, oxo, aminosulfonyl, alkyloxycarbonyl, alkylcarbonyloxy, alkyloxy, cyano, and aminocarbonyl, and (b) the aminocarhonyl optionally is substituted with one or two substituents independently selected from the group consisting of alkyl and alkylsulfonylamino.

[00333] In some embodiments, each R1 is independently selected from the group consisting of alkylcarbonyl and aminocarbonyl, wherein: the alkylcarbonyl optionally is substituted with one or two substituents independently selected from the group consisting of carboxy, hydroxy, halo, amino, nitro, azido, oxo, aminosulfonyl, alkyloxycarbonyl, alkylcarbonyloxy, alkyloxy, carbocyclyl, heterocyclyl, cyano, and aminocarbonyl. 53 2014280939 24 Dec 2014 [00334] In some embodiments, each R1 is independently selected alkylcarbonyl.

[00335] In some embodiments, each R* is independently selected aminocarbonyl. B18. Substituent RJ.

[00336] Each RJ is independently selected from the group consisting of carbocyclylsulfonylamino, heterocyclylsulfonylamino, alkylcarbonylamino, alkenylcarbonylamino, alkynylcarbonylamino, alkyloxycarbonylamino, alkenyloxycarbonylamino, alkynyloxycarbonylamino, alkylsulfonylamino, alkenylsulfonylamino, alkynylsulfonylamino, aminocarbonylamino, alkyloxycarbonylaminoimino, alkylsulfonylaminoimino, alkenylsulfonylaminoimino, and alkynylsulfonylaminoimino, wherein: (a) the amino portion of such substituents optionally is substituted with a substituent independently selected from the group consisting of carbocyclylalkyl, heterocyelylalkyl, alkylcarbonyloxy, aminocarbonylalkyl, alkyl, alkenyl, alkynyl, alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkyloxycarbonyl, alkyloxyalkyloxycarbonyl, alkylcarbonyloxyalkyl, and alkylsulfonyl, wherein: (1) the carbocyclyl portion of the carbocyclylalkyl and the heterocyclyl portion of the heterocyelylalkyl optionally are substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, carboxy, hydroxy, alkyloxy, alkenyloxy, alkynyloxy, halo, nitro, cyano, azido, oxo, and amino, and (2) the amino portion of the aminocarbonylalkyl optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, and alkynyl, (b) the alkyl, alkenyl, and alkynyl portion of such substituents optionally is substituted with one or more substituents independently selected from the group consisting of carboxy, halo, oxo, amino, alkyloxycarbonyl, alkylcarbonyloxy, hydroxy, alkyloxy, carbocyclyl, heterocyclyl, and cyano, wherein: the amino optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy, and alkynyloxy, wherein: the alkyl optionally is substituted with one or more hydroxy; (c) the carbocyclyl and heterocyclyl portions of such substituents optionally are substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, carboxy, hydroxy, alkyloxy, alkenyloxy, alkynyloxy, halo, nitro, cyano, azido, and amino, wherein: the amino optionally is substituted with one or two substituents independently 54 2014280939 24 Dec 2014 selected from the group consisting of alkyl, alkenyl, and alkynyl.

[00337] In some embodiment, each R1 is independently selected from the group consisting of carbocyclylsulfonylamino, heterocyclylsulfonylamino, alkylcarbonylamino, alkenylcarbonylamino, alkynylcarbonylamino, alkyloxycarbonylamino, alkenyloxycarbonylamino, alkynyloxycarbonylamino, alkylsulfonylamino, alkenylsulfonylamino, alkynylsulfonylamino, aminocarbonylamino, alkylsulfonylaminoimino, alkenylsulfonylaminoimino, and alkynylsulfonylaminoimino, wherein: (a) the amino portion of such substituents optionally is substituted with a substituent independently selected from the group consisting of carbocyclylalkyl, heterocyclylalkyl, alkylcarbonyloxy, aminocarbonylalkyl, alkyl, alkenyl, alkynyl, alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkyloxycarbonyl, alkyloxyalkyloxycarbonyl, alkylcarbonyloxyalkyl, and alkylsulfonyl, wherein: (1) the carbocyclyl portion of the carbocyclylalkyl and the heterocyclyl portion of the heterocyclylalkyl optionally are substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, carboxy, hydroxy, alkyloxy, alkenyloxy, alkynyloxy, halo, nitro, cyano, azido, oxo, and amino, and (2) the amino portion of the aminocarbonylalkyl optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, and alkynyl, (b) the alkyl, alkenyl, and alkynyl portion of such substituents optionally is substituted with one or more substituents independently selected from the group consisting of carboxy, halo, oxo, amino, alkyloxycarbonyl, alkylcarbonyloxy, hydroxy, alkyloxy, carbocyclyl, heterocyclyl, and cyano, wherein: the amino optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy, and alkynyloxy, wherein: the alkyl optionally is substituted with one or more hydroxy; (c) the carbocyclyl and heterocyclyl portions of such substituents optionally are substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, carboxy, hydroxy, alkyloxy, alkenyloxy, alkynyloxy, halo, nitro, cyano, azido, and amino, wherein: the amino optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, and alkynyl; and [00338] In some of the above embodiments, each R1 is independently selected from the group consisting 55 2014280939 24 Dec 2014 of carbocyclylsulfonyiamino, heterocyclylsulfonylamino, alkylcarbonylamino, alkenylcarbonylamino, alkynylcarbonylamino, alkyloxycarbonylamino, alkenyloxycarbonylamino, alkynyloxycarbonylamino, alky 1 sulfonylamino, alkenylsulfonylamino, alkynylsulfonylamino, aminocarbonylamino, alkylsulfonylaminoimino, alkenylsulfonylaminoimino, and alkynylsulfonylaminoimino, wherein such substituents are not substituted.

[00339] In some embodiments, each RJ is independently selected from the group consisting of carbocyclylsulfonyiamino, heterocyclylsulfonylamino, alkylcarbonylamino, alkyloxycarbonylamino, alkylsulfonylamino, aminocarbonylamino, and alkylsulfonylaminoimino, wherein: (a) the amino portion of such substituents optionally is substituted with a substituent independently selected from the group consisting of carbocyclylalkyl, heterocyclylalkyl, alkylcarbonyloxy, aminocarbonylalkyl, alkyl, alkylcarbonyl, alkyloxycarbonyl, alkyloxyalkyloxycarbonyl, alkylcarbonyloxyalkyl, and alkylsulfonyl, wherein: (1) the carbocyclyl portion of the carbocyclylalkyl and the heterocyclyl portion of the heterocyclylalkyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, carboxy, hydroxy, alkyloxy, halo, nitro, cyano, oxo, and amino, and (2) the amino portion of the aminocarbonylalkyl optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, and alkynyl, (b) the alkyl portion of such substituents optionally is substituted with one or two substituents independently selected from the group consisting of carboxy, halo, oxo, amino, alkyloxycarbonyl, alkylcarbonyloxy, hydroxy, alkyloxy, carbocyclyl, heterocyclyl, and cyano, wherein: the amino optionally is substituted with one or two substituents independently selected from the group consisting of alkyl and alkyloxy, wherein: the alkyl optionally is substituted with one or more hydroxy; (c) the carbocyclyl and heterocyclyl portions of such substituents optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, carboxy, hydroxy, alkyloxy, halo, nitro, cyano, and amino, wherein: the amino optionally is substituted with one or two substituents independently selected alkyl.

[00340] In some embodiments, each RJ is independently selected from the group consisting of carbocyclylsulfonyiamino, heterocyclylsulfonylamino, alkylsulfonylamino, and alkylsulfonylaminoimino, wherein: 56 2014280939 24 Dec 2014 (a) the amino portion of such substituents optionally is substituted with a substituent independently selected from the group consisting of carbocyclylalkyl, heterocyclylalkyl, alkylcarbonyloxy, aminocarbonylalkyl, alkyl, alkylcarbonyl, alkyloxycarbonyl, alkyloxyalkyloxycarbonyl, alkylcarbonyloxyalkyl, and alkylsulfonyl, wherein: (1) the carbocyclyl portion of the carbocyclylalkyl and the heterocyclyl portion of the heterocyclylalkyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, carboxy, hydroxy, alkyloxy, halo, nitro, cyano, oxo, and amino, and (2) the amino portion of the aminocarbonylalkyl optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, and alkynyl, (b) the alkyl portion of such substituents optionally is substituted with one or two substituents independently selected from the group consisting of carboxy, halo, oxo, amino, alkyloxycarbonyl, alkylcarbonyloxy, hydroxy, alkyloxy, carbocyclyl, heterocyclyl, and cyano, wherein: the amino optionally is substituted with one or two substituents independently selected from the group consisting of alkyl and alkyloxy, wherein: the alkyl optionally is substituted with one or more hydroxy; (c) the carbocyclyl and heterocyclyl portions of such substituents optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, carboxy, hydroxy, alkyloxy, halo, nitro, cyano, and amino, wherein: the amino optionally is substituted with one or two substituents independently selected alkyl.

[00341] In some embodiments, each RJ is independently selected from the group consisting of carbocyclylsulfonylamino, heterocyclylsulfonylamino, alkylsulfonylamino, and alkylsulfonylaminoimino, wherein: the amino portion of such substituents optionally is substituted with a substituent independently selected from the group consisting of carbocyclylalkyl, heterocyclylalkyl, alkylcarbonyloxy, aminocarbonylalkyl, alkyl, alkylcarbonyl, alkyloxycarbonyl, alkyloxyalkyloxycarbonyl, alkylcarbonyloxyalkyl, and alkylsulfonyl, wherein: (1) the carbocyclyl portion of the carbocycly lalkyl and the heterocyclyl portion of the heterocyclylalkyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, carboxy, hydroxy, alkyloxy, halo, nitro, cyano, oxo, and amino, and 57 2014280939 24 Dec 2014 (2) the amino portion of the aminocarbonylalkyl optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, and alkynyl.

[0034211η some embodiments, each RJ is independently selected from the group consisting of carbocyclylsulfonylamino, heterocyclylsulfonylamino, alkylsulfonylamino, and alkyisulfonylaminoimino, wherein: the alkyl portion of the alkylsulfonylamino and alkyisulfonylaminoimino optionally is substituted with one or two substituents independently selected from the group consisting of carboxy, halo, oxo, amino, alkyloxycarbonyl, alkylcarbonyloxy, hydroxy, alkyloxy, carbocyclyl, heterocyclyl, and cyano, wherein: the amino optionally is substituted with one or two substituents independently selected from the group consisting of alkyl and alkyloxy, wherein: the alkyl optionally is substituted with one or more hydroxy.

[00343] In some embodiments, each RJ is independently selected from the group consisting of carbocyclylsulfonylamino, heterocyclylsulfonylamino, alkylsulfonylamino, and alkyisulfonylaminoimino, wherein: the carbocyclyl and heterocyclyl portions of such substituents optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, carboxy, hydroxy, alkyloxy, halo, nitro, cyano, and amino.

[00344] In some embodiments, each RJ is independently selected from the group consisting of carbocyclylsulfonylamino and heterocyclylsulfonylamino, wherein: the carbocyclyl and heterocyclyl portions of such substituents optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, carboxy, hydroxy, alkyloxy, halo, nitro, cyano, and amino. 100345] In some embodiments, each RJ is independently selected from the group consisting of alkylsulfonylamino, alkenylsulfonylamino, alkynylsulfonylamino, and alkyisulfonylaminoimino, wherein: (a) the amino portion of such substituents optionally is substituted with a substituent independently selected from the group consisting of carbocyclylalkyl, heterocyclylalkyl, alkylcarbonyloxy, aminocarbonylalkyl, alkyl, alkylcarbonyl, alkyloxycarbonyl, alkyloxyalkyloxycarbonyl, alkylcarbonyloxyalkyl, and alkylsulfonyl, wherein: (1) the carbocyclyl portion of the carbocyclylalkyl and the heterocyclyl portion of the heterocyclylalkyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, carboxy, hydroxy, alkyloxy, 58 2014280939 24 Dec 2014 halo, nitro, cyano, oxo, and amino, and (2) the amino portion of the aminocarbonylalkyl optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, and alkynyl, (b) the alkyl, alkeny l, and alkynyl portion of such substituents optionally is substituted with one or two substituents independently selected from the group consisting of carboxy, halo, oxo, amino, alkyloxycarbonyl, alkylcarbonyloxy, hydroxy, alkyloxy, carbocyclyl, heterocyclyl, and cyano, wherein: the amino optionally is substituted with one or two substituents independently selected from the group consisting of alkyl and alkyloxy, wherein: the alkyl optionally is substituted with one or more hydroxy.

[00346] In some embodiments, each RJ is an independently selected alkylsulfonylamino, wherein: (a) the amino portion of the alkylsulfonylamino optionally is substituted with a substituent independently selected from the group consisting of carboeyclylalkyl, heterocyclylalkyl, alkylcarbonyloxy, aminocarbonylalkyl, alkyl, alkylcarbonyl, alkyloxycarbonyl alkyloxyalkyloxycarbonyl, alkylcarbonyloxyalkyl, and alkylsulfonyl, wherein: (1) the carbocyclyl portion of the carboeyclylalkyl and the heterocyclyl portion of the heterocyclylalkyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, carboxy, hydroxy, alkyloxy, halo, nitro, cyano, oxo, and amino, and (2) the amino portion of the aminocarbonylalkyl optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, and alkynyl, (b) the alkyl portion of the alkylsulfonylamino optionally is substituted with one or two substituents independently selected from the group consisting of carboxy, halo, oxo, amino, alkyloxycarbonyl, alkylcarbonyloxy, hydroxy, alkyloxy, carbocyclyl, heterocyclyl, and cyano, wherein: the amino optionally is substituted with one or two substituents independently selected from the group consisting of alkyl and alkyloxy, wherein: the alkyl optionally is substituted with one or more hydroxy.

[00347] In some embodiments, each RJ is an independently selected alkylsulfonylamino, wherein: the amino portion of the alkylsulfonylamino optionally is substituted with a substituent independently selected from the group consisting of carboeyclylalkyl, heterocyclylalkyl, alkylcarbonyloxy, aminocarbonylalkyl, alkyl, alkylcarbonyl, alkyloxycarbonyl, 59 2014280939 24 Dec 2014 alkyloxyalkyloxycarbonyl, alkylcarbonyloxyalkyl, and alkylsulfonyl, wherein: (1) the carbocyclyl portion of the carbocyclylalkyl and the heterocyclyl portion of the heterocyclylalkyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, carboxy, hydroxy, alkyloxy, halo, nitro, cyano, oxo, and amino, and (2) the amino portion of the aminocarbonylalkyl optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, and alkynyl.

[00348] In some embodiments, each RJ is an independently selected alkylsulfonylamino, wherein: the amino portion of the alkylsulfonylamino optionally is substituted with a substituent independently selected from the group consisting of carbocyclylalkyl, heterocyclylalkyl, alkylcarbonyloxy, aminocarbonylalkyl, alkyl, alkylcarbonyl, alkyloxycarbonyl, alkyloxyalkyloxycarbonyl, alkylcarbonyloxyalkyl, and alkylsulfonyl.

[00349] In some embodiments, each RJ is an independently selected alkylsulfonylamino, wherein: the alkyl portion of the alkylsulfonylamino optionally is substituted with one or two substituents independently selected from the group consisting of carboxy, halo, oxo, amino, alkyloxycarbonyl, alkylcarbonyloxy, hydroxy, alkyloxy, carbocyclyl, heterocyclyl, and cyano, wherein: the amino optionally is substituted with one or two substituents independently selec ted from the group consisting of alkyl and alkyloxy, wherein: the alkyl optionally is substituted with one or mere hydroxy.

[00350] In some embodiments, each RJ is an independently selected alkylsulfonylamino, wherein: the alkyl portion of the alkylsulfonylamino optionally is substituted with one or two substituents independently selected from the group consisting of carboxy, halo, oxo, amino, alkyloxycarbonyl, alkylcarbonyloxy, hydroxy, alkyloxy, carbocyclyl, heterocyclyl, and cyano.

[00351] In some embodiments, each R1 is an independently selected alkylsulfonylamino. In some such embodiments, each RJ is methylsulfonylamino.

[00352] In some embodiments, each RJ is an independently selected alkylsulfonylaminoimino, wherein: (a) the amino portion of the alkylsulfonylaminoimino optionally is substituted with a substituent independently selected from the group consisting of carbocyclylalkyl, heterocyclylalkyl, alkylcarbonyloxy, aminocarbonylalkyl, alkyl, alkylcarbonyl, alkyloxycarbonyl, alkyloxyalkyloxycarbonyl, alkylcarbonyloxyalkyl, and alkylsulfonyl, wherein: (1) the carbocyclyl portion of the carbocyclylalkyl and the heterocyclyl portion of the heterocyclylalkyl optionally are substituted with one or two substituents 60 2014280939 24 Dec 2014 independently selected from the group consisting of alkyl, carboxy, hydroxy, alkyloxy, halo, nitro, cyano, oxo, and amino, and (2) the amino portion of the aminocarbonylalkyl optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, and alkynyl, (b) the alkyl portion of the alkylsulfonylaminoimino optionally is substituted with one or two substituents independently selected from the group consisting of carboxy, halo, oxo, amino, alkyloxycarbonyl, alkylcarbonyloxy, hydroxy, alkyloxy, carbocyclyl, heterocyclyl, and cyano, wherein: the amino optionally is substituted with one or two substituents independently selected from the group consisting of alkyl and alkyloxy, wherein: the alkyl optionally is substituted with one or more hydroxy.

[00353] In some embodiments, each RJ is an independently selected alkylsulfonylaminoimino, wherein: the amino portion of the alkylsulfonylaminoimino optionally is substituted with a substituent independently selected from the group consisting of carbocyclylalkyl, heterocyclylalkyl, alkylcarbonyloxy, aminocarbonylalkyl, alkyl, alkylcarbonyl, alkyloxycarbonyl, alkyloxyalkyloxycarbonyl, alkylcarbonyloxyalkyl, and alkylsulfonyl, wherein; (1) the carbocyclyl portion of the carbocyclylalkyl and the heterocyclyl portion of the heterocyclylalkyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, carboxy, hydroxy, alkyloxy, halo, nitro, cyano, oxo, and amino, and (2) the amino portion of the aminocarbonylalkyl optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, and alkynyl.

[00354] In some embodiments, each RJ is an independently selected alkylsulfonylaminoimino, wherein: the amino portion of the alkylsulfonylaminoimino optionally is substituted with a substituent independently selected from the group consisting of carbocyclylalkyl, heterocyclylalkyl, alkylcarbonyloxy, aminocarbonylalkyl, alkyl, alkylcarbonyl, alkyloxycarbonyl, alkyloxyalkyloxycarbonyl, alkylcarbonyloxyalkyl, and alkylsulfonyl.

[00355] In some embodiments, each RJ is an independently selected alkylsulfonylaminoimino, wherein: the alkyl portion of the alkylsulfonylaminoimino optionally is substituted with one or two substituents independently selected from the group consisting of carboxy, halo, oxo, amino, alkyloxycarbonyl, alkylcarbonyloxy, hydroxy, alkyloxy, carbocyclyl, heterocyclyl, and cyano, wherein: 61 2014280939 24 Dec 2014 the amino optionally is substituted with one or two substituents independently selected from the group consisting of alkyl and alkyloxy, wherein: the alkyl optionally is substituted with one or more hydroxy.

[00356] In some embodiments, each RJ is an independently selected alkylsulfonylaminoimino, wherein: the alkyl portion of the alkylsulfonylaminoimino optionally is substituted with one or two substituents independently selected from the group consisting of carboxy, halo, oxo, amino, alkyloxycarbonyl, alkylcarbonyloxy, hydroxy, alkyloxy, carbocyclyl, heterocyclyl, and cyano.

[00357] In some embodiments, each RJ is an independently selected alkylsulfonylaminoimino. In some such embodiments, each RJ is methylsulfonylaminoimino.

[00358] In some embodiments, each RJ is independently selected from the group consisting of alkylcarbonylamino and alkyloxycarbonylamino, wherein: the alkyl portion of such substituents optionally is substituted with one or two substituents independently selected from the group consisting of carboxy, halo, oxo, amino, alkyloxycarbonyl, alkylcarbonyloxy, hydroxy, alkyloxy, carbocyclyl, heterocyclyl, and cyano. B19. Substituent RK.

[00359] Each RK is independently selected from the group consisting of aminosulfonyl, alkylsulfonyl, alkenylsulfonyl, and alkynylsulfonyl, wherein: (a) the alkylsulfonyl, alkenylsulfonyl, and alkynylsulfonyl optionally are substituted with one or more substituents independently selected from the group consisting of carboxy, hydroxy, halo, amino, nitro, azido, oxo, aminosulfonyl, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, alkyloxy, alkenyloxy, alkynyloxy, carbocyclyl, heterocyclyl, cyano, and aminocarbonyl, wherein: the amino, aminosulfonyl, and aminocarbonyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, and alkynyl; and (b) the aminosulfonyl optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, and alkynyl.

[00360] In some of the above embodiments, each RK is independently selected from the group consisting of aminosulfonyl, alkylsulfonyl, alkenylsulfonyl, and alkynylsulfonyl, wherein such substituents are not substituted.

[00361] In some embodiments, each RK is independently selected from the group consisting of aminosulfonyl and alkylsulfonyl, wherein: (a) the alkylsulfonyl optionally is substituted with one or two substituents independently selected from the group consisting of carboxy, hydroxy, halo, amino, nitro, oxo, aminosulfonyl, 62 2014280939 24 Dec 2014 alkyloxycarbonyl, alkylcarbonyloxy, alkyloxy, carbocyclyl, heterocyclyl, cyano, and aminocarbonyl; and (b) the aminosulfonyl optionally is substituted with one or two substituents independently selected alkyl.

[00362] In some embodiments, each RK is independently selected from the group consisting of aminosulfonyl and alkylsulfonyl. C. Embodiments of Compounds of Formula I.

[00363] Various embodiments of substituents R1, R2, R3, R4, R5, L, RA, RB, Rc, RD, Rs, RE, RF, Rc, R", R1, RJ, and RK have been discussed above. These substituent embodiments can be combined to form various embodiments of compounds of formula I. All embodiments of compounds of formula I formed by combining the substituent embodiments discussed above are within the scope of Applicants’ invention, and some illustrative embodiments of the compounds of formula I are provided below.

[00364] In some embodiments, the compounds of formula I correspond in structure to formula I-L0: R1

I

R6 R5 is selected from the group consisting of single carbon-carbon bond and double carbon- carbon bond; R1 is selected from the group consisting of hydrogen and methyl; R2 is selected from the group consisting of hydrogen and halo R3 is selected from the group consisting of hydrogen and halo; R4 is selected from the group consisting of Ci-C4-alkyl, Cj-Ce-carbocyclyl, and 5-6-membered heterocyclyl, wherein: (a) the CrC4-aIkyl optionally is substituted with up to three substituents independently selected from the group consisting of halo, oxo, hydroxy, alkyloxy, and trimethylsilyl, and (b) the C3-C6-carbocyclyl and 5-6-membered heterocyclyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, halo, and alkylsulfonylamino; R5 is selected from the group consisting of hydrogen, hydroxy, alkyloxy, and halo; 63 2014280939 24 Dec 2014 R6 is selected from the group consisting of C5-C6-carbocyclyl, 5-6-membered heterocyclyl, fused 2-ring heterocyclyl, and fused 2-ring carbocyclyl, wherein each such substituent is substituted with one, two, or three substituents independently selected from the group consisting of RE, RF, R1, R1, and RK; each Re is independently selected from the group consisting of chloro, fluoro, nitro, hydroxy, oxo, carboxy, amino, imino, aldehydo, and alkylamino; each Rf is an independently selected alkyl optionally substituted with a substituent selected from the group consisting of carboxy, halo, amino, imino, and aminosulfonyl, wherein: the amino, imino, and aminosulfonyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, alkylsulfonyl, and alkylsulfonylamino; each R1 is independently selected from the group consisting of alkylcarbonyl and aminocarbonyl, wherein: the aminocarbonyl optionally is substituted with a substituent selected from the group consisting of alkyl, alkyloxyalkyl, alkylsulfonyl, and alkylsulfonylamino; each RJ is independently selected from the group consisting of alkylsulfonylamino, alkenylsulfonyiamino, alkynylsulfonylamino, and alkylsulfonylaminoimino, wherein: (a) the amino portion of such substituents optionally is substituted with a substituent independently selected from the group consisting of carbocyclylalkyl, neterocyclylalkyl, alkylcarbonyloxy, aminoearbonylalkyl, alkyl, alkylcarbonyl, alkyloxycarbonyl, alkyloxyalkyloxycarbonyl, alkylcarbonyloxyalkyl, and alkylsulfonyl, wherein: (1) the carbocyclyl portion of the carbocyclylalkyl and the heterocyclyl portion of the heterocyclylalkyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, carboxy, hydroxy, alkyloxy, halo, nitro, cyano, oxo, and amino, and (2) the amino portion of the aminoearbonylalkyl optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, and alkynyl, (b) the alkyl, alkenyl, and alkynyl portion of such substituents optionally is substituted with one or two substituents independently selected from the group consisting of carboxy, halo, oxo, amino, alkyloxycarbonyl, alkylcarbonyloxy, hydroxy, alkyloxy, carbocyclyl, heterocyclyl, and cyano, wherein: the amino optionally is substituted with one or two substituents independently selected from the group consisting of alkyl and alkyloxy, wherein: the alkyl optionally is substituted with one or more hydroxy; and 64 2014280939 24 Dec 2014 each RK is independently selected from the group consisting of aminosulfonyl and alkylsulfonyl, wherein: (a) the alkylsulfonyl optionally is substituted with one or two substituents independently selected from the group consisting of carboxy, hydroxy, halo, amino, nitro, oxo, aminosulfonyl, alkyloxycarbonyl, alkylcarbonyloxy, alkyloxy, carbocyclyl, heterocyclyl, cyano, and aminocarbonyl; and (b) the aminosulfonyl optionally is substituted with one or two substituents independently selected alkyl.

[003651 In some embodiments, in the compounds of formula I: =^=-= is selected from the group consisting of single carbon-carbon bond and double carbon-carbon bond; R1 is selected from the group consisting of hydrogen and methyl; R2 is selected from the group consisting of hydrogen and halo; R3 is selected from the group consisting of hydrogen and halo; R4 is selected from the group consisting of CrC4-alkyl, C3-C6-carbocyclyl, and 5-6-membered heterocyclyl, wherein: (a) the Ci-C4-alkyl optionally is substituted with up to three substituents independently selected from the group consisting of halo, oxo, hydroxy, alkyloxy, and trimethylsilyl, and (b) the C3-C(;-carbocyclyl and 5-6-membered heterocyclyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, halo, and alkylsulfonylamino;

Rs is selected from the group consisting of hydrogen, hydroxy, alkyloxy, and halo; L is selected from the group consisting of C(RA)=C(RB), ethylene, and cyclopropyl-1,2-ene; one of Ra and RB is hydrogen, and the other is selected from the group consisting of hydrogen, methyl, methoxy, and halo; R6 is selected from the group consisting of C5-Q,-carbocyclyl and 5-6-membered heterocyclyl, wherein each such substituent is substituted with one, two, or three substituents independently selected from the group consisting of RE, RF, and RJ; each Re is independently selected from the group consisting of chloro, fluoro, nitro, hydroxy, oxo, carboxy, amino, imino, aldehydo, and alkylamino; each Rf is an independently selected alkyl optionally substituted with a substituent selected from the group consisting of carboxy, halo, amino, imino, and aminosulfonyl, wherein: the amino, imino, and aminosulfonyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, alkylsulfonyl, and 65 2014280939 24 Dec 2014 alkylsulfonylamino; each R1 is independently selected from the group consisting of alkylcarbonyl and aminocarbonyl, wherein: the aminocarbonyl optionally is substituted with a substituent selected from the group consisting of alkyl, alkyloxyalkyl, alkylsulfonyl, and alkylsulfonylamino; and each RJ is independently selected from the group consisting of alkylsulfonylamino, alkenylsulfonylamino, alkynylsulfonylamino, and alkylsulfonylaminoimino, wherein: (a) the amino portion of such substituents optionally is substituted with a substituent independently selected from the group consisting of carbocyclylalkyl, heterocyclylalkyl, alkylcarbonyloxy, aminocarbonylalkyl, alkyl, alkylcarbonyl, alkyloxycarbonyl, alkyloxyalkyloxycarbonyl, alkylcarbonyloxyalkyl, and alkylsulfonyl, w'herein: (1) the carbocyclyl portion of the carbocyclylalkyl and the heterocyclyl portion of the heterocyclylalkyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, carboxy, hydroxy, alkyloxy, halo, nitro, cyano, oxo, and amino, and (2) the amino portion of the aminocarbonylalkyl optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, and alkynyl, (b) the alkyl, alkenyl, and alkynyl portion of such substituents optionally is substituted with one or two substituents independently selected from the group consisting of carboxy, halo, oxo, amino, alkyloxycarbonyl, alkylcarbonyloxy, hydroxy, alkyloxy, carbocyclyl, heterocyclyl, and cyano, wherein: the amino optionally is substituted with one or two substituents independently selected from the group consisting of alkyl and alkyloxy, wherein the alkyl optionally is substituted with one or more hydroxy.

[00366] In some embodiments, the compounds of formula I correspond in structure to formula I-L0; R1

is selected from the group consisting of single carbon-carbon bond and double carbon- 66 2014280939 24 Dec 2014 carbon bond; R1 is hydrogen; R2 is selected from the group consisting of hydrogen and halo R3 is hydrogen; R4 is tert-butyi; R5 is selected from the group consisting of hydrogen, hydroxy, methoxy, and halo; R6 is a fused 2-ring carbocyclyl selected from the group consisting of naphthalenyl, dihydronaphthalenyl, tetrahydronaphthalenyl, hexahydronaphthalenyl, octahydronaphthalenyl, decahydronaphthalenyl, indenyl, dihydroindenyl, hexahydroindenyl, octahydroindenyl, pentalenyl, octahydropentalenyl, and hexahydropentalenyl, wherein each such substituent is substituted with a substituent selected from the group consisting of R1' and RJ; R" is alkylsulfonylaminoalkyl; and RJ is alkylsulfonylamino.

[00367] Examples of compounds of formula I (and salts thereof) are shown in Tables 1 through 38 below. The synthesis examples below provide step-by-step preparation instructions for some of these compounds. The remaining compounds were prepared utilizing the general method-of-preparation discussion, specific synthesis examples below, and/or the discussion throughout this application.

Table 1 H

compound substituent(s) IA-L0-1.1 -4-C(H)=MN(H)S(0)2CH3 IA-LO-1.2 -4-C(CH3)=NN(H)S(0)2CH3 IA-LO-1.3 43-F and -4-C(H)=NN(H)S(0)2CH3 and -5-F IA-LO-1.4 -3-F and -4-C(H)=NN(H)S(0)2CH3 IA-LO-1.5 -3-C(H)=NN(H)S(0)2CH3 and -4-OCH3 IA-LO-1.6 -2-F and -3-F and -4-C(H)=NN(H)S(0)2CH3 IA-LO-1.7 -3-C(H)=NN(H)S(0)2CH3 IA-LO-1.8 -3-C(CH3)=NN(H)S(0)2CH3 67 2014280939 24 Dec 2014

Table 2

Table 3

H

substituent(s) as described in the table below compound substituent(s) IB-LO-1.1 -4-C(H)=NN(H)S(0)2CH3 IB-LO-1.2 -4-N(H)S(0)2CH3 IB-LO-1.3 -3-1' and -4-C(H)=NN(H)S(0)2CH3 IB-LO-1.4 -4-C(H)2C(H)2N(H)S(0)2CH3 IB-LO-1.5 -4-C(CH3)=NN(H)S(0)2CH3 IB-LO-1.6 -3-C(H)=NN(H)S(0)2CH3 and -4-OCH3 IB-LO-1.7 -4-N(H)C(0)N(H)S(0)2CH3 IB-LO-1.8 -4-C(0)N(H)N(H)S(0)2CH3 IB-LO-1.9 -3-C(CH3)=NN(H)S(0)2CH3 IB-L0-1.10 -3-C(H)=NN(H)S(0)2CH3 68 2014280939 24 Dec 2014

Table 4

compound R6 ring/ring structure substituent(s) IA-LO-2.1 benzimidazol-2-yl -5-N(H)S(0)2CH3 IA-LO-2.2 benzthiazol-2-yl -6-N(H)S(0)2CH3 IA-LO-2.3 benzthiazol-2yl — IA-LO-2.4 benzthiazol-2-yl -5-N(H)S(0)2CH3 IA-LO-2.5 benzoxazol-2-yl -6-N(H)S(0)2CH3 IA-LO-2.6 benzoxazol-2-yl -6-N02 IA-LO-2.7 benzoxazol-2-yl -5-N02 IA-LO-2.8 benzoxazol-2-yl -5-N(H)S(0)2CH3 IA-LO-2.9 naphthalen-2-yl -6-N(H)S(0)2CH3 IA-L0-2.10 benzimidazol-2-yl -5-N[S(0)2CH3]2 substituent(s) as described in the table below

Table 5

R4 compound ~bT r5 substituent(s) IB-LO-2.1 -C(CH3)3 -och3 -H IB-LO-2.2 -C(CH3)3 -och3 -och3 IB-LO-2.3 -C(CH3)3 -och3 -N(H)S(0)2CH3 IB-LO-2.8 -C(CH3)3 -H -N(H)S(0)2CH3 IB-LO-2.14 -C(CH3)3 -Cl -N(H)S(0)2CH3 IB-LO-2.23 -C(CH3)3 -OC(H)2CH3 -N(H)S(0)2CH3 IB-LO-2.52 -C(CH3)2C(H)2C(H)3 -och3 -N(H)S(0)2CH3 69 2014280939 24 Dec 2014

2014280939 24 Dec 2014

Table 6 substituents) as described in the table below

compound R5 substituent(s) IB-LO-2.4 -OCH3 =NN(H)S(0)2CH3 IB-LO-2.7 -H =NN(H)S(0)2CH3 IB-LO-2.9 -OCH3 (S)-C(H)2N(H)S(0)2CH3 IB-L0-2.10 -OCH3 (R) -F and -C(H)2N(H)S(0)2CH3 IB-LO-2.12 -OCH3 -F and -C(H)2N(H)S(0)2CH3 IB-LO-2.15 -OCH, (R)~C(H)2N(H)S(0)2CH3 IB-LO-2.17 -OCH3 -C(H)2N(H)S(0)2CH3 IB-LO-2.20 -OCH3 (S) -F and -C(H)2N(H)S(0)2CH, IB-LO-2.22 -OCH, (S)-C(CH-,)2N(H)S(0)2CH, IB-LO-2.24 -OCH3 =NN(H)C(0)0CH3 IB-L0-2.2S -OCH3 -CH3 and -C(H)2N(H)S(0)2CH3 IB-LO-2.29 -OCH3 -C(CH3)2N(H)S(0)2CH3 IB-LO-2.31 -OCH3 -N(H)N(H)S(0)2CH3 IB-LO-2.34 -OCH3 -C(0)N(H)S(0)2CH3 IB-LO-2.36 -OCH3 -OH IB-LO-2.37 -OCH3 (R) -C(CH3)2N(H)S(0)2CH3 IB-LO-2.44 -OCH, -N(H)S(0)2CH3 IB-L0-2.50 -OCH3 =0 71 2014280939 24 Dec 2014

Table 7 substituent(s) as described

compound R4 r5 substituent(s) IB-LO-2.51 fS -OCH3 =NN(H)S(0)2CH3 IB-LO-2.55 furan-2-yl -OCH3 =NN(H)S(0)2CH3 Table 8 substituents) as described in the table below

Table 9 substituent(s) 38 described in the table below'

72 2014280939 24 Dec 2014 compound R4 substituent(s) IB-LO-2.41 -C(CH3)3 -C(CH3)2N(H)S(0)2CH3 IB-LO-2.62 -C(H)2N(H)S(0)2CH3 V IB-LO-2.63 -C(H)2N(H)S(0)2CH3 IB-LO-2.65 furan-2-yl -C(H)2N(H)S(0)2CH3 IB-LO-2.67 furan-3-yl -C(H)2N(H)S(0)2CH3 Table 10 substituents) as described in the table below

Table 11 o

substituent(s) as described in the table below compound substituent(s) IB-LO-2.27 -nh2 IB-LO-2.28 -N(H)S(0)2CH3 IB-LO-2.33 -H IB-LO-2.38 -Cl IB-LO-2.39 -nh2 IB-LO-2.46 -N(H)C(H)2 C(H)2CH3 73 2014280939 24 Dec 2014 IB-LO-2.47 \-}p IB-LO-2.49 -N(H)C(0)CH3 Table 12

74 2014280939 24 Dec 2014 o

.X HN'-S-

IB-LO-2.79

O Η

TABLE 13

substituents) as described in the table below compound R5 rb substituent(s) IA-L1-1.3 -och3 -Cl -4-N(H)S(0)2CH3 [Z] IA-L1-1.4 -och3 -F -4-N(H)S(0)2CH3 [Z] LA-L1-1.5 -och3 -F -4-N(H)S(0)2CH3 [E] IA-L1-1.6 -och3 -ch3 -4-N(H)S(0)2CH3 [E] IA-L1-1.9 -och3 -H -4-N(H)S(0)2CH3 [E] 1A-L1-1.10 -och3 -H -4-N(H)S(0)2CH3 [Z] 1A-Ll~i.ll -och3 -H -4-N[C(0)CH3]S(0)2CH3 [E] 1A-L1-1.12 -och3 -H -4-F [E] 75 2014280939 24 Dec 2014 compound R5 rb substituent(s) IA-L1-1.13 -OCH3 -H -4-NH2 [E] IA-L1-1.14 -OCH3 -H -4-OCH3 [E] IA-L1-1.16 -H -H -4-N(H)S(0)2CH3 [E] IA-L1-1.17 -OCH3 -OCH3 -4-N(H)S(0)2CH3 [Z] IA-L1-1.18 -OCH3 -H - [E] IA-L1-1.20 -OCH, -H -4-N(H)S(0)2CH, [Z] IA-H-1.21 -OCH3 -F -4-N(H)S(0)2CH3 [Z]: [E] (1:1) IA-L1-1.22 -OCH3 -H -4-N02 [E] IA-L1-1.23 -OCH3 -Cl -4-N02 [Z] IA-L1-1.24 -OCH3 -ch3 -4-N02 [E] IA-L1-1.2S -H -H -4-N02 [E] IA-L1-1.26 -OCH3 -H -3-F and -4-N(H)S(0)2CH3 [E] IA-L1-1.27 -OCH3 -H -2-OCH3 and -4-N(H)S(0)2CH3 [E] Table 14

compound substituent(s) IB-L1-1.1 -4-N(H)S(0)2CH3 [E] IB-L1-1.4 -2-C(0)0H and -4-N(H)S(0)2CH3 [E] IB-L1-1.5 -3-F and -4-N(H)S(0)2CH, [E] IB-L1-1.6 -2-C(0)H and -4-N(H)S(0)2CH, [E] IB-L1-1.7 -2-C(0)0CH3 and -4-N(H)S(0)2CH3 [E] IB-L1-1.8 -2-C(H)=N(OH) and -4-N(H)S(0)2CH3 [E] IB-L1-1.9 -2-C(0)N(H)CH2CH20CH3 and -4-N(H)S(0)2CH3 [E] IB-Ll-1,10 -2-CH2OH and -4-N(H)S(0)2CH3 [E] IB-Ll-l.il -2-C(0)OC(H)2CH3 and -4-N(H)S(0)2CH3 [E] EB-L1-1.13 -2-C(H)2OCH3 and -4-N(H)S(0)2CH3 [E] IB-L1-1.14 -2-C(0)N(CH3)2 and -4-N(H)S(0)2CH3 [E] 76 2014280939 24 Dec 2014 compound substituent(s) IB-L1-1.15 -2-CH3 and -4-N(H)S(0)2CH3 and -5-F [E] IB-L1-1.16 imidazol-2-yl and -4-N(H)S(0)2CH3 [E] IB-L1-1.17 -2-C(0)N(H)CH3 and -4-N(H)S(0)2CH3 [E] IB-L1-1.18 0 ^ li*° 2XX> 1 and -4-N(H)S(0)2CH3 [E] IB-L1-1.19 -2-C(H)=NOCH3 and -4-N(H)S(0)2CH3 [E] IB-L1-1.21 -2-C(0)NH2 and -4-N(H)S(0)2CH3 [E] IB-L1-1.22 0 -2 An V--* and -4-N(H)S(0)2CH3 [E] IB-L1-1.23 0 -2 and -4-N(H)S(0)2CH3 [E] IB-L1-1.24 -2-C(0)N(CH3)C(H)2C(H)2OCH3 and -4-N(H)S(0)2CH3 [E] IB-U-1.25 -2-C(H)2OC(H)(CH3)2 and -4-N(H)S(0)2CH3 [E] IB-Ll-1.26 J3 "2 ° and -4-N(H)S(0)2CH3 [E] IB-L1-1.27 O -2Λο L~--/ and -4-N(H)S(0)2CH3 [E] IB-L1-1.28 -2-NH2 and -4-N(H)S(0)2CH3 [E] IB-L1-1.29 OH and -4-N(H)S(0)2CH3 [E] IB-L1-1.31 -2-C(H)2N(H)C(H)2C(H)2C(H)(CH3)2 and -4-N(H)S(0)2CH3 [E] IB-L1-1.32 -2-N(H)C(0)0C(CH3)3 and -4-N(H)S(0)2CH3 [E] IB-L1-1.33 -2 Ay and -4-N(H)S(0)2CH3 [E] IB-L1-1.34 -4-N(H)S(0)2CH3 [Z] 77 2014280939 24 Dec 2014

TABLE 15 H

H An O O compound R5 IB-L1-1.45 -C(CH3)2C(H)2OII [E] IB-L1-1.46 furan-2-yl [E] IB-L1-1.47 'Va i / S [E] IB-L1-1.48 <y~~s A [E] IB-L1-1.49 -S(0)2CH3 [E] IB-L1-1.50 furan-3-yl [E] IB-L1-1.51 -I [E] IB-L1-1.52 -Br [E] IB-L1-1.53 pyridin-3-yl [E] IB-L1-1.55 pyridin-4-yl [E] Table 16

compound R* R5 IB-L1-1.2 -F -OCH3 [E] IB-L1-1.12 -H -Cl [E] IB-L1-1.20 -Cl -OCH3 [E] ÏB-L1-1.30 -H -OCH2CH3 [E] 78 2014280939 24 Dec 2014

Table 17

H

compound R5 R6 ring/ring structure substituent(s) IA-L2-L1 -H phenyl -4-N(H)S(0)2CH3 IA-L2-1.2 -H phenyl -2-CHj and -4-N(H)S(0)2CH3 IA-L2-1.3 -H phenyl -2-Cl and -4-N(H)S(0)2CH3 IA-L2-1.4 -OCH3 phenyl — IA-L2-1.26 -och3 pyridin-3-yl -6-N(H)S(0)2CH3 IA-L2-1.7 -och3 phenyl -3-N(H)S(0)2CH, IA-L2-1.8 -OCH3 phenyl -4-N(H)S(0)2CH3 IA-L2-1.9 -OCH3 phenyl -2-CH3 and -4-N(H)S(0)2CH3 IA-L2-1.10 -OCH3 phenyl -3-CH3 and -4-N(H)S(0)2CH3 IA-L2-l.il -OCH3 phenyl 2-C(H)2C(H)3 and -4-N(H)S(0)2CH3 IA-L2-1.12 -OCH3 phenyl -2-F and -4-N(H)S(0)2CH3 IA-L2-1.13 -OCH3 phenyl -3-F and -4-N(H)S(0)2CH3 IA-L2-1.14 -OCH3 phenyl -2-C1 and -4-N(H)S(0)2CH3 IA-L2-1.15 -OCH3 phenyl -3-Cl and -4-N(H)S(0)2CH3 LA-L2-1.16 -OC.H3 phenyl -2-OCH3 and -4-N(H)S(0)2CH3 IA-L2-1.17 -OCH3 phenyl -3-OCF3 and -4-N(H)S(0)2CH3 IA-L2-1.18 -OCH3 phenyl -2-CF3 and -4-N(H)S(0)2CH3 IA-L2-1.19 -OCH3 phenyl -3-CFj and -4-N(H)S(0)2CH3 IA-L2-1.20 -OCH3 phenyl -2-CHj and -4-N(H)S(0)2CH3 and -5-F IA-L2-1.21 -OCH3 phenyl -2-C1 and -3-F and -4-N(H)S(0)2CH3 IA-L2-1.22 -OCH3 phenyl -2-CF3 and -4-N(H)S(0)2CH3 and -5-F IA-L2-1.24 -OCH3 pyridin-2-yl -3-CH3 and -5-N(H)S(0)2CH3 IA-L2-1.25 -OCH3 pyridin-2-yl -5-N(H)S(0)2CH3 IA-L2-1.26 -OCH3 pyridin-3-yl -6-N(H)S(0)2CH3 [C(F)3C(0)0H salt] 79 2014280939 24 Dec 2014

Table is

Table 19

compound R5 ring/ring structure substituent(s) IB-L2-1.1 phenyl -2-CH3 and -4-N(H)S(0)2CH3 IB-L2-1.2 phenyl -2-C1 and -4 N(H)S(0)2CH, IB-L2-1.3 phenyl -2-CH3 and -4-N(H)S(0)2CH3 and -5-F IB-L2-1.4 phenyl -3-F and -4-N(H)S(0)2CH3 and -5-F IB-L2-1.5 phenyl -2-CFj and -4-N(H)S(0)2CH3 and -5-F IB-L2-1.6 phenyl -2-OH and -4-N(H)S(0)2CH3 IB-L2-1.7 phenyl -2-C(0)0CH3 and -4-N(H)S(0)2CH3 IB-L2-1.8 pyridin-2-yl -5-N(H)S(0)2CH3 IB-L2-1.9 pyrazin-2-yl -5-N(H)S(0)2CH3 IB-L2-1.10 phenyl -2-C(CH3)3 and -4-N(H)S(0)2CH3 IB-L2-l.il phenyl 0 ,2 and-4-N(H)S(0)2CH3 IB-L2-1.12 phenyl -2-N(H)C(0)CH3 and -4-N(H)S(0)2CH3 80 2014280939 24 Dec 2014

TABLE 20

IB-L2-2.1

Table 21

substituent(s) as described in the table below compound R5 substituent(s) IA-L3-1.3 -OH — IA-L3-1.4 -OH -4-N(CH3)S(0)2CH3 IA-L3-1.5 -OH -3-N(H)S(0)2CH3 IA-L3-1.6 -OH -4-N(H)S(0)2CH3 IA-L3-1.7 -OH -4-N(H)S(0)2CH2CH(CH3)2 IA-L3-1.8 -OH -4-N(H)S(0)2CH2CH20CH3 IA-L3-1.9 -OH -4-N (H)S(0)2CH2CF 3 1A-L3-1.10 -OH -4-N(H)S(0)2phenyl LA-L3-l.il -OH -3 -C(H)2N(H)S(0)2CH3 IA-L3-1.12 -OH -4-N(H)S(0)2CH2phenyl 81 2014280939 24 Dec 2014 compound R* substitueni(s) IA-L3-1.13 -OH \-SpN // w \ 0 0 ' IA-L3-1.14 -OH H 1 J // 'vS 0 0 IA-L3-1.15 -OH -4-C(H)2C(0)0H IA-L3-1.16 -OH -4-C(H)2S(0)2N(H)CH3 IA-L3-1.17 -OH -4-OC(H)2C=N IA-L3-1.18 -OH -4-0C(H)2C(0)NH2 IA-L3-1.19 -OH -4-0S(0)2CH3 IA-L3-1.20 -OH -2-S(0)2CH3 IA-L3-1.21 -OH -4-S(0)2CH3 IA-L3-1.22 -OH -2-S(0)2NH2 IA-L3-1.24 -och3 ... IA-L3-1.28 -och3 -2-C(H)2CH3 IA-L3-1.30 -och3 -4-C(H)2C(0)0H IA-L3-1.31 -och3 -4-C(H)2S(0)2N(H)CH3 IA-L3-1.32 -och3 -4-CF3 IA-L3-1.33 -och3 -4-ΟΠ IA-L3-1.34 -och3 -2-OCH3 IA-L3-1.35 -och3 -3-OCH3 IA-L3-1.36 -och3 -4-OC.H3 IA-L3-1.37 -och3 -2-OC(H)2CH3 IA-L3-1.38 -och3 -4-OC(H)2C=N IA-L3-1.39 -och3 -4-0C(H)2C(0)NH2 IA-L3-1.40 -och3 -4-OCF3 IA-L3-1.41 -och3 -4-0S(0)2CH3 IA-L3-1.42 -och3 -4-C(0)CH3 IA-L3-1.43 -och3 -4-C(0)C(H)2C(0)0C(H)2CH3 IA-L3-1.44 -och3 -3-C(0)NH2 82 2014280939 24 Dec 2014

2014280939 24 Dec 2014

compound R5 substituent(s) IA-L3-1.67 -och3 P //\\ 0 o IA-L3-1.69 -OCH3 -4-N[C(0)CH3] S(0)2CH3 IA-L3-1.70 -och3 -4-N[C(0)C(H)2CH3]S(0)2CH3 IA-L3-1.71 -OCH3 -4-N[C(0)C(H)2C(H)2CH3]S(0)2CH3 IA-L3-1.72 -och3 -4-N[C(0)C(H)(CH3)2]S(0)2CH3 IA-L3-1.73 -och3 -4-N[C(0)0CH3]S(0)2CH3 IA-L3-1.74 -och3 -4-N[C(0)0C(H)2CH3]S(0)2CH3 IA-L3-1.76 -och3 -4-N[C(0)0C(H)2C(H)(CH3)2]S(0)2CH3 IA-L3-1.77 -och3 -4-N[C(0)0C(H)2C(H)20CH3]S(0)2CH3 IA-L3-1.78 -OCHj -4-S(0)2CH3 IA-L3-1.79 -och3 -2-S(0)2CH3 IA-L3-1.80 -och3 -2-S(0)2NH2 IA-L3-1.81 -och3 -2-CHj and 3-OH IA-L3-1.82 -och3 -2-CH3 and -4-F IA-L3-L83 -och3 -2-CH3 and -4-N(H)S(0)2CH3 IA-L3-1.84 -och3 -2-CF3 and -4-N(H)S(0)2CH3 IA-L3-1.85 -och3 -2-OCH3 and -4-N(H)S(0)2CH3 IA-L3-1.86 -och3 -2-OCH-, and -5-N(H)C(0)CH3 IA-L3-1.87 -och3 -3-N02 and -4-N(H)S(0)2CH3 IA-L3-1.105 -H -4-N(H)S(0)2CH3 IA-L3-1.107 -och3 -4-N(H)2 [C1-] IA-L3-1.108 -och3 -4-N [C(H)2C(H)=C(H)2] S(0)2CH3 IA-L3-1.119 -OH -2-OCH3 and -4-N(H)S(0)2CH3 IA-L3-1.120 -och3 -3-C(H)2N(H)S(0)2CH3 IA-L3-1.121 -och3 iY 0 0 1 IA-L3-1.122 -och3 -4-N(H)S(0)2C(H)2C(H)20H 84 2014280939 24 Dec 2014 compound R5 substituent(s) IA-L3-1.123 -OCH3 -4-N[C(H)20C(0)C(H)2C(H)2CH3]S(0)2CH3 Table 22

H

compound R5 R" ring/ring structure substituent(s) IA-L3-1.89 -OH thiophen-2-yl -3-S(0)2NH2 and -4-C(H)2N(H)S(0)2CH3 IA-L3-1.90 -och3 thiophen-2-yl -3-S(0)2NH2 and -4-C(H)2N(H)S(0)2CH3 IA-L3-1.91 -OH thiophen-2-yl -4-C(H)2N(H)S(0)2CH3 IA-L3-1.94 -OCH3 thiophen-2-yl -4-C(H)2N(H)S(0)2CH3 IA-L3-1.95 -OH thiophen-2-yl -4-C(H)2N(CH3)S(0)2CH3 IA-L3-1.96 -OCH3 thiophen-2-yl -4-C(H)2N[C(0)0C(CH3)3]S(0)2CH3 IA-L3-1.97 -OCH3 thiophen-2-yl 4-C(H)2N(CH3)S(0)2CH3 IA-L3-1.98 -OH thiophen-2-yl -4-C(H)2N[C(0)0C(CH3)3] S(0)2CH3 IA-L3-1.99 -OCH3 pyridin-3-yl -6-N(H)S(0)2CH3 IA-L3-1.100 -och3 pyri din-3-yl -6-n(h)2 [cr] IA-L3-1.101 -OCH3 pyridin-2-yl -5-N[S(0)2CH3]2 IA-L3-1.102 -OCH3 pyridin-2-yl -5-N(H)S(0)2CH3 IA-L3-1.103 -OCH3 cyclohexyl -4-N(H)S(0)2CH3 IA-L3-1.104 -OH thiazol-2-yl Table 23

85 2014280939 24 Dec 2014 compound R4 R5 Rl substituent(s) IA-L3-1.1 -C(CH3)3 -OH -ch3 — IA-L3-1.2 -C(CH3)3 -OH -ch3 -4-N(H)S(0)2CH3 IA-L3-1.27 -C(CH3)3 -OCH3 -ch3 -4-N(H)S(0)2CH3 IA-L3-1.111 -C(H)(CH3)2 -och3 -H -4-N(H)S(0)2CH3 IA-L3-1.112 -ch2ch3 -och3 -H -4-N(H)S(0)2CH3 IA-L3-U13 -ch2ch3 -OH -H -4-N(H)S(0)2CH3 IA-L3-1.114 -H -OH -H -4-N(H)S(0)2CH3 Table 24

substituent(s) as described in the table below compound R1 substituent(s) IA-L3-1.88 -C(H)2OC(0)C(H)2C(H)2CH3 -4-N[C(H)20C(0)CH2CH2CH3]S(0)2CH3 IA-L3-1.25 -ch3 -4 -N(H) S (0)2CH3 IA-L3-1.26 -ch3 -4-N(CH3)S(0)2CH3 IA-L3-1.115 -C(H)2C(0)N(H)CH2CH3 -4-N[C(H)2C.(0)N(H)CH2CH3]S(0)2CH3 IA-L3-1.116 -C(H)20C(0)C(CH3)3 -4-N[C(H)20C(0)C(CH3)3]S(0)2CH3 IA-L3-1.117 -4-N(H)S(0)2CH3 IA-L3-l.il 8 -CH2C=CI12 -4-N[C(H)2C=CH2]S(0)2CH3 Table 25

H

86 2014280939 24 Dec 2014 compound R5 R6 IA-L3-2.1 -OH IA-L3-2.2 -OCH, ,o>° IA-L3-2.3 -OCH3 *Cxx IA-L3-2.4 -OCH3 ,€Cr° IA-L3-2.5 -OH *CCX Table 26

compound RJ Rs IB-L3-1.1 -H -OCH3 IB-L3-1.2 -H -OH IB-L3-1.3 -CH3 -OCH3 IB-L3-1.4 -ch3 -OH 87 2014280939 24 Dec 2014

Table 27

substituent(s) as described in the table below

compound Rs " rL> substituent(s) IA-L4-1.1 -H -H -4-N(H)S(0)2CH3 IA-L4-1.2 -OH -H — IA-L4-1.3 -OH -H -4-N(H)S(0)2CH3 IA-L4-1.4 -OH -H -4-CH2S(0)2CH3 IA-L4-1.5 -OH -H -4-N02 IA-L4-1.6 -OH -H -4-NH2 IA-L4-1.7 -och3 -CH3 -4-N(H)S(0)2CH3 IA-L4-1.8 -och3 -H — IA-L4-1.9 -och3 -H -4-N(H)S(0)2CH3 IA-L4-1.10 -och3 -H -4-CH2S(0)2CH3 IA-L4-l.il -och3 -H -2-OCH, and -4-N(H)S(0)2CH3 IA-L4-1.12 -och3 -H -2-C1 and -4-N(H)S(0)2CH3 Table 28

88 2014280939 24 Dec 2014

Table 29 substituent(s) as described in the table below compound R5 substituent(s) IA-L5-1-1.1 -OH -4-N(H)C(0)0C(CH3)3 IA-L5-1-1.2 -OH -3 - C(H)2N (H) S (0)2CH3 IA-L5-1-1.3 -OH -3 -C(0)0C(H)2CH3 IA-L5-1-1.4 -OH -3-CH3 [C(F)3C(0)0] IA-L5-1-1.5 -OH -4-C(0)0CH3 IA-L5-1-1.6 -OH -3-OH [C(F)3C(0)0] IA-L5-1-1.7 -OH -3-C(0)N[C(H)2CH3]2 [C(F)3C(0)0‘] IA-L5-1-1.8 -OH -3-C(0)NH2 [C(F)3C(0)0-] Table 30

H

compound R5 R6 ring/ring structure substituent(s) IA-L5-1-1.10 -OH piperazin-l-yl -4-C(0)0C(CH3)3 IA-L5-l-l.il -OH pyrrolidin-l-yl -3-N(H)S(0)2CH3 IA-L5-1-1.12 -OH pyrrolidin-l-yl -3-N(H)C(0)OC(CH3)3 IA-L5-1-1.13 -OH morpholin-4-yl -2-C(H)3 and -6-C(H)3 [C(F)3C(0)0'J IA-L5-1-1.14 -OH morpholin-4-yl - 10(1).,0(())()-1 89 2014280939 24 Dec 2014

Table 31

compound Rs IA-L5-2-1.1 -och3 IA-L5-2-1.2 -H Table 33

H

substituents) as described in the table below 90 2014280939 24 Dec 2014 compound substituent(s) IB-L5-2-1.1 -2-C(0)0CH3 and -4-N(H)S(0)2CH3 IB-L5-2-1.2 -4-N(H)S(0)2CH3 Table 34

Table 35 IA-L6-1.1

O , R6 H S // \\ o o IA-L8-1.1

CK , N

R3 compound Rl R5 R6 ring/ring structure substituent(s) IA-L9-1.1 -ch2ch3 -OH cyclohexyl [C(F)30(O) O'] — IA-L9-1.2 -ch3 -OH cyclohexyl [C(F)3C(0) O’] — IA-L9-1.3 -H -OH phenyl -4-N(H)S(0)2CH3 IA-L9-1.4 -H -OCH3 phenyl -4-N(H)S(0)2CH3 91 2014280939 24 Dec 2014

Table 37

IA-L11-1.1 IA-L12-1.1 D Isomers.

[00368] This invention also is directed, in part, to all isomers of the compounds of formula I (and their salts) (/. e., structural and stereoisomers). Structural isomers include chain and position isomers. Stereoisomers include E/Z isomers (i.e., isomers with regard to one or more double bonds), enantiomers (i.e., stereo- isomers that have opposite configurations at all stereogenic centers), and diastereoisomers (i.e., stereo- isomers that have the same configuration at one or more stereogenic centers, but differ at other stereogenic centers). E. Salts.

[00369] This invention also is directed, in part, to all salts of the compounds of formula I. A salt of a compound may be advantageous due to one or more of the salt’s properties, such as, for example, enhanced pharmaceutical stability in differing temperatures and humidities, or a desirable solubility in water or other solvents. Where a salt is intended to be administered to a patient (as opposed to, for example, being in use in an in vitro context), the salt preferably is pharmaceutically acceptable and/or physiologically compatible. The term "pharmaceutically acceptable" is used adjectivally in this patent application to mean that the modified noun is appropriate for use as a pharmaceutical product or as a part of a pharmaceutical product. Pharmaceutically acceptable salts include salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. In general, these salts typically may be prepared by conventional means by reacting, for example, the appropriate acid or base with a compound of the invention. 92 2014280939 24 Dec 2014 [00370] Pharmaceutically acceptable acid addition salts of the compounds of formula I can be prepared from an inorganic or organic acid. Examples of often suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric, and phosphoric acid. Suitable organic acids generally include, for example, aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids. Specific examples of often suitable organic acids include acetate, trifluoroacetate, formate, propionate, succinate, glycolate, gluconate, digluconate, lactate, malate, tartaric acid, citrate, ascorbate, glucuronate, maleate, fumarate, pyruvate, aspartate, glutamate, benzoate, anthranilic acid, mesylate, stearate, salicylate, p-hydroxybenzoate, phenylacetate, mandelate, embonate (pamoate), ethanesulfonate, benzenesulfonate, pantothenate, 2-hydroxyethanesulfonate, sulfanilate, cyclohexylaminosulfonate, algenic acid, beta-hydroxybutyric acid, galactarate, galacturonate, adipate, alginate, bisulfate, butyrate, camphorate, camphorsulfonate, cyclopentanepropionate, dodecylsulfate, glycoheptanoate, glycerophosphate, heptanoate, hexanoate, nicotinate, oxalate, palmoate, pectinate, 2-naphthalesulfonate, 3-phenylpropionate, picrate, pivalate, thiocyanate, tosylate, and undecanoate.

[00371] Pharmaceutically acceptable base addition salts of the compounds of formula I include, for example, metallic salts and organic salts. Preferred metallic salts include alkali metal (group la) salts, alkaline earth metal (group Ila) salts, and other physiologically acceptable metal salts. Such salts may be made from aluminum, calcium, lithium, magnesium, potassium, sodium, and zinc. Preferred organic salts can be made from amines, such as tromethamine, diethylamine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), and procaine. Basic nitrogen-containing groups can be quatemized with agents such as lower alkyl (Ci-Cs) halides (e.g., methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (e.g., decyl, lauryl, myristyl, and stearyl chlorides, bromides, and iodides), arylalkyl halides (e.g., benzyl and phenethyl bromides), and others.

[00372] In some embodiments, the salt is sodium salt of N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydro-pyrimidin-l(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide.

[00373] In some embodiments, the salt is monosodium salt ofN-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide.

[00374] In some embodiments, the salt is disodium salt ofN-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydro-pyrimidin-l(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide.

[00375] In some embodiments, the salt is potassium salt of N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydro-pyrimidin-l(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide.

[00376] In some embodiments, the salt is monopotassium salt of N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide. 93 2014280939 24 Dec 2014 [00377] In some embodiments, the salt is choline salt ofN-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydro-pyrimidin-l(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide.

[00378] In some embodiments, the salt is monocholine salt of N-(6-(3-tert-buty 1-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide.

[00379] In some embodiments, the salt is sodium salt of (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydro-pyrimidin-1 (2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide.

[00380] In some embodiments, the salt is disodium salt of (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxystyTyl)phenyl)methanesulfonamide.

[00381] In some embodiments, the salt is potassium salt of (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide.

[00382] In some embodiments, the salt is monopotassium salt of (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide. F Purity’.

[00383] Compounds of formula I (and salts thereof) with any level of purity (including pure and substantially pure) are within the scope of Applicants’ invention. The term “substantially pure” in reference to a compound/salt/isomer, means that the preparation/composition containing the compound/salt/isomer contains more than about 85% by weight of the compound/salt/isomer, preferably more than about 90% by weight of the compound/salt/isomer, preferably more than about 95% by weight of the compound/salt/isomer, preferably more than about 97% by weight of the compound/salt/isomer, and preferably more than about 99% by weight of the compound/salt/isomer. G. Crystalline Forms of Some Specific Compounds and Salts of The Invention.

Gl. Crystalline Forms ofN-(6~(3-Tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2~ methoxyphenyl)naphthalen-2-yl)methanesulfonamide (compound IB-LO-2.3).

[00384] This invention also relates, in part, to crystalline forms of N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide (compound IB-L0-2.3), namely the solvate, hydrate, and solvent-free crystalline forms discussed below. G1A IB-LO-2.3 Solvates.

[00385] This invention also relates, in part, to an ethanol solvate of compound IB-LO-2.3.

[00386] In some embodiments, the ethanol solvate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 8.3±0.2, 9.7±0.2, 10.6±0.2,13.6±0.2,17.2±0.2, 19.2±0.2, 22.7±0.2,26.9±0.2, and 29.4±0.2 degrees two theta (2Θ). In some such embodiments, the ethanol solvate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 8.3±0.2, 9.7±0.2, 10,6±0.2, 13.6±0.2,17.2±0.2, 19.2±0.2, 22.7±0.2,26.9±0.2, and 94 2014280939 24 Dec 2014 29.4±0.2 degrees 2Θ. In other such embodiments, the ethanol solvate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 8.3±0.2, 9.7±0.2, 10.6±0.2, 13.6±0.2, 17.2±0.2, 19.2±0.2, 22.7±0.2, 26.9±0.2, and 29.4±0.2 degrees 2Θ.

[00387] In some embodiments, the ethanol solvate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 8.3±0.2, 9.7±0.2, 10.0±0.2, 10.6±0.2,13.6±0.2, 17.2±0.2, 17.5±0.2, 19.2±0.2, 19.4±0.2,22.7±0.2, 26.9±0.2, and 29.4±0.2 degrees 2Θ. In some such embodiments, the ethanol solvate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 8.3±0.2, 9.7±0.2, 10.0±0.2, 10.6±0.2, 13.6±0.2, 17.2±0.2, 17.5±0.2, 19.2±0.2, 19.4±0.2, 22.7±0.2, 26.9±0.2, and 29.4±0.2 degrees 2Θ. In other embodiments, the ethanol solvate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 8.3±0.2, 9.7±0.2, 10.0±0.2, 10.6±0.2, 13,6±0.2, 17.2±0.2,17.5±0.2,19.2±0.2, 19.4±0.2, 22.7±0.2, 26.9±0.2, and 29.4±0.2 degrees 2Θ.

[00388] In some embodiments, the ethanol solvate has an X-ray powder diffraction pattern substantially as shown in Figure 1. The 2Θ values for the peaks in Figure I (and their intensities) are as follows: 8,25 (54), 9.67 (74), 9.92 (63), 10.59 (21), 13.64 (49), 17.25 (40), 17,51 (20), 19.19 (66), 19.43 (100), 22.75 (19), 26.92 (25), and 29.39 (18).

[00389] This invention also relates, in part, to an acetonitrile solvate of compound IB-LO-2.3.

[00390] In some embodiments, the acetonitrile solvate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 5.3±0.2, 8.3±0.2, 9.7±0.2, 10.5±0.2, 13.8±0.2, 17.2±0.2, 19.1 ±0.2, and 19.5±0.2 degrees 2Θ. In some such embodiments, the acetonitrile solvate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 5.3±0.2, 8.3±0.2, 9.7±0.2, 10.5±0.2, 13.8±0.2,17.2±0.2, 19.1±0.2, and 19.5±0.2 degrees 2Θ. In other such embodiments, the acetonitrile solvate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 5.3±0.2, 8.3±0.2, 9.7±0.2, 10.5±0.2, 13.8±0.2, 17.2±0.2, 19.Ü0.2, and 19.5±0.2 degrees 2Θ.

[00391] In some embodiments, the acetonitrile solvate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 5.3±0.2, 8.3±0.2, 9.7±0.2, 10.5±0.2, 13.8±0.2, 17.2±0.2, 17.7±0.2, 19.1 ±0.2, 19.5±0.2, 22.0±0.2,22,8±0.2, and 27.2±0.2 degrees 20. In some such embodiments, the acetonitrile solvate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 5.3±0.2, 8.3±0.2, 9.7±0.2, 10.5±0.2, 13.8±0.2, 17.2±0.2, 17.7±0.2, 19.Ü0.2, 19.5±0.2,22.0±0.2, 22.8±0.2, and 27.2±0.2 degrees 2Θ. In other such embodiments, the acetonitrile solvate has an X-ray powder diffraction pattern comprising Five or more peaks selected from the group consisting of 5.3±0.2, 8.3±0.2,9.7±0.2,10.5±0.2,13.8±0.2, 17.2±0.2,17.7±0.2,19.H0.2, 19.5±0.2, 22.0±0.2, 22.8±0.2, and 27.2±0.2 degrees 2Θ. 95 2014280939 24 Dec 2014 [00392] In some embodiments, the acetonitrile solvate has an X-ray powder diffraction pattern substantially as shown in Figure 3. The 2Θ values for the peaks in Figure 3 (and their intensities) are as follows: 5.27 (14), 8.29 (33), 9.72 (100), 10.53 (20), 13.77 (67), 17.25 (38), 17.69 (17), 19.05 (63), 19.47 (58), 22.05 (19), 22.75 (16), and 27.17 (21).

[00393] This invention also relates, in part, to an ethyl acetate solvate of compound ÏB-L0-2.3.

[00394] In some embodiments, the ethyl acetate solvate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 7.9±0.2, 9.3±0.2, 9.7±0.2, 10.6±0.2, 18.7±0,2, 38.5±0.2, and 44.7±0.2 degrees 20. In some such embodiments, the ethyl acetate solvate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 7.9±0.2, 9.3±0.2, 9.7±0.2, 10.6±0.2, 18.7±0.2,38.5±0.2, and 44.7±0.2 degrees 26. In other such embodiments, the ethyl acetate solvate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 7.9±0.2, 9.3±0.2, 9.7±0.2, 10.6±0.2, 18,7±0.2, 38.5±0.2, and 44.7±0.2 degrees 20.

[00395] In some embodiments, the ethyl acetate solvate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 7.9±0.2,9.3±0.2, 9.7±0.2, 10.6±0.2, 13.7±0.2, 17.4±0.2, 18.7±0.2, 21.7±0.2, 22.0±0.2,28.2±0.2, 38.5±0.2, and 44.7±0.2 degrees 20. In some such embodiments, the ethyl acetate solvate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 7.9±0.2, 9.3±0.2, 9.7±0.2, 10.6±0.2, 13,7±0.2, 17.4±0.2, 18.7±0.2,21,7±0.2, 22.0±0.2, 28.2±0.2, 38.5±0.2, and 44.7±0.2 degrees 20. In other such embodiments, the ethyl acetate solvate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 7.9±0.2, 9.3±0.2, 9.7±0.2, 10.6±0.2, 13.7±0.2, 17.4±0.2, 18.7±0.2, 21.7±0.2, 22.0±0.2, 28.2±0.2, 38.5±0.2, and 44.7±0.2 degrees 20.

[00396] In some embodiments, the ethyl acetate has an X-ray powder diffraction pattern substantially as shown in Figure 4. The 20 values for the peaks in Figure 4 (and their intensities) are as follows: 7.94 (24), 9.33 (26), 9.72 (13), 10.58 (23), 13.71 (19), 17.40 (28), 18.72 (44), 21.69 (8), 22.04 (10), 28.23 (8), 38.45 (100), and 44.66 (95).

[00397] This invention also relates, in part, to a 2-propanol solvate of compound IB-LO-2.3.

[00398] In some embodiments, the 2-propanol solvate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 8.2±0.2, 9.3±0.2, 10.1±0.2, 16.3±0.2, 18.1±0.2, 18.6±0.2, 19.4±0.2, 21.6±0.2, and 22.5±0.2 degrees 2Θ. In some such embodiments, the 2-propanol solvate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 8.2±0.2, 9.3±0.2, 10.1=0.2, 16.3±0.2, 18.1±0.2, 18.6±0.2, 19.4±0.2,21.6±0.2, and 22.5±0.2 degrees 20. In other such embodiments, the 2-propanol solvate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 8.2±0.2, 9.3±0.2, 10.Ü0.2, 16.3±0.2, 96 2014280939 24 Dec 2014 18.1=0.2, 18.6±0.2, 19.4=0.2,21,6±0.2, and 22.5±0.2 degrees 2Θ.

[00399] Tn some embodiments, the 2-propanol solvate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 8.2=0.2, 9.3±0.2, 10.1=0.2, 16.3=0.2,18.1=0.2, 18.6±0,2, 19.4±0.2, 21.6±0.2,22.5=0.2,23.8=0.2,26.0±0.2, and 28.0=0.2 degrees 20. In some such embodiments, the 2-propanol solvate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 8.2=0.2, 9.3=0.2, 10.HO.2, 16,3±0.2,18,1=0.2, 18.6=0.2, 19.4=0.2, 21.6=0.2, 22.5=0.2, 23.8=0.2, 26.0=0.2, and 28.0=0.2 degrees 20. In other such embodiments, the 2-propanol solvate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 8.2=0.2,9.3=0.2, 10.1=0.2, 16.3=0.2, 18.1=0.2, 18.6=0.2, 19.4=0.2, 21.6=0.2, 22.5=0.2, 23.8=0.2, 26.0=0.2, and 28.0=0.2 degrees 20.

[00400| In some embodiments, the 2-propanol solvate has an X-ray powder diffraction pattern substantially as shown in Figure 5. The 20 values for the peaks in Figure 5 (and their intensities) are as follows: 8.18(32), 9.26(100), 10.12 (81), 16.28(93), 18.11 (30), 18.59(63), 19.40(67),21.57(60), 22.51 (31), 23.82 (29), 25.94 (24), and 28.05 (29).

[00401] This invention also relates, in part, to a methanol solvate of compound IB-LO-2.3.

[00402] In some embodiments, the methanol solvate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 8.4=0.2, 9.7=0.2, 10.1=0.2, 13.8=0.2, 17.4=0.2, 19.3=0.2, and 19.6=0.2 degrees 20. In some such embodiments, the methanol solvate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 8.4=0.2, 9.7=0.2, 10.1=0.2, 13.8=0.2, 17.4=0.2, 19.3=0.2, and 19.6=0.2 degrees 20. In other such embodiments, the methanol solvate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 8.4=0.2, 9.7=0.2, 10.1=0.2, 13.8=0.2, 17.4=0.2, 19.3=0.2, and 19.6=0.2 degrees 20.

[00403] In some embodiments, the methanol solvate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 8.4=0.2, 9.7=0.2, 10.1=0.2,13.5=0.2, 13.8=0.2, 17.4=0.2, 19.3=0.2, 19.6=0.2, and 27.1=0.2 degrees 20. In some such embodiments, the methanol solvate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 8.4=0.2, 9.7=0.2, 10.1=0.2, 13.5=0.2, 13.8=0.2, 17.4=0.2, 19.3=0.2, 19.6=0.2, and 27.1=0.2 degrees 2Θ. In other such embodiments, the methanol solvate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 8.4=0.2,9.7=0.2, 10.1=0.2,13.5=0.2, 13.8=0.2, 17.4=0.2, 19.3=0.2, 19.6=0.2, and 27.1=0.2 degrees 20.

[00404] In some embodiments, the methanol solvate has an X-ray powder diffraction pattern substantially as shown in Figure 6. The 20 values for the peaks in Figure 6 (and their intensities) are as follows: 8.36 (48), 9.74 (65), 10.05 (74), 13.55 (24), 13.79 (69), 17.40 (32), 19.30 (80), 19.58 (100), and 27.08 (24). 97 2014280939 24 Dec 2014 [00405] This invention also relates, in part, to a 1-propanol solvate of compound IB-LO-2.3.

[00406] In some embodiments, the 1-propanol solvate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 8.2±0.2,9.3±0.2, 10.1+0.2, 15.7+0.2, 16.2+0.2, 18.4+0.2, 19.3+0.2, 21.6+0.2, and 22.8+0.2 degrees 20, In some such embodiments, the 1-propanol solvate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 8.2+0.2, 9.3+0.2, 10.1+0.2, 15.7+0.2, 16.2+0.2, 18.4+0.2, 19.3+0.2, 21.6+0.2, and 22.8+0.2 degrees 2Θ. In other such embodiments, the 1-propanol solvate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 8.2+0.2, 9.3+0.2, 10.1+0.2, 15.7+0.2, 16.2 ±0.2, 18.4+0.2, 19.3+0.2, 21.6+0.2, and 22.8+0.2 degrees 20.

[00407] In some embodiments, the 1-propanol solvate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 8.2+0.2, 9.3+0.2, 10.1+0.2, 10.5+0.2, 15.7+0.2, 16.2 ±0.2, 18.4+0.2, 18.6+0.2, 19.3+0.2, 21.0+0.2, 21.6+0.2, and 22.8+0.2 degrees 2Θ. In some such embodiments, the 1-propanol solvate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 8.2+0.2, 9.3+0.2, 10.1+0.2,10.5+0.2, 15.7+0.2, 16.2+0.2, 18.4+0.2, 18.6+0.2, 19.3+0.2, 21.0+0.2, 21.6+0.2, and 22.8+0.2 degrees 20. In other such embodiments, the 1 -propanol solvate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 8.2+0.2, 9.3+0.2, 10.1+0.2,10.5+0.2, 15.7+0.2, 16.2+0.2, 18.4+0.2, 18.6+0.2, 19.3+0.2, 21.0+0.2, 21.6+0.2, and 22.8+0.2 degrees 20.

[00408] In some embodiments, the 1-propanol solvate has an X-ray powder diffraction pattern substantially as shown in Figure 7. The 20 values for the peaks in Figure 7 (and their intensities) are as follows: 8.15 (27),9.26(87), 10.08(84), 10.47 (62), 15.73 (40), 16.24(100), 18.37(41), 18.59(49), 19.33 (50), 20.97 (28), 21.65 (71), and 22.81 (44).

[00409] This invention also relates, in part, to a process for preparing the above solvates by suspending compound IB-LO-2.3 in the corresponding solvent. GIB. Solvent Free IB-LO-2.3.

[00410] This invention also relates, in part, to a solvent free crystalline form of compound IB-LO-2.3.

[00411] In some embodiments, the solvent free compound IB-LO-2.3 has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 6.2+0.2, 7.9+0.2, 9.9+0.2, 16.2+0.2, and 18.3+0.2 degrees two theta (20). In some such embodiments, the solvent free compound IB-LO-2.3 has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 6.2+0.2, 7.9+0.2, 9.9+0.2, 16.2+0.2, and 18.3+0.2 degrees 2Θ. In other such embodiments, the solvent free compound IB-LO-2.3 has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 6.2+0.2, 7.9+0.2, 9.9+0.2, 16.2+0.2, and 18.3+0.2 degrees 2Θ. 98 2014280939 24 Dec 2014 [00412] In some embodiments, the solvent free compound IB-LO-2.3 has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 6.2+0.2, 7.9+0.2, 9.9+0.2, 10.1+0.2, 14.9+0.2, 16.2+0.2, 18.3+0.2, 19.8+0.2, and 26.5+0.2 degrees 20. In some such embodiments, the solvent free compound IB-LO-2.3 has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 6.2+0.2, 7.9+0.2, 9.9+0.2, 10.1+0.2, 14.9+0.2, 16.2+0.2, 18.3+0.2, 19.8+0.2, and 26.5+0.2 degrees 20. In other such embodiments, the solvent free compound IB-LO-2.3 has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 6.2+0.2, 7.9+0.2, 9.9+0.2, 10.1+0.2, 14.9+0.2, 16.2+0.2, 18.3+0.2, 19.8+0.2, and 26.5+0.2 degrees 20. In yet other such embodiments, the solvent free compound IB-LO-2.3 has an X-ray powder diffraction pattern comprising eight or more peaks selected from the group consisting of 6.2+0.2, 7.9+0.2, 9.9+0.2, 10.1+0.2, 14.9+0.2, 16.2+0.2, 18.3+0.2, 19.8+0.2, and 26.5+0.2 degrees 20.

[00413] In some embodiments, the solvent free compound IB-LO-2.3 has an X-ray powder diffraction pattern substantially as shown in Figure 8. The 20 values for the peaks in Figure 8 (and their intensities) are as follows: 6.20 (36), 7.85 (66), 9.89 (61), 10.12 (75), 14.87 (27), 16.19 (89), 18.32 (100), 19.82 (77), and 26.53 (34).

[00414] This invention also relates, in part, to a process for preparing the solvent free crystalline form of compound IB-LO-2.3 by desolvating one of IB-LO-2.3 solvates discussed above. A solvate can be desolvated by heating the solvate solid for about lOmin at ~125°C. G1C IB-LO-2.3 Hydrate.

[00415] This invention also relates, in part, to a hydrate of compound IB-LO-2.3.

[00416] In some embodiments, the hydrate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 6.4+0.2, 12.9+0.2,17.9+0.2, and 18.9+0.2 degrees 20.

In some such embodiments, the hydrate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 6.4+0.2, 12.9+0.2,17.9+0.2, and 18.9+0.2 degrees 20.

[00417] In some embodiments, the hydrate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 6.4+0.2, 12.9+0.2, 17.5+0.2, 17.9+0.2, 18.9+0.2, and 24.4+0.2 degrees 2Θ. In some such embodiments, the hydrate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 6.4+0.2, 12.9+0.2, 17.5+0.2, 17.9+0.2, 18.9+0.2, and 24.4+0.2 degrees 20. In other such embodiments, the hydrate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 6.4+0.2, 12.9+0.2, 17.5+0.2, 17.9+0.2, 18.9+0.2, and 24.4+0.2 degrees 20.

[00418] In some embodiments, the hydrate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 6,4+0.2, 12.7+0.2, 12.9+0.2, 14.1+0.2, 15.7+0.2, 17.2+0.2,17.5+0.2, 17.9+0.2, 18.9+0.2, 21.2+0.2,24.4+0.2, and 25.0+0.2 degrees 20. In some such 99 2014280939 24 Dec 2014 embodiments, the hydrate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 6.4±0.2, 12.7+0.2, 12.9+0.2. 14.1 ±0.2, 15.7±0.2, 17.2+0.2, 17.5±0.2,17.9±0.2, 18.9+0.2, 21.2+0.2,24.4±0.2, and 25.0±0.2 degrees 2Θ. In other such embodiments, the hydrate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 6.4±0.2, 12,7±0.2, 12.9+0.2, 14.1+0,2, 15.7+0.2, 17.2+0.2, 17.5+0.2, 17.9+0.2, 18.9+0.2,21.2±0.2, 24.4+0.2, and 25.0±0.2 degrees 2Θ.

[00419] In some embodiments, the hydrate has an X-ray powder diffraction pattern substantially as shown in Figure 9. The 2Θ values for the peaks in Figure 9 (and their intensities) are as follows: 6.42 (60), 12.71 (33), 12.89 (58), 14.05 (17), 15.68 (18), 17.22 (44), 17.53 (100), 17.86 (51), 18.87 (77),21.25 (17), 24.35 (28), and 24.95(20).

[00420] This invention also relates, in part, to a process for preparing the hydrate by suspending the above-described solvent free crystalline compound in water. The hydrate was prepared by suspending 300mg of the solvent free crystalline compound in 2ml of water at 45°C for four days. G2. Crystalline Forms of N-(6-(3-Tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide, Monosodium Salt.

[00421] This invention also relates, in part, to crystalline forms of N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl)naphthalen-2-y])methanesulfonamide, monosodium salt, namely the pattern A, pattern B, and pattern C crystalline forms discussed below.

[00422] This invention relates, in part, to a pattern A crystalline monosodium salt.

[00423] In some embodiments, the pattern A monosodium salt has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 4.6±0.2, 10.4±0.2, 12.0+0.2, 15.6+0.2, 18.6+0.2, 22.8±0.2, and 23.9+0.2 degrees 2Θ. In some such embodiments, the pattern A monosodium salt has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 4.6±0.2, 10.4±0.2, 12.0±0.2, 15,6±0.2, 18.6+0.2, 22.8+0.2, and 23.9+0.2 degrees 2Θ. In other such embodiments, the pattern A monosodium salt has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 4.6±0.2, 10.4±0.2, 12.0±0.2, 15.610.2, 18.6+0.2, 22.8±0.2, and 23.9+0.2 degrees 20.

[00424] In some embodiments, the pattern A monosodium salt has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 4.6±0.2, 10.4±0.2, 12.0+0.2, 15.6±0.2, 18.6±0.2, 22.8±0.2,23.3+0.2, and 23.9±0.2 degrees 20. In some such embodiments, the pattern A monosodium salt has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 4.6±0.2, 10.4+0.2, 12.0±0.2, 15.6±0.2, 18.6±0.2, 22.8±0.2, 23.3+0.2, and 23.9+0.2 degrees 20. In other such embodiments, the pattern A monosodium salt has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 4.6+0.2, 10.4±0.2, 12.0+0.2, 100 2014280939 24 Dec 2014 15.6±0.2, 18.6±0.2, 22.8±0.2, 23.3±0.2, and 23.9±0.2 degrees 2Θ.

[00425] In some embodiments, the pattern A monosodium salt has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 4.6±0.2, 10.4±0.2, 12.0±0.2, 15.6±0.2, 16.0±0,2, 18.6±0.2, 22.8±0.2, 23.3±0.2, 23.9±0,2, and 28.3±0.2 degrees 2Θ. In some such embodiments, the pattern A monosodium salt has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 4.6±0.2, 10.4±0.2, 12.0±0.2, 15.6±0.2, 16.0±0.2, 18.6±0.2,22.8±0.2, 23,3±0.2, 23.9±0.2, and 28.3±0.2 degrees 2Θ. In other such embodiments, the pattern A monosodium salt has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 4.6±0.2, 10.4±0.2, 12.0±0.2, 15.6±0.2, 16.0±0.2, 18.6±0.2, 22.8±0.2, 23.3±0.2, 23.9±0.2, and 28.3±0.2 degrees 2Θ. In other such embodiments, the pattern A monosodium salt has an X-ray powder diffraction pattern comprising eight or more peaks selected from the group consisting of 4.6±0.2, 10.4±0.2, 12.0±0.2, 15.6±0.2, 16.0±0.2, 18.6±0.2, 22.8±0.2, 23.3±0.2,23.9±0.2, and 28.3±0.2 degrees 2Θ.

[00426] In some embodiments, the pattern A monosodium salt has an X-ray powder diffraction pattern substantially as shown in Figure 10. The 2Θ values for the peaks in Figure 10 (and their intensities) are as follows: 4.64 (62), 10.41 (38), 12.04 (38), 15.62 (44), 15.99 (44), 18.63 (49), 22.77 (60), 23.29 (40), 23.93 (100), and 28.31 (56).

[00427] This invention also relates, in part, to a process for preparing the pattern A monosodium salt.

The pattern A monosodium salt was prepared by adding 1M aqueous NaOH (0.548ml) to compound IB-LO-2.3 (225.72mg), seeding the resulting suspension with crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyi)naphthalen-2-yl)methanesuIfonamide, disodium salt (prepared as discussed below), and equilibrating the resulting suspension at ambient conditions. The pattern A monosodium salt was formed on the following day through a solution-mediated process. The stoichiometry of the salt was presumed to be 1:1 based on the crystallization procedure. This invention also relates, in part, to a pattern B crystalline monosodium salt.

[00429] In some embodiments, the pattern B monosodium salt has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 5.4±0.2, 10.8±0,2,14.4±0.2, 16.3±0.2,17.0±0.2, 21,6±0.2,22.1±0.2, and 23.7±0.2 degrees 2Θ. In some such embodiments, the pattern B monosodium salt has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 5.4±0.2, 10.8±0.2, 14.4±0.2, 16.3±0.2, 17.0±0.2, 21,6±0.2, 22.1±0.2, and 23.7±0.2 degrees 2Θ. In other such embodiments, the pattern B monosodium salt has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 5.4±0.2, 10.8±0.2, 14.4±0.2, 16.3±0.2, 17.0±0.2, 21.6±0.2,22.U0.2, and 23.7±0.2 degrees 20.

[00430] In some embodiments, the pattern B monosodium salt has an X-ray powder diffraction pattern 101 2014280939 24 Dec 2014 comprising one or more peaks selected from the group consisting of 5.4±0.2, 10.8+0.2, 14.4±0.2, 16.3±0.2, 17.0+0.2,18.8±0.2, 19.2+0.2, 19.6+0.2,21.6+0.2,22.1+0.2, 23.7+0.2,28.8+0.2, 29.1±0.2,and 31.8±0.2 degrees 2Θ. In some such embodiments, the pattern B monosodium salt has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 5.4+0.2, 10.8+0.2, 14.4±0.2, 16.3±0.2, 17.0±0.2, 18.8±0.2, 19.2±0.2, 19.6±0.2, 21.6±0.2, 22.1+0.2, 23.7+0.2, 28.8+0.2, 29.1+0,2, and 31.8+0.2 degrees 2Θ. In other such embodiments, the pattern B monosodium salt has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 5.4+0.2,10.8+0.2, 14.4+0.2, 16.3+0.2, 17.0+0.2, 18.8+0.2, 19.2+0.2, 19.6+0.2, 21.6+0.2, 22.1+0.2, 23.7+0.2, 28.8+0.2, 29.1+0.2, and 31.8+0.2 degrees 20. In other such embodiments, the pattern B monosodium salt has an X-ray powder diffraction pattern comprising eight or more peaks selected from the group consisting of 5.4+0.2, 10.8+0.2, 14.4+0.2,16.3+0.2,17.0+0.2,18.8+0.2, 19.2+0.2,19.6+0.2, 21.6+0.2, 22.1+0.2,23.7+0.2,28.8+0.2, 29.1+0.2, and 31.8+0.2 degrees 20.

[00431] In some embodiments, the pattern B monosodium salt has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 5.4+0.2, 10.8+0.2,14.4+0.2, 16.3+0.2, 17.0+0.2, 18.8+0.2, 19.2+0.2, 19.6+0.2, 21.6+0.2, 22.1+0.2, 23.7+0.2, 28.8+0.2, 29.1+0.2, and 31.8+0.2 degrees 2Θ. In some such embodiments, the pattern B monosodium salt has an X-ray powder diffraction pattern comprising two or more peaks selected from the group consisting of 5.4+0.2, 10.8+0.2, 14.4+0.2, 16.3+0.2,17.0+0.2, 18.8+0.2, 19.2+0.2, 19.6+0.2, 21.6+0.2, 22.1+0.2, 23.7+0.2, 29.1+0.2, and 31.8+0.2 degrees 20. In other such embodiments, the pattern B monosodium salt has an X-ray powder diffraction pattern comprising two or more peaks selected from the group consisting of 5.4+0.2, 10.8+0.2, 14.4+0.2, 16.3+0.2, 17.0+0.2, 18.8+0.2,19.2+0.2,19.6+0.2,21.6+0.2,22.1+0.2, 23.7+0.2,28.8+0.2, and 31.8+0.2 degrees 20. In yet other such embodiments, the pattern B monosodium salt has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 5.4+0.2, 10.8+0.2, 14.4+0.2,16.3+0.2,17.0+0.2,18.8+0.2,19.2+0.2,19.6+0.2, 21.6+0.2, 22.1+0.2, 23.7+0.2, and 31.8+0.2 degrees 20. In yet other such embodiments, the pattern B monosodium salt has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 5.4+0.2, 10.8+0.2, 14.4+0.2, 16.3+0.2, 17.0+0.2, 18.8+0.2, 19.2+0.2, 21.6+0.2,22.1+0.2, and 23.7+0.2 degrees 20. In yet other such embodiments, the pattern B monosodium salt has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 5.4+0.2, 10.8+0.2, 14.4+0.2, 16.3+0.2, 17.0+0.2, 19.2+0.2, 21.6+0.2,22.1+0.2, and 23.7+0.2 degrees 20. In yet other such embodiments, the pattern B monosodium salt has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 5.4+0.2,10.8+0.2,14.4+0.2, 16.3+0.2,17.0+0.2, 18.8+0.2, 21.6+0.2, 22.1+0.2, and 23.7+0.2 degrees 20. In yet other such embodiments, the pattern B monosodium salt has an X-ray powder diffraction pattern comprising three or more peaks selected from 102 2014280939 24 Dec 2014 the group consisting of 5.4±0.2,10.8±0.2, 14.4±0.2,16.3±0.2,17.0±0.2, 21.6±0.2, 22.1±0.2, and 23.7±0.2 degrees 2Θ. In yet other such embodiments, the pattern B monosodium salt has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 5.4±0.2, 10.8±0.2,16.3±0.2, 22.U0.2, and 23.7±0.2 degrees 2Θ.

[00432] In some embodiments, the pattern B monosodium salt has an X-ray powder diffraction pattern comprising peaks at 5.4±0.2, 10.8±0.2, and 16.3±0.2 degrees 2Θ. In some such embodiments, the pattern B monosodium salt has an X-ray powder diffraction pattern comprising peaks at 5.4±0.2, 10.8±0.2, 16.3±0.2, and 22.1±0.2 degrees 2Θ. In other such embodiments, the pattern B monosodium salt has an X-ray powder diffraction pattern comprising peaks at 5.4±0.2, 10.8±0.2, 16.3±0.2, 22.Ü0.2, and 23.7±0.2 degrees 2Θ. In yet other such embodiments, the pattern B monosodium salt has an X-ray powder diffraction pattern comprising peaks at 5.4±0.2, 10.8±0.2,14.4±0.2, 16.3±0.2, 17.0±0.2, 21.6±0.2, 22.1±0.2, and 23.7±0.2 degrees 2Θ. In yet other such embodiments, the pattern B monosodium salt has an X-ray powder diffraction pattern comprising peaks at 5.4±0.2, 10.8±0.2, 14.4±0,2,16.3±0.2,17.0±0.2, 18.8±0.2,21.6±0.2,22.1 ±0.2, and 23.7±0.2 degrees 2Θ. In yet other such embodiments, the pattern B monosodium salt has an X-ray powder diffraction pattern comprising peaks at 5.4±0.2, 10.8±0.2, 14.4±0.2, 16.3±0.2, 17.0±0.2, 19.2±0.2, 21.6±0.2,22.1+0.2, and 23.7±0.2 degrees 2Θ. In yet other such embodiments, the pattern B monosodium salt has an X-ray powder diffraction pattern comprising peaks at 5.4±0.2, 10.8±0.2,14.4±0.2, 16.3=-0.2, 17.0±0.2, 18.8±0.2, 19.2±0.2, 21.6±0.2, 22.1±0.2, and 23.7±0.2 degrees 20. In further such embodiments, the pattern B monosodium salt has an X-ray powder diffraction pattern comprising peaks at 5.4±0.2, 10.8±0.2,14.4±0.2, 16.3±0.2, 17.0±0.2, 18.8±0.2, 19.2±0.2, 19.6±0.2, 21.6±0.2, 22.U0.2, 23.7±0.2, and 31.8±0.2 degrees 20. In yet further such embodiments, the pattern B monosodium salt has an X-ray powder diffraction pattern comprising peaks at 5.4±0.2, 10.8±0.2, 14.4±0.2, 16.3±0.2, 17.0±0.2, 18.8±0.2, 19.2±0.2, 19.6±0.2, 21.6±0.2, 22.Ü0.2, 23.7±0.2, 28.8±0.2, and 31,8±0.2 degrees 20. In yet further such embodiments, the pattern B monosodium salt has an X-ray powder diffraction pattern comprising peaks at 5.4±0.2, 10.8±0.2, 14.4±0.2, 16.3±0.2, 17.0±0.2, 18.8±0.2, 19.2±0.2, 19.6±0.2, 21.6±0.2,22.Ü0.2, 23.7±0.2, 29.U0.2, and 31.8±0.2 degrees 20. In yet further such embodiments, the pattern B monosodium salt has an X-ray powder diffraction pattern comprising peaks at 5.4±0.2, 10.8±0.2, 14.4±0.2, 16.3±0.2, 17.0±0.2, 18.8±0.2, 19.2±0.2, 19.6±0.2, 21.6±0.2, 22.Ü0.2, 23.7±0.2, 28.8±0.2, 29.Ü0.2, and 31.8±0.2 degrees 20.

[00433] In some embodiments, the pattern B monosodium salt has an X-ray powder diffraction pattern substantially as shown in Figure 12. The 20 values for the peaks in Figure 12 (and their intensities) are as follows: 5.36 (100), 10.75 (42), 14.43 (20), 16.34 (60), 17.00 (25), 18.83 (18), 19.24 (18), 19.66 (12), 21.64 (29), 22.12 (41), 23.73 (32), 28.83 (9), 29.10 (9), and31.78 (10).

[00434] This invention also relates, in part, to a process for preparing the pattern B monosodium salt. 103 2014280939 24 Dec 2014

The pattern B monosodium salt can prepared by suspending the pattern A monosodium salt (for example, ~ 30mg) in various organic solvents (e.g., ~ 125ul acetonitrile, ethanol, 1-propanol, or 2-propanol) at room temperature. The pattern B monosodium salt was also prepared by seeding a solution with pattern B monosodium salt. Compound IB-LO-2.3 (12.5g) was dissolved in DMSO (37.5ml) at ~68°C. 1,04g NaOH dissolved in 6.3ml of water, 6.3ml 2-propanol, and 12.5ml 35.2:1 v/v 2-propanol/water was added. The solution was seeded with 125mg of pattern B seeds slurried in 12.5ml of 3 5.2:1 v/v 2-propanol/water, and the crystallization slurry was incubated at ~68°C for ~1.5h. 175ml 35.2:1 v/v 2-propanol/water at ~68°C was added over ~7h, and the crystallization slurry was cooled to ~0°C over no less than 7h. The crystals were isolated by filtration and analyzed by PXRD. The crystals were then dried at ~50°C under vacuum (approximately 3 inches of mercury). The dried crystals were analyzed by PXRD, which showed no change in comparison to the pre-drying sample. The stoichiometry of the pattern B monosodium salt was confirmed by ion chromatography.

[00435] This invention also relates, in part, to a pattern C crystalline monosodium salt.

[00436] In some embodiments, the pattern C monosodium salt has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 5.0±0.2, 12.0±0.2, 17.5±0.2, 18.8±0.2, and 22.7±0.2 degrees 2Θ. In some such embodiments, the pattern C monosodium salt has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 5.0±0.2, 12.0±0.2,17.5±0.2, 18.8±0.2, and 22.7±0.2 degrees 2Θ.

[00437] In some embodiments, the pattern C monosodium salt has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 5.0±0.2, 12.0±0.2, 17.5±0.2, 17.8±0.2,18.8±0.2, and 22.7±0.2 degrees 2Θ. In some such embodiments, the pattern A monosodium salt has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 5.0±0.2, 12.0±0.2, 17.5±0.2, 17.8±0.2, 18.8±0.2, and 22.7±0.2 degrees 2Θ. In other such embodiments, the pattern A monosodium salt has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 5.0±0.2, 12.0±0.2, 17.5±0.2, 17.8±0.2, 18.8±0.2, and 22.7±0.2 degrees 2Θ.

[00438] In some embodiments, the pattern C monosodium salt has an X-ray powder diffraction pattern substantially as shown in Figure 14. The 2Θ values for the peaks in Figure 14 (and their intensities) are as follows: 4.97 (100), 12.03 (24), 17.55 (32), 17.80 (77), 18.79 (23), and 22.74 (33).

[00439] This invention also relates, in part, to a process for preparing the pattern C monosodium salt. The pattern C monosodium salt was prepared as follows. Pattern B monosodium salt (lOOmg) was dissolved in 400ul DMSO and 2ml 12:1 v/v 2-propanol/H20 at 70°C. Pattern B monosodium salt seed crystals were added to the solution, and the solution was then cooled to ambient temperature over 20min. Filtration yielded crystals of the pattern C monosodium salt. 104 2014280939 24 Dec 2014 G3. Crystalline Form ofN-(6-(3-Tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide, Disodium Salt.

[00440] This invention also relates, in part, to a crystalline form of N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide, disodium salt.

[00441] In some embodiments, the disodium salt has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 4.8±0.2,9.6±0.2, 10.5±0.2, 13.0±0.2, 14.6±0.2, 15.4±0.2, 16.8 ±0.2, and 23.0±0.2 degrees 20. In some such embodiments, the disodium salt has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 4.8±0.2, 9.6±0.2,10.5±0.2,13.0±0.2, 14.6±0.2, 15.4±0.2, 16.8 ±0.2, and 23.0±0.2 degrees 20. hi other such embodiments, the disodium salt has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 4.8±0.2,9.6±0.2, 10.5±0.2,13,0±0.2, 14.6±0.2, 15.4±0.2, 16.8 ±0.2, and 23.0±0.2 degrees 20.

[00442] In some embodiments, the disodium salt has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 4.8±0.2, 9.6±0.2, 10.5±0.2, 13.0±0.2, 14.6±0.2, 15.4±0.2, 16.8 ±0.2, 22.7±0.2, 23.0±0.2, and 23.3±0.2 degrees 20. In some such embodiments, the disodium salt has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 4.8±0.2, 9.6±0.2, 10.5±0.2, 13.0±0.2, 14.6±0.2, 15.4±0.2,16.8 ±0.2, 22.7±0.2, 23.0±0.2, and 23.3±0.2 degrees 20. In other such embodiments, the disodium salt has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 4.8±0.2, 9.6±0.2, 10.5±0.2, 13.0±0.2, 14.6±0.2, 15.4±0.2, 16.8 ±0.2, 22.7±0.2, 23.0±0.2, and23.3±0,2 degrees 20.

[00443] In some embodiments, the disodium salt has an X-ray powder diffraction pattern substantially as shown in Figure 15. The 20 values for the peaks in Figure 15 (and their intensities) are as follows: 4.80 (100), 9.59(10), 10.51 (13), 12.98(11), 14.56(8), 15.38(12), 16.84(6), 22.68(10), 23.04 (6),and 23.33 (4).

[00444] This invention also relates, in part, to a process for preparing the disodium salt. The disodium salt was prepared by suspending compound IB-LO-2.3 (52.83mg) in 1M aqueous NaOH (1.1ml) (the molar ratio compound:NaOH was 1:10). The solution was heated to 36°C, and the solid dissolved completely to yield a clear solution. The solution was naturally cooled to ambient temperature, and the salt crystallized in 24h. Alternatively, the disodium salt was prepared by suspending compound IB-LO-2.3 (51mg) in EtOH (1ml). NaOH in 1.2ml of 5:1 v/v EtOH/H20 (2.1 molar equivalent) was added. The reaction mixture was concentrated and 2ml acetonitrile was added to induce crystallization. The stoichiometry of this solid was determined by ion chromatography. G4. Crystalline Form o/N-(6-(3-Tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2~ methoxyphenyl)naphthalen-2-yl)methanesulfonamide, Monopotassium Salt. 105 2014280939 24 Dec 2014 [00445] This invention also relates, in part, to a crystalline form ofN-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide, monopotassium salt.

[00446] In some embodiments, the monopotassium salt has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 5.0±0.2,9.9±0.2, 11.3±0.2, 13.3±0.2, 16.9±0.2, 18.U0.2,19.1±0.2, 20.0±0.2,21.1±0.2, 23.5±0.2, 24.8±0.2, and 25.7±0.2 degrees 2Θ. In some such embodiments, the monopotassium salt has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 5.0±0.2, 9.9±0.2, 11.3±0.2, 13.3±0.2, 16.9±0,2, 18,1±0.2, 19.1±0.2,20.0±0.2, 21.1 ±0.2, 23.5±0.2,24.8±0.2, and 25.7±0.2 degrees 2Θ. In other such embodiments, the monopotassium salt has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 5.0±0.2, 9.9±0.2, 11.3±0.2, 13.3±0.2, 16.9±0.2, 18.1±0.2, 19.1±0.2, 20.0±0.2, 21.1±0.2, 23.5±0.2, 24.8±0.2, and 25.7±0.2degrees 2Θ.

[00447] In some embodiments, the monopotassium salt has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 5.0±0.2,9.9±0.2, 11.3±0.2,13.3±0.2, 16.9±0.2, 18.1±0.2, 19.1±0.2,20.0±0.2, 21.1±0.2,21.5±0.2, 23.5±0.2,24.8±0.2, and 25.7±0.2 degrees 2Θ. In some such embodiments, the monopotassium salt has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 5.0±0.2, 9.9±0.2, 11.3±0.2, 13.3±0.2,16.9±0.2, 18.1±0.2, 19.1±0,2, 20.0±0.2, 21.1±0.2, 21.5±0.2, 23.5±0.2, 24.8±0.2, and 25.7±0.2 degrees 2Θ. In other such embodiments, the monopotassium salt has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 5.0±0.2, 9.9±0.2, 11.3±0.2, 13.3±0.2, 16,9±0.2, 18.1 ±0.2, 19.1±0.2, 20.0±0.2, 21.1±0.2, 21.5±0.2,23.5±0.2, 24.8±0.2, and 25.7±0.2degrees 2Θ.

[00448] In some embodiments, the monopotassium salt has an X-ray powder diffraction pattern substantially as shown in Figure 17. The 2Θ values for the peaks in Figure 17 (and their intensities) are as follows: 4.97 (100), 9.94 (7), 11.33(15), 13.28 (7), 16.91 (5), 18.13 (7), 19.14(4), 20.00(4),21.13 (4), 21.45 (4), 23.54 (4), 24.84 (3), and 25.67 (6).

[00449] This invention also relates, in part, to a process for preparing the monopotassium salt. The monopotassium salt was prepared in aqueous medium. 0.366ml of 1M aqueous KOH was added to 150.56mg of compound IB-LO-2.3 (molar ratio 1:1.2). The resulting suspension was equilibrated at ambient conditions. The monopotassium salt was formed on the following day through a solution-mediated process. Alternatively, the monopotassium salt was prepared by suspending compound IB-LO-2.3 (300mg) in 3ml acetonitrile. KOH in 1,3mL of H20 (2.1 molar equivalent) was added. Additional lml H?0 was added to dissolve all solids. Afterwards, 12ml acetonitrile was added to induce crystallization. The stoichiometry of the salt was confirmed by ion chromatograph. G5. Crystalline Forms ofN-(6-(3-Tert-hutyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2- 106 2014280939 24 Dec 2014 methoxyphenyl)naphthalen-2-yl)methanesulfonamide, Monocholine Salt.

[00450] This invention also relates, in part, to crystalline forms of N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide, monocholine salt, namely the pattern A and pattern B crystalline forms discussed below.

[00451] This invention relates, in part, to a pattern A crystalline monocholine salt.

[00452] In some embodiments, the pattern A monocholine salt has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 10.9±0.2, 12.1 ±0.2, 13.4±0.2, 15.5±0.2, 17.0±0.2,17.8±0.2, 18.3±0.2, 19.5±0.2, and 21.9±0.2 degrees 2Θ. In some such embodiments, the pattern A monocholine salt has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 10.9±0.2, 12.Ü0.2,13.4±0.2, 15.5±0.2,17.0±0.2,17.8±0.2, 18.3±0.2, 19.5±0.2, and 21,9±0.2 degrees 2Θ. In other such embodiments, the pattern A monocholine salt has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 10.9±0.2, 12.1±0.2, 13.4±0.2, 15.5±0.2, 17.0±0.2, 17.8±0.2, 18.3±0.2, 19.5±0.2, and 21,9±0.2 degrees 2Θ.

[00453] In some embodiments, the pattern A monocholine salt has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 10.9±0.2, 12. I±0.2, 13.0±0.2, 13.4±0.2, 13.6±0.2,15.5±0.2, 17.ft±0.2, 17.8±0.2,18.3±0.2,19.5±0.2, I9.7±0.2, and 21.9±0.2 degrees 2Θ. In some such embodiments, the pattern A monocholine salt has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of degrees 2Θ. In other such embodiments, the pattern A monocholine salt has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of degrees 2Θ.

[00454] In some embodiments, the pattern A monocholine salt has an X-ray powder diffraction pattern substantially as shown in Figure 19. The 2Θ values for the peaks in Figure 19 (and their intensities) are as follows: 10.94 (42), 12.06 (20), 12.96 (26), 13.42 (64), 13.64 (27), 15.51 (18), 16.98 (78), 17.81 (26), 18.32(100), 19.49(48), 19.70 (33), and 21.91 (22).

[00455] This invention also relates, in part, to a process for preparing the pattern A monocholine salt. It was prepared in a solvent mixture of tetrahydrofiiran (THF) and methanol. Compound IB-LO-2.3 (56.79mg) was dissolved in THF at 60°C, 40.0 lmg of choline hydroxide solution (45wt% in methanol) was added resulting in a molar ratio of 1:1.2. The crystals formed upon natural cooling to ambient temperature.

[00456] This invention also relates, in part, to a pattern B crystalline monocholine salt.

[00457] In some embodiments, the pattern B monocholine salt has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 8.0±0.2, 9.4±0.2,11.0±0.2, 13.0±0.2, 13.7±0.2, 15.9±0.2, 17.0±0.2, 18.3±0.2, 18.9±0.2, 19.8±0.2, and 22.1 ±0.2 degrees 2Θ. In some such 107 2014280939 24 Dec 2014 embodiments, the pattern B monocholine salt has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 8.0±0,2,9.440.2, 11.040.2, 13.040.2, 13.7±0.2, 15.9±0,2, 17.040.2, 18.3±0.2, 18.9±0.2, 19.840.2, and 22.140.2 degrees 20. In other such embodiments, the pattern B monocholine salt has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 8.0±0.2, 9.4=10.2, 11.040.2, 13.040.2, 13.7 )=0.2, 15.9±0.2, 17.0±0.2, 18.340.2, 18.94=0.2, 19.8±0.2, and 22.140.2 degrees 2Θ.

[00458| In some embodiments, the pattern B monocholine salt has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 8.040.2, 9.440.2, 11.040.2,13.040.2, 13.340.2, 13.740.2, 15.940.2, 17.040.2, 17.440.2, 18.340.2, 18.940.2, 19.840.2, 21.840.2, and 22.140.2 degrees 20. In some such embodiments, the pattern B monocholine salt has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 8.040.2, 9.440.2,11.040.2, 13.040.2, 13.340.2, 13.740.2, 15.940.2, 17.040.2, 17.440.2, 18.340.2, 18.940.2, 19.840.2,21.840.2, and 22.140.2 degrees 20. In other such embodiments, the pattern B monocholine salt has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 8.040.2, 9,440.2, 11.040.2, 13.040.2, 13.340.2, 13.740.2, 15.940.2, 17.040.2, 17.440.2, 18.340.2, 18.940.2, 19.840.2, 21.840.2, and 22.140.2 degrees 20.

[00459| In some embodiments, the pattern B monocholine salt has an X-ray powder diffraction pattern substantially as shown in Figure 21. The 20 values for the peaks in Figure 21 (and their intensities) are as follows: 7.96 (41), 9.38 (34), 10.96 (24), 12.98 (76), 13.34 (33), 13.72 (37), 15.90 (100), 17.03 (60), 17.42 (37), 18.30 (31), 18.85 (93), 19.82 (90), 21.76 (38), and 22.06 (46).

[00460] This invention also relates, in part, to a process for preparing the pattern B monocholine salt. It was prepared by suspending amorphous choline salt in ethyl acetate for seven days. G6. Crystalline Form ofN-(6-(3-Tert-hutyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide, Dicholine Salt.

[00461] This invention also relates, in part, to a crystalline form of N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide, dicholine salt.

[00462] In some embodiments, the dicholine salt has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 8.640.2,11.040.2, 12.940.2,17.040.2, 17.540.2, 18.940.2, 19.840.2, and 21.940.2 degrees 20. In some such embodiments, the dicholine salt has anX-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 8.640.2, 11.040.2, 12.940.2, 17.040.2, 17.540.2, 18.940.2, 19.840.2, and 21.940.2 degrees 20. In other such embodiments, the dicholine salt has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 8.640.2, 11.040.2, 12.940.2,17.040.2, 17.5±0.2,18.940.2, 19.840.2, and 21.940.2 degrees 20. 108 2014280939 24 Dec 2014 [00463] In some embodiments, the dicholine salt has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 8.6±0.2, 11.0±0.2, 12.9±0.2, 17.0±0.2, 17.5±0.2, 18.9±0.2,19.8±0.2, 21.9±0.2, and 22.1±0.2 degrees 2Θ. In some such embodiments, the dicholine salt has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 8.6±0.2, 11.0±0.2, 12.9±0.2, 17.0±0.2, 17.5±0.2, 18,9±0.2, 19.8±0.2, 21.9±0.2, and 22.U0.2 degrees 2Θ.

In other such embodiments, the dicholine salt has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 8.6±0.2, 11.0±0.2,12.9±0.2, 17.0±0.2, 17.5±0.2, 18.9±0.2, 19.8±0.2, 21,9±0.2, and 22.U0.2 degrees 2Θ.

[00464] In some embodiments, the dicholine salt has an X-ray powder diffraction pattern substantially as shown in Figure 23. The 20 values for the peaks in Figure 23 (and their intensities) are as follows: 8.62 (28), 10.98 (29), 12.93 (50), 15.88 (100), 17.03 (42), 17.47 (29), 18.88 (66), 19.82 (57), 21.89 (42), 2.07 (41).

[00465] This invention also relates, in part, to a process for preparing the dicholine salt. It was prepared by suspending compound IB-LO-2.3 (200mg) in 0.75ml MeOH. Choline hydroxide in MeOH (210ml, 45wt%, 2.10 molar equivalent) was added. The reaction mixture was concentrated, and 4ml acetonitrile and 6ml isopropyl acetate were added. The reaction mixture was then seeded with trace amount of the compound IB-LO-2.3 monopotassium salt seed crystals (discussed above). The reaction mixture started to crystallize shortly after. The stoichiometry of the salt was determined by solution ’H NMR. G7. Crystalline Forms of (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide Disodium Salt.

[00466] This invention also relates, in part, to crystalline forms of (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide disodium salt, namely the nonahydrate and tetrahydrate crystalline forms discussed below.

[00467] This invention relates, in part, to a nonahydrate crystalline disodium salt. The crystallographic unit cell parameters of the nonahydrate crystalline disodium salt have been determined to be as follows: a is 8.9A, b is 9.4A, and c is 20.7A (more precisely, a is 8.926(2)A, b is 9.415(2)A, and c is 20.674(5)A); the cell angles are: a - 94.8°, β - 93.3°, and γ -107.0° (more precisely, a is 94.796(4)°, β is 93.345(4)°, and γ is 107.013(4)°); and the cell volume is 1649A3 (more precisely, 1649.3(7)A3). The salt crystallizes in the P-1 space group.

[00468] In some embodiments, the disodium salt nonahydrate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 4.3±0.2, 10.4±0.2, 10.9±0.2„ 11.6±0.2, 12.9±0.2, 14.7±0.2, 16.4±0.2, 17.8±0.2, 19.4±0.2, 19.8±0.2,20.8±0.2, 21.9±0.2, and 23.5±0.2 degrees 20. In some such embodiments, the disodium salt nonahydrate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 4.3±0.2, 10.4±0.2, 109 2014280939 24 Dec 2014 10.9±0.2„ 11,6±0.2,12.9±0.2, 14.7±0.2, 16.4±0.2,17.8±0.2, 19.4±0.2, 19.8±0.2, 20.8±0.2, 21.9±0.2, and 23.5±0.2 degrees 2Θ. In other such embodiments, the disodium salt nonahydrate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 4.3±0.2, 10.4±0.2, 10.9±0.2„ 11,6±0.2, 12.9±0.2, 14.7±0.2, 16.4±0.2, 17.8±0.2, 19.4±0.2, 19.8±0.2,20.8±0.2, 21.9±0.2, and 23.5±0.2 degrees 2Θ.

[00469] In some embodiments, the disodium salt nonahydrate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 4.3±0.2, 10.4±0.2,10.9±0.2„ 11.6±0.2, 12.9±0.2, 14.7±0.2, 14.9±0.2, 16.4±0.2, 17.8±0.2, 19.4±0.2, 19.7±0.2, 19.8±0.2,20.8±0.2, 20.9±0.2, 21.9±0.2, 22.1±0.2, and 23.5±0.2 degrees 2Θ. In some such embodiments, the disodium salt nonahydrate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 4.3±0.2, 10.4±0.2, 10.9±0.2„ 11.6±0.2, 12.9±0.2, 14.7±0.2, 14.9±0.2, 16.4±0.2, 17.8±0.2, 19.4±0.2, 19.7±0.2, 19.8±0.2, 20.8±0.2, 20.9±0.2, 21.9±0.2, 22.U0.2, and23.5±0.2 degrees 2Θ. In other such embodiments, the disodium salt nonahydrate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 4,3±0,2, 10.4±0.2, 10.9^0.2,, 11.6±0.2, 12,9±0.2, 14.7±0.2,14.9±0.2,16.4±0.2, 17.8±0.2, 19.4±0.2,19.7±0.2, 19.8±0.2,20.8±0.2, 20.9±0.2,2l.9±0.2, 22.Ü0.2, and 23.5±0.2 degrees 20.

[00470] In some embodiments, the disodium salt nonahydrate has an X-ray powder diffraction pattern substantially as shown in Figure 24. The 20 values for the peaks in Figure 24 (and their intensities) are as follows: 4.31 (100), 10.36 (12), 10.91 (23), 11.61 (52), 12.93 (24), 14.73 (65), 14.89 (20), 16.44 (41), 17.80 (38), 19.44 (26), 19.67 (37), 19.83 (59), 20.75 (69), 20.89 (21), 21.92 (43), 22.13 (40), and 22.42 (24).

[00471] This invention also relates, in part, to a process for preparing the disodium salt nonahydrate. It was prepared in aqueous medium. Aqueous NaOH (1M, 1.18ml) was added to (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide (compound IB-Ll-l.l) (27.82mg) (molar ratio 1:20 acid:base). The resulting suspension was equilibrated at ambient conditions. The disodium salt nonahydrate formed seven days later through a solution-mediated process. Alternatively, the disodium salt nonahydrate was prepared by suspending 278.8mg of compound IB-Ll-l.l in 1 .25ml THF while heated to about 50°C. Aqueous NaOH (IN, 1.5ml, 2.2molar equivalents) was added. The solid dissolved completely to yield a clear solution, which was naturally cooled to ambient temperatures. The salt crystallized spontaneously. The molecular structure was determined by single crystal diffractometry.

[00472] This invention relates, in part, to a tetrahydratc crystalline disodium salt.

[00473] In some embodiments, the disodium salt tetrahydrate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 4.8±0.2, 12.1±0.2, 14.0±0.2, 110 2014280939 24 Dec 2014 17.0±0,2, 17.5*0.2, 20,9*0.2,21.6±0.2, 25.010.2, and 29.5*0.2 degrees 20. In some such embodiments, the disodium salt tetrahydrate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 4.8±0.2, 12.1*0.2, 14.0±0.2, 17.0*0.2, 17.5±0.2, 20.9±0.2, 21.6±0.2, 25.0±0.2, and 29.5±0.2 degrees 20. In other such embodiments, the disodium salt tetrahydrate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 4.8*0.2,12.1*0.2, 14.0±0.2,17.0*0.2, 17.5±0.2, 20.9*0.2,21.6*0.2,25.0±0.2, and 29,5±0.2 degrees 20.

[00474] In some embodiments, the disodium salt tetrahydrate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 4.8*0.2, 12.1*0.2, 14.0*0.2, 14.4*0.2, 17.0*0.2,17.5*0.2, 20.9*0.2, 21.6*0.2,25.0*0.2,29.5*0.2, and 34.2*0.2 degrees 20. In some such embodiments, the disodium salt tetrahydrate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 4.8*0.2, 12.1*0.2, 14.0*0.2, 14.4*0.2, 17.0*0.2, 17.5*0.2, 20.9*0.2,21.6*0.2, 25.0*0.2,29.5*0.2, and 34.2*0.2 degrees 20. In other such embodiments, the disodium salt tetrahydrate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 4.8*0.2, 12.1*0.2, 14.0*0.2, 14.4*0.2, 17.0*0.2, 17.5*0.2, 20.9*0.2, 21.6*0.2,25.0*0.2, 29.5*0.2, and 34.2*0.2 degrees 20.

[00475] In some embodiments, the disodium salt tetrahydrate has an X-ray powder diffraction pattern substantially as shown in Figure 25. The 20 values for the peaks in Figure 25 (and their intensities) are as follows: 4.81 (100), 12.07 (7), 14.01 (27), 14.41 (8), 16.96 (18), 17.53 (11), 20.87 (18), 21.58 (22), 24.99 (11), 29.47 (9), and 34.20 (9).

[00476] This invention also relates, in part, to a process for preparing the disodium salt tetrahydrate by suspending the nonahydrate disodium salt in an organic solvent (e.g., ethanol, 1-propanol, or 2-propanol). G8. Crystalline Farm of (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)~yl)-2-methoxystyryl)phenyl)methanesulfonamide Dipotassium Salt.

[00477] This invention also relates, in part, to a crystalline (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide dipotassium salt tetrahydrate.

[00478] The crystallographic unit cell parameters of the dipotassium salt tetrahydrate have been determined to be as follows: a is 14.5A, b is 10.8Ά, and c is 35.8A (more precisely, a is 14.454(14)A, b is 10.763(14)A, and c is 35.75(4)A); the cell angle is: β - 98.8° (more precisely, β is 98.82(3)°); and the cell volume is 5499A3 (more precisely, 5499(11)A3). The salt crystallizes in the C2/c space group.

[00479] In some embodiments, the dipotassium salt tetrahydrate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 5.0*0.2, 11.9±0.2, 12.4*0.2, 13.7*0.2, 15.0*0.2, 16.5*0.2, 17.1*0.2, 20.8*0.2,21.3*0.2,22.2*0.2,24.0*0.2, 26.4*0.2, and 29.3*0.2 degrees 20. In some such embodiments, the dipotassium salt tetrahydrate has an X-ray powder diffraction 111 2014280939 24 Dec 2014 pattern comprising three or more peaks selected from the group consisting of 5.0+0.2, 11.9+0.2, 12.4±0.2, 13.7±0.2, 15.0±0.2, 16.5+0.2, 17.1+0.2, 20.8±0.2, 21.3±0.2, 22.2+0.2, 24.0+0.2, 26.4±0.2, and29.3±0.2 degrees 2Θ. In other such embodiments, the dipotassium salt tetrahydrate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 5.0+0.2, 11.9+0.2, 12.4±0.2, 13,7±0,2, 15.0±0.2, 16.5±0,2, 17.1+0.2, 20.8+0.2,21,3+0.2, 22.2±0.2, 24.0±0.2, 26.4+0.2, and 29.3±0.2 degrees 2Θ.

[00480] In some embodiments, the dipotassium salt tetrahydrate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 5.0±0.2, 11.9+0.2, 12.4±0.2, 12.6+0.2, 13.7±0.2, 15.0±0.2, 16.5±0.2, 16.7±0.2, 17.1+0.2, 20.7+0.2,20.8+0.2, 21.3+0.2,22.2+0.2, 22.4+0.2, 24.0±0.2, 26.4±0.2, and 29.3±0.2 degrees 2Θ. In some such embodiments, the dipotassium salt tetrahydrate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 5.0+0.2, 11.9±0.2, 12.4±0.2, 12.6±0.2, 13.7±0.2, 15.0+0.2, 16.5+0.2,16.7+0.2, 17.1+0.2, 20.7±0.2, 20.8±0.2, 21.3±0.2,22.2±0.2, 22.4±0.2, 24.0+0.2, 26.4+0.2, and 29.3+0.2 degrees 2Θ. In other such embodiments, the dipotassium salt tetrahydrate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 5.0+0.2, 11.9+0.2, 12.4+0.2, 12.6+0.2, 13.7+0.2, 15.0+0.2, 16.5+0.2, 16.7+0.2,17.1+0.2, 20.7+0.2, 20.8+0.2, 21.3+0.2,22.2+0.2, 22.4+0.2, 24.0+0.2, 26.4+0.2, and 29.3+0.2 degrees 20.

[00481] In some embodiments, the dipotassium salt tetrahydrate has an X-ray powder diffraction pattern substantially as shown in Figure 27. The 20 values for the peaks in Figure 27 (and their intensities) are as follows: 5.00 (100), 11.86 (34), 12.39 (32), 12.64 (19), 13.70 (23), 15.03 (21), 16.47 (24), 16.66 (24), 17.12 (28), 20.75 (29), 20.81 (33), 21.34 (22), 22.15 (46), 22.38 (31), 24.02 (24), 26.44 (24), and 29.32 (21).

[00482] This invention also relates, in part, to a process for preparing the dipotassium salt tetrahydrate by suspending compound IB-L1-1.1 (261.13mg) in 1.25ml THF while heated to about 50°C. Aqueous KOH (IN, 1.3ml, 2.2 molar equivalent) was added. The solid dissolved completely to yield a clear solution, which was naturally cooled to ambient temperatures. Crystallization occurred during the slow evaporation process. G9. Crystalline Forms of (E)-N-(4-(3-tert-buty!-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide Monopotassium Sail.

[00483] This invention also relates, in part, to crystalline forms of (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydrop>Timidin-l(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide monopotassium salt, namely the trihydrate and dihydrate crystalline forms discussed below.

[00484] This invention relates, in part, to a monopotassium salt trihydrate. The crystallographic unit cell parameters of the trihydrate crystalline monopotassium salt have been determined to be as follows: a is 112 2014280939 24 Dec 2014 9.0A, b is 8.3A, and c is 18.6A (more precisely, a is 9.0393(16)A, b is 8.3332(15)A, and c is 18.582(3)A); the cell angles are: a - 80.5°, β - 85.1°, and γ- 80.5° (more precisely, a is 80.511(2)°, β is 85.134(3)°, and γ is 80.531(2)°); and the cell volume is 1359A3 (more precisely, 1359.3(4)A'). The salt crystallizes in the P-1 space group.

[00485] In some embodiments, the monopotassium salt trihydrate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 4.8±0.2, 10.8±0.2, 11.3±0.2, 13.4±0.2, 15.3±0,2, 16.9±0.2,21.2±0.2,21.7±0.2, 22.1±0.2,22.5±0.2, and 23.0±0.2 degrees 2Θ. In some such embodiments, the monopotassium salt trihydrate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 4.8±0.2,10.8±0.2, 11.3±0.2,13.4±0.2, 15.3±0.2, 16.9±0.2, 21.2±0.2, 21.7±0.2, 22.1±0.2,22.5±0.2, and 23.0±0.2 degrees 20. In other such embodiments, the monopotassium salt trihydrate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 4.8±0.2, 10.8±0.2, 11.3±0.2,13.4±0.2, 15.3±0.2, 16.9±0.2, 21.2±0.2,21.7±0.2, 22.1±0.2,22.5±0.2, and 23.0±0.2 degrees 2Θ.

[00486] In some embodiments, the monopotassium salt trihydrate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 4.8±0.2,10.8±0.2, 11.3±0.2, 13.4±0.2,13.6±0.2, 15.3±0.2, 16.9±0.2,21.2±0.2, 21.7±0.2,21.7±0.2, 22.Ü0.2,22.5±0.2, 22.6±0.2, and 23.0±0.2 degrees 2Θ. In some such embodiments, the monopotassium salt trihydrate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 4.8±0.2, 10.8±0.2, 11.3±0.2, 13.4±0.2, 13.6±0.2, 15.3±0.2, 16.9±0.2, 21.2±0.2,21.7±0.2, 21.7±0.2,22.1±0.2, 22.5±0.2, 22.6±0.2, and 23.0±0.2 degrees 20. In other such embodiments, the monopotassium salt trihydrate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 4.8±0.2, 10.8±0.2, 11.3±0.2, 13.4±0.2, 13.6±0.2, 15.3±0.2, 16.9±0.2, 21.2±0.2, 21.7±0.2, 21.7±0.2, 22.1 ±0.2,22.5±0.2, 22.6±0.2, and 23.0±0.2 degrees 20.

[00487] In some embodiments, the monopotassium salt trihydrate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 4.8±0.2, 10.8±0.2, 11.3±0.2, 13,4±0.2, 13.6±0,2, 15.3±0.2, 16.9±0.2,21.2±0.2,21.7±0.2, 21.7±0.2,22.1±0.2, 22.5±0.2, 22.6±0.2, and 23.0±0.2 degrees 20. In some such embodiments, the monopotassium salt trihydrate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 4.8±0.2, 10.8±0.2, 11.3±0.2,13.4±0.2,15.3±0.2, 16.9±0.2, 21.2±0.2,21.7±0.2, 22.1±0.2, 22.5±0.2, and 23.0±0.2 degrees 20. In other such embodiments, the monopotassium salt trihydrate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 4.8±0.2, 10.8±0.2, 11,3±0.2,13.4±0.2, 15.3±0.2, 16.9±0.2, 21.2±0.2,21.7±0.2, 22.1±0.2,22.5±0.2, and 23.0±0.2 degrees 20.

[00488] In some embodiments, the monopotassium salt trihydrate has an X-ray powder diffraction pattern substantially as shown in Figure 28. The 20 values for the peaks in Figure 28 (and their intensities) arc as 113 2014280939 24 Dec 2014 follows: 4.83 (60), 10.79(100), 11.31 (22), 13.42(41), 13.59(18), 15.32(21), 16.90 (38),21.24(22), 21.68 (20), 21.68 (21), 22.15 (22), 22.55 (29), 22.63 (23), and 23.02 (27).

[00489] This invention also relates, in part, to a process for preparing the monopotassium salt trihydrate.

It was prepared by suspending compound IB-L1-1.1 (108.81 mg) in 0.4ml THF while heated to about 50°C. Aqueous KOH solution (IN, 0.278ml, 1.2 molar equivalent) was added. The solid dissolved completely to yield a clear solution. Additional 1,6ml THF was added to the solution, which was then naturally cooled to ambient temperatures and crystallization was observed. Alternatively, the monopotassium salt trihydrate was prepared by suspending compound IB-Ll-1.1 (343.89mg) in 1,0ml THF while heated to 50°C. Aqueous KOH (1 N, 0.878ml, 1.2 molar equivalent) was added. The solid dissolved completely to yield a clear solution. Ethanol was added to the solution dropwise to a total volume of 4.0ml. The solution was then naturally cooled to ambient temperature and crystallization was observed.

[00490] This invention relates, in part, to a monopotassium salt dihydrate.

[00491] In some embodiments, the monopotassium salt dihydrate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 7.7±0.2, 8.8±0.2, 16.Ü0.2, and 19.7±0.2 degrees 2Θ. In some such embodiments, the monopotassium salt dihydrate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of degrees 2Θ.

[00492] In some embodiments, the monopotassium salt dihydrate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 7.7±0.2, 8.8±0.2, 12.4±0.2, 14.0±0.2, 16.1±0.2, 17.7±0.2, 19.2±0.2, 19.7±0.2, 23.1±0.2, and 29.2±0,2 degrees 2Θ. In some such embodiments, the monopotassium salt dihydrate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 7.7±0.2, 8.8±0.2,12.4±0.2, 14.0±0.2, 16.1±0.2, 17,7±0.2,19.2±0.2, 19.7±0.2, 23.1 ±0.2, and 29.2±0.2 degrees 20. In other such embodiments, the monopotassium salt dihydrate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 7.7±0.2, 8.8±0.2, 12.4±0.2, 14.0±0.2, 16.Ü0.2, 17.7±0.2, 19.2±0.2, 19.7±0.2,23.Ü0.2, and 29.2±0.2 degrees 20.

[00493] In some embodiments, the monopotassium salt dihydrate has an X-ray powder diffraction pattern substantially as shown in Figure 29. The 20 values for the peaks in Figure 29 (and their intensities) are as follows: 7.68 (19), 8.83 (100), 12.40 (7), 13.97 (10), 16.12 (25), 17.75 (9), 19.22 (12), 19.73 (40), 23.05 (9), and 29.21 (7).

[00494] This invention also relates, in part, to a process for preparing the monopotassium salt dihydrate.

It was prepared by suspending the monopotassium salt trihydrate in media of low water activity, such as an ethanol/I IjO mixture (50/1 v/v). Alternatively, the monopotassium salt dihydrate was prepared by dissolving potassium trihydrate solid (1.8g) in 36mL of IP A and 4ml water at 80°C. The resulting 114 2014280939 24 Dec 2014 solution was cooled to 55°C over lh. The solution was then seeded with 7.5mg of dihydrate crystals at 55°C and maintained at 55°C for lh. Heptane (36ml) was then added over 3h. The reaction mixture was cooled to 0°C, and filtration yielded a material containing both di- and trihydrate crystals. The solid was then reslurried in 20mL of 10:1 v/v EtOH/H20 at 50°C for 3h and cooled to 25°C over 5h. The slurry was then mixed at 25°C for additional 3 days and cooled to 0°C over 3h and held at this temperature for 2h. The resulting crystals were filtered and air-dried on filter funnel for 1 h to give dihydrate. The dihydrate monopotassium salt was also prepared by slurrying a mixture of dihydrate and trihydrate crystals in 10:1 v/v EtOH/H20 at 80°C for 2 days. The potassium content was confirmed by ion chromatography. G10. Crystalline Form of (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydrupyrimidin-l(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide 1/7 Potassium Salt.

[00495] This invention also relates, in part, to a crystalline form of (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide 1/7 potassium salt.

[00496] In some embodiments, the 1/7 potassium salt has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 7.7±0.2, 8.3±0.2, 10.1±0.2,10.6±0.2,11.4±0.2, 12.0±0.2, 13.4±0.2,15.6±0.2, 16,3±0.2,16.7±0.2, 17.2±0.2, 18.3±0.2, 18.8±0.2, 19.4±0.2, 19.9±0.2, 20.2±0.2, 20.5±0.2,21.2±0.2, 22.1 ±0.2, and 22.9±0.2 degrees 20. In some such embodiments, the 1/7 potassium salt has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 7.7±0.2, 8.3±0.2, 10.Ü0.2, 10.6±0.2, 11.4±0.2, 12.0±0.2, 13.4±0.2, 15.6±0.2, 16.3±0.2, 16.7±0.2, 17.2±0.2, 18.34 0.2, 18.8±0.2, 19.4±0.2, 19.9±0.2, 20.2±0.2, 20.5±0.2, 21.2±0.2, 22.Ü0.2, and 22.9±0.2 degrees 20. In other such embodiments, the 1/7 potassium salt has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 7.7±0.2, 8,3±0.2, 10.Ü0.2, 10.6±0.2, U.4±0.2, 12,0±0.2, 13.4±0.2, 15.6±0.2, 16.3±0.2, 16.7±0.2,17.2±0.2, 18.3±0.2, 18.8±0.2, 19.4±0.2, 19.9±0.2,20.2±0.2, 20.5±0.2, 21.2±0.2,22.1±0.2, and 22.9±0.2 degrees 20.

[00497] hi some embodiments, the 1/7 potassium salt has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 7.7±0.2, 8.3±0.2, 10.1 ±0.2, 10.6±0.2, 11.4±0.2, 12.0±0.2, 13.4±0.2, 15.6±0.2, 16.3±0.2, 16.7±0.2, 17.2±0.2, 18.3±0.2, 18.8±0.2, 19.4±0.2, 19.9±0.2, 20.2±0.2, 20.5±0.2, 20.8±0.2, 21.2±0.2, 22.1±0.2, 22.9±0.2, 24.3±0.2, 24.9±0.2, and 25.1±0.2 degrees 20. In some such embodiments, the 1/7 potassium salt has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 7.7±0.2, 8.3±0.2, 10.1=)=0.2, 10.6±0.2,11.4±0.2, 12.0±0.2, 13.4±0.2, 15.6±0.2, 16.3±0.2, 16.7±0.2, 17.2±0.2, 18.3±0.2, 18.8±0.2, 19.4±0.2, 19.9±0.2, 20.2±0.2,20.5±0.2, 20.8±0.2,21.2±0.2, 22.1±0.2, 22.9±0.2,24.3±0.2,24.9±0.2, and 25.1±0.2 degrees 20. In other such embodiments, the 1/7 potassium salt has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 7.7±0.2, 8,3±0.2, 10.1±0.2,10.6±0.2, 11.44=0.2, 115 2014280939 24 Dec 2014 12.040.2, 13.440.2, 15.640.2, 16.3±0.2, 16.7±0.2, 17.2±0.2, 18.340.2, 18.840.2, 19.440.2, 19.940.2, 20.240.2, 20.540.2, 20.8±0.2, 21.240.2, 22,140.2, 22.940.2, 24.340.2, 24.940.2, and 25.140.2 degrees 2Θ.

[00498] In some embodiments, the 1/7 potassium salt has an X-ray powder diffraction pattern substantially as shown in Figure 31. The 20 values for the peaks in Figure 31 (and their intensities) are as follows: 7.71 (19), 8.33 (34), 10.10 (100), 10.66 (29), 11.39 (27), 12.04 (22), 13.39 (39), 15.56 (41), 16.27 (62), 16.69 (70), 17.22 (59), 18.31 (18), 18.78 (47), 19.44 (36), 19.89 (28), 20.19 (33), 20.54 (87), 20.80 (33), 21.15 (47), 22.05 (24), 22.82 (67), 24.32 (22), 24.87 (22), and 25.07 (33).

[00499] This invention also relates, in part, to a process for preparing the 1/7 potassium salt. It was prepared by suspending compound IB-L1-1.1 (2g) 6ml THF at 50°C. One molar equivalent of KOH dissolved in 4.3ml water was added, and the reaction mixture was heated to 65°C to dissolve all solids. The solution was then cooled to ambient temperatures over 2h and spontaneous crystallization took place. The slurry was then cooled to 5°C and held at that temperature for 2h. The pale yellow crystals were filtered and air-dried for 24h at ambient conditions. The potassium content was determined by ion chromatography.

Gil. Crystalline Form of(E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l (2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide Monodiethyl amine Salt Tetrahydrate.

[00500] This invention also relates, in part, to crystalline (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide monodiethylamine salt tetrahydrate.

[00501] In some embodiments, the monodiethylamine salt tetrahydrate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 9.540.2, 10.040.2, 11.840.2, 12.140.2, 14.440.2, 16.840.2, 17.640.2, 19.840.2,20.840.2, 21.440.2,21.840.2, and 29.840.2 degrees 2Θ. In some such embodiments, the monodiethylamine salt tetrahydrate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 9.540.2, 10.040.2, 11.840.2, 12.140.2, 14.440.2, 16.840.2, 17.640.2, 19.840.2, 20.840.2,21.440.2, 21.840.2, and 29.840.2 degrees 20. In other such embodiments, the monodiethylamine salt tetrahydrate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 9.540.2, 10.040.2, 11.840.2, 12.140.2, 14.440.2, 16.840.2, 17.640.2, 19.840.2, 20.840.2,21.440.2, 21.840.2, and 29.840.2 degrees 20.

[00502] In some embodiments, the monodiethylamine salt tetrahydrate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 9.540.2,10.040.2, 11.840.2, 12.140.2, 14.440.2, 16.840.2, 17.640.2, 19.440.2, 19.840.2, 20.840.2, 21.440.2, 21.840.2,21.940.2, and 29.840.2 degrees 20. In some such embodiments, the monodiethylamine salt tetrahydrate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 9.540.2, 10.040.2, 11.840.2, 12.140.2, 14.440.2, 16.840.2, 17.640.2, 19.440.2, 19.840.2,20.840.2,21.440.2, 116 2014280939 24 Dec 2014 21.8±0.2, 21.9±0,2, and 29.8±0.2 degrees 2Θ. In other such embodiments, the monodiethylamine salt tetrahydrate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 9.5±0.2, 10.0±0.2, 11.8±0.2, 12.Ü0.2, 14.4±0.2, 16.8±0.2, 17.6±0.2,19.4±0.2, 19.8±0.2, 20.8±0.2, 21.4±0.2,21.8±0.2, 21.9±0.2, and 29.8±0.2 degrees 2Θ.

[00503] In some embodiments, the monodiethylamine salt tetrahydrate has an X-ray powder diffraction pattern substantially as shown in Figure 32. The 2Θ values for the peaks in Figure 32 (and their intensities) are as follows: 9.45 (100), 9.97 (31), 11.85 (67), 12.09 (16), 14.38(22), 16.80(9), 17.59(10), 19.39 (8), 19.83 (21), 20.85 (25), 21.37 (12), 21.75 (34), 21.87 (8), and 29.78 (7).

[00504] This invention also relates, in part, to a process for preparing the monodiethylamine salt tetrahydrate. It was prepared in aqueous medium. Compound IB-L1-I.1 was slowly added to 500ul of 1M diethylamine until no more solid can be dissolved into the solution. The solution was then evaporated slowly at ambient temperatures and the salt crystallized 2 days later. Alternatively, the monodiethylamine salt tetrahydrate was prepared by suspending 64.15mg of compound IB-L1-1.1 in 400ul 1M diethylamine while heated to 50°C. About 5 drops of THF (~ 20ul) was added. The solid dissolved completely upon addition to yield a clear solution. The solution was then evaporated at ambient temperature, and the salt crystallized 4 days later. The stoichiometry of the salt was confirmed by solution 'H NMR. G12. Crystalline Forms of (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide (compound IB-L1-1.1).

[00505] This invention also relates, in part, to crystalline forms of (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2H)-yl)-2-methoxystyryl)phenyl)methanesuIfonamide (compound IB-L1-1.1), namely the true polymorphs (pattern A, pattern B, pattern C, and pattern D) and hydrate (pattern AH, pattern BH, pattern CH, and pattern DH) crystalline forms discussed below. G12A. IB-L1-L1 True Polymorphs.

[00506] This invention relates, in part, to pattern A crystalline (E)-N-(4-(3-tert-butyl~5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide.

[00507] In some embodiments, the pattern A polymorph has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 5.8±0.2, 9.9±0.2, 11.8±0.2, 12.4±0.2, 14.5±0.2, 18.8±0.2, 22.7±0.2, and 29.2±0.2 degrees 20. In some such embodiments, the pattern A polymorph has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 5.8±0.2, 9.9±0.2, 11.8±0.2, 12.4±0.2,14.5±0.2, 18.8±0.2, 22.7±0.2, and 29.2±0.2 degrees 20. In other such embodiments, the pattern A polymorph has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 5.8±0.2, 9.9±0.2, 11,8±0.2,12.4±0.2, 14.5±0.2, 18.8±0.2, 22.7±0.2, and 29.2±0.2 degrees 20. 117 2014280939 24 Dec 2014 [00508] In some embodiments, the pattern A polymorph has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 5.8+0.2,9.9±0.2, 11.8+0.2, 12.4±0.2, 14.0±0.2, 14.5±0.2, 1S.3±0.2, 18.5+0.2, 18.8±0.2, 22.2±0.2, 22.7±0.2, 23.8±0.2, 26.0±0.2, and 29.2+0.2 degrees 2Θ. In some such embodiments, the pattern A polymorph has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 5.8±0.2, 9.9±0.2, 11.8±0.2, 12.4+0.2, 14.0±0.2, 14.5±0.2, 15.3=0.2, 18.5±0.2, 18.8±0.2,22.2±0.2, 22.7+0.2, 23.8±0.2, 26.0±0.2, and 29.2±0.2 degrees 2Θ. In other such embodiments, the pattern A polymorph has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 5.8+0.2, 9,9+0.2, 11.8+0.2, 12.4±0.2, 14.0±0.2, 14.5+0.2, 15.3+0.2, 18.5±0.2, 18.8+0.2,22.2+0.2, 22.7+0.2,23.8+0.2, 26.0+0.2, and 29.2+0.2 degrees 20.

[00509] In some embodiments, the pattern A polymorph has an X-ray powder diffraction pattern substantially as shown in Figure 34. The 2Θ values for the peaks in Figure 34 (and their intensities) are as follows: 5.85 (28), 9.88 (51), 11.79(73), 12.38 (56), 14.03 (38), 14.45(100), 15.27(29), 18.52(39), 18.80 (47), 22.24 (40), 22.72 (77), 23.76 (39), 25.98 (22), and 29.21 (64).

[00510] This invention also relates, in part, to a process for preparing pattern A polymorph. Pattern A polymorph was prepared as discussed in Example F below.

[00511] This invention relates, in part, to pattern B crystalline (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2 H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide.

[00512] In some embodiments, the pattern B polymorph has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 11.5+0.2, 13.3+0.2, 15.4+0.2, 16.4+0.2, 17.1+0.2, 18.6+0.2, 19.4+0.2,20.4+0.2, 21.6+0.2, 22.4+0.2, 24.0+0.2, 26.8+0.2, and 29.0+0.2 degrees 20. In some such embodiments, the pattern B polymorph has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 11.5+0.2, 13.3+0.2, 15.4+0.2, 16.4+0.2, 17.1+0.2, 18.6+0.2, 19.4+0.2, 20.4+0.2, 21.6+0.2, 22.4+0.2, 24.0+0.2, 26.8+0.2, and 29.0+0.2 degrees 20. In other such embodiments, the pattern B polymorph has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 11.5+0.2, 13.3+0.2, 15.4+0.2, 16.4+0.2, 17.1+0.2, 18.6+0.2, 19.4+0.2, 20.4+0.2,21.6+0.2,22.4+0.2,24.0+0.2, 26.8+0.2, and 29.0+0.2 degrees 20.

[00513] In some embodiments, the pattern B polymorph has an X-ray powder diffraction pattern substantially as shown in Figure 36. The 2Θ values for the peaks in Figure 36 (and their intensities) are as follows: 11.52(71), 13.30(87), 15.37(100), 16.42(60), 17.13 (69), 18.60 (97), 19.37(56),20.40(62), 21.55 (55), 22.41 (39), 23.99 (33), 26.81 (31), and 28.98 (50).

[00514] This invention relates, in part, to pattern C crystalline (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide. 118 2014280939 24 Dec 2014 [00515] In some embodiments, the pattern C polymorph has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 7.7±0.2, 10.1±0.2, 10.6±0.2,12.0 ±0.2,13.4±0.2,16.2±0.2,19.4±0.2,20.5±0.2,21.4±0.2, 22.0±0.2, 22.6±0.2,24.3±0.2, and 27.6±0.2 degrees 20. In some such embodiments, the pattern C polymorph has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 7.7±0.2, 10.1±0.2, 1Q.6±0.2, 12.0 ±0.2, I3.4±0.2, 16.2±0,2, 19.4±0.2, 20.5±0.2,21.4±0.2, 22.0±0.2,22.6±0.2, 24.3±0.2, and 27.6±0.2 degrees 20. In other such embodiments, the pattern C polymorph has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 7.7±0.2, 10,1±0.2,10.6±0.2, 12.0 ±0.2, 13.4±0.2, 16.2±0.2, 19.4±0.2,20.5±0.2,21.4±0.2, 22.0±0.2,22.6±0.2, 24.3±0.2, and 27.6±0.2 degrees 20.

[00516] In some embodiments, the pattern C polymorph has an X-ray powder diffraction pattern substantially as shown in Figure 37. The 20 values for the peaks in Figure 37 (and their intensities) are as follows: 7.69 (27), 10.13 (27), 10.64 (49), 12.01 (31), 13.39 (33), 16.25 (91), 19.44 (46), 20.49 (100), 21.40 (35), 22.03 (37), 22.60 (30), 24.32 (23), and 27.55 (27).

[00517] This invention relates, in part, to pattern D ciystalline (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-mcthoxystyryl)phenyl)methanesulfonamide.

[00518] In some embodiments, the pattern D polymorph has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 5.8±0.2, 10.7±0.2, 11.2±0.2, 15.2±0.2, 16.1±0.2, 16.9±0.2, 19.9±0.2,22.1±0.2, 24.7±0.2, and 26.0±0.2 degrees 20. In some such embodiments, the pattern D polymorph has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 5.8±0.2, 10.7±0.2, 11.2±0.2, 15.2±0.2, 16.1±0.2, 16.9±0.2, 19.9±0.2, 22.1±0.2,24.7±0.2, and 26.0±0.2 degrees 20. In other such embodiments, the pattern D polymorph has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 5.8±0.2, 10.7±0.2, 11.2±0.2, 15.2±0.2, 16.1±0.2,16.9H).2, 19.9±0.2, 22.1±0.2, 24.7±0.2, and 26.0±0.2 degrees 20.

[00519] In some embodiments, the pattern D polymorph has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 5.8±0.2, 10.7±0.2, 11.2±0.2, 15.2±0.2, 16.1±0.2, 16.9±0.2, 17.1±0.2, 19.9±0.2, 20.1±0.2,22.1±0.2, 24.7±0.2, and 26.0±0.2 degrees 20. In some such embodiments, the pattern D polymorph has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 5.8±0.2, 10.7±0.2, 11.2±0.2, 15.2±0.2, 16.1±0.2, 16.9±0.2, 17.1±0.2, 19.9±0.2, 20.1±0.2,22.1±0.2,24.7±0.2, and 26.0±0.2 degrees 20. In other such embodiments, the pattern D polymorph has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 5.8±0.2, 10.7±0.2, 11.2±0.2, 15.2±0.2, 16.1±0.2, 16.9±0.2, 17.1±0.2, 19.9±0.2, 20.1±0.2, 22.1±0.2,24.7±0.2, and 26.0±0.2 degrees 20. 119 2014280939 24 Dec 2014 [00520] In some embodiments, the pattern D polymorph has an X-ray powder diffraction pattern substantially as shown in Figure 38. The 2Θ values for the peaks in Figure 38 (and their intensities) are as follows: 5.81 (24), 10.70 (91), 11.23 (60), 15.17 (28), 16.10(48), 16.89(100), 17.10(42), 19.88 (81), 20.12 (100), 22.12 (59), 24.72 (37), and 25.91 (24).

[00521] This invention also relates, in part, to a process for preparing pattern B, C, and D polymorphs by heating pattern A polymorph to about 160, about 225, and about 268°C, respectively using DSC. G12B IB-L1-1.1 Hydrates.

[00522] This invention also relates, in part, to hydrates of compound IB-L1-1.1, namely to hydrates A, B, C, D, and E discussed below.

[00523] This invention relates, in part, to a pattern A (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydro-pyrimidin-1 (2H)-yl)-2-methoxy styryl)phenyl)methanesulfonamide hydrate.

[00524] In some embodiments, the pattern A hydrate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 5.1±0.2, 7.9±0.2, 9.5±0.2, 10.3±0.2, 13.7±0.2, 16.5±0.2, 17.1 ±0.2, 17.5±0.2, 18.8±0.2, 19.2±0.2, 20.7±0.2,21.3±0.2, 21.6±0.2,25.8±0.2, 26.8±0.2, and 28.4±0.2 degrees 2Θ. In some such embodiments, the pattern A hydrate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 5.1±0.2, 7.9±0.2, 9.5±0.2, 10.3±0.2, 13.7±0.2, 16.5±0.2, 17.1±0.2, 17.5±0.2,18.8±0.2, 19.2±0.2, 20.7±0.2,21.3±0.2, 21.6±0.2, 25.8±0.2,26.8±0.2, and 28.4±0.2 degrees 2Θ. In other such embodiments, the pattern A hydrate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 5.1±0.2,7.9±0.2,9.5±0.2, 10.3±0.2, 13.7±0,2,16.5±0.2, 17.1±0.2, 17.5±0.2, 18,8±0.2, 19.2±0.2, 20.7±0.2, 21.3±0.2, 21.6±0.2, 25.8±0.2,26.8±0.2, and28.4±0.2 degrees 2Θ.

[00525] In some embodiments, the pattern A hydrate has an X-ray powder diffraction pattern substantially as shown in Figure 39. The 20 values for the peaks in Figure 39 (and their intensities) are as follows: 5.13 (13), 7.87 (80), 9.45 (100), 10.29 (60), 13.7 (28), 16.54 (30), 17.07 (17), 17.51 (40), 18.80 (99), 19.18 (74), 20.69 (21), 21.25 (21), 21.63 (23), 25.85 (32), 26.81 (20), and 28.35 (27).

[00526] This invention also relates, in part, to a process for preparing the pattern A hydrate by suspending pattern A polymorph (discussed above) in ethyl acetate. The recovered pattern A hydrate contains ~1 water molecules per molecule of compound IB-Ll-1,1.

[00527] This invention also relates, in part, to a pattern B (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydro-pyrimidin-l(2H)-yI)-2-methoxystyryl)phenyl)methanesulfonamide hydrate.

[00528] In some embodiments, the pattern B hydrate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 6.3±0.2, 7.7±0.2, 10.4±0.2, 12.7±0.2,13.3±0.2, 14,9±0,2, 15.4±0.2, 16.4±0.2, 18.6±0.2, 18.9±0.2, 19.4±0.2,22.5±0.2,23.5±0.2, 24.0±0.2, 26.8±0.2, and 29.0±0.2 degrees 20. In some such embodiments, the pattern B hydrate has an X-ray powder diffraction 120 2014280939 24 Dec 2014 pattern comprising three or more peaks selected from the group consisting of 6.3±0.2, 7.7±0.2, 10.4±0.2, 12.7+0.2, 13.3 tO.2, 14.9±0.2, 15.4+0.2, 16.4±0.2, 18.6±0.2, 18.9±0.2, 19.4±0.2, 22.5+0.2, 23.5±0.2, 24.0±0.2, 26.8+0.2, and 29.0±0.2 degrees 2Θ. In other such embodiments, the pattern B hydrate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 6.3+0.2, 7.7±0.2, 10.4±0.2, 12.7±0.2, 13.3±0.2, 14.9±0.2, 15.4±0.2, 16.4+0.2,18.6+0.2, 18.9+0.2, 19.4±0.2, 22.5±0.2, 23.5±0.2, 24.0±0.2, 26.8+0.2, and 29.0±0.2 degrees 20.

[00529] in some embodiments, the pattern B hydrate has an X-ray powder di (fraction pattern comprising one or more peaks selected from the group consisting of 6.3±0.2, 7.7±0.2, 10.4±0.2, 12.7±0.2, 13.3±0.2, 13.5+0,2, 14.9+0.2, 15.4+0.2, 16.4±0.2, 18.5±0.2, 18.6±0.2, 18.9+0.2, 19.4±0.2, 22.5+0.2,23.5+0.2, 24.0+0.2, 26.8±0.2, and 29.0+0.2 degrees 20. In some such embodiments, the pattern B hydrate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 6.3+0.2,7.7+0.2, 10.4+0.2, 12.7±0.2, 13.3+0.2,13.5±0.2, 14.9±0.2, 15.4+0.2, 16.4+0.2, 18.5±0.2, 18.6±0.2, 18.9+0.2,19.4±0.2,22.5+0.2,23.5±0.2, 24.0+0.2, 26.8+0.2, and 29.0±0.2 degrees 20. In other such embodiments, the pattern B hydrate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 6.3+0.2, 7.7+0.2, 10.4±0.2, 12,7±0.2,13.3+0.2,13.5±0,2, 14.9±0.2, 15.4+0.2,16.4±0.2, 18.5+0.2, 18.6+0.2, 18.9+0.2, 19.4+0.2, 22.5+0.2,23.5+0.2,24.0+0.2, 26.8±0.2, and 29.0+0.2 degrees 20.

[00530] In some embodiments, the pattern B hydrate has an X-ray powder diffraction pattern substantially as shown in Figure 41. The 2Θ values for the peaks in Figure 41(and their intensities) are as follows: 6.31 (7), 7.72(14), 10.45 (24), 12.67 (26), 13.30(88), 13.50(44), 14.89(70), 15.40 (100), 16.43 (43), 18.46 (47), 18.63 (86), 18.91 (26), 19.42 (33), 22.52 (47), 23.52 (44), 24.02 (20), 26.82 (40), and 28.97 (49).

[00531] This invention also relates, in part, to a process for preparing the pattern B hydrate by suspending pattern A polymorph (discussed above) in acetonitrile/water (9/1 v/v). The recovered pattern B hydrate contains ~0.7 water molecules per molecule of compound IB-L1-1.1.

[00532] This invention also relates, in part, to a pattern C (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide hydrate.

[00533] In some embodiments, the pattern C hydrate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 10.5±0,2, 13.3+0.2, 14.9+0.2, 15.4±0.2, 16.4±0.2, 18.6±0.2, 19.0±0.2, 19.4±0.2, 22.5+0.2, 23.5±0.2, 26.9±0.2, and 29.0±0.2 degrees 2Θ. In some such embodiments, the pattern C hydrate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 10.5+0.2, 13.3±0.2, 14.9±0.2, 15.4±G.2, 16.4+0.2, 18,6+0.2, 19.0+0.2, 19.4±0.2, 22.5+0,2,23.5+0.2,26.9+0.2, and 29.0+0.2 degrees 2Θ. In other such embodiments, the pattern C hydrate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 10.5+0.2,13.3+0.2, 14,9+0.2, 15.4+0.2,16.4+0.2,18.6+0.2, 121 2014280939 24 Dec 2014 19.0±0.2, 19.440.2,22,540.2, 23.540.2,26.9±0.2, and 29.0±0.2 degrees 20.

[00534] In some embodiments, the pattern C hydrate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 10.540.2, 13.3±0.2, 13.540.2, 14.9±0.2, 15.440.2, 16.440.2, 18.640.2, 19.040.2, 19.440.2,22.540.2, 23.540.2, 26.940.2, and 29.040.2 degrees 20. In some such embodiments, the pattern C hydrate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 10.540.2, 13.340.2, 13.540.2, 14.940.2, 15.440.2, 16.440.2, 18.640.2, 19.040.2, 19.4±0.2, 22.540.2, 23.540.2,26.940.2, and 29.040.2 degrees 20. In other such embodiments, the pattern C hydrate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 10.540.2, 13.340.2, 13.540.2, 14.940.2, 15.440.2, 16.440.2, 18.640.2, 19.040.2, 19.440.2,22.540.2, 23.540.2,26.940.2, and 29.040.2 degrees 20.

[00535] In some embodiments, the pattern C hydrate has an X-ray powder diffraction pattern substantially as shown in Figure 43. The 20 values for the peaks in Figure 43 (and their intensities) are as follows: 10.47(21), 13.31 (56), 13.49 (31), 14.91 (28), 15.40 (86), 16.43 (48), 18.61 (100), 18.96 (20), 19.44(19), 22.55 (26), 23.54 (39), 26.84 (29), and 28.99 (54).

[00536] This invention also relates, in part, to a process for preparing the pattern C hydrate by suspending pattern A polymorph (discussed above) in water. The recovered pattern C hydrate contains ~1 water molecules per molecule of compound IB-L1-1.1.

[00537] This invention also relates, in part, to a pattern D (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide hydrate.

[00538] The crystallographic unit cell parameters of the pattern D hydrate salt have been determined to be as follows: a is 17.8A, b is 9.6A, and c is 27.0A (more precisely, a is 17.783(2)A, b is 9.5651(12)A, and c is 27.014(4)A); the cell angle is: β - 93.3° (more precisely, β is 93.256(2)°); and the cell volume is 4588A3 (more precisely, 4587.5(10)A3), The salt crystallizes in the C2/c space group.

[00539] In some embodiments, the pattern D hydrate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 6.640.2, 10.040.2,10.5±0.2, 11.140.2,11.6±0.2, 12.240.2, 14.240.2, 16.640.2, 17.140.2, 17.740.2,18.540.2, 18.840.2, 19.340.2,21.440.2,22.740.2, 23.140.2, 23.640.2, 24.640.2,25.240.2,27.240.2,29.140.2, and 31,0±0.2 degrees 20. In some such embodiments, the pattern D hydrate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 6.640.2,10,0±0,2,10.5±0.2,11.140.2,11.640.2,12.240.2, 14.240.2, 16.640.2,17.140.2, 17.74-0.2, 18.540.2, 18.840.2, 19.340.2,21.440.2, 22.740.2,23.140.2, 23.640.2, 24.640.2, 25.240.2, 27.240.2,29.140.2, and 31.040.2 degrees 20. In other such embodiments, the pattern D hydrate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 6.640.2,10.040.2, 10.5±0.2,11.140.2,11.640.2,12.240.2,14.240.2, 16.640.2, 17.140.2, 17.740.2, 18.540.2, 18.840.2, 19.340.2,21.440.2,22.740.2, 23.140.2,23.640.2, 122 2014280939 24 Dec 2014 24.6±0.2,25.2±0.2,27.2±0,2, 29.1 ±0.2, and 31.0±0.2 degrees 2Θ.

[00540] In some embodiments, the pattern D hydrate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 6.6±0.2,10.0±0.2, 10.5±0.2, 11.1±0.2, 11.6±0.2, 12.2±0.2, 12.5±0.2, 14.2±0.2, 16.6±0.2, 17.1±0.2, 17.7±0.2, 18.5±0.2, 18.8±0.2, 19.3±0.2, 21.4±0.2, 22.7±0.2, 22.8±0.2, 23.U0.2, 23.6±0.2,24.6±0.2, 24.9±0.2, 25.2±0.2,27.2±0.2, 29.1±0.2, and 3 l.O±0.2 degrees 2Θ. In some such embodiments, the pattern D hydrate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 6.6±0.2, 10.0±0.2, 10.5±0.2, 11.1±0.2, 11.6±0.2, 12.2±0.2, 12.5±0.2, 14.2±0.2, 16.6±0.2, 17.1±0.2, 17.7±0.2, 18.5±0.2, 18.8±0.2, 19.3±0.2,21,4±0.2,22.7±0.2,22.8±0.2, 23.1±0.2,23.6±0.2,24.6±0.2,24.9±0.2, 25.2±0.2, 27.2±0.2, 29.1±0,2, and 31.0±0.2 degrees 2Θ. In other such embodiments, the pattern D hydrate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 6.6±0.2, 10.0±0.2, 10.5±0.2, 1LI±0.2, 11.6±0.2, 12.2±0.2, 12.5±0.2, 14.2±0.2, 16.6±0.2, 17.1±0.2, 17.7±0.2, 18.5±0.2, 18.8±0.2, 19.3±0.2,21.4±0.2,22.7±0.2, 22.8±0.2, 23.1±0.2, 23.6±0.2, 24.6±0.2, 24.9±0.2, 25.2±0.2, 27.2±0.2, 29.1±0.2, and 31,0±0.2 degrees 2Θ.

[00541] In some embodiments, the pattern D hydrate has an X-ray powder diffraction pattern substantially as shown in Figure 45. The 2Θ values for the peaks in Figure 45 (and their intensities) are as follows: 6.55 (10),9.96(12), 10.51 (37), 11.09(31), 11.62(100), 12.24(44), 12.54(40), 14.22(15), 16.62(68), 17.07 (22), 17.77 (21), 18.52 (82), 18.84 (47), 19.30 (63), 21.45 (34), 22.67 (30), 22.80 (34), 23.08 (20), 23.57 (58), 24.63 (73), 24.88 (26), 25.24 (21), 27.23 (36), 29.06 (41), and 31.04 (21).

[00542] This invention also relates, in part, to a process for preparing the pattern D hydrate. It was prepared by suspending pattern A polymorph (discussed above) in ethanol. Alternatively, it was prepared by suspending compound IB-L1-1.I (103.03mg) in 400ul THF while heated to about 55°C. Aqueous NaOH (1M, 264ul, 1.2 molar equivalent) was added. The solid dissolved completely to yield a clear solution. Ethanol (1.6ml) was added to the solution. The solution was allowed to cool naturally to ambient temperatures. Crystals were formed during the slow evaporation process. Although it appears that the lattice can accommodate as much as 0.5 water molecules per molecule of compound IB-L1-1.1, the recovered pattern D hydrate contained ~0.2 water molecules per molecule of compound IB-L1-1.1.

[00543] This invention also relates, in part, to a pattern E (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide hydrate.

[00544] The crystallographic unit cell parameters of the pattern E hydrate crystalline disodium salt have been determined to be as follows: a is 9.5Ά, b is 14.5A, and c is 17.3A (more precisely, a is 9,462(2)A, b is 14.462(3)A, and c is 17.281 (4)A); the cell angles are: a - 84.9°, β - 80.8°, and γ - 81.8° (more precisely, a is 84.863(4)°, β is 80.760(4)°, and γ is 81.751(4)°); and the cell volume is 2304A3 (more precisely, 2304.4(9)A3). The salt crystallizes in the P-1 space group. 123 2014280939 24 Dec 2014 [00545| In some embodiments, the pattern E hydrate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 6.240.2, 7.840.2, 10.2±0.2, 10.740.2. 12.140.2, 16.340.2, 19.740.2, 20.9±0.2, 21.840.2, 24.540.2, and 28.040.2 degrees 2Θ. In some such embodiments, the pattern E hydrate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 6.240.2, 7.840.2, 10.240.2, 10.740.2,12.140.2, 16.340.2,19.740.2, 20.940.2, 21.840.2, 24.540.2, and 28.040.2 degrees 2Θ. In other such embodiments, the pattern E hydrate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 6.240.2, 7.840.2, 10.240.2, 10.740.2, 12.140.2, 16.340.2, 19.740.2, 20.940.2, 21.840.2, 24.540.2, and 28.040.2 degrees 20.

[00546] In some embodiments, the pattern E hydrate has an X-ray powder diffraction pattern comprising one or more peaks selected from the group consisting of 6.240.2, 7.840.2, 10.240.2, 10.440.2, 10.740.2, 12.140.2, 16.340.2, 19.740.2, 20.940.2, 21.840.2, 24.540.2, and 28.0±0.2 degrees 20. In some such embodiments, the pattern E hydrate has an X-ray powder diffraction pattern comprising three or more peaks selected from the group consisting of 6.240.2, 7.840.2, 10.240.2, 10.440.2, 10.740.2,12.140.2, 16.340.2, 19.740.2, 20.940.2, 21.840.2, 24.540.2, and 28.040.2 degrees 20. In other such embodiments, the pattern E hydrate has an X-ray powder diffraction pattern comprising five or more peaks selected from the group consisting of 6.240.2, 7.840.2, 10.240.2, 10.440.2, 10.740.2, 12.140.2, 16.340.2, 19.740.2.20.940.2, 21.840.2, 24.540.2, and 28.040.2 degrees 20.

[00547] In some embodiments, the pattern E hydrate has an X-ray powder diffraction pattern substantially as shown in Figure 46. The 20 values for the peaks in Figure 46 (and their intensities) are as follows: 6.19(6), 7.81 (18), 10.17(13), 10.40(14), 10.68 (39), 12.06(20), 16.29(78), 19.72(32), 20.88(100), 21.77 (27), 24.52 (25), and 28.01 (27).

[00548] This invention also relates, in part, to a process for preparing the pattern E hydrate. It was prepared by suspending compound IB-L1-1.1 (56.76mg) in 200ul THF while heated. Aqueous NaOH (1M, 146uL, 1.2 molar equivalent) was added, which yielded a clear solution. Ethanol (800ul) was added to the solution. The solution was allowed to cool naturally to ambient temperatures. Crystals were formed during the slow evaporation process. Although it appears that the lattice can accommodate as much as one water molecule per molecule of compound IB-L1-1.1, the recovered pattern D hydrate contained ~0.25 water molecules per molecule of compound IB-L1-1.1. H. Compositions, [00549] This invention also is directed, in part, to compositions comprising one or more compounds and/or salts of the invention (including the crystalline compounds and salts discussed in section G above). In some embodiments, the compositions comprise one or more substantially phase pure crystalline forms (compounds/salts/solvates/hydrates) discussed in section G above. The compositions can be 124 2014280939 24 Dec 2014 pharmaceutical compositions. {00550] In some embodiments, the compositions further comprise one or more additional therapeutic agents. Such therapeutic agents can, but need not be, additional HCV inhibitors.

[00551] The preferred composition depends on the method of administration, and typically comprises one or more conventional pharmaceutically acceptable carriers, adjuvants, and/or vehicles (together referred to as "excipients''). Formulation of drugs is generally discussed in, for example, Hoover, J., Remington's Pharmaceutical Sciences (Mack Publishing Co., 1975) and Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems (Lippincott Williams &amp; Wilkins, 2005).

[00552] Solid dosage forms for oral administration include, for example, capsules, tablets, pills, powders, and granules. In such solid dosage forms, the compounds or salts are ordinarily combined with one or more excipients. If administered per os, the compounds or salts can be mixed with, for example, lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets can contain a controlled-release formulation, as can be provided in, for example, a dispersion of the compound or salt in hydroxypropylmethyl cellulose. In the case of capsules, tablets, and pills, the dosage forms also can comprise buffering agents, such as sodium citrate, or magnesium or calcium carbonate or bicarbonate. Tablets and pills additionally can be prepared with enteric coatings.

[00553] Liquid dosage forms for oral administration include, for example, pharmaceutically acceptable emulsions (including both oil-in-water and water-in-oil emulsions), solutions (including both aqueous and non-aqueous solutions), suspensions (including both aqueous and non-aqueous suspensions), syrups, and elixirs containing inert diluents commonly used in the art (e.g., water). Such compositions also can comprise, for example, wetting, emulsifying, suspending, flavoring (e.g., sweetening), and/or perfuming agents.

[00554] Parenteral administration includes subcutaneous injections, intravenous injections, intramuscular injections, intrastemal injections, and infusion. Injectable preparations (e.g., sterile injectable aqueous or oleaginous suspensions) can be formulated according to the known art using suitable dispersing, wetting agents, and/or suspending agents. Acceptable vehicles and solvents include, for example, water, 1,3-butanediol, Ringer's solution, isotonic sodium chloride solution, bland fixed oils (e.g., synthetic mono- or diglycerides), fatty acids (e.g., oleic acid), dimethyl acetamide, surfactants (e.g., ionic and non-ionic detergents), and/or polyethylene glycols.

[00555] Formulations for parenteral administration may, for example, be prepared from sterile powders or granules hav ing one or more of the excipients mentioned for use in the formulations for oral 125 2014280939 24 Dec 2014 administration. A compound or salt of the invention can be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. The pH may be adjusted, if necessary, with a suitable acid, base, or buffer.

[00556] Suppositories for rectal administration can be prepared by, for example, mixing a compound or salt of the invention with a suitable nonirritating excipient that is solid at ordinary temperatures, but liquid at the rectal temperature, and will therefore melt in the rectum to release the drug. Suitable excipients include, for example, cocoa butter; synthetic mono-, di-, or triglycerides, fatty acids, and/or polyethylene glycols.

[00557] Topical administration includes the use oftransdermal administration, such as transdermal patches or iontophoresis devices.

[00558] Other excipients and modes of administration known in the pharmaceutical art also may be used.

[00559] Applicants have discovered that some I-Ll compounds in which R6 and the phenyluracil are in trans-position relative to the double bond, when in solution, tend to convert into the corresponding cis-isomer upon exposure to light; thus, it may be desirable to store such solutions under conditions that reduce exposure to light (e.g., in an amber bottle or in a dark place).

[00560] The preferred total daily dose of the compound or salt (administered in single or divided doses) is typically from about 0.001 to about 100mg/kg, more preferably from about 0.001 to about 30mg/kg, and even more preferably from about 0.01 to about 10mg/kg (/.<?.,mg of the compound or salt per kg body weight). Dosage unit compositions can contain such amounts or submultiples thereof to make up the daily dose. In many instances, the administration of the compound or salt will be repeated a plurality of times. Multiple doses per day typically may be used to increase the total daily dose, if desired.

[00561] Factors affecting the preferred dosage regimen include the type, age, -weight, sex, diet, and condition of the patient; the severity of the pathological condition; the severity of the pathological condition; the route of administration; pharmacological considerations, such as the activity, efficacy, pharmacokinetic, and toxicology profiles of the particular compound or salt used; whether a drug delivery system is utilized; and whether the compound or salt is administered as part of a drug combination. Thus, the dosage regimen actually employed can vary widely, and therefore, can derive from the preferred dosage regimen set forth above. ƒ. Kits.

[00562] This invention also is directed, in part, to a kit comprising one or more compounds and/or salts of the in invention. The kit can optionally contain one or more additional therapeutic agents and/or instructions for, for example, using the kit. 326 2014280939 24 Dec 2014 J. Methods of Use.

[00563J This invention also is directed, in part, to a method for inhibiting replication of an RNA virus.

The method comprises exposing the virus to one or more compounds and/or salts of this invention. In some embodiments, replication of the RNA virus is inhibited in vitro. In other embodiments, replication of the RNA virus is inhibited in vivo. In some embodiments, the RNA virus whose replication is being inhibited is a single-stranded, positive sense RNA virus. In some such embodiments, the RNA virus whose replication is being inhibited is a virus from the Flaviviridae family. In some such embodiments, the RNA virus whose replication is being inhibited is HCV.

[00564] This invention also is directed, in part, to a method for inhibiting HCV RNA polymerase. The method comprises exposing the polymerase with one or more compounds and/or salts of this invention.

Jn some embodiments, HCV RNA polymerase activity is inhibited in vitro. In other embodiments, IICV RNA polymerase activity is inhibited in vivo.

[00565] The term “inhibiting” means reducing the level of RNA virus replication/HCV polymerase activity either in vitro or in vivo. For example, if a compound/salt of the invention reduces the level of RNA virus replication by at least about 10% compared to the level of RNA virus replication before the virus was exposed to the compound/salt, then the compound/salt inhibits RNA virus replication. In some embodiments, the compound/salt can inhibit RNA virus replication by at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 95%.

[00566] This invention also is directed, in part, to a method for treating a disease that can be treated by inhibiting HCV RNA polymerase. Thus, this invention also is directed, in part, to a method for treating hepatitis C in an animal in need of such treatment. These methods comprise administering to the animal one or more compounds and/or salts of the invention, and, optionally, one or more additional therapeutic agents. In some embodiments, a therapeutically effective amount of the compound(s) and/or salt(s) is administered to the animal. "Treating" means ameliorating, suppressing, eradicating, preventing, reducing the risk of, and/or delaying the onset of the disease being treated. Applicants specifically intend that the term “treating” encompass administration of the compounds and/or salts of the invention to an HCV-negative patient that is a candidate for an organ transplant. The methods of treatment are particularly suitable for use with humans, but may be used with other animals, particularly mammals. A "therapeutically-effective amount" or "effective amount" is an amount that will achieve the goal of treating the targeted condition.

[00567] In some embodiments, the methods comprise combination therapy, wherein the compound(s) and/or salt(s) of the invention is/are co-administered with a second (or even a third, fourth, etc.) compound, such as, for example, another therapeutic agent used to treat hepatitis C (e.g., interferon or 127 2014280939 24 Dec 2014 interferon/ribavirin combination, or an HCV inhibitor such as, for example, an HCV polymerase inhibitr or an HCV protease inhibitor). The compound(s) and/or salt(s) of this invention can also be coadministered with therapeutic agents other than therapeutic agents used to treat hepatitis C (e.g., anti-HIV agents). In these co-administration embodiments, the compound(s) and/or salt(s) of the invention and the second, etc. therapeutic agent(s) may be administered in a substantially simultaneous manner (e.g., or within about 5 minutes of each other), in a sequential manner, or both. It is contemplated that such combination therapies may include administering one therapeutic agent multiple times between the administrations of the other. The time period between the administration of each agent may range from a few seconds (or less) to several hours or days, and will depend on, for example, the properties of each composition and active ingredient (e.g., potency, solubility, bioavailability, half-life, and kinetic profile), as well as the condition of the patient. The compound(s) and/or salt(s) of this invention and the second, etc. therapeutic agent may also be administered in a single formulation.

[00568] This invention also is directed, in part, to a use of one or more compounds and/or salts of the invention, and, optionally one or more additional therapeutic agents to prepare a medicament. In some embodiments, the medicament is for co-administration with one or more additional therapeutic agents.

[00569] In some embodiments, the medicament is for inhibiting replication of an RNA virus.

[00570] In some embodiments, the medicament is for treating hepatitis C.

[00571] This invention also is directed, in part, to one or more compounds and/or salts of the invention, and, optionally one or more additional therapeutic agents, for use as a medicament. In some embodiments, the medicament is for inhibiting replication of an RNA virus. In other embodiments, the medicament is for treating hepatitis C. K. Intermediate Compounds.

[00572] This invention also is directed, in part, to intermediates that correspond in structure to formula H that can be used to prepare the compounds of formula I (and their salts)(although some intermediates can also be used, just like the compounds of formula I, as HCV inhibitors, and one skilled in the art can determine such ability of the compounds of formula II by utilizing, for example, the methods discussed below):

128 2014280939 24 Dec 2014

R5 [00573] 1η formula Π: =^=, R1, R2, R3, R4, and R5 are as discussed above for the compounds of formula I; and X2 is halo.

[00574] The various embodiments for ===, R1, R2, R3, R4, and Rs (as well as their combinations) discussed above apply to the compounds of formula II. As to X2, in some embodiments, X2 is selected from the group consisting of chloro, bromo, and iodo. In other embodiments, X2 is selected from the group consisting of chloro and bromo. In yet other embodiments, X2 is selected from the group consisting of chloro and iodo. In yet other embodiments, X2 is selected from the group consisting of iodo and bromo. In further embodiments, X2 is fluoro. In yet further embodiments, X2 is chloro. In yet further embodiments, X2 is bromo. And in yet further embodiments, X2 is iodo.

[00575] The various embodiments for ==, R1, R2, R3, R4, R5, and X2 discussed above can be combined to form various embodiments of compounds of formula II, and all embodiments of compounds of formula Π so formed are within the scope of Applicants’ invention. Some exemplary embodiments of the compounds (and salts thereof) of formula Π are discussed below.

[00576] In some embodiments, the compounds of formula Π correspond in structure to formula IIA: R,

I x2 [00577] In other embodiments, the compounds of formula II correspond in structure to formula IIB: R1 "τνΎ (HB) 1 R4 [00578] In some embodiments of the compounds of formula Π: R1 is selected from the group consisting of hydrogen, methyl, and nitrogen-protecting group; R2 is selected from the group consisting of hydrogen and halo; R3 is selected from the group consisting of hydrogen and halo; 129 2014280939 24 Dec 2014 R4 is selected from the group consisting of Ci-Ci-alkyl, Cs-CVcarbocyclyl, and 5-6-membered heterocyclyl, wherein: (a) the CrC4-alkyl optionally is substituted with up to three substituents independently selected from the group consisting of halo, oxo, hydroxy, alkyloxy, and trimethylsilyl, and (b) the C3-C6-carbocyclyl and 5-6-membered heterocyclyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, halo, and alkylsulfonylamino; R5 is selected from the group consisting of hydrogen, hydroxy, alkyloxy, and halo; and X2 is selected from the group consisting of chloro, bromo, and iodo.

[00579] In some embodiments of the compounds of formula II: is a double carbon-carbon bond; R1 is hydrogen; R2 is selected from the group consisting of hydrogen and halo; R3 is hydrogen; R4 is tert-butyl; R5 is selected from the group consisting of hydrogen, hydroxy, and methoxy; and X2 is selected from the group consisting of bromo and iodo.

[00580] In some embodiments of the compounds of formula II: R' is selected from the group consisting of hydrogen and methyl; R2 is selected from the group consisting of hydrogen and methyl; R3 is selected from the group consisting of hydrogen and methyl; R4 is tert-butyl; R5 is selected from the group consisting of hydroxy and methoxy; and X2 is selected from the group consisting of chloro, bromo, and iodo.

[00581] In some embodiments of the com pounds of formula II: ----is a double carbon-carbon bond; R' is hydrogen; R2 is hydrogen; R3 is hydrogen; R4 is tert-butyl; R5 is selected from the group consisting of hydroxy and methoxy; and X2 is selected from the group consisting of chloro, bromo, and iodo.

[00582] In some embodiments, the compound of formula II is selected from the group consisting of 130 2014280939 24 Dec 2014 o Η ,Ν, τ τ ο

ο ο

αι-ΐ) ^ [00583] The discussion below provides instructions for the preparation of intermediate compounds of formula II (and salts thereof). L. Starting Compounds. [00584] This invention also is directed, in part, to starting compounds that correspond in structure to formula ΠΙ that can be used to prepare the compounds of formulas II and I (and their salts): R,

[00585] In formula III, =-=^, JR1, R2, and R3 are as discussed above for the compounds of formula I and II. The various embodiments for ~ ~, R1, R2, and R3 (as well as their combinations) discussed above apply to the compounds of formula ΠΙ. The various embodiments for ==, R1, R2, and R3 discussed above can be combined to form various embodiments of compounds of formula ΠΙ, and all embodiments of compounds of formula III so formed are within the scope of Applicants’ invention. Some exemplary embodiments of the compounds (and salts thereof) of formula III are discussed below.

[00586] In some embodiments of the compounds of formula III: R1 is selected from the group consisting of hydrogen, methyl, and nitrogen-protecting group; R2 is selected from the group consisting of hydrogen and halo; and R3 is selected from the group consisting of hydrogen and halo.

[00587] In some embodiments of the compounds of formula III: ~~~= is a double carbon-carbon bond; R1 is selected from the group consisting of hydrogen; R2 is selected from the group consisting of hydrogen and halo; and R3 is selected from the group consisting of hydrogen.

[00588] In some embodiments of the compounds of formula III: 131 2014280939 24 Dec 2014 R1 is selected from the group consisting of hydrogen and methyl; R2 is selected from the group consisting of hydrogen and methyl; and R3 is selected from the group consisting of hydrogen and methyl.

[00589] In some embodiments, the compound of formula III is uracil.

[00590] This invention also is directed, in part, to starting compounds that correspond in structure to formula IV that can be used to prepare the compounds of formulas Π and I (and their salts): ΧΙ'γ^Γ-Χί (IV) R4 [00591] In formula IV: R4, Rs, and X2 are as discussed above for the compounds of formula I and II; and X1 is halo.

[00592] The various embodiments for R4, R5, and X2 (as well as their combinations) discussed above apply to the compounds of formula IV. As to X1, in some embodiments, X1 is selected from the group consisting of chloro, bromo, and iodo. In other embodiments, X1 is selected from the group consisting of chloro and bromo. In yet other embodiments, X1 is selected from the group consisting of chloro and iodo. In yet other embodiments, X1 is selected from the group consisting of iodo and bromo. In further embodiments, X1 is fluoro. In yet further embodiments, X1 is chloro. In yet further embodiments, X1 is bromo. And in yet further embodiments, X1 is iodo. As to X1 and X2, in some embodiments, X1 and X2 are identical.

[00593] The various embodiments for R4, R5, X1, and X2 discussed above can be combined to form various embodiments of compounds of formula IV, and all embodiments of compounds of formula III so formed are within the scope of Applicants’ invention. Some exemplary embodiments of the compounds (and salts thereof) of formula TV are discussed below.

[00594] In some embodiments of the compounds of formula IV: R4 is selected from the group consisting of Ci-C.ralkyl, CrC6-carbocyclyl, and 5-6-membered heterocyclyl, wherein: (a) the Q-C4-alkyl optionally is substituted with up to three substituents independently selected from the group consisting of halo, oxo, hydroxy, alkyloxy, and trimethylsilyl, and (b) the C3-Ce-carbocyclyl and 5-6-membered heterocyclyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, halo, and alkylsulfonylamino;

Rs is selected from the group consisting of hydrogen, hydroxy, and alkyloxy; 132 2014280939 24 Dec 2014 X1 is selected from the group consisting of chloro, bromo, and iodo; and X1 is selected from the group consisting of chloro, bromo, and iodo.

[00595] In some embodiments of the compounds of formula IV: R4 is selected from the group consisting of tert-butyl; R5 is selected from the group consisting of hydrogen, hydroxy, and methoxy; X1 is selected from the group consisting of bromo and iodo; and X2 is selected from the group consisting of bromo and iodo.

[00596] In some embodiments of the compounds of formula IV; R4 is selected from the group consisting of tert-butyl; R5 is selected from the group consisting of hydroxy and methoxy; X1 is selected from the group consisting of chloro, bromo, and iodo; and X2 is selected from the group consisting of chloro, bromo, and iodo.

[00597] In some embodiments of the compounds of formula IV: R4 is tert-butyl;

Rs is selected from the group consisting of hydroxy and methoxy; X1 is selected from the group consisting of chloro, bromo, and iodo; and X2 is selected from the group consisting of chloro, bromo, and iodo.

[00598] In some embodiments, the compound of formula IV is selected from the group consisting of

, and [00599] The discussion below provides instructions for the preparation of starting compounds of formula IV (and salts thereof). L. Methods for Preparation.

[00600] This invention also is directed, in part, to a process for preparing compounds of formula Π. The process comprises reacting a compound of formula ΠΙ with a compound of formula IV in the presence of (i) copper (1) salt catalyst and (ii) nitrogenous heteroaryl ligand; 133 2014280939 24 Dec 2014

100601] In the above process, R1, R2, R3, R4, R5, X1, and X2 are as discussed above.

[00602] Applicants have discovered that the process generally results in the substitution of the N1 hydrogen of uracil derivative compound ΙΠ thus resulting in intermediate compound II. When X2 in intermediate compound Π is chloro, bromo, or iodo, then compound II is is suitable for subsequent reaction (e.g., Suzuki coupling with an appropriate boronic acid or boronate ester) to provide compound of formula I. In other words, when X2 in intermediate compound II is chloro, bromo, or iodo, the above process is suitable for preparing compounds of formula I as well.

[00603] In some embodiments, compound ΠΙ is uracil, and compound IV corresponds in structure to a compound selected from the group consisting of compound IV-I, IV-Br, and IV-CL, with compounds IV-I and IV-Br typically resulting in better yield than compound IV-C1.

[00604] Suitable Cu(I) catalysts include, for example, Cul, CuBr, CuCl, Cu20, and C,H3C(0)OCu. In some embodiments, the catalyst is selected from the group consisting of Cul and CuBr. In some such embodiments, the catalyst is Cul. In other such embodiments, the catalyst is CuBr.

[00605] In some embodiments, the process is conducted in the presence of a base. In some such embodiments, the base is an inorganic base. Suitable inorganic bases include, for example, potassium, sodium, and cesium salts (e.g., K2C03, K3P04, Cs2C03, Na2C03). In some embodiments, the base is selected from the group consisting of potassium salt and cesium salt. In some such embodiments, the salt is selected from the group consisting of K3P04 and Cs2C03. In some embodiments, the base comprises a potassium salt. In some such embodiments, the potassium salt is K2C03. In other such embodiments, the potassium salt is K3P04. In some embodiments, the base comprises a cesium salt. In some such embodiments, the potassium salt is Cs2C03.

[00606] Typically, the process is conducted in the presence of a solvent. Suitable solvents include, for example, dimethylsulfoxide (DMSO), dimethylformamide (DMF), and acetonitrile (MeCN). In some embodiments, the solvent is DMSO.

[00607] Typically, the process is conducted at a temperature of from about 40 to about 130°C.

[00608] In some embodiments, the nitrogenous heteroaryl ligand comprises 8-hydroxyquinoline. In other 134 2014280939 24 Dec 2014 embodiments, the ligand comprises 2-(2-pyridyl)-benzimidazole. In yet other embodiments, the ligand comprises a picolinamide compound corresponding in structure to formula V: R14

[00609) In formula V, R11, R12, R13, R14, R15, RIS, and R17 are independently selected from the group consisting of hydrogen, C^-perfluoroalkyl, C^-alkyloxy, CM-haloalkyl, chloro, or cyano. In some embodiments, Ru, R12, R13, R14, R15, R16, and R17 are independently selected from the group consisting of hydrogen, methyl, methoxy, trifluoromethyl, chloro, and cyano. In some embodiments, the ligand of formula V comprises N-(4-cyanophenyl)picolinamide. In other embodiments, the ligand of formula V comprises N-(2-cyanophenyl)picolinamide.

[00610] In some embodiments, the process comprises (a) preparing a compound of formula IV; and (b) reacting a compound of formula HI with a compound of formula IV in the presense of (i) copper (I) salt catalyst and (ii) nitrogenous heteroaryl ligand, optionally in the presence of inorganic base.

[00611] Compound of formula TV-I can be prepared by, for example, converting 2-tert-butylphenol into 2-tert-butyl-4,6-diiodophenol (by, for example, reacting it with Nal and NaOCl), and then converting the 2-tert-butyl-4,6-diiodophenol into l-tert-butyl-3,5-diiodo-2-methoxybenzene (by, for example, treating it with CH3I in the presence of a base, such as, for example, NaOH).

135 2014280939 24 Dec 2014

[00612] Compound of formula IV-Br can be prepared by, for example, converting 2-tert-butylphenol into 2,4-dibromo-6-tert-butylphenol (by, for example, reacting it with l,3-dibromo-5,5-dimethylimidazo-lidine-2,4-dione), and then converting the 2,4-dibromo-6-tert-butylphenol into l,5-dibromo-3-tert-butyl-2-methoxybcnzene (by, for example, treating it with CH31 in the presence of KOtBu).

[00613] Additional information about the preparation of compounds of formulas I and II (and their salts) is provided in the general discussion and/or specific synthesis examples below. In the discussion below, R\ R2, R3, R4, R5, L, Ra, Rb, Rc, Rd, R6, Re, Rf, Rg, Rh, R1, Rj, Rk, X1, and X2 have the meaning discussed above unless otherwise stated. SCHEME 1 OR9 OR9

(1-8) N02 (1-9) NH2 [00614] Compound (1-1), wherein R7 is, for example, hydrogen or -C02Me, and R8 is, for example, hydrogen or t-butyl, may be treated with nitric acid in solvents such as, for example, acetic acid or water in a temperature range of about 0 to about 35°C over about 1 to about 5h to provide compound (1-2). Compound (1-2) may then be reduced using conditions known to those skilled in the art to furnish the corresponding aniline (1-3). Typical conditions for this reduction include using hydrogen at a pressure of about 1 to about 5 atmospheres in the presence of a catalyst such as, for example, palladium or platinum on charcoal in a solvent such as, for example, tetrahydrofuran, ethyl acetate, ethanol, or hexane at or near ambient temperature over a period of about 1 to about 12h. Dependent on the functional groups present, 136 2014280939 24 Dec 2014 an alternative reduction procedure may be more appropriate such as, for example, using iron powder in the presence of a mild acid such as, for example, ammonium chloride or dilute hydrochloric acid at reflux temperatures in a mixture of solvents containing, for example, methanol, water, and/or tetrahydrofuran over about 1 to about 12h. Another set of reduction conditions includes the use of sodium borohydride in a solvent mixture such as, for example, water and tetrahydrofuran. Yet another set of reduction conditions includes the use of tin(Il) chloride in the presence of hydrochloric acid in such solvents as, for example, water and methanol or mixtures thereof.

[00615] Compound (1-2) may be modified prior to reduction. For example, treatment of compound (1-2), wherein R7 is hydrogen, with iodine monochloride in a mixture of methanol and water at or near ambient temperature over a period of about 8 to about 24h supplies compound (1-4), wherein X1 is iodine. Alternatively, compound (1-2) can be treated with pyridinium hydrobromide perbromide in a solvent such as, for example, acetic acid at or near ambient temperature over a period of about 2 to about 16h to provide compound (1-4), wherein X1 is bromine. Modifications may be introduced at the phenol moiety in compound (1-4). For example, the phenol may be alkylated with alkyl halides (e.g., methyl iodide), alkyl sulfates (e.g., methyl sulfate), alkenyl halides (e.g., allyl bromide), alkynyl halides (e.g., propargyl bromide) in the presence of a base such as, for example, potassium carbonate in acetone, sodium hydride in dimethylformamide, or potassium t-butoxide in tetrahydrofuran, at temperatures from about 0 to about 35°C over a period of about 1 to about 24h to provide compound (1-5), wherein R9 is, for example, alkyl, alkenyl, or alkynyl. Alternatively, alkylation may be achieved by using a reagent such as (trimethylsilyl) diazomethane in solvents such as, for example, methanol or t-butyl methyl ether, or mixtures thereof in a sealed tube at or near room temperature over about 8 to about 24h. Compound (1-5) may subsequently be reduced to compound (1-6) using the iron powder or tin(II) chloride conditions described above. An alternative reduction procedure employs hydrogenation at approximately 1 atmosphere pressure with a catalyst such as 5% platinum on sulfided carbon in a solvent such as methanol. Protection of the resultant aniline of compound (1-6) with, for example, a t-butyl carbamate can be achieved by treatment with di-tert-butyl dicarbonate in a solvent such as, for example, tetrahydrofuran or dioxane at a temperature of about 50 to about 65°C for about 1 to about 8h provides compound (1-7).

[00616] Modifications may also occur at the phenol moiety in compound (1-2). One skilled in the art may alkylate the phenol of compound (1-2) using, for example, the conditions described above to obtain compound (1-8). Compound (1-8) is transformed into compound (1-9) using, for example, one or more of the appropriate reduction conditions described above.

[00617] Another modification of the phenol group in compound (1-2) is sulfonylation to furnish compound (1-8), wherein R9 is alkylsulfonyl, carbocyclylsulfonyl, or haloalkylsulfonyl. Such a compound may be prepared by exposing compound (1-2) to sulfonyl chlorides such as, for example, 137 2014280939 24 Dec 2014 methanesulfonyl chloride, cyclohexanesulfonyl chloride, benzenesulfonyl chloride, or 3-chloropropane sulfonyl chloride in the presence of a base such as, for example, triethylamine, diisopropylethylamine, or pyridine in a solvent such as, for example, dichloromethane at or near ambient temperature for a period of about 1 to about 24h. One skilled in the art can then transform compound (1-8) into compound (1-9) with an appropriate set of reduction conditions.

Scheme 2

[00618] Aniline (2-4) can be prepared through use of the Curtius rearrangement. To this end, compound (2-1), wherein R4 is not amino, can be treated in refluxing thionyl chloride with a catalytic amount of dimethylformamide for about 1 to about 4h to obtain acid chloride (2-2). Treatment with thionyl chloride at the reflux temperature in solvents such as, for example, chloroform or toluene also furnishes compound (2-2). Compound (2-2) can be reacted with an aqueous solution of sodium azide in a solvent such as, for example, acetone over about 1 to about 8h to provide acyl azide (2-3). Compound (2-3) can then undergo a Curtius rearrangement in refluxing solvents such as dioxane or toluene. The intermediate isocyanate is hydrolyzed with an aqueous acid such as dilute hydrochloric acid in a solvent such as dimethoxyethane to provide compound (2-4). 138

Scheme 3

2014280939 24 Dec 2014 100619] Compound (3-1), wherein R10 is, for example, hydrogen, bromine, iodine, or -C02Me, can be treated with an acrylic acid either neat at or near ambient temperature in a solvent such as, for example, toluene and heated to reflux over a period of about 15 to about 48h to supply compound (3-2). When excess of an acrylic acid is used, compound (3-3) is produced. Compound (3-2) or (3-3) can be treated with urea in a solvent such as, for example, acetic acid at about 100 to about 120CC over about 2 to about 48h to supply compound (3-4).

Scheme 4

[00620] Compound (4-2) can be prepared from compound (3-1) dissolved in solvents such as, for example, dimethylformamide or dimethylacetamide by the addition of a benzene solution of (E)-3-methoxyacryloyl isocyanate (prepared as described by Santana, L.; et al. J. Heterocyclic Chem. 1999, 36,293-295.) at a temperature of about -40 to about -15°C under an inert atmosphere and then warming to ambient temperature for from about 30 min to about 4h. Compound (4-2) can be treated with an acid such as, for example, sulfuric acid in mixtures of water and ethanol in a temperature range of from about 90 to about 110°C for about 1 to about 8h to supply compound (4-3). Alternatively, compound (4-2) can be cyclized to uracil (4-3) under the basic conditions described by IJeno, Y.; et al. J. Org. Chem. 70:7925-7935 (2005). 139 2014280939 24 Dec 2014 SCHEME 5

[00621] Compound (5-1) can be hydrolyzed with a base such as, for example, sodium hydroxide, lithium hydroxide, or potassium hydroxide in a solvent such as, for example, methanol, ethanol, or tetrahydrofuran, or mixtures thereof. The resultant reaction mixture can be stirred for a period of about 6 to about 48h at ambient temperature. Acidification with a dilute aqueous acid supplies compound (5-2) where the ester has been hydrolyzed and the tetrahyrdopyrimidine ring opened.

[00622] Cyclization of compound (5-2) to compound (5-3) can be accomplished by treatment with a strong acid such as, for example, concentrated hydrochloric acid in a temperature range of about 90 to about 120 °C over a period of about 1 to about 3h. Compound (5-3) can be treated in refluxing thionyl chloride, with or without a catalytic amount of dimethylformamide, for about 1 to about 4h to deliver acid chloride (5-4). Treatment with thionyl chloride at the reflux temperature in solvents such as, for example, chloroform or toluene also furnishes compound (5-4).

[00623] Compound (5-4) can be treated with an amine or the corresponding salt (5-5) in solvents such as, for example, dioxane, dimethylformamide, dimethylacetamide, or dichloromethane optionally in the presence of a base such as, for example, pyridine, triethylamine, or diisopropylethylamine at temperatures ranging from at or near ambient to about 100 °C for between about 1 and about 24h to provide compound (5-6).

[00624] Alternatively, compound (5-3) can be converted directly to compound (5-6) by reacting with an equimolar amount of amine (5-5) with a coupling reagent such as, for example, bis(2-oxo-3-140 2014280939 24 Dec 2014 oxazolidinyl)phosphinic chloride (BOPC1), 0-(7-azabenzotriazol-l-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate (HATU), or 0-benzotriazol-l-yl-N,N,N’,N’-tetramethyluronium tetrafluoroborate (TBTU) along with a coupling auxiliary such as, for example, l-Hydroxy-7-azabenzotriazole (HOAT) or 1 -hydroxybenzotriazole hydrate (HOBT) in the presence or absence of a base such as, for example, N-methyl morpholine, diisopropylethylamine in solvents such as, for example, tetrahydrofuran, N,N-dimethylacetamide, Ν,Ν-dimethylfonnamide, pyridine, and chloroform. Typical reactions can be carried out at between about 0 to about 65°C or may be carried out in a microwave reactor to facilitate coupling. SCHEME 6

[00625] Compound (6-1) can be converted to compound (6-5) using the transformations described in Scheme 5 above. 141 2014280939 24 Dec 2014 o o

o

Scheme 7

1. heat 2. H30+ (7-6)

[00626] Compound (7-1) may be converted to acyl azide (7-2) in a two-step process. First, compound (7-1) can be treated in refluxing thionyl chloride with or without a catalytic amount of dimethyl-formamide for about 1 to about 4h to deliver the corresponding acid chloride. Treatment with thionyl chloride at the reflux temperature in solvents such as, for example, chloroform or toluene also furnishes the desired acid chloride. The acid chloride can be reacted with an aqueous solution of sodium azide in a solvent such as, for example, acetone over about 1 to about 8h to provide acyl azide (7-2). Compound (7-2) can then undergo a Curtius rearrangement in refluxing solvents such as, for example, dioxane or toluene. The intermediate isocyanate is hydrolyzed with an aqueous acid such as, for example, dilute hydrochloric acid in a solvent such as, for example, dimethoxyethane to provide compound (7-3). Compound (7-3) may be converted to compound (7-6) using either acid chloride (7-4) or carboxylic acid (7-5) and the amide bond forming conditions described in Schemes 5 and 6. 142 2014280939 24 Dec 2014

[00627] Compound (8-1) can be activated for nitration by removal of the methyl group with BBr3 initially added at about 0 °C and then refluxed for about 10 to about 24h in a solvent such as, for example, dichloromethane to provide compound (8-2). The phenol (8-2) can be treated with nitric acid in acetic acid over a period of about 1 to about lOh at or near ambient temperature to supply compound (8-3). Compound (8-3) is then converted to the corresponding methyl ether (8-4) by treatment with a solution of (trimethylsilyl)diazomethane in tetrahydrofuran in a solvent such as, for example, methanol or a mixture of methanol and tetrahydrofuran at or near ambient temperature over about 8 to about 24h. Compound (8-4) may be reduced to compound (8-5) using a set of reduction conditions described in Scheme 1 and suitable for the functional groups present. Compound (8-5) can be converted into compound (8-8) by coupling with acid chloride (7-4) or carboxylic acid (7-5) using conditions for amide bond formation described in Schemes 5 and 6. 143 2014280939 24 Dec 2014

Scheme 9

[00628] Compound (9-1) can be treated in refluxing thionyl chloride for about 1 to about 4h to obtain acid chloride (9-2). Treatment with thionyl chloride at the reflux temperature in solvents such as, for example, chloroform or toluene also furnishes compound (9-2). Compound (2) is converted to the corresponding aldehyde (9-3) by reduction with lithium tri-f-butoxyaluminum hydride in a solvent such as, for example, tetrahydrofuran at about -78 °C over from about 1 to about 8h. The reduction can also be achieved by treatment with indium chloride and tributyltin hydride in the presence of triphenylphosphine in a solvent such as tetrahydrofuran or toluene at temperatures from about -40 to about 0°C. Compound (9-3) can be treated with compound (9-4) in the presence of a base such as potassium /-butoxide in a solvent such as dichloromethane at or near room temperature over a period of about 1 to about 8h to provide compound (9-5). SCHEME 10

[00629] Compound (10-1), wherein X1 is halo (e.g., bromine, iodine) can undergo a Suzuki reaction with vinyl boronic acid (10-2) to provide compound (10-3). The reaction typically requires the use of a base 144 2014280939 24 Dec 2014

and a catalyst. Examples of bases include, for example, potassium carbonate, potassium phosphate, potassium t-butoxide, sodium carbonate, cesium carbonate, and cesium fluoride. Examples of catalysts include, for example, tris(dibenzylidineacetone)dipalladium (0), palladium acetate, bis(triphenyl phosphine)palladium (II) chloride, tetrakis(triphenylphosphine)palladium, dichloro[l,l'-bis(di-tert-butylphosphino)ferrocene] palladium (II), or dichloro[l,r-bis(diphenylphosphino)ferrocene] palladium (II) dichloromethane adduct. The reaction may be conducted in a solvent such as, for example, water, dioxane, dimethoxyethane, dimethylformamide, toluene, ethanol, tetrahydrofuran and the like or mixtures thereof. The reaction may be conducted at ambient or elevated temperatures.

Scheme 11

[00630] Compound (11-1) can be converted to compound (11-2) by treatment with diazomethane in a solvent such as, for example, tetrahydrofuran in the presence of palladium acetate at or near room temperature over a period of about 30 min to about 4h.

Cul/Pd catalyst

[00631] Compound (9-3) can be treated with dimethyl l-diazo-2-oxopropylphosphonate (prepared as described by Ohira, S., Syn. Comm. 19:561-564 (1989)) in the presence of a base like potassium carbonate in a solvent such as, for example, methanol for about 8 to about 24h at or near room temperature to supply alkyne (12-2). Compound (12-2) is then treated with R6-X2, wherein X2 is iodine, bromine, or -O-triflate, in the presence of copper (I) iodide, palladium catalyst, base, and optionally additional triphenylphosphine in an inert atmosphere to provide compound (12-3). Suitable palladium catalysts include, for example, tris(dibenzylidineacetone)palladium (0), palladium acetate, bis(triphenylphosphine)palladium (II) chloride, ortetrakis(triphenylphosphine)palladium. Bases, which 145 2014280939 24 Dec 2014

Me3Si—= R6_xi - (13-1) Cul/Pd catalyst R6—== (13-3)

can be used, include, for example, triethylamine, diethylamine, diisopropylethylamine, potassium carbonate optionally in the presence of tetrabutylammonium bromide, and sodium bicarbonate. Solvents that may be used include, for example, acetonitrile, dimethylformamide, water, dioxane, and tetrahydrofuran, or mixtures thereof. The reaction can be conducted from room temperature to the reflux temperature of the solvents for about 1 to about 48h. Heating at about 50 to about 120°C in a microwave reactor from between about 5 and about 15 min also provides compound (12-3).

Scheme 13

-OH R6 ~ΞΞ- siMe3 - (13-2) o o [00632] Compound (13-1), wherein X1 is bromine or iodine, can be reacted in an inert atmosphere with (trimethylsilyl)acetylene in the presence of a catalyst such as, for example, palladium acetate/triphenylphosphine or copper iodide/bis(triphenylphosphine)palladium (II) chloride and a base such as, for example, triethylamine in a solvent such as, for example, toluene or acetonitrile to furnish compound (13-2). The reaction can be heated to about 70°C to about 100°C optionally in a sealed tube over a period of about 30 min to about 48h. Compound (13-2) are converted to compound (13-3) by treatment with a base such as, for example, potassium carbonate or sodium hydroxide in a solvent such as, for example, methanol at ambient temperature. Compound (13-3) are reacted with compound (13-4), wherein X2 is bromine or iodine, in the presence of copper (I) iodide, palladium catalyst, base, and optionally additional triphenylphosphine in an inert atmosphere to provide compound (13-5). Suitable palladium catalysts include, for example, tris(dibenzylidineacetone)dipalladium (0), palladium acetate, bis(triphenylphosphine)palladium (II) chloride, ortetrakis(triphenylphosphine)palladium. Bases, which can be used, include, for example triethylamine, diethylamine, diisopropylethylamine, potassium carbonate optionally in the presence of tetrabutylammonium bromide, and sodium bicarbonate. Solvents that may be used include, for example, acetonitrile, dimethylformamide, water, dioxane, and tetrahydrofuran, or mixtures thereof. The reaction can be conducted from about 40°C to the reflux temperature of the solvents for about 15 min to about 48h. Microwave heating at about 50°C to about 120°C from between about 5 and about 15 min is an alternative heating process to provide compound (13-5). 146

2014280939 24 Dec 2014 [00633] Compound (11-1) is reduced to supply compound (14-2). Typical conditions for this reduction include using hydrogen at a pressure of about 1 to about 5 atmospheres in the presence of a catalyst such as, for example, palladium or platinum on charcoal in a solvent such as, for example, tetrahydrofuran, ethyl acetate, ethanol, or hexane at or near ambient temperature over a period of about 1 to about 12h. SCHEME 15

[00634] Compound (15-1) can be converted in a two-step sequence to compound (15-2). The initial step involves reduction of the aromatic nitro moiety with iron powder in the presence of a mild acid such as, for example, ammonium chloride or dilute hydrochloric acid at temperatures from about 60 to about 80°C in a mixture of solvents containing, for example, methanol, water, and tetrahydrofuran over about 1 to about 12h. The second step consists of exposure of the aniline, prepared in the first step, to methanesulfonyl chloride in the presence of a base such as pyridine in a solvent such as dichloromethane at or near ambient temperature. 147 2014280939 24 Dec 2014

Scheme 16 h2n rE,F,G,H,U,K X2 re,f,g,h,i,j,k

Vj? (16-1) (16-4)

02N

MeS02Cl OO re,f,g,hj,jx =—SiMe, -X2 S"V/ (16-2) X2 _ o o =—Si Me, A'/ £Λ\ (16-3) -SiMe, re.rghjjv; 1. Fe/NH4C1 2. MeSOjCi °2N / (16-5) -—SiMe, [00635] Aniline (16-1) and aromatic nitro compound (16-4), wherein X2 is, for example, bromine, iodine, or triflate, can be converted to compound (16-3). Compound (16-1) can be transformed to compound (16-2) by treatment with methanesulfonyl chloride in the presence of a base such as pyridine in a solvent such as dichloromethane. Then compound (16-2) is converted to compound (16-3) by treatment in an inert atmosphere with (trimethylsilyl)acetylene in the presence of a catalyst such as, for example, palladium acetate, bis(triphenylphosphine)palladium (Π) chloride, bis(triphenylphosphine)pa!ladium (II) chloride in combination with copper(I) iodide and, when X2 is bromine, triphenylphosphine, and a base such as, for example, triethylamine in a solvent such as toluene or acetonitrile at approximately 80°C. [00636] Compound of formula (16-4) can be reacted in an inert atmosphere with (trimethylsilyl) acetylene in the presence of a catalyst such as, for example, bis(triphenylphosphine)palladium (II) chloride/ copper(I) iodide and a base such as, for example, triethylamine in a solvent such as, for example, acetonitrile at approximately 80°C to give compound (16-5). Compound (16-5) can be converted to compound (16-3) in a two-step sequence. The initial step involves reduction of the aromatic nitro moiety with iron powder in the presence of a mild acid such as, for example, ammonium chloride or dilute hydrochloric acid at temperatures from about 60 to about 80°C in a mixture of solvents containing, for example, methanol, water, and tetrahydrofuran over about 1 to about 12h. The second step consists of exposure of the aniline, prepared in the first step, to methanesulfonyl chloride in the presence of a base such as pyridine in a solvent such as dichloromethane at or near ambient temperature. [00637] Removal of the trimethylsilyl group of compound (16-3) is accomplished as described for the production of compound (13-3) in Scheme 13 above. 148 2014280939 24 Dec 2014

Scheme 17

[00638] Compound (17-1) can be mesylated to provide compound (17-2) by treatment with methanesulfonyl chloride in the presence of a base such as, for example, pyridine in a solvent such as, for example, dichloromethane. Compound (17-3) can be exposed to borane dimethyl sulfide complex in a solvent such as, for example, tetrahydrofuran at approximately about 0 to about 10°C to supply compound (17-4). Compounds (17-2) and (17-4) can be combined with acetaldehyde in refluxing tetrahydrofuran. Subsequent treatment with water at room temperature yields compound (17-5).

Scheme 18 BH -THF NBS P(OEt)3 R6-C02H -?---- R6-CH,OH -- R6-CH2Br -" R6-CH2P(0)(OF,t)2 PPh3 (18-1) (18-2) (18-3) (18-4) [00639] Carboxylic acid (18-1) can be reduced with boron tetrahydrofuran complex with heating to provide alcohol (18-2). Compound (18-2) is converted to the corresponding bromide (18-3) with N-bromosuccinimide and triphenylphosphine in solvents such as, for example, dichloromethane at room temperature in several hours. Treatment of compound (18-3) with triethyl phosphite at about ]20°C for about 1 to about 3h supplies compound (18-4). Compound (18-4) can be used for example to make compound (9-5) as described in Scheme 9.

Scheme 19 R6-CHO (19-1) HP(0)(OEt)2 NCS, PPh3

Cl

pTsOH (MeO)3CH

NaOMe OH A R6 P(OEt)2 (19-2) 0 R6 (19-3) P(OEt)2 O R6-CH(OMe)2 (19-5)

149 2014280939 24 Dec 2014 [00640] Benzaldehyde (19-1) can be treated with diethyl phosphonate in the presence of a base such as, for example, sodium methoxide in a solvent such as, for example, methanol at room temperature to provide compound (19-2). Compound (19-2) can be treated with N-chlorosuccinimide and triphenylphosphine in dichloromethane at room temperature to yield compound (19-3). Compound (19-2) can also be reacted with (diethylamino)sulfur trifluoride (DAST) to supply compound (19-4).

[00641] Compound (19-1) can also be treated with p-toluenesulfonic acid and trimethyl orthoformate in methanol at about 50°C to provide acetal (19-5). Compound (19-5) can be converted to compound (19-6) by exposure to triethyl phosphite and boron trifluoride diethyl etherate at about -20°C to about ambient temperature.

[00642] Compounds (19-3), (19-4), and (19-6) can be used for example to make compound (9-5) as described in Scheme 9.

Scheme 20

[00643] Phenol (20-1), wherein R4 is other than amino, is treated with a source of electrophilic halide, such as, for example, iodine monochloride to provide dihalogenated compound (20-2), wherein X1 and X2 are independently bromine or iodine. Compound (20-2) is transformed to compound (20-3) by reaction of an alkylating agent such as, for example, methyl sulfate with a base such as, for example, potassium carbonate in refluxing acetone. Alternatively, methyl iodide in the presence of a base such as, for example, potassium r-butoxide in a solvent such as, for example, tetrahydrofuran, or dimethylformamide also furnish compound (20-3). In yet another alternative, compound (20-2) can be methylated with (trimethylsilyl)diazomethane in a solvent such as, for example, t-butyl methyl ether. Compound (20-3) can be reacted with uracil, ligand (20-4), copper (I) iodide, and potassium phosphate in dimethyl sulfoxide at about 40°C to about 100°C to supply compound (20-5).

[00644] For example, when in compound (20-3), R4 is tert-butyl, X1 is iodo, and X2 is iodo or bromo, 150 2014280939 24 Dec 2014 compound (20-3) can be stirred with uracil and compound (20-4) in the presence of Cul and K2PO4 in DMSO for about 15 to about 24h at about 60°C to supply compound (20-5). Alternatives to ligand (20-4) for making (20-5) are 8-hydroxyquinoline and 2-(2-pyridyl)-benzimidazole. rb,f,g.iu,j,k. OH (21-1)

Scheme 21

OSiMe2tBu (21-3) owo re,f,g,ii,u,k NH2 re,f,g,h,t,j,k N f

MeS02Cl

RE.F,GH,U,K <3,0 \N'/ H. N ^

OwO H 's^

nBu4NF

(CFjSO^O OSiMe2tBu (21-4) OSiMe2tBu (21-5) OH (21-6) oso2cf3 (21-7) [00645] Compound (21-1) can be nitrated with nitric acid in acetic acid in a temperature range of about 10 to about 15°C to give compound (21-2). The phenol moiety of compound (21-2) can be protected as a silyl ether, e.g. t-butyldimethylsilyl ether, by treatment with a silyl chloride such as, for example, t-butyl dimethylsilyl chloride and imidazole in a solvent such as, for example, dimethyl formamide at ambient temperature to furnish compound (21-3). Compound (21-3) may then be reduced using conditions known to those skilled in the art to furnish the corresponding aniline (21-4).

[00646] Typical conditions for this reduction include using hydrogen at a pressure of about 1 to about 5 atmospheres in the presence of a catalyst such as, for example, palladium or platinum on charcoal in a solvent such as, for example, tetrahydrofuran, ethyl acetate, ethanol, methanol, or hexane at or near ambient temperature over a period of about 1 to about 12h. Dependent on the functional groups present, an alternative reduction procedure may be more appropriate such as, for example, using iron powder in the presence of a mild acid such as, for example, ammonium chloride or dilute hydrochloric acid at reflux temperatures in a mixture of solvents containing, for example, methanol, water, and tetrahydrofuran over about 1 to about 12h.

[00647] Aniline (21-4) can then by sulfonylated with methanesulfonyl chloride in the presence of pyridine in a solvent such as, for example, dichloromethane. The starting material and reagents are combined at about 0°C and then allowed to gradually warm to ambient temperature over the course of the reaction to supply compound (21-5). The silyl ether protecting group is removed under conditions familial· to one 151 2014280939 24 Dec 2014 skilled in the art. For example, tetrabutylammonium fluoride in tetrahydrofuran at room temperature transforms compound (21-5) to compound (21-6). The phenol group of compound (21-6) may be sulfonylated with trifluoromethanesulfonic anhydride in the presence of a base such as, for example, pyridine in a solvent such as, for example, dichloromethane at room temperature to provide compound (21-7). Compound (21-7) can be used as described in Scheme 12 to make compound (12-3).

Scheme 22

[00648] Compound (22-1) is converted to compound (22-2) in a two-step sequence. First, compound (22-1) can be hydrolyzed with a base such as, for example, sodium hydroxide, lithium hydroxide, or potassium hydroxide in a solvent such as, for example, methanol, ethanol, or tetrahydrofuran, or mixtures thereof. The resultant reaction mixture can be stirred for a period of about 6 to about 48h at ambient temperature. Second, the intermediate carboxylic acid is treated in refluxing thionyl chloride with or without a catalytic amount of dimethylformamide for about 1 to about 4h to deliver acid chloride (22-2). Treatment with thionyl chloride at reflux temperature in solvents such as, for example, chloroform or toluene also furnishes compound (22-2). Treatment of the carboxylic acid with oxalyl chloride in dichloromethane with a catalytic amount of dimethylformamide also furnishes compound (22-2).

[00649] Compound (22-2) can be treated with an amine or the corresponding salt in a solvent such as, for example, dioxane, dimethylformamide, dimethylacetamide, or dichloromethane optionally in the presence of a base such as, for example, pyridine, triethylamine or diisopropylethylamine at temperatures ranging from at or near ambient to about 100°C for between about 1 and about 24h to provide compound (22-4) 152 2014280939 24 Dec 2014

wherein R11 and R12 are independently hydrogen or RF, or taken together with the nitrogen to which they are attached form a 5-6-membered heterocyclyl or a fused 2-ring heterocyclyl.

[00650] Compound (22-2) is converted to the corresponding aldehyde (22-3) by reduction with lithium tri-f-butoxyaluminum hydride in a solvent such as, for example, tetrahydrofuran at about -60°C to about -78°C. SCHEME 23

[00651] Compound (22-3) can be converted to compound (23-2) wherein Rn and R12 are independently hydrogen or RF, or taken together with the nitrogen to which they are attached form a 5-6-membered heterocyclyl or a fused 2-ring heterocyclyl by treatment with an amine, N(Rn)(R12), in the presence of a reductant such as, for example, sodium triacetoxyborohydride or sodium cyanoborohydride in a solvent such as, for example, methanol, ethanol, dichloromethane, dimethylacetamide, or dimethylformamide over a period of about 1 to about 24h. The reaction often proceeds best at an acidic pH that can be maintained by the addition of acetic acid or hydrochloric acid.

[00652] Compound (22-3) can also be converted to compound (23-3) by reduction with lithium tri-t-butoxyaluminum hydride in a solvent such as tetrahydrofuran at room temperature. 153 2014280939 24 Dec 2014 SCHEME 24

[00653] Compound (23-3) can be converted to compound of formula (24-2) by treatment with thionyl chloride in dichloromethane at room temperature. Compound (24-2) can be treated with a sodium alkoxide, Rl3ONa, in a heated solution of the corresponding alcohol to provide compound (24-3), wherein R13 is hydrogen or RF.

Scheme 25

(25-3) (25-4) [00654]Compound (25-1) can be brominated by treatment with, for example, pyridinium hydrobromide perbromide in a solvent such as, for example, acetic acid at or near ambient temperature over a period of about 1 to about 8h to give compound (25-2). The amino group of compound (25-2) can be removed by exposure to t-butyl nitrite in a solvent such as, for example, dimethylformamide at a temperature initially 154 2014280939 24 Dec 2014 at ambient temperature and then increased to the range of about 50 to about 65 °C to give compound (25-3). Additional aliquots of t-butyl nitrite can be added at ambient temperature followed by heating until the transformation is complete. Compound (25-3) can be reduced to compound (25-4) by, for example, treatment with iron and ammonium chloride.

Scheme 26

[00655] Compound (26-1), wherein each Z is independently N or CH can be converted to a boronic acid ester for use in Suzuki reactions. For example, compound of formula (26-1) can be converted to compound (26-2), wherein R14 is hydrogen or methanesulfonyl (when excess methanesulfonyl chloride is used) by treatment with methanesulfonyl chloride in pyridine at approximately ambient temperature in about 1 to about 8h.

[00656] Compound (26-2) can be transformed to compound of (26-3) by treatment with pinacol-borane in the presence of a catalyst such as, for example, tris(dibenzylidineacetone)dipalladium (0), ligand such as, for example, tri-t-butylphosphine, and a base such as triethylamine in solvents such as, for example, tetrahydrofuran, dioxane, or toluene at temperatures ranging from ambient to about 130°C.

[00657] Alternatively, compound (26-2) can be reacted with bis(pinacolato)diboron in the presence of a catalyst such as, for example, Combiphos® Pd6, dichloro[l,l'-bis(diphenylphosphino)ferrocene] palladium (II) dichloromethane adduct, or palladium acetate in the presence of a ligand such as, for example, 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (XPhos), and a base such as, for example, potassium acetate in solvents such as, for example, toluene, dioxane, tetrahydrofuran, dimethylformamide or dimethyl sulfoxide in temperatures from about 60 to about 130°C to give compound (26-3).

[006581 Compound (26-3) can be converted to protected compound (26-4) by treatment with benzyl chloroformate initially at about 0°C in the presence of saturated aqueous sodium bicarbonate in a mixture of acetone and water. This can be warmed to ambient temperature and maintained at that temperature for 155 2014280939 24 Dec 2014 about 12 to about 24h. Subsequently, compound (26-4) can be converted to the boronic acid pinacol ester (26-5) using the reaction conditions described above.

Scheme 27

[00659] Compound (26-5), wherein each Z is independently N or CH, can be coupled with compound (1-7) under Suzuki reaction conditions to provide compound (27-3). Such conditions include, for example, use of a palladium catalyst such as, for example, tris(dibenzylidineacctone)palladium (0), palladium acetate, bis(triphenylphosphine)palladium (II) chloride, tetrakis(triphenylphosphine)palIadium, or dichloro[l,l'-bis(diphenylphosphino)ferrocene] palladium (II) dichloromethane adduct; base such as, for example, potassium carbonate, potassium phosphate, potassium Z-butoxide, sodium carbonate, cesium carbonate, or cesium fluoride; and solvent such as, for example, toluene, ethanol, water, or tetrahydrofuran, or mixtures thereof heated in the temperature range from about 40 to about 130°C.

[00660] Compound (27-3) can be transformed to compound (27-4) in a three-step process. The initial step involves removal of the t-butoxycarbonyl protecting group with an acid such as, for example, trifluoroacetic acid in solvent such as, for example, dichloromethane or hydrochloric acid in dioxane at room temperature over about 1 to about 24h. Subsequently, the dihydropyrimidinedione can be introduced as described in Scheme 3.

[00661] Compound (27-5) can be obtained from compound (27-4) in a two-step sequence. First, the 156 2014280939 24 Dec 2014 protecting group is removed from the naphthyl amine under reductive conditions. Typically, hydrogenation (~1 atmosphere pressure) in the presence of a catalyst such as, for example, 10% palladium on charcoal in a solvent such as, for example, ethyl acetate at or near ambient temperature over a period of about 8 to about 24h. Second, the naphthyl amine can now be sulfonylated by treatment with methanesulfonyl chloride in the presence of a base such as triethylamine in a solvent (e.g., dichloromethane) at room temperature over about 20 min to about 4h. SCHEME 28 OR9

[00662] Compound (28-1), wherein each Z is independently N or CH, and R15 is, for example, hydrogen, -NHS02Me, -N(S02Me)2, or methoxy can be coupled with compound (1-7) under Suzuki reaction conditions to provide compound (28-2). Such conditions include, for example, use of palladium catalyst such as, for example, tris(dibenzylidineacetone) palladium (0), palladium acetate, bis(triphenylphosphine)palladium (II) chloride, tetrakis(triphenylphosphine)palladium, or dichloro[l,T-bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct; a base such as potassium carbonate, potassium phosphate, potassium r-butoxide, sodium carbonate, cesium carbonate, or cesium fluoride; and solvent such as, for example, toluene, ethanol, water or tetrahydrofuran, or mixtures thereof heated in the temperature range from about 40 to about 130°C. The reaction is typically deoxygenated with an inert gas such as nitrogen prior to heating. The heating may occur in conventional glassware, a sealed tube, or in a microwave reactor over about 1 to about 24h.

[00663] Compound (28-2) can be transformed to compound (28-3) in a three-step process. The initial step involves removal of the t-butoxycarbonyl protecting group with an acid such as, for example, trifluoroacetic acid in solvent such as, for example, dichloromethane or hydrochloric acid in dioxane at room temperature over about 1 to about 24h. Subsequently, the uracil can be introduced as described in Scheme 4. 157 2014280939 24 Dec 2014

Scheme 29

o

[00664] Compound (28-1), wherein each Z is independently N or CH, and R15 is, for example, hydrogen, -NHSOjMe, -N(S02Mc)2, or methoxy can be coupled with compound of formula (29-2), wherein X1 is, for example, bromine or iodine, under Suzuki reaction conditions to provide compound of formula (28-3). Such conditions include, for example, use of palladium catalyst such as, for example, tris(dibenzylidineacetone)palladium (0), palladium acetate, bis(triphenylphosphine)palladium (II) chloride, tetrakis(triphenylphosphine) palladium , dichloro[l,l'-bis(diphenylphosphino)ferrocene] palladium (II) dichloromethane adduct, or bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane; base such as, for example, potassium carbonate, potassium phosphate, potassium (-butoxide, sodium carbonate, cesium carbonate, or cesium fluoride; and solvent such as, for example, toluene, ethanol, water, or tetrahydrofuran, or mixtures thereof heated in the temperature range from about 40 to about 130°C. The reaction is typically deoxygenated with an inert gas such as nitrogen prior to heating. The heating may occur in conventional glassware, a sealed tube, or in a microwave reactor over about 1 to about 24h. SCHEME 30

H I

158 2014280939 24 Dec 2014 [00665] Compound (30-1), wherein X1 is bromine or iodine, n is 1 or 2, and Z is CH or N, can be reacted with bis(pinacolato)diboron in the presence of a catalyst such as, for example, Combiphos® Pd6, dichloro[l,r-bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct, or palladium acetate in the presence of a ligand such as 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (XPhos), and a base such as potassium acetate in solvents such as, for example, toluene, dioxane, tetrahydrofuran, dimethylformamide or dimethyl sulfoxide in temperatures from 60-130°C to give compound (30-2). The reaction is typically deoxygenated with an inert gas such as nitrogen prior to heating. The heating may occur in conventional glassware, a sealed tube, or in a microwave reactor over 1 to 24h. Compound (30-3) can be reacted with compound (30-2) to give compound (30-4) employing the conditions described in Scheme 29.

[00666] Treatment of compound (30-4) with methanesulfonylhydrazide in solvent such as, for example, tetrahydrofuran, methanol, or ethanol, or a mixture thereof at ambient temperature to about 100°C over a period of 8 to 48h provides compound (30-5).

Scheme 31

[00667] Compound (31-1) can be treated with hexamethylditin or hexabutylditin in the presence of a catalyst such as, for example, bis(triphenylphosphine)palladium (II) chloride in a solvent such as, for example, toluene or dioxane heated to about 50 to about 130°C to supply compound (31-2). Compound (31-2) can be treated with compound (31-3) in presence of catalyst such as, for example, tris(dibenzy-lidine acetone)palladium (0) and ligand such as tri(2-furyl)phosphine in solvent such as, for example, toluene, dioxane, or tetrahydrofuran heated to about 40 to about 130°C to give compound (31-4). 159 2014280939 24 Dec 2014 SCHEME 32

[00668) Compound (32-1) can be reacted with compound (32-2) under the Suzuki reaction conditions to give compound (32-3). Treatment with methanesulfonylhydrazide as described in Scheme 30 provides compound (32-4).

Scheme 33

[006691 Compound (33-1) can be reacted with compound (33-2) under Suzuki reaction conditions to give compound (33-3). Compound (33-3) can be converted to compound (33-4) by first constructing the uracil ring. Then, the methyl carboxylate can be converted into the corresponding aldehyde. Compound (33-4) can be treated with methanesulfonylhydrazide to provide compound (33-5). 160 2014280939 24 Dec 2014

[00670] Dinitroaniline (34-1) can be sulfonylated with methanesulfonyl chloride in the presence of a base like, for example, pyridine in a solvent such as, for example, dichloromethane at room temperature over a period of about 8 to about 36h to give compound (34-2). Compound (34-2) can be converted to compound (34-3) using iron powder in the presence of a mild acid such as, for example, ammonium chloride or dilute hydrochloric acid at reflux temperatures in a mixture of solvents, such as, for example, methanol, water, and tetrahydrofuran over about 1 to about 12h. SCHEME 35

[00671] Compound (35-1) can be reacted with compound (35-2), wherein Z1 is O, S, or NH and R16 is hydrogen, -NHSOzMe, or N02, in the presence of charcoal exposed to air in solvent such as, for example, toluene heated from about 90 to about 110°C for about 24 to about 72h to give compound (35-3). SCHEME 36

[00672] Compound (36-1), wherein Z2 is O or S, can be reduced to compound (36-2) using iron powder in 161 2014280939 24 Dec 2014 the presence of a mild acid such as, for example, ammonium chloride or dilute hydrochloric acid at temperatures of about 60 to about 90°C in solvents such as, for example, methanol, ethanol, water, and tetrahydrofuran, or mixtures thereof over about 30 min to about 12h. Compound (39-2) can be sulfonylated with methanesulfonyl chloride in the presence of a base like, for example, pyridine in a solvent such as, for example, dichloromethane at room temperature over a period of about 8 to about 36h.

Scheme 37

[00673] Compound (37-1) can be sulfonylated with methanesulfonyl chloride in the presence of a base like, for example, pyridine in a solvent such as, for example, dichloromethane at room temperature over a period of about 8 to about 36h to give compound (37-2). Compound (37-2) can be reacted with (4-methoxyphenyl)methanethiol in the presence of a base such as, for example, potassium carbonate in a solvent such as, for example, dimethylformamide heated to about 90 to about 110°C for about 8 to about 24h to give compound (37-3). Compound (37-3) can be reduced to compound (37-4) using iron powder in the presence of a mild acid such as, for example, ammonium chloride or dilute hydrochloric acid at temperatures of about 60 to about 90°C in solvent such as, for example, methanol, ethanol, water, and tetrahydrofuran, or mixtures thereof over about 30 min to about 12h. Compound (37-4) can be transformed to compound (37-5) in the presence of mercury(II) acetate, anisole, and trifluoroacetic acid at about 0 °C for about 30 to about 90 min and subsequently bubbling hydrogen sulfide through the mixture. 162 2014280939 24 Dec 2014

Compound (37-5) can be treated with compound (37-6) in the presence of p-toluenesulfonic acid and triphenylphosphine in a solvent such as, for example, toluene heated to reflux for about 2 to about 16h to supply compound (37-7).

Scheme 38

[00674] Compound (38-1), wherein X1 is bromine or iodine and Z" is O or S, can be reacted with 2,5-hexanedione in the presence of a p-toluenesulfonic acid and pyridine heated in benzene to give compound of formula (38-2). Compound (38-2) can be reacted with bis(pinacolato)diboron in the presence of a catalyst such as, for example, Combiphos® Pd6, dichloro[l,r-bis(diphenylphosphino)ferrocene] palladium (II) dichloromethane adduct, or palladium acetate in the presence of a ligand such as, for example, 2-dicyclohexylphosphino-2',4’,6'-triisopropylbiphenyl (XPhos), and a base such as, for example, potassium acetate in a solvent such as, for example, toluene, dioxane, tetrahydrofuran, dimethylform-amide or dimethyl sulfoxide at a temperature from about 60 to about 130°C to give compound (38-3). Compound (38-3) can be reacted with compound (38-4) to give compound (38-5) under Suzuki reaction conditions. Such conditions include, for example, use of a palladium catalyst such as, for example, dihydrogen dichlorobis(di-t-butylphosphinito-KP)palladate(2-), tris(dibenzylidineacetone) palladium (0), palladium acetate, bis(triphenylphosphine)palladium (Π) chloride, tetrakis (triphenylphosphine)palladium, or dichloro[l,r-bis(diphenylphosphino)ferrocene] palladium (II) dichloromethane adduct; a base such as, for example, potassium acetate, potassium carbonate, potassium phosphate, potassium /-butoxide, sodium 163 2014280939 24 Dec 2014 carbonate, cesium carbonate, or cesium fluoride; and solvent such as, for example, toluene, ethanol, water or tetrahydrofuran, or mixtures thereof heated in the temperature range from about 40 to about 130°C.

[00675] Compound (38-5) can be treated with hydroxylamine hydrochloride in heated ethanol to remove the pyrrole-protecting group. Then treatment with methanesulfonyl chloride in the presence of a base such as, for example, pyridine in a solvent such as, for example, dichloromethane at or near ambient temperature supplies compound (38-6).

EXAMPLES

[00676] The following examples are merely illustrative, and not limiting to this disclosure in any way.

[00677] Example A. Preparation of (E)-N-(3-tert-butyl-5-iodo-4-methoxyphenylcarbamoyl)-3-methoxy acrylamide.

[00678] Part A. Preparation of 2-tert-butyl-4-nitrophenol.

[00679[To a vigorously stirred solution of 2-tert-butylphenol (lOg, 66.6mmoi) in heptane (67ml) was added at a fast drip a solution of 70% nitric acid (4.25ml, 66.6mmol) diluted with water (4.25ml). The resulting dark red/brown mixture was stirred vigorously for 2h. The suspended solid was collected by filtration washed with hexane (300mL), water (200mL) and once again with hexane (200mL) to give a cocoa colored powder that was dried to constant mass (4.65g, 35.6%).

[00680] Part B. Preparation of2-tert-butyl-6-iodo-4-nitrophenol.

[00681] To the product from Part A (4.5g, 23.05mmol) dissolved in MeOH (120ml) and water (30mL) was added iodine monochloride (1.155ml, 23.05mmol) drop wise over a period of lOmin. The mixture was stirred for 2h and diluted into IL of water and allowed to stand overnight. The solid material was collected by filtration and washed 3x50mL with water and dried under vacuum overnight to give a tan solid (7.14g, 96%).

[00682] Part C. Preparation of l-tert-butyl-3-iodo-2-methoxy-5-nitrobenzene.

[00683] To an ice bath cooled solution of the product from Part B (5.5g, 17.13mmol) in MTBE (15inl) in a 50mL pressure vessel was added 2.0M TMS diazomethane (12.85ml, 25.7mmol) followed by drop-wise addition of methanol (l.OmL) resulting in calm bubbling. The vessel was sealed and stirred at room temperature for 16h, cooled and the pressure was released. The solution was partitioned between EtOAc and water. The organic layer was washed with 1 .OM HC1, saturated potassium carbonate solution, and saturated NaCl. The organic layer was dried over sodium sulfate, filtered and concentrated to give a red 164 2014280939 24 Dec 2014 oil that was used without purification (5.4g, 84%).

[00684] Part D. Preparation of 3-tert-butyl-5-iodo-4-methoxyaniline.

[00685] A mixture of the product from Part C (5.80g, 17.31mmol), ammonium chloride (1.389g, 26.0mmol), and iron (4.83g, 87mmol) in THF/MeOH/water (200mL total, 2/2/1) was refluxed for 2h, cooled and filtered through Celite. The filtrate was evaporated and the residue was partitioned between water and EtOAc. The organic layer was washed with saturated brine, dried with sodium sulfate, filtered and evaporated to give a brown oil (5.28g, 100% yield).

[00686] Part E. Preparation of (E)-N-(3-tert-butyl-5-iodo-4-methoxyphenylcarbamoyl)-3-methoxy acrylamide.

[00687] To a solution of the product from Part E (3.05g, lOmmol) in DMF (50ml) at -20°C under N2 was added at a fast drip a 0.4M solution in benzene of (E)-3-methoxyaciyloyl isocyanate (50.0ml, 20,00mmol, prepared by the method of Santana et al., 1. Heterocyclic Chem. 36:293 (1999). The solution was stirred for 15min at -20°C, warmed to room temperature for 45min and diluted into EtOAc. The EtOAc layer was washed 4 x 300mL with water, 2 x lOOmL with brine, dried (Na2S04) and concentrated to a brown solid. The residue was triturated in Et20/hexane to give a fine powder that was collected by filtration and dried to give a tan powder (2.46g, 57%).

[00688] Example B. Preparation of l-(3-tert-butyl-5-iodo-4-methoxyphenyl)dihydropyrimidine-2,4(lH,3H)-dione.

O

[00689] To a suspension of the product from Example A (2.46g, 5.69mmol) in ethanol (50ml) was added a solution of 5.5mL of H2S04 in 50mL water and the mixture was heated at 110°C for 2.5h to give a clear solution. The solution was cooled and diluted with 50mL of water while stirring to give an off-white solid that was collected by filtration, washed with water and dried (2.06g, 90%). 165 2014280939 24 Dec 2014 [00690] Example C. Preparation of 1 -(3-tert-butyl-5-iodo-4-methoxyphenyl)pyrimidine-2,4( 1 H,3H)-dione.

H

[00691] Part A. Preparation of 2-tert-butyl-4,6-diiodophenol.

[00692] A solution of 2-tert-butvlphenol (20.0g, 133mmol) in methanol (266mL) was treated with sodium hydroxide pellets (6.39g, 160mmol), The mixture was stirred until all the sodium hydroxide had dissolved and was then cooled in an ice-salt bath to -2°C. Sodium iodide (15.0g, lOOmmol) was added and then 10 % sodium hypochlorite solution (45mL, 73.3mmol) was added drop wise at a rate such that the solution temperature rose no higher than 1.3°C. This sequence of events was repeated (3x) until a total of 60g (400mmol) of sodium iodide had been added and the sodium hypochlorite solution was added until the solution color changed from a light green-yellow color to the color of weak iced tea. This required all but 16mL of the 180mL total sodium hypochlorite solution measured out. With continued cooling at ca. 2°C, a solution of sodium thiosulfate pentahydrate (20g) in water (lOOmL) was added drop wise over 20min. After addition, the solution was acidified to pH 3 by drop wise addition of concentrated hydrochloric acid (ca. 35mL required of 40mL placed in the addition funnel). The precipitate was collected by filtration and washed with >1 liter of water. The salmon-colored solid was sucked as dry as possible, and dried in a vacuum oven at 50°C for 18h. These procedures afforded the product (49.61g, 93%) as a tan solid.

[00693] Part B. Preparation of l-tert-butyl-3.5-diiodo-2-methoxybenzene.

[00694] A solution of the product from Part A (20.Og, 49.7mmol) in acetone (l40mL) was treated with methyl iodide (3,9mL, 8.83g, 62.2mmol) and 50 % (w/w) sodium hydroxide solution (3.02mL, 4.58g, 57.2mmol) followed by stirring at ambient temperature for 48h, The mixture was concentrated in vacuo to a volume of ca. 50-60mL, followed by dilution with heptane (80mL) and water (50mL). The layers were separated and the organic layer was extracted with saturated sodium chloride solution. Drying (Na2SC>4) and concentration in vacuo afforded the product (20.59g, 99%) as a light yellow oil.

[00695] Part C. Preparation of l-(3-tert-butyl-5-iodo-4-methoxypheny])pyrimidine-2,4(lH,3H)-dione.

[00696] A suspension of the product from Part B (12.04g, 28.9mmol), uracil (3.89g, 34.7mmol), N-(2-cyanophenyl)pieolinamide (1.29g, 5.79mmol) and tribasic potassium phosphate (12.9g, 60.8mmol) in DMSO (181mL) was degassed by nitrogen sparge for 1 h. The mixture was then treated with copper (I) iodide (55Img, 2.89mmol) and degassing was continued for another 1 Omin. The mixture was then 166 2014280939 24 Dec 2014 warmed at 60°C for 18h. The mixture was then poured into water (600mL) and acidified to pH 3 by addition of 4N hydrochloric acid solution. The mixture was diluted with ethyl acetate, and the organic layer was extracted with water (3x), saturated ammonium chloride solution (lx) and saturated sodium chloride solution. The solution was dried and treated with (3-mercaptopropyl) silica gel, followed by stirring for 2h. The mixture was filtered and concentrated in vacuo. The solid obtained was triturated with ether-ethyl acetate (>10:1) and collected by filtration and washed with ether. After drying in a vacuum oven at 50°C for 2h, these procedures afforded the product (2.75 g) as a white solid. The mother liquors were concentrated in vacuo to afford an amber solid. This material was chromatographed over a Flash 65 silica gel cartridge, eluting with 20-100 % ethyl acetate in hexanes. These procedures afforded a nearly white solid, which was triturated with ether-hexanes and collected by filtration. After drying in a vacuum oven for 3h, these procedures afforded another 4.31 g of the product as a white solid. Total yield: 7.06g (61 %).

[00697]Example D. Preparation of l-(3-teri-Butyl-5-iodo-4-methoxyphenyl)pyrimidine-2,4(lH,3H)-dione.

H

[00698] Part A. Preparation of 2-tert-butyl-4,6-diiodophenol.

[00699] 2-tert-Butylphenol (99.95g, 665.36mmol) was dissolved in 1250mL methanol and converted to the corresponding phenoxide with 31,96g (799.0mmol, 1.2equiv.) of sodium hydroxide by stirring the sodium hydroxide pellets at room temperature, and then cooling the reaction mixture in an ice/salt bath. Sodium iodide (299.34g, 1997.07mmol, 3.0equiv.) and 8.3% bleach (1265.83g, 1411.39mmol, 2.1equiv.) were added to the cold reaction solution in four equal portions, the bleach being added while keeping the reaction mixture at <0°C. 500mL of 20% (w/w) sodium thiosulfate solution was added over an 18-minute period, with the temperature rising from -0.6°C to 2.5°C. The pH of the reaction mixture was adjusted to approximately 3 by adding 197.5mL of cone. HC1 over a period of 97min with the reaction temperature going from 1.2°C to 4.1°C. The resulting slurry was filtered, and the wet cake washed with ~ 2L of water. The wet cake was left on the Buchner funnel under vacuum overnight (approximately 15h) to yield 289.33g (potency adjusted yield = 254.6 Ig) of the title product.

[00700] PartB. Preparation of l-teri-butyl-3,5-diiodo-2-methoxybenzene. 167 2014280939 24 Dec 2014 [00701] The product from Part A (93%assay, 21,6g, 50mmol) was dissolved in 140mL of acetone. Methyl iodide (4.2mL, 67.5mmol, 1.35equiv.) was added, followed by 50% aqueous sodium hydroxide (5.0g, 62.5mmol, 1.25equiv.). The reaction was stirred overnight, then concentrated to approximately 50-60mL. 80mL of heptanes was added followed by 50mL of water, and the layers were shaken and separated, and the aqueous layer was back extracted with 20mL of heptanes. The organic layers were combined and washed twice with 50mL each of 10% aqueous NaCl to afford 91.1 grams of a heptane solution, which assayed to 19.1 g of the title compound.

[00702] Part C. Preparation of l-(3-feri-Butyl-5-iodo-4-methoxyphenyl)pyrimidine-2,4(lH,3H)-dione.

[00703] Uracil (33.3g, 297mmol, 1,2equiv.), K3P04 (106g, 500mmol, 2.1equiv.), Cul (4.6g, 24.2mmol, 0.1 equiv.), and 7V-(2-cyanophenyl)picolinamide (6.4g , 28.7mmol, 0.12equiv.) were charged to a flask and inerted with argon. The l-fert-butyl-3,5-diiodo-2-methoxybenzene was solvent switched into MeCN, dissolved in 1L DMSO and sparged with argon and added to the solids. The reaction was heated to 60°C for 16h. After cooling, the reaction was diluted with 2L EtOAc and washed with 2.6L water (back extracted with 3 x 1L EtOAc). The combined organic layers were washed with 2 x 1L of 0.25M (CuOAc)2 then 2 x 830mL 15% NH^Cl then 800mL brine. The organic layer was then concentrated and chased with 1L heptane, then triturated with refluxing 85:15 (v/v) heptane:iPrOAc for 4h. After cooling, the product was collected by filtration and washed with an additional 330mL of 85 :15 v/v heptanes: EtOAc to yield after drying 66.9g (70% yield) of the product as a white solid.

[00704] Example E. Preparation ofiV-(6-(3-ter/-Butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide.

H

[00705] A solution of lOOmL of water and 300mL of THF was sparged with nitrogen and then transferred via canula and nitrogen pressure to a flask containing 19.9965g (49.96mmol) of the product from Example D, 20.8234g (59.97mmol, 1,20equivalents) of 77-(6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)naphthalen-2-yI)methanesulfonamide, and 21.871 lg (103.03mmol, 2.06equivalents) of potassium phosphate which had been purged with nitrogen. The resulting solution was again sparged with nitrogen.

[00706] THF (lOOmL) was sparged with nitrogen and then transferred via canula and nitrogen pressure to a flask containing 462.8mg (0.51mmol, 0.01 equivalents) of Pdodba, and 735.8mg (2.52mmol, 0.05 equivalents) of l,3,5,7-tetramethyl-6-phenyl-2,4,8-trioxa-6-phosphaadamantane, which had been purged 168 2014280939 24 Dec 2014 with nitrogen. The resulting solution was again sparged with nitrogen.

[00707] The initial THF/water solution was transferred via eanula and nitrogen pressure to the flask containing the catalyst and ligand in THF. The reaction was warmed to 50°C and stirred overnight under positive nitrogen pressure. A sample of the reaction was taken the following morning. HPLC of the sample showed 0.28 PA% iodouracil starting material, 76.8 PA% product, and 5.2 PA% boronate.

[00708] The reaction was cooled to room temperature and washed, in three portions, with a solution of 5.84g of L-cysteine and 81.4g of sodium chloride in 550mL of water which had been sparged with nitrogen. The THF solution was filtered through a celite pad. The pad was rinsed with lOOmL of THF, which was combined with the original THF solution. The TPIF solution was concentrated on the rotary evaporator to 136g. To the white slurry was added 405mL of ethyl acetate with good agitation. The slurry was filtered after stirring overnight. The wet cake was washed with 2X50mL of ethyl acetate. The solid, an ethyl acetate solvate, was dried in the vacuum oven at 50°C. It weighed 25.49g.

[00709] The solid and 8.7g of 3-mercaptopropyl derivatized silica gel was stirred in 500mL of THF then filtered through a celite pad. The filtrate was concentrated on the rotary evaporator to give 13.08g of white solid. The solid that had been filtered off on the celite pad was extracted with 500mL of THF at 60°C. The THF solution was concentrated to 66g and treated with 206mL of ethyl acetate. The solid which precipitated was filtered and dried, yielding 9.13g of product. This solid was combined with the original solid and slurried in 1 OOmL of 200 proof 3A ethanol. It was filtered and dried in the vacuum oven at 50°C to give 20.74g of product.

[00710] Example F. Preparation of (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide.

[00711]The boronic acid (96% potency) (3.75g, 15.6mmol, 1.2eq), product from Example D (5.0g, 12.5mmol), Cytec ligand (175mg, 5mol%), Pd2(dba)3 (46mg, 0,4mol%) and potassium phosphate (5.25g, 25.0mmol, 2eq.) were charged to a 3 neck RB flask. The solids were purged with nitrogen for lOmin. 75mL 4:1 THF:water was sparged lOmin and charged to the flask. The mixture was stirred to dissolve 169 2014280939 24 Dec 2014 the solids followed by heating the mixture at 50°C in darkness overnight. HPLC showed the reaction was not complete after stirring overnight (~ 2% iodouracil remained). The reaction mixture was diluted with 375mL DCM and 250ml 10% citric acid. The mixture was shaken in a sep funnel and the layers were separated. The DCM layer was washed with a solution of 0.6g L-cysteine in 250ml 5% NaHC03 for 30min which changed the DCM layer color from orange to yellow, Repeated the 0.6g L-cysteine in 250ml 5% NaHC03 for 30min treatment followed by a 250ml 5% NaHC03 wash, and a 250ml 10% NaCl wash. The DCM layer was treated with 2gm thiourea silica for 30min. Added 1 gm carbon to decolorize mixed 5min and filtered through hy-flo. The wet cake was washed with DCM. The DCM solution was then stripped to give 6.74g of a light yellow solid. The solids were -92% pure. The solids were heated in a mixture of 192ml DCM and 9mlL MeOH. They never completely dissolved. Cooled to room temp with mixing. 80ml heptane was added and more product began to crystallize. The slurry stirred over the weekend. Added 50ml heptane in portions until a total of 230ml heptane was added. The product was filtered. Filtrate was measured at 1.21mg/mL at 21 Onm and 1.35 at 220nm, which equals a 522-582mg loss in the liquors or 9-10% loss vs. theoretical. The wet cake was washed with 50ml of a 27ml Heptane:22ml DCM: 1ml MeOH mixture. The wash contained 0.5mg/mL product or 25mg (0.4% vs. theoretical). Product yield 5.22gm (88.9%), purity 99.2%PA. Iodouracil was removed in the crystallization. Samples were submitted to solid state for analysis and analytical for Pd determination. NMR did not show any residual solvent.

[00712]Example 1. Preparation of (E)-N,-((3’-tert-butyl-5’-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2’-methoxybiphenyl-4-yl)methylene)methanesulfonohydrazide (compound IB-LÖ-1.1).

[00713] Part A. Preparation of 2-tert-butyl-4-nitrophenol.

[00714] To a vigorously stirred solution of 2-tert-butylphenol (10g, 66.6mmol) in heptane (67ml) was added at a fast drip a solution of 70% nitric acid (4.25ml, 66.6mmol) diluted with water (4.25ml). The resulting dark red/brown mixture was stirred vigorously for 2h. The suspended solid was collected by filtration washed with hexane (300mL), water (200mL) and once again with hexane (200mL) to give a cocoa colored powder that was dried to constant mass (4.65g, 35.6%).

[00715] Part B. Preparation of 2-bromo-6-tert-butyl-4-nitrophenol.

[00716] A solution of the product from Part A (l.Og, 5.12mmol) in glacial acetic acid (10.25mL) was 170 2014280939 24 Dec 2014 treated portion wise with pyridine hydrobromide perbromide (1.80g, 5.63mmoI) followed by stirring at room temperature for 2h. Additional pyridinium hydrobromide perbromide (3.80g) was added in two portions and after another 3h of stirring, the reaction was complete. The mixture was poured into ice water, and the mixture treated with a small amount of sodium sulfite. The resulting solid was filtered and dried under vacuum to give the title compound as a brown solid (1.40g, 100 %).

[00717] Part C. Preparation of l-bromo-3-tert-butyl-2-methoxy-5-nitrobenzene.

[00718] A solution of the product from Part B (1.40g, 5.11mmol) in 10:1 t-butylmethylether-methanol (25,5mL) was treated with 2.0M trimethylsilyldiazomethane in ether (5.1mL, 10.21mmol), followed by stirring at room temperature for 18h. The mixture was concentrated under vacuum to afford a yellow oil, which was purified by silica gel column chromatography eluting with EtOAc/hexanes to give the title compound as a yellow oil (1,36g, 92 %).

[00719] Part D. Preparation of tert-butyl 3-bromo-5-tert-butyl-4-methoxyphenylcarbamate.

[00720] A solution of the product from Part C (960mg, 3,33mmol) in methanol (17mL) was treated with 5 % platinum on sulfided carbon (lOOmg), followed by hydrogenation under balloon pressure for 3h, and then filtered through celite and concentrated under vacuum to afford the 3-bromo-5-tert-butyl-4-methoxyaniline as ayellow oil(860mg, 3.33mmol, 100%). A solution of this material in THF (17mL) was treated with di-tert-butyl dicarbonate (800mg, 3.66mmol) followed by warming at reflux for 2h. Concentration under vacuum afforded a beige solid, which was purified by silica gel column chromatography eluting with EtOAc/hexanes. Solid was triturated with hexanes, collected by filtration, and dried under vacuum to give the title compound as a nearly white solid (890mg, 75 %).

[00721] Part E. Preparation of methyl 5 ’-(tert-butoxycarbonylamino)-3 ’-tert-butyl-2’-methoxy biphenyl-4-carboxylate.

[00722] Toluene (2ml) and ethanol (2ml) were combined with the product from Part E (281 mg, 0.78mmol), methyl 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzoate (41 lmg, 1,57mmol) and 1M sodium carbonate (0.78ml, 0.78mmol) and de-gassed for 20min with N2. Tetrakis(triphenyl-phosphine)palladium(O) (18mg, 0.016mmol) was added and de-gassing continued for 5-10min. Heated at 100°C in a sealed tube for 18h, cooled and concentrated under vacuum. Purification by silica gel column chromatography eluting with EtOAc/hexanes gave the title compound (182mg, 56%).

[00723] PartF. Preparation of methyl 5’-amino-3’-tert-butyl-2’-methoxybiphenyl-4-carboxylate.

[00724] To a solution of the product from Part E (180mg, 0.43mmol) in CH2CI2 (4ml) was added trifluoroacetic acid (2ml). Stirred for 30min and concentrated under vacuum. Dissolved in EtOAc and washed with 10% NaHC03 and brine. Dried over Na2S04, filtered and concentrated under vacuum to give title compound (136mg, 100%).

[00725] Part G. Preparation of 3’-tert-butyl-5’-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2’-methoxy 171 2014280939 24 Dec 2014 biphenyl-4-carboxylate.

[00726] To a solution of the product from Part F (120mg, 0.38mmol) in DMF (2.5ml) at -25°C was added drop wise, (E)-3-methoxyaciyloyl isocyanate (1.34ml, 0.76mmol) keeping the temperature below -10°C until completion. The mixture was warmed to room temperature, stirred for 4h and poured into ether. Washed with water and brine. Dried over Na2S04, filtered and concentrated under vacuum. Purification by silica gel column chromatography eluting with EtOAc/hexanes gave (E)-methyl-3’-tert-butyl-2 ’-methoxy-5 ’ -(3-(3 -methoxyacryloyl)ureido)biphenyl-4-carboxylate (105mg, 62%). Added ethanol (3ml), H2O (3ml) and cone. H2SO4 (0.3ml) and heated at 100°C for lh. Cooled, poured into H20 and extracted with EtOAc. Dried over Na2S04, filtered and concentrated under vacuum. Purification by silica gel column chromatography eluting with 2% CH3OH/CHCI3 gave the title compound (73mg, 79%).

[00727] Part II. Preparation of 3’-tert-butyl-5’-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2’-methoxy biphenyl-4-carbaldehyde.

[00728] A solution of the product from Part G (73mg, 0.18mmol) in dioxane (1ml) was treated with 0.5M LiOH (1ml, 0.36mmol) at room temperature for lh, poured into IN HC1 and extracted with EtOAc. Dried over Na2S04, filtered and concentrated under vacuum to give 3’-tert-butyl-5’-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2’-methoxybiphenyl-4-carboxylic acid (69mg, 98%). Dissolved inthionyl chloride (2ml) and refluxed for 3h, cooled and concentrated under vacuum. Azeotroped twice with toluene to give 3,-tert-butyl-5’-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2’-methoxybiphenyl-4-carbonyl chloride (72mg, 100%) which was dissolved in THF (1.7ml) and cooled to -78°C. 1M lithium tri-tert-butoxyaluminum hydride (THF) (0.19ml, 0.19mmol) was added drop wise and stirring was continued at -78°C for 2h. Quenched with IN HC1 (1ml) and warmed to room temperature. Added water and extracted with EtOAc. Washed with 10% Nal ICO-, dried over Na2S04, filtered and concentrated under vacuum. Purification by silica gel column chromatography eluting with 1:1 EtOAc/hexanes gave the title compound (23mg, 35%).

[00729] Part I. Preparation of (E)-N’-((3’-tert-butyl-5’-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2’-methoxybiphenyl-4-yl)methylene)methanesulfonohydrazide.

[00730] A solution of the product from Part H (23 mg, 0.061 mmol) in CH3OH (0.8ml) was treated with methanesulfonohydrazide (7.7mg, 0.07mmol) at room temperature for lh, warmed to 35°C for 2h, cooled and concentrated under vacuum. Purification by silica gel column chromatography eluting with 5% CH3OH/CHCI3 gave title compound (14.8mg, 52%). 1HNMR(300 MHz CDC13) ppm 1.44 (s, 9 H) 3.21 (s, 3 H) 3.32 (s, 3 H) 5.82 (d, J= 8.09 Hz, 1 H) 7.14-7.24 (m, 1 H) 7.35 (d, ,/=8.09 Hz, 1 H) 7.61 (d, ./=8.46 Hz, 2 H) 7.75 (d, /=8.46 Hz, 2 H) 7.79 (s, 1 H) 7.87 (s, 1 H) 8.21 (br s, 1 H). MS (ES1+) m/z 471 (M+H)+. 172 2014280939 24 Dec 2014 [00731]Example 2. Preparation of (E)-N'-((3'-tert-butyl-5'-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2'-methoxybiphenyl-4-yl)methylene)methanesulfonohydrazide (compound IA-LO-1.1).

[00732] Part A. Preparation of 2-tert-butyl-6-iodo-4-nitrophenol.

[00733] To the product from Example 1, Part Λ (4.5g, 23.05mmol) dissolved in MeOH (120ml) and water (30mL) was added iodine monochloride (1.155ml, 23,05mmol) drop wise over a period of lOmin. The mixture was stirred for 2h and diluted into 1L of water and allowed to stand overnight. The solid material was collected by filtration and washed 3 x 50mL with water and dried under vacuum overnight to give a tan solid (7.14g, 96%).

[00734] PartB. Preparation of l-tert-butyl-3-iodo-2-methoxy-5-nitrobenzene.

[00735] To an ice bath cooled solution of the product from Part A (5.5g, 17.13mmol) in MTBE (15ml) in a 50mL pressure vessel was added 2.0M TMS diazomethane (12.85ml, 25.7mmol) followed by drop-wise addition of methanol (1 .OmL) resulting in calm bubbling. The vessel was sealed and stirred at room temperature for 16h, cooled and the pressure was released. The solution was partitioned between EtOAc and water. The organic layer was washed with 1 .OM HC1, saturated potassium carbonate solution, and saturated NaCl. The organic layer was dried over sodium sulfate, filtered and concentrated to give a red oil that was used without purification (5.4g, 84%). |00736]Part C. Preparation of 3-tert-butyl-5-iodo-4-methoxyaniline.

[00737] A mixture of the product from Part B (5.80g, 17.31 mmol), ammonium chloride (1.389g, 26.0mmol), and iron (4.83g, 87mmol) in THF/MeOH/water (200mL total, 2/2/1) was refluxed for 2h, cooled and filtered through Celite. The filtrate was evaporated and the residue was partitioned between water and EtOAc. The organic layer was washed with saturated brine, dried with sodium sulfate, filtered and evaporated to give a brown oil (5.28g, 100% yield).

[00738] Part D. Preparation of l-(3-tert-butyl-5-iodo-4-methoxyphenyl)dihydropyrimidine-2,4(lH,3H)-dione.

[00739] The product from Part € (8.2g, 26.9mmol) was treated with acrylic acid (5.53ml, 81mmol) and stirred overnight to give an extremely viscous mixture. The mixture was treated with acetic acid (60mL) and urea (7.3g 120mmol), heated at 120°C for 24h, cooled and concentrated. The residue was azeotroped 3 x lOOmL with toluene to give a brown/tan solid. The solid was suspended in a mixture of 50mL EtOAc 173 2014280939 24 Dec 2014 and lOOmL of saturated NaHC03 and stirred for thirty min to neutralize any remaining acetic acid. The solid was collected by filtration and washed repeatedly with 50mL portions of water and finally with 3:1 hexane/EtOAc (50mL) to give an off-white solid that was dried to constant mass (7. lg, 66%).

[00740] Part E. Preparation of 3'-tert-butyl-5'-(2,4-dioxotetrahydropyrimidin-l(2H)-yI)-2’-methoxy biphenyl-4-carbaldehyde.

[00741] A mixture of the product from Part D (10 lmg, 0.25mmol), 4-formyIphenylboronic acid (56.2mg, O.38mmol), 1M sodium carbonate (0.25mL, 0.25mmol) and l,l'-bis(diphenylphosphino) ferrocene-palladium(Il)dichloride dichloromethane complex (10.2mg, 0.013mmol) in toluene/ethanol (2mL, 1/1) was purged with bubbling N2 for 5min and microwaved at 100°C for 15min. Extracted with EtOAc and washed with brine. Dried over Na2SC>4, filtered and concentrated under vacuum. Purification by silica gel column chromatography eluting with MeOH/CH2Cl2 (1% to 5%) gave the title compound (92mg, 97%).

[00742] Part F. Preparation of (E)-N'-((3'-tert-butyl-5'-(2,4-dioxotetrahydropyrimidin- l(2H)-yl)-2'-methoxybiphenyl-4-yl)methylene)methanesulfonohydrazide.

[00743] A mixture of the product from Part E (90mg, 0.24mmol) and methanesulfonohydrazide (29mg, 0.26mmol) in methanol (4mL) was heated at 40°C for 2h. Evaporated and purified by silica gel column chromatography eluting with MeOH/CH2Cl2 (1 % to 4%) to give the title compound (80mg, 72%). m.p. 209-211°C. 'H NMR (300 MHz, DMSO-D6) 5 1.39 (s, 9 H) 2.70 (t, J=6.62 Hz, 2 H) 3.08 (s, 3 H) 3.24 (s, 3 H) 3.80 (t, J=6.62 Hz, 2 H) 7.17 (d, J=2.57 Hz, 1 H) 7.24 (d, J=2.94 Hz, 1 H) 7.59 (d, J=8.46 Hz, 2 H) 7.77 (d, J=8.46 Hz, 2 H) 8.04 (s, 1 H) 10.33 (s, 1 H) 11.10 (s, 1 H).

[00744] Example 3. Preparation of N-(6-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l (2H)-yl)-2-methoxyphenyI)naphthalen-2-yl)methanesulfonamide (compound IA-LO-2.9).

H

[00745] Part A. Preparation of 6-bromo-2-naphthoic acid.

[00746] A solution of methyl 6-bromo-2-naphthoate (7.70g, 29.0mmol) in 2:1 THF:water (150mL) was treated with lithium hydroxide hydrate (2.44g, 58,lmmol) followed by stirring at room temperature for 48h. Concentrated under vacuum, diluted with water and cooled to 0°C. Acidified to pH3 with 4N HC1. Solids were collected by filtration, dissolved in toluene-EtOAc (ca. 2L) and washed with brine. Dried over Na2S04, filtered and concentrated under vacuum. Brown solid was triturated with ether, collected by filtration, and dried under vacuum to give the title compound as a nearly white solid (5.07g, 70%). 174 2014280939 24 Dec 2014 [00747] Part B. Preparation of 6-bromonaphthalen-2-amine.

[00748] A solution of the product Part A (5.07g, 20.19mmol) and triethylamine (4.22mL, 3.07g, 30.3mmol) in dry DMF (155mL) was treated with the diphenylphosphoroyl azide (6.55mL, 8.34g, 30.3mmol) followed by stirring at room temperature for 3h. The solution was then treated with water (20mL) followed by warming at 100°C for lh. The solution was cooled and the flask fitted with a short-path distillation head and the DMF removed by distillation under high vacuum. The solid residue was dissolved in EtOAc and washed with saturated sodium bicarbonate solution. Filtered through celite and the filtrate was washed with water (3x) and then with brine. Dried over Na2S04, filtered and concentrated under vacuum to give the title compound as a beige solid (4.48g, 100 %).

[00749] Part C, Preparation of benzyl 6-bromonaphthalen-2-ylcarbamate.

[00750] A mixture of the product from Part B (1.79g, 8.06mmol) and saturated sodium bicarbonate solution (18mL) in acetone (40mL) at 0 °C was treated drop wise with benzyl chloroformate. The mixture was stirred at 0°C for 1 h, and then allowed to gradually warm to room temperature over 18h. The mixture was diluted with EtOAc and water and the layers separated. The organic layer was extracted with water and washed with brine. Dried over Na2S04, filtered and concentrated under vacuum. Purification by silica gel column chromatography eluting with EtOAc/hexanes gave the title compound as a pink solid (1.5g, 52%).

[00751] Part D. Preparation of benzyl 6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)naphthalen-2-yl carbamate.

[00752] A resealable Schlenk tube containing a solution of the product from Part C (1.42g, 3.99mmol), bis(pinacolato)diboron (1.11 g, 4.39mmol), and potassium acetate (1.17g, 11,96mmol) in DMF (28mL) was degassed by three freeze-thaw cycles. The solution was treated with l,l’-bis(diphenyl phosphino)ferrocene palladium (11) chloride dichloromethane complex (98mg, 0.12mmol), followed by degassing by two additional freeze-thaw cycles. The Schlenk tube was then sealed and the mixture warmed at 80°C for 18h. Cooled and diluted with ethyl acetate and water. The mixture was treated with Darco G-60 and then filtered through celite. The filtrate was extracted with water (4x) and saturated sodium chloride solution. Dried over Na2S04, filtered and concentrated under vacuum afforded a light brown oil. Purification by silica gel column chromatography eluting with EtOAc/hexane gave the title compound as a colorless oil (910mg, 57 %).

[00753] Part E. Preparation of 2-tert-butyl-4-nitrophenol.

[00754] To a vigorously stirred solution of 2-tert-butylphenol (lOg, 66.6mmol) in heptane (67ml) was added at a fast drip a solution of 70% nitric acid (4.25ml, 66.6mmol) diluted with water (4.25ml). The resulting dark red/brown mixture was stirred vigorously for 2h. The suspended solid was collected by filtration washed with hexane (300mL), water (200mL) and once again with hexane (200mL) to give a 175 2014280939 24 Dec 2014 cocoa colored powder that was dried to constant mass (4.65g, 35.6%).

[00755] Part F. Preparation of 2-bromo-6-tert-butyl-4-nitrophenol.

[00756] A solution of the product from Part E (l.Og, 5.12mmol) in glacial acetic acid (10.25mL) was treated portion wise with pyridine hydrobromide perbromide (1,80g, 5.63mmol) followed by stirring at room temperature for 2h. Additional pyridinium hydrobromide perbromide (3.6g) was added in two portions and after another 3h of stirring, the reaction was complete. The mixture was poured into ice water, and the mixture treated with a small amount of sodium sulfite. The resulting solid was filtered and dried under vacuum to give the title compound as a brown solid (1.40g, 100 %).

[00757] Part G. Preparation of l-bromo-3-tert-butyl-2-methoxy-5-nitrobenzene.

[0075B] A solution of the product from Part F (1.40g, 5.11 mmol) in 10:1 t-butylmethylether-methanol (25.5mL) was treated with 2.0M trimethylsilyldiazomethane in ether (5.1mL, 10.21mmol), followed by stirring at room temperature for 18h, The mixture was concentrated under vacuum to afford a yellow oil, which was purified by silica gel column chromatography eluting with EtOAc/hexanes to give the title compound as a yellow oil (1.36g, 92 %).

[00759] Part H. Preparation of tert-butyl 3-bromo-5-tert-butyl-4-methoxyphenylcarbamate.

[00760] A solution of the product from Part G (960mg, 3.33mmol) in methanol (17mL) was treated with 5 % platinum on sulfided carbon (lOOmg), followed by hydrogenation under balloon pressure for 3h, and then filtered through celite and concentrated under vacuum to afford the 3-bromo-5-tert-butyl-4-methoxyaniline as a yellow oil (860mg, 3.33mmol, 100%). A solution of this material in THF (17mL) was treated with di-tert-butyl dicarbonate (800mg, 3.66mmol) followed by warming at reflux for 2h. Concentration under vacuum afforded a beige solid, which was purified by silica gel column chromatography eluting with EtOAc/hexanes. Solid was triturated with hexanes, collected by filtration, and dried under vacuum to give the title compound as a nearly white solid (890mg, 75 %).

[00761] Part I. Preparation of benzyl 6-(3-tert-butyl-5-(tert-butylcarbamoyl)-2-methoxyphenyl) naphthalen-2-yl carbamate.

[00762] Toluene (928ul) and EtOH (928ul) were combined with the product from Part H (133mg, 0.37mmol), the product from Part D (299mg, 0.74mmol) and 1M sodium carbonate (371ul, 0.37mmol) and de-gassed for 20min with nitrogen. Tetrakis(triphenylphosphine)palladium(0) (8.6mg, 7,4umol) was added and de-gassing continued 5-10min, Heated at 85-90°C for 18h, cooled and concentrated under vacuum. Purification by silica gel column chromatography eluting with EtOAc/hexanes gave the title compound (102mg, 49%).

[00763] Part J. Preparation of benzyl 6-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl)naphthalen-2-ylcarbamate.

[00764] A solution of the product from Part I (1 OOmg, 0.18mmol) in CH2C12 (1.0ml) was treated with 176 2014280939 24 Dec 2014 trifluoroacetic acid (0.5ml, 6.5mmol) at room temperature for Ih. Concentrated under vacuum. Dissolved in ethyl acetate, washed with 10% NaHC03, brine. Dried over Na2S04, filtered and concentrated under vacuum. Dissolved in toluene (1.0ml) and added Et3N (25ul, 0.18mmol) and acrylic acid (13ul, 0.19mmol) and the mixture was refluxed for 16h. Concentrated under vacuum. Dissolved in acetic acid (1.0ml, 17.5mmol) and added urea (11.9mg, 0.20mmol) and refluxed for 72h. Cooled and poured into ice water, extracted three times with CHC13, combined extracts, dried over Na2S04, filtered and concentrated under vacuum. Purification by silica gel column chromatography eluting with EtOAc/hexanes gave title compound (57.5mg, 58%).

[00765] Part K. Preparation ofN-(6-(3-tert-butyl~5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide.

[00766] Combined the product from Part J (56mg, O.lOmmol) and EtOAc (1.0ml) and added 10% palladium on carbon (lOmg). Stirred under a balloon of H2 gas for I6h. Filtered through Celite and concentrated under vacuum. Dissolved in CH2C12 (1.0ml), added Et3N (16ul, 0.115mmol) and methanesulfonyl chloride (8.7ul, 0.112mmol) and stirred at room temperature for 30min. Concentrated under vacuum and purification by silica gel column chromatography eluting with EtOAc/hexanes gave the title compound (lOmg, 20%). 'll NMR (300 MHz, DMSO-/6) 5 1.34 - 1.48 (m, 9 H) 2.71 (t, J= 6.62 Hz, 2 H) 3.08 (s, 3 H) 3.21 (s, 3 H) 3.82 (t,/=6.62 Hz, 2 H) 7.26 (s, 2 H) 7.41 (dd,/=8.82, 1.84 Hz, 1 H) 7.59 - 7.76 (m, 2 H) 7.89 - 8.04 (m, 3 H) 10.03 (s, 1 H) 10.34 (s, 1 H); MS (ESI+) m/z 496 (M+H)+; (ESI-) m/z 494 (M-H)\ [00767] Example 4A. Preparation of N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonainide (compound IB-LO-2.3).

H

[00768] Part A. Preparation of N-(6-bromonaphthalen-2-yl)methanesulfonamide.

[00769] A solution of the product from Example 3, Part B (4,48g, 20.17mmol) in pyridine (lOOmL) was treated drop wise with methanesulfonyl chloride (1.97mL, 2.89 g, 25.2mmol) followed by stirring at room temperature for lh. Diluted with toluene and concentrated under vacuum twice. The residue was extracted with EtOAc and washed with water, 1M citric acid and brine. Treated with Darco G-60, dried over Na2S04, filtered through celite and concentrated under vacuum. Solid was triturated with ether-hexane, collected by filtration and dried under vacuum to give the title compound as a faint pink solid 177 2014280939 24 Dec 2014 (3.32g, 55 %).

[00770] Part B. Preparation of N-(6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)naphthalen-2-yl) methanes ulfonamide.

[00771] A mixture of the product from Part A (1.00g, 3.33mmol), bis(pincolato)diboron (1.27g, 5.00mmol), potassium acetate (0.98 g, 9.99mmol) and Combiphos Pd6 (84mg, 0.17mmol) in toluene (22mL) was heated at reflux for 3h. Cooled and diluted with ethyl acetate and water. The mixture was treated with Darco G-60 and filtered through celite. The filtrate was washed with water and brine. Dried over Na2S04, filtered and concentrated under vacuum. Oil was dissolved in ether and precipitated by addition of hexanes. The product was collected by filtration and washed with hexanes. Evaporation of the filtrate and purification by silica gel column chromatography eluting with EtOAc/hexanes. The title compound from crystallization and chromatography was obtained as a white solid (927mg, 80%).

[00772] Part C. Preparation oftert-butyl 3-tert-butyl-4-methoxy-5-(6-(methylsulfonamido) naphthalen-2-yl)phenylcarbamate.

[00773] Combined the product from Example 3, Part H (87mg, 0.243mmol), the product from Part B (169mg, 0.486mmol), toluene (1,0ml), ethanol (1.0ml) and sodium carbonate (0.243ml, 0.243mmol) in a sealed tube and de-gassed with N2 gas for 20min. Tetrakis(triphenylphosphine)palladium(0) (5.61mg, 4.86pmol) was added and de-gassing was continued another 5-10 min. Heated at 90-95°C for 16h. Cooled and concentrated under vacuum. Purification by silica gel column chromatography eluting with EtOAc/hexanes gave the title compound (92.2mg, 76 %).

[00774] Part D. Preparation of N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide.

[00775] A solution of the product from Part C (90mg, O.lSOmmol) in CH2C12 (2.0ml) was treated with trifluoroacetic acid (1.0ml, 12.98mmol) at room temperature for lh. Concentrated under vacuum, dissolved residue in EtOAc, washed with 10% NaHC03, and brine. Dried over Na2S04, filtered and concentrated under vacuum. Dissolved in DMF (1,4ml) and cooled to -25°C and added (E)-3-methoxy- acryloyl isocyanate (0.633ml, 0.361mmol) drop wise while maintaining the temperature below -10°C. Warmed to room temperature and stirred for 2h. Poured into ether, washed with water, and brine. Dried over Na2S04, filtered and concentrated under vacuum. Added a mixture of H2S04 (0.1ml, 1.876mmol), water (1.0ml) and EtOH (1.0ml) and stirred at 100°C 16h. Cooled and concentrated under vacuum. Poured into water, extracted with EtOAc, combined extracts and washed with brine. Dried over Na2S04, filtered and concentrated under vacuum. Purification by silica gel column chromatography eluting with MeOH/CHCl3 gave the title compound (53mg, 59%). 'H NMR (300 MHz DMSO-c/6) δ 1.42 (s, 9 H) 3.08 (s, 3 H) 3.25 (s, 3 H) 5.65 (d, ./=7.72 Hz, 1 H) 7.34 (dd, /=15.81, 2.57 Hz, 2 H) 7.42 (dd,/=8.82, 1.84 Hz, 1 H) 7.65 - 7.76 (m, 2 H) 7.80 (d, /=8.09 Hz, 1 H) 7.96 (t, /= 8.27 Hz, 2 H) 8.02 (s, 1 H) 10.04 178 2014280939 24 Dec 2014 (s, 1 Η) 11.41 (s, 1 H); MS (ESI+) m/z 494 (M+H)+; (ESI-) m/z 492 (M-H)\ [00776] Example 4B. Preparation of N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide (compound IB-LO-2.3).

[00777] Part A. Preparation of 2-tert-butyl-6-iodo-4-nitrophenol.

[00778] To the product from Example 3, Part E (4.5g, 23.05mmol) dissolved in MeOH (120ml) and water (30mL) was added iodine monochloride (1.155ml, 23.05mmol) drop wise over a period of lOmin. The mixture was stirred for 2h and diluted into 1L of water and allowed to stand overnight. The solid material was collected by filtration and washed 3 x 50mL with water and dried under vacuum overnight to give a tan solid (7.14g, 96%).

[00779] Part B. Preparation of l-tert-butyl-3-iodo-2-methoxy-5-nitrobenzene.

[00780] To an ice bath cooled solution of the product from Part A (5.5g, 17.13mmol) in MTBE(15ml) in a 50mL pressure vessel was added 2.0M trimethylsilyl diazomethane (12.85ml, 25.7mmol) followed by drop-wise addition of methanol (1 .OmL) resulting in calm bubbling. The vessel was sealed and stirred at room temperature for 16h, cooled and the pressure was released. The solution was partitioned between EtOAc and water. The organic layer was washed with LOM HC1, saturated potassium carbonate solution, and saturated NaCl, The organic layer was dried over sodium sulfate, filtered and concentrated to give a red oil that was used without purification (5.4g, 84%).

[00781] Part C. Preparation of 3-tert-butyl-5-iodo-4-methoxyaniline.

[00782] A mixture of the product from Part B (5.80g, 17.31mmol), ammonium chloride (1.389g, 26.0mmol), and iron (4.83g, 87mmol) in THF/MeOH/water (200mL total, 2/2/1) was refluxed for 2h, cooled and filtered through Celite. The filtrate was evaporated and the residue was partitioned between water and EtOAc. The organic layer was washed with saturated brine, dried with sodium sulfate, filtered and evaporated to give a brown oil (5.28g, 100% yield).

[00783] Part D. Preparation of (E)-N-(3-tert-butyl-5-iodo-4-methoxyphenylearbamoyl)-3-methoxy acrylamide.

[00784] To a solution of the product from Part C (3.05g, lOmmol) in DMF (50ml) at -20 °C under N2 was added at a fast drip a 0.4M solution in benzene of (E)-3-methoxyacryloyl isocyanate (50.0ml, 20.00mmol, prepared by the method of Santana et al., J. Heterocyclic. Chem. 36:293 (1999). The solution was stirred for 15min at -20 °C, wanned to room temperature for 45min and diluted with EtOAc. 179 2014280939 24 Dec 2014

The organic was washed with water and brine. Dried over Na2SC>4, filtered and concentrated to a brown solid. The residue was triturated in EtiO/hexane to give a fine powder that was collected by filtration and dried under vacuum to give the title compound as a tan powder (2.46g, 57%).

[00785] Part E. Preparation of l-(3-tert-butyl-5-iodo-4-methoxyphenyl)dihydropyrimidine-2,4(lH,3H)-dione.

[00786] To a suspension of the product from Part D (2.46g, 5.69mmol) in ethanol (50ml) was added a solution of 5.5mL of H2S04 in 50mL water and the mixture was heated at 110°C for 2.5h to give a clear solution. Cooled and diluted with 50mL of water while stirring to give an off-white solid that was collected by filtration, washed with water and dried under vacuum to give the title compound (2.06g, 90%).

[00787] Part F. Preparation of N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide.

[00788] In a microwave tube, the product from Part E (104mg, 0.26mmol), the product from Example 4A, Part B (108mg, 0.31mmol), and 1.0M sodium carbonate solution (312pL, 0.31mmo!) in 1:1 ethanol-toluene (1,7mL) was degassed by nitrogen sparge for 15min. 1 ,l'-Bis(diphenylphosphino) ferrocene palladium (II) chloride dichloromethane complex (9mg, 0.011 mmol) was added, and degassing was continued for another 5min. The tube was sealed and heated in the microwave at 100°C for lh. Diluted with dichloromethane and washed with 1M citric acid solution and brine. The organic layer was then stirred with (3-mercaptopropyl) silica gel for lh. Filtered through celite and concentrated under vacuum. Triturated with ether, methanol, and then again with ether to give the title compound as a nearly white solid (32mg, 25 %). *H NMR (300 MHz, DMSO-i/*): δ 11.41 (d, J=1.84 Hz, 1 H) 10.04 (s, 1 H) 8.03 (s, 1 H) 7.96 (t, J=8.09 Hz, 2 H) 7.80 (d, J=8.09 Hz, 1 H) 7.63 - 7.79 (m, 2 H) 7.35 - 7.45 (m, 1 H) 7.37 (d, J=2.57 Hz, 1 H) 7.32 (d, J=2.57 Hz, 1 H) 5.65 (dd, J=8.09,2.21 Hz, 1 H) 3.25 (s, 3 H) 3.09 (s, 3 H) 1.43 (s, 9 H). MS (+ESI) m/z (rel abundance): 494 (100, M+H), 511 (90, M+NH4), 987 (20, 2M+H), 1009 (8, 2M+Na), [00789] Example 5. Preparation ofN-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl)quinolin-2-yl)methanesulfonamide (compound IB-LO-2.5).

H

[00790] Part A. Preparation of (E)-N-(4-bromophenyl)-3-methoxyacrylamide.

[00791] Combined 4-bromoaniline (285mg, 1.659mmol), CH2CI2 (2.0ml) and pyridine (0.25ml, 180 2014280939 24 Dec 2014 3.09mmol) and slowly added (E)-3-methoxyacryloyl chloride (200mg, 1.659mmol) and stirred at room temperature for 2h. The resulting yellow solid was filtered off and washed with water. The solid was dried under vacuum to give the title compound (406mg, 96 %).

[00792] Part B. Preparation of 6-Bromoquinolin-2( 1 H)-one.

[00793] The product from Part A (395mg, 1,542mmol) was added in portions to H2S04 (4.5ml). Stirred for 3h at room temperature, poured onto crushed ice. Solid filtered, washed with water and dried under vacuum to give the title compound (203mg, 59 %).

[00794] Part C. Preparation of 6-bromo-2-chloroquinoline.

[00795] To phosphorus oxychloride (2.5ml, 26.8mmol) was added, in portions, the product from Part B (200mg, 0.893mmol). Refluxed for lh, cooled to room temperature and poured onto crushed ice. Extracted with CHCfi, extracts combined, dried overmgStTt, filtered and concentrated under vacuum to give the title compound (173mg, 80%).

[00796] Part D. Preparation of 6-bromo-2-aminoquinoIine.

[00797] The product from Part C (173mg, 0,713mmol), acetamide (843mg, 14.27mmoI) and potassium carbonate (493mg, 3.57mmol) were combined and heated at 200 °C for 2h. Cooled to room temperature, whereupon it solidified. Dissolved in a mixture of CHCfi and water. Aqueous layer was extracted twice more with CHCI3, extracts were combined, washed with brine, dried over Na2SO^, filtered and concentrated under vacuum. Purification by silica gel column chromatography eluting with MeOH/CHClg gave title compound (92mg, 58 %).

[00798] Part E. Preparation of N-(6-bromoquinolin-2-yl)-N-(methylsulfonyl)methanesulfonamide.

[00799] Combined the product from Part D (90mg, 0.403mmol) and CH2C12 (2.0ml) and added triethylamine (0.062ml, 0.444mmol) and methanesulfonyl chloride (0.035ml, 0.444mmol). Stirred at room temperature 16h. Added triethylamine (0.062ml, 0.444mmol) and methanesulfonyl chloride (0.035ml, 0.444mmol) and stirred at room temperature for lh. Diluted with EtOAc, washed with 10% citric acid, 10% NaHC03 and brine. Dried over Na2S04, filtered and concentrated under vacuum. Dissolved in EtOAc and poured into excess hexane. Solid collected by filtration to give the title compound (94mg, 61%).

[00800] Part F. Preparation of N-(methylsulfonyl)-N-(6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl) quinolin-2-yl)mcthanesulfonamide.

[00801] Combined the product from Part E (94mg, 0.248mmol), bis(pinacolato)diboron (94mg, 0.372mmol), potassium acetate (73.0mg, 0.744mmol), Combi-Phos®PD6 (6.22mg, 0.012mmol) and toluene (1.5ml) and refluxed 18h. Cooled to room temperature, diluted with EtOAc and water, filtered through Celite, separated the phases, washed the organic phase with brine. Dried over Na2SQ4, filtered 181 2014280939 24 Dec 2014 and concentrated under vacuum. Purification by silica gel column chromatography eluting with EtOAc/hexanes gave title compound (67mg, 63%).

[00802] Part G. Preparation ofN-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl)quinolin-2-yl)methanesulfonamide.

[00803] Combined in a microwave tube the product from Example 4B, Part E (27mg, 0.067mmol), the product from Part F (37.4mg, 0.088mmol), ethanol (1.0ml), toluene (1.0ml) and 1M sodium carbonate (0.067ml, 0.067mmol) and the solution was degassed using N2 gas for 20min. Tetrakis- (triphenyl-phosphine)palladium(O) (1,559mg, 1,349μτηοΙ) was added and the solution was degassed an additional 5min. The tube was sealed and heated in the microwave at 100°C for 45min. Cooled solution diluted with 1:1 EtOAc:water and filtered through Celite. Aqueous layer was extracted twice more with EtOAc, combined organic extracts and washed with brine. Dried over Na2S04, filtered and concentrated under vacuum. Purification by silica gel column chromatography eluting with MeOH/CHCl3 gave title compound (13.7mg, 41%). 'HNMR (300 MHz, CDC13) δ 1.45 (s, 9 H) 3.18 (s, 3 H) 3.30 (s, 3 H) 5.83 (dd, ^ 7.91, 2.02 Hz, 1 H) 6.99 (d, ./= 8.82 Hz, 1 H) 7.21 (d, 7=2.57 Hz, 1 H) 7.36 (d, 7=7.'72 Hz, 1 H) 7.52 (d, 7=8.46 Hz, 1 H) 7.82 - 7.91 (m, 2 H) 7.98 (d, 7=9.19 Hz, 1 H) 8.29 (s, 1 H); MS (ESI+) m/z 495 (M+H)+; (ESI-) m/z 493 (M-Hf.

[00804] Example 6. Preparation of (E)-N'-(5-(3-tert-butyI-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl)-2,3-dihydro-l H-inden-l-ylidene)methanesulfonohydrazide (compound IB-LO-2.4).

O /

[00805] Part A. Preparation of 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2,3-dihydro-lH-inden-l-one.

[00806] A mixture of 5-bromo-2,3-dihydro-lH-inden-1 -one (2.50g, 11.85mmol), bis(pinacolato) diboron (3.6 lg, 14.21mmol), potassium acetate (3.49g, 35.5mmol) and Combiphos Pd6 (178mg, 0.36mmol) in toluene (60mL) was heated at reflux for 8h. Cooled, diluted with EtOAc and extracted with water (2 x) and washed with brine. Dried over Na2S04 and stirred for lh with (3-mercaptopropyl) silica gel. Filtered and concentrated under vacuum to afford a yellow solid. Purification by silica gel column chromatography eluting with EtOAc/hexanes gave a yellow solid. Triturated with cold hexanes, filtered and dried under vacuum to give the title compound as a fine nearly white solid (1,99g, 65%). A second 182 2014280939 24 Dec 2014 crop of crystals (140mg) was obtained from the mother liquors, bringing the yield to 70%.

[00807] Part B. Preparation of l-(3-tert-butyl-4-methoxy-5-(l-oxo-2,3-dihydro-lH-inden-5-yl)phenyl) pyrimidine-2,4( 1H,3 H)-dione.

[00808] In a microwave tube, a suspension of the product from Example 4B, Part E (130mg, 0.33mmol), the product from Part A (K)lmg, 0.39mmol), and 1.0M sodium carbonate solution (390pL, 0.39mmol) in 1:1 ethanol-toluene (1.20mL) was degassed by nitrogen sparge for 15min. The mixture was treated with l,r-bis(diphenylphosphino)ferrocene palladium (II) chloride dichloromethane complex (13mg, 0.016mmol) and degassing was continued for another 5min and heated at 100°C in the microwave for lh. Cooled, diluted with EtOAc and extracted with 1M citric acid solution and brine. The organic layer was then stirred with (3-mercaptopropyl) silica gel for lh. Filtered and concentrated under vacuum. Purification by silica gel column chromatography eluting with EtOAc/hexanes gave the title compound as a white solid (80mg, 61 %).

[00809] Part C. Preparation of (E)-N’-(5-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl)-2,3-dihydro-lH-inden-l-ylidene)methanesulfonohydrazide.

[00810] A suspension of the product from Part B (77mg, 0.19mmol) and methanesulfonylhydrazide (22mg, 0.20mmol) in 3:1 TTIF:MeOH (1.9mL) was warmed at 60°C for 24h. The mixture was concentrated under vacuum and the residue was purified by silica gel column chromatography eluting with EtOAc/hexanes to give the title compound as a white solid (62mg, 66 %). 'H NMR (300 MHz, DMSO-ift): δ 11.40 (d, 1=1.84 Hz, 1 H) 9.94 (s, 1 H) 7.76 (dd, 1=13.97, 8.09 Hz, 2 H) 7.52 7.59 (m, 1 H) 7.51 (d, 1=8.46 Hz, 1 H) 7.11 - 7.40 (m, 2 H) 3.28 (s, 3 H) 2.96 - 3.19 (m, 5 H), 2.85 (m, 2 H), 1.40 (s, 9 H). MS (+ESI) m/z (rel abundance): 497 (100, M+H), 1015 (5, 2M+Na).

[00811] Example 7. Preparation ofN-(2-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl)benzo[d]oxazol-5-yl)methanesulfonamide (compound IB-LÖ-2.6).

[00812] Part A. Preparation of methyl 3-tert-butyl-2-hydroxy-5-nitrobenzoate.

[00813] Methyl 3,5-di-tert-butyl-2-hydroxybenzoate (28.66g, 108.4mmol) was dissolved with stirring in 430mL glacial acetic acid and the resulting mixture was treated drop wise with fuming nitric acid (90%, 179.26mL). When the addition was complete, the resulting mixture was stirred for 2.5h. The reaction 183 2014280939 24 Dec 2014 mixture was poured into a 2.0L of crushed ice and allowed to stand 30min. Afterwards, 1.0L of water was added and the ice water mixture was allowed to melt. The mixture was then filtered, washed with water and dried to provide the title compound (24.57g, 89%).

[00814] Part B. Preparation of methyl 3-tert-butyl-2-methoxy-5-nitrobenzoate.

[00815] Methyl 3-tert-butyl-2-hydroxy-5-nitrobenzoate (11.41g, 45.0mmol), potassium carbonate(9.34g, 67.6mmol), acetone (200mL), and dimethyl sulfate (6.46g, 67.6mmol) were added together. The resultant mixture was then heated to reflux for 16h. The mixture was then filtered and the solid was washed with ethyl acetate. The resulting organic liquid was then concentrated under vacuum to an oil and redissolved in ethyl acetate (600mL). The organic solution was then washed with water, dried, filtered and concentrated under vacuum to an oil that was then subjected to purification via column chromatography (gradient of 5% to 40% EtOAc/Hexanes) to yield the title compound as an oil (10.42, 87%).

[00816] Part C. Preparation of methyl 5-amino-3-tert-butyl-2-methoxybenzoate, [00817] Methyl 3-tert-butyl-2-methoxy-5-nitrobcnzoatc (10.42g, 39.0mmol), iron powder (325mesh, 10.89g, 195mmol), ammonium chloride (3.13g, 58.5mmol), water (30mL), and methanol (150mL) were added together. The resultant mixture was then refluxed for lh. The mixture was then cooled to room temperature, filtered through celite, and the celite washed with methanol. The filtrate was then concentrated under vacuum and dissolved in ethyl acetate (600mL). The resultant solution was then washed with water and brine. The organic extract was then dried, filtered and concentrated under vacuum to yield the title compound as an oil (9.25g, 100%).

[00818] Part D. Preparation of (E)-methyl 3-tert-butyl-2-methoxy-5-(3-(3-methoxyacryloyl)ureido) benzoate. 100819] The product obtained as described in Part C (2.0g, 8.43mmol) was dissolved in 30mL of N,N-dimethylacetamide and cooled to -25°C. A O.SMolar solution of E-3-methoxyacryloyl isocyanate in benzene (21.9mL, 10.96mmol) was added drop wise and the resulting solution was stirred at ambient temperature for 4h, and then poured into water. The product was extracted into dichloromethane, washed with brine, dried over sodium sulfate, filtered and evaporated under vacuum to give 100% yield.

[00820] Part E. Preparation of methyl 3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyben zoate.

[00821] The product from Part D (3.1g, 8.51mmol) was dissolved in ethanol (60mL). Sulfuric acid (6mL) was added to water (60mL) then this solution was added in one portion to the ethanol. The heterogeneous mixture was heated at 100°C for 3h. The ethanol was removed under vacuum, and then the aqueous solution was extracted with dichloromethane and evaporated to dryness. This residue was purified by flash chromatography, eluting with 1% methanol/dichloromethane to yield 1.23g (44%).

[00822] Part F. Preparation of 3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-184 2014280939 24 Dec 2014 methoxybenzoic acid.

[00823] The product from Part E (] .23g, 3.7mmol) was taken up in ethanol (5mL) and IMolar sodium hydroxide solution (lOmL) and stirred at ambient temperature for 18h, The solution was diluted with 1M HC1 and the resulting solid was filtered and dried to give 0.945 g (80%).

[00824] Part G. Preparation of 3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2H)-yl)-2-methoxy benzaldehyde.

[00825] The product from Part F (0.945g, 2.97mmol) was taken up in thionyl chloride (4.5mL) and the mixture was heated at 80°C for 40min. After evaporation to dryness, the acid chloride was dissolved in dry THF (8mL) and cooled to -78°C. A IMolar solution of lithium tri-tert-butoxyaluminum hydride in THF (3.0mL, 3.0mmol) was added drop wise. After 45min the cold reaction was quenched with 1M HC1 (5mL), extracted into ethyl acetate, and purified by flash column, eluting with dichloromethane followed by 1% methanol/dichloromethane to give 0.635 g (71%).

[00826] Part H. Preparation of l-(3-tert-butyl-4-methoxy-5-(5-nitrobenzo[d]oxazol-2-yl)phenyl) pyrimidine-2,4(1H,3 H)-dione.

[00827] The product from Part G (400mg, 1.323tnmol), 2-amino-4-nitrophenol (204mg, 1,323mmol), Charcoal (Darco KB, 191 mg, 15.88mmol) and toluene (50mL) were added to a flask and the mixture was heated to 120°C, and stirred open to the air for 48h. Filtered through Celite and concentrated under vacuum. Purification by silica gel column chromatography eluting with CH2Cl2/MeOH gave the title compound (300mg, 52%).

[00828] Part I. Preparation of N-(2-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl)benzo[d]oxazol-5-yl)methanesulfonamide.

[00829] To the product from Part H (300mg, 0.687mmol), iron (192mg, 3.44mmol), and ammonium chloride (55mg, 1.031mmol) was added to a mixture of THF (15mL), EtOH (15mL) and water (4.5mL). The resultant solution was heated to 90°C for 45min, and cooled. Filtered through Celit, washed with ethanol, and concentrated under vacuum. The solid was dissolved in ethyl acetate, and washed with water. Dried over Na2S04, filtered and concentrated under vacuum. Purification by silica gel column chromatography eluting with CIIjCl,-/MeOH provided the aniline. The solid (75mg, 0.185mmol) was dissolved in CH;C1?. (5mL), and pyridine (0.045mL, 0.554mmol) and methanesulfonyl chloride (0.025mL, 0.323mmol) were added and stirred at room temperature for 16h. CH2C12 was added followed by washing with a IN HC1. Dried over Na2S04, filtered and concentrated under vacuum. Purification by silica gel column chromatography eluting with CftCh/MeOH provided the title compound as a solid (9.8mg, 3%, two steps). 1H NMR (300MHz, DMSO-d6); δ 11.46 (s,lH), 9.85 (s,lH), 7.91 (d, J=2.2Hz, 1H), 7.81 (dd, J=9.9,8.8Hz, 2H), 7.68 (d, J=2.2Hz, 1H), 7.56 (d, J=2.6Hz, 1H), 7.33 (dd, J=8.8,1.8Hz, 1H), 5.68 (d, J=7.7Hz, 1H), 3.64 (s, 3H), 3.00 (s, 3H), 1.42 (s, 9H). MS: m/z 485 (M+H)+. 185 2014280939 24 Dec 2014 [00830] Example 8. Preparation of l-(3-tert~butyl-4-methoxy-5-(6-nitrobenzo[d]oxazol-2-yI)phenyl) dihydropyrimidine-2,4(lH,3H)*dione (compound IA-LO-2.6).

[00831] Part A. Preparation of 3-(3-tert-butyl-4-methoxy-5-(methoxycarbonyl)phenylamino) propanoic acid, [00832] The product from Example 7, Part C (16.44g, 69.3mmol) was dissolved in toluene (200mL),

This mixture was heated to reflux and acrylic acid added over time (lmL of acrylic acid added every 3h, 5.23mL total, 76.2mmol). The mixture was then refluxed for 24h. The mixture was then cooled and concentrated under vacuum to dryness to yield an oil as the crude title compound that was used directly in the next reaction.

[00833| Part B. Preparation of methyl 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxybenzoate.

[00834] The product from Part A (21.43g, 69.3mmol), urea (10.4g, 173mmol) and acetic acid (glacial, 200mL) were added together. The mixture was then heated to 120°C for 18.5h followed by concentration under vacuum to dryness to an oil. To this oil was added methanol (13mL), and ethyl acetate (350mL). The resultant mixture was allowed to stand for 24-48h whereby a precipitate formed. The resulting solid was filtered off and washed with a small amount of methanol (lOmL) and then air dried to yield the title compound as a solid (15,26g, 66%).

[00835] Part C. Preparation of 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy benzoic acid.

[00836] The product from Part B (4.52g, 13.52mmol), methanol (70mL), and tetrahydrofuran (70mL) were added together. The mixture was then stirred vigorously until a homogenous solution resulted.

Once homogenous, a solution of aqueous sodium hydroxide (1.0M, 68mL) was added. The mixture was then stirred for 12h, the mixture was then concentrated under vacuum to remove the organic solvent, followed by the addition of aqueous hydrochloric acid (1.0M, 80mL) that resulted in solid formation. The mixture was then concentrated under vacuum. To this material was added hydrochloric acid (12M, lOOmL) and the resultant material heated to 100°C for 1.5h. The reaction was then cooled and water 186 2014280939 24 Dec 2014 added. The resulting solid was filtered, washed with water, and dried to yield the title compound as a solid (3.55g, 82%).

[00837] Part D. Preparation of 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy benzaldehyde.

[00838] The product obtained in Part C (4,07g, 12.71mmol) and thionyl chloride (40.82mL, 559mmol) were combined and the mixture was refluxed for 2h, followed by concentration under vacuum to provide a light yellow colored solid product. The solid was dissolved in tetrahydrofuran (125mL), the solution cooled to -78°C and LiAl(0/Bu)3 (1M, 14mL) was added slowly over lOmin while maintaining the temperature at -78°C. The mixture was stirred at 78°C for 2h. The reaction was quenched with hydrochloric acid (aq., 1M, 25mL) at -78°C. The mixture was warmed to room temperature and ethyl acetate was added. The layers were separated and the aqueous layer was washed with ethyl acetate. The organic extracts were combined and washed with half saturated sodium bicarbonate solution. The organic layer was dried, filtered and concentrated under vacuum to yield a solid as the title compound (3.73g, 96%).

[00839] Part E. Preparation of l-(3-tert-butyl-4-methoxy-5-(6-nitrobenzo[d]oxazol-2-yl)phenyl)dihydro pyrimidine-2,4(1 H,3H)-dione.

[00840] A mixture of the product from Part D (75mg, 0.246mmol), 2-amino-5-nitrophenol (38mg, 0,0246mmol) and Darco KB charcoal (excess) was refluxed in toluene (lOmL) for 24h under exposure to atmospheric of oxygen. Cooled, filtered and purified by reverse phase HPLC chromatography eluting with a 40-100% gradient of acetonitrile in water (0.1% TFA) to provide the title compound as a solid (96mg, 64%). 'H NMR (300 MHz, DMSO-d6): δ 1.42 (s, 9 H) 2.74 (t, J=6.80 Hz, 2 H) 3.66 (s, 3 H) 3.82 - 3.88 (m, 2 H) 7.56 (d, J=2.57 Hz, 1 H) 7.91 (d, J=2.57 Hz, 1 H) 8.09 (d, 1=8.82 Hz, 1 H) 8.37 (dd, 1=8.82, 2.21 Hz, 1 H) 8.84 (d, 1=2.21 Hz, 1 H) 10.44 (s, 1 H). MS ESI+ (439) (M+H)+.

[00841] Example 9. Preparation of N-(2-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl)benzo[d]oxazol-6-yl)methanesulfonamide (compound IA-LO-2.5).

O

187 2014280939 24 Dec 2014 [00842]The product from Example 8 (96mg. 0.219mmol) was reacted a iron (0.614g, l.lOmmol), and ammonium chloride (0,176g, 0.329mmol) in the presence of a mixture of tetrahydrofuran (5mL), ethanol (5mL) and water (3mL). The slurry was heated to 90°C for 45min, cooled to ambient temperature. Filtered through a pad of celite (1 Og), washed with ethanol (20mL), and the filtrate was concentrated under vacuum to a solid. The resulting solid was dissolved in ethyl acetate and washed with water. Dried over Na2S04, filtered and concentrated under vacuum to a yellow solid, providing the corresponding aniline. The solid was dissolved in dichloromethane (lOmL), pyridine (0.670mL, 0.657mmol) and methanesulfonyl chloride (0.221mL, 0.329mmol) were added and the solution stirred at room temperature 16h. CH2CI2 was added followed by washing with a IN aq. HC1 solution. Dried over Na2S04, filtered and concentrated under vacuum. Purification by silica gel column chromatography eluting with 98:2 CH2Cl2:MeOH gave the title compound as a solid (25mg, 21%, two steps). ‘H NMR (300 MHz, DMSO-d6): δ 1.41 (s, 9 H) 2.73 (t, J=6.62 Hz, 2 H) 3.06 (s, 3 H) 3.61 (s, 3 H) 3.83 (t, J=6.62 Hz, 2 H) 7.28 (dd, J=8.46, 1.84 Hz, 1 H) 7.48 (d, J=2.57 Hz, 1 H) 7.65 (d, J=1.84 Hz, 1 H) 7.80 (d, M.47 Hz, 1 H) 7.82 (d, J=4.04 Hz, 1 H) 10.03 (s, 1 H) 10.41 (s, 1 H). MS ESI+ (487) (M+H)+.

[00843]Example 10. Preparation of l-(3-tert-butyl-4-methoxy-5-(5-nitrobenzo[d]oxazol-2-yI)phenyl) dihydropyrimidine-2,4(lH,3H)-dione (compound IA-LO-2.7).

[00844]The product from Example 8, Part D (150mg, 0.493mmol) was reacted with 2-amino-4-nitrophenol (76mg, 0.493mmol) according to the procedures from Example 8, Part E to provide the title compound as a solid (70mg, 32%). 'H NMR (300 MHz, DMSO-d6): δ 1.42 (s, 9 H) 2.74 (t, J=6.80 Hz, 2 H) 3.65 (s, 3 H) 3.85 (t, J=6.62 Hz, 2 H) 7.55 (d, J=2.57 Hz, 1 H) 7.89 (d, J=2.94 Hz, 1 H) 8.12 (d, J=8.82 Hz, 1 H) 8.40 (dd, J=9.01,2.39 Hz, 1 H) 8.76 (d, J=2.21 Hz, 1 H) 10.43 (s, 1 H). MS ESI+ (439) (M+H)+. 188 2014280939 24 Dec 2014 [00845]Example 11. Preparation ofN-(2-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl)benzo[d]oxazol-5-yl)methanesulfonamide (compound IA-LO-2.8).

[00846] The product from Example 10 (65mg, 0.148mmol) was reacted according to the procedures from Example 9 to provide the title compound as a solid (42mg, 44%). 'H NMR (300 MHz, DMSO-d6): δ 1.41 (s, 9 H) 2.73 (t, J=6.43 Hz, 2 H) 3.01 (s, 3 H) 3.60 (s, 3 H) 3.83 (t, J=6.43 Hz, 2 H) 7.31 (dd, J=8.64, 2.02 Hz, 1 H) 7.49 (d, J=2.94 Hz, 1 H) 7.56 (d, J=2.21 Hz, 1 H) 7.67 (d, J=2.21 Hz, 1 H) 7.81 (s, 1 H) 9.82 (s, 1 H) 10.41 (s, 1 H). MS ESI+ (487) (M+H)+.

[00847] Example 12. Preparation of l-(3-(benzo[d]thiazol-2-yl)-5-tert-butyl-4-methoxyphenyl)dihydro pyrimidine-2,4(lH,3H)-dione (compound IA-LO-2.3).

[00848] The product from Example 8, Part D (75mg, 0.246mmoi) was reacted with 2-aminobenzene thiol (0.026mL, 0.246mmol) according to the procedures from Example 8, Part E to provide the title compound as a solid (25mg, 25%). ’ll NMR (300 MHz, DMSO-d6): δ 1.44 (s, 9 H) 2.73 (t, J=6.43 Hz, 2 H) 3.62 (s, 3 H) 3.84 (t, J=6.62 Hz, 2 H) 7.46 (d, J=2.57 Hz, 1 H) 7.48 - 7.60 (m, 2 H) 7.86 (d, J=2.57 Hz, 1 H) 8.13 (dd, J=17.28, 7.72 Hz, 2 H) 10.40 (s, 1 H). MS ESI+ (410) (M+H)+. 189 2014280939 24 Dec 2014 [00849]Example 13. Preparation of N-(2-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl)-lH-benzo[d]imidazol-5-yl)methanesulfonamide (compound IA-LO-2.1).

[00850] Part A. Preparation ofN-(3,4-dinitrophenyl)methanesulfonamide.

[00851] A mixture of 3,4-dinitroaniline (5.27g, 28.8mmoi), methanesulfonyl chloride (3.36mL, 43.1mmol) and pyridine (5.82mL, 71.9mmol) in CH2CI2 (lOOmL) was stirred for 24h. Mixture was concentrated under vacuum to provide a crude semi-solid title compound that was used without further purification. ]00852] Part B. Preparation of N-(3,4-diaminophenyl)methanesulfonamide.

[008531 The product from Part A (7.5 lg, 28.8mmol) was reacted with iron (16g, 288mmol) and NH4CI (3.84g, 71.9mmol) in refluxing CH3OH (lOOmL) and water (20mL) for 2 h. Filtered through celite and concentrated under vacuum. Purification by silica gel column chromatography eluting with MeOH/CH2Cl2 provided the title compound as a dark semi-solid (0.5g, 8%).

[00854] Part C. Preparation of N-(2-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy phenyl)-lH-benzo[d]imidazol-5-yl)methanesulfonamide.

[00855] A mixture of the product from Example 8, Part D (200mg, 0.657mmol) was reacted with the product from Part B (132mg, 0.657mmol) according to the procedures from Example 8, Part E to provide the title compound as a solid (112mg, 34%). ’H NMR (300 MHz, DMSO-dg): δ 1.43 (s, 9 H) 2.72 (t, J=6.62 Hz, 2 H) 2.93 (s, 3 H) 3.44 (s, 3 H) 3.82 (t, J=6.43 Hz, 2 H) 7.07 - 7.14 (m, 1 H) 7.38 (d, J=2.57 Hz, 1 H) 7.48 - 7.64 (m, 2 H) 7.72 (d, J=2.57 Hz, 1 H) 9.57 (s, 1 H) 10.38 (s, 1 H) 12.55 (s, 1 H). MS ESI+ (486) (M+H)+. 190 2014280939 24 Dec 2014 [00856]Example 14. Preparation ofN-(2-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl)benzo[d]thiazoI-6-yl)methanesulfonamide (compound IA-LO-2.2).

O

[00857] Part A. Preparation of N-(3-chloro-4-nitrophenyl)methanesulfonamide.

[00858] A mixture of 3-chloro-4-nitroaniline (4.85g, 28.1mmol), methanesulfonyl chloride (3.29mL, 42.2mmol) and pyridine (6.82mL, 84mmol) in THF (lOOmL) was stirred for 24h. Poured in 1M HC1 (500mL). The resulting precipitate was filtered and air-dried to provide the title compound as a solid (7.03g, 100%).

[00859] Part B. Preparation of N-(3-(4-methoxybenzylthio)-4-nitrophenyl)methanesulfonamide.

[00860] A mixture of the product from Part A (7.0g, 27.9mmol), (4-methoxyphenyl)methanethiol (3.89mL, 27.9mmol) and K2C03 (11.58g, 84mmol) in DMF was heated at 100°C for 12h. Cooled and poured into 1M HC1 (800mL). The resulting precipitate was filtered and air-dried to provide the title compound as a yellow solid (6.98g, 68%).

[00861] Part C. Preparation of N-(4-amino-3-(4-methoxybenzylthio)phenyl)methanesulfonamide.

[00862] The product from Part B (6,98g, 19,0mmol) was reacted according to the procedures from Example 13, Part B to provide the title compound as a yellow semi-solid (4.44 g, 69%).

[00863] Part D. Preparation of N,N'-(3,3'-disulfanediylbis(4-amino-3,l-phenylene))dimethane-sulfonamide.

[00864] The product from Part C (708mg, 2.09mmol) was reacted with mercuric (II) acetate (667mg, 2.09mmol), anisole (0.457mL, 4.18mmol) and TFA (lOmL) at 0°C for 45min. Concentrated under vacuum and dissolved in MeOH. Hydrogen sulfide gas was bubbled into solution for lh followed by filtration and concentration under vacuum. Purification by silica gel chromatography eluting with EtOAc/hexane gave the title compound as a yellowish solid (340mg, 75%).

[00865] Part E. Preparation of N-(2-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl)benzo[d]thiazol-6-yl)methanesulfonamide.

[00866] The product from Part D (lOOmg, 0.23mmol) was reacted with the product from Example 8, Part B (140mg, 0.46mmol), triphenylphosphine (60.4mg, 0.23mtnol) and 4-methylbenzene- sulfonic acid 191 2014280939 24 Dec 2014 (0.0054mL, 0.046mmol) in refluxing toluene for 3h. Concentrated under vacuum and purified by reverse phase HPLC chromatography eluting a 40-100% gradient of acetonitrile in water (0.1% TFA) to give the title compound as a solid (99mg, 43%). *H NMR (300 MHz, DMSO-d6): δ 1.43 (s, 9 H) 2.73 (t, J=6.62 Hz, 2 H) 3.07 (s, 3 H) 3.63 (s, 3 H) 3.83 (t, J=6.62 Hz, 2 H) 7.39 (dd, J=8.82, 2.21 Hz, 1 H) 7.45 (d, J=2.57 Hz, 1 H) 7.83 (d, J=2.57 Hz, 1 H) 7.95 (d, J=2.21 Hz, 1 H) 8.05 (d, J=8.82 Hz, 1 H) 10,03 (s, 1 H) 10.39 (s, 1 H). MS ESI+ (503) (M+H)+.

[00867] Example 15. Preparation of N-(2-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl)benzo[d]thiazol-5-yl)methanesulfonamide (compound IA-LO-2.4).

[00868] Part A. Preparation of N-(4-chloro-3 -nitrophenyl)methanesulfonamide.

[00869] A mixture of 4-chloro-3-nitroaniline (5.0g, 29mmol), methanesulfonyl chloride (2.37mL, 30.4mmol) and pyridine (5.9mL, 72.4mmol) in THF (lOOmL) was stirred for 24h. Poured in 1M HC1 (500mL). The resulting precipitate was filtered and air-dried to provide the title compound as a solid (6.7g, 92%).

[00870] Part B. Preparation of N-(4-(4-methoxybenzylthio)-3-nitrophenyl)methanesulfonamide.

[00871] A mixture of the product from Part A (3,0g, 12mmol), (4-methoxyphenyl)methanethiol (1.67mL, 12mmol) and K2C03 (4.96g, 36mmol) in DMF was heated at 100“C for 12h. Cooled and poured into 1M HC1 (800mL). The resulting precipitate was filtered and air-dried to provide the title compound as a yellow solid (1,95g, 44.2%).

[00872] Part C. Preparation of N-(3-amino-4-(4-methoxybenzylthio)phenyl)methanesulfonamide.

[00873] The product from Part B (1,43g, 3.88mmol) was reacted according to the procedures from Example 13, Part B to provide the title compound as a white solid (1.3 lg, 100%).

[00874] Part D. Preparation of N,N'-(4,4'-disulfanediylbis(3-amino-4,l-phenylene))dimethane-sulfonamide.

[00875] The product from Part C (75mg, 0.222mmol) was reacted with mercuric (II) acetate (70.6mg, 0.222mmol), anisole (0.048mL, 0.443mmol) and TFA (lOmL) at 0°C for 45min. Concentrated under vacuum and dissolved in MeOH. Hydrogen sulfide gas was bubbled into solution for lh followed by 192 2014280939 24 Dec 2014 filtration and concentration under vacuum. Purification by silica gel column chromatography eluting with EtOAc/Hexane gave the title compound as a yellowish solid (34mg, 71%).

[00876] Part E. Preparation of N-(2-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy phenyl)benzo[d]thiazol-5-yl)methanesulfonamide.

[00877] The product from Part D (50mg, 0.115mmol) was reacted with the product from Example 8, Part D (70mg, 0.230mmol), triphenylphosphine (30.2mg, 0.115mmol) and 4-methylbenzenesulfonic acid (0.00267mL, 0.023mmol) in refluxing toluene for 3h. Concentrated under vacuum and purified by reverse phase HPLC chromatography eluting with a 40-100% gradient of acetonitrile in water (0.1% TFA) to give the title compound as a solid (40mg, 33%). 'H NMR (300 MHz, DMSO-de): δ 1.43 (s, 9 H) 2.73 (t, J=6.80 Hz, 2 H) 3.05 (s, 3 H) 3.63 (s, 3 H) 3.84 (t, J=6.62 Hz, 2 H) 7.35 (dd, J=8.64,2.02 Hz, 1 H) 7.46 (d, J=2.94 Hz, 1 H) 7.86 (d, J=2.94 Hz, 1 H) 7.92 (d, J=1.84 Hz, 1 H) 8.10 (d, J=8.46 Hz, 1 H) 9.98 (s, 1 H) 10.40 (s, 1 H). MS ESI+ (503) (M+H)+.

[00878] Example 16. Preparation of l-(3-tert-butyl-4-methoxy-5-(naphthalen-2-yl)phenyl) pyrimidine-2,4(1 H,3 H)-dione (compound IB-LO-2.1).

[00879] Part A. Preparation of tert-butyl 3-tert-butyl-4-methoxy-5-(naphthalen-2-yl)phenyl carbamate.

[00880] In a resealable Schlenk tube, a solution of the product from Example 3, Part H (200mg, 0.56mmol), naphthalene-2-boronic acid (144mg, 0.84mmol), and 1.0M sodium carbonate solution (558pL, 0. 56mmol) in toluene (2.8mL) was degassed by nitrogen sparge for lOmin. The mixture was treated with l,r-bis(diphenylphosphino)ferrocene palladium (II) chloride dichloromethane complex (14mg, 0.017mmol) and degassing was continued for another 5min. The Schlenk tube was sealed and warmed at 95°C for 18h. Cooled and diluted with ethyl acetate and water. Treated with Darco G-60 and filtered through celite. Filtrate was extracted with water (2 x) and with brine. Dried over Na2S04, filtered and concentrated. Purification by silica gel column chromatography eluting with 10-75 % EtOAc in hexanes gave the title compound as an oil (210mg, 93 %).

[00881] Part B. Preparation of 3-tert-butyl-4-methoxy-5-(naphthalen-2-yl)aniline.

[00882] The product from Part A (210mg, 0.52mmol) was dissolved in 4N HC1 in dioxane (4.0mL) and stirred at room temperature for lh. Concentration under vacuum afforded a solid, which was suspended in ethyl acetate and stirred with saturated sodium bicarbonate solution. The organic layer was dried over Na2S04, filtered and concentrated under vacuum to give the title compound, as a brown oil (11 lmg, 70 193 2014280939 24 Dec 2014

H

%).

[00883]Part C, Preparation of (E)-N-(3-tert-butyl-4-methoxy-5-(naphthalen-2-yl)phenylcarbamoyl)-3-methoxyacrylamide. 100884] A solution of the product from Part B (11 lmg, 0.36mmol) in dry DMF (2.9mL) at -20°C was treated with (E)-3-methoxyacryloyl isocyanate solution (0.66mL, of 0.55M in benzene, 0.36mmol) followed by gradual warming to room temperature. After stirring for 30min, the mixture was cooled again to -20°C and more (E)-3-methoxyacryloyI isocyanate solution (l.OmL, 0.55mmol) was added.

After wanning again to room temperature for 30min, the reaction was complete. Diluted with EtOAc and extracted with water and brine. Dried over Na2SC>4, filtered and concentrated under vacuum. Purification by silica gel column chromatography eluting with 10-100 % EtOAc in hexane gave the title compound as a light yellow oil (144mg, 92%).

[00885] Part D. Preparation of 1 -(3 -tert-butyl-4-methoxy-5-(naphthalen-2-yl)phenyl)pyrimidine-2,4(lH,3H)-dione.

[00886] A suspension of the product from Part C (144mg, 0.33mmol) in 2:2:1 ethanol-water-THF (15mL) was treated with IN sulfuric acid solution (3.0mL) followed by warming at 100°C for 24h. Cooled and diluted with EtOAc and extracted with water and brine. Dried over Na2S04, filtered and concentrated under vacuum. Purification by silica gel column chromatography eluting with 10-100% EtOAc in hexane gave the title compound as a white solid (62mg, 47 %). *H NMR (300 MHz, DMSO-d6): δ 11.42 (s, 1 H), 8.08 (s, 1 H), 7.90 - 8.04 (m, 3 H), 7.81 (d, J=7.72 Hz, 1 H), 7.72 (d, J=8.46 Hz, 1 H), 7.56 (dd, J=6.25, 3.31 Hz, 2 H), 7.39 (d, J=2.57 Hz, 1 H), 7.33 (d, J=2.57 Hz, 1 H), 5.65 (d, J=7.72 Hz, 1 H), 3.24 (s, 3 H), 1.43 (s, 9 H). MS +ESI m/z (rel abundance): 401 (100, M+H), 418 (30, M+NH4).

[00887] Example 17. Preparation of l-(3-tert-butyl-4-methoxy-5-(6-methoxynaphthalen-2-yl)phenyl) pyrimidine-2,4(1H,3 H)-dione (compound IB-LO-2.2). A-998288.0 [00888] Part A. Preparation oftert-butyl 3-tert-butyl-4-methoxy-5-(6-methoxynaphthalen-2-yl)phenyl carbamate.

[00889] The product from Example 3, Part H (158mg, 0.44mmol) was reacted with 6-methoxy-naphthalen-2-ylboronic acid (107mg, 0.52mmol) according to the procedures from Example 16, Part A 194 2014280939 24 Dec 2014 to provide the title compound as a white solid (92mg, 47 %).

[00890] Part B. Preparation of 3-tert-butyl-4-methoxy-5-(6-methoxynaphthalen-2-yl)aniline.

[00891] The product from Part A (92mg, 0.21mmol) was reacted according to the procedures from Example 16, Part B to provide the title compound as a pink solid (71 mg, 99%).

[00892] Part C. Preparation of (E)-N-(3-tert-butyl-4-methoxy-5-(6-methoxynaphthalen-2-yl)phenyl carbamoyl)-3 -methoxyacrylamide.

[00893] The product from Part B (71 mg, 0.21 mmol) was reacted according to the procedures from Example 16, Part C to provide the title compound as a buff-colored solid (58mg, 59 %).

[00894] Part D. Preparation of l-(3-tert-butyl-4-methoxy-5-(6-methoxynaphthalen-2-yl)phenyl) pyrimidine-2,4( 1 H,3 H)-dione.

[00895] A solution of the product from Part C (58mg, 0.13mmol) in 2:1:1 ethanol-THF-water (4.0mL) was treated with 1.0M sulfuric acid solution (3.0mL) followed by warming at 95°C for 24h. Cooled and diluted with EtOAc. Extracted with water and brine. Dried over Na?S04, filtered and concentrated under vacuum. Purification by silica gel column chromatography eluting with 10-100 % EtOAc in hexanes gave the product as a faint pink solid (28mg, 52%). 'H NMR (300 MHz, DMSO-t&amp;): δ 11.41 (s, 1 H), 8.00 (s, 1 H), 7.91 (dd, J-8.64, 4.60 Hz, 2 H), 7.80 (d, J=7.72 Hz, 1 H), 7.67 (d, J=8.82 Hz, 1 H), 7.34 -7.47 (m, 2 H), 7.21 - 7.32 (m, 1 H), 7.20 (dd, J=9.01, 2.39 Hz, 1 H), 5.65 (d, 3=7.72 Hz, 1 H), 3.90 (s, 3 H), 3.24 (s, 3 H), 1.42 (s, 9 H). MS +ESI m/z (rel abundance): 431 (100, M+H), 448 (45, M+NH4).

[00896]Example 18. Preparation ofN-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl) phenyl)naphthalen-2-yl)methanesu lfonamide (compound ÏB-L0-2.8).

H

H N, Λ o o [00897] Part A. Preparation of 2-bromo-4-tert-butyl-6-nitroaniline.

[00898] A suspension of 4-tert-butyl-2-nitroaniline (1.033g, 5.32mmol) in glacial acetic acid (7.8mL) was warmed with a heat gun until all solids had dissolved. The solution was then cooled and treated portion wise with pyridinium hydrobromide perbromide (1,96g, 6.12mmol). After addition, the solution was stirred at room temperature for lh. The mixture was added to water (50mL) and treated with a small amount of sodium sulfite. After stirring for 30min, the precipitate was collected by filtration. The solid obtained was washed with water and dissolved in EtOAc. Washed with water and brine. Dried over Na2S04, filtered and concentrated under vacuum to provide the title compound as a yellow-orange solid 195 2014280939 24 Dec 2014 (1.36g, 94%).

[00899] Part B. Preparation of l-bromo-3-tert-butyl-5-nitrobenzene.

[00900] A solution oftert-butyl nitrite (300pL of 90%, 261 mg, 2.27mmol) in dry DMF (4mL) was wanned at 50°C and was treated with a solution of the product from Part A (414mg, 1.52mmol) in DMF (3.5mL). After a few minutes stirring, the solution began to bubble vigorously. After warming at 50°C for lh, additional (300μΕ) tert-hutyl nitrite was added followed by warming at 50°C for lh. After 18h at room temperature, tert-butyl nitrite (1.2mL) was added and the mixture warmed at 50°C for 2h. Cooled and diluted with EtOAc. Washed with water and brine. Dried over Na2S04, filtered and concentrated under vacuum. Purification by silica gel column chromatography eluting with 5-40 % ethyl acetate in hexanes gave the title compound as a light yellow oil (159ing, 41 %).

[00901] Part C. Preparation of 3-bromo-5-tert-butylaniline. ]00902] A solution of the product from Part B (770mg, 2.98mmol) in 3:3:1 methanol-water-THF (14.9mL) was treated with ammonium chloride (239mg, 4.47mmol) and iron powder (833mg, 14.92mmol) followed by warming at reflux for 8h. Diluted with EtOAc and water and filtered through celite. The filtrate was extracted with water and brine. Dried over Na2S04, filtered and concentrated under vacuum to give the title compound as a yellow oil.

[00903] Part D. Preparation of (E)-N-(3-bromo-5-tert-butylphenylcarbamoyl)-3-methoxy acrylamide.

[00904] A solution of the product from Part C (681mg, 2.99mmol) in dry DMF (23mL) at -30°C was treated drop wise with a 0.4M solution of (E)-3-methoxyacryloyl isocyanate in benzene (14.9mL, 5.96mmol). The solution was stirred at -30°C for 30min followed by warming gradually to room temperature, and then stirred for 18h. Diluted with EtOAc and washed with water and brine. Dried over Na2S04, filtered and concentrated under vacuum to afford a yellow solid, which was triturated with ether-hexanes and collected by filtration. Dried under vacuum to give the title compound as a light brown powder. (951 mg, 90 %).

[00905] Part E. Preparation of l-(3-bromo-5-tert-butylphenyl)pyrimidine-2,4( 1 H,3H)-dione.

[00906] A suspension of the product from Part D (951mg, 2.68mmol) in ethanol (25mL) was treated with a solution of concentrated sulfuric acid (2.60mL, 4.78g, 18.22mmol) in water (13.4mL) followed by warming at 100°C for lh. Cooled and concentrated to remove ethanol. Cooled to 0°C and the precipitate was collected by filtration and washed with water. Dried under vacuum to give the title compound as an orange solid (619mg, 72 %).

[00907] Part F. Preparation ofN-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)phenyl) naphthalen-2-yl)methanesulfonamide.

[00908] In a microwave tube, a suspension of the product from Part E (104mg, 0.32mmol), the product from Example 4A, Part B (134mg, 0.39mmol), and 1.0M sodium carbonate solution (386pL, 0.39mmol) 196 2014280939 24 Dec 2014 in 1:1 ethanol-toluene (2.1 mL) was degassed by nitrogen sparge for 1 Omin. The solution was treated with l,r-bis(di-tert-butylphosphino)ferrocene-palladium (II) dichloride (20mg, 0.031mmol) and degassing was continued for another 5min. The mixture was heated at 100°C in the microwave for 30min. Diluted with EtOAc and washed with water and brine. Dried over Na2S04 and treated with (3-mercapto propyl) silica gel for 30min. Filtered and concentrated under vacuum to afford an amber solid, which was triturated with ether-hexanes. Collected the solid by filtration and dried under vacuum to provide the title compound (81 mg, 54 %). 'llNMR(300 MHz, DMSO-cfe): δ 11.46 (s, 1 H) 10.05 (s, 1 H), 8.25 (s, 1 H) 7.98 (dd, 1=11.58, 9.01 Hz, 1 H) 7.86 - 7.93 (m, 1 H) 7.78 - 7.85 (m, 2 H) 7.72 (s, 1 H) 7.67 (s, 1 H) 7.31 - 7.51 (m, 2 H) 5.70 (dd, J=7.72,2.21 Hz, 1 H) 3.08 (s, 3 Η) 1.39 (s, 9 H). (00909]Example 19. Preparation of (E)-N'-(5-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)phenyl)-2,3-dihydro-1 H-inden-l-ylidene)methanesulfonohydrazide (compound IB-LO-2.7).

[00910] Part A. Preparation of 1 -(3-tert-butyl-5-(l-oxo-2,3-dihydro-1 H-inden-5-yI)phenyl) pyrimidine-2, 4(lH,3H)-dione.

[00911] In a microwave tube, a suspension of the product from Example 18, Part E, the product from Example 6, Part A (144mg, 0.56mmol), 1.0M sodium carbonate solution (557pL, 0.56mmol) in 1:1 ethanol-toluene (3.0mL) was degassed by nitrogen sparge for 15min. l,l'-Bis(di-t-butylphosphino) ferrocene palladium (II) chloride complex (15mg, 0.023mmol) was added and degassing was continued for an additional 5 min, The tube was sealed and the mixture was heated at 100°C in the microwave for 30 min. Diluted with EtOAc and water. Washed with 1M citric acid solution, water, and brine. The organic was stirred with (3-mercaptopropyl) silica gel for lh. Dried over Na2S04, filtered and concentrated under vacuum. Purification by silica gel column chromatography eluting with 10-100 % EtOAc in hexanes gave the title compound as an off-white solid (86mg, 50 %).

[00912] Part B. Preparation of (E)-N'-(5-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl) phenyl)-2,3-dihydro-lH-inden-l-ylidene)methanesulfonohydrazide.

[00913] The product from Part A (80mg, 0.21mmol) was reacted according to the procedures from Example 6, Part C to provide the title compound as a white solid (73mg, 73 %). 'H NMR (300 MHz, DMSO-i/«): δ 11.44 (s, 1 H) 9.92 (s, 1 H) 7.64 - 7.98 (m, 5 H) 7.57 (s, 1 H) 7.45 (s, 1 H) 5.68 (d, J=7.72 197 2014280939 24 Dec 2014

Hz, 1 H) 3.00 - 3.20 (m, 5 H) 2.85 (d, 3=12.50 Hz, 2 H) 1.36 (s, 9 H). MS +ESI m/z (rel abundance): 467 (100, M+H).

[00914] Example 20. Preparation of 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxy-N-(4-(methylsulfonamido)phenyl)benzamide (compound 1A-L3-1.6).

H

[00915] Part A. Preparation of methyl 3-tert-buty l-2-hydroxy-5-nitrobenzoate.

[009161 Methyl 3,5-di-tert-butyl-2-hydroxybenzoate (28.66g, 108.4mmol) was dissolved with stirring in 430mL glacial acetic acid and the resulting mixture was treated drop wise with fuming nitric acid (90%. 179.26mL). When the addition was complete, the resulting mixture was stirred for 2.5h. The reaction mixture was poured into a 2.0L of crushed ice and allowed to stand 30min. Afterwards, 1.0L of water was added and the ice water mixture was allowed to melt. The mixture was then filtered, washed with water and dried to provide the title compound (24.57g, 89%).

[00917] Part B. Preparation of methyl 5-amino-3-tert-butyl-2-hydroxybenzoate.

[00918] The product of Part A (0.43g, 1,70mmol) was treated with a catalytic amount of Pd/C in THF (10ml,) under hydrogen balloon for 3h. The flask was purged with nitrogen and the mixture was filtered, concentrated, and purified by column chromatography on silica gel, eluting with 50% hexane/dichloromethane, followed by dichloromethane to yield 0.37g (98%).

[00919] Part C. Preparation of methyl 5-(3-amino-3-oxopropylamino)-3-tert-butyl-2-hydroxy benzoate.

[00920] The product of Part B (0.37g, 1.66mmol) and acrylic acid (0,12uL, 1.74mmol) were combined in toluene (lOmL) and heated at reflux for 20h. The solution was concentrated to dryness.

[00921] Part D. Preparation of methyl 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin- l(2H)-y 1)-2-hydroxybenzoate.

[00922] The product of Part C was dissolved in glacial acetic acid (5mL) and treated with urea (0.24g, 4.0mmol) at 120°C for 3h. The solution was diluted with cold water, extracted into ethyl acetate, concentrated, and purified by column chromatography on silica gel, eluting with 1%, then 2%, then 4% methanol/diehloro- methane to give both product (0.25g, 46%) and open dihydrouracil (0.112g, 20%).

[00923] Part E. Preparation of 3-tert-butyl-5-(l-(2-carboxyethyl)ureido)-2-hydroxybenzoic acid.

[00924] The products from Part D were dissolved in methanol (6mL) and 1M sodium hydroxide solution was added (15mL). After 20h, the solution was adjusted to pH2 with concentrated hydrochloric acid and 198 2014280939 24 Dec 2014 extracted into ethyl acetate, dried over sodium sulfate, and concentrated to give 0.303g (89%).

[00925] Part F. Preparation of 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxy-benzoic acid.

[00926] The product from Part E (0.303g, 0.93mmol) was taken up into 7mL of concentrated hydrochloric acid and heated in an open flask at 120°C for lh, during which time the excess acid evaporated off to leave dry product 0.20g (70%).

[00927] Part G. Preparation of 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxy-N-(4~ (methylsulfonamido)phenyl)benzamide.

[00928] The product from Part F (0.13g, 0.42mmol) was heated with thionyl chloride (3mL) at 90°C for 1.5h in an open flask leaving dry acid chloride, which was taken up in dioxane (4mL). N-(4-amino-phenyl)methanesulfonamide.HCl (0.070mg, 0.31mmol) was added and the solution was heated at90°C for lh. The mixture was concentrated and then triturated with dichloromethane, filtered, and dried to give 0.071 mg (48%) of the title compound. 1H NMR (300 MHz, DMSO-D6) δ ppm 1.39 (s, 9 H), 2.73 (t, J=6.62 Hz, 2 H), 2.99 (s, 3H), 3.78 (t, 1=6.62 Hz, 2 H), 7.24 (d, J=8.82 Hz, 2 H), 7.40 (d, J=2.21 Hz, 1 H), 7.60 (d, J=9.19 Hz, 2 H), 7.89 (d, J=2.21 Hz, 1 H), 9.74 (s, 1 H), 10.39 (s, 1 H), 10.44 (s, 1 H),13.30 (s, 1 H).

[00929] Example 21. Preparation of 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxy-N-(4-(2-methoxyethylsulfonamido)phenyl)benzamide (compound IA-L3-1.8).

H

[00930] Part A. Preparation of tert-butyl 4-(vinylsulfonamido)phenylcarbamate.

[00931] A solution of tert-butyl 4-aminophenylcarbamate (2.63g, 12.63mmol) and triethylamine (7.04mL, 50.5 lmmol) were combined in dichloromethane (50mL) and cooled in an ice bath. After drop wise addition of 2-chloroethanesulfonyl chloride (1.45mL, 13.9mmol), the solution was stirred at ambient temperature for 4h then diluted with 0.5M HC1 and extracted into dichloromethane. The product was purified by column chromatography on silica gel, eluting with 1% methanol/dichloromethane to give 2.48g (66%).

[00932] Part B. Preparation of tert-butyl 4-(2-methoxyethylsulfonamido)phenylcarbamate.

[00933] The product from Part A (0.70g, 2.35mmol) was heated at 60°C in a sealed tube with lOmL 199 2014280939 24 Dec 2014 methanol and 5mL of 25% weight sodium methoxide in methanol for 16h. The solution was diluted with water and adjusted to pH 6 with 1M HC1, then extracted into dichloromethane and concentrated to give 0.582g (75%).

[00934] Part C. Preparation of N-(4-aminophenyl)-2-methoxyethanesulfonamide.

[00935] The product from Part B (0.582g, 1,76mmol) was taken up in 15mL of 4M HC1 in dioxane and stirred at ambient temperature for 20h. The solution was diluted with dichloromethane and the solid product was filtered off and dried to give 0.395g (84%).

[00936] Part D. Preparation of 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxy-N-(4-(2-methoxyethylsulfonamido)phenyl)benzamide.

[00937] The product from Example 20, Part F (0.05g, 0.163mmol) was treated with thionyl chloride (0.5mL) and the product from Part C (0.038g, 0.163mmol) as in Example 20, Part G to give 0.038g (45%) of the title compound. lH NMR (300 MHz, DMSO-D6): δ ppm 1.39 (s, 9 H), 2.73 (t, J=6.62 Hz, 2 H), 3.20 (s, 3 H), 3.33 - 3.42 (m, 2 H), 3.67 (t, J=6,25 Hz, 2 H), 3.78 (t, J=6.62 Hz, 2 H), 7.23 (d, J=9.19 Hz, 2 IT), 7.40 (d, J=2.21 Hz, 1 H), 7.58 (d, J=9.19 Hz, 2 H), 7.89 (d, J=2.21 Hz, 1 H), 9.80 (s, 1 H), 10.39 (s, 1 H), 10.44 (s, 1 H), 13.30 (s, 1 H).

[00938] Example 22. Preparation of 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy-N-(4-methylsulfonamido)phenyl)benzamide (compound IA-L3-1.51).

[00939] Part A. Preparation of methyl 3-tert-butyl-2-hydroxy-5-nitrobenzoate.

[00940] Methyl 3,5-di-tert-butyl-2-hydroxybenzoate (28.66g, 108.4mmol) was dissolved with stirring in 430mL, glacial acetic acid and the resulting mixture was treated drop wise with fuming nitric acid (90%, 179.26mL). When the addition was complete, the resulting mixture was stirred for 2.5h. The reaction mixture was poured into a 2.0L of crushed ice and allowed to stand 30min. Afterwards, 1.0L of water was added and the ice water mixture was allowed to melt. The mixture was then filtered, washed with water and dried to provide the title compound (24.57g, 89%).

[00941] Part B. Preparation of methyl 3-tert-butyl-2-methoxy-5-nitrobenzoate.

[00942] The product from Part A (11.41g, 45.0mmol), potassium carbonate (9.34g, 67.6mmol), acetone (200mL), and dimethyl sulfate (6.46g, 67.6mmol) were added together. The resultant mixture was then heated to reflux for 16h. The mixture was then filtered and the solid was washed with ethyl acetate. The 200 2014280939 24 Dec 2014 resulting organic liquid was then concentrated under vacuum to an oil and redissolved in ethyl acetate (600mL). The organic solution was then washed with water, dried, filtered and concentrated under vacuum to an oil that was then subjected to purification via column chromatography (gradient of 5% to 40% EtOAc/Hexanes) to yield the title compound as an oil (10.42, 87%).

[00943] Part C. Preparation of methyl 5-amino-3-tert-butyl-2-methoxybenzoate.

[00944] The product from PartB (10.42g, 39.0mmol), iron powder (325mesh, 10.89g, 195mmol), ammonium chloride (3.13g, 58.5mmol), water (30mL), and methanol (150mL) were added together. The resultant mixture was then refluxed for lh. The mixture was then cooled to room temperature, filtered through celite, and the celite washed with methanol. The filtrate was then concentrated under vacuum and dissolved in ethyl acetate (600mL). The resultant solution was then washed with water and brine.

The organic extract was then dried, filtered and concentrated under vacuum to yield the title compound as an oil (9.25g, 100%).

[00945] Part D. Preparation of 3-(3-tert-butyl-4-methoxy-5-(methoxycarbonyl)phenylamino) propanoic acid.

[00946] The product from Part C (16.44g, 69.3mmol) was dissolved in toluene (200mL). This mixture was heated to reflux and acrylic acid added over time (ImL of acrylic acid added every 3h, 5.23mL total, 76.2mmol). The resulting mixture was refluxed for 24h. The mixture was cooled and concentrated to dryness under vacuum to yield the crude title compound as an oil that was used directly in the next reaction.

[00947] Part E. Preparation of methyl 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxybenzoate.

[00948] The product from Part D (21.43g, 69.3mmol), urea (10.4g, 173mmol) and acetic acid (glacial, 200mL) were added together. The mixture was then heated to 120°C for 18.5h followed by concentration under vacuum to dryness to an oil. To this oil was added methanol (13mL), and ethyl acetate (350mL). The resultant mixture was allowed to stand for 24-48h whereby a precipitate formed. The resulting solid was filtered off and washed with a small amount of methanol (lOmL) and then air dried to yield the title compound as a solid (15.26g, 66%).

[00949] Part F. Preparation of 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidm-l(2H)-yI)-2-methoxy benzoic acid.

[00950] The product from Part E (4.52g, 13.52mmol), methanol (70mL), and tetrahydrofuran (70mL) were added together. The mixture was then stirred vigorously until a homogenous solution resulted.

Once homogenous, a solution of aqueous sodium hydroxide (1.0M, 68mL) was added. The mixture was then stirred for 12h, the mixture was then concentrated under vacuum to remove the organic solvent, followed by the addition of aqueous hydrochloric acid (1.0M, 80mL) that resulted in solid formation. The 201 2014280939 24 Dec 2014 mixture was then concentrated under vacuum. To this material was added hydrochloric acid (12M, lOOmL) and the resultant material heated to 100°C for 1.5h. The reaction was then cooled and water added. The resulting solid was filtered, washed with water, and dried to yield the title compound as a solid (3.55g, 82%).

[00951] Part G. Preparation of 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-] (2H)-yl)-2methoxybenzoyl chloride.

[00952] The product from Part F (2H)-yl)-2-methoxybenzoic acid (4.07g, 12.71mmol) and thionyl chloride (40.82mL, 559mmol) were added together. The mixture was then refluxed for 2h, followed by concentration under vacuum to provide the product as a light-yellow solid.

[00953] Part H. Preparation of 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2PI)-yl)-2-methoxy-N-(4-methylsulfonamido)phenyl)benzamide.

[00954] The product prepared in Part G (0.55g, 1.71mmole) was dissolved in CPpCf (35ml) and added drop wise to a suspension in CH2CI2 (40ml) containing N-(4-aminophenyI)mcthanesulfonamide hydrochloride salt (0.38g, 1.7 Immole) and pyridine (0.41ml, 5.1mmole). The reaction mixture was stirred 18h at room temperature. The reaction mixture was filtered and diluted with 400ml CH2CI2. The organic layer was washed with IN H3P04, 10% NaHC03 and 10% NaCl and dried over anhydrous solid sodium sulfate. The drying agent was filtered and the organic layer was evaporated in vacuo leaving the title compound as a crème-colored solid (474mg, 57%). 'H NMR (300 MHz, DMSO-D6) δ ppm 1.37 (s, 9 H) 2.71 (t, J= 6.62 Hz, 2 H) 2.95 (s, 3 H) 3.77 (s, 3 H) 3.80 (d, 2 H) 7.20 (d, J=9.19 Hz, 2 PI) 7.28 (d, J=2.57 Hz, 1 H) 7.33 (d, J=2.94 Hz, 1 H) 7.69 (d, J=9.19 Hz, 2 H) 9.59 (s, 1 H) 10.35 (s, 1 PI) 10.38 (s, 1 H).

[00955] Example 23. Preparation of 4-(3-tert-butyl-5-(2,4-dioxotetraliydropyrimidin-l(2H)-y 1)-2-hydroxybenzamido)phenyl methanesulfonate (compound IA-L3-1.19).

[00956] Part A. Preparation of 4-(tert-butoxycarbonylamino)phenyl methanesulfonate.

[00957] Tert-butyl-4-hydroxyphenylcarbamate (l.Og, 4.78mmol) and triethylamine (0.80mL, 5.73mmol) were combined in dichloromethane (50mL), cooled in an ice bath and treated with methanesulfonyl chloride (0.41mL, 5.26mmol). The solution was stirred at ambient temperature for 2h, then was washed with 1M HC1, dried over sodium sulfate, filtered, and concentrated to give 1.2g (87%). 202 2014280939 24 Dec 2014 |00958]Part B. Preparation of 4-aminophenyl methanesulfonate hydrochloride.

[00959] The product from Part A (1.2g, 4.18mmol) was treated with 4 M HC1 in dioxane (lOmL) at ambient temperature and stirred for 18h. The mixture was concentrated and the solid was triturated with dichloromethane, filtered, and dried to give 0.855g (92%), [00960] Part C. Preparation of 4-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxy benzamido)phenyl methanesulfonate.

[00961] The product from Example 20, Part F (0.055g, 0.18mmol) was treated with thionyl chloride (0.4mL, 5.4mmol) at 80°C for 35min then concentrated to dryness. This acid chloride was dissolved in dioxane (2mL) and treated with the product from Part B (0.060g, 0.27mmol) and pyridine (0.037mL, 0.45mmol). The resulting mixture was stirred at 80°C for Ih, diluted with 1M HC1, extracted into ethyl acetate, concentrated and purified by column chromatography on silica gel, eluting with dichloromethane followed by 2% methanol/dichloromethane to give 0.05 5g (64%) of the title compound. 'H NMR (300 MHz, DMSO-D6) δ ppm 1.39 (s, 9 H), 2.74 (t, J=6.62 Hz, 2 H) 3.40 (s, 3 H), 3.79 (t, J=6.80 Hz, 2 H), 7.36 - 7.45 (m, 3 H) 7.76 (d, J=9.19 Hz, 2 H), 7.90 (d, 1=2.21 Hz, 1 H), 10.40 (s, 1 H), 10.58 (s, 1 H) 13.13 (s,lH).

[00962] Example 24. Preparation of 3-tert-huty 1 -5-(2,4-dioxotetrahydropyrimidin-1 (2/7)-yl)-2-mcthoxy-A-methyl-iV-(4-(methylsulfonamido)phenyl)benzamide (compound 1A-L3-1.27).

[00963] Part A. Preparation of iert-butyl 4-aminophenyl(methyI)carbamate.

[00964] A mixture of iV-methyl-4-nitroaniline (l.OOg, 6.57mmol), di-/er/-butyl dicarbonate (2,51g, 11.50mmol), and DMAP (40mg, O.33mmol) in dichloromethane (35mL) was stirred at reflux for 2h. The reaction mixture was washed with water (20mL), dried over Na2SC>4, filtered and concentrated under vacuum. The residue was dissolved in a mixture of THF (12mL) and methanol (12mL). To the resulting solution was added iron powder (1.50g, 27.0mmol) and a solution of ammonium chloride (0.54g, 10.1 lmmol) in water (5mL). The mixture was stirred at 70°C for 3h, cooled to room temperature and filtered through celite, and concentrated under vacuum. The residue was azeotropically dried using toluene (3X) and then triturated with ether to give a solid that was removed by filtration. The filtrate was concentrated under vacuum to give the title compound (1.45g, 99%). 203 2014280939 24 Dec 2014 100965] Part B. Preparation of AA(4-(methylamino)phenyl)methanesulfonamide hydrochloride.

[00966] The product prepared in Part A (1.45g, 6.52mmol) was dissolved in anhydrous dichloromethane (25mL) and treated with pyridine (1.32mL, 16.3 lmmol) and methanesulfonyl chloride (0.57mL, 7.18mmol). The resulting solution was stirred at room temperature for 3h, and then poured into 0.5M aq. HC1 (25mL). The layers were separated and the aqueous phase was washed with dichloromethane (2 x 25mL). The combined organic layers were dried over NaïSCh, filtered and concentrated under vacuum. Column chromatography on silica gel using 1% methanol in chloroform as the eluent gave tert-butyl methyl(4-(methylsulfonamido)phenyl) carbamate (1.3 lg, 67%), which was dissolved in 4N HC1 in 1,4-dioxane (20mL). The resulting solution was stirred at 40°C for lh and concentrated under vacuum. The residue was triturated with dichloromethane to give the title compound as a solid that was collected by filtration and dried under vacuum (0.99 g, 96%).

[00967] Part C. Preparation of 3 -ier/-butyl-5-(2,4-dioxotetrahydropyrimidin-1 (2//)-yl)-2-methoxy-JV-methyl-iV-(4-(methylsulfonamido)phenyl)benzamide.

[00968] The product prepared in Example 22, Part G (40mg, 0.13mmol) and thionyl chloride (0.3mL, 4mmol) were refluxed for 30min, followed by concentration under vacuum. The residue was dissolved in anhydrous JV.A-dimethylacetamide (2mL), and to the resulting solution was added the product from Part B (30mg, 0.13mmol) and pyridine (0.025mL, 0.3 lmmol). The mixture was stirred at 80°C for 30min, and was partitioned between IN HC1 (5mL) and ethyl acetate (3 x 5mL). The organic extracts were combined, dried over Na2S04, filtered and concentrated under vacuum to yield a crude product that was purified by column chromatography on silica gel eluting with 19:1 MeOH:CHCl3 to give the title compound as a colorless solid (45mg, 72%). lH NMR (500 MHz, DMSO-D6) δ ppm 1.07 (s, 9 H), 2.69 (t, 7=6.1 Hz, 2 H), 2.83 (s, 3 H) 3.33 - 3.38 (m, 5 H) 3.73 (s, 3 H) 6.92 (d,7=8.5 Hz, 2 H) 7.01 (d, 7=9.2 Hz, 2 H) 7.06 (d, 7=2.4 Hz, 1 H) 7.12 (d, 7=2.4 Hz, 1 H) 9.52 - 9.73 (m, 1 H) 10.28 (s, 1 H). 204 2014280939 24 Dec 2014 [00969] Example 25. Preparation of (N-(4-(3-tert-butyl-5-(3-(butyryloxymethy 1)-2,4-dioxotetrahydro pyrimidin-l(2H)-yl)-2-methoxybenzamido)phenyl)methylsulfonamido)methyl butyrate (compound IA-L3-1.88).

o Ί o

O

[00970] The product from Example 22, Part G (0.098g, 0.20mmole) was dissolved in DMSO (2ml) and treated with potassium carbonate (0.166g, 1.20mmole) and chloromethyl butyrate (0.41 lg, 3.0mmol).

The mixture was stirred 20h at room temperature. The reaction mixture was partitioned with ethyl acetate and water. The organic layer was washed with brine and dried over anhydrous solid sodium sulfate. The drying agent was filtered and the solvent evaporated under vacuum. The residue was purified with silica gel eluting with ethyl acetate/hexane (10% to 80%) to give two major fractions. The first fraction was purified with silica gel eluting with methanol/dichloromethane (1% to 3%) to give the title compound as a foam (0.014, 10%). 'll NMR (300 MHz, DMSO-D6) δ ppm 0.88 (m, 6 H) 1.38 (s, 9 H) 1.55 (m, 4 H) 2.26 (t, J=7.17 IIz, 2 II) 2.39 (t, J=7.17 Hz, 2 H) 2.95 (t, J=6.62 Hz, 2 H) 3.14 (s, 3 H) 3.77 (s, 3 H) 3.81 (t, )=6.62 Hz, 2 IT) 5.57 (s, 2 IT) 5.68 (s, 2 H) 7.35 (d, J=2.57 Hz, 1 H) 7.38 (d, J=2.94 Hz, 1 H) 7.42 (d, J=8.82 Hz, 2 H) 7.79 (d, J=8.82 Hz, 2 H) 10.60 (s, 1 H).

[00971]Example 26. Preparation of (N-(4-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxybenzamido)phenyl)methylsulfonamido)methyl butyrate (compound IA-L3-1.64).

O O " 205 2014280939 24 Dec 2014 [00972] The product from Example 22, Part G (0.098g, 0.20mmole) was dissolved in DMSO (1ml) and treated with Cesium carbonate (0.209g, 0.64mmole) and bromomethyl acetate (0.123g, 0.80mmol). The mixture was stirred 4h at room temperature. 'The reaction mixture was partitioned with ethyl acetate and water. The organic layer was washed with brine and dried over anhydrous solid sodium sulfate. The drying agent was filtered and the solvent evaporated under vacuum. The residue was purified by HTP group by preparative HPLC on a Waters Nova-Pak® HR Cl8 6um 60A Prep-Pak® cartridge column (40mm x 100mm). A gradient of acetonitrile (A) and lOmM ammonium acetate in water (B) was used, at a flow rate of 70mL/min (0-0.5min 10% A, 0.5-12.Omin linear gradient 10-95% A, 12,0-15.0min 95% A, 15.0-17.0min linear gradient 95-10% A) to give the title compound as a white solid (0.034g, 30%). m.p. 229-230°C. ’H NMR (300 MHz, DMSO-D6) δ ppm 1.38 (s, 9 H) 2.11 (s, 3 H) 2.72 (t, J=6.80 Hz, 2 H) 3.15 (s, 3 H) 3.78 (m, 5 H) 5.55 (s, 2 H) 7.30 (d, J=2.57 Hz, 1 H) 7.35 (d, J=2.57 Hz, 1 H) 7.42 (d, J=9.19 Hz, 2 H) 7.79 (d, J=8.82 Hz, 2 H) 10.36 (s, 1 H) 10.58 (s, 1 H).

[00973] Example 27. Preparation of A-(3-/e^bmyl-5-(2:4-dioxotetrahydropynrnidin-l(2/7)-y 1)-2-methoxyphenyl)-4-(methylsulfonamido)benzamide (compound IA-L4-1.9).

O

[00974] Part A. Preparation of 2-fórt-butyl-lmethoxy-4-nitrobenzene.

[00975] A 1:1 mixture of AcOH and fuming HN03 (0.6mL) was slowly added to a solution of 2-tert-butylphenol (1,0g, 6.6mmol) in cyclohexane (3mL) at 0°C. The resulting dark mixture was stirred at 0°C for lh, followed by the addition of hexanes (5mL). The resulting solid was collected by filtration and washed with hexanes to give a light greenish solid (0.37g, 29%), The solid was dissolved in acetone (10ml), and to the resulting solution was added K2CO3 (0.3g, 2.2mmol), followed by the drop wise addition of Me2S04 (0.27mL, 2.8mmol). The resulting mixture was stirred at room temperature overnight, and then poured into IN HC1 (20mL). The mixture was extracted with EtOAc (3x 20mL), dried over Na2SC>4, filtered and concentrated to provide the title compound as an oil (0.4g, quant.).

[00976] Part B. Preparation of l-(3-/ert-butyl-4-methoxyphenyl)dihydropyrimidine-2,4(7JT,377)-dione.

[00977] The product described in Part A was dissolved (0.4g, 1,9mmol) in EtOAc (lOmL) and treated with 10% Pd on carbon (50mg). The mixture was stirred at ambient temperature under latm H2 overnight. The mixture was filtered through celite and concentrated under vacuum to give a crude 206 2014280939 24 Dec 2014 product that was purified on silica gel. The product was eluted using 1:1 EtOAc:hexanes, and isolated as an oil (0.23g, 68%). Acrylic acid (O.lmL, 1.46mmol) and toluene (lOmL) were added to the isolated oil and the resulting mixture was heated at 100°C overnight, and then concentrated in vacuo to give a dark oil. The oil was treated with AcOH (5mL) and urea (0.2g, 3,3mmol), and the mixture was heated at 120°C for 6h. The mixture was cooled to ambient temperature, poured into water (20mL) and extracted with EtOAc (3 x lOmL). The combined organic layers were dried over Na2S04, filtered and concentrated under vacuum to give a crude product that was purified by column chromatography on silica gel using 1:1 EtOAc:hexanes. The title compound was obtained as a colorless solid (0.144g, 41%).

[00978] Part C. Preparation of l-(3-iert-butyl-4-hydroxy-5-nitrophenyl)dihydropyrimidine-2,4(1H,3H)-dione.

[00979] The product prepared in Part B (l.OOg, 3.62mmol) was dissolved in CH2Cl2(25mL) at 0°C and treated with a 1M solution of BBr3 in CH2C12 (18mL, 18mmol). The mixture was stirred at reflux overnight and poured into water (50mL). The mixture was extracted with 3:1 CH2Cl2:2-PrOH (2 x 50mL), and the combined extracts were dried overmgS04, filtered and concentrated under vacuum. The crude product was purified by column chromatography on silica using 2:1 EtOAc:hexanes to elute the product, obtained as a solid (0.60g, 63%). The solid was suspended in AcOH (20mL), to which was added fuming HNOj (0.105mL). The resulting solution was stirred at room temperature lh and poured into ice water (1 OOmL). The mixture was extracted with 3:1 CH2Cl2:2-PrOH (2 x 50mL), and the combined extracts were dried overmgS04, filtered and concentrated under vacuum. The residue was triturated with ether to give a solid that was collected by filtration (0.40 g, 57%).

[00980] Part D. Preparation of l-(3-amino-5-/ert-butyl-4-methoxyphenyl)dihydropyrimidine-2,4(1 H,3H)-diom.

[00981] The product prepared in Part C (0,31g, 1.01 mmol) was dissolved in 1:1 THF:MeOH (50mL) and treated with a 2M solution of trimethylsiiyldiazomethane in THF (1.5mL, 3.0mmol). The resulting solution was stirred at ambient temperature overnight, and concentrated under vacuum. The crude product was purified by column chromatography on silica gel using 1:1 EtOAcrhexanes and a colorless solid (0.235g, 72%) was obtained. The solid was dissolved in 1:1 CH2CI2:MeOH (50mL), treated with 10% Pd/C (25mg), and the mixture was stirred at ambient temperature under latm H2 for 2h. The mixture was filtered through celite and concentrated under vacuum to obtain the title compound (0.215g, quant.).

[00982] Part E. Preparation of A-(3-/er/~buty 1-5-(2,4-dioxotetrahydropyrimidin-l(2//)-yl)-2-methoxyphenyl)-4-nitrobenzamide.

[00983] The product obtained in Part D (0.215g, 0.74mmol) was dissolved in anhydrous CH2CI2 (50mL) and treated with 4-nitrobenzoyl chloride (0.164g, 0.88mmol) and pyridine (0.07mL, 0.88mmol). The resulting mixture was stirred at ambient temperature overnight, washed with water (50mL), dried over 207 2014280939 24 Dec 2014

Na2SC>4, filtered and concentrated under vacuum. The crude product was purified by column chromatography on silica gel using 1:1 EtOAc:hexanes to give the title compound (0.26g, 80%).

[00984] Part F. Preparation of N-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l (2H)-yl)-2-methoxyphenyl)-4-(methylsulfonamido)benzamide.

[00985] The product obtained in Part E (0.26g, 0.59mmol) was dissolved in a 2:1 mixture of CH2Cl2:MeOH (6mL), treated with 10% Pd on carbon (30mg) and stirred at ambient temperature under latm H2 for 2h, filtered through celite and concentrated under vacuum. The residue was dissolved in anhydrous CH2CI2 (lOmL) treated with methanesulfony! chloride (0.054mL, OJOmmol) and pyridine (0.056mL, OJOmmol). The resulting mixture was stirred at room temperature overnight, partitioned between water (20mL) and 3:1 C^CfJ-PrOH (3 x 20mL). The combined organic layers were dried over Na2S04, filtered and concentrated under vacuum. The crude product was purified by column chromatography on silica gel using 19:1 ChbCT^eOH to give the title compound as a solid (0.12g, 42%). 'H NMR (300 MHz, DMSO-D6) δ ppm 1.37 (s, 9 H), 2.70 (t, J=6.62 Hz, 2 H), 3.10 (s, 3 H), 3.71 (s, 3 H), 3.76 (t, J=6.62 Hz, 2 H), 7.11 (d, ./=2.57 Hz, 1 H) 7.30 (d, /=8.82 Hz, 2 H) 7.37 (d, /=2.57 Hz, 1 H), 8.02 (d, /^8.82 Hz, 2 H), 9.86 (s, 1 H) 10.20 (s, 1 H) 10.33 (s, 1 H).

[00986JExample 28. Preparation ofN-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl)-4-(methylsulfonylmethyl)benzamide (compound IA-L4-1.10).

[00987]Thionyl chloride (0.3 lmL, 4.2mmol) and 4-(methylsulfonylmethyl)benzoic acid (0.03g, 0.14mmol) were combined and heated at 85°C for 30min then concentrated to dryness. This acid chloride was dissolved in N, N- dimethylacetamide (2mL) with the product from Example 27, Part D (0.041g, 0.14mmol) and pyridine (0.025mL, 2.2mmol) and heated at 100°C for 20min, then cooled to ambient temperature and diluted with 1M HC1. The solid precipitate was isolated by filtration, triturated with methanol and dried to give the title compound ) the title compound (0.0175g, 26%). H NMR (300 MHz, DMSO-D6) δ ppm 1.37 (s, 9 H), 2.71 (t, J=6.62 Hz, 2 H), 2.95 (s, 3 H), 3.72 (s, 3 H), 3.77 (t, J=6.62 Hz, 2 H), 4.60 (s, 2 H), 7.13 (d, J=2.94 Hz, 1 H), 7.38 (d, J=2.57 Hz, 1 H), 7.56 (d, J=8.09 Hz, 2 H) 8.05 (d, J=8.09 Hz, 2 H), 10.03 (s, 1 H), 10.33 (s, 1 H). 208 2014280939 24 Dec 2014 (00988] Example 29. Preparation of (E)-N-(4-(3Tert-butyl-5<2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide (compound IA-L1-1.9).

O

H

[00989] Part A. Preparation of methyl 3-tert-butyl-2-hydroxy-5-nitrobenzoale.

[00990] Methyl 3,5-di-tert-butyl-2-hydroxybenzoate (28.66g, 108.4mmol) was dissolved with stirring in 430mL glacial acetic acid and the resulting mixture was treated drop wise with fuming nitric acid (90%, 179.26mL). When the addition was complete, the resulting mixture was stirred for 2.5h. The reaction mixture was poured into a 2.0L of crushed ice and allowed to stand 30min. Afterwards, 1,0L of water was added and the ice water mixture was allowed to melt. The mixture was then filtered, washed with water and dried to provide the title compound (24.57g, 89%).

[00991] Part B. Preparation of methyl 3-tert-butyl-2-methoxy-5-nitrobenzoate.

[00992] Methyl 3-tert-butyl-2-hydroxy-5-nitrobenzoatc (11.41g, 45.0mmol); potassium carbonate(9.34g, 67.6mmol), acetone (200mL), and dimethyl sulfate (6.46g, 67.6mmol) were added together. The resultant mixture was then heated to reflux for 16h. The mixture was then filtered and the solid was washed with ethyl acetate. The resulting organic liquid was then concentrated under vacuum to an oil and redissolved in ethyl acetate (600mL). The organic solution was then washed with water, dried, filtered and concentrated under vacuum to an oil that was then subjected to purification via column chromatography (gradient of 5% to 40% EtOAc/Hexanes) to yield the title compound as an oil (10.42, 87%).

[00993] Part C. Preparation of methyl 5-amino-3-tert-butyl-2-methoxybenzoate.

[00994] Methyl 3-tert-butyl-2-methoxy-5-nitrobenzoate (10.42g, 39.0mmol), iron powder (325mesh, 10.89g, 195mmol), ammonium chloride (3.13g, 58,5mmol), water (30mL), and methanol (150mL) were added together. The resultant mixture was then refluxed for 1 h. The mixture was then cooled to room temperature, filtered through celite, and the celite washed with methanol. The filtrate was then concentrated under vacuum and dissolved in ethyl acetate (600mL). The resultant solution was then washed with water and brine. The organic extract was then dried, filtered and concentrated under vacuum to yield the title compound as an oil (9.25g, 100%).

[00995] Part D. Preparation of 3-(3-tert-butyl-4-methoxy-5-(methoxycarbonyl)phenylamino) propanoic acid. 209 2014280939 24 Dec 2014 [00996] The product from Part C (16.44g, 69,3mmol) was dissolved in toluene (200mL). This mixture was heated to reflux and acrylic acid added over time (lmL of acrylic acid added every 3h, 5.23mL total, 76.2mmol). The mixture was then refluxed for 24h. The mixture was then cooled and concentrated under vacuum to dryness to yield an oil as the crude title compound that was used directly in the next reaction.

[00997] Part E. Preparation of methyl 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-] (2H)-yl)-2-methoxy benzoate.

[00998] The product from Part D (21.43g, 69.3mmol), urea (10.4g, 173mmol) and acetic acid (glacial, 200mL) were added together. The mixture was then heated to 120°C for 18.5h followed by concentration under vacuum to give an oil. To this oil was added methanol (13mL), and ethyl acetate (350mL). The resultant mixture was allowed to stand for 24-48h whereby a precipitate formed. The resulting solid was filtered off and washed with a small amount of methanol (lOmL) and then air dried to yield the title compound as a solid (15,26g, 66%).

[00999] Part F. Preparation of 3-tert-buty 1-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy benzoic acid.

[001000] The product from Part D (4.52g, 13.52mmol), methanol (70mL), and tetrahydrofuran (70mL) were added together. The mixture was then stirred vigorously until a homogenous solution resulted. Once homogenous, a solution of aqueous sodium hydroxide (1.0M, 68mL) was added. The mixture was then stirred for 12h, the mixture was then concentrated under vacuum to remove the organic solvent, followed by the addition of aqueous hydrochloric acid (1.0M, 80mL) that resulted in solid formation. The mixture was then concentrated under vacuum. To this material was added hydrochloric acid (12M, lOOmL) and the resultant material heated to 100°C for 1,5h. The reaction was then cooled and water added. The resulting solid was filtered, washed with water, and dried to yield the title compound as a solid (3.55g, 82%).

[001001] Part G. Preparation of 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy-benzaldehyde.

[001002] The product obtained in Part F (4.07g, 12.71mmol) and thionyl chloride (40.82mL, 559mmol) were combined and the mixture was refluxed for 2h, followed by concentration under vacuum to provide a light yellow colored solid product. The solid was dissolved in tetrahydrofuran (125mL), the solution cooled to -78°C and LiAlH(0/Bu)3 (1M, 14mL) was added slowly over lOmin while maintaining the temperature at -78°C. The mixture was stirred at -78°C for 2h, and the reaction was quenched with hydrochloric acid (aq., 1M, 25mL) at -78°C. The mixture was warmed to room temperature and ethyl acetate was added. The layers were separated and the aqueous layer was washed with ethyl acetate. The organic extracts were combined and washed with half saturated sodium bicarbonate solution. The organic layer was dried, filtered and concentrated under vacuum to yield the title compound as a solid (3,73g, 210 2014280939 24 Dec 2014 96%).

[001003] Part H. Preparation of l-(3-tert-butyl-4-methoxy-5-(4-nitrostyryl)phenyl)dihydro- pyrimidine-2,4(lH,3H)-dione.

[001004] The product prepared in Part G (l.OOg, 3.29mmol) and diethyl 4-nitrobenzyl- phosphonate (0.853g, 3.12mmol) were dissolved in dichloromethane (50mL). Solid potassium /ert-butoxide (0.737g, 6.57mmol) was added portion wise at room temperature. The resultant dark red solution was stirred for 1,5h at room temperature. IN aqueous HC1 (50mL) solution was added and the mixture was stirred 30min, and then diluted with dichloromethane (50mL). The resultant organic layer was separated and dried. The material was purified by column chromatography on silica gel using 99/1 dichloromethane/methanol as eluent to obtain the title compound as a solid (1.12g, 80%).

[001005] Part I. Preparation of Preparation of(E)-N-(4-(3-tert-butyl-5-(2,4-dioxotetrahydro-pyrimidin-l(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide.

[001006] The product obtained in Part H (1.1 g, 2.60mmol), iron (0.725g, 12.99mmol), and ammonium chloride (0.208g, 3.90mmol) was added to a mixture of tetrahydrofuran (40mL), ethanol (40mL) and water (12mL). The slurry was heated to 90°C for 45min, and then cooled to ambient temperature. The solution was filtered through a pad of celite (lOg), washed with ethanol (20mL), and the filtrate concentrated under vacuum to a solid. The resulting solid was dissolved in ethyl acetate (lOOmL), and the solution was washed with water (50mL) and dried over Na2SÜ4. The drying agent was filtered off and the solvent removed under vacuum to give the aniline adduct as a yellow solid (830mg).

[001007] The solid (830mg, 2.109mmol) was dissolved in dichloromethane (50mL), and pyridine (0.512mL, 6.33mmol) and methanesulfonyl chloride (O.lBlmL, 2.32mmol) were added and the resulting solution was stirred at room temperature 16h. Dichloromethane (lOOmL) was added followed by extraction with a IN aq. HC1 solution (2 x 50mL). The organic layer was dried, concentrated under vacuum and purified by column chromatography on silica gel using 98/2 CPfjCh/MeOH to provide the title compound as a solid (480mg, 39%, two steps), m.p. = 260-261 °C (trans-isomer) *H NMR (500 MHz, DMSO-d6): δ ppm 1.37 (s, 9H), 2.71 (t, J=6.7Hz, 2H), 3.01 (s, 3H), 3.75 (s, 3H), 3.79 (t, J=6.6Hz, 2H), 7.13 (d, J=16.5Hz, 1H), 7.15 (d, J=2.4Hz, 2H), 7.23 (d, J=8.5Hz, 2H), 7.25 (d, J=16.5 Hz, 1H), 7.51 (d, J=2.4Hz, HI), 7.61 (d, J=8.6Hz, 2H), 9.80(bs, IH), 10.30 (s, 1H). (trans-isomer). 211 2014280939 24 Dec 2014 [001008] Example 30. Preparation of (Z)-N-(4-(2-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl)-l -chlorovinyl)phenyl)methanesulfonamide (compound IA-L1-1.3).

[001009] Part A. Preparation of diethyl hydroxy(4-nitrophenyl)methylphosphonate. ]001010] The title compound was prepared as described in Taylor, WP, et. Al, Bioorg. Med. Chem. 4:1515-1520 (1996). 4-Nitrobenzaldehyde (3.0g, 19,85mmol) and diethyl phosphonate (2.74g, 19.85mmol) were combined and treated with a 0.5N solution of sodium methoxide in methanol (0.993mL, 0.496mmol). The resulting red-orange solution was stirred 12h at room temperature. The reaction mixture was extracted with dichloromethane (20mL) followed by half saturated ammonium chloride (20mL). The organic layer was separated, dried and concentrated under vacuum to provide the title compound as a semi-solid (5.1g, 89%).

[001011] Part B. Preparation of diethyl chloro(4-nitrophenyl)methylphosphonate.

[001012] The product prepared in Part A (500mg, 1.729mmol) was dissolved in dichloromethane (lOmL) and treated with triphenylphosphine (998mg, 3.80mmol), followed by N-chlorosuccinimide (462mg, 3.46mmol). The mixture was stirred at room temperature for 18h. The solution was concentrated under vacuum and the residue was purified by column chromatography using silica gel eluting with a 1/1 mixture of hexanes/ethyl acetate to provide the title compound as an oil (262mg, 49%)· [001013] Part C. Preparation of (Z)-N-(4-(2-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl)-l-chlorovinyl)phenyl)methanesulfonamide.

[001014] The product prepared in Example 29, Part G (lOOmg, 0.329mmole) was treated with the product obtained from Part B using the procedures described in Example 29, Part H and Example 29, Part I to provide 39mg of the title compound. 'H NMR (300 MHz, DM.SO-d6): δ ppm 1.36 (s, 9H), 2.71 (t, J=6.8Hz, 2H), 3.06 (s, 3H), 3.71 (s, 3H), 3.78 (t, J=6.8Hz, 2H), 7.23 (d, J=2.6 Hz, 1H), 7.27 (s, 1H), 7.28 (d, J=8.6Hz, 2H), 7.48 (d, J=2.6 Hz, 1H), 7.78 d, J=8.8 Hz, 1H), 10.05(s, 1H), 10.34 (s, III). 212 2014280939 24 Dec 2014 [001015] Example 31. Preparation of (E)-l-(3-tert-butyl-5-(4-fluorostyryl)-4-methoxyphenyl) dihydropyrimidine-2,4(lH,3H)-dione (compound IA-L1-1.12).

[001016] The title compound was prepared according the procedures described in Example 29, Part H and Example 29, Part I using the product obtained in Example 29, Part G (50mg, 0.164mmol) and diethyl 4-fiuorobenzylphosphonate (40.5mg, 0.164mmol). The title compound was obtained as a solid (30mg, 46%). 'H NMR (300 MHz, DMSO-d6): δ ppm 1.37 (s, 9H), 2.72 (t, J=6.6Hz, 2H), 3.76 (s, 3H), 3.79 (t, =6.6Hz, 2H), 7.21 (m, 4H), 7.30 (d, J=16.3Hz, 1H), 7.53 (d, J=2.6Hz, 1H), 7.73 (m, 2H), 10.35 (s, 1H).

[001017] Example 32. Preparation of (Z)-N-(4-(2-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyI)-l-fluorovinyl)phenyl)methanesulfonamide (compound IA-L1-1.4).

[001018] Part A. Preparation of diethyl fluoro(4-nitrophenyl)methylphosphonate.

[001019] The title compound was prepared as described in Taylor, WP, et. Al, Bioorg. Med. Chem. 4:1515-1520 (1996). The product from Example 30, Part A (500mg, 1,729mmol) was dissolved in dichloromethane (lOmL) and treated by drop wise addition of (diethylamino)sulfur trifluoride (DAST) (2.5mL, 18.9mmol). The mixture was stirred at room temperature for 18h. A solution of half saturated sodium phosphate monobasic (20mL) was added followed by dichloromethane (20mL) addition and separation of the resulting organic phase. The organic solution was dried and concentrated under vacuum, and then subjected to column chromatography using silica gel eluting with a 1/1 mixture of hexanes/ethyl acetate to provide the title compound as an oil (215mg, 43%).

[001020] Part B. Preparation of (Z)-N-(4-(2-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-213 2014280939 24 Dec 2014 methoxyphenyl)-l-fluorovinyl)phenyl)methanesulfonamide.

[001021] The product prepared as described in Part A (lOOmg, 0.329mmole) was treated with the product prepared in Example 29, Part G (96mg, 0.329mmole) according to the procedures described in Example 29, Part H and Example 29, Part I to provide 53mg of the title compound as a 1/1 mixture of cis/trans isomers. Reverse phase HPLC chromatographic separation using a 40-100% gradient of acetonitrile in 0.1% aqueous trifluoroacetic acid provided the title compound as a solid (20mg). *H NMR (300 MHz, DMSO-de): δ ppm 1.37 (s, 9H), 2.71 (t, J-6.8Hz, 2H), 3.06 (s, 3H), 3.77 (s, 3H), 3.78 (m, 2H), 6.62 (d, J=40.4Hz, 1H), 7.18 (d, J=2.6Hz, 1H), 7.30 (d, J=8.4Hz, 2H), 7.55 (d, J=2.6Hz, 1H), 7.75 (d, J=8.8Hz, 2H), 10.08 (s, 1H), 10.33 (s, 1H).

[001022] Example 33. Preparation of (E)-N-(4-(2-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl)-l-fluorovinyl)phenyl)methanesulfonamide (compound IA-L1-1.5).

[001023] Reverse phase HPLC chromatographic separation of the 1/1 mixture of cis/trans isomeric material (53mg) from Example 32, Part A using a 40-100% gradient of acetonitrile in 0.1% aqueous trifluoroacetic acid provided the title compound as a solid (16.5mg). 'H NMR (300 MHz, DMSO-da): δ ppm 1.33 (s, 9H), 2.60 (t, J=6.6Hz, 2H), 3.01 (s, 3H), 3.57 (t, J=6.6Hz, 2H) 3.79 (s, 3H), 6.46 (d, J=21,3Hz, 1H), 6.87 (d, J=2.2Hz, 1H), 7.14 (m, 3H), 7.36 (d, J=8.8Hz, 2H), 10.02 (s, 1H), 10.24 (s, 1H).

[001024] Example 34. Preparation of(E)-N-(4-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl> 2-methoxystyryl)-2-fluorophenyl)methanesulfonamide (compound IA-Ll-1.26)

[001025] Part A. Preparation of 4-(bromomethyl)-2-fluoro-l-nitrobenzene.

[001026] (3-Fluoro-4-nitrophenol)methanol (1.24g, 7.25mmol) was dissolved in dichloromethane 214 2014280939 24 Dec 2014 (7.5ml.) and treated with triphenylphosphine (2.281g, 8.70mmol) followed by N-bromosuccinimide (1.548g, 8.70mmol). The mixture was stirred at room temperature for 2h. Water (50mL) and dichloromethane (40mL) were added, and the organic layer was separated and dried. The solution was concentrated under vacuum and purified by column chromatography using silica gel eluting with a 5/1 mixture of hexanes/ethyl acetate to provide the title compound as a solid (1.27g, 75%).

[001027] Part B. Preparation of diethyl 3-fluoro-4-nitrobenzylphosphonate.

[001028] The product prepared in Part A (1.27g, 5.43mmol) was added to triethyl phosphite (8mL, 54.3mmol) and the solution heated to 120°C for lhr. After cooling, the excess triethyl phosphite was removed by heating under vacuum and the residue subjected to column chromatography on silica gel using 99/1 dichloromethane/methanol as eluent to obtain the crude title compound as an oil (800mg).

[001029] PartC. Preparation of (E)-N-(4-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxystyryl)-2-fluorophenyl)methanesulfonamide.

[001030] The product described in Example 29, Part G (533mg, 1.751 mmole) was treated with the product described in Part B (510mg, 1.751mmole) according to the procedures described in Example 29, Part H and Example 29, Part I to provide 80mg of the title compound. ‘H NMR (300 MHz, DMSO-d6): δ ppm 1.37 (s, 9H), 2.71 (t, J=6.5Hz, 2H), 3.05 (s, 3H), 3.76 (s, 3H), 3.79 (t, J=6.6Hz, 2H), 7.18 (m, 2H), 7.36 (d, J=16.5Hz, 1H), 7.39 (m, 1H), 7.44 (m, 1H), 7.52 (d, J=2.6Hz, 1H), 7.63 (m, 1H), 9.65 (s, 1H), 10.35 (s, 1H).

[001031] Example 35. Preparation of N-(4-(2-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl)cyclopropyl)phenyl)methanesulfonamide (compound IA-L8-1.I).

O

[001032] The product obtained as described in Example 29, Part I (30mg, 0.064mmol) was dissolved in tetrahydrofuran (2mL) and treated with 0.95mL of a 0.67M ether solution of diazomethane (0.636mmol) followed by palladium acetate (0.7mg, 0.003 lmmol). The mixture was stirred for30 min at room temperature followed by removal of the solid by filtration and concentration of the filtrate. The filtrate was purified by column chromatography on silica gel using 98/2 dichloromethane/methanol as eluent to obtain the title compound as a solid (21.6mg, 70%). m.p. 265-266°C. 'H NMR (300 MHz, DMSO-d6): δ ppm 1.33 (s, 9H) 1.50 (m, 2H), 2.13 (m, 1H), 2.27 (m, 1H), 2.69 (t, J=6,6Hz, 2H), 2.94 (s, 3H), 3.63 (s, 215 2014280939 24 Dec 2014 3Η), 3.74 (t, J=6.6Hz, 2H),6.84 (d, J=2.6Hz, 1H), 7.04 (d, J=2.6Hz, 1H), 7.14 (d, J=8.8Hz, 2H), 7.20 (d, J=8.8Hz, 2H), 9.60 (s, 1H), 10.29 (s, 1H).

[001033] Example 36. Preparation of N-(4-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenethyl)phenyl)methanesulfonamide (compound IA-L5-2-1.1).

[001034] The product obtained as described in Example 29, Part I (415mg, 0.88mmol) was dissolved in methanol (30mL) and treated with 50mg of 10% palladium on carbon. The slurry was stirred for 48h at room temperature under latm of hydrogen. The reaction mixture was filtered through celite and concentrated in vacuo to provide the title compound as a solid (230mg, 55%). m.p. 233-234°C. ‘H NMR (300 MHz, DMSO-d6): δ ppm 1.34 (s, 9H), 2.68 (t, J=6.8Hz, 2H), 2.86 (s, 4H), 2.93 (s, 3H), 3.70 (m, 2H), 3.74 (s, 3H), 7.11 (m, 4H), 7.23 (m, 2H), 9.59 (s, 1H), 10.29 (s,).

[001035] Example 37. Preparation of (E)-N-(4-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)styryl)phenyl)methanesulfonamide (compound IA-L1-1.16)

H

[001036] Part A. Preparation of methyl 3-tert-butyl-5-(chlorocarbonyl)benzoate.

[001037] A mixture of 3-tert-butyl-5-(methoxycarbonyl)benzoic acid (9.18g, 38.9mmol, prepared by the method of Carter et. al., W02005021500A1), thionyl chloride (75mL) and 1 drop of DMF in toluene (200mL) was heated at reflux for 2h, cooled and concentrated. The residue was azeotroped with toluene (3 x 50mL )and dried under high vacuum to give the title compound as an off-white waxy solid (9.9g, quantitative yield).

[001038] Part B. Preparation of methyl 3-(azidocarbonyl)-5-tert-butylbenzoate. 216 2014280939 24 Dec 2014 [001039] To the product of Part A (9.9g, 38.9mmol) in acetone (200ml) was added at a fast drip a solution of sodium azide (10.12g, 156mmol) dissolved in water (20mL). The mixture was stirred for 2h and diluted with EtOAc. The organic layer was washed with H20, saturated brine, dried (Na2S04), filtered and concentrated to give the title compound as a white solid (9.9g, 97%).

[001040] Part C. Preparation of methyl 3-amino-5-tert-butylbenzoate.

[001041] The product from Part B (9.9g, 37.9mmol) in toluene (lOOmL) was heated at reflux for lh and concentrated to give the intermediate isocyanate which was dissolved in DME (60mL) treated with 8% HC1 (150mL) and stirred for 16h. The mixture was concentrated and the residue was dissolved in water, neutralized with solid sodium bicarbonate and extracted 3 x lOOmL with EtOAc. The organics were combined, washed with saturated NaCl, dried (Na2S04), filtered and concentrated. The crude product was chromatographed on silica eluting with 2:1 hexane/EtOAc to give the title compound as an oil (2.7g, 35%).

[001042] Part D. Preparation of methyl 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxybenzoate.

[0010431 A mixture of the product of Part C (2.34g, 11,29mmol) and acrylic acid (2.32ml, 33.9mmol) in toluene (60ml) was heated at reflux under nitrogen for 24h, cooled and concentrated. The resulting residue was then treated with urea (2.03g, 33.9mmol) in acetic acid (35ml) and heated at 120°C for 24h, cooled and concentrated. The residue was azeotroped 3 x 50mL with toluene and dissolved in 1 OOmL of EtOAc. The organic layer was washed with dilute aqueous NaHC03, H?0, saturated brine, dried (Na2S04), filtered and concentrated to give the title compound as a white solid (2.1g, 61%).

[001044] Part E. Preparation of 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)benzoic acid.

[001045] A mixture of the product from Part D (1.8g, 5.91mmol)and lMNaOH (29,6ml, 29.6mmol) in MeOH (15ml) and THF (15mL) was stirred for 24h and concentrated. The residue was treated with 50mL of 1M HC1 and extracted into EtOAc. The EtOAc layer was washed with H20, saturated brine, dried (Na2SQ4), filtered and concentrated to give a white solid. This intermediate urea was combined with 20mL of concentrated HC1 and heated at 100°C for lh, cooled and diluted with 75mL of ice water to give a white powder which was collected by filtration and dried to constant mass to give the title compound (1.6g, 93%).

[001046] Part F. Preparation of (E)-N-(4-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl) styryl)phcnyl)methanesulfonamide.

[001047] The product described in Part E was treated with thionyl chloride and lithium tri-tert-butoxyaluminum hydride according to procedures described in Example 29, Part G to produce 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)benzaldehyde. The aldehyde was treated with diethyl 4-nitrobenzylphosphonate according the procedures described in Example 29, Part H and Example 29, 217 2014280939 24 Dec 2014

Part I to provide the title compound (85mg). 'H NMR (300 MHz, DMSO-d6): δ ppm 1.32 (s, 9 H) 2.72 (t, J=6.43 Hz, 2 H) 3.01 (s, 3 H) 3.82 (t, J=6.62 Hz, 2 H) 7.18 - 7.25 (m, 5 H) 7.39 (s, 1 H) 7.46 (s, 1 H) 7.58 (d, J=8.46 Hz, 2 H) 9.84 (s, 1 H) 10.37 (s, 1 H).

[001048] Example 38. Preparation of (Z)-N-(4-(2-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidm-l(2H)-yl)-2-methoxyphenyl)-l-methoxyvinyl)phenyl)methanesulfonamide (compound IA-L1-1.17).

H

[001049] Part A. Preparation of 1 -(dimethoxymethyl)-4-nitrobenzene.

[001050] A flask equipped with a magnetic stir bar and vigreux column was charged with 4-nitro-benzaldehyde (5.0g, 33.1mmol), pyridinium p-toluenesulfonate (1.66g, 6.62mmol), trimethoxymethane (3.5lg, 33.1mmol) and methanol (lOOmL). The mixture was heated at 50°C for 12h and was concentrated in vacuo. The residue was redissolved in EtOAc and washed with aq. NaOH (1M), H20 and brine. The mixture was dried (Na2S04), fdtered and concentrated in vacuo to yield the title compound as a clear, light yellow oily product (6.36g, 97%).

[001051] Part B. Preparation of diethyl methoxy(4-nitrophenyl)methylphosphonate.

[001052] The product from Part A (3.0g, 15.2mmol) and triethyl phosphite (2,53g, 15.2mmol) were dissolved in dichloromethane (30mL) under a nitrogen atmosphere, cooled to -20°C and treated with drop wise addition of boron trifluoride etherate (2.27g, 16mmol). The mixture was allowed to slowly warm to room temperature overnight with stirring. Water was added and the resulting mixture was stirred 5min, separated and the organic layer was dried (Na2S04), filtered and concentrated in vacuo to a solid residue. The residue was purified on silica gel (100% EtOAc to 3% CITOH/EtOAc) to yield the title compound as a light yellow oily product (3.78 g , 82%).

[001053] Part C. Preparation of (Z)-N-(4-(2-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl)-1 -methoxyvinyl)phenyl)methanesulfonamide.

[001054] The product obtained according to the procedure described in Example 29, Part G (400mg, 1.314mmole) was treated with the product obtained in Part B (399mg, 1.314mmole) according to the procedures described in Example 29, Part H and Example 29, Part I to provide the title compound (17mg, 6%). 'H NMR (300 MHz, DMSO-d6): § ppm 1.36 (s, 9 H) 2.71 (t, J=6.62 Hz, 2 H) 3.05 (s, 3 H) 218 2014280939 24 Dec 2014 3.58 (s, 3 H) 3.75 (s, 3 H) 3.76 - 3.81 (in, 2 H) 6.25 (s, 1 H) 7.11 (d, J=2.57 Hz, 1 H) 7.27 (d, 3=8.46 Hz, 2 H) 7.60 (d, J=8.82 Hz, 2 H) 7.67 (d, J=2.57 Hz, 1 H) 9.96 (s, 1 H) 10.32 (s, 1 H).

[001055] Example 39. Preparation of (E)-l-(3-tert-butyl-4-methoxy-5-styrylphenyl)dihydro-pyrimidine-2,4(lH,3H)-dione (compound IA-L1-1.18).

O

[001056] The product obtained according to procedure described in Example 29, Part G (50mg, 0.164mmole) was treated with diethyl benzylphosphonate (0.034ml, 0.164mmole) according to the procedure described in Example 29, Part H to provide the title compound (13mg , 19%). 'll NMR (300 MHz, DMSO-de): δ ppm 1.37 (s, 9 H) 2.72 (t, J=6.62 Hz, 2 H) 3.76 (s, 3 H) 3.80 (t, J=6.80 Hz, 2 H) 7.16 - 7.18 (m, 1 H) 7.21 - 7.23 (m, 1 H) 7.29 - 7.33 (m, 2 H) 7.36 - 7.43 (m, 2 H) 7.54 (d, J=2.57 Hz, 1 H) 7.64 (d, J=7.35 Hz, 2 H) 10.35 (s, 1 H).

[001057] Example 40. Preparation of (E)-l-(3-tert-butyl-4-methoxy-5-(4-methoxystyryl)phenyl) dihydropyrimidine-2,4(lH,3H)-dione (compound IA-L1-1.14).

O

[001058] The product obtained according to procedure described in Example 29, Part G (50mg, 0.164mmole) was treated with diethyl 4-methoxybenzylphosphonate (0.028ml, 0.164mmole) according to the procedure described in Example 29, Part H to provide the title compound (4mg , 4%). *H NMR (300 MHz, DMSO-d6): δ ppm 1.37 (s, 9 H) 2.71 (t, J=6.62 Hz, 2 H) 3.70 - 3.81 (m, 8 H) 6.96 (d, J=8.82 Hz, 2 H) 7.13 (d, 3=2.21 Hz, 1 H) 7.15 (d, J=2.57 Hz, 2 H) 7.50 (d, J=2.57 Hz, 1 H) 7.58 (d, J=8.46 Hz, 2 H) 10.34 (s, 1II). 219 2014280939 24 Dec 2014

H Nv [001059] Example 41 A. Preparation of (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxystyryl)phenyl)methanesuIfonamide (compound EB-L1-1.1). Λ o o [001060] Part A. Preparation of (E)-methyl 3-tert-butyl-2-methoxy-5-(3-(3-methoxyacryloyl)ureido) benzoate.

[0010611 The product obtained as described in Example 29, Part C (2.0g, 8.43mmol) was dissolved in 30mL of Ν,Ν-dimethylacetamide and cooled to -25°C. A 0.5Molar solution of E-3-methoxyacryloyl isocyanate in benzene (21.9mL, 10.96mmol) was added drop wise and the resulting solution was stirred at ambient temperature for 4h, and then poured into water. The product was extracted into dichloromethane, washed with brine, dried over sodium sulfate, filtered and evaporated under vacuum to give the title compound.

[001062] PartB. Preparation of methyl 3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxybenzoate.

[001063] The product from Part A (3.1g, 8.51mmol) was dissolved in ethanol (60mL). To this solution was added a mixture of concentrated sulfuric acid (6mL) and water (60mL). The heterogeneous mixture was heated at 100°C for 3h. The ethanol was removed under vacuum, and then the aqueous solution was extracted with dichloromethane and evaporated to dryness. This residue was purified by column chromatography on silica gel, eluting with 1% methanol/dichloromethane to yield the title compound (1.23g,44%).

[001064] Part C. Preparation of 3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy benzoic acid.

[001065] The product from Part B (1.23g, 3.7mmol) was taken up in ethanol (5mL) and 1M sodium hydroxide solution (lOmL) and stirred at ambient temperature for 18h. The solution was acidified with 1M HC1 and the resulting solid was filtered and dried to give the title compound (0.945 g,80%).

[001066] PartD. Preparation of 3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy benzaldehyde.

[001067] The product from Part C (0.945g, 2.97mmol) was taken up in thionyl chloride (4.5mL) and the mixture was heated at 80°C for 40min. After evaporation to dryness, the acid chloride was dissolved in dry THF (8mL) and cooled to -78°C. AIM solution of lithium tri-tert-butoxyaluminum hydride in THF 220 2014280939 24 Dec 2014 (3.0mL, 3.Ommol) was added drop wise. After 45min the cold reaction was quenched with 1M HC1 (5mL), extracted into ethyl acetate, and purified by column chromatography on silica gel, eluting with dichloromethane followed by 1% methanol/dichloromethane to give the title compound (0.635 g, 71%).

[001068] PartE. Preparation of (E)-1-(3-tert-butyl-4-methoxy-5-(4-nitrostyryl)phenyl)pyrimidine-2,4( 1 H,3H)-dione.

[001069] The product of Part D (0.634g, 2.1mmol) and diethyl 4-nitrobenzylphosphonate (0.573g, 2.1 mmol) were combined in dichloromethane (25mL) at ambient temperature. Potassium tert- butoxide (0.494g, 4.4mmol) was added portion wise and the resulting red/brown heterogeneous mixture was stirred for 1.5h. This mixture was quenched with 1M HC1 (15mL), poured into water and extracted into ethyl acetate, and the crude product was purified by column chromatography on silica gel, eluting with 1% methanol/dichloromethane to give the title compound (0.735g, 83%).

[001070] PartF. Preparation of (E)-1-(3-(4-aminostyryl)-5-tert-butyl-4-methoxyphenyl)pyrimidine-2,4(1 H,3H)-dione.

[001071] The product from Part E (0.735g, l,74mmol), ammonium chloride (0.14g, 2.62mmol), and iron (0.487g, 8.72mmol) were combined in a solution of ethanol (lOmL), water (5mL), and THF (lOmL) and heated at 75°C for lh. The mixture was filtered through diatomaceous earth, rinsing well with THF and concentrated to give the title compound.

[001072] Part G. Preparation of (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yi)-2-methoxystyryl)phenyl)methanesulfonamide.

[001073] The product from Part F (0.683g, 1.75mmol) and pyridine (0.564mL, 6,98mmol) were combined in dichloromethane (15mL) at ambient temperature. Methane sulfonylchloride (0.163mL, 2.1mmol) was added drop wise and the solution was stirred for 18h. The mixture was poured into 1M HC1 and extracted into dichloromethane, concentrated, and purified by column chromatography on silica gel, eluting with 1%, 2% methanol/dichloromethane. Trituration from dichloromethane provided a solid that was filtered and dried to give the title compound as a colorless powder (0.465g , 57%). 'H NMR (300 MHz, DMSO-D6) δ ppm 1.38 (s, 9 H), 3.01 (s, 3 H), 3.79 (s, 3 H) 5.65 (d, J=7.72 Hz, 1 H), 7.17 -7.28 (m, 5 H), 7.58 - 7.70 (m, 3 H), 7.75 (d, J=7.72 Hz, 1 H), 9.86 (s, 1 Η), 11.42 (s, 1 H). 221 2014280939 24 Dec 2014 [001074] Example 41B. Preparation of (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxystyiyl)phenyl)methanesulfonamide (compound IB-Ll-1.1).

H

[001075] Part A. Preparation of N-(4-ethynylphenyl)methanesulfonamide.

[001076] In a 2L, 3-neck round-bottom flask equipped with an overhead stirrer was added 4-ethynylaniline (30g, 256mmol) and pyridine (42.5ml, 525mmol) in dichloromethane (512ml) to give an orange solution. The mixture was cooled to 5°C and methanesulfonyl chloride (19.96ml, 256mmol) was added drop wise over 15min. The reaction solution was stirred at 5°C for 2h and washed with 1M aqueous HC1 (3x250mL). The dichloromethane layer was then washed sequentially with saturated aqueous NaHCO?, water, and saturated aqueous NaCl. The dichloromethane layer was dried over sodium sulfate and treated simultaneously with decolorizing charcoal for 30min, the solution then filtered through Celite and the filtrate was concentrated. The pink/orange solid was dissolved in a minimal amount of hot ethyl acetate (50-75mL) and slowly diluted with hexanes (500-600ml) to give orange crystals that were collected by filtration and dried to provide the title compound (40.0g, 80%).

[001077] Part B. Preparation of (E)-4-(methylsulfonamido)styrylboronic acid.

[001078] (Reference: Org. Prep. Proc. Int., 2004, 36, 573-579) To a flask was added borane-methyl sulfide complex (8,03mL, 85mmol) followed by tetrahydrofuran (16mL) and the mixture then cooled to 0°C. (1 R)-(+)-alpha-pinene (26.2mL, 169mmol) was then added drop wise (over lOmin) to the ice-cooled solution. The mixture was then stirred at 0°C for lh followed by stirring 2h at room temperature. The resulting thick white slurry was cooled to -40°C in a dry ice/acetone bath, followed by the addition of the product from Part A (15.0g, 77mmol) dissolved in 60mL of THF, drop wise over 30min. After the addition was complete, the mixture was stirred for an additional hour at -35°C, then lh at room temperature. The light yellow solution was then cooled to 0°C and acetaldehyde (61 4mL, 1088mmol) added, then the mixture refluxed at 50QC for 18h. The solvent was then removed under vacuum to provide an orange syrup, to which water (115mL) was added and the heterogeneous mixture stirred for 3h at room temperature. The light yellow solid generated was collected and washed with water (250mL) then dried in a vacuum oven overnight. The resultant material was then dissolved in boiling acetone (190mL), which provided a homogenous yellow solution, followed by removal of the solution from heating and the addition of hexanes (365ml) over 5min time. A white solid formed in the solution and the 222 2014280939 24 Dec 2014 mixture was stirred until the solution cooled to room temperature, then the white solid was collected and dried in a vacuum oven for lhr to provide the title compound (12.1 g, 85%).

[001079J PartC. Preparation of 2-tert-butyl-4-nitrophenol.

[001080] To a vigorously stirred solution of 2-tert-butylphenol (lOg, 66.6mmol) in heptane (67ml) was added at a fast drip a solution of 70% nitric acid (4.25ml, 66.6mmol) diluted with water (4.25ml). The resulting dark red/brown mixture was stirred vigorously for 2h, The suspended solid was collected by filtration washed with hexane (300mL), water (200mL) and once again with hexane (200mL) to give a cocoa colored powder that was dried to constant mass (4.65g, 35.6%).

[001081] PartD. Preparation of 2-bromo-6-tert-butyl-4-nitrophenol.

[001082] A solution of the product from Part C (l.Og, 5.12mmol) in glacial acetic acid (10.25mL) was treated portion wise with pyridine hydrobromide perbromide (1.80g, 5.63mmol) followed by stirring at room temperature for 2h. Additional pyridinium hydrobromide perbromide (3,6g) was added in two portions and after another 3h of stirring, the reaction was complete. The mixture was poured into ice water, and the mixture treated with a small amount of sodium sulfite. The resulting solid was filtered and dried under vacuum to give the title compound as a brown solid (1.40g, 100 %).

[001083] Part E. Preparation of l-bromo-34ert-butyl-2-methoxy-5-nitrobenzene.

[001084] A solution of the product from Part D (1,40g, 5.1 lmmol) in 10:1 t-butylmethylether-methanol (25.5mL) was treated with 2.0M trimethylsilyldiazomethane in ether (5.1mL, 10.21mmol), followed by stirring at room temperature for 18h. The mixture was concentrated under vacuum to afford a yellow oil, which was purified by silica gel column chromatography eluting with EtOAc/hexanes to give the title compound as a yellow oil (1.36g, 92 %).

[001085] Part F. Preparation of tert-butyl 3-bromo-5-tert-butyl-4-methoxyphenylcarbamate.

[001086] A solution of the product from Part E (960mg, 3,33mmol) in methanol (17mL) was treated with 5 % platinum on sulfided carbon (lOOmg), followed by hydrogenation under balloon pressure for 3h, and then filtered through celite and concentrated under vacuum to afford the 3-bromo-5-tert-butyl-4-methoxyaniline as a yellow oil (860mg, 3.33mmol, 100%). A solution of this material in THF (17mL) was treated with di-tert-butyl dicarbonate (800mg, 3.66mmol) followed by warming at reflux for 2h. Concentration under vacuum afforded a beige solid, which was purified by silica gel column chromatography eluting with EtOAc/hexanes. Solid was triturated with hexanes, collected by filtration, and dried under vacuum to give the title compound as a nearly white solid (890mg, 75 %).

[001087] Part G. Preparation of (E)-N-(3-bromo-5-tert-butyl-4-methoxyphenylcarbamoyl)-3-methoxyacrylamide.

[001088] The product from Part F (2.0g, 5.58mmol) was dissolved in dichloromethane (lOmL) and trifluoroacetic acid (5mL) added. The solution was stirred at room temperature for lh followed by 223 2014280939 24 Dec 2014 concentration under vacuum and the addition of 10% aqueous sodium bicarbonate (50mL), followed by extraction with ethyl acetate (3 x 50mL). The combined organic extracts were dried and concentrated to provide a residue that was dissolved in 1 OmL of Ν,Ν-dimethylacetamide and cooled to -25°C. A 0.5 molar solution of E-3-methoxyacryloyl isocyanate in benzene (20.3mL, 11.16mmoI) was added drop wise and the resulting solution was stirred at ambient temperature for 4h, and then poured into water. The product was extracted into dichloromethane, washed with brine, dried over sodium sulfate, filtered and evaporated under vacuum to give the title compound.

[001089] Part H. Preparation of l-(3-bromo-5-tert-butyl-4-methoxyphenyl)pyrimidine-2,4(lH,3H)-dione.

[001090] The product from Part G (2.15g, 5.58mmol) was dissolved in ethanol (lOmL). To this solution was added a mixture of concentrated sulfuric acid (ImL) and water (lOmL). The heterogeneous mixture was heated at 100°C for 2h. The ethanol was removed under vacuum, and then the aqueous solution was extracted with dichloromethane and evaporated to dryness. This residue was purified by column chromatography on silica gel, eluting with 1% methanol/dichloromethane to yield the title compound (1.35g, 69%).

[001091] Part I. Preparation of (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide.

[001092] The product from Part H (8.0g, 22.65mmol), the product from Part B (5.90g, 24.46mmol), l,r-bis(di-tert-butylphosphino)ferrocene palladium dichloride (0.738g, 1.132mmol), and potassium phosphate (9.62g, 45.3mmol) were dissolved in a mixture of tetrahydrofuran (128mL) and water (32mL). Nitrogen gas was bubbled through the resultant mixture for 10 min followed by heating the solution at 50°C for 5h in darkness. The reaction was allowed to cool to room temperature followed by the addition of saturated aqueous ammonium chloride (50mL), water (200mL), and the solution extracted with dichloromethane (600mL). To the organic extract was added magnesium sulfate, and 3-mercaptopropyl-functionalized silica gel (20 g) and the resultant solution stirred in darkness for 18h. The solids were then removed by filtration and the filtrate concentrated under vacuum and subjected to silica gel column chromatography using a 99/1 to 99/2 dichloromethane/methanol gradient to provide the title compound (7.4 g, 70%). ‘H NMR (300 MHz, DMSO-D6) δ ppm 1.38 (s, 9 H), 3.01 (s, 3 H), 3.79 (s, 3 H) 5.65 (d, J=7.72 Hz, 1 H), 7.17 - 7.28 (m, 5 H), 7.58 - 7.70 (m, 3 H), 7.75 (d, J=7.72 Hz, 1 H), 9.86 (s, 1 Η), 11.42 (s, 1 H). 224 2014280939 24 Dec 2014 [001093] Example 42. Preparation of (E)-N-(4-(3-tert-butyl-5-(5-fluoro-2,4-dioxo~3,4-dihydro-pyrimidin-1 (2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide (compound IB-L1-1.2).

[001094] Part A. Preparation of methyl 3-tert-butyl-5-(5-fluoro-6-methoxy-2,4-dioxotetrahydro-pyrimidin-l(2H)-yl)-2-methoxybenzoate.

[001095] The fluorination procedure was performed as described in Lal, GS, et al. J. Org Chem., 60:7340-7342 (1995). The product from Example 41A, Part B (0.42g, 1.26mmol) and Selectfluor™ (0.672g, 1.9mmol) were combined in a mixture of acetonitrile (8mL) and methanol (ImL) and heated at 90°C under N2 for 5h. The solution was diluted with water, extracted into ethyl acetate, washed with sodium bicarbonate solution, concentrated and purified by column chromatography on silica gel to give the title compound (0.138g, 29%).

[001096] Part B. Preparation of methyl 3-tert-butyl-5-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxybcnzoate.

[001097] The product from Part A (0.134g, 0.35mmol) and triethylamine (ImL) were combined in methanol (4mL) and stirred at ambient temperature for 18h. The solution was quenched with 1M HC1, extracted into dichloromethane and concentrated to give the title compound (0.113g , 92%).

[001098] Part C. Preparation of 3-tert-butyl-5-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxybenzoic acid.

[001099] The product from Part B (0.113g, 0.32mmol) was treated as described in Example 41 A, Part C to give the title compound (0.088g, 81%).

[001100] Part D. Preparation of 3-tert-butyl-5-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxybenzaldehyde.

[001101] The product from Part C (0.088g, 0.26mmol) was treated as described in Example 41A, Part D to give the title compound (0.075g, 90%).

[001102] Part E. Preparation of (E)-l-(3-tert-butyl-4-methoxy-5-(4-nitrostyryl)phenyl)-5-fluoropyrimidine-2,4(lH,3H)-dione.

[001103] The product of Part D (0.075g, 0.23mmol) was treated as described in Example 41A, Part E 225 2014280939 24 Dec 2014 to give 0.077g (75%).

[001104] PartF. Preparation of (E)-l-(3-(4-aminostyryl)-5-tert-butyl-4-methoxyphenyl)-5-fluoropyrimidine-2,4( 1 H,3 H)-dione.

[001105] The product of Part E (0.077g, 0.18mmol) was treated as described in Example 41A, Part F to give the title compound (0.07 lg, 94%).

[001106] Part G. Preparation of (E)-N-(4-(3-tert-butyl-5-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide.

[001107] The product of Part F (0.071g, 0.17mmol) was treated as described in Example 41A, Part G to give the title compound (0.048g, 57%). 1IINMR (300 MHz, DMSO-D6): δ ppm 1.38 (s, 9 H), 3.01 (s, 3 H), 3.79 (s, 3 H) 7.19 - 7.27 (m, 5 H), 7.62 (d, J=8.82 Hz, 2 H), 7.66 (d, 1=2.57 Hz, 1 II), 8.25 (d, 1=6.99 Hz, 1H).

[001108] Example 43. Preparation of N-(4-((3~tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl)ethynyl)-3-methylphenyl)methanesulfonamide (compound IA-L2-1.9).

[001109] Part A. Preparation of 2-tert-butyl-4-nitrophenol.

[001110] To a vigorously stirred solution of 2-tert-butylphenol (lOg, 66.6mmol) in heptane (67ml) was added at a fast drip a solution of 70% nitric acid (4.25ml, 66.6mmol) diluted with water (4.25ml). The resulting dark red/brown mixture was stirred vigorously for 2h. The suspended solid was collected by filtration washed with hexane (300mL), water (200mL) and once again with hexane (200mL) to give the title compound as a cocoa colored powder that was dried to constant mass (4.65g, 35.6%).

[001111] PartB. Preparation of 2-tert-butyl-6-iodo-4-nitrophenol.

[001112] To the product from Part A (4.5g, 23.05mmol) dissolved in MeOH (120ml) and water (30mL) was added iodine monochloride (1.155ml, 23.05mmol) drop wise over a period of lOmin. The mixture was stirred for 2h and diluted into 1L of water and allowed to stand overnight. The solid material was collected by filtration and washed 3 x 50mL with water and dried under vacuum overnight to give the title compound as a tan solid (7.14g, 96%).

[001113] Part C. Preparation of l-tert-butyl-3-iodo-2-methoxy-5-nitrobenzene.

[001114] To an ice bath cooled solution of the product from Part B (5.5g, 17.13mmol) in MTBE (15ml) in a 50mL pressure vessel was added 2.0M TMS diazomethane (12.85ml, 25.7mmol) followed by drop-wise addition of methanol (1 .OmL) resulting in calm bubbling. The vessel was sealed and stirred at room 226 2014280939 24 Dec 2014 temperature for 16h, cooled and the pressure was released. The solution was partitioned between EtOAc and water. The organic layer was washed with 1 .OM HC1, saturated potassium carbonate solution, and saturated NaCl. The organic layer was dried over sodium sulfate, filtered and concentrated to give the title compound as a red oil that was used without purification (5.4g, 84%).

[001115] PartD. Preparation of 3-tert-butyl-5-iodo-4-methoxyaniline.

[001116] A mixture of the product from Part C (5.80g, 17.31mmol), ammonium chloride (1.389g, 26.0mmol), and iron (4.83g, 87mmol) in THF/MeOH/water (200mL total, 2/2/1) was refluxed for 2h, cooled and filtered through Celite. The filtrate was evaporated and the residue was partitioned between water and EtOAc. The organic layer was washed with saturated brine, dried with sodium sulfate, filtered and evaporated to give the title compound as a brown oil (5.28g, 100% yield).

[001117] PartE. Preparation of l-(3-tert-butyl-5-iodo-4-methoxyphenyl)dihydropyrimidine-2,4(lH,3H)-dione.

[001118] The product from Part D (8.2g, 26.9mmol) was treated with acrylic acid (5.53ml, 81mmol) and stirred overnight to give an extremely viscous mixture. The mixture was treated with acetic acid (60mL) and urea (7.3g 120mmol), heated at 120°C for 24h, cooled and concentrated. The residue was azeotroped 3 x 1 OOmL with toluene to give a brown/tan solid. The solid was suspended in a mixture of 50mL EtOAc and lOOmL of saturated NaHCOj and stirred for 30min to neutralize any remaining acetic acid. The solid was collected by filtration and washed repeatedly with 50mL portions of water and finally with 3:1 hexane/EtOAc (50mL) to give the title compound as an off-white solid that was dried to constant mass (7.1 g, 66%).

[001119] PartF. Preparation ofN-(4-iodo-3-methylphenyl)methanesuIfonamide, [001120] A solution of 4-iodo-3-methylaniline (4.37g, 18.75mmol) in CH2CI2 (25ml) was treated with pyridine (6.07ml, 75mmol) followed by drop wise addition of methanesulfonyl chloride (1,607ml, 20.63mmol) to give a reddish/orange mixture. The mixture was stirred for 2h, concentrated and diluted with EtOAc. The EtOAc layer was washed with 1M HC1, water, saturated NaCl, dried (Na2S04) and filtered. The EtOAc filtrate was treated with activated charcoal for 30min at 50°C and filtered through a lOg silica plug and concentrated to give the title compound as a light yellow solid (5.5g, 94%).

[001121] Part G. Preparation of N-(3-methyl-4-((trimethylsilyl)ethynyl)phenyl)methanesulfonamide.

[001122] A mixture of the product from Part F (3.1 lg, 1 Ommol), copper(I) iodide (0.067g, 0.35mmol), dichlorobis(triphenylphosphine)palladium (II) (0.35 lg, 0.50mmol), triethylamine (6.97ml, 50.Ommol) and trimethylsilyl acetylene (1.684ml, 12.0mmol) in acetonitrile (50ml) was purged with bubbling N2 for 5min and heated under N2 at 80°C for 30min. The reaction mixture was poured into 200mL of EtOAc and partitioned with water adding enough 1M HC1 to bring the pH to 1. The mixture was stirred vigorously for 15min and the layers were separated. The EtOAc layer was washed sequentially with 10% 227 2014280939 24 Dec 2014 aqueous NaHC03, water, and saturated NaCl, dried over Na2SC>4 and filtered. The filtrate was treated with 2.0g of Silicycle Si-thiol silica gel, stirred for 2h and filtered though a 1 inch pad of silica gel. The filtrate was concentrated and the residue was flash chromatographed on silica eluting with 9:1 hexane/EtOAc --> 3:1 hexane/EtOAc to give the title compound as a beige solid (2.7g, 96%).

[001123] Part H. Preparation of N-(4-ethynyl-3-methylphenyl)methanesulfonamide.

[001124] The product from Part G (1.13g, 4.01 mmol) in MeOH (20.07ml) was treated with lMNaOH (8.43ml, 8.43mmol), stirred for lh, partitioned into EtOAc/water and carefully acidified to pH 3 with 1M HC1. The EtOAc layer was washed with brine, dried (Na2S04) and concentrated to give the title compound as a tan solid (820mg, 98%).

[001125] Parti. Preparation ofN-(4-((3-tert-butyI-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yi>-2-methoxyphenyl)ethynyl)-3-methylphenyl)methanesulfonamide.

[001126] A mixture of the products from Part E (1.38g, 3.43mmol), Part H (0.79g, 3.78mmol), copper(I) iodide (0.023g, 0.12mmol) dichlorobis(triphenylphosphine)palladium (II) (0.12g, 0.172mmol) and triethylamine (2.392ml, 17.16mmol) in acetonitrile (60ml) was purged with bubbling N2 for 5min and heated in an oil bath under N2 at 80°C for 20min. The reaction mixture was poured into 400mL of warm EtOAc and partitioned with water adding enough 1M HC1 to bring the pH to 1. The mixture was stirred vigorously for 15min and the layers were separated. The EtOAc layer was washed sequentially with 10% NaHC03, water, and saturated NaCl. The organic layer was dried (Na2S04), and filtered. The filtrate was treated with 4.0g of Silicycle Si-thiol silica gel, heated at gentle reflux for 2h, cooled and filtered though a linch pad of silica gel. The filtrate was concentrated to a yellow solid that was recrystallized by dissolving in hot EtOAc/MeOH (270mL/30mL), reducing the volume to lOOmL and allowing to cool.

The resulting precipitate was collected by filtration and recrystallized a second time to give the title compound as a white solid (760mg, 46%). m.p. >280° C. 'HNMR (300 MHz, DMSO-D6) δ ppm 1.35 (s, 9 H) 2.46 (s, 3 H) 2.70 (t, /= 6.62 Hz, 2 H) 3.05 (s, 3 H) 3.77 (t, /=6.62 Hz, 2 H) 4.04 (s, 3 H) 7.08 (dd, /=8.46,1.84 Hz, 1 H) 7.14 (s, 1 H) 7.25 (d, J=2.57 Hz, 1 H) 7.36 (d, /=2.57 Hz, 1 H) 7.50 (d, /=8.46 Hz, 1 H) 9.99 (s, 1 H) 10.36 (s, 1 H). 228 2014280939 24 Dec 2014 [001127] Example 44. Preparation of N-(4-((3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl) phenyl)ethynyl)-3-chlorophenyl)methanesulfonamide (compound IA-L2-1.3).

[001128] Part A. Preparation of methyl 3-tert-butyl-5-(chlorocarbonyl)benzoate.

[001129] A mixture of 3-tert-butyl-5-(methoxycarbonyl)benzoic acid (9.18g, 38.9mmol, prepared by the method of Carter et, al., W02005021500A1), thionyl chloride (75mL) and 1 drop of DMF in toluene (200mL) was heated at reflux for 2h, cooled and concentrated. The residue was azeotroped with toluene (3 x 50mL) and dried under high vacuum to give the title compound as an off-white waxy solid (9.9g, quantitative yield).

[001130] PartB. Preparation of methyl 3-(azidocarbony))-5-tert-butylbenzoate.

[001131] To the product of Part A (9.9g, 38.9mmol) in acetone (200ml) was added at a fast drip a solution of sodium azide (10.12g, 156mmol) dissolved in water (20mL). The mixture was stirred for 2h and diluted with EtOAc. The organic layer was washed with H20, saturated brine, dried (Na2SC>4), filtered and concentrated to give the title compound as a white solid (9.9g, 97%).

[001132] Part C. Preparation of methyl 3-amino-5-tert-butylbenzoate.

[001133] The product from Part B (9.9g, 37.9mmol) in toluene (lOOmL) was heated at reflux for lh and concentrated to give the intermediate isocyanate which was dissolved in DME (60mL) treated with 8% HC1 (150mL) and stirred for 16h. The mixture was concentrated and the residue was dissolved in water, neutralized with solid sodium bicarbonate and extracted 3 x lOOmL with EtOAc. The organics were combined, washed with saturated NaCl, dried (Na2S04), filtered and concentrated. The crude product was chromatographed on silica eluting with 2:1 hexane/EtOAc to give the title compound as an oil (2.7g, 35%).

[001134] Part D. Preparation of methyl 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxybenzoate.

[001135] A mixture of the product of Part C (2.34g, 11.29mmol) and acrylic acid (2.32ml, 33.9mmol) in toluene (60ml) was heated at reflux under nitrogen for 24h, cooled and concentrated. The resulting residue was then treated with urea (2.03g, 33.9mmol) in acetic acid (35ml) and heated at 120°C for 24h, cooled and concentrated. The residue was azeotroped 3 x 50mL with toluene and dissolved in lOOmL of EtOAc. The organic layer was washed with dilute bicarbonate, H20, saturated brine, dried (Na2S04), 229 2014280939 24 Dec 2014 filtered and concentrated to give the title compound as a white solid (2.1 g, 61%).

[001136] PartE. Preparation of 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)benzoic acid.

[001137] A mixture of the product from Part D (1.8g, 5.91mmol) and 1M NaOH (29.6ml, 29.6mmol) in MeOH (15ml) and THF (15mL) was stirred for 24h and concentrated. The residue was treated with 50mL of 1M HC1 and extracted into EtOAc. The EtOAc layer was washed with H20, saturated brine, dried (Na2S04), filtered and concentrated to give a white solid. This intermediate urea was combined with 20mL of concentrated HC1 and heated at 100°C for 1 h, cooled and diluted with 75mL of ice water to give a solid that was collected by filtration and dried to constant mass to give the title compound as a colorless powder (l.6g, 93%).

[001138] PartF, Preparation of 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)benzaldehyde.

[001139] A solution of the product of Part E (0.8g, 2,76mmol) in sulfureus dichloride (25mL) was heated at reflux for 1,5h, cooled and concentrated. The residue was azeotroped 3 x 25mL with toluene to give a white powder. This acid chloride was dissolved in anhydrous THF (25mL), cooled to -78°C under nitrogen and treated drop wise with 1M lithium tri-tert-butoxyaluminum hydride (3.03mL, 3.03mmol) in THF. The solution was stirred at -78°C for 3h and quenched cold with 1M HC1, warmed to ambient temperature and extracted 3 x 25mL with EtOAc. The organic extracts were combined, washed with water, 10% bicarbonate, saturated brine and dried with sodium sulfate. The EtOAc was filtered and concentrated to give the title compound as a white solid (0.77g, quantitative yield).

[H01140J Part G. Preparation of l-(3-tert-butyl-5-ethynylphenyl)dihydropyrimidine-2,4(lH,3H)-dione.

[001141] A mixture of the product from Part G (913mg, 3mmol), dimethyl 1-diazo-2-oxopropyl phosphonate (749mg, 3.90mmol, prepared by the method of Ohira, Syn. Comm. 19 (3&amp;4) 561-564 (1989), and potassium carbonate (829mg, 6.00mmol) in MeOH (20ml) was stirred for 16h and carefully acidified with 1M HC1. The mixture was extracted 2 x 50mL with CH2C12. The organics were combined, washed with water, saturated NaCl, dried (Na2S04), filtered and concentrated. The crude product was purified via silica gel chromatography eluting with 20:1 (CH2Cl2/MeOH) to give the title compound as a white solid (415mg, 46%).

[001142] PartH. Preparation of N-(4-((3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl) phenyl)ethynyl)-3-chlorophenyl)methanesulfonamide.

[001143] A mixture of the product from Part G (40.5mg, 0.15mmol), copper(l) iodide (1.4mg, 7.5pmol), bis(triphenylphosphine)palladium(II) chloride (5.26mg, 7.50pmol), N-(3-chloro-4-iodophenyl) methanesulfonamide (52.2mg, 0.158mmol, prepared from 3-chloro-4-iodo aniline by the method of Example 43, Part F) and triethylamine (0.105ml, 0.750mmol) in acetonitrile (2mL) was combined in a sealed microwave 5mL tube and purged with N2 bubbling for 5min. The mixture was heated by microwave at 70°C for 5min, cooled and concentrated. The crude material was purified on a 4g silica 230 2014280939 24 Dec 2014 cartridge eluting with 99.5:0.5 CHoCT/MeOH --> 97:3 (^CWMeOH. The desired fractions were combined and concentrated. The material was triturated in a minimal amount of EtOAc and the white solid was collected by filtration and dried to give the title compound (28mg, 39%). m.p. 278-280°C. ]H NMR (300 MHz, DMSO-D6) δ ppm 1.31 (s, 9 H) 2.72 (t, ,/=6.62 Hz, 2 H) 3.12 (s, 3 H) 3.82 (t, /=6.62 Hz, 2 H) 7.20 (dd,/=8.46, 2.21 Hz, 1 H) 7.35 (s, 2 H) 7.38 - 7.46 (m, 2 H) 7.66 (d,/=8.46 Hz, 1 H) 10.31 (s, 1 H) 10.41 (s, 1 H).

[001144] Example 45. Preparation of N-(6-((3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl)ethynyl)pyridin-3-yl)methanesulfonamide (compound IA-L2-1.25).

O

[001145] Part A. Preparation of N-(6-iodopyridin-3-yl)methanesulfonamide.

[001146] To a solution of 6-iodopyridin-3-amine (1.077gm, 4,90mmole) in dichloromethane (40ml) and pyridine (1.98ml, 24.49mmole) at ice bath temperature was added methanesulfonyl chloride (0.401ml, 2.444mmole). The mixture was allowed to warm to room temperature and stir four days. The reaction mixture was treated with 5% acetic acid and allowed to stir 20min at room temperature. The organic phase was washed with water (2x50ml), dried (MgS04) and concentrated in vacuo. The residue was slowly added in portions to rapidly stirred water (100ml) and the resulting solid collected by filtration, washed with water and dried in vacuo to give the title compound (0.7287g, 49.9%).

[001147] PartB. Preparation of N-(6-((trimethylsilyl)ethynyl)pyridin-3-yl)methanesulfonamide.

[001148] The product from Part A (566mg, 1.899mmole) was combined with copper (I) iodide (17mg, 0.089mmole) and bis(triphenylphosphine) palladium (II) chloride (73mg, 0.104mmole) in a pressure tube. Anhydrous acetonitrile (17ml) added followed by triethylamine (1.323ml, 9.49mmole), Nitrogen was bubbled through the resulting yellow suspension with stirring for 5min then added trimethylsilyl acetylene (0.526ml, 3.80mmole). The vessel was immersed in a pre-heated oil bath at 80°C. The reaction mixture was allowed to stir with heating for 2h then cooled to room temperature and transferred to a round bottom flask. The volatiles were removed in vacuo and the brown residue fractionated by (flash)silica gel chromatography (ethyl acetate/hexanes) to give the title product (0.4539g, 89%) as a tan 231 2014280939 24 Dec 2014 solid.

[001149] PartC. Preparation of N-(6-ethynylpyridin-3-yl)methanesulfonamide.

[001150] The product from Part B (0.533gm, 1.984mmole) was dissolved in methanol (17ml) and a 2N sodium hydroxide (2ml, 4.17mmole) solution was added drop wise at room temperature. The mixture was allowed to stir lh. The reaction mixture was concentrated in vacuo. The residue was partitioned between ethyl acetate and water and the pH adjusted to neutral with glacial acetic acid. The organic phase was diluted with additional ethyl acetate then washed several times with brine and concentrated in vacuo to give the title compound as a tan solid (0.3266g, 84%).

[001151] PartD. Preparation ofN-(6-((3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl)ethynyl)pyridin-3-yl)methanesulfonamide.

[001152] The product from Part C (75mg, 0,382mmole) was combined with the product obtained as described in Example 43, Part E (146mg, 0.363mtnole), copper (I) iodide (7.42mg, 0.039mmole) and bis(triphenylphosphine) palladium (II) chloride (18.24mg, 0.026mmole) in a heavy wall glass tube and the vessel sealed with a septum crimp cap. Under an atmosphere of nitrogen added anhydrous acetonitrile (10ml) followed by triethylamine (0.266ml, 1.91 Immole). Nitrogen was bubbled through the resulting brown suspension for 5 min and then the tube was immersed in a pre-heated 80°C oil bath. The reaction was monitored by LC/MS. Three additional aliquots of the alkyne (a total of 71mg, 0.362mmole) each in THF (1ml), were added via syringe over the course of 8h. The reaction mixture was subsequently poured into 150ml of warm (45°C) ethyl acetate, partitioned with brine (75ml) and allowed to stir 15min. The aqueous phase was extracted with ethyl acetate (2x25ml) and the combined organic phase dried (MgS04) and filtered. The filtrate was treated with a gram of Silicycle Sithiol silica gel and heated under nitrogen with stirring for 90min. The silica gel was removed by filtration and after concentration in vacuo the crude product isolated as a pale orange solid. The title compound (0.1315gm, 73.1%) was obtained as an off white solid by (flash) silica gel chromatography using a step gradient of ethyl acetate in hexanes followed by methanol in dichloromethane. m.p. 191-192.5°C (d). *H NMR (300 MHz, DMSO-D6) δ ppm 1.35 (s, 9 H) 2.70 (t, J= 6.62 Hz, 2 H) 3.12 (s, 3 H) 3.78 (t, J= 6.62 Hz, 2 H) 4.07 (s, 3 H) 7.30 (d, .7=2.94 Hz, 1 H) 7.40 (d, J=2.57 Hz, 1 H) 7.65 (d, J= 1.47 Hz, 2 H) 8.44 (s, 1 H) 10.29 - 10.34 (m, 1 H) 10.38 (s, 1H). 232 2014280939 24 Dec 2014 [001153] Example 46. Preparation of N-(4-((3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl)ethynyl)-3-(trifluoromethyl)phenyl)methanesulfonamide (compound IA-L2-1.18).

[001154] Part A. Preparation of N-(4-bromo-3-(trifluoromethyl)phenyl)methanesulfonamide.

[001155] The title compound was prepared by the reaction of 4-bromo-3-(trifluoromethyl)aniline with methanesulfonyl chloride as described in Example 45, Part A.

[001156] PartB. Preparation of N-(3-(trifluoromethyl)-4-((trimethylsilyl)ethynyl)phenyl)methane sulfonamide.

[001157] The product from Part A (2.00gm, 6.29mmole) was combined with triphenylphosphine (0.21 lgm, 0.805mmole) and palladium (II) acetate(0,099gm, 0.440mmole) in a 250ml round bottom flask equipped with a condenser and the reaction was performed as described by W.B Austin et al, J. Org. Chem., 46 (11):2280 (1981). Toluene (40ml) was added followed by triethylamine (80ml) and trimethylsiiylacetylene (4.41ml, 31.4mmole). The resulting yellow solution was purged with nitrogen for 5min at room temperature. The reaction mixture was heated under nitrogen in an oil bath at 80°C for 24h, Cool to room temperature and filter. The filtrate was concentrated in vacuo and the residue chromatographed on silica gel (ethyl acetate-hexanes) to give the title compound as a tan solid (1.4554gm, 69%).

[001158] PartC. Preparation of N-(4-ethynyl-3-(trifluoromethyl)phenyl)methanesulfonamide.

[001159] The product from Part B (0.378gm, 1.126mmole) was dissolved in methanol (8ml) and treated with potassium carbonate (0.322gm, 2.331 mmole) at room temperature. After 90min the reaction mixture was partitioned between ethyl acetate and dilute HC1. The organic phase was water washed then dried (MgS04) and concentrated in vacuo. The residue was purified by silica gel chromatography (ethyl acetate-hexane) to give the title compound as a clear oil, which slowly crystallizes on standing (0.2502g, 84%).

[001160] Part D. Preparation of N-(4-((3-tert-butyI-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl)ethynyl)-3-(trifluoromethyl)phenyl)methanesulfonamide. 233 2014280939 24 Dec 2014 [001161] The product from Part C (0.2502gm, 0.950mmole) was treated with the product obtained as described in Example 43. Part E (0.364gm, 0.905mmole) as detailed in Example 45, Part D. The title compound (0.3195g, 65.7%) was obtained as a white solid by trituration of the crude product with ether-dichloromethane. m.p. 257.5-261°C (d). ’HNMR (300 MHz, DMSO-D6) δ ppm 1.35 (s, 9 H) 2.71 (t, /=6.62 Hz, 2 H) 3.14 (s, 3 H) 3.78 (t, /=6.43 Hz, 2 H) 4.03 (s, 3 H) 7.29 (d, /=2.57 Hz, 1 H) 7.34 (d, /=2.57 Hz, 1 H) 7.48 - 7.56 (m, 1 H) 7.60 (s, 1 H) 7.83 (d, /=8.09 Hz, 1 H) 10.37 (s, 1 H) 10.45 (s, 1 H).

[001162] Example 47. Preparation ofN-[4-(acetyl-methanesulfonyl-amino)-phenyl]-3-tert-butyl-5-(2,4-dioxo-tetrahydro-pyrimidin-1 -yl)-2-methoxy-benzamide (compound IA-L3-1.69).

O

[001163] Part A. Preparation of 3-tcrt-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy-benzoyl chloride.

[001164] The product from Example 29, Part F, (2H)-yl)-2-methoxybenzoic acid (4.07g, 12.71mmol) and thionyl chloride (40.82mL, 559mmol) were added together. The mixture was then refluxed for 2h, followed by concentration under vacuum to provide the product as a light-yellow solid.

[001165] Part B. Preparation of N-[4-(acetyl-methanesulfonyl-amino)-phenyl]-3-tert-butyl-5-(2,4-dioxo-tetrahydro-pyrimidin-1 -yl)-2-methoxy-benzamide.

[001166] The product obtained from Part A (0.073g , 0.15mmole) was dissolved in pyridine (2ml) and treated drop wise with acetic anhydride (0.042mL, 0.45mmol). The mixture was stirred 3h at room temperature. The reaction mixture was concentrated in vacuo and the residue was dissolved in ethyl acetate (25ml). The organic layer was washed with aq. HC1, aq. NaHC03, brine, and dried over anhydrous solid sodium sulfate. The drying agent was filtered and the solvent evaporated under vacuum giving the title compound as a white solid (55mg, 68%). nip 228-229°C. 1H NMR (300 MHz, DMSO-D6) 5 ppm 1.38 (s, 9 H) 1.92 (s, 3 H) 2.72 (t, /=6.62 Hz, 2 H) 3.52 (s, 3 H) 3.73 - 3.82 (m, 5 H) 7.32 (d, /=2.57 Hz, I H) 7.36 (d, /=2.94 Hz, 1 H) 7.44 (d, /=8.82 Hz, 2 H) 7.83 (d, /=8.82 Hz, 2 H) 10.37 (s, 1 H) 10.64 (s, 1 H). 234 2014280939 24 Dec 2014 [001167] Example 48. Preparation ofN-(6-(3-bromo-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide (compound IB-LO-2.69).

O

[001168] Part A. Preparation of 2-bromo-4,6-diiodophcnol.

[001169] A 1L round-bottom flask was charged with 2-bromophenol (Aldrich, 8.65g, 50mmol) and methanol (100ml) to give a colorless solution. Sodium hydroxide (2.40g, 60.0mmol) was added and stirred until the hydroxide pellets had dissolved. The solution was cooled in an ice water bath and sodium iodide (5.6g, 37,4mmol) was added followed by drop-wise addition of sodium hypochlorite (17mL, 27.5mmol) to give a transparent brown/red solution and gradual precipitation of a thick, white solid. The addition of sodium iodide and bleach was repeated 3 times to give an orange mixture that was stirred for 2h, treated with a solution of sodium thiosulfate in water (20g in 1 OOmL), stirred for 15min and treated drop-wise with concentrated HC1 to a constant pH of 1. The mixture was stirred for 15min and filtered to collect a white solid that was washed repeatedly with water and dried to constant mass (14.7g, 69%).

[001170] PartB. Preparation of l-bromo-3,5-diiodo-2-methoxybenzene.

[001171] A 500mL round-bottom flask was charged with the product from Part A (14.7g, 34,6mmol), iodomethane (2.70ml, 43.3mmol), and sodium hydroxide (2.101ml, 39.8mmol) in acetone (96ml) to give a tan solution. The mixture was stirred for 24h and concentrated. The residue was dissolved in ethyl acetate, washed with water and saturated sodium chloride, dried over sodium sulfate, filtered and concentrated to give a white solid. The solid was recrystallized from hot hexane to give a white solid that was collected by filtration (12.3g, 81%).

[001172] Part C. Preparation of l-(3-bromo-5-iodo-4-methoxyphenyI)pyrimidine-2,4(lH,3H)-dione.

[001173] A 250mL round-bottom flask was charged with the product from Part B (8.09g, 18.44mmol), pyrimidine-2,4(lH,3H)-dione (2.273g, 20.28mmol), N-(2-cyanophenyl)picolinamide (0.823g, 3.69mmol), copper (I) iodide (0.351g, 1.844mmol) and potassium phosphate (8.22g, 38.7mmol) in DMSO (70ml). The mixture was sealed, sparged with nitrogen for 15min and heated at 60°C for 16h. The mixture was partitioned with ethyl acetate and water. The organic layer was washed with 1M HC1, water, brine, dried with sodium sulfate, and filtered. The filtrate was treated with 3-mercaptopropyl functionalized silica gel (Aldrich catalog# 538086), filtered through celite and evaporated to give an off-white solid (3.92g, 50%). 235 2014280939 24 Dec 2014 [001174] PartD. Preparation of N-(6-(3-bromo-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl)naphthaIen-2-yl)methanesulfonamide.

[0011751 To a 5mL microwave tube was added the product from Part C (212mg, 0.50mmol), the product from Example 4A, Part B (174mg, 0.50mmol), potassium phosphate (223mg, 1.05mmol), PA-Ph (CAS 97739-46-3, 4.38mg, 0.015mmol) and tris(dibenzylideneacetone)dipalladium(0) (4.58mg, 5.00pmol) in tetrahydrofuran (3.0ml) and water (1.0ml). The tube was sealed and the mixture was sparged with nitrogen for 5min and then stirred for 24h. The reaction mixture was partitioned with ethyl acetate and 1M HCI. The organic layer was washed with saturated sodium bicarbonate, brine, dried with sodium sulfate and filtered. The filtrate was treated with 3-mercaptopropyl functionalized silica gel (Aldrich catalog # 538086), filtered through celite and evaporated. The residue was triturated with methanol/ CH2CI2 to give the title compound as a white solid (256mg, 51 %). ’H NMR (300 MHz, DMSO-D6) δ ppm 3.08 (s, 3 H) 3.43 (s, 3 H) 5.68 (d, 1=8.09 Hz, 1 H) 7.43 (dd, 1=8.82, 2.21 Hz, 1 H) 7.60 (d, 1=2.57 Hz, 1 H) 7.72 (m, 2 H) 7.82 (d, 1=3.31 Hz, 1 H) 7.84 (d, 1=1.84 Hz, 1 H) 7.96 (m, 2 H) 8.09 (s, 1 H) 10.07 (s, 1 H) 11.49 (s, 1 H). MS (ESI-) m/z 513.9, 515.9 (M-H)+.

[001176] Example 49. Preparation of N-(6-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy-3-(5-methylfuran-2-yl)phenyl)naphthalen-2-yl)methanesulfonamide (compound IB-LO-2.58).

[001177] To a 5mL microwave tube was added the product of Example 48 (52mg, O.lOlmmol), 4,4,5,5-tetramethyl-2-(5-methylfuran-2-yl)-l,3,2-dioxaborolane (0.025ml, 0.121mmol), l,l'-bis(di-tert-butylphosphino)ferrocene palladium dichloride (3.28mg, 5.04 μ mol) and potassium phosphate (42.8mg, 0.201 mmol) in THF (3.0ml) and water (1.0ml). The tube was sealed and the mixture was sparged with nitrogen for 5min and then heated at 50°C for 3h. The cooled mixture was partitioned with ethyl acetate and 1M HCI. The organic layer was washed with saturated sodium bicarbonate, brine, dried with sodium sulfate, filtered and concentrated. The filtrate was treated with 3-mercaptopropyl functionalized silica gel, filtered and evaporated. The residue was purified by reverse phase chromatography to give the desired product as a white solid (23mg, 44%, m.p.l74-178°C.) *H NMR (300 MHz, DMSO-D6) δ ppm 2.38 (s, 3 H) 3.09 (s, 3 H) 3.33 (s, 3 H) 5.69 (dd, J=7.72, 2.21 Hz, 1 IT) 6.30 (d, J=3.31 Hz, 1 H) 7.00 (d, J=3.3I Hz, 1 H) 7.43 (m, 2 H) 7.74 (d, J=2.57 Hz, 2 H) 7.78 (dd, J=8.46, 1.84 Hz, 1 H) 7.85 (d, J=8.09 236 2014280939 24 Dec 2014

Hz, 1 H) 7.97 (t, J=8.82 Hz, 2 H) 8.12 (s, 1 H) 10.05 (s, 1 Η) 11.46 (d, J=2.21 Hz, 1 H). MS (ES1+) m/z 518 (M+H)+.

[001178] Example 50. Preparation of N-(6-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy-3-(thiophen-3 -yl)phenyl)naphthalen-2-yl)methanesulfonamide (compound IB-LO-2.53).

(001179] The title compound was prepared according to the procedure of Example 49 substituting thiophen-3-ylboronic acid for 4,4,5,5-tetramethyl-2-(5-methylfuran-2-yl)-l ,3,2-dioxaborolane to give a white solid (12mg, 23%). 'H NMR (300 MHz, DMSO-D6) δ ppm 3.07 (s, 3 H) 3.22 (s, 3 H) 5.69 (d, J=7.72 Hz, 1 H) 7.41 (dd, J=8.64, 2.02 Hz, 1 H) 7.50 (d, J=2.94 Hz, 1 H) 7.59 (dd, J=5.13, 1.08 Hz, 1 H) 7.69 (m, 3 H) 7.76 (dd, J=8.64, 1.65 Hz, 1 H) 7.89 (d, J=7.72 Hz, 1 H) 7.95 (τη, 3 H) 8.09 (s, 1 H) 10.05 (s, 1 Η) 11.47 (s, 1 H). MS (ES1+) m/z 520 (M+H)'.

[001180] Example 51. Preparation of N-(6-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy-3-(thiophen-2-yl)phenyl)naphthalen-2-yl)methanesulfonamide (compound IB-L0-2.61).

[001181] The title compound was prepared according to the procedure of Example 49 substituting thiophen-2-ylboronic acid for 4,4,5,5-tetramethyl-2-(5-methylfuran-2-yl)-l,3,2-dioxaborolane to give a white solid (8mg, 15%). *H NMR (300 MHz, DMSO-D6) δ ppm 3.08 (s, 3 H) 3.30 (s, 3 H) 5.70 (d, 1=8.09 Hz, 1 H) 7.19 (dd, 1=5.33, 3.86 Hz, 1 H) 7.42 (dd, 1=8.82, 2.21 Hz, 1 H) 7.49 (d, 1=2.57 Hz, 1 H) 7.69 (dd, 1=5.15, 1.20 Hz, 1 H) 7.80 (m, 3 H) 7.88 (d, 1=7.72 Hz, 1 H) 7.92 (d, 1=2.57 Hz, 1 H) 7.98 (m, 2 H) 8.12 (s, 1 H) 10.06 (s, 1 Η) 11.48 (s, 1 H). MS (ESI+) m/z 520 (M+H)+. 237 2014280939 24 Dec 2014 [001182] Example 52. Preparation of N-(6-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-3-(furan-2-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide (compound IB-LO-2.59).

[001183] The title compound was prepared according to the procedure of Example 49 substituting furan-2-ylboronic acid for 4,4,5,5-tetramethyl-2-(5-methylfuran-2-yl)-l,3,2-dioxaborolane to give a white solid (16mg, 32%). Ή NMR (300 MHz, DMSO-D6) δ ppm 3.09 (s, 3 H) 3.35 (s, 3 H) 5.69 (d, 1=7.72 Hz, 1 H)6.69(dd, 1=3.31, 1.84 Hz, 1 H) 7.11 (d,J=3.31 Hz, 1 H) 7.43 (dd, 1=8.82,2.21 Hz, 1 H)7.49(d, 1=2.94 Hz, 1 H) 7.80 (m, 5 H) 7.96 (m, 2 H) 8.13 (s, 1 H) 10.06 (s, 1 Η) 11.47 (s, 1 H). MS (ESI-) m/z 502.1 (M-H)+.

[001184] Example 53. Preparation of N-(6-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-3-(furan-3-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide (compound IB-L0-2.64).

[001185] The title compound was prepared according to the procedure of Example 49 substituting furan-3-ylboronic acid for 4,4,5,5-tetramethyl-2-(5-methylfuran-2-yl)-l,3,2-dioxaborolane to give a white solid (6mg, 12%). 'H NMR (300 MHz, DMSO-D6) δ ppm 3.09 (s, 3 H) 3.30 (s, 3 H) 5.69 (dd, 1=7.71, 1.83 Hz, 1 H) 7.10 (dd, 1=1.74, 0.78 Hz, 1 H) 7.42 (dd, 1=8.82,2.21 Hz, 1 H) 7.46 (d, 1=2.57 Hz, 1 H) 7.73 (d, 1=2.21 Hz, 1 H) 7.76 (d, 1=2.57 Hz, 1 H) 7.78 (d, 1=1.84 Hz, 1 H) 7.81 (t, 1=1.84 Hz, 1 H) 7.86 (d, 1=7.72 Hz, 1 H) 7.96 (t, 1=8.82 Hz, 2 H) 8.10 (s, 1 H) 8.28 (s, 1 H) 10.05 (s, 1 Η) 11.48 (s, 1 H). MS (ESI-) m/z 502.1 (M-H)+. 238 2014280939 24 Dec 2014 [001186] Example 54. Preparation of N-(6-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy-biphenyl-3-yI)naphthalen-2-yl)methanesulfonamide (compound IB-LO-2.71).

[001187] The title compound was prepared according to the procedure of Example 49 substituting phenylboronic acid for 4,4,5,5-tetramethyl-2-(5-methylfuran-2-yl)-l,3,2-dioxaborolane. The crude product was purified by silica gel chromatography eluting with 3% methanol/ CH2CI2 to give a white solid (1Omg, 8%). *H NMR (300 MHz, DMSO-D6) δ ppm 3.08 (s, 3 H) 3.12 (s, 3 H) 5.69 (dd, J=7.81, 1.47 Hz, 1 H) 7.36 (m, 5 H) 7.56 (d, J=2.57 Hz, 1 H) 7.64 (m, 2 H) 7.74 (d, 1=2.21 Hz, 1 H) 7.78 (dd, 1=8.46, 1.84 Hz, 1 H) 7.94 (m, 3 H) 8.11 (s, 1 H) 10.04 (s, 1 H) 11.47 (s, 1 H). MS (ESI-) m/z 512 (M-H)+.

[001188] Example 55. Preparation of N-(6-(3'-chloro-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxybiphenyl-3-yl)naphthalen-2-yl)methanesulfonamide (compound IB-L0-2.74).

[001189] The title compound was prepared according to the procedure of Example 49 substituting 3-chlorophenylboronic acid for 4,4,5,5-tetramethyl-2-(5-methylfuran-2-yl)-l,3,2-dioxaborolane to give a white solid (38mg, 68%). ‘H NMR (300 MHz, DMSO-D6) δ ppm 3.09 (s, 3 H) 3.13 (s, 3 H) 5.70 (dd, 1=8.09,2.21 Hz, 1 H) 7.43 (dd, 1=8.82,2.21 Hz, 1 H) 7.52 (m, 3 H) 7.62 (m, 2 H) 7.72 (m, 2 H) 7.79 (dd, 1=8.46, 1.47 Hz, 1 H) 7.95 (m, 3 H) 8.12 (s, 1 H) 10.05 (s, 1 H) 11.47 (d, 1=2.21 Hz, 1 H). MS (ESI-) m/z 546 (M-H)+. 239 2014280939 24 Dec 2014 [001190] Example 56, Preparation ofN-(6-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy-3-(5-methylthiophen-2-yl)phenyI)naphthalen-2-yl)methanesulfonamide (compound IB-LO-2.73).

4,4,5,5-tetramethyl-2-(5-methylthiophen-2-yl)-l,3,2-dioxaborolane for4,4,5,5-tetramethyl-2-(5-methyl-furan-2-yl)-l,3,2-dioxaborolane to give a white solid (22mg, 41%). 'H NMR (300 MHz, DMSO-D6) δ ppm 2.49 (s, 3 H) 3.09 (s, 3 H) 3.29 (s, 3 H) 5.69 (dd, J=8.09, 2.21 Hz, 1 H) 6.87 (d, J=2.57 Hz, 1 H) 7.43 (m, 2 H) 7.54 (d, J=3.68 Hz, 1 H) 7.76 (m, 2 H) 7.85 (s, 1 H) 7.87 (d, J=5.15 Hz, 1 H) 7.98 (t, J=9.01 Hz, 2 H) 8.11 (s, 1 H) 10.06 (s, 1 Η) 11.47 (d, J=2.21 Hz, 1 H). MS (ESI+) m/z 534 (M+H)\ [001192] Example 57. Preparation of N-(6-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-3-(l-hydroxy-2-methylpropan-2-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide (compound IB-L0-2.54).

[001193] Part A. Preparation of 2-(2-hydroxy-3,5-diiodophenyl)acetic acid.

[001194] To a 250mL round bottom flask was added 2-(2-hydroxyphenyl)acetic acid (Aldrich, 3.04g, 20mmol) in acetonitrile (50ml) to give a colorless solution. N-iodosuccimide (9.00g, 40.0mmol) was added portionwise over 15min to give a red/brown transparent solution that was stirred for 16h, The mixture was concentrated and the resulting solid was triturated in 75mL of water and filtered to collect an orange solid that was dried under vacuum. The crude solid was recrystallized from toluene to give a light orange powder (6.0g, 74%).

[001195] PartB. Preparation of methyl 2-(3,5-diiodo-2-methoxyphenyl)acetate.

[001196] To a 250mL round-bottom flask was added the product from Part A (6g, 14.85mmol), potassium carbonate (6.16g, 44.6mmol), and dimethyl sulfate (4.12g, 32.7mmol) in acetone (49.5ml) to 240 2014280939 24 Dec 2014 give a brown suspension. Heated at reflux for 16h, cooled, concentrated and the residue was partitioned between EtOAc and water. The EtOAc layer was washed with brine, dried (Na2S04) and concentrated to a brown oil that was chromatographed on a 40g silica cartridge eluting with 3:1 hexane/EtOAc to give a yellow oil (6.0g, 94%).

[001197] Part C. Preparation of methyl 2-(3,5-diiodo-2-methoxyphenyl)-2-methylpropanoate.

[001198] To a lOOmL round-bottom flask under nitrogen was added the product from Part B (l,728g, 4mmol) in anhydrous THF (20ml) and HMPA (2ml) to give a colorless solution. Methyl iodide (1.251ml, 20.00mmol) was added and the solution was cooled to -40°C. Potassium t-butoxide(12.00ml, 12.00mmol) was added dropwise and the mixture was stirred at -40 to -20°C for 30min and quenched with 1M HC1 to a pH of 1. The mixture was extracted 3 X 40ml with EtOAc. The extracts were combined, washed with brine, dried (NajSOH and concentrated. The crude product was flash chromatographed on a 40g ISCO silica cartridge eluting with 9:1 hexane/EtOAc to give the bis-methylated product as a yellow oil (1,63g, 89%).

[001199] Part D. Preparation of 2-(3,5-diiodo-2-methoxyphenyl)-2-methylpropanoic acid.

[001200] A suspension of the product from Part C (2.63g, 5.72mmol) in MeOH (40ml) and THF (40ml) was treated with 4.0M sodium hydroxide (28ml, 112mmol) and heated at 80°C for 48 h. The organic solvent was evaporated and the remaining aqueous solution was acidified with 1M HC1 producing a solid that was collected by filtration, washed with water and dried to give the desired carboxylic acid (2.46g, 96%).

[001201] Part E. Preparation of 2-(3,5-diiodo-2-methoxyphenyl)-2-methylpropan-l-ol.

[001202] A solution of the product from Part D (l.OOg, 2,242mmol) in THF (40ml) was treated dropwise with borane THF complex 1,0M (20ml, 20mmol) and then heated at 50°C for 24 h. The mixture was treated with methanol (20mL), refluxed for 30 min and concentrated. The resulting residue was washed with water, brine, dried with sodium sulfate, filtered and evaporated. The residue was chromatographed on silica gel eluting with hexane/EtOAc (4:1) to give the desired product (810mg, 84%).

[001203] PartF. Preparation oftert-butyl(2-(3,5-diiodo-2-methoxyphenyl)-2-methylpropoxy)-dimethylsilane, [001204] A solution of the product from Part E (432mg, l.OOOmmol) in DMF (5ml) was treated with tert-butyldimethylchlorosilane (301mg, 2.000mmol), and imidazole (204mg, 3.00mmol) and stirred for 2h. The mixture was partitioned between 1M HC1 and ethyl acetate. The organic layer was washed with saturated sodium bicarbonate, brine, dried with sodium sulfate, filtered and evaporated. The residue was chromatographed on silica gel eluting with hexane/EtOAc (9:1) to give the desired product (522mg, 96%).

[001205] Part G. Preparation of 1-(3-( l-(tert-butyldimethylsilyloxy)-2-methylpropan-2-yI)-5-iodo-4-241 2014280939 24 Dec 2014 methoxypheny l)pyrimid ine-2,4( 1 H,3 H)-dione.

[001206] To a 50mL round-bottom flask was added the product from Part F (520mg, 0.952mmol), pyrimidine-2,4( 1H,3 H)-dione (117mg, 1.047mmol), N-(2-cyanophenyl)picolinamide (42,5mg, 0.190mmol), copper(I) iodide (18.13mg, 0.095mmol) and potassium phosphate (424mg, 1.999mmol) in DMSO (5ml). The vessel was sealed, sparged with nitrogen and then heated at 60°C for 24h. The mixture was partitioned between 1M HC1 and ethyl acetate. The organic layer was washed with saturated sodium bicarbonate, brine, dried with sodium sulfate, and filtered. The filtrate was treated with 3-mercaptopropyl functionalized silica gel, filtered and evaporated. The residue was chromatographed on silica gel eluting with hexane/EtOAc (3:2) to give the product as a solid (285mg, 65%).

[001207] PartH. Preparation of hHti-P-O-itert-butyldimethylsilyloxy^-methylpropan^-yfl-S-P^-dioxo-S^-dihydropyriniidin-l^H^yO^-methoxyphenyOnaphthalen^-y^methanesulfonamide.

[001208] To a 5mL microwave tube was added the product from Part G (50mg, 0.094mmol), the product from Example 4A, Part B (32.7mg, 0.094mmol), potassium phosphate (42.0mg, 0.198mmol), PA-Ph (CAS 97739-46-3) (0.827mg, 2.83 pmol) and tris(dibenzylideneacetone)palladium(0) (0.863mg, 0.943pmol) in THF (3.0ml) and water (1.0ml). The vessel was sealed and the mixture was sparged with nitrogen for 5min and then heated at 50°C for 2h. The mixture was partitioned between 1M HC1 and ethyl acetate. The organic layer was washed with saturated sodium bicarbonate, brine, dried with sodium sulfate and filtered. The filtrate was treated with 3-mercaptopropyl functionalized silica gel, filtered and evaporated. The residue was chromatographed on silica gel eluting with hexane/EtOAc (3:7) to give a solid (32mg, 54%).

[001209] Part I. Preparation of N-( 6-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-3-(l-hydroxy-2-methylpropan-2-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide.

[001210] The product from Part H (3 lmg, 0.050mmol) in THF (2.0ml) was treated with 1M TBAF (0.3ml, 0.3mmol) in THF and stirred overnight. The mixture was partitioned with water and ethyl acetate. The organic layer was washed with brine three times, dried with sodium sulfate, filtered and evaporated. The residue was chromatographed on silica gel eluting with 2% to 8% methanol in CH2C12 to give a solid (2lmg, 83%). Melting point: 256-257°C. 'H NMR (300 MHz, DMSO-D6) δ ppm 1.35 (s, 6 H) 3.08 (s, 3 H) 3.23 (s, 3 H) 3.67 (d, 3=4.78 Hz, 2 H) 4.72 (t, 3=4.78 Hz, 1 H) 5.65 (d, 3=8.09 Hz, 1 H) 7.36 (m, 3 H) 7.74 (m, 3 H) 7.98 (m, 3 II) 10.04 (s, 1 Η) 11.41 (s, 1 H). MS (ESI+) m/z 527 (M+ NH4)+. 242 2014280939 24 Dec 2014 [001211] Example 58. Preparation of N-(6-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy-3-(l-methoxy-2-methylpropan-2-yl)phenyl)naphthalen-2-yl)methanesulfonamide (compound IB-LO-2.66).

[001212] Part A. Preparation of l,5-diiodo-2-methoxy-3-(l-methoxy-2-methylpropan-2-yI)benzene.

[001213] To a 25mL round-bottom flask was added the product from Example 57, Part E. (259mg, 0.6mmol) and sodium hydride (28.8mg, 1.200mmol) in THF (5ml). The mixture was stirred for 30min and iodomethane (0.045 1, 0.720mmol) was added. The mixture was stirred for 16h and partitioned between ethyl acetate and 1M HC1. The organic layer was washed with saturated sodium bicarbonate, brine, dried with sodium sulfate, filtered and evaporated to give an oil (235mg, 88%).

[001214] FartB. Preparation of l-(3-iodo-4-methoxy-5-(l-melhoxy-2-methylpropan-2-y l)phenyl)pyrimidine-2,4( 1H, 3 H)-d ione.

[001215] In a 25mL round-bottom flask was added the product from Part A (230mg, 0.516mmol), pyrimidine-2,4(lH,3H)-dione (63.6mg, 0.567mmol), N-(2-cyanophenyl)picolinamide (23.02mg, 0.103mmol), copper(I) iodide (9.82mg, 0.052mmol) and potassium phosphate (230mg, 1.083mmol) in DMSO (5ml). The vessel was sealed, sparged with nitrogen and heated at 60°C for 16h. The mixture was cooled and partitioned between ethyl acetate and 1M HC1. The organic layer was washed with saturated sodium bicarbonate, brine, dried with sodium sulfate, filtered and evaporated. The residue was chromatographed on silica gel eluting with 2% to 5% methanol in CH2C12 to give a solid (140mg, 63%).

[001216] Part C. Preparation ofN-(6-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy-3-(l-methoxy-2-methylpropan-2-yI)phenyl)naphthalen-2-yl)methanesulfonamide.

[001217] In a 5ml microwave tube was added the product from Part B (43mg, O.lOOmmol), the product from Example 4A, Part B (34.7mg, O.lOOmmol), potassium phosphate (44.6mg, 0.210mmol), PA-Ph (CAS 97739-46-3) (0.876mg, 3.00pmol) and tris(dibenzylideneacetone)palladium(0) (0.915mg, 0.999μηιο1) in THF (3.0ml) and water (1.0ml). The vessel was sealed, sparged with nitrogen for 5min and heated at 50UC for 2h. The mixture was partitioned with ethyl acetate and 1M HC1. The organic layer was washed with saturated sodium bicarbonate, brine, dried with sodium sulfate, filtered. The filtrate was treated with 3-mercaptopropyl functionalized silica gel, filtered and evaporated. The residue was triturated with methanol/ CH2C12 (1:1) to give a solid (28mg, 54%). 'H NMR (300 MHz, DMSO-243 2014280939 24 Dec 2014

D6) δ ppm 1.39 (s, 6 H) 3.08 (s, 3 H) 3.23 (s, 3 H) 3.25 (s, 3 H) 3.61 (s, 2 H) 5.65 (d, J=7.72 Hz, 1 H) 7.27 (d, J=2.57 Hz, 1 H) 7.37 (d, J=2.57 Hz, 1 H) 7.42 (dd, 1=8.64,2.02 Hz, 1 H) 7.69 (dd, 1=8.46, 1.84 Hz, 1 H) 7.73 (d, 1=2.21 Hz, 1 H) 7.78 (d, 1=7.72 Hz, 1 H) 7.95 (t, 1=8.27 Hz, 2 H) 8.02 (s, 1 H) 10.04 (s, 1 H) 11.41 (s, 1 H). MS (ESI+) m/z 541 (M+NH4)+.

[001218] Example 59. Preparation of methyl 2-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy-3-(6-(methylsulfonamido)naphthalen-2-yl)phenyl)-2-methylpropanoate (compound IB-L0-2.70). &amp; methoxyphenyl)-2-methylpropanoate.

[001220] To a lOOmL round-bottom flask under N2 was added the product from Example 57, Part C (410mg, 0.891mmol), lH-pyrimidine-2,4-dione (120mg, 1.069mmol), and potassium phosphate tribasic (397mg, 1.872mmol) in DMSO (5ml) to give a colorless suspension. N-(2-cyanophenyl) picolinamide (39.8mg, 0.178mmol) was added and the mix was sparged with N2 for 5min. Copper(I) iodide (16.97mg, 0.089mmol) was added and the mix was sparged once again for 10min, placed under N2 and heated at 60°C for 18h. The mixture was cooled and partitioned between EtOAc and water adjusting the pH to 1 with HC1. The aqueous layer was extracted 2X with EtOAc. The organics were combined, washed with water, saturated NaTICOa, and saturated NaCl. The organic layer was dried (Na^SO/,). treated with 3-mercaptopropyl functionalized silica, filtered and concentrated. The crude product was purified by chromatography on an ISCO 40 g silica cartridge eluting with 3% MeOH in CH2C12 to give a white foam (269mg, 68%).

[001221] PartB. Preparation of methyl 2-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy-3-(6-(methylsulfonamido)naphthalen-2-yl)phenyl)-2-methylpropanoate.

[001222] To a 20mL microwave tube was added the product from Part A (0.444g, I .Ommol), the product from Example 4A, Part B (0.365g, 1.050mmol), and potassium phosphate tribasic (0.446g, 2.1 OOmmol) in 3:1 tetrahydrofuran-water (12ml) and degassed by nitrogen sparge for 20min. The solution was then treated with PA-Ph (CAS 97739-46-3) (8.77mg, 0.030mmol) and tris(dibenzylidene-acetone)palladium(0) (9.16mg, lO.OOpmol) followed by degassing for another 5min. The microwave tube was then sealed and 244 2014280939 24 Dec 2014 warmed at 50°C for 18h, cooled and partitioned between EtOAc and water adjusting the pH to 1 with 1M HC1, The EtOAc layer was washed with water, saturated NaHC03, and saturated NaCl. The organic layer was dried over sodium sulfate, stirred for 1 h with 3-mercaptopropyl functionalized silica, fdtered and concentrated. The crude product was purified by chromatography on an ISCO 12g silica cartridge eluting with 1-3% MeOH in CH2Cl2to give light tan crystals (480mg, 98%). H NMR (300 MHz, DMSO-D6) δ ppm 1.52 (s, 6 H) 3.08 (s, 3 H) 3.14 (s, 3 H) 3.64 (s, 3 H) 5.67 (dd, J=8.09, 1.84 Hz, 1 H) 7.37 - 7.48 (m, 3 H) 7.65 (dd, J=8.46, 1.84 Hz, 1 H) 7.73 (d, J=2.21 Hz, 1 H) 7.83 (d, J=8.09 Hz, 1 H) 7.96 (dd, J=8.64, 5.70 Hz, 2 H) 8.01 (s, 1 H) 10.05 (s, 1 Η) 11.45 (s, 1 H). MS (ESI-) m/z 536 (M-H)+.

[001223] Example 60. Preparation of 2-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy-3-(6-(methylsulfonamido)naphthalen-2-yl)phenyl)-2-methylpropanoic acid (compound IB-LO-2.77).

[001224] A mixture of the product from Example 59 (108mg, 0.2mmol) and sodium hydroxide (ImL, 4.00mmol) in methanol, THF, water (3:3:1, lOmL) was heated at 80°C for 18h, cooled and carefully acidified to pH 1 with concentrated HC1 resulting in the formation of a white precipitate. The solid was collected by fi Itration, washed with water and dried. The crude material was triturated in 1 mL of 1:1 EtOAc/MeOH, sonicated for 5min and the solid was collected by filtration as a bright white solid (58mg, 54% yield), mp >300°C. Ή NMR (300 MHz, DMSO-D6) δ ppm 1.50 (s, 6 H) 3.08 (s, 3 H) 3.18 (s, 3 H) 5.66 (d, J=7,72 Hz, 1 H) 7.34 - 7.45 (m, 3 H) 7.67 (dd, J=8.64, 1.65 Hz, 1 H) 7.73 (d, J=1.84 Hz, 1 H) 7.82 (d, J=7.72 Hz, 1 H) 7.96 (dd, J=9.01, 4.60 Hz, 2 H) 8.02 (s, 1 H) 10.04 (s, 1 Η) 11.43 (s, 1 H) 12.15 (s, 1 H). MS (ESI-) m/z 522 (M-H)+. 245 2014280939 24 Dec 2014 [001225] Example 61. Preparation of methyl 5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy-3-(6-(methylsulfonamido)naphthalen-2-yl)benzoate (compound IB-LO-2.72).

[001226] Part A. Preparation of methyl 3,5-diiodo-2-methoxybenzoate.

[00122η A mixture of 2-hydroxy-3,5-diiodobenzoic acid (3.9g, lO.Ommol) potassium carbonate (4.15g, 30.0mmol) and dimethyl sulfate (2.77g, 22.0mmol) in acetone (33ml) was heated at reflux for 16h, cooled and concentrated. The residue was dissolved in EtOAc and washed with water, brine, dried (Na2S04), filtered and concentrated to give an off-white solid (4.2g, quantitative yield).

[001228] PartB. Preparation of methyl 5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-3-iodo-2-methoxybenzoate.

[001229] To a lOOmL round-bottom flask under N? was added the product from Part A (2.09g, 5.0mmol), lH-pyrimidine-2,4-dione (0.67g, 6.0mmol), and potassium phosphate tribasic (2.2g, 10.5mmol) in DMSO (20ml) to give a colorless suspension. N-(2-cyanophenyl)picolinamide (220mg, I .Ommol) was added and the mix was sparged with N2 for 5min. Copper(I) iodide (95mg, 0.5mmol) was added and the mix was sparged once again for lOmin, placed under N2 and heated at 60°C for 18h. The mixture was cooled and partitioned between EtOAc and water adjusting the pH to 1 with HC1. The aqueous layer was extracted 2X with EtOAc. The organics were combined, washed with water, saturated NaHC03, and saturated NaCl. The organic layer was dried (Na2S04), treated with 3-mercaptopropyl functionalized silica, filtered and concentrated. The crude product was purified by chromatography on an ISCO 40g silica cartridge eluting with 3% McOH in CH2C12 to give a white foam (l.Og, 50 %).

[001230] PartC. Preparation of methyl 5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy-3-(6-(methylsulfonamido)naphthalen-2-yl)benzoate.

[001231] A mixture of the product from Part B (lOlmg, 0.25mmol), the product from Example 4A,

Part B (91mg, 0.263mmol), and potassium phosphate tribasic (11 lmg, 0.525mmol) in 3:1 tetrahydro-furan-water (12mL) was degassed by nitrogen sparge for 20min. The solution was then treated with PA-Ph (CAS 97739-46-3) (2.192mg, 7.50pmol) and tris(dibenzylideneacetone)palladium(0) (2.289mg, 2.500pmol) followed by degassing for another 5min. The microwave tube was then sealed, warmed at 50°C for 18h, cooled and partitioned between EtOAc and water adjusting the pH to 1 with 1M HC1. The 246 2014280939 24 Dec 2014

EtOAc layer was washed with water, saturated NaHC03, and saturated NaCl. The organic layer was dried Na2S04, stirred for lh with 3-mercaptopropyl functionalized silica, filtered and concentrated. The crude product was purified by chromatography on an ISCO 12g silica cartridge eluting with 3% MeOH in CH2C12 to give an off-white foam (80mg, 63 %). 'H NMR (300 MHz, DMSO-D6) δ ppm 3.09 (s, 3 H) 3.45 (s, 3 H) 3.89 (s, 3 H) 5.69 (d, J=7.72 Hz, 1 H) 7.43 (dd, J=8.82,2.21 Hz, 1 H) 7.68 - 7.79 (m, 4 H) 7.84 (d, 1=7.72 Hz, 1 H) 7.89 - 8.01 (m, 2 H) 8.09 (s, 1 H) 10.06 (s, 1 Η) 11.49 (s, 1 H). MS (ESI-) m/z 494 (M-H)+.

[001232] Example 62. Preparation ofN-(6-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-3-iodo-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide (compound IB-LO-2.57).

[001233] Part A. Preparation of 1,3,5-triiodo-2-methoxybenzene.

[001234] In a 250mL pressure vessel was added 2,4,6-triiodophenol (5g, 10.60mmol) in MTBE (60ml) to give a yellow solution. The solution was cooled in an ice bath and 2.0M trimethylsilyldiazomethane (7.95ml, 15.90mmol) was added at a fast drip followed by dropwise addition of methanol (6mL) resulting in calm bubbling. The vessel was sealed and stirred at room temperature for 4h. The reaction solution was partitioned between EtOAc and water and the organic layer was washed with 1M HC1, saturated NaHCO j, and saturated NaCl. The EtOAc was dried (MgS04), filtered and concentrated to give a tan solid that was used without purification (4.8g, 94 %).

[001235] Part B. Preparation of 1-(3,5-diiodo-4-methoxyphenyl)pvrimidine-2,4(lH,3H)-dione.

[001236] To a lOOmL round-bottom flask under N2 was added the product from Part A (3,5g, 7.2mmol), lH-pyrimidine-2,4-dione (0.97g, 8.64mmol), and potassium phosphate tribasic (3.2g, 15.0mmol) in DMSO (50ml) to give a colorless suspension. N-(2-cyanophenyl)picolinamide (320mg, l,44mmoi) was added and the mix was sparged with N2 for 5min, Copper(I) iodide (137mg, 0.72mmol) was added and the mix was sparged once again for lOmin, placed under N2 and heated at 60°C for 18h. The mixture was cooled and partitioned between EtOAc and water adjusting the pH to 1 with HC1. The aqueous layer was extracted 2X with EtOAc. The organics were combined, washed with water, saturated NaH0O3, and saturated NaCl, dried (Na2S04), treated with 3-mercaptopropyl functionalized silica, filtered and concentrated. The resulting solid was triturated in 2:1 hexane/EtOAc to give an off white powder (2.2g, 247 2014280939 24 Dec 2014 62 %).

[001237] Part C. Preparation of N-(6-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-3-iodo-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide.

[001238] A mixture of the product from Part B l-(3,5-diiodo-4-methoxyphenyl)pyrimidine-2,4(lH,3H)-dione(118mg, 0.25mmol), the product from Example 4A, Part B (87mg, 0.25mmol), 1,1’-bis(diphenylphosphino)ferrocene-palladium(II)dichloride CH2C12 complex (10.21mg, 0.013mmol) and sodium carbonate (0.250ml, 0.25mmol) in toluene (1,0ml) and ethanol (1.0ml) was sparged with nitrogen for 5min and microwaved at 1 ()0°C for 30min. The mixture was cooled and partitioned with ethyl acetate and 1M HC1. The organic layer was washed with saturated sodium bicarbonate, brine, dried with sodium sulfate, filtered and evaporated. The residue was chromatographed on silica eluting with ethyl acetate/hexane (2:3 to 4:1) to give the title compound (16mg, 11%). 'H NMR (300 MHz, DMSO-D6) δ ppm 3.08 (s, 3 H) 3.35 (s, 3 H) 5.67 (d, J=8.09 Hz, 1 H) 7.42 (dd, 1=8.82, 2.21 Hz, 1 H) 7.59 (d, 1=2.57 Hz, 1 H) 7.73 (m, 2 H) 7.81 (d, 1=8.09 Hz, 1 H) 7.95 (m, 3 H) 8.09 (s, 1 H) 10.06 (s, 1 H) 11.47 (s, 1 H). MS (ESI-) m/z 562 (M-H)+, [001239] Example 63. Preparation of N-(6-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy-3-((trimethylsilyl)ethynyl)phenyl)naphthalen-2-yl)methanesulfonainide (compound IB-LO-2.78).

[001240] In a 5mL microwave tube were combined ethynyltrimethylsilane (0.044ml, 0.32mmol), the product from Example 62 (45.1mg, 0.08mmol), copper(I) iodide (0.762mg, 4.0pmol), bis(triphenyl-phosphine)palladium(II) chloride (2.81 mg, 4.0μιηοΙ) and triethylamine (0.056ml, 0.40mmol) in acetonitrile (2ml). The mixture was sparged with nitrogen for 5min, sealed and microwaved at 80°C for 20min. The reaction mixture was cooled and partitioned with ethyl acetate and water. The organic layer was washed with brine, dried with sodium sulfate, filtered and evaporated. The residue was chromatographed on silica eluting with 1-4% methanol in CH2C12 to give a solid, (18mg, 42%) m.p.175-178°C. 'H NMR (300 MHz, DMSO-D6) δ ppm 0.25 (s, 9 H) 3.07 (s, 3 H) 3.65 (s, 3 H) 5.66 (dd, 1=7.91, 2.02 Hz, 1 H) 7.41 (dd, 1=8.82, 2.21 Hz, 1 H) 7.58 (m, 2 H) 7.69 (dd, J=8.46, 1.84 Hz, 1 H) 7.72 (d, J=2.21 Hz, 1 H) 7.81 (d, J=7.72 Hz, 1 H) 7.93 (m, 2 H) 8.05 (d, .1=1.32 Hz, 1 H) 10.04 (s, 1 Η) 11.45 (d, J—2.21 Hz, 1 H). MS (ESI+) m/z 534 (M+H)+. 248 2014280939 24 Dec 2014 [001241] Example 64. Preparation of N-(6-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy-3-(methylsulfonyl)phenyl)naphthalen-2-y!)methanesulfonamide (compound IB-LO-2.68).

[001242] Part A. Preparation of 4-nitrobenzene-2-diazo-1-oxide.

[001243] To a 250mL round-bottom flask was added 2-amino-4-nitrophenol (6.165g, 40.0mmol) in 48% tetrafluoroboric acid (15ml). Sodium nitrite (2.76g, 40.0mmol) in water (6ml) was added dropwise at 0°C and the mixture was stirred at room temperature for 30min. The solid was collected by filtration, washed with tetrafluoroboric acid and water. The solid was suspended in acetone (50ml), filtered and dried to give a solid (3.31 g, 50%).

[001244] PartB. Preparation of 2-(methylthio)-4-nitrophenol.

[001245] To a 1L beaker was added the product from Part A (2.70g, 16.35mmol) in ice water (250g) to give a brown suspension. Copper (0.520g, 8.18mmol) was added, followed by addition of sodium thiomethoxidc (2.292g, 32.7mmol) in water (50ml) slowly. The mixture was stirred at room temperature for 24h. The mixture was filtered and the filtrate was acidified with 1M HC1 producing a solid that was collected by filtration and dried (2.53 g, 84%).

[001246] PartC. Preparation of 2-(methylsulfonyl)-4-nitrophenol.

[001247] To a 250mL round-bottom flask was added the product from Part B (1.11 lg, 6.00mmol) in MeOH (20ml) to give a brown suspension. Oxone (7.746g, 12.60mmol) in water (20ml) was added slowly at 0°C. The mixture was warmed to room temperature, stirred for lh and partitioned with ethyl acetate and 1M HC1. The organic layer was washed with brine, dried with sodium sulfate, filtered and evaporated. The residue was chromatographed on silica gel eluting with 1% to 5% methanol in Cff Cfi to give a solid (0.472g, 36%) [001248] PartB. Preparation of2-iodo-6-(methylsulfonyl)-4-nitrophenol.

[001249] To a 50mL round-bottom flask was added the product from Part C (470mg, 2.164mmol) in MeOH (10ml) and water (2.5ml). Iodine monochloride (0.130ml, 2.60mmol) in CH2CI2 (2.0mL) was added dropwise and the mixture was stirred at room temperature, poured into water (200mL) and stirred for lOmin, The resulting solid was collected by filtration and dried (636mg, 86%).

[001250] Part E. Preparation of l-iodo-2-methoxy-3-(methylsulfonyl)-5-nitrobenzene. 249 2014280939 24 Dec 2014 [001251] To a 50mL pressure vessel was added the product from Part D (630mg, 1.836mmol) in MTBE (6ml) to give a yellow solution. The mixture was cooled in an ice bath and 2M trimethyisilyl-diazomethane (1.377ml, 2.75mmol) was added at a fast drip followed by dropwise addition of MeOH (0.4ml) resulting in calm bubbling. The vessel was sealed and stirred at room temperature for lh. The mixture was partitioned with ethyl acetate and 1M HC1. The organic layer w'as washed with saturated sodium bicarbonate, brine, dried with sodium sulfate, filtered and evaporated to give an off-white solid (655mg, 100%).

[001252] PartF. Preparation of 3-iodo^i-methoxy-5-(methylsulfonyl)aniline.

[001253] To a 250mL round-bottom flask was added the product from Part E (0.650g, 1.820mmol), ammonium chloride (0,146g, 2.73mmol), and iron (0.508g, 9.10mmo!) in THF/MeOH/water (50ml, 2/2/1). The mixture was refluxed for 2h, cooled and filtered. The filtrate was evaporated and the residue was partitioned with ethyl acetate and water. The organic layer was washed with brine, dried with sodium sulfate, filtered and evaporated to give a solid (590mg, 99%).

[001254] Part G. Preparation of (E)-N-(3-iodo-4-methoxy-5-(methylsulfonyl)phenylcarbamoyl)-3-methoxy aery 1 am i de.

[001255] To a lOOmL round-bottom flask was added the product from Part F (500mg, l,528mmol) in DMF (15.0ml). The solution was cooled under nitrogen to -20°C and (E)-3-methoxyacryloyl isocyanate (15.28ml, 6.1 lmmol; prepared as described by Santana, L.; et al. J. Heterocyclic Chem. 1999,36, 293-295) was added dropwise. The mixture was stirred at this temperature for 15min, then warmed to room temperature and stirred for 45min. The mixture was diluted with ethyl acetate and washed by water (3 x 50ml), brine (3 x 50ml), dried with sodium sulfate, filtered and evaporated. The residue was triturated with ethyl acetate/hexane to give a solid (425mg, 61%).

[001256] Part H. Preparation of l-(3-iodo-4-methoxy-5-(methylsulfonyl)phenyi)pyrimidine-2,4(lH,3H)-dione.

[001257] To a lOOmL round-bottom flask was added the product from Part G (420mg, 0.925mmol) in ethanol (10ml) to give a suspension. Concentrated sulfuric acid (lmL, 18.76mmol) in water (10ml) was added and the mixture was heated at 110°C for 2h. The reaction mix was cooled, diluted with water (50ml) and stirred for lOmin. The solid material was collected by filtration, washed with water and dried to give a white solid (325mg, 83%).

[001258] Part I. Preparation of N-(6-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy-3-(methylsulfonyl)phenyl)naphthalen-2-yl)methanesulfonamide.

[001259] To a 5mL microwave tube was added the product from Part H (63.3mg, 0.15mmol), the product from Example 4A, Part B (52.1 mg, 0.150mmol), l,l'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride complex (6,12mg, 7.50pmol) and 1M sodium carbonate (0.150ml, O.lSOmmol) in 250 2014280939 24 Dec 2014 the solvents of toluene (1.0ml) and ethanol (1,0ml). The vessel was sealed and the mixture was sparged with nitrogen for 5min and microwaved at 100°C for 30min. The mixture was partitioned with ethyl acetate and 1M HC1. The organic layer was washed with saturated sodium bicarbonate, brine, dried with sodium sulfate, filtered and evaporated. The residue was purified on silica gel eluting with 1% to 8% methanol in CH2CI2 to give crude product. A final trituration in 1; 1 methanol/ethyl acetate afforded pure solid (26mg, 34%). 'H NMR (300 MHz, DMSO-D6) δ ppm 3.10 (s, 3 H) 3.44 (s, 3 H) 3.45 (s, 3 H) 5.71 (d, J=8.09 Hz, I H) 7.44 (dd, J=8.82, 2.21 Hz, 1 H) 7.75 (d, J= 1.84 Hz, 1 H) 7.80 (dd, J=8.46, 1.84 Hz, 1 H) 7.86 (d, J=8.09 Hz, 1 H) 7.91 (d, J=2.57 Hz, 1 H) 7.96 (d, J=2.57 Hz, 1 H) 8.00 (m, 2 H) 8.16 (d, J=1.47 Hz, 1 H) 10.10 (s, 1 Η) 11.51 (s, 1 H). MS (ESI+) m/z 533 (M+NH4)+.

[001260] Example 65. Preparation of N-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy-3-(6-(methylsulfonamido)naphthalen-2-yl)phenyl)methanesulfonamide (compound IB-LO-2,75).

[001261] Part A. Preparation of 2,4-diiodo-6-nitrophenol.

[001262] To a solution of 2-nitrophenoI (2.78g, 20mmol) in MeOH (120ml) and water (30mL) was added dropwise a solution of iodine monochloride (2.105ml, 42.0mmol) in 1 OmL CH2C12. The mixture was stirred for 2h, poured into 600mL water, stirred and sonicated for 30min. The mixture was filtered to collect a yellow solid that was washed 3x with water (50mL each wash) and dried to constant mass (7.3g, 93%). m [001263] PartB. Preparation of l,5-diiodo-2-methoxy-3-nitrobenzene.

[001264] A 50mL pressure vessel was charged with the product from Part A and MTBE (10ml) to give a yellow solution. The solution was cooled in an ice bath and 2M trimethylsilyldiazomethane (2.251ml, 4.50mmol) was added at a fast drop followed by dropwise addition of MeOH (0.6ml) resulting in calm bubbling. The vessel was sealed and stirred allowing warm to room temperature over 4h. The mixture was partitioned with ethyl acetate and 1M HC1. The organic layer was washed with saturated sodium bicarbonate, brine, dried with sodium sulfate, filtered and evaporated to give a yellow solid (1,22g, 100%).

[001265] Part C. Preparation of 3,5-diiodo-2-methoxyaniline.

[001266] In a 250 round-bottom flask was added the product from Part B (0.98g, 2.420mmol), 251 2014280939 24 Dec 2014 ammonium chloride (0.194g, 3.63mmol), and iron (0.676g, 12.1 Ommol) in THF/methanol/water (20ml/20ml/10ml). The mixture was refluxed for 16ho, cooled and filtered. The filtrate was evaporated and the residue was partitioned with water and ethyl acetate. The organic layer was dried with sodium sulfate, filtered and evaporated to give an oil (780mg, 86%).

[001267] Part D. Preparation of l-(3-amino-5-iodo-4-methoxyphenyl)pyrimidine-2,4(lH,3H)-dione, [001268] In a 25mL round-bottom flask was added the product from Part C (650mg, 1,734mmol), pyrimidine-2,4( 1H,3 H)-dione (214mg, 1.907mmol), N-(2-cyanophenyl)picolinamide (77mg, 0.347mmol), copper(I) iodide (33.0mg, 0.173mmol) and potassium phosphate (773mg, 3.64mmol) in DMSO (5ml). The vessel was sealed and the mixture was sparged with nitrogen for 15min and heated at 60°C for 16h. The mixture was partitioned with ethyl acetate and 1M HC1. The organic layer was washed with saturated sodium bicarbonate, brine, dried with sodium sulfate and filtered. The filtrate was treated with 3-mercaptopropyl functionalized silica gel, filtered and evaporated. The residue was chromatographed on silica eluting with 5:95 methanol/D CH2C12CM to give a solid (125mg, 20%).

[001269] PartE. Preparation of N-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-3-iodo-2-methoxy-phenyl)methanesulfonamide.

[001270] A solution of the product from Part D (1 lOmg, 0.306mmol) in pyridine (2ml) was treated with methanesulfonyl chloride (0.048ml, 0.612mmol) and stirred for 24h. The solvent was evaporated and the residue was partitioned with ethyl acetate and 1M HC1. The organic layer was washed with brine, dried with sodium sulfate, filtered and evaporated. The residue was purified on silica gel eluting with 2% to 5% methanol in CH2C12 to give a solid (20mg, 15%).

[001271] Part F. Preparation ofN-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy-3-(6-(methylsulfonamido)naphthalen-2-yl)phenyl)methanesulfonamide.

[001272] To a 5mL microwave tube was added the product from Part E (18mg, 0.041mmol), Example 4A, Part B (14.30mg, 0.041mmol), potassium phosphate (18.35mg, 0.086mmol), PA-Ph (CAS 97739-46-3) (0.361mg, 1.235μτηο1) and tris(dibenzylideneacetone)dipalladium(0) (0,377mg, 0.412μηιοΙ) in THF (3.0ml) and water (1.0ml). The vessel was sealed and the mixture was sparged with nitrogen for 5min and heated at 50°C for 2h. The mixture was partitioned with ethyl acetate and 1M HC1. The organic layer w'as washed with saturated sodium bicarbonate, brine, dried with sodium sulfate, filtered and evaporated. The residue was purified on silica gel eluting with 2% to 5% methanol in CH2C12 to give a solid. A final trituration in 1:1 methanol/ CH2C12 gave the desired product (7mg, 32%). 'll NMR (300 MHz, DMSO-D6) δ ppm 3.09 (s, 3 H) 3.17 (s, 3 H) 3.37 (s, 3 H) 5.69 (dd, 1=7.91,2.02 Hz, 1 H) 7.34 (d, J=2.57 Hz, 1 H) 7.43 (dd, 1=8.82, 2.21 Hz, 1 H) 7.47 (d, 1=2.57 Hz, 1 H) 7.73 (m, 2 H) 7.81 (d, 1=8.09 Hz, 1 H) 7.94 (d, 1=6.25 Hz, 1 H) 7.97 (d, 1=6.62 Hz, 1 H) 8.07 (s, 1 H) 9.45 (s, 1 H) 10.05 (s, 1 Η) 11.45 (d, 1=1.84 Hz, 1 H). MS (ESI-) m/z 529 (M-H). 252 2014280939 24 Dec 2014 [001273] Example 66. Preparation of N-(6-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy-3-(trifluoromethyl)phenyl)naphthalen-2-yl)methanesulfonamide (compound IB-LO-2.56).

[001274] Part A. Preparation of 4-iodo-2-(trifluoromethyl)phenol.

[001275] To a solution of 2-(trifluoromethyl) phenol (3.24g, 20mmol) in MeOH (40ml) was added sodium hydroxide (0.960g, 24.0mmol) and stirred until the hydroxide was dissolved. The mixture was cooled to 0°C and sodium iodide was added (3.0g, 20mmol) followed by dropwise addition of 10% aqueous sodium hypochlorite (9.0ml, 14.6mmol). The addition of sodium iodide followed by sodium hypochlorite was repeated twice more. The mixture was stirred at ambient temperature for 2h and treated dropwise with concentrated HC1 to pH 1. The mixture was extracted 3 X with EtOAc. The extracts were combined, washed with brine, dried with sodium sulfate, filtered and evaporated. The residue was purified on silica gel eluting with EtOAc/hexane (1:9) to give the mono-iodo product (5.0 g, 87%).

[001276] Part B. Preparation of 2-bromo-4-iodo-6-(trifluoromethyl)phenol.

[001277] In a 250mL round-bottom flask was added the product from Part A (5.00g, 17.36mmol) and l,3-dibromo-5,-dimethylhydantoin (2.73g, 9.55mmol) in CHC13 (80ml) to give an orange solution. The mixture was stirred for 2h, washed with water, brine, dried with sodium sulfate, filtered and evaporated. The crude product was purified on silica gel eluting with ethyl acetate/hexane (5:95) to give a solid (3.5g, 54%).

[001278] Part C. Preparation of l-bromo-5-iodo-2-methoxy-3-(trifluoromethyl)benzene.

[001279] A mixture of the product from Part B (3.2g, 8.72mmol), iodomethane (1.36ml, 21.8mmol), and 50% sodium hydroxide (0,507ml. 9.59mmol) in acetone (20ml) was stirred for 24h. The solvent was evaporated and the residue was partitioned with ethyl acetate and water. The organic layer was washed with brine, dried with sodium sulfate, filtered and evaporated. The crude material was purified on silica gel eluting with ethyl acetate/hexane (5:95) to give a solid (2.67g, 80%).

[001280] Part D. Preparation of l-(3-bromo-4-methoxy-5-(trifluoromethyl)phenyl)pyrimidine-2,4 (lH,3H)-dione.

[001281] In a 20mL microwave tube was added the product from Part C (762mg, 2.0mmol), pyrimidine-2,4(1 H,3 H)-dione (247mg, 2.2mmol), N-(2-cyanophenyl)picolinamide (89mg, 0.4mmol), copper(I) 253 2014280939 24 Dec 2014 iodide (38.1mg, 0.2mmol) and potassium phosphate (892mg, 4.2mmol) in DMSO (10ml). The vessel was sealed and the mixture was sparged with nitrogen for 15min and heated at 60°C for 16h. The mixture was partitioned with ethyl acetate and 1M HC1. The organic layer was washed with saturated sodium bicarbonate, brine, dried with sodium sulfate and filtered. The filtrate was treated with 3-mercaptopropyl functionalized silica gel, filtered and evaporated. The residue was purified on silica gel eluting with ethyl acetate/hexane (2:3) to give the desired product (63mg, 9%).

[001282] PartE. Preparation of N-(6-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy-3-(trifluoromethyl)phenyl)naphthalen-2-yl)methanesulfonamide.

[001283] In a 5mL microwave tube was added the product from Part D (60mg, 0.164mmol), the product from Example 4A, Part B (62.8mg, 0.181mmol), l,T-bis(di-tert-butylphosphino)ferrocene palladium dichloride (5.36mg, 8.22pmol) and potassium phosphate (69.8mg, 0.329mmol) in THF/water (3ml/lml). The vessel was sealed and the mixture was sparged with nitrogen for 5min and heated at 60°C for 2h.

The mixture was partitioned with ethyl acetate and 1M HC1. The organic layer was washed with saturated sodium bicarbonate, brine, dried with sodium sulfate and filtered. The filtrate was treated with 3-mercaptopropyl functionalized silica gel, filtered and evaporated. The residue was purified by reverse phase chromatography to give the title compound as a solid (26mg, 31%). H NMR (300 MHz, DMSO-D6) δ ppm 3.10 (s, 3 H) 3.37 (s, 3 H) 5.71 (dd, J=7.72,2.21 Hz, 1 H) 7.44 (dd, J=8.82, 2.21 Hz, 1 H) 7.75 (s, 1 H) 7.78 (d, J=1.84 Hz, 1 H) 7.88 (m, 3 H) 7.98 (d, J=3.31 Hz, 1 H) 8.01 (d, J=3.68 Hz, 1 H) 8.15 (s, 1 H) 10.09 (s, 1 Η) 11.51 (d, J=2.21 Hz, 1 H). MS (ESI-) m/z 504.1 (M-H)+.

[001284] Example 67. Preparation of N-(6-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy-3-(perfluoroethyl)phenyl)naphthalen-2-yl)methanesulfonamide (compound IB-L0-2.60).

O

[001285] Part A. Preparation of 1 -methoxy-4-nitro-2-(perfluoroethyl)benzene.

[001286] To a 250mL round-bottom flask was added 2-bromo-l-methoxy-4-nitrobenzene (3.5g, 15.08mmol), copper(I) iodide (5.75g, 30.2mmol), and sodium 2,2,3,3,3-pentafluoropropanoate (5,25g, 28.2mmol) in DMF (75ml) and toluene (25ml) to give a tan suspension. The mixture was heated at 150°C and toluene was removed by a Dean-Stark trap. The mixture was heated at 155°C for 6h under nitrogen, cooled and poured into lOOmL of water and lOOmL of ether, filtered through a 1-inch plug of Celite and 254 2014280939 24 Dec 2014 the plug was rinsed with ether. The filtrate layers were separated. The organic layer was washed with brine, dried (Na2S04) filtered and concentrated. The dark oil was flash chromatographed on an Isco 40g silica cartridge eluting with 4:1 hexane/EtOAc to give a yellow oil that was a (3:1) mix of desired material and starting material (1,5g, 37%).

[001287J Part B. Preparation of 4-nitro-2-(perfluoroethyl)phenol.

[001288] In a lOOmL round-bottom flask was added the product from Part A (1.4g, 5.16mmol) and pyridine hydrochloride (4g, 34.6mmol) neat. The mixture was heated at 210°C for 20min, cooled, and partitioned between EtOAc and water. The organic layer was washed with brine, dried (Na2S04) and concentrated. The crude product was flash chromatographed on an Isco 12g silica cartridge eluting with 3:2 hecxane/EtOAc to give a yellow oil (1.3g, 98%).

[001289] Part C. Preparation of 2-iodo-4-nitro-6-(perfluoroethyI)phenol.

[001290] In a lOOmL round-bottom flask was added the product from Part B (1.3g, 5.06mmol) and N-iodosuccinimide (1.251 g, 5.56mmol) in acetonitrile (16.85ml) to give a yellow solution. The solution was stirred for 16h, diluted with lOOmL EtOAc and washed 2 x 50ml with 10% sodium thiosulfate, brine, dried (Na2S04) and concentrated to an orange semisolid. The semisolid was flash chromatographed on an Isco 40g silica cartridge eluting with 3:1 hexane EtOAc to give a deep yellow/orange oil (1.3g, 67%).

[001291] Part D. Preparation of l-iodo-2-methoxy-5-nitro-3-(perfluoroethyI)benzene.

[001292] In a lOOmL round-bottom flask was added the product from Part C (1.04g, 2,72mmol) potassium carbonate (0.563g, 4.07mmol) and dimethyl sulfate (0.41 lg, 3.26mmoI) in acetone (20ml) to give a brown suspension. The mixture was heated at gentle reflux for 16h, cooled, diluted into EtOAc, washed with water and brine. The organic layer was dried Na2S04, filtered and concentrated to a yellow oil that was purified by flash chromatography on an Isco 40g silica cartridge eluting with 9:1 hexane/EtOAc (600mg, 56%).

[001293] Part E. Preparation of 3-iodo-4-methoxy-5-(perfluoroethyl)aniline.

[001294] In a 250mL round-bottom flask was added the product from Part D (0.6g, 1.51 lmmol), iron (0.422g, 7.56mmol), and ammonium chloride (0.121g, 2.267mmol) in a solvent mix of EtOH (9ml), THF (9ml) and water (3ml) to give a brown suspension that was heated at 95-100°C for 2h. The reaction mix was filtered through a plug of Celite and the Celite was rinsed repeatedly with EtOH. The filtrate was concentrated and the residue was dissolved in EtOAc, washed with water, brine, dried (Na2S04), filtered and concentrated to give an oil (560mg, 99%).

[001295] PartF. Preparation of l,5-diiodo-2-methoxy-3-(perfluoroethyI)benzene.

[001296] In a 25mL round-bottom flask under nitrogen was added the product from Part E (0.565g, 1.539mmol), tert-butyl nitrite (0.293ml, 2.463mmol), copper(I) iodide (0.293g, 1.539mmol), sodium iodide (0.231g, 1.539mmoi) and iodine (0.195g, 0,770mmol) inDME (15.39ml) to give a brown 255 2014280939 24 Dec 2014 suspension. The mixture was heated at 60°C for 3h, cooled and filtered through Celite washing the Celite pad well with EtOAc. The EtOAc filtrate was treated with 10% sodium thiosulfate, brine, dried (Na2SC>4), filtered and concentrated to a dark oil. The crude material was purified by flash chromatography on an Isco 40g silica cartridge eluting with 95:5 hexane/EtOAc to give a yellow oil (360mg, 49%).

[001297] Part G. Preparation of l-(3-iodo-4-methoxy-5-(perfluoroethyl)phenyl)pyrimidine-2,4(lH,3H)-dione.

[001298] In a 20mL microwave tube was added the product from Part F (0.36g, 0.753mmol), 1H-pyrimidine-2,4-dione (O.lOlg, 0.904mmol), potassium phosphate tribasic (0.336g, 1.582mmol) N-(2-cyanophenyl)picolinamide (0.034g, 0.151mmol) and copper® iodide (0.014g, 0.075mmol in DMSO (7ml). The vessel was sealed and the mixture was sparged with N2 for 30min, heated at 60°C for 24h, cooled and diluted into EtOAc. The EtOAc layer was washed with 1M HC1, saturated NaHC03, and saturated NaCl, dried (Na2S04), filtered and concentrated. The residue was flash chromatographed on an Isco 40g silica cartridge eluting with hexane —> 1:1 hexane/EtOAc to give a yellow foam (lOOmg, 29%).

[001299] Part H. Preparation of N-(6-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy-3-(perfluoroethyl)phenyl)naphthalen-2-yl)methanesulfonamide.

[001300] In a 5mL microwave tube were combined the product from Part G (0.1 Og, 0.216mmol), Example 4A, Part B (0.075g, 0.216mmol), and potassium phosphate tribasic (0.096g, 0.454mmol) in 3:1 tetrahydrofuran-water (5mL) and degassed by nitrogen sparge for lOmin. The mixture was then treated with PA-Ph (CAS 97739-46-3) (1.898mg, 6.49μπιοΙ) and tris(dibenzylideneacetone)dipalladium(0) (1.982mg, 2.164pmol) followed by degassing for another 5min. The flask was then sealed and stirred at 50°C for 16h and partitioned between EtOAc and water. The EtOAc layer was washed with 0.1M HCI, saturated NaHCOj, and saturated NaCl. The organic was dried Na2S04, stirred for 0.5h with 3-mercapto-propyl functionalized silica to remove metals, filtered and concentrated. The crude product was purified by chromatography on an Isco 12g silica cartridge eluting with CH2Cl2 --> 3% MeOH in CH2C12 to give a light yellow foam (84mg, 99%) m.p. 162-165°C. !H NMR (300 MHz, DMSO-D6) δ ppm 3.10 (s, 3 H) 3.33 (s, 3 H) 5.70 (d, J=7.72 Hz, 1 H) 7.44 (dd, J=8.82,2.21 Hz, 1 H) 7.70 - 7.76 (m, 2 H) 7.80 (d, J=2.57 Hz, 1 H) 7.86 (d, J=8.09 Hz, 1 H) 7.91 (d, J=2.57 Hz, 1 H) S.00 (dd, J=8.82,2.94 Hz, 2 H) 8.12 (s, 1 H) 10.10 (s, 1 H) 11.50 (s, 1 H). MS (ESI-) mJz 554 (M-H)+. 256 2014280939 24 Dec 2014

[001301] Example 68. Preparation of (E^N'-tö-iS-^d-dioxo-S^-dihydropyrimidin-l^Hl-yO^-methoxy-S-ithiophen^-yOphenyO^S-dihydro-l H-inden-l-ylidene)methanesulfonohydrazide (compound IB-LO-2.51).

O

[001302] Part A. Preparation of l-(3-bromo-4-methoxy-5-(1-oxo-2,3-dihydro-lH-inden-5-yl)phenyl)-pyrimid ine-2,4( 1 H,3 H)-dione.

[001303] In a lOOmL round-bottom flask was added the product from Example 48, Part C (846mg, 2.00mmol), Example 6, Part A (516mg, 2.000mmol), potassium phosphate (892mg, 4.20mmol), PA-Ph (CAS 97739-46-3) (17.54mg, 0.060mmol) and tris(dibenzylideneacetone)-dipalladium(0) (18.31mg, 0.020mmol) in THF (12.0ml) and water (4.0ml). The vessel was sealed and the mixture was sparged with nitrogen for 5min and stirred at ambient temperature for 72h. The mixture was partitioned with ethyl acetate and 1M HC1. The organic layer was washed with saturated sodium bicarbonate, brine, dried with sodium sulfate and filtered. The filtrate was treated w ith 3-mereaptopropyl functionalized silica gel, filtered through celite and evaporated. The residue was purified with silica gel eluting with 1 to 4% methanol in CH2CI2 to give a solid (690mg, 81%).

[001304] Part B. Preparation of (E)-N'-(5-(3-bromo-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxypheny 1)-2,3 -dihydro-1 H-inden-1 -yl idene)methanesulfonohydrazide.

[001305] In a 50mL round-bottom flask was added the product from Part A (685mg, 1.603mmol) and methanesulfonohydrazide (194mg, 1,764mmol) in MeOH (20ml). The mixture was wanned to 40°C and stirred for 24h. The mixture was cooled, filtered and washed with methanol to give a solid (569mg, 68%).

[001306] Part C. Preparation of (E)-N'-(6-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy-3-(thiophen-2-yl)phenyl)-2,3-dihydro-lH-inden-l-ylidene)methanesulfonohydrazide, [001307] In a 5mL microwave tube was added the product from Part B (52mg, O.lOOmmol), thiophen-2-ylboronic acid (12.81 mg, O.lOOmmol), l,l'-bis(di-tert-butylphosphino)ferrocene palladium dichloride (3.26mg, 5.01μιηοΙ) and potassium phosphate (42.5mg, 0.200mmol) in THF (3.0ml) and water (1.0ml). The mixture was sparged by nitrogen for 5min and heated at 50°C for 3h, The mixture was partitioned with ethyl acetate and 1M HC1. The organic layer was washed with saturated sodium bicarbonate, brine, dried with sodium sulfate and filtered. The filtrate was treated with 3-mercaptopropyl functionalized 257 2014280939 24 Dec 2014 silica gel, filtered through celite and evaporated. The residue was purified by reverse phase chromatography AA method to give a white solid (27mg, 52%). 'H NMR (300 MHz, DMSO-D6) δ ppm 2.86 (m, 2 H) 3.09 (s, 3 H) 3.14 (m, 2 H) 3.32 (s, 3 H) 5.69 (d, 3=7.72 Hz, 1 H) 7.18 (dd, ¢=5.15, 3.68 Hz, 1 H) 7.41 (d, 3=2.57 Hz, 1 H) 7.63 (m, 3 H) 7.75 (m, 2 H) 7.86 (d, J=8.09 Hz, 1 H) 7.91 (d, 3=2.94 Hz, 1 H) 9.96 (s, 1 Η) 11.48 (s, 1 H). MS (ESI+) m/z 523 (M+H)+.

[001308] Example 69. Preparation of (E)-N’-(6-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-3-(furan-2-yl)-2-methoxyphenyl)-2,3-dihydro-1 H-inden-1 -ylidene)methanesulfonohydrazide (compound IB-L0-2.55).

O

[001309] In a 5ml microwave tube was added the product from Example 68, Part B (52mg, 0.1 OOmmol), furan-2-ylboronic acid (11.20mg, 0.1 OOmmol), 1,1 '-bis(di-tert-butylphosphino)ferrocene palladium dichloride (3.26mg, 5.01pmol) and potassium phosphate (42.5mg, 0.200mmol) in THF (3.0ml) and water (1,0ml). The mixture was sparged by nitrogen for 5min and heated at 50°C for 3h. The mixture was partitioned with ethyl acetate and 1M HC1. The organic layer was washed with saturated sodium bicarbonate, brine, dried with sodium sulfate and filtered. The filtrate was treated with 3-mercaptopropyl functionalized silica gel, filtered through celite and evaporated. The residue was purified by reverse phase chromatography AA method to give a solid (24mg, 47%). ’H NMR (300 MHz, DMSO-D6) δ ppm 2.86 (m, 2 H) 3.09 (s, 3 H) 3.14 (m, 2 H) 3.36 (s, 3 H) 5.68 (d, 3=8.09 Hz, 1 H) 6.69 (dd, 3=3.31, 1.84 Hz, 1 H) 7.09 (d, 3=3.31 Hz, 1 H) 7.41 (d, 3=2.57 Hz, 1 H) 7.62 (m, 2 H) 7.75 (d, 3=8.09 Hz, 1 H) 7.80 (d, 3=2.57 Hz, 1 H) 7.86 (m, 2 H) 9.97 (s, 1 Η) 11.46 (s, 1 H). MS (ESI+) m/z 507 (M+H)+. 258 2014280939 24 Dec 2014 [001310] Example 70. Preparation of N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-ethoxyphenyl)naphthalen-2-yl)methanesulfonamide (compound IB-LO-2.23).

O

[001311] Part A. Preparation of 2-tert-butyl-4-iodophenol.

[001312] To a 250mL round-bottom flask was added 2-tert-butylphenol (3.76g, 25mmol) in MeOH (50.0ml) to give a colorless solution. Sodium hydroxide (1,200g, 30.0mmol) was added and the mix was stirred until the hydroxide was completely dissolved. The solution was cooled to 0°C and treated with sodium iodide (1.75g, 11.6mmol) followed by dropwise addition of 10% sodium hypochlorite solution (7.2ml, 1 l.ómmol). The addition of sodium iodide followed by sodium hypochlorite was repeated twice and the mixture was stirred at 0°C for 30min. The mixture was treated with 10% w7w solution of sodium thiosulfate, stirred for 30min and treated with concentrated HC1 dropwise to a constant pH of 1. The mixture was extracted 3X with EtOAc. The extracts were combined, washed with brine, dried (MgS04), filtered and concentrated. The crude oil was flash chromatographed on an ISCO 80g silica cartridge eluting with hexane ~> 4:1 hexane/EtOAc to give a yellow oil (5.2g, 75%), [001313] Part B. Preparation of 2-bromo-6-tert-butyl-4-iodophenol.

[001314] To a 250mL round-bottom flask was added the product from Part A (4.8g, 17.38mmol) and l,3-dibromo-5,5-dimethylhydantoin (2.61g, 9.13mmol) in chloroform (87ml) to give an orange solution. The reaction mixture was stirred for 2h resulting in a black solution that was washed with water, brine, dried (Na2S04) and concentrated. The black oil was flash chromatographed on a 120g Isco silica cartridge eluting with hexane to give a pinkish solid (4.84g, 78%).

[0013151 Part C. Preparation of l-bromo-3-tert-butyl-2-ethoxy-5-iodobenzene.

[001316] To a 50mL round-bottom flask was added the product from Part B (888mg, 2,5mmol), ethyl iodide (409mg, 2.63mmol), and potassium carbonate (415mg, 3.00mmol) in acetone (12ml) to give a green suspension. The mixture was heated at reflux for 16h, cooled and concentrated. The residue was partitioned between water and EtOAc. The organic layer was washed twice with brine, dried over Na2S04, filtered and concentrated to a red oil. The oil was flash chromatographed on an Isco 40g silica cartridge eluting with hexane to give a clear oil (820mg, 86%).

[001317] Part D. Preparation of l-(3-bromo-5-tert-butyl-4-ethoxyphenyl)pyrimidine-2,4(lH,3H)-dione. 259 2014280939 24 Dec 2014 [001318] In a 20mL microwave tube under nitrogen flush was added the product from Part C (0.4g, 1.044mmol), lH-Pyrimidine-2,4-dione (0.140g, 1.253mmol), and potassium phosphate tribasic (0.465g, 2.193mmol) in DMSO (5ml) to give a colorless suspension. N-(2-cyanophenyl)picolinamide (0.047g, 0.209mmol) was added and the mix was sparged with nitrogen for lOmin. Copper® iodide (0.020g, 0.104mmol) was added and the mix was sparged once again for 1 Omin, placed under nitrogen and heated at 60°C for 18h. The mixture was cooled and partitioned between EtOAc and water adjusting the pH to 1 with HC1. The aqueous layer was extracted 2X with EtOAc. The organics were combined, washed with water, saturated NaHC03, and saturated NaCI. The organic layer was dried (Na2S04), stirred with 3-mercaptopropyl functionalized silica for Ih, filtered and concentrated. The crude product was purified by chromatography on an ISCO 12g silica cartridge eluting with 2% MeOH in CH2C12 to give a white powder (266mg, 69%).

[001319] Part E. Preparation of N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-ethoxyphenyl)naphthalen-2-yl)methanesulfonamide.

[0013201 In a 5mL microwave tube was added the product from Part D (55.1mg, 0.15mmol), the product from Example 4A, Part B (52.1mg, 0.150mmol), potassium phosphate tribasic (63.7mg, 0.300mmol) and l,T-bis(di-tert-butylphosphino)ferrocene palladium dichloride (4.89mg, 7.50pmol) in THF (3ml) water (1ml). The mixture was sparged for lOmin with nitrogen, heated sealed at 50°C for 4h, cooled and diluted into EtOAc. The EtOAc layer was washed with 1M HC1, saturated NaHC03, saturated NaCI, dried (Na2S04) and treated simultaneously with mercaptopropyl silica gel, filtered and concentrated. The residue was flash chromatographed on a 12g Isco silica cartridge eluting with 2% MeOH in CH2C12 to give a solid, (16mg, 21%) m.p. 196-202°C. *H NMR (300 MHz, DMSO-D6) δ ppm 1.00 (t, J=6.99 Hz, 3 H) 1.44 (s, 9 H) 3.09 (s, 3 H) 3.43 (q, J=7.11 Hz, 2 H) 5.64 (dd, J=7.91, 1.29 Hz, 1 H) 7.32 (d, J=2.94 Hz, 1 H) 7.36 (d, J=2.94 Hz, 1 H) 7.41 (dd, J-8.82,2.21 Hz, 1 H) 7.72 (s, 1 H) 7.74 (d, J=1.47 Hz, 1 H) 7.80 (d, J=7.72 Hz, 1 H) 7.90 - 8.00 (m, 2 H) 8.05 (s, 1 H) 10.04 (s, 1 Η) 11.41 (s, 1 H). MS (ESI-) m/z 506 (M-H)+. 260 2014280939 24 Dec 2014 [001321] Example 71. Preparation ofN-(6-(3-tert-butyl-2-chloro-5-(2,4-dioxo~3,4-dihydropyrimidin-l(2H)-yl)phenyl)naphthalen-2-yl)methanesulfonaniide (compound IB-LO-2.14).

O

[001322] Part A. Preparation of 2-bromo-6-tert-butyl-4-iodoaniline.

[001323] In a 50mL round-bottom flask was added 2-bromo-6-tert-butylaniline [prepared by the method of Onitsuka, et.al. Organometallics, 25(5), 2006, pp 1270-1278] (1.18g, 5.17mmol) and sodium bicarbonate (0.782g, 9.31mmol) in water (5ml). The mixture was cooled in an ice bath and iodine (1.444g, 5.69mmol) was added in several portions. The mixture was wanned to ambient temperature and stirred for 16h. The mixture was treated with aqueous sodium thiosulfate, extracted by ethyl acetate, dried with sodium sulfate, filtered and evaporated. The residue was purified on silica gel eluting with 5% ethyl acetate in hexane to give an oil (1.2g, 65%).

[001324] Part B. Preparation of l-bromo-3-tert-butyl-2-chloro-5-iodobenzene.

[001325] To a mixture oftert-butyl nitrite (0.198ml, 1.5mmol) and copper(II) chloride (161mg, 1.2mmol) in acetonitrile (5mL) was added the product from Part A (354mg, l.Ommol) as a solution in acetonitrile (5mL). The mixture was heated at 60°C for 30min, cooled, partitioned with ethyl acetate and 1M HC1. The organic layer was washed with brine, dried with sodium sulfate, filtered and evaporated. The residue was purified on silica gel eluting with 5% ethyl acetate in hexane to give the product (300mg, 81%).

[001326] PartC. Preparation of l-(3-bromo-5-tert-butyl-4-chlorophenyl)pyrimidine-2,4(lH,3H)-dione.

[001327] In a 20mL microwave tube was added the product from Part B (300mg, 0.803mmol), pyrimidine-2,4(lH,3II)-dione (99mg, 0.884mmol), N-(2-cyanophcnyl)picolinamide (35.9mg, 0.161mmol), copper(I) iodide (15.30mg, 0.080mmol) and potassium phosphate (358mg, 1.687mmol) in DMSO (5ml). The mixture was sealed, purged with nitrogen and heated at 60°C for 4h. The mixture was partitioned with ethyl acetate and 1M HC1. The organic layer was washed with saturated sodium bicarbonate, brine, dried with sodium sulfate and filtered. The filtrate was treated with 3-mercaptopropyl functionalized silica gel, filtered and evaporated. The residue was purified on silica gel eluting with 10% to 40% ethyl acetate in hexane to give a solid (175mg, 61%).

[001328] Part D. Preparation ofN-(6-(3-tert-butyl-2-chloro-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-261 2014280939 24 Dec 2014 yl)phenyl)naphthalen-2-yl)methanesulfonamide.

[001329] In a 5mL microwave tube was added the product from Part C (35.8mg, 0.1 Ommol), the product from Example 4A, Part B (38.2mg, 0.1 lOmmol), l,r-bis(di-tert-butylphosphino)ferrocene palladium dichloride (3.26mg, S.OOpmol) and potassium phosphate (42.5mg, 0.200mmol) in THF/Water (3ml: lml). The mixture was purged with nitrogen for 5min and heated at 60°C for 2h, The mixture was partitioned with ethyl acetate and 1M HC1. The organic layer was washed with saturated sodium bicarbonate, brine, dried with sodium sulfate and filtered. The filtrate was treated with 3-mercaptopropyl functionalized silica gel, filtered and evaporated. The residue was purified on silica gel eluting with 1:1 ethyl acetate/hexane to give a solid that was triturated with 1 % methanol in CH2C12 to give a white solid (29mg, 55%), melting point: > 280°C. Ή NMR (300 MHz, DMSO-D6) δ ppm 1.53 (s, 9 H) 3.08 (s, 3 H) 5.69 (d, J=7.72 Hz, 1 H) 7.42 (m, 2 H) 7.52 (dd, J=8.46, 1.84 Hz, 1 H) 7.56 (d, J=2.57 Hz, 1 H) 7.74 (d, J—1.84 Hz, 1 H) 7.84 (d, J=7.72 Hz, 1 H) 7.88 (s, 1 H) 7.91 (d, J=8.82 Hz, 1 H) 7.95 (d, J=9.19 Hz, 1 H) 10.04 (s, 1 Η) 11.46 (s, 1 IT). MS (ESI-) m/z 496 (M-H)+.

[001330] Example 72. Preparation of A-((6-(3-ter^butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2fï)-yl)-2-methoxyphenyl)benzo[ίƒ]isoxazol-3-yL)methyl)methanesulfonamide (compound IB-LO-2.45).

[001331] Part A. Preparation ofiV-((6-bromobenzo[iflisoxazol-3-yl)methy])-JV-(4-methoxybenzyl)-methanesulfonamide.

[001332] To a refluxing solution of 6-bromo-3-methylbenzo[d]isoxazole (l.Og, 4.72mmol) in CC14 (25ml) was added l-bromopyrrolidine-2,5-dione (0.923g, 5.19mmol) and benzoic peroxyanhydride (0.114g, 0.472mmol). The mixture was refluxed for 6h, and then cooled to room temperature, filtered thru celite, and concentrated in vacuo. The crude product was purified by column chromatography on silica gel using CH2C12 as the eluent to give the dibromide as a solid (0.84g, 43%). To a solution of the dibromide (0.20g, 0.687mmol) and A-(4-inethoxybenzyl)mcthanesulfonamide (0.148g, 0.687mmol) in EtOH (3ml) was added IN aq. NaOH (0.722ml, 0.722mmol), and the resulting mixture was stirred at 80°C for 90min. The mixture was partitioned between 0.1N aq. HCL (lOmL) and EtOAc (2 x lOmL), and the combined organic layers were dried over Na2S04, filtered and concentrated in vacuo. The crude 262 2014280939 24 Dec 2014 product was purified by column chromatography on silica gel using 2:3 EtOAc:hexanes as eluent to give the title compound as an oil (65 mg, 22%).

[001333] Part B. Preparation of A-(4-methoxybenzyl)-A-((6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[c/]isoxazol-3-yl)methyl)methanesulfonamide.

[001334] A solution of the product from Part A (56mg, 0.132mmol), bis(pinacolato)diboron (37mg, 0.145mmol), and potassium acetate (39mg, 0.395mmol) in 1,4-dioxane (1.3mL) was degassed by bubbling with N2 gas for 15min. 1,1 '-Bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (3mg, 0.004mmol) was added, and the resulting mixture was stirred at 80°C for 16h, filtered and concentrated in vacuo. The crude product was purified by column chromatography on silica gel using 1:2 EtOAc:hexanes as the eluent to give the title compound as a colorless oil (49mg, 79%).

[001335] Part C. Preparation of A-((6-(3-fert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2T/)-yl)-2-methoxyphcnyl)benzo[a]isoxazol-3-yl)methyl)-iV-(4-methoxybenzyl)methancsulfonamide.

[001336] A mixture of the product from Example C (31.8mg, 0.079mmol), the product from Part B (45mg, 0.095mmol) in EtOH (0.5mL), toluene (0.5m.L) 1M aq. Na2C03 (0.095mL, 0.095mmol) was degassed by bubbling with N2 gas for lOmin. 1,1'- Bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane complex (2mg, 2.4pmol) was added, and degassing with N2 was continued for 5min. The reaction mixture was sealed and heated at 100°C in a microwave reactor for lh. The mixture was concentrated in vacuo, and the crude product was purified by column chromatography on silica gel using 1:9 MeOHCHCE as the eluent. The title compound was obtained as a light brown solid (41 mg, 83%).

[001337] PartD. Preparation of A-((6-(3-h?ri-buty 1-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2//)-yl)-2-methoxyphenyl)benzo[<7]isoxazol-3-yl)methyl)methanesulfonamide.

[0013381 A solution of the product from Part C (39mg, 0.063mmol) in TFA (0.5mL) was stirred at 40°C for 6h. TFA was removed in vacuo and the crude product was purified by column chromatography on silica gel using 4% MeOH in CHCI3 as the eluent to give the title compound (13mg, 41%). ’H NMR (300 MHz, CDCI3) δ 8.39 (s, 1 H) 7.74 - 7.82 (m, 2 H) 7.57 (dd, 7=8.27, 1.65 Hz, 1 H) 7.36 (d, 7= 7.72 Hz, 1 H) 7.25 (d, 7=2.57 Hz, 1 H) 7.19 (d, 7^2.94 Hz, 1 H) 5.82 (dd, 7=7.72, 2.21 Hz, 1 H) 5.25 - 5.33 (m, 1 H) 4.70 (d, 7=6.25 Hz, 2 H) 3.29 (s, 3 H) 3.12 (s, 3 H) 1.45 (s, 9 H). 263 2014280939 24 Dec 2014 [001339] Example 73. Preparation of methyl 2-(5-(3-/erf-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2//)-yl)-2-methoxyphenyl)-2,3-djhydro-1//-inden-l-ylidene)hydrazinecarboxylate (compound IB-L0-2.24).

[001340] To a solution of the product from Example 6, Part B (0.05g, 0.124mmol) in MeOH (1ml) was added methyl carbazate (17mg, 0.185mmol). The mixture was stirred at 60°C for 16h, and then concentrated in vacuo. The crude product was purified by column chromatography on silica gel using 5% MeOH in ClfiCfi as the eluent to give the title compound (44mg, 74%). *H NMR (300 MHz, DMSO-d6) δ 11.40 (s, 1 H) 10.05 (s, 1 H) 7.78 (d, /=8.09 Hz, 1 H) 7.69 (d, /=7.72 Hz, 1 H) 7.45 - 7.57 (m, 2 H) 7.24 - 7.33 (m, 2 H) 5.64 (d,/=8.09 Hz, 1 H) 3.71 (s, 3 H) 3.28 (s, 3 H) 3.06 - 3.16 (m, 2 H)2.78 - 2.88 (m, 2 H) 1.40 (s, 9 H).

[001341] Example 74. Preparation of l-(3-iert-butyl-4-methoxy-5-(l-oxoisoindolin-5-yl)phenyl)-pyrimidinc-2,4( 1//,3 /7)-dione (compound IB-L0-2.30).

[001342] Part A. Preparation of 5-bromo-2-(2,4-dimethoxybenzyl)isoindolin-l-one.

[001343] To a solution of methyl 4-bromo-2-(bromomethyl)benzoate (l.Og, 3.25mmol) and (2,4-dimethoxyphenyl)methanamine (0.65g, 3.90mmol) in THF (16mL) was added triethylamine (0.9lmL, 6.5mmol), and tlie resulting mixture was stirred at room temeprature for 16h. The resulting solid was filtered off, and the filtrate was concentrated in vacuo. The crude product was purified by column chromatography on silica gel using 1:4 EtOAc;hexanes as the eluent to give the title compound as a colorless solid (0.52g, 44%). 264 2014280939 24 Dec 2014

O

[001344] Part B. Preparation of 2-(2,4-dimethoxybenzyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-y l)isoindolin-1 -one.

[001345] The product from Part A (lOOmg, 0.276mmol) was subjected to the conditions described for Example 72, Part B to give the title compound as an oil (107mg, 95%).

[001346] Part C. Preparation of l-(3-tert-butyl-5-(2-(2,4-dimethoxybenzyl)-l-oxoisoindolin-5-yl)-4-methoxyphenyl)pyrimidine-2,·4(1//, 3//)-dione.

[001347] The product from Part C (44mg, 0.11 lmmol) was subjected to the conditions described for Example 72, Part € to give the title compound (50mg, 81%).

[001348] Part D. Preparation of l-(3-iert-butyl-4-methoxy-5-(l-oxoisoindolin-5-yl)phenyl) pyrimidine-2,4( 1//,3//)-dione.

[001349] A solution of the product from Part C (48mg, 0,086mmo!) in CH2CI2 (0.3ml) and TFA (0.6ml, 7.79mmol) was stirred at room temperature for 16h, and then concentrated in vacuo. The crude product was purified by column chromatography on silica gel using 5% MeOH in CHCI3 as the eluent to give the title compound as a colorless solid (22mg, 63%). 'H NMR (300 MHz, DMSO-d6) δ 11.41 (d, ./=1.84 Hz, 1 H) 8.61 (s, 1 H) 7.72 - 7.83 (m, 3 H) 7.62 - 7.69 (m, 1 H) 7.29 - 7.36 (m, 2 H) 5.65 (dd,J=8.09, 2.21 Hz, 1 H) 4.44 (s, 2 H) 3.25 (s, 3 H) 1.41 (s, 9 H).

[001350] Example 75. Preparation of rV-(2-(6-(3-/er/-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2//)-yl)-2-methoxyphenyl)-l//-inden-3-yl)propan-2-yl)methanesulfonamide (compound IB-LO-2.41).

[001351] Part A. Preparation of 6-bromo-l//-indene-3-carbonitrile.

[001352] To a solution of 5-bromo-2,3-dihydro-lH-inden-l-one (lg, 4.74mmol) in anhydrous THF (15ml) at -10°C was added 2M lithium diisopropylamide in THF (0.242ml, 0.483mmol) dropwise. The resulting mixture was stirred at -10°C for 15min before diethylcyanophosphonate (0.791ml, 5.21mmol) was added dropwise. Following the addition, the mixture was allowed to warm to room temperature, and was stirred at room temperature for 3h. The mixture was cooled to -78°C and borontrifluoride diethyl etherate (1.196ml, 9.52mmol) was added dropwise. Following the addition, the mixture was stirred at -78°C for lh and was then allowed to warm to room temperature and was stirred at room temperature for 265 2014280939 24 Dec 2014 16h. The mixture was concentrated in vacuo, and the residue was partitioned between EtOAc (50mL) and H2O (2 X 50mL). The organic layer was dried over Na2S04, filtered and concentrated in vacuo, and the crude product was purified by column chromatography on silica gel using 9:1 EtOAc:hexanes as the eluent. The title compound was obtained as an tan solid (0.72g, 69%).

[001353] Part B. Preparation of iV-(2-(6-bromo-l,ff-inden-3-yl)propan-2-yl)methanesulfonamide.

[001354] Anhydrous cerium(III) chloride (0.224g, 0.909mmol) was flame dried under vacuum and placed under dry N2. Anhydrous THF (1.5ml) was added, and the resulting mixture was stirred under N2 at 45°C for 48h. The mixture was cooled to room temperature, and the product from Part A (O.lg, 0.454mmol) was added. The resulting mixture was cooled to -78°C, and a 1,5M solution of methyl-lithium lithium bromide complex (0.757ml, 1,136mmol) in Et20 was added dropwise over 15min. Following the addition, the mixture was allowed to warm to -20°C and was stirred for 24h. Concentrated aq. NH4OH (0.3mL) was added dropwise, and the mixture was allowed to warm to room temperature, was stirred for 30min, and was then filtered and washed with THF (2 x 5mL). The filtrate was concentrated in vacuo, and the crude product was purified by column chromatography on silica gel using 5% MeOH in CH2C12 as the eluent to give a solid (23mg, 20%). To a solution of this solid (23mg, 0.091 mmol) in 0¾¾ (lmL) was added methanesulfonyl chloride (0.01 lmL, 0.137mmol). The mixture was cooled to 0°C and diisopropylethylamine (0.024ml, 0.137mmol) was added dropwise. The resulting mixture was stirred at room temperature for 90min, and was then partitioned between 0.1 N aq. HC1 (2mL) and CH2CI2 (3 x 2mL). The combined organic layers were dried over Na2S04, filtered and concentrated in vacuo, and the crude product was purified by column chromatography on silica gel to give the title compound (17mg, 56%).

[001355] Part C. Preparation of 7/-(2-(6-(4,4,5,5-tetrarnethy 1-1,3,2-dioxaboroIan-2-yl)-177-inden-3-yl)propan-2-yl)methanesulfonamide.

[001356] The product from Part C (50mg, O.lSlmmol) was subjected to the conditions described for Example 72, Part B to give the title compound as a colorless solid (37mg, 65%).

[001357] Part D. Preparation ofiV-(2-(6-(3-/ert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2/7)-yl)-2-methoxyphenyl)-17f-mden-3-yl)propan-2-yl)methanesulfonamide.

[001358] The product from Part C (35mg, 0.093mmol) was subjected to the conditions described for Example 72, Part C to give the title compound as a colorless solid (41mg, 84%). *H NMR (300 MHz, DMSO-d6) δ 11.40 (s, 1 H) 7.94 (d, 7=8.09 Hz, 1 H) 7.78 (d, 7=8.09 Hz, 1 H) 7.65 (d, >1.50 Hz, 1 H) 7.56 (s, 1 H) 7.48 (dd, 7=8.09, 1.47 Hz, 1 H) 7.27 (s, 2 H) 6.48 (s, 1 H) 5.63 (d, >8.09 Hz, 1 H) 3.43 (s, 2 H) 3.25 (s, 3 H) 2.63 (s, 3 H) 1.68 (s, 6 H) 1.41 (s, 9 H). 266 2014280939 24 Dec 2014 [001359J Example 76. Preparation of A-((6-(3-rm-butyI-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2//)-yl)-2-methoxyphenyl)benzo[Z?]thiophen-3-yl)methyl)methanesulfonamide (compound IB-LO-2.11).

[001360] Part A. Preparation of ethyl 6-bromobenzo[7>|thiophene-2-carboxy]ate.

[001361] A solution of ethyl thioglycolate (0.65g, 5.42mmol), 4-bromo-2-fluorobenzaldehyde (1 0g, 4.93mmol) and triethylamine (1.25mL, 12.3mmol) in DMSO (5mL) was heated at 75°C for 2h. The mixture was partitioned between H20 (50mL) and CH2C12 (2 x 50mL), and the combined organic layers were dried over Na2S04. The drying agent was filtered off, and the solvent was removed in vacuo to give the title compound as an oil (1.29g, 92%).

[001362] Part B. Preparation of 6-bromobenzo[ü>]thiophene-2-carboxylic acid.

[001363] To a solution of the product from Part A (1.21g, 4.24mmol) in THF (lOmL) was added a solution of LiOH (0.305g, 12,73mmol) in H20 (4mL) and the resulting mixture was stirred at 40°C for 2h. The mixture was partitioned between H20 (50mL) and CH2CI2 (50mL). The aqueous layer was adjusted to pH = 2 using IN HC1, and extracted with CH2C12 (2 x 50mL). The combined organic layers were dried over Na2SC>4, filtered and concentrated in vacuo to give the title compound as an oil (1,04g, 95%).

[001364] PartC. Preparation of 6-bromobenzo[è]thiophene.

[001365] The product from Part B (0.70g, 2.73mmol) and DBU (1.35mL, 8.94mmol) were combined in DMA (6mL) in a sealed tube and heated at 200°C in a microwave reactor for 70min. The resulting dark solution was diluted with 1 M HC1 (20mL) and extracted with CH2C12 (2 x 20mL). The combined organic layers were dried over Na2S04, filtered and concentrated in vacuo, and the crude product was purified by column chromatography on silica gel using CH2C12 as the eluent to give the title compound as an oil (0.484g 83%).

[001366] PartD. Preparation of 6-bromo-3-(chloromethyl)benzo[6]thiophene.

[001367] To a solution of the product from Part C (0.484g, 2.27mmol) in benzene (0.20mL) was added 37% aq. formaldehyde solution (lmL) and concentrated HC1 (ImL). The resulting mixture was heated at 70°C for lh. while HC1 gas was bubbled through the mixture. The mixture was partitioned between H20 (20mL) and CH2C12 (2 x 20mL), and the combined organic layers were dried over Na2S04, filtered and 267 2014280939 24 Dec 2014 concentrated in vacuo. The crude product was purified by column chromatography on silica gel using CH2C12 to give the title compound as a waxy solid (0.49g, 82%).

[001368] Part E. Preparation of A-((6~bromobenzo[/>Jthiophen-3-yl)methyl)-/V-(2,4-dimethoxybenzyl) methanesulfonamide.

[001369] To a solution of the product form Part D (275mg, 1.05mmol) and A'-(2.4-dimethoxybenzyl)-methanesulfonamide (284mg, 1.15mmol) in DMA (6mL) was added K2C03 (160mg, 1.15mmoi), and the mixture was stirred at room temperature for 3h. The mixture was partitioned between H20 (20mL) and Et20 (2 x 20mL), and the combined organic layers were dried over Na2S04, filtered and concentrated in vacuo. The crude product was purified by column chromatography on silica gel using 2% EtOAc in CH2C12 as the eluent to give the title compound as a waxy solid (316mg, 64%).

[001370] Part F. Preparation of /V-(2,4~dimethoxybenzyl)-N-((6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[b]thiophen-3-yl)methyl)methanesulfonamide.

[001371] The product from Part E (300mg, 0.64mmol) was subjected to the conditions described for Example 72, Part B to give the title compound as a waxy solid (248mg, 75%).

[001372] Part G. Preparation of A-((6-(3-teri-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2i:/)-yl)-2-methoxyphcnyl)benzo[0]thiophen-3-yl)methyl)-iV-(2,4-dimethoxybenzyl)methanesulfonainide.

[001373] The product from Part F (214mg, 0.414mmol) was subjected to the conditions described for Example 72, Part C to give the title compound as a light yellow solid (238mg, 87%).

[001374] Part H. Preparation of A-((6-(3-iert-biityl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2//)-yl)-2-methoxyphenyl)benzo[b]thiophen-3-yl)methyl)methanesulfonamide.

[001375] To a solution of the product from Part G (230mg, 0.34mmol) in CH2C12 (4mL) was added trifluoroacetic acid (0.5mL), and the mixture was stirred at room temperature for 30min. The solution was diluted with CH2C12 (lOmL) and extracted with saturated aq. NaHC03 (2 x lOmL). The organic layer was dried over Na2S04, filtered and concentrated in vacuo, and the crude product was purified by column chromatography on silica gel eluting with 3% MeOH in CH2C12 to give the title compound as an off-white solid (149mg, 84%). 'H NMR (300 MHz, DMSO-d6) δ 11.41 (s, 1 H) 8.16 (d, /=1.10 Hz, 1 H) 8.02 (d, /=8.46 Hz, 1 H) 7.79 (d, /=7.72 Hz, 1 H) 7.71 (s, 1 H) 7.60 - 7.66 (m, 2 H) 7.29 - 7.38 (m, 2 H) 5.65 (d, /=7,72 Hz, 1 H) 4.44 (d,/=5.88 Hz, 2 H) 3.24 (s, 3 H)2.95 (s, 3 H) 1.42 (s, 9 H). 268 2014280939 24 Dec 2014 [001376] Example 77. Preparation ofA-(2-(3-ierr~butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2//)-yl)-2-methoxyphenyl)-l,2,3,4-tctrahydroisoquinolin-6-yl)methanesulfonamide (compound IB-LO-2.19).

[001377] Part A. Preparation of l-(3-amino-5-/er/-butyl-4-methoxyphenyl)pyrimidine-2,4(1//,3//)-dione.

[001378] To a solution of the product from Example 7, Part F (170mg, 0.534mmol) and triethylamine (223uL, 1,6mmol) in THF (5mL) was added diphenylphosphorylazide (173uL, 0.80mmol). The resulting mixture was stirred at room temperature for lh, and was then stirred at 45°C for lh. Water (280uL) was added, and the resulting mixture was stirred at 50°C for lh, and then stirred at room temperature for 16h. The solution was diluted with H20 (lOmL), and the resulting solid was filtered off. The solid was suspended in 1M aq. HC1 and filtered to give the amine product as the HC1 salt. This salt was suspended in aq. NaHC03 (20mL) and extracted with EtOAc (2 x 20mL). The combined organic layers were dried over Na2S04, filtered and concentrated in vacuo to give the title compound as a colorless solid (55mg, 36%).

[001379] Part B. Preparation of l-(3-/ert-butyl-4-methoxy-5-(6-nitro-3,4-dihydroisoquinolin-2(l//)-yl)phenyl)pyrimidine-2,4( 1 Z/,3//)-dione.

[001380] A solution of the product from Part A (1 OOmg, 0.28mmol) and 2-(2-(methylsulfonyloxy)-ethyl)-4-nitrobenzyl methanesulfonate (196mg, 0.68mmol) were in anhydrous DMA (4mL) was stirred at 80°C for 18h. The cooled mixture was partitioned between H20 (20mL) and EtOAc (2 x 20mL), and the combined organic layers were dried over Na2S04, filtered and concentrated in vacuo. The residue was suspended in CH2C12 and filtered to remove unreacted aniline starting material. The filtrate was concentrated in vacuo, and the crude product was purified by column chromatography on silica gel eluting with 1% MeOH in CH2C12 to give the title compound as a light yellow solid (39.3mg, 31%).

[001381] PartC. Preparation ofAr-(2-(3-/err-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2//)-yl)-2-methoxyphenyl)-l,2,3,4-tetrahydroisoquinolin-6-yl)methanesulfonamide.

[001382] To a solution of the product from Part B (35mg, 0.078mmol) in THF (0,5mL), MeOH (0,5mL) and H20 (0.25mL) was added Fe powder (17.4mg, 0.41mmol) and NH4CI (6.2mg, 0.12mmol, and the resulting mixture was stirred at 70°C for lh. The hot mixture was filtered through celite and rinsed with THF and MeOH. The filtrate was concentrated and dried in vacuo to give a solid. To a solution of the solid (32mg, 0.076mmol) and pyridine (26uL, 0.32mmol) in CH2C12 (1.5mL) was added methanesulfonyl 269 2014280939 24 Dec 2014 chloride (7.7uL, 0,099mmol). The mixture was stirred at room temperature for Ih then concentrated in vacuo. The crude product was purified by column chromatography on silica gel eluting with 5% MeOH in CH2C12 to give the title compound as a light yellow solid (7mg, 19%). 'H NMR (300 MHz, DMSO-d6) δ 7.71 (d, J=8.09 Hz, 1 H) 7.14 - 7.21 (m, 1 H) 7.05 - 7.12 (m, 3 H) 6.98 (d, J=2.57 Hz, 1 H) 5.65 (d, 3=7.72 Hz, 1 H) 4.18 (s, 2 H) 3.86 (s, 3 H) 3.03 (t, J=4.23 Hz, 2 H) 2.99 (s, 3 Η) 1.38 (s, 9 H).

[001383] Example 78. Preparation of A-(2-(3-/tJr/-butyl-5-(2,4-dioxo-3,4-dihydiOpyrimidin-l(2/7)-yl)-2-methoxyphenyl)isoindolin-5-yl)methanesulfonamide (compound IB-LO-2.79). /

[001384] Part Λ. Preparation of (4-nitro-l ,2-phenylene)bis(methylene)dimethanesulfonate.

[001385] To a solution of 4-nitrophthalic acid (500mg, 2.37mmol) in THF (24mL) at room temperature was added a 1M solution of BH3«THF complex (9.95mL, 9.95mmol) dropwise. This solution was stirred at 65°C for lh, and then allowed to cool to room temperature. To the mixture was added MeOH (lmL), and the mixture was stirred for 30min and concentrated in vacuo. The residue was partitioned between 1M aq. HC1 (20mL) and EtOAc (2 x 20mL), and the combined organic layers were dried over Na2S04, filtered and concentrated in vacuo. The crude product was purified by column chromatography on silica gel eluting with 3% MeOH in ΟΗ2012 to give an oil (253mg, 58%). To a solution of the oil (250mg, 2.37mmol) and triethylamine (438uL, 3.14mmol) in anhydrous CH2C12 (30mL) at 0°C was added methanesulfonyl chloride (234uL, 3.0mmol) dropwise. The solution was stirred at room temperature for 18h, and was partitioned between 1M aq. HC1 (20mL) and CH2C12 (2 x 20mL). The combined organic layers were dried over Na2S04, filtered and concentrated in vacuo. The crude product was purified by column chromatography on silica gel eluting with CH2C12 to give the title compound (150mg, 32%).

[001386] Part B. Preparation of l-(3-/err-butyl-4-methoxy-5-(5-nitroisoindolin-2-yl)phenyl) pyrimidine-2,4(1/7,3//)-dione.

[001387] To a solution of the product of Part A (1 lOmg, 0.324mmol) and the product of Example 77, Part A (113mg, 0.389mmol) in anhydrous 1,4-dioxane (4mL) was added sodium bicarbonate (60mg, 0.71 mmol) and diisopropylethylamine (142uL, 0,81mmol) and the resulting mixture was stirred at 95°C for 16h. The mixture was partitioned between 0.5M aq. HC1 (1 OmL) and CH2C12 (2 x 1 OmL), and the combined organic layers were dried over Na2SC>4, filtered and concentrated in vacuo. The crude product 270 2014280939 24 Dec 2014

O

'0 was purified by column chromatography on silica gel eluting with 1% MeOH in CH2C12 to give the title compound as a light yellow solid (1 lOmg, 78%).

[001388] Part C. Preparation of 7V-(2-(3-fórt-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2/7)-yl)-2-methoxyphenyl)isoindolin-5-yl)methanesulfonamide.

[001389] The product from Part B (lOOmg, 0.25mmol) was subjected to the conditions described for Example 77, Part C to give the title compound as an off-white solid (53mg, 45%). 'H NMR (300 MHz, DMSO-de) δ 11.37 (s, 1 H) 9.70 (s, 1 H) 7.71 (d, J=7.72 Hz, 1 H) 7.34 (d, J=8.09 Hz, 1 H) 7.23 (d, J=1.84 Hz, 1 H) 7.13 (dd, J=8.09, 1.84 Hz, 1 H) 6.98 (d, J=2.57 Hz, 1 H) 6.81 (d, J=2.21 Hz, 1 H) 5.62 (d, J=7.72 Hz, 1 H) 4.52 (s, 2 H) 4.50 (s, 2 H) 3.63 (s, 3 H) 2.98 (s, 3 Η) 1.38 (s, 9 H).

[001390] Example 79. Preparation of/V-((6-(3-ter/-butyl-5-(2:4-dioxo-3,4-dihydropyrimidin-l(2/7)-yl)-2-methoxyphenyl)-l/i-inden-3-yl)methyl)methanesulfonamide (compound IB-LO-2.13). s— [001391] Part A. Preparation of 5-hromo-l-(tnmethylsilyloxy)-2,3-dihydro-l//-indene-l-carbonitrile.

[001392] To a solution of 5-bromo-2,3-dihydro-177-inden-l-one (lO.Og, 47.4mmol) and A-methyl-morpholine A-oxide (1.67g, 14.21mmol) in CH2C12 (50ml) was added trimethylsilylcyanide (7.05g, 71.1 mmol), and the resultant solution was stirred at room temperature for 72h, and then concentrated in vacuo. The crude product was purified by column chromatography on silica gel using 5% EtOAc in hexanes as the eluent to give the title compound as a colorless liquid (12.65g, 86%).

[001393] PartB. Preparation of l-(aminomethyl)-5-bromo-2,3-dihydro-1/T-inden-l -ol.

[001394] To a solution of the product from Part A (18.44g, 59,4mmol) in anhydrous Et20 (250mL) under N2 gas at 0°C was added a IM solution ofLiAIEL, in Et20 (62,4mL, 62.4mmol) dropwise over Ih. Following the addition, the mixture was allowed to warm to rt and was stirred at room temperature for 2h. The mixture was cooled in an ice bath while H20 (4.3mL) was added dropwise, followed by the addition of 15% aq. NH4OH (4.3mL), and then H20 (13mL). The mixture was stirred at room temperature for 15min, and then filtered through celite and rinsed with EtOAc. The filtrate was concentrated in vacuo, and the residue was suspended in Et20 (40mL) to give a precipitate that was filtered and dried to give the title compound as a colorless solid (10.Og, 70%).

[001395] Part C. Preparation of (6-bromo-lH-inden-3-yl)methanamine hydrochloride salt. 271 2014280939 24 Dec 2014 [001396] To a solution of the product from Part B (lO.Og, 41.3mmol) in MeOH (lOOmL) was added 6N aq. HC1 (125mL) and the mixture was stirred at 70°C for 3h and then allowed to cool to room temperature. MeOH was removed in vacuo to give a precipitate that was collected by filtration, washed with H2O, and dried in vacuo to provide the title compound as a colorless solid (9.89g, 92%).

[001397] PartD. Preparation ofA-((6-bromo-17/-inden-3-yl)methyI)methanesulfonamide.

[001398] To a suspension of the product from Part C (6.46g, 24.8mmol) in anhydrous CH2C12 (260mL) was added methanesulfonyl chloride (3.86mL, 49.6mmol) and diisopropylethylamine (13.0mL, 74.4mmol), and the resulting mixture was stirred at room temperature for 1 Oh. The solution was washed with IN aq. HC1 (2 x 300mL), and the organic layer was dried over Na2S04, filtered and concentrated in vacuo. The residue was suspended in Et20 (1 OOmL) to give a precipitate that was collected by filtration and dried to give the title compound as a colorless solid (6.25g, 83%).

[001399] Part E. Preparation of A-((6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l.W-inden-3-yl)methyl)methanesulfonamide.

[001400] A solution of the product from Part D (2.0g, 6.62mmol), bis(pinacolato)diboron (1,85g, 7.28mmol), potassium acetate (1 -95g, 19.86mmol) and l,r-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (0.27g, 0.331mmol) in anhydrous 1,4-dioxane (80mL) under N2 was stirred at 95°C for 8h. The cooled mixture was filtered through celite, washed with EtOAc (2 x 20mL) and then concentrated in vacuo. The crude product was purified by column chromatography on silica gel using 1:2 EtOAc:hexanes as the eluent to give the title compound as a colorless oil (2.02g, 87%).

[001401] PartF. Preparation of Ar-((6-(3-ieri-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2#)-yl)-2-methoxyphenyl)-1 //-indcn-3-yl)mcthyl)methanesulfonamide.

[001402] A mixture of the product from Part E (3.14g, 8.99mmol), the product from Example C (3.78g, 9.44mmol), tripotassium phosphate (3.82, 17.98mmol), l,3,5,7-tetramethyi-2,4,8-trioxa-6-phospha-6-phenyl-adamantane (Cytec [97739-46-3]) (105mg, 0.36mmol), and tris(dibenzylidineacetone)-dipalladium(O) (165mg, 0.18mmol) was placed under N2 gas. To the mixture was added, via canula, a mixture of THF (45mL) and H20 (15mL) that had been degassed by bubbling Ar gas for 1 Omin. The resulting mixture was further degassed by bubbling with Ar for an additional 15mm, The mixture was stirred at 50°C for 1,5h while Ar was continuously bubbled through the solution. Additional tris(dibenzyl idineacetone)dipalladium(O) (55mg, 0.6mmol) in THF (2mL) was added, and the mixture was stirred at 50°C for lh. The mixture was allowed to cool to rt, and was partitioned between CH2C12 (300ml) and IN aq. HC1 (150mL). To the orange organic layer was added 3-mercaptopropyl-functionalized silica gel (lOg, Aldrich) andmgS04, and the mixture was stirred at room temperature for 16h, filtered and concentrated in vacuo. The crude product was purified by column chromatography on 272 2014280939 24 Dec 2014 silica gel using 3:1 EtOAc:hexanes as the eluent to give the title compound as a colorless solid (2.7g, 61%). 'H NMR (300 MHz, DMSO-d6) δ 11.40 (s,lH), 7.78 (d, J=7.4Hz,lH), 7.66 (s,lH), 7.60 (d,J=7.7Hz,lH), 7.50 (m,2H), 7.25 (m,2H), 6.56 (m,lH), 5.64 (dd, J=2.2,7.7Hz,lH), 4.18 (d, J=5.1Hz,2H), 3.46 (s,2H), 3.25 (s,3H), 2.96 (s,3H), 1.41 (s,9H).

[001403] Example 80. Preparation ofJV-(5-(3-iert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(277)-yl)-2-methoxyphenyl)-2,3-dihydro-l//-inden-l-yl)methanesulfonohydrazide (compound IB-LO-2.31).

[001404] To a solution of the product from Example 6, Part C (lOOmg, 0.201mmol) was in THF (2mL) and MeOH (2mL) was added 2 drops of 10% HCI in MeOH, followed by sodium cyanoborohydride (19mg, 0.302mmol). The mixture was adjusted to pH 4 with the addition of 10% HCI in MeOH, and was then stirred at room temperature for Ih. The resulting mixture was partitioned between saturated aq. sodium bicarbonate (5mL) and CH2CI2 (20mL), and the organic layer was dried over Na2S04, filtered and concentrated. The crude product was purified by column chromatography on silica gel using 3% MeOH in CH2CI2 as the eluent to provide the title compound as a colorless solid (58mg, 58%). 'H NMR (300 MHz, DMSO-d6) δ 11.39(s,lH), 8.18(d,J=3.7Hz,lH), 7.77(d,J=7.7Hz,1H), 7.51(d,J=8.1Hz,lH), 7.38(m,2H), 7.27(d,J=2.6Hz,lH), 7.21(d,J=2.9Hz,lH), 5.63(d,J=7.7Hz,lH), 5.25(m,lH), 4.39(m,lH), 3.27(s,3H), 2.98(m,lH), 2.83(s,3H), 2.78(m,lH), 2.22(m,lH), 2.07(m,lH), 1.40(s,9H).

[001405] Example 81. Preparation of l-(3-fer?-butyl-5-(l-hydroxy-2,3-dihydro-17/-inden-5-yl)-4-methoxyphenyl)pyrimidine-2,4(177,3/7)-dione (compound IB-LO-2.36).

[001406] To a solution of the product from Example 6, Part B (150mg, 0.371mmol) in MeOH (3mL) and CH2CI2 (3mL) was added sodium borohydride (28mg, 0.742mmol), and the mixture was stirred at room temperature for 1 h. The mixture was partitioned between IN aq. HCI (1 OmL) and CH2C12 (20mL), 273 2014280939 24 Dec 2014 and the organic layer was dried over NajSCh, filtered and concentrated in vacuo. The crude product was purified by column chromatography on silica gel using 5% MeOH in ClfClj as the eluent to provide the title compound as a colorless solid (90mg, 60%). ‘H NMR (300MHz, DMSO-d6): δ 11.39(s,lH), 7.44(d, J= 4.0Hz, 1H), 7.40 (m, 2H), 7.21 (d, J= 2.6 Hz, 1H), 7.26 (d, J= 2.6 Hz, 1H), 5.63 (d, J= 8.1 Hz, 1H), 5.29 (d, J= 5.9 Ηζ,ΙΗ), 5.09 (m, 1H), 3.26 (s, 3H), 2.97 (m, 1H), 2.79 (m, 1H), 2.38 (m, 1H), 1.83 (m, 1H), 1.40 (s, 9H).

[001407] Example 82. Preparation of l-(3-tert-butyl-5-(2-(2,5-dimethyl-l//-pyrrol-l-yl)benzo[d] thiazol-6-yl)-4-mcthoxyphenyl)pyrimidine-2,4( UT,3jy)-dione (compound IB-LO-2.47).

[001408] Part A. Preparation of 6-bromo-2-(2,5-dimethyl-lH-pyrrol-l-yI)benzo[r/]thiazole.

[001409] A solution 6-bromobenzo[<i]thiazol-2-amine (5.75g, 25.1mmol), hexane-2,5-dione (2.95mL, 25.1mmol), and PPTS (0.95g, 3.76mmol) in benzene (100ml) was refluxed for 16h while water was removed with a Dean-Stark trap. The cooled mixture was poured into EtOAc (lOOmL) and extracted with saturated aq. NaHCC>3 (2 x lOOmL) and brine. The organic layer was dried over Na2S04, filtered and concentrated in vacuo. The crude product was purified by column chromatography on silica gel using 9:1 EtOAcrhexanes as the eluent to give the title compound as an orange oil (6.46g, 84%).

[001410] PartB. Preparation of2-(2,5-dimethyl-lH-pyrrol-l-yl)-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzo[d]thiazole.

[001411] A mixture of the product from Part A (3.24g, 10.54mmol), bis(pinacolato)diboron (4.0 lg, 15.81mmol), bis(di-tert-butyl(hydroxy)phosphino)palladium(II) dichloride (0.264g, 0.527mmol), and potassium acetate (3.1 Og, 31,6mmol) in anhydrous toluene (25mL) was degassed by bubbling with N2 gas for 15min, and then heated at reflux under N2 for 72h. The cooled mixture was filtered through celite and washed with EtOAc, and the filtrate was concentrated in vacuo. The crude product was purified by column chromatography on silica gel using 9:1 EtOAcihexanes as the eluent to give the title compound (2.77g, 74%).

[001412] Part C. Preparation of l-(3-/err-butyl-5-(2-(2,5-dimethyI-l//-pyrrol-l-yl)benzo[d]lhiazol-6-yl)-4-methoxyphenyl)pyrimidine-2,4(17/,37/)-dionc.

[001413] The product from Part B (405mg, 1.14mmol) was subjected to the conditions described for Example 72, Part C to give the title compound (430mg, 68%). 'H NMR (300 MHz, DMSO-dó) δ 11.43 274 2014280939 24 Dec 2014 (d,7=2.21 Hz, 1 H) 8.32 (d, 7=1.47 Hz, 1 H) 8.12 (d, ./=8.46 Hz, 1 H) 7.80 (d, 7=7.72 Hz, 1 H) 7.76 (dd, ^=8.46,1.84 Hz, 1 H) 7.35 (q, J=2.57 Hz, 2 H) 5.97 (s, 2 H) 5.66 (dd,./=7.72, 2.21 Hz, 1 H) 3.30 (s, 3 H) 2.30 (s, 6 H) 1.43 (s, 9H).

[001414] Example 83. Preparation of l-(3-(2-aminobenzo[7]thiazol-6-yl)-5-rer/-butyl-4-methoxy-phenyl)pyrimidine-2,4(1//,3/7)-dione (compound IB-LO-2.27).

[001415] To a solution of the product from Example 82 (4.0g, 8.0mmol) in trifluoroacetic acid (50mL) was added a few drops of H20, and the resulting mixture was stirred at 80°C for 2.5h, and then concentrated in vacuo. A solution of the residue in MeOH was neutralized using cone. Νϋ,ΟΗ, concentrated in vacuo, and the crude product was purified by column chromatography on silica gel using 9:1 CH2Cl2:MeOH as the eluent to give the title compound (3.3g, 98%). *H NMR (300 MHz, DMSO-d6) δ 11.40 (s, 1 H) 7.81 (s, 1 H) 7.77 (d, 3=8.09 Hz, 1 H) 7.57 (s, 1 H) 7.40 (s, 1 H) 7.33 - 7.38 (m, 1 H) 7.25 (s, 1 H) 5.60 - 5.69 (m, 1 H) 3.26 (s, 3 H) 1.40 (s, 9 H).

[001416] Example 84. Preparation of iV-(6-(3-/eri-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2/7)-yl)-2-methoxyphenyl)benzo[c/]thiazol-2-yl)methanesulfonamide (compound IB-LO-2.28).

[001417] To a solution of the product from Example 83 (0.35g, 0.83mmol) in anhydrous CH2C12 (50mL) was added methanesulfonyl chloride (194gL, 2.49mmol) and pyridine (1.34mL, 16.6mmol). The resulting mixture was stirred at room temperature for 16h and concentrated in vacuo. The crude product was purified by C-l 8 reverse-phase HPLC using an acetonitrile:H20 (0.1% TFA) gradient to give the title compound (19mg, 4%). 'H NMR (300 MHz, DMSO-d6) δ 13.09 (s, 1 Η) 11.41 (d, ./=1.84 Hz, 1 H) 7.96 (d, 7=1.47 Hz, 1 H) 7.77 (d, ./=8.09 Hz, 1 H) 7.57 (dd, 1 H) 7.42 (d, ./=8.09 Hz, 1 H) 7.25 - 7.32 (m, 2 H) 5.64 (dd, 7=8.09, 2.21 Hz, 1 H) 3.25 (s, 3 H) 3.02 (s, 3 H) 1.40 (s, 9 H). 275 2014280939 24 Dec 2014 [001418] Example 85. Preparation of l-(3-(benzo[/]thiazol-6-yl)-5-rert-butyl-4-mcthoxyphenyI) pyrimidine-2,4( 1 ΗβΗ)-ά\οη&amp; (compound IB-LO-2.33).

[001419] To a solution of the product from Example 83 (30mg, 0.071mmol) in anhydrous 1,4-dioxane (3mL) under N2 was added isoamyl nitrite (19pL, 0.142mmol). The resulting mixture was stirred at reflux for lh, and concentrated in vacuo. The crude product was purified by C-18 reverse-phase HPLC using an acetonitrile:H20 (0.1 % TFA) gradient to give the title compound (14mg, 48%). 'H NMR (300 MHz, DMSO-d6) δ 11.42 (d, /=1.84 Hz, 1 H) 9.44 (s, 1 H) 8.34 (d, /=1.47 Hz, 1 H) 8.19 (d, /=8.46 Hz, 1 H) 7.79 (d,/=7.72 Hz, 1 H) 7.73 (dd,/=8.46, 1.84 Hz, 1 H) 7.32 - 7.37 (m, 2 H) 5.65 (dd,/=7.91, 2.39 Hz, 1 H) 3.24 (s, 3 H) 1.42 (s, 9 H).

[001420] Example 86. Preparation of 7V-(6-(3-tert-buty 1-5-(2,4-dioxo-3,4-dihydropyrimidin- l (2//)-yl)-2-methoxyphcnyl)benzo[/|t:hiazol-2-yl)acetamide (compound IB-LO-2.49).

[001421] A mixture of the product from Example 83 (30mg, 0.071 mmol) and acetic anhydride (3mL) was stirred at 100°C for 2h, and then allowed to cool to room temperature. The resulting solid was collected by filtration, washed with H20, and dried to give the title compound as an off-white solid (29mg, 88%). ‘HNMR (300 MHz, DMSO-d6) δ 12.42 (s, 1 Η) 11.41 (d, J=2.21 Hz, 1 H) 8.12 (d, J=1.47 Hz, 1 H) 7.82 (d, J=8.46 Hz, 1 H) 7.78 (d, J=8.09 Hz, 1 H) 7.61 (dd, J=8.46, 1.84 Hz, 1 H) 7.31 (q, J=2.70 Hz, 2 H) 5.64 (dd, J=8.09, 2.21 Hz, 1 H) 3.24 (s, 3 H) 2.22 (s, 3 H) 1.41 (s, 9 H). 276 2014280939 24 Dec 2014 [001422] Example 87. Preparation of l-(3-/eri-butyl-4-methoxy-5-(2-(propylamino)benzo[^thiazol-6-yl)phenyl)pyrimidine-2,4( 1 //,3/7)-dione (compound IB-LO-2.46).

H

[001423] Part A. Preparation of l-(3-/er/-butyl-5-(2-chlorobenzo[iflthiazol-6-yl)-4-methoxyphenyl) pyrimidine-2,4( 177,3.H)-dione.

[001424] To a mixture of the product from Example 83 (50mg, 0.118mmol) and copper(II) chloride (24mg, 0.178mmol) in acetonitrile (3mL) at 0°C was added tert-butyl nitrite (21 pL, 0.178mmol). The mixture was stirred at 0°C for Ih, and then warmed to 65°C and stirred for 2h, The mixture was concentrated in vacuo and purified by column chromatography on silica gel using 5% MeOH in CH2C12 to give the title compound as an off-white solid (43mg, 82%).

[001425] Part B. Preparation of l-(3-ter/-butyl-4-methoxy-5-(2-(propylamino)benzo[(f]thiazol-6-yl) phenyl)pyrimidine-2,4( 17/,3/7)-dione.

[001426] A mixture of the product from Part A (50mg, 0.1 lmmol), 1-aminopropane (9pL, 0.1 lmmol), and K2C03 (15.6mg, O.llmmol) in anhydrous DMF (5mL) was stirred at 100°Cfor24h. The mixture was concentrated in vacuo and purified by column chromatography on silica gel using 2% MeOH in EtOAc as the eluent to give the title compound as an off-white solid (21 mg, 40 %). NMR (300 MHz, DMSO-d6)5 11,39 (d, >1.84 Hz, 1 H) 8.12 (t,>5.52 Hz, 1 H) 7,82 (d,> 1.47 Hz, 1 H) 7.77(d,>7.72 Hz, 1 H) 7.44 (t, >9.01 Hz, 1 H) 7.37 - 7.41 (m, 1 H) 7.25 (s, 2 H) 5.63 (dd, >7.91, 2.02 Hz, 1 H) 3.33 -3.38 (m, 2 H) 3.26 (s, 3 H) 1.56 - 1.69 (m, 2 H) 1.40 (s, 9 H) 0.94 (t,>7.35 Hz, 3 H).

[001427] Example 88. Preparation of l-(3-?er/-butyl-4-methoxy-5-(3-methylbenzofuran-6-yl)phenyl)-pyrimidine-2,4(l//,377)-dione (compound IB-LO-2.42).

[001428] Part A. Preparation of methyl 2-(2-acetyl-5-bromophenoxy)acetate.

[001429] A solution of l-(4-bromo-2-hydroxyphenyl)ethanone (1.35g, 6.28mmol) in anhydrous DMF (16mL) was treated in several portions with sodium hydride (377mg of 60% in oil, 226mg, 9,42mmol) 277 2014280939 24 Dec 2014 followed by stirring at room temperature for 30min. The mixture was then treated with methyl bromo-acetate (871 μΤ, 1.45g, 9.48minol) dropwise (solution became warm after addition was complete) followed by stirring at room temperature for 18h. The mixture was diluted with ethyl acetate and extracted with water (4x) and saturated sodium chloride solution. Drying (Na2S04) and concentration in vacuo afforded a nearly colorless solid, which was purified by column chromatography on silica gel, eluting with 20-100% ethyl acetate in hexanes. These procedures afforded the title compound as a colorless solid (1.47g, 82%).

[001430] Part B. Preparation of 2-(2-acetyl-5-bromophenoxy)acetic acid.

[001431] A solution of the product from Part A (1.47g, 5.12mmol) in tetrahydrofuran (26mL) was treated with 1.0N sodium hydroxide solution (6.7mL, 6.7mmol) followed by stirring at room temperature for 3h, at which point the reaction was complete. The mixture was concentrated in vacuo to remove tetrahydrofuran and then was diluted with water and cooled to 0°C. The mixture was acidified to pH 3 by addition of IN hydrochloric acid solution, and then the product extracted with ethyl acetate. The organic layer was extracted with saturated sodium chloride solution and dried (Na2S04). Concentration in vacuo afforded the title compound as a colorless solid (1.36g, 97%).

[001432] PartC. Preparation of 6-bromo-3-methylbenzofuran.

[001433] A solution of the product from Part B (500mg, 1.83mmol) in acetic anhydride (9.2mL) was treated with sodium acetate (300mg, 3.66mmoI) followed by warming at reflux for 18h. The mixture was cooled to room temperature and diluted with toluene and concentrated in vacuo to azeotropically remove acetic anhydride. This process was repeated 3x. The mixture was then diluted with ethyl acetate and stirred with saturated sodium bicarbonate solution for lh. The layers were separated and the organic layer was extracted with saturated sodium chloride solution. Drying (Na2S04) and concentration in vacuo afforded amber oil, which was purified by column chromatography on silica gel, eluting with 8-50 % ethyl acetate in hexanes. These procedures afforded the title compound as a colorless liquid (316mg, 82%).

[001434] Part D. Preparation of 4,4,5,5-tetramethyl-2-(3-methylbenzofuran-6-yl)-l,3,2-dioxaborolane.

[001435] In a microwave tube, a mixture of the product from Part C (303mg, 1.44mmol), bis(pinacolato)diboron (401 mg, 1.58mmol) and potassium acetate (423mg, 4.31mmol) in anhydrous dioxane (5mL) was degassed by nitrogen sparge for I5min. The mixture was treated with 1,1 '-bis-(diphenylphosphino)ferrocene palladium (II) chloride dichloromethane complex (24mg, 0.029mmol) followed by degassing for another 5min. The microwave tube was sealed and the mixture was warmed at 90°C for 18h, The mixture was cooled and diluted with ethyl acetate and extracted with water and saturated sodium chloride solution. The organic layer was dried (Na2S04) and stirred with (3-mercapto-propyl) silica gel for lh. The mixture was filtered and concentrated in vacuo to afford a brown semisolid, 278 2014280939 24 Dec 2014 which was purified by column chromatography on silica gel, eluting with 8-40% ethyl acetate in hexanes. These procedures afforded the title compound as colorless oil, which slowly solidified upon standing (307mg, 83%).

[001436] Part E. Preparation of l-(3-ierr-butyl-4-methoxy-5-(3-methylbenzofuran-6-yI)phenyl)-pyrimidine-2,4( 17/,3//)-dione.

[001437] In a microwave tube, a solution of the product from Part D (3 07mg, 1.19mmol), the product from Example € (414mg, 1.03mmol), l,3,5,7-tetramethyl-2,4,8-trioxa-6-phospha-6-phenyl-adamantane (Cytec [97739-46-3]) (15mg, 0.052mmol), and tribasic potassium phosphate (439mg, 2.07mmol) in 3:1 tetrahydrofuran-water (8mL) was degassed by nitrogen sparge for 20min. The mixture was treated with tris(dibenzylideneacetone)dipalladium (0) (12mg, 0.012mmol) followed by degassing for another lOmin. During this period, the solution turned from an initially deep maroon color to a greenish brown color.

The microwave tube was sealed and the solution warmed at 50°C for 56h. The solution was cooled and diluted with ethyl acetate and acidified with 1M citric acid solution. The organic layer was extracted with saturated sodium chloride solution, dried (Na2S04), and then stirred with (3-mercaptopropyl) silica gel for Ih. After filtration and concentration in vacuo, the residue obtained was purified by column chromatography on silica gel, eluting with 4-20% acetone in dichloromethane, followed by a second column chromatography on silica gel, eluting with 20-100% ethyl acetate in hexanes. These procedures afforded the title compound as a colorless solid (355mg). Ή NMR (300 MHz, DMSO-4,): δ 11.40 (d, /-1.84 Hz, 1 H) 7.74 - 7.92 (m, 2 H) 7.58 - 7.76 (m, 2 H) 7.46 (dd, ./=8.09, 1.47 Hz, 1 H) 7.30 (q, ./=2.82 Hz, 2 H) 5.64 (dd, J=8.09,2.21 Hz, 1 H) 3.22 (s, 3 H) 2.25 (s, 3 H) 1.41 (s, 9 H).

[001438] Example 89. Preparation of JV-((6-(3-/er^butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2ƒ/)-yl)-2-methoxyphenyl)benzofuran-3 -yl)methyl)methanesulfonamide (compound IB-LO-2.18).

O o4·

[001439] Part A. Preparation of 6-bromo-3-(bromomethyl)benzofuran.

[001440] A solution of the product from Example 88, Part C (l.Og, 4.74mmol) and dibenzoyl peroxide (287mg, 1.19mmol) in chlorobenzene (24mL) at reflux was treated in four portions with N-bromosuccinimide (843mg, 4.74mmol) over 30min. The mixture was then stirred at reflux for 2h. The mixture was cooled, filtered and concentrated and purified by column chromatography on silica gel, 279 2014280939 24 Dec 2014 eluting with 7-30% chloroform in hexanes. The procedures afforded the title compound as a light yellow oil (43 8mg, 32%).

[001441] Part B. Preparation of fV-((6-bromobenzofuran-3-yl)methyl)-iV-(4-methoxybenzyl)methane-sulfonamide.

[001442] A solution of the product from Part A (515mg, 1.78mmol), iV-(4-methoxybenzyl)methane-sulfonamide (421 mg, 1.95mmol), and potassium carbonate (260mg, 1.95mmol) in anhydrous DMF (8.9mL) was stirred at 70°C for 3h. The mixture was cooled and diluted with ethyl acetate and extracted with water (4x). The organic layer was then extracted with saturated sodium chloride solution and dried (Na2S04). Concentration in vacuo afforded a beige solid. This material was purified by column chromatography on silica gel. eluting with 20-100% ethyl acetate in hexanes. These procedures afforded the title compound as a colorless solid (224mg, 35%).

[001443] Part C, Preparation of IV-(4-methoxybenzyl)-JV-((6-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)benzofuran-3-yl)methyl)methanesulfonamide.

[001444] The product from Part B (186mg, 0.44mmol) was subjected to the conditions described for Example 88, Part D to afford the title compound as a colorless solid (177mg, 86%).

[001445] Part D. Preparation of 7V-((6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2/7)-yl)-2-methoxyphenyl)benzofuran-3-yl)methyl)-iV-(4-methoxybenzyl)methanesulfonamide.

[001446] In a microwave tube, a suspension of the product from Part C (169mg, 0.36mmol), the product from Example C (143mg, 0,36mmol), and 1.0M sodium carbonate solution (0.5mL, 0.50mmol) in 1:1 ethanol-toluene (3mL) was degassed by nitrogen sparge for 20min. The solution was treated with 1,1-bis(diphenylphosphino)ferrocene-palladium(II) chloride dichloromethane complex (7mg, 9pmol) followed by degassing for another 5min. The microwave tube was sealed and the mixture heated a 100°C in the microwave oven for lh. The mixture was diluted with ethyl acetate and water, and acidified with 1M citric acid solution. The organic layer was extracted with saturated sodium chloride solution, dried (Na2S04), and allowed to stand overnight over (3-mercaptopropyl) silica gel. Filtration and concentration in vacuo afforded an off-white foam which was purified by column chromatography on silica gel, eluting with 5-30% ethyl acetate in dichloromethane. The procedures afforded the title compound as a colorless solid (96mg, 43%).

[001447] Part E. Preparation of Ar-((6-(3-iert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(27/)-yl)-2-methoxyphenyl)benzofuran-3-yl)methyl)methanesulfonamide.

[001448] A solution of the product from Part D (88mg, 0.14mmo) in dichloromethane (1.4mL) was treated with trifluoroacetic acid (1.4mL) followed by stirring at room temperature for 18h, and then stirring at 40°C for 2h. The mixture was concentrated in vacuo to afford a dark, purple-brown foam, which was subjected to column chromatography on silica gel, eluting with 5-50% ethyl acetate in 280 2014280939 24 Dec 2014

methylene chloride to afford an impure material, which was purified by reverse phase chromatography on a C-l 8 column, eluting with 1 % water-TFA/acetonitrile. The procedures afforded the title compound as a solid (3.9mg). ‘HNMR(300 MHz, DMSO-4;): δ 11.31 - 11.48 (m, 1 H) 8.01 (s, 1 H) 7.68 - 7.94 (m, 2 H) 7.40 - 7.65 (m, 2 H) 7.10 - 7.38 (m, 2 H) 5.65 (dd, J=7.91,2.02 Hz, 1 H) 4.33 (d, J=5.88 Hz, 2 H) 3.23 (s, 3 H) 2.95 (s, 3 H) 1.41 (s, 9 H). (001449] Example 90. Preparation of AL((5-(3-?ert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2/f)-yl)-2-methoxyphenyl)-l-methyl-2,3-dihydro-l//-inden-l-yl)methyl)methanesulfonamide (compound IB-L0-2.25).

OO

VS

H

[001450] Part A. Preparation of 5-bromo~l-(l,3-dithian-2-yl)-2,3-dihydro-lf/-inden-l-ol.

[001451] A solution of 1,3-dithiane (11.96g, 99mmol) in anhydrous tetrahydrofuran (lOOmL) at -30°C was treated dropwise over lOmin with n-butyllithium (2.5M in hexanes, 38.4mL, 96mmol) followed by stirring at -15°C for 2h. The solution was then treated with a solution of 5-bromo-2,3-dihydro-l//-inden-1-one (15g, 71.1 mmol) in anhydrous tetrahydrofuran (250mL) over lh, maintaining the temperature between -9°C and 2°C. rfhe mixture was then allowed to set in the refrigerator at 2 8°C for 18h. The solution was concentrated in vacuo to afford a maroon oil, which was treated with 1 N hydrochloric acid solution and extracted with ether. The ether layer was extracted with saturated sodium chloride solution, dried (Na2S04) and concentrated in vacuo to afford an amber oil (23.55g).

[001452] PartB. Preparation of 2-(5-bromo-2,3-dihydro-17/-inden-l-ylidene)-1,3-dithiane.

[001453] A solution of the product from Part A (23.55g, 71 .lmmol) in benzene (350mL) was treated with p-toluenesulfonic acid monohydrate (3.0g) followed by stirring at reflux for lh while removing water by means of a Dean-Stark trap. The mixture was extracted with saturated sodium bicarbonate solution and then with saturated sodium chloride solution. Drying (Na2S04) and concentration in vacuo afforded the product as an amber, oil (22.27g).

[001454] Part C. Preparation of 5-bromo-2,3-dihydro-l//-indene-1 -carboxylic acid.

[001455] A solution of the product from Part B (22.27g, 71 .lmmol) in glatial acetic acid (375mL) was treated with concentrated hydrochloric acid solution (125mL) followed by stirring at reflux for 3h. The mixture was cooled and concentrated in vacuo by azeotroping off the acetic acid and water with toluene (3x), The brown oil obtained was filtered through a plug of 70-230 mesh silica gel in a 2L sintered glass 281 2014280939 24 Dec 2014 funnel (volume of silica gel ca. 1800mL) eluting with dichloromethane to remove non-polar impurities (1,3-propanedithiol, inter alia) and then with ethyl acetate to elute the title compound, which was obtained as a brown solid (9.85g, 58%).

[001456] PartD. Preparation of methyl 5-bromo-2,3-dihydro-l//-indene-l-carboxylate.

[001457] A suspension of the product from Part C (9.85g, 40.9mmol) in methanol (400mL) was treated with 4 N hydrogen chloride in 1,4-dioxane (125mL) and the mixture was stirred at reflux for 8h. The mixture was concentrated in vacuo to afford brown oil, which was purified by column chromatography on silica gel, eluting with 0-30% methyl t-butyl ether in chloroform. These procedures afforded the title compound as an amber oil (7,99g, 77%).

[001458] PartE. Preparation of methyl 5-bromo-l -methyl-2,3-dihydro-l//-indene-l -carboxyl ate.

[001459] A solution of the product from Part D (2.03g, 7.96mmol) in anhydrous tetrahydrofuran (40mL) at -78°C under N2 was treated dropwise with lithium bis(trimethylsilyl)amide (1 .OM in tetrahydrofuran, 9.55mL, 9.55mmol) over 1 Omin. The solution was stirred at -78°C for 45min and then treated with methyl iodide (1,5mL, previously dried by passage through a plug of basic alumina). The mixture was then gradually allowed to warm to rt and was stirred for 18h. The mixture was quenched by addition of saturated ammonium chloride solution (2mL). The mixture was concentrated in vacuo to remove tetrahydrofuran and the residue was diluted with ethyl acetate. The mixture was extracted with saturated ammonium chloride solution and with saturated sodium chloride solution. Drying (Na2S04) and concentration in vacuo afforded the title compound as an amber oil (2.06g, 96%).

[001460] Part F. Preparation of 5-bromo-1-methvl-2.3-dihydro-l//-indene-l -carboxylic acid.

[001461] A solution of the product from Part E (2,06g, 7.65mmol) and potassium trimethylsilanoate (5.5g of 90%, 4.91g, 38.3mmol) in tetrahydrofuran (40mL) was stirred at reflux for 3h. The mixture was cooled and concentrated in vacuo to remove tetrahydrofuran. The maroon residue was dissolved in water (ca. 175mL) and extracted with methyl t-butyl ether. The aqueous phase was cooled to 0°C and acidified to pH 3 by addition of concentrated hydrochloric acid solution. The mixture was extracted with ethyl acetate (2x) and then with saturated sodium chloride solution. The solution was dried (Na2S04) and treated with Darco G-60, followed by filtration through celite. The filtrate was concentrated in vacuo to afford the title compound as a light yellow solid (1,93g, 99%).

[001462] Part G. Preparation of 5-bromo-l -methyl-2,3-dihydro-1 //-indene-1 -carboxamide.

[001463] A solution of the product from Part F (1.56g, 6.12mmol) and DMF (473 pL, 447mg, 6.12mmol) in hexanes (lOOmL) was treated with oxalyl chloride (1.61mL, 2.32g, 18.4mmol) followed by stirring at room temperature for 1 h. The mixture was treated with celite and then filtered through celite. The filtrate was concentrated in vacuo and dissolved in acetone (75mL) and cooled to 0°C. The solution was treated with 28% aqueous ammonia solution (75mL) followed by stirring at 0°C for 3 Omin and then 282 2014280939 24 Dec 2014 warming to room temperature. The mixture was concentrated in vacuo and extracted with ethyl acetate. The organic layer was extracted with saturated sodium chloride solution and dried (Na2S04). Concentration in vacuo afforded the title compound as an oil (1,55g, 100%).

[001464] Part H. Preparation of (5-bromo-1 -methyl-2,3 -dihydro- l/f-inden-1 -yl)methanamine hydrochloride.

[001465] In a flask equipped with a vigreaux column and a short path distillation head, a solution of the product from Part G (1.21g, 4.76mmol) in anhydrous tetrahydrofuran (8mL) was warmed to a gentle reflux and treated dropwise with borane-dimethylsulfide complex (904pL, 723mg, 9.52mmol). The resulting mixture was stirred at reflux for 2h, The solution was cooled to rt and carefully treated with methanol until bubbling ceased, followed by careful treatment with 4N hydrogen chloride in 1,4-dioxane solution (4mL). The mixture was then concentrated in vacuo. The colorless solid obtained was triturated with ether and collected by filtration. After drying in a vacuum oven at 50°C for 2h, the title compound was obtained as a colorless solid (893 mg, 68%).

[001466] Parti. Preparation of ferr-butyl(5-bromo-1 -methyl-2,3-dihydro-1 //-inden-1 -yljmethyl-carbamate.

[001467] A suspension of the product from Part H(893mg, 3.23mmo) in tetrahydrofuran (16mL) was treated with di-tert-butyl dicarbonate (846mg, 3.87mmol) and saturated sodium bicarbonate solution (7.2mL, ca. 6.46mmol) followed by stirring at room temperature for 18h. The mixture was diluted with ethyl acetate and extracted with water and saturated sodium chloride solution. The solution was dried (Na2S04) and concentrated in vacuo. The residue was purified by flash chromatography, eluting with 5-40% ethyl acetate in hexanes. These procedures afforded the title compound as a colorless solid (1,03g, 94%).

[001468] Part J. Preparation of tert-butyl (l-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2,3-dihydro-lH-inden-l-yl)methylcarbamate.

[001469] The product from Part I (1.03g, 3.03mmol) was subjected to the conditions described for Example 88, Part D to afford the title compound as a colorless solid (977mg, 83%).

[001470] PartK. Preparation of tert-butyl (5-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2//)-yl)-2-methoxyphenyl)-l-methyl-2,3-dihydro-l//-inden-l-yl)methylcarbamate.

[001471] The product from Part J (965mg, 2.49mmol) was subjected to the conditions described for Example 89, Part D to afford the title compound as a colorless solid (618mg, 47%).

[001472] PartL. Preparation ofïV-((5-(3-/err-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2/ï)-yl)-2-methoxypheny 1)-1 -methy 1-2,3-d ihydro-1//-inden-l-yl)methyl)methanesulfon amide.

[001473] The product from Part K (446mg, 0.84mmol) was dissolved in 4N hydrogen chloride in dioxane solution (12mL), followed by stirring at room temperature for 18h. The suspension of colorless 283 2014280939 24 Dec 2014

solid obtained was then concentrated in vacuo. This material was suspended in dichloromethane (5mL) and cooled to 0°C, followed by sequential treatment with triethylamine (280pL, 203mg, 2.01 mmol) and methanesulfonyl chloride (81pL, 120mg, 1 .OSmmol). The mixture was stirred at 0°C for lh and then warmed to room temperature and diluted with dichloromethane. The mixture was extracted with 1M citric acid solution and then dried (Na2S04) and concentrated in vacuo. The residue was dissolved in 3:1 tetrahydrofuran-water (8mL) and treated with potassium carbonate (23 lmg, 1.68mmol) followed by stirring at room temperature for lh. The mixture was concentrated in vacuo and the residue diluted with water and then acidified to ca. pH 2 by addition of 1M citric acid. The product was extracted with ethyl acetate and the organic layer was extracted with saturated sodium chloride solution. Drying (Na2SQ|) and concentration in vacuo afforded a colorless solid, which was purified by column chromatography on silica gel, eluting with 30-100% ethyl acetate in hexanes. The procedures afforded the title compound as a colorless solid (184mg, 43%). *H NMR (300 MHz, DMSO-/„): δ 11.39 (s, 1 H) 7.77 (d, /=7.72 Hz, 1 H) 7.14-7.48 (m, 5 H) 7.06 (t,/=6.62 Hz, 1 H) 5.63 (d,/=7.72 Hz, 1 H) 3.18-3.33 (m, 3 H) 2.96 - 3.15 (m, 2 H) 2.85 - 3.00 (m, 2 H) 2.70 - 2.87 (m, 3 H) 2.10 - 2.34 (m, 1 H) 1.63 - 1.90 (m, 1 Η) 1.40 (s, 9 H) 1.20- 1.34 (m, 3 H).

[001474] Example 91. Preparation of A-((5-(3-ie/7-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2//)-yI)-2-methoxyphenyl)-1 -fluoro-2,3 -dihydro-1 //-inden-1 -yl)methyl)methanesulfonamide (compound IB-L0-2.12).

[001475] Part A. Preparation of 5-(5-bromo-2,3-dihydro-l//-inden-l-ylidene)-2,2,3,3,7,7,8,8-octamethyl-4,6-dioxa-3,7-disilanonane.

[001476] To a solution of the product from Example 90, Part C (1.2g, 4,98mmoI) in anhydrous THF (5mL) was added TBSC1 (1.726g, 11.45mmoI), and the resulting yellow solution was cooled to 0°C in an ice bath. A 1.0M solution of LiHMDS in THF (11.95mL, 11.95mmol) was added dropwise over 5min, and the resulting dark red solution was stirred at 0°C for 90min, and then at room temeprature for 6h. The solvent was removed in vacuo and the oily semi solid residue was treated with pentane (2 x 35mL) to precipitate LiCl. The slurry was filtered and the solvent was removed in vacuo to give the title compound as a brown oil (2.3g).

[001477] Part B. Preparation of 5-bromo-l-fiuoro-2,3-dihydro-l//-indene-l-carboxyIic acid. 284 2014280939 24 Dec 2014 [001478] To a mixture of l-chloromethyl-4-fluoro-l,l-diazoniabicyclo[2.2.2.]octane bis(tetrafluoro-borate)(Selectfluor, 2.26g, 6.37mmoi in CH3CN (20mL) was added the product from Part A (2.3g, 4.90mmol) in CH3CN (6mL). The resulting yellow-orange solution was stirred at room temperature overnight. The reaction mixture was poured into 50mL IN HC1 (aqueous), extracted with EtOAc (2 x 35mL). The combined organic extracts are washed with 0.5NNaOH (3 x 30mL). The combined aqueous extracts are washed with EtOAc (2 x 25mL), then adjusted mixture to pH 1 with 5N HC1 (1 OmL). The resulting cloudy brown solution was extracted with EtOAc (2 x 50mL), the combined organic layers were washed with 10% NaCl and then treated with decolorizing carbon and stirred for lh. The mixture was dried over anhydrous Na2S04(s), Filtered through Celite and the solvent removed in vacuo to give the title compound as leaving a yellow oil (0.84g).

[001479] Part C. Preparation of 5-bromo-l-fluoro-2,3-dihydro-lH-indene-l-carbonyl chloride.

[001480] To a solution of the product from Part B (0.95g, 3.67mmol) in CH2C12 was added oxalyl chloride (0.96mL, 1 l.OOmmol), followed by DMF (0.28mL). The resulting bubbling solution was stirred at room temperature for 2h, filtered through Celite, and the solvent was removed in vacuo to give the title compound as a brown oil (0.99g).

[001481] Part D. Preparation of 5-bromo-l-fluoro-2,3-dihydro-lII-indene-l-carboxamide.

[001482] To a solution of the product from Part C (0.99g, 3.57mmol) in acetone (20mL) and at 0°C was added aqueous NH4OH (28%, 0.28mL, 3.57mmol), and the resulting dark brown mixture was stirred at 0°C for lh. The reaction mixture was concentrated in vacuo, and the residue was partitioned between water and EtOAc (2 x 50mL). The combined organic extracts were washed with IN H3PO4, 10%

NaHC03 (aq), 10% NaCl, and dried over anhydrous Na2S04(s), filtered and concentrated in vacuo. The brown solid was purified by column chromatography on silica gel using a solvent gradient of CFI2CI2/MeOH (99/lto96/4). The title compound was obtained as a brown solid (0.205g, 22 %).

[001483] PartE. Preparation of/ert-butyl (5-bromo-l-fluoro-2,3-dihydro-l/i-inden-l-yl)methyl-carbamate.

[001484] To a solution of the product from Part D (0.234g, 0.907mmol) in anhydrous THF (5mL) at 80°C was added borane-DMS complex (0.172mL, 1.813mmol) dropwise. The reaction tlask was equipped with a short-path condenser, and the mixture was stirred at reflux for 2h, collecting THF and DMS. The mixture was then cooled to room temperature and MeOH (5mL) was added, followed by 4N HC1 in 1,4-dioxane (5mL). The solvent was removed in vacuo to give a colorless solid (0.25g, 98%).

The solid was dissolved in THF (5mL), and to the solution was added triethylamine (0.137mL, 0.980mmol), followed by di-terf-butyl dicarbonate (0.214g, 0.980mmol). The cloudy mixture was stirred at room temperature for 30min, and 10% aq. NaHC03 (ImL) was added. The resulting mixture was stirred at room temperature for 18h and then concentrated in vacuo to an oily residue. The residue was 285 2014280939 24 Dec 2014 dissolved in EtOAc (50mL), washed with water, IN H3PO4,10% NaCl, and dried over anhydrous Na2S04(s). The drying agent was filtered off, and the solvent was removed in vacuo to give the title compound as an oil (0.27g, 88%).

[001485] Part F. Preparation of 7e/7-butyl (l-fluoro-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2,3-di hydro-1 77-inden-1 -yl)methylcarbamate.

[001486] The product from Part E (0.27g, 0.784mmol) was subjected to the conditions described for Example 72, Part B to give the title compound as a tan solid (0.159g, 52 %).

[001487] Part G. Preparation of/eri-butyI (5-(3-ter/-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2/7)-yl)-2-methoxyphenyl)-l-fluoro-2,3-dihydro-l/7-inden-l-yl)methylcarbamate.

[001488] To a solution of the product from Part F (0.159g, 0.405mmol), the product from Example C (0.162g, 0.405 mol), 1,3,5,7 tetramethyl-2,4,8-trioxa-6-phospha-6-phenyl adamantane (PA-Ph, CAS 97739-46-3) (3.55 g, 0.012mmol) in THF (3mL) was added K3PO4 (0.18lg, 0.851mmol) and water (lmL), followed by tris(dibenzylideneacetone)dipalladium(0) catalyst (3.71mg, 0.00405mmol). The resulting mixture was degassed by bubbling with N2 for 20min, and then stirred at room temperature for 12h. The reaction mixture was diluted with EtOAc (50mL), washed with IN H3P04, 10% NaHC03, 10% NaCl, and dried over anhydrous Na2S04(s). The mixture was filtered and solvent was removed in vacuo to give a brown oil, which was purified by column chromatography on silica gel, eluting with 98/2 CH2Cl2/MeOH. The title compound was isolated as a colorless solid (0.118g, 54%). f001489] Part H. Preparation of/V-((5-(3-fór/-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-] (2/7)-yl)-2-methoxyphenyl)-l-fluoro-2,3-dihydro-l//-inden-l-yl)methyl)methanesulfonamide.

[001490] The product from Part G (0.118g, 0.219mmol) was dissolved in 4N HC1 in 1,4-dioxane (2mL) and stirred at room temperature for lh. The solvent was removed in vacuo and the residue was suspended in CH2C12 and evaporated (2 x 4mL) to give a colorless solid (0.10g, 96%), This solid was dissolved in CH2CI2 (lmL) and the resulting slurry was stirred in an ice bath. Triethylamine (0.059mL, 0.422mmol) was added to the slurry resulting in a clear solution and to this was added methanesulfonyl chloride (0.02mL, 0.253mmol). The resulting mixture was stirred in the ice bath for lh. The reaction mixture was diluted with CH2C12 50mL, washed with IN H3PO4, 10% NaHC03, 10% NaCl, and dried over anhydrous Na2S04(s). The drying agent was filtered off, and solvent was removed in vacuo leaving a crude product that was purified by column chromatography on silica gel, eluting with a gradient of 1:1 to 3:7 hexane:EtOAc, The title compound was obtained as a colorless solid (64mg, 62 %). H NMR (300 MHz, DMSO-d6) δ 11.39 (s, 1 H) 7.77 (d, J=7.72 Hz, 1 H) 7.30 - 7.48 (m, 3 H) 7.12 - 7.32 (m, 3 H) 5.63 (d, ./=7.72 Hz, 1 H) 3.27 (s, 3 H) 2.94 - 3.08 (m, 4 H) 2.91 (s, 3 H) 2.17 - 2.38 (m, 1 H) 1.76 - 1.97 (m, 1 H) 1.40 (s, 9 H). 286 2014280939 24 Dec 2014 [001491] Example 92. Preparation of /V-(6-(3-fert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2//)-yl)-2-methoxyphenyl)-3,4-dihydroisoquinolin-2( l//)-yl)methanesulfonamide (compound IB-LO-2.43).

[001492] Part A. Preparation of iV-(3-bromophenethyl)-2,2,2-trifluoroacetamide.

[001493] To a solution of 2-(3-bromophenyl)ethanamine (lOg, 50.0mmol) in dichloromethane (200ml) at 0°C were added 2,6-lutidine (6.40ml, 55.0mmol) and then trifluoroacetic anhydride (7.77ml, 55.0mmol) dropwise, and the reaction was stirred at room temperature overnight. Water was added at 0°C and the reaction was washed with 1M HC1, H20, and sat NaHC03. The organic was dried overmgS04, filtered and concentrated to provide the title compound as a tan solid (14,7g, 99%).

[001494] PartB. Preparation of l-(6-bromo-3,4-dihydroisoquinolin-2(l/7)-yl)-2,2,2-trifluon>ethanone.

[001495] To the product from Part A (14.70g, 49.6mmol) and paraformaldehyde (2.39g, 80mmol) was added a mixture of acetic acid (81ml) and sulfuric acid (53.7ml) at room temperature. The suspension was stirred for 60h during which time it became a solution. The reaction was poured into cold water. The reaction was diluted with ethyl acetate and washed with water, sat NaHCOj, and brine. The organic layer was dried overmgS04, filtered and concentrated to provide the title compound, contaminated with the 8-bromo isomer, as a colorless oil (10.5 g, 67%).

[001496] Part C. Preparation of 6-bromo-l,2,3,4-tetrahydroisoquinoline.

[001497] To a solution of the product from Part B (9.5g, 30.8mmol) in methanol (231ml) and water (77ml) at room temperature was added potassium carbonate (8.52g, 61.7mmol) and the reaction was stirred at room temperature for 30min. The reaction was diluted with water and 25% isopropanol in chloroform and the pH was adjusted to 9 with IN HC1. The mixture was extracted twice with 25% isopropanol in chloroform. The combined organic layers were dried overmgS04, filtered and concentrated to give the title compound, contaminated with the 8-bromo isomer (6.55g, quantitative).

[001498] PartD. Preparation of 6-bromo-2-nitroso-l,2,3,4-tetrahydroisoquinoline.

[001499] To a solution of the product from Part C (6.55g, 30.9mmol) in acetic acid (61.8ml) and 3N aq. hydrochloric acid (10.29ml, 30.9mmol) at 0°C was added 1.9M sodium nitrite (20.64ml, 39.2mmol) dropwise, and the reaction was stirred at room temperature overnight. The solvent was evaporated and the reaction was diluted with 25% isopropanol in chloroform and sat NaHCCh. The aqueous layer was 287 2014280939 24 Dec 2014 extracted twice with 25% isopropanol in chloroform. The combined organic layers were dried overmgS04, filtered and concentrated to give the title compound, contaminated with the 8-bromo isomer (6.97 g, 94%).

[001500] Part E. Preparation of 6-bromo-3,4-dihydroisoquinolin-2(lH)-amine.

[001501] To a solution of the product from Part D (0.5g, 2.074mmol) in methanol (4.15ml) was added zinc (0.542g, 8.30mmol) and the reaction was cooled to 0°C, followed by dropwise addition of AcOH (4.15ml). The reaction was warmed to rt and the reaction was stirred for 2.5h. The reaction was filtered and the solid was washed with methanol. The filtrate was evaporated and the residue was diluted with water and 25% isopropanol in chloroform and saturated NaHC03 was added. A white solid was removed by filtration, and the aqueous layer was extracted twice with 25% isopropanol in chloroform. The combined organic layers were dried overmgS04, filtered and concentrated to give the title compound, contaminated with the 8-bromo isomer (0.472g, quantitative).

[001502] Part F. Preparation of tert-butyl 6-bromo-3,4-dihydroisoquinoIin-2(l//)-ylcarbamate.

[001503] A solution of the product from Part E (0.472g, 2.078mmol) in THF (20.78ml) was cooled to 0°C followed by addition of di-/m-butyl dicarbonate (0.531ml, 2.286mmol), and the reaction was stirred at room temperature overnight. Solvent was removed in vacuo, and the crude product was purified by column chromatography on silica gel (isolated lower Rf product) using a gradient starting with dichloromethane and ending with 10% ethyl acetate in dichloromethane to give the title compound (49mg, 73%).

[001504] Part G. Preparation of /ert-butyl 6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinolin-2(I77)-ylcarbamate.

[001505] A solution of the product from PartF(100mg, 0,306mmol), bis(pinacolato)diboron (85mg, 0.336mmol), and potassium acetate (57.3μ1, 0.917mmol) in 1,4-dioxane (3.0mL) was degassed by bubbling with N2 gas for 15min. l,r-Bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (11.18mg, 0.015mmol) was added, and the resulting mixture was stirred at 95°C for 16h. The cooled solution was diluted with 25% isopropanol in chloroform and washed with water. The organic layer was dried overmgS04, filtered and concentrated in vacuo. The product was purified by column chromatography on silica gel eluting with a gradient starting with dichloromethane and ending with 25% ethyl acetate in dichloromethane to give the title compound (70mg, 61%).

[001506] Part H, Preparation of tert-butyl 6-(3-/ert-butj'l-5-(2,4-dioxo-3,4-dihydropyrimidin-l(27/)-yl)-2-methoxypheny 1)-3,4-dihydroisoquinoiin-2(l//)-ylcarbamate.

[001507] A mixture of the product from Example C (74.8mg, 0.187mmol), the product from Part G (70mg, 0.187mmol) in EtOH(l.OmL), toluene(l.OmL) 1M aq. Na2C03 (28Ιμΐ, 0.281mmoi) was degassed by bubbling with N2 gas for lOmin. 1,1- Bis(diphenylphosphino)ferrocene-palladium(lI) 288 2014280939 24 Dec 2014 dichloride dichloromethane complex (6.84mg, 9.35pmol) was added, and degassing with N2 was continued for 5min. The reaction mixture was sealed and heated at 78°C for 16h. The reaction was cooled and diluted with 25% isopropanol in chloroform and washed with water. The organic was dried overmgSCM, filtered and concentrated. The crude product was purified by column chromatography on silica gel, eluting with a gradient starting with dichloromethane and ending with ethyl acetate to give the title compound (53 mg, 54%).

[001508] Parti. Preparation of ,V-(6-(3-/ert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2i/)-yl)-2-methoxyphenyl)-3,4-dihydroisoquinolin-2(lf/)-yl)methanesulfonamide.

[001509] To a solution of the product from Part H (25mg, 0.048mmol) in dichloromethane (0.5mL) at room temperature was added TFA (0.5mL) and the reaction was stirred for 30min, and then concentrated in vacuo. The residue was diluted with 25% isopropanol in chloroform and washed with sat NaHCOj. The organic layer was dried overmgS04, filtered and concentrated to give a solid (17.8mg, 88%). To a solution of the solid in pyridine (0.5mL) at 0°C was added methanesulfonyl chloride (12,6μ1, 0.162mmol) and the reaction was stirred at room temperature for 90min. Methanol was added and the reaction was stirred for lOmin. The residue was diluted with 25% isopropanol in chloroform and washed with sat NaHC03. The organic layer was dried overmgS04, filtered and concentrated, and the product was purified by column chromatography on silica gel eluting with a gradient starting with dichloromethane and ending with ethyl acetate to give the title compound (1 lmg, 52%). *H NMR (300 MHz, DMSO-d6) δ 11.39 (s, 1 H) 8.53 (s, 1 H) 7.76 (d, /=7.72 Hz, 1 H) 7.11 - 7.42 (m, 5 H) 5.63 (d, /=7.72 Hz, 1 H) 4.04 (s, 2 H) 3.28 (s, 3 H) 3.10 (d, /=5.52 Hz, 2 H) 2.98 (s, 3 H) 2.90 - 3.05 (m, 2 H) 1.40 (s, 9 H).

[001510] Example 93. Preparation of iV-((6-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(277)-y])-3-(furan-2-yl)-2-methoxyphenyl)-1 /7-inden-3-yl)methyl)methanesulfonamide (compound IB-LO-2.65).

O

[001511] Part A. Preparation of.V-((6-(3-bromo-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2//)-yl)-2-methoxyphenyl)-lff-inden-3-yl)methyl)methanesulfonamide.

[001512] The product from Example 48, Part C (0.242gm, 0.573mmol) and the product from Example 79, Part E (0.200gm, 0,57mmol) was subjected to the conditions described for Example 79, Part F to 289 2014280939 24 Dec 2014 give the title compound as an off-white solid (0.104gm, 35%).

[001513] Part B. Preparation of #-((6-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2/7)-yl)-3-(furan-2-yl)-2-methoxyphenyl)-l/f-inden-3-yl)methyl)methanesulfonamide.

[001514] A solution of the product from Part A (25.2mg, 0.049mmol) in 3:1 v/v THF-water (1.3mL) was combined in a microwave tube at room temperature with furan-2-ylboronic acid (6.91 mg, 0.062mmol) and potassium phosphate (16.84mg, 0.097mmol). To this was added l,l'-bis(di-tert-butyl-phosphino)ferrocene palladium dichloride (1.65mg, 2.53umole). The tube was sealed and the resulting mixture was purged with nitrogen for 4min and then heated for 16.5h in an oil bath at 50°C. The reaction mixture was partitioned between dilute HC1 and ethyl acetate, and the organic phase was dried (MgS04) and concentrated in vacuo. The residue was purified by chromatography on silica gel (ethyl acetate-hexanes) to give the title compound as an off white solid (11.4mg, 46%). 'H NMR (300 MHz, DMSO-d6) δ 11.45 (s, 1 H) 7.80 - 7.89 (m, 2 H) 7.73 - 7.79 (m, 2 H) 7.56 - 7.63 (m, 2 H) 7.50 (t, > 6.07 Hz, 1 H) 7.38 (d, ./=2.94 Hz, 1 H) 7.09 (d, >3.31 Hz, 1 H) 6.68 (dd, >3.68, 1.84 Hz, 1 H) 6.58 (s, 1 H) 5.68 (d, >7.72 Hz, 1 H) 4.19 (d,>5.15 Hz, 2 H) 3.48 (s, 2 H) 3.34 (s, 3 H) 2.96 (s, 3 H).

[001515] Example 94. Preparation of #-((6-(5-(2,4-dioxo-3,4-dihydropyrimidin~l(2/7)-yl)-2-rnethoxy-3-(thiophen-2-yl)phenyl)-l//-inden-3-yl)methyl)methanesulfonamide (compound IB-LO-2.63).

[001516] The product from Example 93, Part A (26.5mg, 0.051 mmol) was reacted with thiophen-2-yl boronic acid (8.3mg, 0.065mmol) as described in Example 93, Part B to give the title compound as an off-white solid (8.6mg, 32%). ’ll NMR (300 MHz, DMSO-d6) δ 11.47 (s, 1 H) 7.86 (d, >7.72 Hz, 2 H) 7.55 - 7.78 (m, 5 H) 7.50 (t, >6.25 Hz, 1 II) 7.38 (d, >2.57 Hz, 1 H) 7.16 - 7.21 (m, 1 H) 6.58 (s, 1 H) 5.69 (d, >7.72 Hz, 1 H) 4.19 (d, >4.78 Hz, 2 H) 3.48 (s, 2 H) 3.30 (s, 3 H) 2.96 (s, 3 H). 290 2014280939 24 Dec 2014 [001517] Example 95. Preparation ofiV-((6-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(27/)-yi)-2-methoxy-3-(thiophen-3-yl)phenyl)-l//-inden-3-yl)methyl)methanesulfonamide (compound IB-LO-2.62).

[001518] The product from Example 93, Part A (25.9mg, 0.050mmol) was reacted with thiophen-3-yl boronic acid (8.1 mg, 0.063mmol) as described in Example 93, Part B to give the title compound as an off-solid (8.6mg, 33%). ’H NMR (300 MHz, DMSO-d6) δ 11.45 (d, 7= 1.84 Hz, 1 H) 7.93 (d, ./=2.94 Hz, 1 H) 7.87 (d, 7= 7.72 Hz, 1 H) 7.53 - 7.75 (m, 6 H) 7.49 (t, ./=6.25 Hz, 1 H) 7.39 (d, ./=2.57 Hz, 1 H) 6.57 (s, 1 H) 5.68 (dd, 7= 7.91,2.02 Hz, 1 H) 4.19 (d, ./=5.15 Hz, 2 H) 3.47 (s, 2 H) 3.21 (s, 3 H) 2.96 (s, 3 H).

[001519] Example 96. Preparation of A-((6-(5-(2,4-dioxo-3,4-dίhydr<:>pyriπ^idin-i(2//)-yl)-3-(furan-3-yl)-2-methoxyphenyl)-l.ί/-inden-3-yl)methyl)methanesulfonamide (compound IB-LO-2.67).

O

[001520] The product from Example 93, Part A (25.9mg, 0.050mmol) was reacted with furan-3-yl boronic acid (7.2mg, 0.064mmol) as described in Example 93, Part B to give the title compound as an off-white solid (10.6mg, 45%). ’H NMR (300 MHz, DMSO-d6) δ 11.46 (s, 1 H) 7.84 (d, ./=8.09 Hz, 1 H) 7.80 (t, 7=1.84 Hz, 1 H) 7.68 - 7.75 (m, 2 H) 7.54 - 7.64 (m, 2 H) 7.50 (t, 7=6.07 Hz, 1 H) 7.35 (d, J= 2.57 Hz, 1 H) 7.08 (d, 7=1.47 Hz, 1 H) 6.57 (s, 1 H) 5.68 (d, 7=8.09 Hz, 1 H) 3.47 (s, 2 H) 3.30 (s, 3 H) 2.96 (s, 3 H). 291 2014280939 24 Dec 2014 [001521] Example 97. Preparation of l -(3-/er/-butyl-4-nieihoxy-5-(l -(methylsulfonyl)indolin-5-yl) phenyl)pyrimidine-2,4(ljy,37/)-dione (compound IB-LO-2.32).

O

[001522] Part A. Preparation of 5-bromo-l-(methylsulfonyl)indoline.

[001523] To DMF (5.0ml) was added sodium hydride (53mg, 1.3mmol) and the solution stirred at room temperature for 30min. 5-Bromoindoline (240mg, 1.2mmol) was added and the solution was stirred at room temperature for 30min. Methanesulfonyl chloride (94ul, 1.2mmol) was added and the solution stirred at room temperature overnight, then concentrated in vacuo. The crude product was purified by column chromatography on silica gel eluting with 2% CH3OH/CHCI3 to give the title compound (202mg, 60%).

[001524] Part B. Preparation of l-(methylsulfonyl)-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl) indoline.

[001525] The product from Part A (192mg, 0.70mmol) was subjected to the conditions described for Example 72, Part B to give the title compound (114mg, 51%).

[001526] Part C. Preparation of l-(3-/eri-butyl-4-methoxy-5-(l-(methylsuIfonyl)indoiin-5-yl)phenyl) pyrimidine-2,4(l//,3/7)-dione.

[001527] The product from Example C (58mg, 0.145mmol) and the product from Part B (56.2ing, 0.174mmol) were subjected to the conditions described for Example 72, Part C to give the title compound as a colorless solid (12mg, 18%). *H NMR (300 MHz, DMSO-/6): δ 11.40 (d, /=1.84 Hz, 1 H) 7.76 (d, /=7.72 Hz, 1 H) 7.53-7.67 (m, 1 H) 7.45 (s, 1 H) 7.32-7.41 (m, 2 H) 7.23 (dd, /=13.60, 2.57 Hz, 2 H) 5.63 (dd, /=8.09, 2.21 Hz, 1 H) 3.99 (t, /=8.46 Hz, 2 H) 3.29 (s, 3 H) 3.18 (t, /=8.46 Hz, 2 H) 3.04 (s, 3 H). 292 2014280939 24 Dec 2014 [001528] Example 98. Preparation ofjV-(6-(3-ierr-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2i7)-yl)-2-methoxyphenyl)quinoxalin-2-yl)methanesulfonamide (compound IB-LO-2.26).

[001529] Part A. Preparation of iV-(4-bromo-2-nitrophenyl)-3-oxobutanamide.

[001530] A solution of diketene (0.32ml, 4,15mmol) in toluene (2ml) was added to an 80°C solution of 4-bromo-2-nitroaniline (900mg, 4.15mmol) in toluene (7ml) and the solution was heated at reflux for 5h. Triethylamine (0.58ml, 4.15mmol) in toluene (2ml) was added and refluxing was continued for 30min. The cooled solution was concentrated in vacuo and the crude product purified by column chromatography on silica gel eluting with 2:1 hexane/EtOAc to give the title compound as a yellow solid (920mg, 74%).

[001531] PartB. Preparation of 6-bromoquinoxalin-2(lH)-one.

[001532] To a solution of sodium hydroxide (337mg, 8.4mmol) in H2O (2.1ml) was added the product from Part A (423mg, 1.4mmol) and stirring was continued at 65°C for lh. The cooled solution was diluted with H2O (4ml) and sodium borohydride (31.9mg, 0.84mmol) was added and stirring was continued at room temperature for l,5h. Ice was added to the solution followed by dropwise addition of 6N HC1 until acidic. The resulting solid was collected by filtration, washed with II20, and dried in a vacuum oven to give the title compound (273mg, 86%).

[001533] Part C. Preparation of 6-bromo-2-chloroquinoxaline.

[001534] To a flask containing phosphorus oxychloride (3.4ml, 36.5mmol) was added the product from Part B (255mg, 1.1 mmol) and the solution was heated at 60°C overnight. The solution was cooled to room temperature, poured over ice and the resulting solid collected by filtration to give the title compound (239mg, 87%).

[001535] Part D. Preparation of 6-bromo-A-(4-methoxybenzyl)quinoxalin-2-amine.

[001536] To a solution of the product from Part C (2.8g, 11.5mmol) in ethanol (58ml) was added (4-methoxyphenyl)methanamine (7.5ml, 57.5mmol) and the solution was stirred at room temperature for lh. Solvent was concentrated in vacuo and the crude product was purified by column chromatography on silica gel eluting with 20% EtOAc/hexane to give the title compound (1.97g, 50%).

[001537] Part E. Preparation of A-(4-methoxybenzyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) quinoxalin-2-amine.

[001538] The product from Part D (500mg, 1,45mmol) was subjected to the conditions described for 293 2014280939 24 Dec 2014

Example 72, Part B to give the title compound (378mg, 66%), [001539] Part F. Preparation of l-(3-fert-butyl-4-methoxy-5-(2-(4-methoxybenzylamino)quinoxalin-6-yI)phenyl)pyrimidine-2,4( 1 //,3//)-dione.

[001540] The product from Part E (133mg, 0.34mmol) was subjected to the conditions described for Example 72, Part C to give the title compound (125mg, 82%).

[001541] PartG. Preparation of7V-(6-(3-fert-butyl~5-(2,4-dioxo-3,4-dihydropyrimidin-l(2//)-yl)-2-methoxyphenyl)quinoxalin-2-yl)methanesulfonamide.

[001542] To a solution of the product from Part F (87mg, 0.16mmol) in CH2C12 (1.6ml) and H20 (0,07ml) was added DDQ (40.4mg, O.lSmmol) and stirred vigorously at room temperature for Ih. The solution was filtered through Celite and the dark solid collected on the Celite was dissolved in 5ml CH3OH. The methanol solution was filtered, solvent removed in vacuo and the crude intermediate was dissolved in pyridine (0.6ml). Methanesulfonyl chloride (1 lul, 0.14mmol) was added and the solution was heated at 60°C overnight. The cooled solution was concentrated in vacuo and the crude product was purified by column chromatography on silica gel eluting with 2% CH3OH/CHCI3 to give the title compound (7.7mg, 12%). ‘H NMR (300 MHz, CDC13) δ 8.42 (s, 1 H) 8.29 (s, 1 H) 8.13 (s, 1 H) 7.88 (d, 1 H) 7.54 (s, 1 H) 7.19-7.43 (m, 4 H) 5.83 (dd, ./=7,91,2.39 Hz, IH) 3.32 (s, 3 H) 3.27 (s, 3 H) 1.46 (s, 9 H).

[001543] Example 99. Preparation ofiV-(5-(3-iert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2i/)-yl)-2-methoxyphenyl)-2,3-dihydro-l//-inden-l-yl)methanesulfonamide (compound IB-LO-2.44). / -s=o

11 O

[001544] Part A. Preparation of 5-bromo-2,3-dihydro-l//-inden-l-ol.

[001545] A suspension of 5-bromo-2,3-dihydro-lH-inden-l-one (2.07g, 9.81mmol) in ethanol (49mL) was treated with the sodium borohydride (186mg, 4.90mmol) all at once. After a few minutes, the solution warmed slightly and all solids dissolved. After stirring at room temperature for Ih, the mixture was concentrated in vacuo to remove ethanol. The gum obtained was partitioned between ethyl acetate and water. The organic layer was extracted with saturated sodium bicarbonate solution (2 x) and saturated sodium chloride solution. Drying (Na2S04) and concentration in vacuo afforded the title compound (3.05g, 98%) as a colorless oil, which crystallized upon pumping under high vacuum 294 2014280939 24 Dec 2014 overnight.

[001546] Part B. Preparation of l-azido-5-bromo-2,3-dihydro-l//-indene.

[001547] A solution of the product from Part A (l.Olg, 4.73nimol) in toluene (8.1mL) was treated with the diphenyl phosphoroyl azide (1,23mL, 1,56g, 5.67mmol) followed by cooling to 0°C. The solution was treated dropwise with DBU (855pL, 863mg, 5.67mmol) followed by stirring at 0°C for 2h, and then warming to room temperature for 48h. The mixture was diluted with ethyl acetate and extracted with water and 1 M citric acid solution, and then with saturated sodium chloride solution. Drying (Na2S04) and concentration in vacuo afforded a brown oil, which was purified by flash chromatography, eluting with 5-50 % ethyl acetate in hexanes. These procedures afforded the title compound (889mg, 79%) as a light yellow oil.

[001548] Part C. Preparation of 5-bromo-2,3-dihydro-1/T-inden-l -amine.

[001549] To a-15°C solution of 1M lithium aluminum hydride in THF (0.84ml, 0.84mmol) in THF (0.88ml) was added dropwise a solution of the product from Part B (200mg, 0.84mmol) and the solution was warmed to room temperature and stirred overnight. The solution was cooled to -10°C and 4:1 THF:H20 (0.5ml) was added dropwise. The solution was stirred at room temperature for 4h, filtered through Celite and the filtrate concentrated in vacuo to give the title compound (151mg, 85%).

[001550] PartD, Preparation of.A/-(5-bromo -2,3-dihydro-l//-inden-l-yl)methanesulfonamide.

[001551] To a solution of the product from Part C (150mg, 0.71 mmol) in pyridine (3.5ml) was added methanesulfonyl chloride (61 ul, 0.78mmol) and the solution was stirred at room temperature overnight. The solution was concentrated in vacuo and the crude product was purified by column chromatography on silica gel eluting with 20% EtOAc/hexane to give the title compound (11 lmg, 54%). 1001552] Part E. Preparation of A-(5-(3-ieri-butyI-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2//)-yl)-2-methoxyphenyl)-2,3-dihydro-l//-inden-l-yl)methanesulfonamide.

[001553] The product from Part D (109mg, 0.38mmol) was subjected to the conditions described for Example 72, Part B and Part C to give the title compound (39mg, 60%). 'H NMR (300 MHz, DMSO-d6) δ 11.39 (d, /= 1.84 Hz, 1 H) 7.77 (d, J= 7.72 Hz, 1 H) 7.58 (d, /=8.82 Hz, 1 H) 7.39-7.48 (m, 3 H) 7.27 (d, /=2.57 Hz, 1 H) 7.19-7.23 (m, 1 H) 5.63 (dd, /=8.09, 2.21 Hz, 1 H) 4.86 (q, /=7.97 Hz, 1 H) 3.27 (s, 3 H) 3.04 (s, 3 H) 2.90-3.01 (m, 1 H) 2.71-2.90 (m, 1 H) 2.52-2.62 (m, 1 H) 1.85-1.98 (m, 1 Η) 1.40 (s, 9 H). 295 2014280939 24 Dec 2014 [001554] Example 100. Preparation of iV-((5-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2f7)-yl)-2-methoxyphenyl)-253-dihydro-l//-inden-l-yl)methyl)methanesulfonamide (compound IB-LO-2.17).

O

II o=s"

[001555] Part A. Preparation of (£)-5-bromo-l -(methoxymethylene)-2,3 -dihydro- li/-indene.

[001556] To a suspension of (methoxymethyl)triphenylphosphonium chloride (39.7g, 116mmol) in THF (210ml) at -20°C was added dropwise 1M potassium t-butoxide (95ml, 95mmol) and the solution stirred at -20°C for 20min. To this solution was added dropwise a solution of 5-bromo-2,3-dihydro-lH-inden-l-one (lO.Og, 47.4mmol) in THF (230ml) and stirring was continued at -20°C for 30min then warmed to room temperature and stirred for 2h. The solution was filtered through Celite and the filtrate was concentrated in vacuo to give crude product which was purified by chromatography on a silica gel cartridge eluting with CH2Cl2/hexane to give the title compound (10.56g. 93%).

[001557] PartB. Preparation of 5-bromo-2,3-dihydro-l//-indene-l -carbaldehyde.

[001558] To a solution of the product from Part A (1,44g, 6.0mmol) in CH2C12 (30ml) at-78°C was added dropwise 1M boron tribromide in CH2C12 (13.8ml, 13.8mmol) and stirring was continued at-78°C for 4h. The solution was poured into an ice-saturated, sodium bicarbonate mixture and stirred vigorously. The layers were separated and the aqueous layer was extracted with CH2C12 (2x), the organic extracts were combined, dried (Na2S04), and concentrated in vacuo to give crude product which was purified by column chromatography on silica gel eluting with 10% EtOAc/hexane to give the title compound (604mg, 45%).

[001559] Part C. Preparation of l-(5-bromo-2,3-dihydro-l/7-inden-l-yl)-iV-(4-methoxybenzyI)-methanamine.

[001560] To a solution of the product from Part B (300mg, 1.3mmol) in CH3OH (18.5ml) was added 4-methoxybenzylamine (0.17ml, 1.3mmol) and decaborane (49mg, 0.4mmol) and stirring was continued at room temperature for 1 h, solvent was concentrated in vacuo and the crude product was purified by column chromatography on silica gel eluting with 3% CH3OH/CHCl3 to give the title compound (264mg, 57%).

[001561] PartD. Preparation of A-((5-bromo-2,3-dihydro-1 //-in den-l-yl)methyl)-A;-(4-methoxy-benzyl)methanesulfonamid e. 296 2014280939 24 Dec 2014 [001562] To a solution of the product from Part C (88mg, 0.25mmol) in CH2CI2 (1.0ml) was added triethylamine (39ul, 0.28mmol) and methanesulfonyl chloride (22ul, 0.28mmol) and stirring was continued at room temperature for lh, solvent was concentrated in vacuo and the crude product was purified by column chromatography on silica gel eluting with EtOAc/hexane to give the title compound (55mg, 51%).

[001563] Part E. Preparation of N-(4-methoxybenzyl)-N-((5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2,3 -dihydro-1 H-inden-1 -yl)methy I )methanesulfonamide.

[001564] The product from Part D (1.15g, 2.71mmol) was subjected to the conditions described for Example 72, Part B to give the title compound (840mg, 66%).

[001565] PartF. Preparation of7V-((5-(3-/ert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2F/)-yl)-2-methoxyphenyl)-2,3 -dihydro- IH- inden-1 -yl)methyl)methanesulfonamide.

[001566] The product from Part E (840mg, 2.1mmol) was subjected to the conditions described for Example 72, Part C and the isolated material (1.28g, 2.07mmol) was dissolved in CH2CI2 (10ml) and trifluoroacetic acid (10ml) was added slowly. After stirring at room temperature for lh, solvent was concentrated in vacuo and the crude product was suspended in 10% NaUCOi, extracted with CH2C12 (3x), the organic extracts combined, dried (Na2S04), and solvent concentrated in vacuo to give crude product which was purified by column chromatography on silica gel eluting with 2% CH3OH/CHCI3 to give title compound (0.84g, 81%). 'H NMR (300 MHz, DMSO-^) 5 11.39 (s, 1 H) 7.77 (d, ./=8.09 Hz, 1 H) 7.29-7.59 (m, 3 H) 7.25 (d, 7=2.94 Hz, 1 H) 7.10-7.22 (m, 2 H) 5.63 (dd, 7=7.72, 1.84 Hz, 1 H) 3.93 (s, 3 H) 3.26 (s, 2 H) 3.23-3.40 (m, 1 H) 2.89 (s, 3 H) 2.71-3.09 (m, 2 H) 2.14-2.32 (m, 1 H) 1.75-1.95 (m, 1 H) 1.40 (s, 9H).

[001567] Example 101. Preparation of 5-(3-tórt-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2rif)-yl)-2-methoxyphenyl)-jV-(rnethylsul fonyl)-2,3-dihydro-1 //-indene-l-carboxamide (compound IB-L0-2.34). O I!

[001568] Part A. Preparation of 5-bromo-2,3-dihydro-l//-indene-l-carboxylic acid.

[001569] To a solution of the product from Example 100, Part B (300mg, 1.3 mmol) and 2-methyl-2-pentene (8ml) in tert-butanol (32ml) was added a solution of sodium chlorite (l ,36g, 0.12mmol) in H20 297 2014280939 24 Dec 2014 (12ml) containing sodium dihydrogen phosphate (1.07g, 8.9mmol) and the mixture was stirred vigorously for 20min at room temperature. Solvents were concentrated in vacuo and the residue was diluted with H20, extracted with EtOAc (3x), extracts combined, dried (Na2S04), and concentrated in vacuo to give the title compound (180mg, 56%).

[001570] PartB. Preparation of 5-bromo-;V-(methylsulfonyl)-2,3-dihydro-l//-indene-l-carboxamide.

[001571] To a solution of the product from Part A (lOOmg, 0.42mmol) in CH2CI2 (1.7ml) was added carbonyldiimidazole (67.3mg, 0.42mmol) and the reaction was stirred for 2h at room temperature. Methanesulfonamide (39.5mg, 0.42mmol) and DBU (62.5mg, 0.42mmol) were added and stirring was continued at room temperature for 2h. Solution was diluted with CH2CI2, washed IN HC1, brine, dried (Na2S04), concentrated in vacuo and the crude product was purified by column chromatography on silica gel eluting with 20% EtOAc/hexane to give the title compound (121 mg, 92%).

[001572] Part C. Preparation of JV-(methylsulfony 1)-5-(4,4,5,5-tetramethy I-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1 ff-indene-1 -carboxamide.

[001573] The product from Part B (159mg, O.Smmol) was subjected to the conditions described for Example 72, Part B to give the title compound (144mg, 79%).

[001574] PartD. Preparation of 5-(3-re/V-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2//)-y 1)-2-m ethoxvp h cny I )-lV-(me thy 1 sulfonyl)-2,3 -dihydro-1H- indene-1 -carboxamide.

[001575] The product from Part C (134mg, 0.34mmol) was subjected to the conditions described for Example 72, Part C to give title compound (14mg, 8%). 'H NMR (300 MHz, CDC13) 5 8,11 (m, 1 H) 7.08-7.57 (m, 7 H) 5.80 (dd, 7=7.91,2.39 Hz, 1 H) 4.07 (dd, 7=9.01, 6.07 Hz, 1 H) 3.33 (s, 3 H) 3.08 (s, 3 H) 2.91-3.22 (m, 1 H) 2.35-2.74 (m, 1 H) 1.44 (s, 9H) 1.17-1.34 (m, 1 H) 0.60-1.00 (m, 1 H).

[001576] Example 102. Preparation of l-(3-(2-aminobenzo[7|thiazol-6-yl)-5-tert-butyl-4-methoxy-phenyl)pyrimidine-2,4(177,37T)-dione (compound IB-LO-2.39).

H

[001577] The title compound was prepared using the procedures described for the preparation of Example 83, substituting 5-bromo[7jthiazol-2-amine for 6-bromobenzo[7]thiazol-2-amine. 'H NMR (300 MHz, DMSO-d6) δ 11.40 (d, J=1.84 Hz, 1 H) 8.40 (s, 2 H) 7.84 (d, J=8.09 Hz, 1 H) 7.78 (d, J=7.72 Hz, 1 H) 7.54 (d, J=1.47 Hz, 1 H) 7.27 - 7.32 (m, 3 H) 5.64 (dd, J=8.09, 2.21 Hz, 1 H) 3.27 (s, 3 H) 1.41 (s, 9 H). 298 2014280939 24 Dec 2014 [001578] Example 103. Preparation ofjV-(2-(5-(3-/eri-butyl-5-(2,4-dioxo-3,4-dihydropyrirnidin-l(2//)-yl)-2-methoxyphenyl)-2,3-dihydro-l//-inden-l-yI)propan-2-yl)methanesulfonamide (compound IB-L0-2.29).

[001579] To a solution of the product from Example 75, Part D (20mg, 0.038mmol) in 1:1 benzene: MeOH (0.6ml) was added platinum(IV) oxide (lmg). The resulting mixture was stirred under 1 atm H2 at room temperature for lh, and then filtered thru celite, and concentrated in vacuo. The crude product was purified by column chromatography on silica gel using 3% MeOH in CHCI3 as the eluent to give the title compound as a solid (14mg, 70%). 'H NMR (300 MHz, DMSO-d*) δ 11.39 (s, 1 H) 7.77 (d, ./=7.72 Hz, 1 H) 7.58 (d, J= 8.09 Hz, 1 H) 7.28 - 7.38 (m, 2 H) 7.21 - 7.26 (m, 2 H) 7.07 (s, 1 H) 5.63 (d, ./=7.72 Hz, 1 H) 3.61 (dd, ./=8.64, 5.33 Hz, 1 H) 3.25 (s, 3 H) 3.00 (s, 3 H) 2.75 - 2.98 (m, 2 H) 1.97 - 2.21 (m, 2 H) 1.40 (s, 9 H) 1.24 (d, ./=8.46 Hz, 6 H).

[001580] Example 104. Preparation of (5)-iV-(2-(5-(3-fert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2/7)-yl)-2-mcthoxypheny 1)-2,3-dihydro-1//-inden-l -yl)propan-2-yi)methancsulfonamide (compound IB-LO-2.22). Q, X)

(001581] The product from Example 103 (lOmg) was subjected to chiral chromatography (Chiralpak AD-H column; eluting with 1:3 2-PrOH:hexanes(0.1% TFA)). Isolation of the earlier eluting component gave the title compound (4.4mg). 'll NMR identical to the product from Example 103. 299 2014280939 24 Dec 2014 [001582] Example 105. Preparation of (7?)-Ar-(2-(5-(3-/er/-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2//)-yl)-2-methoxyphenyl)-2,3-dihydro-l//-inden-l-yl)propan~2-yl)methanesulfonamide (compound IB-L0-2.37).

[001583] The product from Example 103 (lOmg) was subjected to chiral chromatography (Chiralpak AD-H column; eluting with 1:3 2-PrOH:hexanes(0.1% TFA)). Isolation of the later eluting component gave the title compound (4.2mg). 'H NMR identical to the product from Example 103.

[001584] Example 106. Preparation of (£)-iV-((5-(3-ieri-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin- 1 (2H)-y\)-2-methoxypheny 1)-2,3-dihydro- lif-inden- l-yl)methyl)methanesulfonamide (compound IB-L0-2.9).

[001585] The product from Example 100, Part F (20mg) was subjected to chiral chromatography (Chiralpak AD-H column; eluting with 1:4 2-PrOH:hexanes(0.1% TFA)). Isolation of the earlier eluting component gave the title compound (5.3mg). 'H NMR identical to the product from Example A-100, PartF. 300 2014280939 24 Dec 2014 [001586] Example 107, Preparation of (/?)-iV-((5-(3-/grt-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2#)-yl)-2-methoxyphenyl)-2,3-dihydro-li7-inden-l-yl)methyl)methanesulfonamide (compound IB-L0-2.15).

[001587] The product from Example 100, Part F (20mg) was subjected to chiral chromatography (Chiralpak AD-H column; eluting with 1:4 2-PrOH:hexanes(0.1% TFA)). Isolation of the later eluting component gave the title compound (5.7mg). 'H NMR identical to product from Example 100, Part F.

[001588] Example 108. Preparation of(tST)-Ar-((5-(3-/e>7-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2//)-yl)-2-methoxypheny 1)-l-fluoro-2,3-dihydro-l//-inden-l-yl)methy|)mcthanesulfonamide (compound IB-L0-2.20).

[001589] The product from Example 91, Part H was subjected to the conditions described in Example 104 to give the title compound. 'H NMR identical to the product from Example 91, Part H.

[0015901 Example 109. Preparation of (/?)-A7-((5-(3-iert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2//)-yl)-2-methoxvphenyl)-1 -fluoro-2,3 -dihydro- l/f-inden-1 -yl)methyl)methanesu lfonamide (compound IB-L0-2.10).

301 2014280939 24 Dec 2014 [001591] The product from Example 91, Part H was subjected to the conditions described in Example 104 to give the title compound. H NMR identical to the product from Example 91, Part H.

[001592] Example 110. Preparation ofiV-(6-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2//)-yl)-2-methoxy-3-tert-pentylphenyl)naphthalen-2-yl)methanesulfonamide (compound IB-LO-2.52).

O

H

[001593] Part A. Preparation of l-(3-reri-butyl-5-iodo-4-methoxyphenyl)pyrimidine-2,4(l//3ii)-dione.

[001594] 2-teri-Amylphenol (5.0g, 30mmol) was reacted according to the procedure from Example C, Part A, Part B, and Part C to provide the title product as a colorless solid.(6.7g, 56% overall yield for 3 steps).

[001595] Part B. Preparation of//-(6-(5-(2,4-dioxo-3,4-dihydropyrimidin-1(2/f)-yl)-2-methoxy-3-tert-pentylphenyl)naphthalen-2-yl)methanesulfonamide.

[001596] The product from Part A (lOOmg, 0.241 mmol), the product from Example 4A, Part B (92mg, 0.266mmol), sodium carbonate (38.4mg, 0.362mmol) and l,r-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (9.9mg, 0.012mmol) were dissolved in a toluene (4mL) and ethanol (4mL) solvent mixture which was sparged with nitrogen for lOmin, then the mixture heated to 85°C for 18h. To the solution was then added Cl/Cf (20mL) followed by IN aqueous HC1 (lOmL), the organic layer separated 3-mercaptopropyl silica gel (lOOmg) and magnesium sulfate added. The solution was concentrated and purified by column chromatography on silica gel using 3% MeOH in CHjCh as the eluent to provide the title compound as a colorless solid (71mg, 58%). ‘H NMR (300

302 2014280939 24 Dec 2014 [001597] Example 111. Preparation of iV-((6-(3-ieri-butyI-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2//)-yl)-2-methoxyphenyl)-li7-inden-3-yl)methyl)-/V-methylmethanesulfonamide (compound IB-LO-2.16). // O*?

[001598] Part A. Preparation of JV-methyl-A-((6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l//-inden-3-yl)methyl)methanesulfonamide.

[001599] To a solution of the product from Example 79, Part E (210mg, 0.60mmol) in anhydrous THF (5ml) was added a 1.0M solution of lithium bis(trimethylsilyl)amide in toluene (0.60ml, 0.60mmol), and the resulting mixture was stirred at room temperature for 5min. Iodomethane (0.075ml, 1.20mmol) was added and the mixture was stirred at room temperature for 2h, and was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried with sodium sulfate, filtered and concentrated in vacuo. The residue was purified by column chromatography on silica gel eluting with a gradient of ethyl acetate/ in hexane (10% to 25%) to give the title compound as a solid (125mg, 57%).

[001600] Part B. Preparation of N-((6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl)-lH-inden-3-yl)methyl)-N-methylmethanesulfonamide.

[001601] A mixture of the product from Example C (60.0mg, 0.15mmol), the product of Part A (54.5mg, O.lSmmol), potassium phosphate (66.9mg, 0.315mmol), PA-Ph (CAS 97739-46-3, 1.32mg, 4.5μιηο1) and tris(dibenzylideneacetone)dipalladium(0) (1.37mg, l.Spmol) in tetrahydrofuran (3.0ml) and water (1.0ml) was purged with N2 for 30min. The mixture was stirred at 50°C for 2h, and then partitioned between ethyl acetate and 1M HC1. The organic layer was washed with saturated sodium bicarbonate, brine, dried with sodium sulfate, and filtered. The filtrate was treated with 3-mercaptopropyl functionalized silica gel, filtered through celite and concentrated in vacuo. The crude product was purified by column chromatography on C-18 reversed-phase silica gel using a solvent gradient of 10-100% acetonitrile in water(0.1% TFA) to give the title compound as a solid (19mg, 24%). 'H NMR (300 MHz, DMSO-dfj) δ 11.40 (d, J=1.84 Hz, 1 H) 7.78 (d, J=7.72 Hz, 1 H) 7.65 (m, 2 H) 7.49 (dd, J=7.72, 1.47 Hz, 1 H) 7.26 (m, 2.57 Hz, 2 H) 6.63 (s, 1 H) 5.64 (dd, J=7.72, 2.21 Hz, 1 H) 4.26 (s, 2 H) 3.51 (s, 2 H) 3.26 (s, 3 H) 3.01 (s, 3 H) 2.72 (s, 3 Η) 1.41 (s, 9 H). 303 2014280939 24 Dec 2014 [001602] Example 112. Preparation of AH(6-(3-feri-butyl-5-(2,4-dioxo-3,4-dihydropyrimidm-l(2iï)-yl)-2-methoxyphenyl)benzo[£]thiophen-2-yl)methyl)methanesulfonamide (compound IB-LO-2,40).

[001603] Part A. Preparation of ethyl 6-bromobenzo[è]thiophene-2-carboxylate.

[001604] To a solution of 4-bromo-2-fluorobenzaldehyde (1.02g, 4.83mmoI) in DMSO (4mL), was added ethyl 2-mercaptoacetate (0.58mL, 5.3 lmmol), followed by Et3N (1.35mL, 9.65mmol), and the mixture was heated at 80°C for 3h. The resulting dark mixture was poured into water (50mL) and extracted with EtOAc (2 x 50mL). The combined organic extracts were washed with 10% NaCl, dried over anhydrous Na2S04) fdtered and concentrated in vacuo to give the title compound as a light yellow waxy solid (1.29g, 94%).

[001605] PartB. Preparation of (6-bromobenzo[£>]thiophen-2-yl)methanol.

[001606] To a solution of the product from Part A (0,82g, 2.88mmol) in Et20 (20mL) at 0°C was added a 1M solution of lithium aluminum hydride in Et20 (3.16mL, 3.16mmol) dropwise, and the resulting slurry w'as stirred between 5-10°C for lh. The slurry was treated with 0.3mL H20, 0.3mL 15 % aq NaOH, 0.7mL H20, stirred 30min, filtered and concentrated in vacuo to give the title compound as a colorless solid (0.58g, 83%).

[001607] Part C. Preparation of 6-bromo-2-(bromomethyl)benzo[è]thiophene.

[001608] A mixture of the product from Part B (85mg, O.35mmol), A-bromosuccinimide (74mg, 0.413mmol) and triphenylphosphine (106mg, 0.403mmol) in CH2Cl2(2mL) was stirred at room temperature for 2h. The reaction mixture was diluted with 50mL CH2C12, washed with water, 10% NaHC03 and 10% NaCl, dried over anhydrousmgS04, filtered and concentrated in vacuo. The residue was purified by column chromatography on silica gel eluting with 9:1 hexane:EtOAc to yield the title compound as a white solid (96mg, 89%).

[001609] Part D. Preparation of A-(4-methoxybenzyl)methanesulfonamide.

[001610] To a solution of (4-methoxyphenyl)methanamine (1.317g, 9.60mmol) in CH2C12 (lOmL) was added methanesulfonyl chloride (0.34mL, 4.36mmol) dropwise. The mixture was stirred at room temperature for 2h. The reaction mixture was diluted with 50mL CH2C12 washed with IN H3P04, 10% NaCl, dried over anhydrousmgS04, filtered and concentrated in vacuo to give the title compound as a white solid (0.84g, 89%).

[001611] PartE. Preparation of A-((6-bromobenzo[6]thiophen-2-yl)methyl)-A-(4-methoxybenzyi)- 304 2014280939 24 Dec 2014 methanesulfonam ide.

[001612] A solution of the product from Part D (0.223g, 1.037mmol) in EtOH (2mL) and 1.0M NaOH (l.lmL, 1.1 mmol) was added to a slurry containing the product from Part C (0.317g, 1.037mmol) in EtOH (4mL). The resulting slurry was heated at reflux for lh. and then concentrated in vacuo to give a pasty solid. The residue was partitioned between 40mL water and 40mL EtOAc. The organic layer was washed with IN H3PO4, 10% NaHC03, 10% NaCl, dried over anhydrous Na2S04, filtered and concentrated in vacuo leaving a yellow oil. The crude product was purified by column chromatography on silica gel eluting with CH2C12 to give the title compound as a colorless solid (0.15g, 33%).

[001613] Part F. Preparation of Ar-(4-methoxybenzyl)-AL((6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzo[è]thiophen-2-yl)methyl)methanesulfonamide.

[001614] The product from Part E (0.15g, 0.34mmol) was subjected to the conditions described for the preparation of Example 72, Part B to give the title compound as a colorless solid (0.121g, 73%).

[001615] PartG. Preparation ofJV-((6-(3-/ert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(277)-y!)-2-methoxyphenyl)benzo[è]thiophen-2-yl)methyl)-jV-(4-methoxybenzyl)methanesulfonamide.

[001616] The product from Part F (24mg, 0.049mmol) was subjected to the conditions described for the preparation of Example 72, Part € to give the title compound as a colorless solid (20mg, 65%).

[001617] PartH. Preparation of .V-((6-(3-fer/-butyl-5-(2,4-dioxo-3,4-dihydropynmidin-l(2i7)-yl)-2-methoxyphenyl)benzo[h]thiophen-2-yl)methyl)methanesulfonamide.

[001618] A solution of the product from Part G (14ing, 0.022mmol) in CH2CI2 (0.3mL) and TFA (0.3mL) was stirred at room temperature for 4h and then concentrated in vacuo. The residue was partitioned between lOmL CH2CI2 and 2mL 10% aq. NaHCCh and the organic layer was concentrated in vacuo. The crude product was purified by column chromatography on silica gel eluting with 99:1 CH2Cl2:MeOH to give the title compound as a colorless solid (5mg, 44%). 'H NMR (300 MHz, DMSO-d6) δ 11.40 (s, I H) 8.09 (s, 1 H) 7.82 - 7.97 (m, 3 H) 7,79 (d, J=7.72 Hz, 1 H) 7.47 - 7.63 (m, 1 H) 7.40 (s, 1 H) 7.26 - 7.34 (m, 1 H) 5.64 (d, J= 7.72 Hz, 1 H) 4.48 (d, J=5.88 Hz, 2 H) 3.23 (s, 3 H) 2.95 (s, 3 H) 1.41 (s, 9 H). 305 2014280939 24 Dec 2014 [001619] Example 113. Preparation ofiV-((6-(3-ieri-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2/f)-yl)-2-methoxyphcnyl)benzo[è]thiophen-3-yl)methyl)-iV-methylmethanesulfonamide (compound IB-L0-2.21).

[001620] Part A. Preparation of AT-((6-bromobenzo|7>]thiophen-3-yl)methyl)-A,-methylmethanesulfon-amide.

[001621] A mixture of the product from Example 76, Part D (0.100g, 0.382mmol), /V-methylmethane-sulfonamide (45.9mg, 0.421mmol) and potassium carbonate (0.127g, 0.918mmol) in TV.A-dimethylacet-amide (5mL). The mixture was stirred at 80°C for 11 h, cooled to room temperature and partitioned between diethylether and water (3x), dried overmgSO^, filtered and concentrated in vacuo to give the title compound as a colorless waxy solid (0.128g, quant.).

[001622] PartB. Preparation of /V-methyl-/V-((6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzo [è]thiophen-3-yl)methyl)methanesulfonamide.

[001623] The product from Part A (0.128g, 0.382mmol) was subjected to the conditions described for the preparation of Example 72, Part B to give the title compound as a colorless, crystalline solid (0.120g, 82%).

[001624] PartC. Preparation of,V-((6-(3-fer/-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2//)-yl)-2-methoxyphenyl)benzo[è]thiophen-3-yl)methyl)-jV-methylmethanesulfonamïde.

[001625] The product from Part B (50.6mg, 0.133mmol) was subjected to the conditions described for the preparation of Example 79, Part F to give the title compound as a colorless solid (61,5mg, 88%). 'H NMR (300 MHz, DMSO-d6) δ 11.41 (s, 1 H) 8.17 (d, ./=1.47 Hz, 1 H) 8.09 (d, /=8.09 Hz, 1 H) 7.74 -7.85 (m, 2 H) 7.63 (dd, /=8.46, 1.47 Hz, 1 H) 7.29 - 7.36 (m, 2 H) 5.65 (d, /=7.72 Hz, 1 H) 4.52 (s, 2 H) 3.24 (s, 3 H) 3.03 (s, 3 H) 2.70 (s, 3 H) 1.42 (s, 9 H). 306 2014280939 24 Dec 2014 [001626] Example 114. Preparation of (E)-N-(4-(3-bromo-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxystyryl)phenyl)rnethanesulfonamide (compound IB-L1-1.52).

[001627] Part A. Preparation of 2-bromo-4,6-diiodophenol.

[001628] A 1L round-bottom flask was charged with 2-bromophenol (8.65g, 50mmol) and methanol (100ml) to give a colorless solution. Sodium hydroxide (2.40g, 60.0mmol) was added and stirred until the hydroxide pellets had dissolved. The solution was cooled in an ice water bath and sodium iodide (5.6g, 37.4mmol) was added followed by drop-wise addition of sodium hypochlorite (17mL, 27.5mmol) to give a transparent brown/red solution and gradual precipitation of a thick, white solid. The addition of sodium iodide and bleach was repeated 3 times to give an orange mixture that was stirred for 2h, treated with a solution of sodium thiosulfate in water (20g in lOOmL), stirred for 15min and treated drop-wise with concentrated HC1 to a constant pH of 1. The mixture was stirred for 15min and filtered to collect a white solid that was washed repeatedly with water and dried to constant mass (14.7g, 69%).

[001629] Part B. Preparation of l-bromo-3,5-diiodo-2-methoxybenzene.

[001630] A 500mL round-bottom flask was charged with the product from Part A (14.7g, 34.6mmol), iodomethane (2.70ml, 43.3mmol), and sodium hydroxide (2.101ml, 39.8mmol) in acetone (96ml) to give a tan solution. The mixture was stirred for 24h and concentrated. The residue was dissolved in ethyl acetate, washed with water and saturated sodium chloride, dried over sodium sulfate, filtered and concentrated to give a white solid. The solid was recrystallized from hot hexane to give a white solid that was collected by filtration (12.3 g, 81%).

[001631] Part C. Preparation of l-(3-bromo-5-iodo-4-methoxypheny!)pyrimidine-2,4(lH,3H)-dione.

[001632] A 250mL round-bottom flask was charged with the product from Part B (8.09g, 18.44mmol), pyrimidine-2,4(lH,3H)-dione (2,273g, 20.28mmol), N-(2-cyanophenyl)picolinamide (0.823g, 3.69mmol), copper (I) iodide (0.35lg, 1.844mmol) and potassium phosphate (8.22g, 38.7mmol) in DMSO (70ml). The mixture was sealed, sparged with nitrogen for 15min and heated at 60°C for 16h. The mixture was partitioned with ethyl acetate and water. The organic layer was washed with 1M HC1, water, brine, dried with sodium sulfate, and filtered. The filtrate was treated with 3-mercaptopropyl functionalized silica gel (Aldrich catalog #538086), filtered through celite and evaporated to give an off-white solid (3.92g, 50%). 307 2014280939 24 Dec 2014 [001633] Part D. Preparation of (E)-N-(4-(3-bromo-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide.

[001634] To a 100ml round-bottom flask was added the product from Part C (846mg, 2.0mmol), the product from Example 41B, Part B (482mg, 2.000mmol), potassium phosphate (892mg, 4.20mmol), l,3,5,7-tetramethyl-6-phenyl-2,4,8-trioxa-6-phosphaadamante (PA-Ph) (CAS 97739-46-3) (17.54mg, 0.060mmol) and tris(dibenzylideneacetone)dipalladium(0) (18.31mg, 0.020mmol) in THF (12.0ml) and water (4.0ml). The flask was sealed and the mixture was sparged with nitrogen for 5min and stirred at ambient temperature for 72h. The mixture was partitioned with ethyl acetate and 1M HCl. The organic layer was washed with saturated sodium bicarbonate, brine, dried with sodium sulfate and filtered. The filtrate was treated with 3-mercaptopropyl functionalized silica gel, filtered and evaporated. The residue was triturated with a minimal amount of methanol/ CH2C12 to give the title compound as a white solid (595mg, 60%). lHNMR (300 MHz, DMSO-d6) δ ppm 3.03 (s, 3 H) 3.82 (s, 3 H) 5.69 (dd, J=7.72,1.50 Hz, 1 H) 7.24 (d, J=8.46 Hz, 2 H) 7.35 (m, 2 H) 7.61 (d, J=8.46 Hz, 2 H) 7.69 (d, J=2.21 Hz, 1 H) 7.78 (d, 1=8.09 Hz, 1 H) 7.87 (d, 1=2.21 Hz, 1 H) 9.90 (s, 1 H) 11.50 (s, 1 H). MS (ESI-) m/z 490,492 (M-H)+.

[001635] Example 115. Preparation of (E)-N-(4-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy-3-(thiophen-2-yl)styryl)phenyl)methanesulfonamide (compound IB-L1-1.48).

O

[001636] To a 5ml microwave tube was added the product from Example 114, Part D (40mg, 0.081mmol), thiophen-2-ylboronic acid (10.40mg, 0.081mmol), l,l'-bis(di-tert-butylphosphino)ferrocene palladium dichloride (2.65mg, 4.06pmol) and potassium phosphate (34.5mg, 0.162mmol) in THF (3.0ml) and water (1.0ml). The vessel was sealed and the mixture was sparged by nitrogen for 5min and heated at 50°C for 3h. The mixture was partitioned with ethyl acetate and 1M HCl. The organic layer was washed with saturated sodium bicarbonate, brine, dried with sodium sulfate and filtered. The filtrate was treated with 3-mercaptopropyl functionalized silica gel, filtered through celite and evaporated. The residue was purified by reverse phase chromatography to give the title compound as a white solid (20mg, 50%). 'H NMR (300 MPIz, DMSO-d6) δ ppm 3.03 (s, 3 H) 3.70 (s, 3 H) 5.70 (dd, J=7.72, 2.21 Hz, 1 H) 7.18 (dd, 1=5.43, 4.05 Hz, 1 H) 7.25 (d, J=8.82 Hz, 2 H) 7.35 (s, 2 H) 7.63 (d, 1=8.82 Hz, 2 H) 7.68 (m, 2 H) 7.77 308 2014280939 24 Dec 2014 (m, 2 H) 7.83 (d, J=7.72 Hz, 1 H) 9.89 (s, 1 Η) 11.49 (d, J=2.21 Hz, 1 H). MS (ESI+) m/z 496 (M+H)+.

[001637] Example 116. Preparation of (E)-N-(4-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-3-(furan-2-yl)-2-methoxystyryl)phenyl)methanesulfonamide (compound IB-L1-1.46),

O

[001638] The title compound was prepared according to the procedure of Example 115 substituting furan-2-ylboronic acid for thïophen-2-yIboronic acid to give a white solid (22mg, 56%). lH NMR (300 MHz, DMSO-ds) δ ppm 3.03 (s, 3 H) 3.76 (s, 3 H) 5.69 (d, J=7.72 Hz, 1 H) 6.69 (dd, 3=3.31, 1.84 Hz, 1 H) 7.08 (d, J=2.57 Hz, 1 H) 7.25 (d, J=8.46 Hz, 2 H) 7.36 (m, 2 H) 7.63 (d, J=8.82 Hz, 2 H) 7.67 (d, 3=2.57 Hz, 1 H) 7.77 (d, 3=2.57 Hz, 1 H) 7.82 (m, 3=7.72 Hz, 2 H) 9.88 (s, 1 H) 11.48 (s, 1 H). MS (ESI+) m/z 497 (M+NH4)+.

[001639] Example 117. Preparation of (E)-N-(4-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy-3-(pyridin-4-yl)styryl)phenyl)methanesulfonamide (compound IB-L1-1.55).

[001640] The title compound was prepared according to the procedure of Example 115 substituting 4-(4,4,5,5-tetramethyl-l,3,2-dioxaboro]an-2-yl)pyridine for thiophen-2-ylboronic acid to give a white solid (15mg, 38%). ’H NMR (300 MHz, DMSO-d*) δ ppm 3.03 (s, 3 H) 3.49 (s, 3 H) 5.72 (dd, 3=7.72, 2.21 Hz, 1 H) 7.25 (d, 3=8.46 Hz, 2 H) 7.38 (d, 3=4.41 Hz, 2 H) 7.51 (d, 3=2.57 Hz, 1 H) 7.63 (d, 3=8.82 Hz, 2 H) 7.80 (d, 3=5.88 Hz, 2 H) 7.85 (d, 3=7.72 Hz, 1 H) 7.97 (d, 3=2.57 Hz, 1 H) 8.77 (d, 3=6.25 Hz, 2 H) 9.90 (s, 1 H) 11.51 (d, 3=2.21 Hz, 1 H). MS (ESI+) m/z 491 (M+H)+. 309 2014280939 24 Dec 2014 [001641] Example 118. Preparation of (E)-N-(4-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H>-yI)-2-methoxy-3-(pyridin-3- yl)styryl)phenyl)methanesulfonamide (compound IB-L1-1.53).

[001642] The title compound was prepared according to the procedure of Example 115 substituting 3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine for thiophen-2-ylboronic acid to give a white solid (19mg, 48%). ‘H NMR (300 MHz, DMSO-d6) δ ppm 3.02 (s, 3 H) 3.45 (s, 3 H) 5.71 (dd, J=8.09, 2.21 Hz, 1 H) 7.24 (d, J=8.46 Hz, 2 H) 7.37 (d, J=2.94 Hz, 2 H) 7.47 (d, >2.57 Hz, 1 H) 7.63 (m, 3 H) 7.85 (d, )=1.12 Hz, 1 H) 7.93 (d, >2.57 Hz, 1 H) 8.15 (m, 1 H) 8.68 (dd, >4.80 Hz, 1.47 Hz, 1 H) 8.86 (d, >1.84 Hz, 1 H) 9.89 (s, 1 Η) 11.50 (d, J=2.21 Hz, 1 H). MS (ESI+) m/z 491 (M+H)+.

[001643] Example 119. Preparation of (E)-N-(4-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy-3-(thiophen-3-yl)styryl)phenyl)methanesulfonamide (compound IB-L1-1.47).

O

[001644] The title compound wras prepared according to the procedure of Example 115 substituting thiophen-3-ylboronic acid for thiophen-2-ylboronic acid to give a white solid (19mg, 38%). II NMR (300 MHz, DMSO-ds) δ ppm 3.02 (s, 3 H) 3.55 (s, 3 H) 5.69 (d, J=8.09 Hz, 1 H) 7.24 (d, 1=8.46 Hz, 2 H) 7.36 (s, 2 H) 7.55 (m, 2 H) 7.61 (d, J=8.46 Hz, 2 H) 7.67 (dd, 1=5.15, 2.94 Hz, 1 H) 7.78 (d, >2.57 Hz, 1 H) 7.83 (d, J=7.72 Hz, 1 H) 7.93 (dd, >2.57, 0.96 Hz, 1 H) 9.88 (s, 1 Η) 11.48 (s, 1 H). MS (ESI-) m/z 494 (M-H)+. . 310 2014280939 24 Dec 2014 [001645] Example 120. Preparation of (E)-N-(4-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-y 1)-3-(furan-3-yl)-2-methoxystyryl)phenyl)methanesulfonamide (compound IB-L1-1.50).

O

[001646] The title compound was prepared according to the procedure of Example 115 substituting furan-3-ylboronic acid acid for thiophen-2-ylboronic acid to give a white solid (14mg, 29%). !H NMR (300 MHz, DMSO-d6) δ ppm 3.02 (s, 3 H) 3.69 (s, 3 H) 5.69 (d, J=8.09 Hz, 1 H) 7.05 (dd, J=2.57,0.90 Hz, 1 H) 7.24 (d, J-8.82 Hz, 2 H) 7.34 (s, 2 H) 7.61 (m, 3 H) 7.74 (d, J=2.57 Hz, 1 H) 7.80 (m, 2 H) 8.25 (s, 1 H) 9.88 (s, 1 Η) 11.49 (s, 1 H). MS (ESI-) m/z 478 (M-H)+.

[0016471 Example 121. Preparation of (E>N-(4-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-3-(1-hydroxy-2-methylpropan-2-yl)-2-methoxystyryl)phenyl)methanesulfonamide (compound IB-L1-1.45).

O

[001648] Part A. Preparation of 2-(2-hydroxy-3,5-diiodophenyl)acetic acid.

[001649] To a 250mL round-bottom flask was added 2-(2-hydroxyphenyl)acetic acid (Aldrich, 3.04g, 20mmol) in acetonitrile (50ml) to give a colorless solution. N-iodosuccimide (9.00g, 40.0mmol) was added portionwise over 15min to give a red/brown transparent solution that was stirred for 16h. The mixture was concentrated and the resulting solid was triturated in 75mL of water and filtered to collect an orange solid that was dried under vacuum. The crude solid was recrystallized from toluene to give a light orange powder (6.0g, 74%).

[001650] PartB. Preparation of methyl 2 -(3,5-diiodo-2-methoxyphenyl)acetate.

[001651] To a 250mL round-bottom flask was added the product from Part A (6g, 14.85mmol), potassium carbonate (6.16g, 44.6mmol), and dimethyl sulfate (4.12g, 32.7mmol) in acetone (49.5ml) to give a brown suspension. The suspension was heated at reflux for 16h, cooled, concentrated and the 311 2014280939 24 Dec 2014 residue was partitioned between EtOAc and water. The EtOAc layer was washed with brine, dried (Na2S04) and concentrated to a brown oil that was chromatographed on a 40g silica cartridge eluting with 3:1 hexane/EtOAc to give a yellow oil (6.0g, 94%).

[001652] Part C. Preparation of methyl 2-(3,5-diiodo-2-methoxyphenyl)-2-methylpropanoate.

[001653] To a lOOmL round-bottom flask under nitrogen was added the product from Part B (1.728g, 4mmol) in anhydrous THF (20ml) and HMPA (2ml) to give a colorless solution, Methyl iodide (1.251ml, 20.00mmol) was added and the solution was cooled to -40°C. Potassium t-butoxidc(12.00ml, 12.00mmol) was added drop-wise and the mixture was stirred at -40 to -20°C for 30min and quenched with 1M HC1 to a pH of 1. The mixture was extracted 3 X 40ml with EtOAc. The extracts were combined, washed with brine, dried (NajSOfj and concentrated. The crude product was flash chromatographed on a 40g ISCO silica cartridge eluting with 9:1 hexane/EtOAc to give the bis-methylated product as a yellow oil (1.63g, 89%).

[001654] PartD. Preparation of 2-(3,5-diiodo-2-methoxyphenyl)-2-methylpropanoic acid.

[001655] A suspension of the product from Part C (2.63g, 5.72mmol) in MeOH (40ml) and THF (40ml) was treated with 4.0M sodium hydroxide (28ml, 112mmol) and heated at 80°C for 48h. The organic solvent was evaporated and the remaining aqueous solution was acidified with 1M HC1 producing a solid that was collected by filtration, washed with water and dried to give the desired carboxylic acid (2.46g, 96%).

[001656] Part E. Preparation of 2-(3,5-diiodo-2-methoxyphenyl)-2-methylpropan-l-ol.

[001657] A solution of the product from Part D (1,00g, 2.242mmol) in THF (40ml) was treated drop-wise with borane THF complex 1.0M (20ml, 20mmol) and then heated at 50°C for 24h. The mixture was treated with methanol (20mL), refluxed for 30min and concentrated. The resulting residue was washed with water, brine, dried with sodium sulfate, filtered and evaporated. The residue was chromatographed on silica gel eluting with hexane/EtOAc (4:1) to give the desired product (810mg, 84%).

[001658] Part F. Preparation of tert-butyl(2-(3,5-diiodo-2-methoxyphenyl)-2-methylpropoxy)-dimethylsilane.

[001659] A solution of the product from Part E (432mg, l.OOOmmol) in DMF (5ml) was treated with tert-butyldimethylchlorosilane (301mg, 2.000mmol), and imidazole (204mg, 3.00mmol) and stirred for 2h. The mixture was partitioned between 1M HC1 and ethyl acetate. The organic layer was washed with saturated sodium bicarbonate, brine, dried with sodium sulfate, filtered and evaporated. The residue was chromatographed on silica gel eluting with hexane/EtOAc (9:1) to give the desired product (522mg, 96%).

[001660] Part G. Preparation of l-(3-(l-(tert-butyldimethylsilyloxy)-2-methylpropan-2-yl)-5-iodo-4-methoxypheny l)pyrimid ine-2,4( 1 H,3 H)-dione. 312 2014280939 24 Dec 2014 [001661] To a 50mL round-bottom flask was added the product from Part F (520mg, 0.952mmol), pyrimidine-2,4(lH,3H)-dione (117mg, 1,047mmol), N-(2-cyanophenyl)picolinamide (42.5mg, 0.190mmol), copper(I) iodide (18.13mg, 0.095mmol) and potassium phosphate (424mg, 1.999mmol) in DMSO (5ml). The vessel was sealed, sparged with nitrogen and then heated at 60°C for 24h. The mixture was partitioned between 1M HC1 and ethyl acetate. The organic layer was washed with saturated sodium bicarbonate, brine, dried with sodium sulfate, and filtered. The filtrate was treated with 3-mercaptopropyl functionalized silica gel, filtered and evaporated. The residue was chromatographed on silica gel eluting with hexane/EtOAc (3:2) to give the product as a solid (285mg, 65%).

[001662] Part H. Preparation of (E)-N-(4-(3-(l-(tert-butyldimethylsilyloxy)-2-methyIpropan-2-yi)-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide.

[001663] To a 5ml microwave tube was added the product from Part G (53mg, O.lmmol), the product from Example 41B, Part B (24mg, O.lmmol), potassium phosphate (44.0mg, 0.2mmol), PA-Ph (CAS 97739-46-3) (0.87mg, 3.0pmol) and tris(dibenzylideneacetone)palladium(0) (0.9mg, 1 rimol) in THF (3.0ml) and water (1,0ml). The vessel was sealed and the mixture was sparged with nitrogen for 5min and then heated at 50°C for 2h. The mixture was partitioned between 1M HC1 and ethyl acetate. The organic layer was washed with saturated sodium bicarbonate, brine, dried with sodium sulfate and filtered. The filtrate was treated with 3-mercaptopropyl functionalized silica gel, filtered and evaporated. The residue was chromatographed on silica gel eluting with hexane/EtOAc (1:1) to give a solid (50mg, 83 %).

[001664] Parti. Preparation of (E)-N-(4-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-3-(l-hydroxy-2-methylpropan-2-yl)-2-methoxystyryl)phenyl)methanesulfonamide, [001665] A solution of the product from Part H (120mg, 0.20mmol) in THF (5.0ml) was treated with 1 M TBAF (0.800ml, 0.800mmol) in THF and stirred for 16h. The mixture was partitioned with water and ethyl acetate. The organic layer was washed (3 X brine), dried with sodium sulfate, filtered and evaporated. The residue was chromatographed on silica gel eluting with 4% methanol in CH2C12 to give a solid (85mg, 88 %). 'H NMR (300 MHz, DMSO-d6) δ ppm 1.30 (s, 6 H) 3.01 (s, 3 FI) 3.62 (d, J=5.52 Hz, 2 H) 3.77 (s, 3 H) 4.67 (t, J=5.33 Hz, 1 H) 5.66 (d, J=8.09 Hz, 1 H) 7.21 (m, 5 H) 7.62 (m, 3 H) 7.72 (d, J=8.09 Hz, 1 H) 9.85 (s, 1 Η) 11.42 (s, 1 H). MS (ESI+) m/z 503 (M+NH4)+. 313 2014280939 24 Dec 2014 [001666] Example 122. Preparation of (E)-N-(4-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-3-iodo-2-methoxystyryl)phenyl)methanesulfonamide (compound IB-L1-1.51).

[001667] Part A. Preparation of 1,3,5-triiodo-2-methoxybenzene.

[001668] In a 250mL pressure vessel was added 2,4,6-triiodophenol (5g, 10.60mmol) in MTBE (60ml) to give a yellow solution. The solution was cooled in an ice bath and 2.0M trimethylsilyldiazomethane (7.95ml, 15.90mtnol) was added at a fast drip followed by dropwise addition of methanol (6mL) resulting in calm bubbling. The vessel was sealed and stirred at room temperature for 4h. The reaction solution was partitioned between EtOAc and water and the organic layer was washed with 1M HC1, saturated NaHCOj, and saturated NaCl. The EtOAc was dried (MgS04), filtered and concentrated to give a tan solid that was used without purification (4.8g, 94 %).

[001669] Part B, Preparation of 1-(3,5-diiodo-4-methoxyphenyl)pyrimidine-2,4(lH,3H)-dione.

[001670] To a 1 OOmL round-bottom flask under 1¾ was added the product from Part A (3.5g, 7.2mmol), lH-pyrimidine-2,4-dione (0.97g, 8.64mmol), and potassium phosphate tribasie (3.2g, 15.0mrnol) in DMSO (50ml) to give a colorless suspension. N-(2-cyanophenyl)picolinamide (320mg, 1.44mmol) was added and the mix was sparged with N2 for 5min. Copper(I) iodide (137mg, 0.72mmol) was added and the mix was sparged once again for lOmin, placed under N2 and heated at 60°C for 18h. The mixture was cooled and partitioned between EtOAc and water adjusting the pH to 1 with HC1. The aqueous layer was extracted 2X with EtOAc. The organics were combined, washed with water, saturated NaHC03, and saturated NaCl, dried (Na2S04), treated with 3-mercaptopropyl functionalized silica, filtered and concentrated. The resulting solid was triturated in 2:1 hexane/EtOAc to give an off white powder (2.2g, 62 %).

[001671] Part C. Preparation of (E)-N~(4-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-3-iodo-2-methoxystyryl)phenyl)methanesulfonamide.

[001672] In a 5ml microwave tube was mixed the product from Part B (141 mg, 0.30mmol), the product from Example 41B, Part B (72.3mg, 0.300mmol), l,r-bis(diphenylphosphino)ferrocene-palladium(II)dichloride CH2C12 complex (12,25mg, 0.015mmol) and potassium phosphate (70,0mg, 0.330mmol) in THF (3.0ml) and water (1.0ml). The mixture was sparged with nitrogen for 5min and 314 2014280939 24 Dec 2014 heated at 50°C for 2h. The mixture was partitioned with ethyl acetate and 1M HC1. The organic layer was washed with saturated sodium bicarbonate, brine, dried with sodium sulfate and filtered. The filtrate was treated with 3-mercaptopropyl functionalized silica gel, filtered and evaporated. The residue was chromatographed on silica eluting with 5% methanol in CH2CI2 to give a solid (47mg, 29%). 'HNMR (300 MHz, DMSO-de) δ ppm 3.02 (s, 3 H) 3.77 (s, 3 H) 5.67 (d, J=7.72 Hz, 1 H) 7.28 (m, 4 H) 7.60 (d, J=8.82 Hz, 2 H) 7.76 (d, J=8.09 Hz, 1 H) 7.81 (d, J=2.57 Hz, 1 H) 7.86 (d, J=2.21 Hz, 1 H) 9,90 (s, 1 H) 11.48 (s, 1 H). MS (ESI-) m/z 538 (M-H)+.

[001673] Example 123. Preparation of (E)-N-(4-(5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy-3-(methylsulfonyl)styryl)phenyl)methanesulfonamide (compound IB-L1-1.49).

[001674J Part A. Preparation of 4-nitrobenzene-2-diazo-l-oxide, [001675] To a 250mL round-bottom flask was added 2-amino-4-nitrophenol (6.165g, 40.0mmol) in 48% tetrafluoroboric acid (15ml). Sodium nitrite (2.76g, 40.0mmol) in water (6ml) was added dropwise at 0°C and the mixture was stirred at room temperature for 30min. The solid was collected by filtration, washed with tetrafluoroboric acid and water. The solid was suspended in acetone (50ml), filtered and dried to give a solid (3,3lg, 50%).

[001676] Part B. Preparation of 2-(methylthio)-4-nitrophenol.

[001677] To a 1L beaker was added the product from Part A (2.70g, 16.35mmol) in ice water (250g) to give a brown suspension. Copper (0.520g, 8.18mmol) was added, followed by addition of sodium thiomethoxide (2.292g, 32.7mmol) in water (50ml) slowly. The mixture was stirred at room temperature for 24h. The mixture was filtered and the filtrate was acidified with 1M HC1 producing a solid that was collected by filtration and dried (2,53g, 84%).

[001678] PartC. Preparation of 2-(methylsulfonyl)-4-nitrophenol.

[001679] To a 250mL round-bottom flask was added the product from Part B (1.11 lg, 6.00mmol) in MeOH (20ml) to give a brown suspension. Oxone (7.746g, 12.60mmol) in water (20ml) was added slowly at 0°C. The mixture was warmed to room temperature, stirred for lh and partitioned with ethyl acetate and 1M HC1. The organic layer was washed with brine, dried with sodium sulfate, filtered and evaporated. The residue was chromatographed on silica gel eluting with 1% to 5% methanol in CH2CI2 to 315 2014280939 24 Dec 2014 give a solid (0.472g, 36%) [001680] PartD. Preparation of 2-iodo-6-(methylsulfonyl)-4-nitrophenol.

[001681] To a 50mL round-bottom flask was added the product from Part C (470mg, 2.164mmol) in MeOH (10ml) and water (2.5ml), Iodine monochloride (0.130ml, 2.60mmol) in CH2C12 (2.0mL) was added drop-wise and the mixture was stirred at room temperature, poured into water (200mL) and stirred for lOmin. The resulting solid was collected by filtration and dried (636mg, 86%).

[001682] PartE. Preparation of l-iodo-2-methoxy-3-(methylsulfonyl)-5-nitrobenzene.

[001683] To a 50mL pressure vessel was added the product from Part D (630mg, 1.836mmol) in MTBE (6ml) to give a yellow solution. The mixture was cooled in an ice bath and 2M trimethylsilyl-diazomethane (1,377ml, 2,75mmol) was added at a fast drip followed by drop-wise addition of MeOH (0.4ml) resulting in calm bubbling. The vessel was sealed and stirred at room temperature for lh. The mixture was partitioned with ethyl acetate and 1M HC1. The organic layer was washed with saturated sodium bicarbonate, brine, dried with sodium sulfate, filtered and evaporated to give an off-white solid (655mg, 100%).

[001684] Part F. Preparation of 3-iodo-4-methoxy-5-(methylsulfonyl)aniline.

[001685] To a 250mL round-bottom flask was added the product from Part E (0.650g, 1.820mmol), ammonium chloride (0.146g, 2.73mmol), and iron (0,508g, 9.10mmo!) in THF/MeOH/water (50ml, 2/2/1). The mixture was refluxed for 2h, cooled and filtered. The filtrate was evaporated and the residue was partitioned with ethyl acetate and water. The organic layer was washed with brine, dried with sodium sulfate, filtered and evaporated to give a solid (590mg, 99%).

[001686] Part G. Preparation of (E)-N-(3-iodo-4-methoxy-5-(methylsulfonyl)phenylcarbamoyl)-3-methoxy acrylamide.

[001687] To a 1 OOmL round-bottom flask was added the product from Part F (500mg, 1.528mmol) in DMF (15.0ml). The solution was cooled under nitrogen to -20°C and (E)-3-methoxyacryloyl isocyanate (15.28ml, 6.1 Immol; prepared as described by Santana, L.; et al. J. Heterocyclic Chem. 1999, 36,293-295) was added dropwise. The mixture was stirred at this temperature for 15min, then warmed to room temperature and stirred for 45min. The mixture was diluted with ethyl acetate and washed by water (3 x 50ml), brine (3 x 50ml), dried with sodium sulfate, filtered and evaporated. The residue was triturated with ethyl acetate/hexane to give a solid (425mg, 61%).

[001688] Part H. Preparation of l-(3-iodo-4-methoxy-5-(methylsulfonyl)phenyl)pyrimidine-2,4(lH,3H)-dione.

[001689] To a lOOmL round-bottom flask was added the product from Part G (420mg, 0.925mmol) in ethanol (10ml) to give a suspension. Concentrated sulfuric acid (lmL, 18.76mmol) in water (10ml) was added and the mixture was heated at 110°C for 2h. The reaction mix was cooled, diluted with water 316 2014280939 24 Dec 2014 (50ml) and stirred for lOmin. The solid material was collected by filtration, washed with water and dried to give a white solid (325mg, 83%).

[001690] Part I. Preparation of (E)-N-(4-(5-(2,4-dioxo-3,4~dihydropyrimidin-1(2H)-yl)-2-methoxy-3-(methylsulfonyl)styryl)phenyl)methanesulfonamide.

[001691] In a 5ml microwave tube was added the product from Part H (63.3mg, 0.15mmoi), the product from Example 41B, Part B (36.2mg, 0.150mmol), potassium phosphate (66.9mg, 0.315mmol), PA-Ph (CAS 97739-46-3) (1.315mg, 4.50pmol) and tris(dibenzylideneacetone)dipalladium(0) (1,374mg, 1 .SOOpmol) in THF (3.0ml) and water (1.0ml). The vessel was sealed and the mixture was sparged with nitrogen for 5min and heated at 50°C for 2h. The mixture was partitioned with ethyl acetate and 1M HC1. The organic layer was washed with saturated sodium bicarbonate, brine, dried with sodium sulfate and filtered. The filtrate was treated with 3-mercaprpropyl functionalized silica gel, filtered and evaporated. The residue was triturated with methanol/ CH2C12 to give a solid (62mg, 84%). 'll NMR (300 MHz, DMSO-d6) δ ppm 3.03 (s, 3 H) 3.37 (s, 3 H) 3.94 (s, 3 H) 5.72 (d, J=7.72 Hz, 1 H) 7.26 (m, 3 H) 7.45 (m, 1 H) 7.65 (d, .1=8.46 Hz, 2 H) 7.77 (d, J=2.57 Hz, 1 H) 7.81 (d, J=8.09 Hz, 1 H) 8.21 (d, J=2.57 Hz, 1 H) 9.93 (s, 1 Η) 11.52 (s, 1 H). MS (ESI+) m/z 509 (M+NH4)+.

[001692] Example 124. Preparation of (£)-methyl 2-(3-ierf-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2/v/)-yl)-2-methoxystyryl)-5-(methylsulfonamido)benzoate (compound IB-L1-1.7).

[001693] Part A. Preparation of methyl 2-((diethoxyphosphoryl)methyl)-5-nitrobenzoate.

[001694] To a solution of methyl 2-methyl-5-nitrobenzoate (0.40 g, 2.05mmol) in CC14 (20ml) was added /V-bromosuccinimide (365mg, 2.05mmol) and 2,2'-azobisisobutyronitrile (34mg, 0.21mmol). The resulting mixture was stirred at reflux for 18h, cooled to room temperature and partitioned between EtOAc (50ml) and H20 (50ml). The organic layer was dried over Na2S04, filtered and concentrated in vacuo. The crude product was purified by column chromatography on silica gel using 1:3 EtOAc:hexanes as the eluent to give the bromide as an oil (345mg, 61%). The oil was placed in triethylphosphite (5ml) and heated with stirring at 120°C for 3h. The mixture was allowed to cool to room temperature, and the crude product was purified by column chromatography on silica gel using 5% MeOII in CH2CI2 as the eluent. The title compound was obtained as an oil (313mg, 75%). 317 2014280939 24 Dec 2014

[001695] Part B. Preparation of (£)-methyl 2-(3-i’ert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(211)-yl)-2-methoxystyryl)-5-nitrobenzoate.

[001696] To a solution of the product from Part A (360mg, 1,09mmol) and the product from Example 41A, Part D (329mg, 1,09mmol) in anhydrous Cl I2C12 (10ml) was added potassium /ert-butoxide (305mg, 2.72mmol). The resulting dark red solution was stirred at room temperature for lh, and then poured into 1 N aq. HCI (10ml), The resulting mixture was extracted with CH2C12 (10ml), dried over Na2S04, filtered and concentrated in vacuo to give a solid. A solution of the solid in thionyl chloride (2.3ml) was heated at B5°C for 30min, and the thionyl chloride was removed in vacuo. The residue was stirred in a 2:1 mixture of CH2C12 and MeOH (3ml) for 30min, and evaporated to dryness in vacuo. The crude product was purified by column chromatography on silica gel using 3% MeOH in CH2CI2 as the eluent to give the title compound (350mg, 69%).

[001697] Part C. Preparation of (i')-methyl 2-(3-/er/-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2//)-yl)-2-methoxystyryi)-5-(methylsulfonamido)benzoate.

[001698] To a solution of the product from Part B (465mg, 0.97mmol) in a 2:2:1 mixture of THF:MeOH:H20 (10ml) was added iron powder (271mg, 4.85mmol), and ammonium chloride (78mg, 1,46mmol). The mixture was heated at 80°C for 45min, filtered through celite, and concentrated to dryness in vacuo. The residue was combined with methanesulfonyl chloride (0.16ml, 2.0mmol) and triethylamine (0.392ml, 4.85mmol) in anhydrous CH2C12 (10ml) and the resulting mixture was stirred at room temperature for 3h. The mixture was partitioned between 1 N HCI (20ml) and CH2C12 (20ml), and the organic layer was dried over Na2S04, filtered and concentrated in vacuo. The crude product was purified by column chromatography on silica gel using 3% MeOH in CH2C12 as the eluent to give the title compound (270mg, 53%). ‘H NMR (300 MHz, DMSO-d6) δ 11.42 (s, 1 H) 10.07 (s, 1 H) 7.90 (d, ./=8.82 Hz, 1 H) 7.66 - 7.79 (m, 3 H) 7.52 (d, 7=2.57 Hz, 1 H) 7.44 (dd, 7=8.64, 2.39 Hz, 1 H) 7.14 - 7.26 (m, 2 H) 5.65 (dd, 7=7.72, 1.84 Hz, 1 H) 3.86 (s, 3 H) 3.79 (s, 3 H) 3.04 (s, 3 Η) 1.38 (s, 9 H).

[001699] Example 125. Preparation of (£)-2-(3-fer/-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2//)-yl)-2-methoxystyryl)-5-(methylsulfonamido)benzoic acid (compound IB-L1-1.4). NHS02Me [001700) A solution of the product from Example 124 (55mg, 0.104mmol) in THF (1ml) and IN aq. 318 2014280939 24 Dec 2014

NaOH (1ml) was stirred in the dark at room temperature for 1.5h. IN aqueous HC1 was added until pH 3, and the resulting mixture was extracted with EtOAc (2 x 2ml). The combined organic layers were dried over Na2S04, filtered and concentrated to give the title compound (53mg, 99%). 1H NMR (300 MHz, DMSO-df,) δ 13.22 (br s, 1 Η) 11.40 (d, J=2.2\ Hz, 1 H) 10.02 (s, 1 H) 7.72 - 7.91 (m, 3 H) 7.68 (d, /= 2.57 Hz, 1 H) 7.49 (d,/=2.57 Hz, 1 H) 7.42 (dd, ./=8.64, 2.39 Hz, 1 H) 7.21 (d, ./=2.57 Hz, 1 H) 7.16 (d, /=16.18 Hz, 1 H) 5.64 (dd,/=7.72, 2.21 Hz, 1 H) 3.79 (s, 3 H) 3.04 (s, 3 H) 1.38 (s, 9 H). (001701] Example 126. Preparation of (£)-iVr-(4-(3-ter/-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2^)-yl)-2-methoxystyryl)-3 -(morpholine-4-carbonyl)phenyl)methanesulfonamide (compound IB-L1-1.23).

[001702] Part A. Preparation of (i?)-2-(3-rert-butyI-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2/()-yl)-2-methoxystyryl)-5-(methylsulfonamido)benzoyl chloride.

[001703] A solution of the product from Example 125 (257mg, 0.50mmol) in thionyl chloride (1.5ml) was heated at 85°C for 40min and then concentrated and dried in vacuo to give the title compound as a solid (0.27 g).

[001704] Part B. Preparation of (£)-Ar-(4-(3-iert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2i7)-yl)-2-methoxystyryl)-3-(morpholine-4-carbonyl)phenyl)methanesulfonamide.

[001705] To a solution of the product from Part A (24mg, 0.045mmol) in anhydrous CH2C12 (1ml) was added morpholine (0.02ml, 0.226mmol). The mixture was stirred at room temperature for 2h, and then partitioned between 1 N aq. HC1 (5ml) and EtOAc (2 x 5ml). The combined organic layers were dried over Na2S04, filtered and concentrated in vacuo. The crude product was purified by column chromatography on silica gel using 4% MeOH in CH2C12 as the eluent to give the title compound (19mg, 71%). ‘H NMR (300 MHz, DMSO-d6) δ ppm 11.41 (d, /=1.84 Hz, 1 H) 10.04 (s, 1 H) 7.85 (d, /=8.46 Hz, 1 H) 7.75 (d, /=8.09 Hz, 1 H) 7.52 (d, /=2.57 Hz, 1 H) 6.99 - 7.34 (m, 5 H) 5.65 (dd, /=7.72, 1.84 Hz, 1 II) 3.76 (s, 3 II) 3.56 - 3.71 (m, 4 II) 3.40 - 3.51 (m, 2 II) 3.11 - 3.22 (m, 2 II) 3.06 (s, 3 II) 1.38 (s, 9 IT). 319 2014280939 24 Dec 2014

[001706) Example 127. Preparation of (£)-Ar-(4-(3-/er/-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2/f)-yl)-2-methoxystyryl)-3-(hydroxymethyl)phenyl)methanesulfonamide (compound IB-L1-1.10).

[001707] To a solution of the product from Example 126, Part A (375mg, 0.705mmol) in anhydrous THF (5ml) at 0°C under N2 gas was added a 1.0 M solution of lithium ferf-butoxyaluminiumhydride (1.8ml, 1.8mmol) dropwise. The resulting mixture was stirred at 0°C for 30 min, and then allowed to warm to room temperature and was stirred for lh. The mixture was partitioned between 1 N aq. HC1 (10ml) and EtOAc (2 x 10ml). The combined organic layers were dried over Na2S04, fdtered and concentrated in vacuo. The crude product was purified by column chromatography on silica gel using 3% MeOH in CH2C12 as the eluent to give the title compound (220mg, 63%). ’H NMR (300 MHz, DMSO-d6) δ ppm 11.41 (s, 1 H) 9.82 (s, 1 H) 7.73 (t, 7=8.27 Hz, 2 H) 7.66 (d, 7=2.57 Hz, 1 H) 7.31 - 7.39 (m, 2 H) 7.20 (d, 7=2.57 Hz, 1 H) 7.12 - 7.19 (m, 2 H) 5.65 (d, 7=8.09 Hz, 1 H) 5.28 (t, 7=5.52 Hz, 1 H) 4.65 (d,7=5.52 Hz, 2 H) 3.79 (s, 3 H) 3.00 (s, 3 H) 1.38 (s, 9 H).

[001708] Example 128. Preparation of (£)-77-(4-(3-ieri-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2/7)-yl)-2-methoxystyryl)-3-(methoxymethyl)phenyl)methanesulfonamide (compound IB-L1-1.13).

O NHS02Me [001709] To a solution of the product from Example 127 (32mg, 0.064mmol) in anhydrous CH2C12 (1ml) was added thionyl chloride (23pL, 0.32mmol), and the resulting mixture was stirred at room temperature for 30min. The mixture was partitioned between saturated aq. NaHC03 (5ml) and CH2C12 (5ml) and the organic layer was dried over Na2S04, filtered and concentrated. The residue was dissolved in MeOH (1 ml), and a solution of 25% NaOMe in MeOH (58pL, 0.254mmol) was added. The resulting mixture was stirred at 50°C for 2h. The mixture was partitioned between 1 N aq. HC1 (10ml) and EtOAc 320 2014280939 24 Dec 2014 % (2 x 10ml), The combined organic layers were dried over Na2S04, filtered and concentrated in vacuo.

The crude product was purified by column chromatography on silica gel using 3% MeOH in CH2CI2 as the eluent to give the title compound (15mg, 46%). *H NMR (300 MHz, DMSO-d6) δ 11.43 (s, 1 H) 9.86 (s, 1 H) 7.62 - 7.87 (m, 3 H) 7.12 - 7.39 (m, 5 H) 5.66 (d, J=7.72 Hz, 1 H) 4.58 (s, 2 H) 3.78 (s, 3 H) 3.35 (s, 3 H) 3.00 (s, 3 H) 1.38 (s, 9 H).

[001710] Example 129. Preparation of (£)-jV-(4-(3-/ert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2//)-yl)-2-methoxystyryl)-3-((isopentylamino)methyl)phenyl)methanesulfonamide (compound IB-L1-1.31).

O

[001711] Part A. Preparation of (£)-jV-(4-(3-/<?r/-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2/i)-yl)-2-methoxystyryl)-3-formylphenyl)methanesulfonamide.

[001712] To a solution of the product from Example 127 (0.60 g, 1.20mmol) in anhydrous DMA (15ml) was added 2-iodoxybenzoic acid (336mg, 1,20mmol). The mixture was stirred at room temperature for lh, and then partitioned between EtOAc (20ml) and H20 (2x 20ml). The organic layer was dried over Na2S04, filtered and concentrated in vacuo. The crude product was purified by column chromatography on silica gel using 2% MeOH in CH2C12 as the eluent to give the title compound as a colorless solid (395mg, 66%). Ή NMR (300 MHz, DMSO-d6) δ ppm 11.43 (d,./ 2.21 Hz, 1 Η) 10.45 (s, 1 H) 10.15 (s, 1 H) 8.06 (d, ./=16.18 Hz, 1 H) 7.97 (d, ./=8.82 Hz, 1 H) 7.73 - 7.78 (m, 2 H) 7.69 (d, ./=2.57 Hz, 1 H) 7.51 (dd, J=8.64, 2.39 Hz, 1 H) 7.30 (d, ./=16.18 Hz, 1 H) 7.26 (d, J= 2.57 Hz, 1 H) 5.66 (dd, J=7.72,2.21 Hz, 1 H) 3.81 (s, 3 H) 3.07 (s, 3 Η) 1.39 (s, 9 H).

[001713] Part B. Preparation of (£)-A-(4-(3-/erf-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2//)-yl)-2-methoxystyryl)-3-((isopentylamino)methyl)phenyl)methanesulfonamide.

[001714] To a solution of the product from Part A (50mg, 0.1 Ommol) and 3-methylbutan-l-amine (12pL, O.lOmmol) in anhydrous THF (3ml) was added sodium triacetoxyborohydride (32mg, 0.15mmol) and AcOH (9pL, 0.15mmol). The resulting mixture was stirred at room temperature for 4 h, and then partitioned between H20 (10ml) and EtOAc (2 x 10ml). The combined organic layers were dried over Na2S04, filtered and concentrated in vacuo. The crude product was purified by column chromatography on silica gel using 3% MeOH in CH2C12 as the eluent to give the title compound (37mg, 65%). 'll NMR (300 MHz, DMSO-d6) δ 11.45 (d, J=\.84 Hz, 1 H) 10.04 (s, 1 H) 8.80 - 8.87 (m, 1 H) 7.88 (d, ./=8.46 Hz, 321 2014280939 24 Dec 2014 1 Η) 7.71 - 7.77 (m, 2 Η) 7.41 - 7.48 (m, 1 Η) 7.37 (d, ./=2.21 Hz, 1 H) 7.21 - 7.29 (m, 3 H) 5.67 (dd, ./=7.91,2.02 Hz, 1 H) 4.30 - 4.38 (m, 2 H) 3.80 (s, 3 H) 3.10 (s, 3 H) 2.95 - 3.04 (m, 2 H) 1.49- 1.67 (m, 3 Η) 1.38 (s, 9 H) 0.86 (d, J= 6.25 Hz, 6 H).

[001715] Example 130. Preparation of iV-(4-(3-fórr-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2//)-yl)-2-methoxystyryl)-3-((£)-(methoxyimino)methyl)phenyl)methanesulfonamide (compound IB-L1-1.19).

[001716] To a solution of the product from Example 129, Part A (35mg, 0.070mmol) in EtOH (2ml) was added O-methoxylamine hydrochloride (29mg, 0.35mmol) and sodium bicarbonate (30mg, 0,35mmol). The resulting mixture was stirred at 70°C for 2h. To the mixture was added 1N aq. HCl (1 ml) to give a colorless precipitate that was filtered and dried to give the title compound as a colorless solid (24mg, 64%). *H NMR (300 MHz, DMSO-d6) δ ppm 11.43 (d, ./=2.21 Hz, 1 H) 9.94 (s, 1 H) 8.74 (s, 1 H) 7.79 - 7.85 (m, 2 H) 7.76 (d, ./=7.72 Hz, 1 H) 7.57 - 7.65 (m, 2 H) 7.32 (dd, ./=8.64, 2.39 Hz, 1 H) 7.23 (d, J=2.57 Hz, 1 H) 7.18 (d,./=16.18 Hz, 1 H) 5.66 (dd, ./=7.72, 2.21 Hz, 1 H) 3.93 (s, 3 H) 3.79 (s, 3 H) 3.03 (s, 3 H) 1.38 (s, 9 H).

[001717] Example 131. Preparation of (£)-JV-(4-(3-teri-butyl-5-(2,4~dioxo-3,4-dihydropyrimidin-l(2//)-yl)-2-methoxystyryl)-3-(oxazol-2-yl)phenyl)methanesulfonamide (compound IB-L1-1.26).

[001718] To a solution of the product from Example 126, Part A (80mg, 0.15mmol) in tetramethylene sulfone (1.5ml) was added 1//-1,2,3-triazole (10pL, 0.17mmol) and potassium carbonate (73mg, 0.53mmol). The mixture was heated for 35min at 130°C in a microwave reactor. After cooling to room temperature, the mixture was partitioned between 1 N aqueous HCl (10ml) and EtOAc (2 x 10ml). The combined organic layers were dried over Na2S04, filtered and concentrated in vacuo. The crude product 322 2014280939 24 Dec 2014 was purified by column chromatography on silica gel using 3% MeOH in CH2CI2 as the eluent to give the title compound (37mg, 46%). 'll NMR (300 MHz, DMSO-d6) δ 11.41 (d,/=1.84 Hz, 1 H) 10.10 (s, 1 H) 8.29 (d, /=1.10 Hz, 1 H) 8.05 (d,/=16.18 Hz, 1 H) 7.95 (d,/=8.82 Hz, 1 H)7.82 (d,/=2.21 Hz, 1 H) 7.74 (d, /=8.09 Hz, 1 H) 7.51 (d, /=2.57 Hz, 1 H) 7.46 (d, /=0.74 Hz, 1 H) 7.39 (dd, /=8.64,2.39 Hz, 1 H) 7.20 - 7.30 (m, 2 H) 5.65 (dd,/=7.91,2.02 Hz, 1 H) 3.80 (s, 3 H) 3.07 (s, 3 H) 1.38 (s, 9 H).

[001719] Example 132. Preparation of (E)-iV-(4-(3-/ert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2i/)-yl)-2-methoxystyry 1)-3-(l//-imidazol-2-yl)phenyl)methanesulfonamide (compound IB-L1-1.16).

O

[001720] To a solution of the product from Example 129, Part A (50mg, O.lOmmol) in EtOH (2ml) was added glyoxal (57uL, 0.50mmol) and concentrated aqueous NH4OH (70uL, O.SOmmol). The resulting mixture was stirred at room temperature for 16h. To the mixture was added 1 N aq. HC1 until pH = 7, and the mixture was partitioned between H20 (10ml) and EtOAc (2 x 10ml). The combined organic layers were dried over Na2S04, filtered and concentrated in vacuo. The crude product was purified by column chromatography on silica gel using 5% MeOH in CH2CI2 as the eluent to give the title compound (27mg, 50%). 'H NMR (300 MHz, DMSO-d6) δ 12.39 (s, 1 Η) 11.40 (d,/=1.84 Hz, 1 H)9.98(s, 1 H)7.89(d, /=8.82 Hz, 1 H) 7.66 - 7.76 (m, 2 H) 7.38 (t, /=2.21 Hz, 2 H) 7.23 - 7.31 (m, 2 H) 7.06 - 7.21 (m, 3 H) 5.63 (dd, /=8.09, 1.84 Hz, 1 H) 3.78 (s, 3 H) 3.07 (s, 3 Η) 1.37 (s, 9 H).

[001721] Example 133. Preparation of (£)-fer/-butyl 2-(3-fórf-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2/7)-yI)-2-methoxystyryl)-5-(methylsulfonaniido)phenylcarbamate (compound IB-L1-1.32).

O

[001722] To a solution of the product from Example 125 (75mg, 0.146mmol) in /ert-butanol (4ml) was added diphenylphosphoryl azide (47pJL 0.219mmol) and triethylamine (3 lpL, 0.219mmol). The resulting 323 2014280939 24 Dec 2014 mixture was stirred at 80°C for 18h. The cooled mixture was partitioned between H20 (10ml) and EtOAc (2 x 10ml). The combined organic layers were dried over Na2S04, filtered and concentrated in vacuo.

The crude product was purified by column chromatography on silica gel using 3% MeOH in CH2CI2 as the eluent to give the title compound (16mg, 19%). 'HNMR (300 MHz, DMSO-ds) δ 11.45 (d, ,/=1.84 Hz, 1 H) 9.86 (s, 1 H) 9.03 (s, 1 H) 7.75 (d, >7.72 Hz, 2 H) 7.55 (d, >2.57 Hz, 1 H) 7.10 - 7.33 (m, 4 H) 7.04 (dd,>8.64, 2.39 Hz, 1 H) 5.66 (dd,>7.91, 2.02 Hz, 1 H) 3.78 (s, 3 H) 3.02 (s, 3 H) 1.45 (s, 9 H) 1.38 (s, 9 H).

[001723] Example 134. Preparation of (E)-j?V-(3-amino-4-(3-iert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2i7)-yl)-2-methoxystyryl)phenyl)methanesulfonamide (compound 1B-L1-1.28).

[001724] The procedure described for the preparation of Example 133 provided the title compound, which was purified by column chromatography on silica gel using 5% methanol in CIT2CI2 as the eluent (6mg, 9%). !H NMR (300 MHz, DMSO-d6) δ 11.44 (d, >2.21 Hz, 1 H) 9.55 (s, 1 IT) 7.77 (d, >2.57 Hz, 1 H) 7.75 (d, >8.09 Hz, 1 H) 7.45 (d, >8.46 Hz, 1 H) 7.33 (d, >15.81 Hz, 1 H) 7.15 (d, >2.57 Hz, 1 H) 7.00 (d, >16.18 Hz, 1 H) 6.56 (d, >2.21 Hz, 1 H) 6.44 (dd, >8.46, 2.21 Hz, 1 H) 5.66 (dd, >7.91, 2.02 Hz, 1 H) 5.56 (s, 2 H) 3.78 (s, 3 H) 2.97 (s, 3 H) 1.37 (s, 9 H).

[001725] Example 135. Preparation of (/T)-iV-(4-(3-iert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2//)-yl)-2-methoxystyryl)-2-fluorophenyl)methanesulfonamide (compound IB-L1-1.5).

[001726] Part A. Preparation of (3-fluoro-4-nitrophenyl)methanol.

[001727] To a solution of 3-fIuoro-4-nitrobenzoic acid (2.0 g, 10.8mmol) in THF (50ml) at 0°C was added BH3-Me2S complex (2.215ml, 22.15mmol) drop-wise. The mixture was stirred at 0°C for 3h, and was then stirred at 65°C for 18h. To the cooled mixture was added ice (50g), followed by 1 N aq. HCI 324 2014280939 24 Dec 2014 (100ml), and the resulting mixture was extracted with EtOAc (200ml). The organic layer was dried over Na2S04, filtered and concentrated in vacuo to provide the title compound as a white solid (1.79g, 97%).

[001728] PartB. Preparation of 4-(bromomethyl)-2-fluoro-l-nitrobenzene.

[001729] A solution of the product from Part A (1.79 g, 10.46mmol), JV-bromosuccinimide (2.234 g, 12.55mmol) and triphenylphosphine (3.29 g, 12.55mmol) in CH2CI2 (100ml) and THF (50ml) was stirred at room temperature for 3h. The mixture was partitioned between HjO (200ml) and EtOAc (400ml), and the organic layer was dried over Na2S04, filtered and concentrated in vacuo. The crude product was purified by column chromatography on silica gel using 1:1 EtOAc:hexanes as the eluent to give the title compound (1.14 g, 47%).

[001730] Part C. Preparation of diethyl 3-fluoro-4-nitrobenzylphosphonate.

[001731] The product from Part B (1.25 g, 5,34mmol) was subjected to the conditions described for Example 34, Part B to provide the title product (0.75 g, 48%).

[001732] Part D, Preparation of(£)-A-(4-(3-/err-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2//)-yl)-2-methoxystyryl)-2-fluorophenyl)methanesulfonamide.

[001733] The product from Part C (0.193 g, 0.662mmol) was subjected to the conditions described for Example 41 A, Part E, Part F, and Part G to provide the title product as a colorless solid (15mg, 5%).

[001734] Example 136. Preparation of (A>AL(4-(3-/erf-but}i-5-(2,4-dioxo-3)4-dihydropyrimidin-l(2//)-yl)-2-methoxystyryl)-2-fluoro-5-methylphenyl)methanesulfonamide (compound IB-L1-1.15).

[001735] Part A. Preparation of iV-(4-bromo-2-fluoro-5-methylphenyl)methanesulfonamide.

[001736] To a solution of 4-bromo-2-fluoro-5-methylaniline (2.04 g, lO.Ommol) in anhydrous CH2C12 (20ml) and pyridine (3.23ml, 40.0mmol) was added methanesulfonyl chloride (0.86ml, 1 l.Ommol) and the resulting mixture was stirred at room temperature for 2h. Solvent was removed in vacuo, and the residue was partitioned between EtOAc and 1M aq. HC1. The organic layer was washed with saturated aqueous NaHC03, brine and then dried over Na2S04. The drying agent was filtered off, and the filtrate was concentrated to give the title compound as a solid (2.80 g, 99%).

[001737] PartB. Preparation ofN-(4-ethynyl-2-fluoro-5-methylphenyl)methanesulfonamide. 325 2014280939 24 Dec 2014 [001738] A mixture of the product from Part A (3.0 g, 10.63mmol), triphenylphosphine (0.279 g, 1.06mmol), trimethylsilylacetate (6.0ml, 42.5mmol) and palladium(II) acetate (0.12 g, 0.53mmol) in triethylamine (30ml) and toluene (15ml) under N2 was heated at 80°C for 5h. The mixture was allowed to cool to room temperature, and was partitioned between EtOAc and 1M aq. HCI. The organic layer was washed with saturated NalICO, and brine, dried over Na2S04, filtered and concentrated in vacuo. The crude product was purified by column chromatography on silica gel using a solvent gradient of 10% to 35% EtOAc in hexanes to give an oil (3.0 g, 94%). To a solution of the oil (3.0 g, lO.Ommol) in MeOH (50ml) was added 1M aq. NaOH (21ml, 21.0mmol), and the resulting mixture was stirred at room temperature for 45min. The mixture was partitioned between EtOAc and 1M aq. HCI, and the organic layer was washed with brine and dried over Na2S04. The drying agent was filtered off, and the filtrate was concentrated in vacuo to give the title compound as a solid (2.3 g, quant.).

[001739] Part C. Preparation of (£)-5-fluoro-2-methyl-4-(methylsulfonamido)styrylboronic acid.

[001740] The product from Part B (0.20 g, 0.88mmol) was subjected to the conditions described for the preparation of Example 41B, Part B to give the title compound (42mg, 17%).

[001741] PartD. Preparation of (£)-A-(4-(3-/eri-butyl-5-(2,4-dioxo-3,4-dihydropynmidin-l(2/f)-yl)-2-methoxystyiyl)-2-fluoro-5-methylphenyl)methanesulfonamide.

[001742] The product from Part C (40mg, 0.15mmol) was subjected to the conditions described for the preparation of Example 41B, Part I to give the title compound (5 lmg, 83%). 'HNMR (300 MHz, DMSO-d6) δ 11.42 (d, /-2.21 Hz, 1 H) 9.59 (s, 1 H) 7.70 - 7.78 (m, 2 H) 7.66 (d, ./-11.77 Hz, 1 H) 7.20 -7.32 (m, 3 H) 5.65 (dd, /=7.72,2,21 Hz, 1 H) 3.79 (s, 3 H) 3.05 (s, 3 H) 2.38 (s, 3 H) 1.38 (s, 9 H).

[001743] Example 137. Preparation of methyl 2-(3-te/7-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2//)-yl)-2-methoxyphenethy!)-5-(methylsulfonamido)benzoate (compound IB-L5-2-1.1).

Ό [001744] To a solution of the product from Example 124(40mg, 0.076mmol) in MeOH (2ml) and THE (2ml) was added 10% Pd/C (20mg) and the resulting mixture was stirred at room temperature under 1 atm H2 for 16h. The mixture was filtered through celite and concentrated in vacuo to give a solid (27.5mg, 68%). 'H NMR (300 MHz, DMSO-d6) δ 11.39 (s, 1 H) 9.88 (s, 1 H) 7.61 - 7.71 (m, 2 H) 7.28 - 7.36 (m, 2 H) 7.20 (d, ./=2.57 Hz, 1 H) 7.13 (d, /=2.94 Hz, 1 H) 5.64 (d, /=7.72 Hz, 1 H)3.83 (s, 3 H) 3.75 (s, 3 H) 3,14 (dd, /=10.30, 5.88 Hz, 2 H) 2.96 (s, 3 II) 2.83 - 2.92 (m, 2 H) 1.34 (s, 9 H). 326 2014280939 24 Dec 2014 [001745] Example 138. Preparation of/VL(4-(3-fer/-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2//)-yl)-2-methoxyphenethyl)phenyl)methanesulfonamide (compound IB-L5-2-1.2).

[001746] The product from Example 41B, Part M (200mg, 0,426mmol) was dissolved in MeOH (10ml) followed by the addition of 10% Palladium on activated Carbon (50mg). The resultant mixture was evacuated and a hydrogen balloon attached then stirred at room temperature for 48h, The mixture was then filtered through celite and the filtrate concentrated under vacuum to an oil which was dissolved in ethanol (4ml) then a IN solution of aqueous sodium hydroxide (3.8ml, 3.8mmol) was added and the solution stirred at room temperature for 18h. The ethanol was then removed under vacuum and a 1N solution of aqueous hydrochloric acid (4ml) was added to acidify the mixture followed by extraction with EtOAc (2 x 1 OmL). The organic extracts were combined, dried and purified by column chromatography on silica gel using 5% MeOH in CH2C12 as the eluent to provide the title compound as a colorless solid (82mg, 41%). 'H NMR (300MHz, DMSO-d6) δ 11.39 (s, 1H), 9.60 (s, 1H), 7.65 (d, ./=8.1 Hz, 1H), 7.23 (m, 3IT), 7.17 (m, 3H), 5.64 (d,/=7.7Hz, 1H), 3.77 (s, 3H), 2.93 (s, 3H), 2.88 (br s, 4H), 1.35 (s, 9H).

[001747] Example 139. Preparation of (E)-7V-(4-(3-fer/-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l (2//)-yl)-2-ethoxystyryl)pheny l)methanesulfonamide (compound IB-L1-1.30).

O

[001748] Part A. Preparation of 2-tert-butyl-4-iodophenol.

[001749] To a 250mL round-bottom flask was added 2-tert-butylphenol (3.76g, 25mmol) in MeOH (50.0ml) to give a colorless solution. Sodium hydroxide (1.200g, 30.0mmol) was added and the mix was stirred until the hydroxide was completely dissolved. The solution was cooled to 0°C and treated with 327 2014280939 24 Dec 2014 sodium iodide (1.75g, 1 l.ómmol) followed by drop-wise addition of 10% sodium hypochlorite solution (7.2ml, 11.6mmol). The addition of sodium iodide followed by sodium hypochlorite was repeated twice and the mixture was stirred at 0°C for 30min. The mixture was treated with 10% w/w solution of sodium thiosulfate, stirred for 30min and treated with concentrated HC1 dropwise to a constant pH of 1. The mixture was extracted 3X with EtOAc. The extracts were combined, washed with brine, dried (MgS04), filtered and concentrated. The crude oil was flash chromatographed on an Isco 80g silica cartridge eluting with hexane to > 4:1 hexane/EtOAc to give a yellow oil (5.2g, 75%).

[001750] PartB. Preparation of 2-bromo-6-tert-butyl-4-iodophenol.

[001751] To a 250mL round-bottom flask was added the product from Part A (4.8g, 17.38mmol) and l,3-dibromo-5,5-dimethylhydantoin (2.6lg, 9.13mmol) in chloroform (87ml) to give an orange solution. The reaction mixture was stirred for 2h resulting in a black solution that was washed with water, brine, dried (Na2S04) and concentrated. The black oil was flash chromatographed on a 120g Isco silica cartridge eluting with hexane to give a pinkish solid (4,84g, 78%).

[001752] Part C. Preparation of l-bromo-3-tert-butyl-2-ethoxy-5-iodobenzene.

[001753] To a 50mL round-bottom flask was added the product from Part B (888mg, 2.5mmol), ethyl iodide (409mg, 2,63mmol), and potassium carbonate (415mg, 3.00mmol) in acetone (12ml) to give a green suspension. The mixture was heated at reflux for 16h, cooled and concentrated. The residue was partitioned between water and EtOAc. The organic layer was washed twice with brine, dried over Na2S04, filtered and concentrated to a red oil. The oil was flash chromatographed on an Isco 40g silica cartridge eluting with hexane to give a clear oil (820mg, 86%).

[001754] Part D. Preparation of l-(3-bromo-5-tert-butyl-4-ethoxyphenyl)pyrimidine-2,4(lH,3H)-dione.

[001755] In a 20mL microwave tube under nitrogen flush was added the product from Part C (0.4g, 1.044mmol), lH-Pyrimidine-2,4-dione (0.140g, 1.253mmol), and potassium phosphate tribasic (0.465g, 2.193mmol) in DMSO (5ml) to give a colorless suspension. N-(2-cyanophenyl)picolinamide (0.047g, 0.209mmol) was added and the mix was sparged with nitrogen for lOmin. Copper® iodide (0.020g, 0.104mmol) was added and the mix was sparged once again for lOmin, placed under nitrogen and heated at 60°C for 18h. The mixture was cooled and partitioned between EtOAc and water adjusting the pH to 1 with HC1. The aqueous layer was extracted 2X with EtOAc. The organics were combined, washed with water, saturated NaHC03, and saturated NaCl. The organic layer was dried (Na2S04), stirred with 3-mercaptopropyl functionalized silica for lh, filtered and concentrated. The crude productwas purified by chromatography on an Isco 12g silica cartridge eluting with 2% MeOH in CH2C12 to give a white powder (266mg, 69%).

[001756] Part E. Preparation of (£)-A-(4-(3-?eri-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2//)-yl)-2-ethoxystyryl)phenyl)methanesulfonamide. 328 2014280939 24 Dec 2014 [001757] A mixture of the product from Part D (5 5.1 mg, 0.15mmol), the product from Example 41B, PartB (36.2mg, 0.150mmol), potassium phosphate tribasic (63.7mg, 0.300mmol) and l,l'-bis(di-tert-butylphosphino)ferrocene palladium dichloride (4.89mg, 7.50pmol) in THF (3ml) water (1ml) was sparged for lOmin with nitrogen, and then sealed and heated at 50 °C for 4h. The mixture was cooled to room temperature and diluted into EtOAc. The EtOAc layer was washed with 1M HC1, saturated NaHC03, saturated NaCl, dried (Na2S04) and treated simultaneously with mercaptopropyl silica gel, filtered and concentrated. The crude product was purified by column chromatography on silica gel using 2% MeOH in CH2C12 as the eluent to give the title compound as a solid (40mg, 55%) m.p. 265-266 °C. 'H NMR (300 MHz, DMSO-d6) δ 11.42 (s, 1 H) 9.87 (s, 1 H) 7.76 (d, J=8.09 Hz, 1 H) 7.55 - 7.66 (m, 3 H) 7.17 - 7.27 (m, 5 H) 5.65 (dd, J=7.72, 1.47 Hz, 1 H) 3.89 (q, J=6.74 Hz, 2 H) 3.02 (s, 3 H) 1.45 (t, J=6.99 Hz, 3 H) 1.39 (s, 9 H).

[001758] Example 140. Preparation ofA-(4-((3-cyclopropyl-5-(2,4-dioxotetrahydropyrimidin-l(2/i)-yl)-2-methoxypheny l)ethynyl)pheny l)methanesulfonamide (compound IA-L2-1.23).

[001759] Part A. Preparation of 3-bromo-2-methoxy-5-nitrobenzaldehyde.

[001760] Into an appropriately sized pressure bottle was placed commercially available 3-bromo-2-hydroxy-5-nitrobenzaldehyde (2.46gm, lO.OOmmol), iodomethane (6.23mL, lOOmmol), silver oxide (2.317g, lO.OOmmol) and acetonitrile (50mL). The bottle was sealed and heated with stirring at 50°C for 2h. The reaction mixture was filtered through celite and the filtrate concentrated to give a solid residue that was triturated with hexane, collected by filtration and dried. The resulting solid was purified by silica gel chromatography (hexane-ethylacetate) to give the title compound (1.2g, 46%).

[001761] PartB. Preparation of3-cyclopropyl-2-methoxy-5-nitrobenzaldehyde.

[001762] The product from Part A (0.65gm, 2.50mmol) was combined with cyclopropyl boronic acid (0.279g, 3.25mmol), potassium phosphate (1.85g, 8.75mmol), tricyclohexylphosphine teterafluoroborate (0.092gm, 0.250mmol), palladium (II) acetate (0.028gm, 0.125mmol) and toluene-water, 20:1 v/v (12mL) in a microwave tube. The reaction mixture was purged with nitrogen for 5min then heated at 100°C in a 329 2014280939 24 Dec 2014 microwave reactor for 20min. The mixture was subsequently partitioned with ethyl acetate and water. The organic phase was washed with brine and concentrated in vacuo to give a residue that was purified by chromatography on silica gel (hexane-ethylacetate) to afford the title compound as a white solid (0.47g, 85%).

[001763] Part C. Preparation of l-cyclopropyl-3-ethynyl-2-methoxy-5-nitrobenzene.

[001764] The product from Part B (0.20g, 0.904mmol) was reacted with l-diazo-2-oxopropyl phosphonate (0.182g, 0.949mmol), prepared by the method of Ohira, Syn. Comm. 19 (3&amp;4) 561-564 (1989), as described in Example 44 Part G. The crude product was purified by chromatography on silica gel (ethylacetate-hexanes) to give the title compound as a pale yellow oil which crystallizes in standing (0.155 g, 79%).

[001765] PartD. Preparation of7V-(4-((3-cyclopropyl-2-methoxy-5-nitrophenyl)ethynyl)phenyl) methanesulfonamide.

[001766] The product from Part C (0.155g, 0.712mmol) was combined in a round bottom flask with N-(4-iodophenyl)methanesulfonamide (0.212gm, 0.712mmol), prepared as in Example 43, Part F substituting 4-iodoaniline for 4-iodo-3-methylaniline. To this mixture was added copper (I) iodide (10.3 lmg, 0.054mmol), bis(triphenylphosphine)palladium(II)chloride (0.034g, 0,048mmol), triethylamine (0.496mL, 3.56mmol) and anhydrous acetonitrile (14mL). A reflux condenser was attached and the mixture was purged with nitrogen for 5min and then heated under nitrogen in an oil bath at 80°C for 1 h. The reaction mixture was concentrated in vacuo and the crude product was purified by chromatography on silica gel column eluting with ethylacetate-hexanes to give the title compound as a yellow solid (0.1887g, 68.6%).

[001767] Part E. Preparation of A-(4-((5-amino-3-cyclopropyl-2-methoxyphenyl)ethynyl)phenyl) methanesulfonamide.

[001768] The product from Part D (0.184gm, 0.475mmol) was combined with iron (0.133gm, 2.38mmol) and ammonium chloride (0.050gm, 0.932mmol) in a round bottom flask. To this was added ethanol (ImL), tetrahydrofuran (THF) (2mL) and water (2mL), and the resulting mixture heated with vigorous stirring under nitrogen to 80°C in an oil bath a total of 4.5h. On completion of heating the reaction mixture was filtered through a pad of sand and celite. The filter pad was washed with THF and the combined filtrates concentrated in vacuo. The residue was partitioned between water and dichloromethane. The organics were washed with water and then dried (MgS04) and concentrated. The residue was purified by chromatography on silica gel eluting with ethylacetate-hexanes to give the title compound as an amber oil (0.1098g, 65%).

[001769] PartF. Preparation of A?-(4-((3-cyclopropyl-5-(2,4-dioxotetrahydropyrimidin-1 (2H)-y\)-2-methoxyphenyl)ethynyl)phenyl)methanesulfonamide. 330 2014280939 24 Dec 2014 [001770] The product from Part E (0.1098g, 0.308mmol) was reacted with acrylic acid (1.27mL, 18.48mmol) as described in Example 43 Part E. The crude product in acrylic acid was treated with urea (0.094g, 1.558mmol) and glacial acetic acid (1.3mL ) then heated under nitrogen to 120°C in an oil bath for eleven hours. The reaction mixture was concentrated in vacuo and diluted with water. The resulting solid was collected by vacuum filtration, washed with water and dried in vacuo to give the title compound as a yellow solid (0.0877g, 63%). Purification by chromatography on silica gel using ethylacetate-hexane then dichloromethane-methanol gave analytical material. ’ll NMR (300 MHz, DMSO-d6) δ 10.36 (s, 1 H) 10.08 (s, 1 H) 7.53 (d, /=8.82 Hz, 2 H) 7.26 (dd, J=5.52, 2.94 Hz, 3 H) 6.84 (d, /=2.57 Hz, 1 H) 3.94 (s, 3 H) 3.73 (t,/=6.62 Hz, 2 H) 3.06 (s, 3 H) 2.68 (t, /=6.62 Hz, 2 H) 2.16 (s, 1 H) 0.94 - 1.03 (m, 2 H) 0.63 -0.74 (m, 2II).

[001771] The following compounds were prepared utilizing the above discussion: [001772] (E)-N'-(l-(3'-tert-butyl-5’-(2,4-dioxotetrahydropyrimidin-l(2H)-yi)-2,-methoxybiphenyl-4-yl) ethylidene)methanesulfonohydrazide (compound IA-L0-1.2). ]H NMR (300 MHz, DMSO-d6) δ ppm 1.39 (s, 9 H) 2.26 (s, 3 H) 2.70 (t, J=6.62 Hz, 2 H) 3.10 (s, 3 H) 3.24 (s, 3 H) 3.80 (t, J=6.62 Hz, 2 H) 7.17 (d, J=2.57 Hz, 1 H) 7.24 (d, J=2.57 Hz, 1 H) 7.57 (d, J=8.46 Hz, 2 H) 7.87 (d, J=8.46 Hz, 2 H) 10.12 (s, 1 H) 10.33 (s, 1 H).

[001773] (E)-N'~((3'-tert-butyl-5'-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-3,5-difluoro-2’-methoxy biphenyl-4-yl)methylene)methanesulfonohydrazide (compound IA-LO-1.3). ‘H NMR (300 MHz, DMSO-de) δ ppm 1.39 (s, 9 H) 2.70 (t, J=6.62 Hz, 2 H) 3.08 (s, 3 H) 3.30 (s, 3 H) 3.80 (t, J=6.43 Hz, 2 H) 7.26 (d, 1=2.57 Hz, 1 H) 7.34 (m, 3 H) 8.11 (s, 1 H) 10.36 (s, 1 Η) 11.39 (s, 1 H).

[001774] (E)-N'-((3'-tert-butyl-5'-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-3-fluoro-2’-methoxy biphenyl-4-yl)methylene)methanesulfonohydrazide (compound IA-LO-1.4). 'H NMR (300 MHz, DMSO-d„) δ ppm 1.39 (s, 9 H) 2.70 (t, 1=6.62 Hz, 2 H) 3.11 (s, 3 H) 3.28 (s, 3 H) 3.80 (t, 1=6.80 Hz, 2 H) 7.22 (d, 1=2.57 Hz, 1 H) 7.28 (d, 1=2.57 Hz, 1 H) 7.45 (m, 2 H) 7.94 (t, 1=8.09 Hz, 1 H) 8.20 (s, 1 H) 10.35 (s, 1 H) 11.32 (s, 1 H).

[001775] (E)-N'-((3'-tert-butyl-5'-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2',4-dimethoxy-biphenyl-3-yl)methylene)methanesulfonohydrazide (compound IA-LO-1.5). 1H NMR (300 MHz, UMSO-d6) δ ppm 1.39 (s, 9 H) 2.70 (t, 1=6.62 Hz, 2 H) 3.03 (s, 3 H) 3.24 (s, 3 H) 3.78 (t, 1=6.80 Hz, 2 H) 3.90 (s, 3 H) 7.12 (d, 1=2.57 Hz, 1 H) 7.22 (m, 2 H) 7.54 (dd, 1=8.46, 2.21 Hz, 1 H) 7.86 (d, 1=2.21 Hz, 1 H) 8.34 (s, 1 H) 10.32 (s, 1 H) 11.05 (s, 1 H).

[001776] (E)-N'-((3'-tert-butyl-5'-(2,4-dioxotetrahydropyrimidm-l(2H)-yl)-2,3-difluoro-2'-methoxy biphenyl-4-yl)methylene)methanesulfonohydrazide (compound IA-LO-1.6). 'H NMR (500 MHz, DMSO-ds) δ ppm 1.38 (s, 9 H) 2.70 (t, 1=6.41 Hz, 2 H) 3.11 (s, 3 H) 3.28 (s, 3 H) 3.79 (t, 1=6.71 Hz, 2 H) 7.18 (d, 1=2.44 Hz, 1 H) 7.35 (m, 2 H) 7.74 (t, 1=7.32 Hz, 1 H) 8.19 (s, 1 H) 10.32 (s, 1 Η) 11.44 (s, 1 H). 331 2014280939 24 Dec 2014 [001777] (E)-N'-((3'-tert-butyl-5'-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2'-methoxybiphenyl-3-yl) methylene)methanesu!fonohydrazide (compound IA-LO-1.7). 'HNMR (300 MHz, DMSO-D6) δ ppm 1.39 (s, 9 H) 2.70 (t, J=6,62 Hz, 2 H) 3.07 (s, 3 H) 3.23 (s, 3 H) 3.80 (t, J=6.43 Hz, 2 H) 7.17 (d, J=2.57 Hz, 1 H) 7.25 (d, J=2.57 Hz, I H) 7.54 (m, 2 H) 7.73 (m, 2 H) 8.06 (s, 1 H) 10.33 (s, 1 Η) 11.11 (s, 1 H).

[001778] (Z)-N'-(l-(3'-tert-butyl-5'-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2'-methoxybiphenyl-3-yl) ethvlidene)methanesulfonohydrazide (compound IA-LO-1.8). 'H NMR (300 MHz, DMSO-d6) δ ppm 1.39 (s, 9 H) 2.26 (s, 3 H) 2.70 (t, 7=6.80 Hz, 2 H) 3.07 (s, 3 H) 3.22 (s, 3 H) 3.80 (t, 7=6.62 Hz, 2 H) 7.18 (d, 7=2.57 Hz, 1 H) 7.24 (d, 7=2.94 Hz, 1 H) 7.46 - 7.59 (m, 2 H) 7.79 (d, 7=7.35 Hz, 1 H) 7.84 (s, 1 H) 10.11 (s, l H) 10.33 (s, 1 H).

[001779] N-(3-(2-(3-tert-buty 1-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl) oxazol-5-yl)phenyl)methanesulfonamide (compound IA-L0-1.9) [001780] l-(3-tert-butyl-4-methoxy-5-(5-(3-nitrophenyl)oxazol-2-yl)phenyl)dihydropyrimidine-2,4(lH,3H)-dione (compound IA-L0-1.10) [001781] l-(3-tert-butyl-4-methoxy-5-(5-(4-nitrophenyl)oxazol-2-yl)phenyl)dihydropyrimidine-2,4(l H,3H)-dione (compound IA-L0-l.il) [001782] N-(3'-tert-butyl-5'-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2'-methoxybiphenyl-4-yl) methanesulfonamide (compound IB-LO-1.2). 'H NMR (300 MHz, CDC13) δ ppm 1.43 (s, 9H) 3.07 (s, 3H) 3.32 (s,3H) 5.82 (dd, 7=8.09, 2.21 Hz, lH)6.79(s, 1H) 7.14 (d, 7=2.94 Hz, 1H)7.21 (d, 7=2.57 Hz, 1H) 7.28 (d,2H) 7.35 (d, 7=8.09 Hz, 1H) 7.54 (d, 7=8.46 Hz, 2H) 8.31 (s, 1H).

[001783] (E)-N'-((3'-tert-butyl-5'-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-3-fluoro-2'-methoxy biphenyl-4-yl)methylene)methanesulfonohydrazide (compound IB-LO-1.3). lH NMR (300 MHz, DMSO-d,;) δ ppml 1.42 (s, 1 Η) 11.33 (s, 1 H) 8.21 (s, 1 H) 7.95 (s, 1 H) 7.78 (d, J=7.72 Hz, 1 H) 7.39 -7.59 (m, 2 H) 7.35 (s, 2 H) 5.65 (dd, J=7.91, 2.02 Hz, 1 H) 3.20 - 3.44 (m, 3 H) 3.11 (s, 3 H) 1.40 (s, 9 H).

[001784] N-(2-(3'-tert-butyl-5'-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2,-methoxybiphenyl-4-yl) ethyl)methanesulfonamide (compound IB-LO-1.4). 'H NMR (300 MHz, CDCI3) δ ppm 1.43 (s, 9H) 2.86-2.99 (m, 2H) 2.91 (s,3H)3.31 (s, 3H) 3.38-3.51 (m, 2H) 5.80 (dd, 7=8.09,2.21 Hz, 1H) 7.12 (d, 7=2.57 Hz, 1H) 7.21 (d, 7=2.57 Hz, 1H) 7.26-7.32 (m, 1H) 7.35 (d, 7=8.09 Hz, 1H) 7.52 (d, 7=8.09 Hz, 2H) 7.78 (d, 7=7.72 Hz, 1H) 8.15 (s, 1H).

[001785] (E)-N'-(l-(3'-tert-butyl-5'-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2,-methoxy biphenyl-4-yl)ethylidene)methanesulfonohydrazide (compound IB-LO-1.5). 'H NMR (300 MHz, DMSO-dc) δ ppm 11.40 (s, 1 H) 10.13 (s, 1 H) 7.88 (d, J=8.09 Hz, 2 H) 7.78 (d, J=7.72 Hz, 1 H) 7.60 (d, J=8.09 Hz, 2 H) 7.29 (d, J=4.04 Hz, 2 H) 5.64 (dd, J=7.72, 1.84 Hz, 1 H) 3.27 (s, 3 H) 3.10 (s, 3 H) 2.27 (s, 3 H) 1.40 (s, 9 H).

[001786] (E)-N'-((3'-tert-butyI-5'-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2’,4-dimethoxy biphenyl-3-332 2014280939 24 Dec 2014 yl)methylene)methanesulfonohydrazide (compound IB-LO-1.6). 'll NMR (300 MHz, DMSO-d6) δ ppm 11.38 (s, 1 H) 11.05 (s, 1 H) 8.34 (s, 1 H) 7.88 (s, 1 H) 7.75 (d, 1=8.09 Hz, 2 H) 7.41 - 7.66 (m, 1 H) 7.00 - 7.37 (m, 3 H) 5.63 (d, J=7.72 Hz, 1 H) 3.91 (s, 3 H) 3.27 (s, 3 H) 3.03 (s, 3 H) 1.40 (s, 9 H).

[0017871 N-(3'-tert-butyl-5'-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2'-methoxybiphenyl-4-ylcarbamoyl)methanesulfonamide (compound IB-LO-1.7). 'H NMR (300 MHz, DMSO-d6) δ ppm 1.39 (s, 9H) 2.50 (s, 3H) 3.26 (s, 3H) 5.63 (dd, 7=7.91,2.02 Hz, 1H) 7.23 (d, 2H) 7.38-7.63 (m, 5H) 7.76 (d, 7=8.09 Hz, 1H) 8.95 (s, 1H) 10.46 (s, 1H) 11.39 (d,>=2.21 Hz, 1H).

[001788] N'-(3'-tert-butyI-5'-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2'-methoxybiphenyl carbonyl) methanesulfonohydrazide (compound IB-LO-1.8). 'H NMR (300 MHz, DMSO-d^) δ ppm 1.41 (s, 9H) 3.03 (s, 3H) 3.26 (s, 3H) 5.65 (dd, 7=7.72, 1.84 Hz, 1H) 7.27-7.36 (m, 2H) 7.73 (dd, 7=28.31, 8.09 Hz, 4H) 8.01 (d, 7=8.09 Hz, 2H) 9.65 (s, 1H) 10.82 (s, 1H) 11.41 (s, 1H).

[001789] (E)-N'-(l-(3'-tert-buty 1-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2'-methoxybiphenyl-3-yl)ethylidene)methanesulfonohydrazide (compound IB-LO-1.9). 'H NMR (300 MHz, DMSO-Dg) δ ppm 11.40 (s, 1 H) 10.12 (s, 1 H) 7.82-7.99 (m, 1 H) 7.62-7.82 (m, 2 H) 7.35 - 7.71 (m, 2 H) 7.30 (s, 2 H) 5.64 (dd, J=7.91,2.02 Hz, 1 H) 3.26 (s, 3 H) 3.07 (s, 3 H) 2.27 (s, 3 H) 1.40 (s, 9 H).

[001790] (E)-N'-((3'-tert-butyl-5'-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2'-methoxy biphenyl-3-yl)methylene)methanesulfonohydrazide (compound IB-LO-1.10). H NMR (300 MHz, CDC13) δ ppm 1.44 (s, 9H) 3.19 (s, 311) 3.31 (s, 3H) 5.44 (s, 1H) 5.82 (d, 7=7.72 Hz, 1H) 7.17 (d,7=2.57 Hz, 1H) 7.24 (d, 7=2.57 Hz, 1H) 7.36 (d, 7=7.72 Hz, 1H) 7.48 (t, 7=7.72 Hz, 1H) 7.63 (d, 7=7.72 Hz, 1H) 7.70 (d, 7=7.72 Hz, 1H) 7.80 (s, 1H) 7.88 (s, 1H) 8.32 (s, 1H).

[001791] N-(2-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl)-lH-benzo[d]imidazol-5-yl)-N-(methylsulfonyl)methanesulfonamide (compound IA-L0-2.10) 'H NMR (300 MHz, DMSO-D6) δ ppm 1.45 (s, 9 H) 2.73 (t, J=6.62 Hz, 2 H) 3.48 (s, 3 H) 3.56 (s, 6 H) 3.83 (t, J=6.80 Hz, 2 H) 4.05 (s, 1 H) 7.38 (dd, J=8.46, 1.84 Hz, 1II) 7.46 (d, J=2.57 Hz, 1 H) 7.71 (d, J=8.46 Hz, 1 H) 7.76 (d, J=2.57 Hz, 1 H) 7.82 (d, J=1.84 Hz, 1 H) 10.41 (s, 1 H) 1001792] N-((6-(3-tert-butyl-2-chloro-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)phenyl)benzo [b]thiophen-3-yl)methyl)methanesulfonamide (compound IB-LO-2.35). ’H NMR (300 MHz, DMSO-d^) δ ppm 1.52 (s, 9 H) 2.95 (s, 3 H) 4.44 (d, 1=5.88 Hz, 2 H) 5.68 (d, J=8.09 Hz, 1 H) 7.40 (d, J=2.57 Hz, 1 H) 7.46 (dd, J=8.09,1.47 Hz, 1 H) 7.56 (d, J=2.57 Hz, 1 H) 7.62 (t, J=6.07 Hz, 1 H) 7.72 (s, 1 H) 7.83 (d, J=8.09 Hz, 1 H) 8.01 (m, 2 Η) 11.46 (s, 1 H).

[001793] l-(3-tert-butyl-5-(2-chlorobenzo[d]thiazol-6-yl)-4-methoxyphenyl)pyrimidine-2,4(lH,3H)-dione (compound IB-LO-2.38). 'HNMR(300 MHz, DMSO-D6) δ ppm 1.41 (s, 9 H) 3.24 (s, 3 H) 5.65 (dd, J=8.09,2.21 Hz, 1 H) 7.34 (s, 2 H) 7.73 (dd, J=8.64, 1.65 Hz, 1 H) 7.79 (d, J=8.09 Hz, 1 H) 8.07 (d, J=8.46 Hz, 1II) 8.30 (d, J=1.84 Hz, 1 H) 11.42 (d, J=1.84 Hz, 1 H) 333 2014280939 24 Dec 2014 [001794] N-(2-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2H)-yl)-2-methoxyphenyl)quinolin-6-yl)methanesulfonamide (compound IB-LO-2.48).

[001795] l-(3-tert-butyl-4-methoxy-5-(l-oxo-2,3-dihydro-lH-inden-5-yl)pheny])pyrimidine~2,4(lH,3H)-dione (compound IB-L0-2.50).

[001796] N,N'-(6,6'-(5-(2,4-dioxo-3,4-dihydropyrimidin~ 1 (2H)-yl)-2-methoxy-1,3 -phenylene) bis(naphthalene-6,2-diyl))dimethanesulfonamide (compound IB-LO-2.76). 'H NMR (300 MHz, DMSO-d6) δ ppm 3.08 (s, 6 H) 3.13 (s, 3 H) 5.72 (d, J=8.18 Hz, 1 H) 7.43 (dd, 3=8.46, 1.84 Hz, 2 H) 7.59 (s, 2 H) 7.79 (m, 4 H) 7.96 (m, 5 H) 8.14 (s, 2 H) 10.05 (s, 2 H) 11.48 (s, 1 H).

[001797] (E)-N-(4-(l-(3-tert-buty)-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl) prop-1-en-2-yl)phenyl)methanesulfonamide (compound IA-L1-1.6). H NMR (300 MHz, DMSO-d6) δ 2.14 (s, 3 H) 2.70 (t, 3=6.62 Hz, 2 H) 3.01 (s, 3 H) 3.68 (s, 3 H) 3.78 (t, 3=6.62 Hz, 2 H) 6.82 (s, 1 H) 7.10 - 7.17 (m, 2 H) 7.23 (d, 3=8.46 Hz, 2 H) 7.59 (d, 3=8.46 Hz, 2 H) 9.78 (s, 1 H) 10.32 (s, 1 H).

[001798] (Z)-N-(4-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxystyryl)phenyl) methanesulfonamide (compound IA-L1-1.10). lH NMR (300 MHz, DMSO-d6) δ 10.23 (s, 1 H) 9.74 (s, 1 H) 7.23 (d, 3=8.46 Hz, 2 H) 7.13 (d, 3=2.57 Hz, 1 H) 7.06 (d, 3=8.82 Hz, 2 H) 6.92 (d, 3=2.57 Hz, 1 H) 6.54 - 6.67 (m, 2 H) 3.78 (s, 3 H) 3.57 (t, 3=6.62 Hz, 2 H) 2.96 (s, 3 H) 2.60 (t, 3=6.80 Hz, 2 H) 1.34 (s, 9 H).

[001799] (E)-N-(4-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxystyiyl) phenyl)-N-(methylsulfonyl)acetamide (compound IA-Ll-l.il). 'H NMR (300 MHz, DMSO-de) δ 10.36 (s, 1 H) 7.77 (d, 3=8.46 Hz, 2 H) 7.56 (d, 3=2.21 Hz, 1 H) 7.39 - 7.50 (m, 3 H) 7.25 (d, 3=16.55 Hz, 1 H) 7.19 (d, 3=2.57 Hz, 1 H) 3.74 - 3.85 (m, 5 H) 3.54 (s, 3 H) 2.72 (t, 3=6.62 Hz, 2 H) 1.94 (s, 3 H) 1.38 (s, 9 H).

[001800] (E)-1 -(3-(4-aminostyryl)-5-tert-butyl-4-methoxyphenyl)dihydropyrimidine-2,4( 1 H,3H)-dione (compound IA-L1-1.13). 'H NMR (300 MHz, DMSO-d6) δ 1.36 (s, 9 H) 2.70 (t, 3=6.62 Hz, 2 H) 3.74 (s, 3 H) 3.77 (t, 3=6.62 Hz, 2 H) 5.34 (s, 1 H) 6.57 (d, 3=8.46 Hz, 2 H) 6.98 (s, 1 H) 7.07 (d, 3=2.21 Hz, 1 H) 7.17 (s, 2 H) 7.30 (d, 3=8.09 Hz, 2 H) 7.45 (d, 3=2.21 Hz, 1 H) 10.32 (s, 1 H).

[001801] (Z)-N-(4-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxystyryl)phenyl) methanesulfonamide (compound IA-L1-1.20). ’H NMR (500 MHz, DMSO-d6): δ ppm 1.37 (s, 9H), 2.71 (t, 3=6.7Hz, 2H), 3.01 (s, 3H), 3.75 (s, 3H), 3.79 (t, 3=6.6Hz, 2H), 7.13 (d, 3=16.5Hz, 1H), 7.15 (d, 3=2.4Hz, 2H), 7.23 (d, 3=8.5Hz, 2H), 7.25 (d, 3=16.5 Hz, 1H), 7.51 (d, 3=2.4Hz, 1H), 7.61 (d, 3=8.6Hz, 2H), 9.80(bs, 1H), 10.30 (s, 1H).

[001802] N-(4-(2-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl)-l-fluorovinyl)phenyl)methanesulfonamide (compound IA-L1-1.21). (racemic mixture (1:1) of compounds IA-L1-1.4 and IA-L1-1.5).

[001803] (E)-l-(3-tert-butyl-4-methoxy-5-(4-nitrostyryl)phenyl)dihydropyrimidine-2,4(lH,3H)-dione 334 2014280939 24 Dec 2014 (compound IA-L1-1.22).

[001804] l-{3-tert-butyl-5-[(Z)-2-chloro-2-(4-nitro-phenyl)-vinyl]-4-methoxy-phenyl}-dihydro-pyrimidine-2,4-dione (compound IA-L1-1.23).

[001805] l-{3-tert-butyl-4-methoxy-5-[(E)-2-(4-nitro-phenyl)-propenyl]-phenyl}-dihydro-pyrimidine-2,4-dione (compound ÏA-L1-1.24).

[001806] l-{3-tert-Butyl-5-[(E)-2-(4-nitro-phenyl)-vinyl]-phenyl}-dihydro-pyrimidine-2,4-dione (compound IA-L1-1.25). ‘ll NMR (300 MHz, DMSO-D6) δ ppm 1.33 (s, 9 H) 2.70 - 2.77 (m, 2 H) 3.84 (t, J=6.80 Hz, 2 H) 7.33 (s, 1 H) 7.49 (d, 3=4.04 Hz, 2 H) 7.56 (d, 3=5.88 Hz, 2 H) 7.89 (d, 3=8.82 Hz, 2 H) 8.25 (d, J=8.82 Hz, 2 H) 10.40 (s, 1 H) [001807] N-(4-{(E)-2-[3-tert-Butyl-5-(dioxo-tetrahydro-pyrimidm-l-yl)-2-methoxy-phenyl]-vinyl}-3-methoxy-phenyl)-methanesulfonamide (compound IA-L1-1.27). ’H NMR (300 MHz, DMSO-D6) δ ppm 10.33 (s, 1 H) 9.86 (s, 1 H) 7.64 (d, ./=8.46 Hz, 1 H) 7.45 (d, ./=2.21 Hz, 1 H) 7.26 (s, 2 H) 7.12 (d, ./=2.21 Hz, 1 H) 6.89 (s, 1 H) 6.85 (dd, ./=8.46, 1.84 Hz, 1 H) 3.84 (s, 3 H) 3.78 (t,/=6.80 Hz, 2 H) 3.74 (s, 3 H) 3.04 (s, 3 H) 2.71 (t, ./=6.62 Hz, 2 H) 1.37 (s, 9 H) [001808] N-(4-{(E)-2-[3-tert-Butyl-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-l-yl)-2-methoxy-phenyl]-vinyl}-3-formyl-phenyl)-methanesulfonamide (compound IB-L1-1.6). 'Η NMR (300 MHz, DMSO-D6) δ ppm 1.39 (s, 9 H) 3.07 (s, 3 H) 3.81 (s, 3 H) 5.66 (dd, J=7.72, 2.21 Hz, 1 H) 7.26 (d, J=2.57 Hz, 1 H) 7.30 (d, J= 16.18 Hz, 1 H) 7.51 (dd, J=8.64, 2.39 Hz, 1 H) 7.69 (d, 1=2.57 Hz, 1 H) 7.73 - 7.78 (m, 2 H) 7.97 (d, J=8.82 Hz, 1 H) 8.06 (d, J=16.18 Hz, 1 H) 10.15 (s, 1 H) 10.45 (s, 1 H) 11.43 (d, 3=2.21 Hz, 1 H) [001809] N-[4-{(E)-2-[3-tert-Butyl-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-l-yl)-2-methoxy-phenyl]-vinyl}-3-(hydroxyimino-methyl)-phenyl]-methanesulfonamide (compound IB-L1-1.8). 'H NMR (300 MHz, DMSO-d6) δ 1.38 (s, 9 H) 3.03 (s, 3 H) 3.79 (s, 3 H) 5.66 (dd, J=7.91,2.02 Hz, 1 H) 7.16 (d, J= 15.81 Hz, 1 H) 7.22 (d, J=2.57 Hz, 1 H) 7.26 (dd, J=8.64,2.39 Hz, 1 H) 7.59 (d, J=16.18 Hz, 1 H) 7.63 (d, J=2.21 Hz, 1 H) 7.73 - 7.83 (m, 3 H) 8.64 (s, 1 H) 9.96 (s, 1 Η) 11.42 (d, 3=2.21 Hz, 1 Η) 11.50 (s, 1 H).

[001810] 2-{(E)-2-[3-tert-Butyl-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-l-yl)-2-methoxy-phenyl]-vinyl}-5-methanesulfonylamino-N-(2-methoxy-ethyl)-benzamide (compound IB-L1-1.9). ‘H NMR (300 MHz, DMSO-D6) δ 1.38 (s, 9 H) 3.05 (s, 3 H) 3.20 (s, 3 H) 3.37 - 3.49 (m, 4 H) 3.78 (s, 3 H) 5.64 (d, J=7.72 Hz, 1 H) 7.15 (d, 3=2.57 Hz, 1 H) 7.20 (d, 3=2.57 Hz, 1 H) 7.24 (s, 2 H) 7.28 (dd, 3=8.46, 2.21 Hz, 1 H) 7.42 (d, 3=2.57 Hz, 1 H) 7.73 (d, 3=7.72 Hz, 1 H) 7.87 (d, 3=8.82 Hz, 1 H) 8.49 (t, 3=5.15 Hz, 1 H) 9.99 (s, 1 H) 11.42 (s, 1 H).

[001811] 2-{(E)-2-[3-tert-Butyl-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-l-yl)-2-methoxy-phenyl]-vinyl}-5-methanesulfonylamino-benzoic acid ethyl ester (compound IB-Ll-l.il). *H NMR (300 MHz, DMSO-d6) δ 1.31 (t, 3=7.17 Hz, 3 H) 1.38 (s, 9 H) 3.05 (s, 3 H) 3.79 (s, 3 H) 4.33 (q, 3=7.23 Hz, 2 H) 335 2014280939 24 Dec 2014 5.65 (dd, .1=7.72, 2.21 Hz, 1 H) 7.15 - 7.25 (m, 2 H) 7.46 (dd, J=8.64,2.39 Hz, 1 H) 7.52 (d, J=2.57 Hz, l H) 7.68 (d, J=2.57 Hz, 1 H) 7.71 -7.81 (m, 2 H) 7.90 (d, J=8,46Hz, 1 H) 10.06 (s, 1 H) 11.42 (d, J=l. 84 Hz, 1 H).

[001812] N-(4-{(E)-2-[3-tert-Butyl-2-chloro-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-l-yl)-phenyl]~ vinyl}-phenyl)-methanesulfonamide (compound IB-Ll-1,12). 'H NMR (300 MHz, DMSO-ds) δ ppm 1.49 (s, 9 H) 3.02 (s, 3 H) 5.69 (d, 1=7.72 Hz, 1 H) 7.22 (m, 3 H) 7.41 (d, 1=2.21 Hz, 1 H) 7.51 (d, 1=16.18 Hz, 1 H) 7.59 (d, J=8.82 Hz, 2 H) 7.78 (d, J=2.21 Hz, 1 H) 7.80 (d, J=8.09 Hz, 1 H) 9.90 (s, 1 H) 11.47 (s, 1 H).

[001813] 2-{(E)-2-[3-tert-Butyl-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-l-yl)-2-methoxy-phenyl]-vinyl}-5-methanesulfonylammo-N,N-dimethyl-benzamide (compound IB-L1-1.14). 'H NMR (300 MHz, DMSO-ds) δ 1.37 (s, 9 H) 2.76 (s, 3 H) 3.03 (s, 3 H) 3.05 (s, 3 H) 3.76 (s, 3 H) 5.64 (dd, 1=7.91,1.65 Hz, 1 H) 6.95 (d, 1=16.55 Hz, 1 H) 7.02 (d, 1=2.21 Hz, 1 H) 7.17 - 7.25 (m, 2 H) 7.27 (dd, 1=8.64, 2.39 Hz, 1 11)7.48 (d, 1=2.57 Hz, 1 H) 7.74 (d, 1=8.09 Hz, 1 H) 7.82 (d, 1=8.82 Hz, 1 H) 10.03 (s, 1 H) 11.39 - 11.43 (m, 1 H).

[001814] 2-{(E)-2-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-l-yI)-2-methoxy-phenyl]-vinyl}-5-methanesulfonylamino-N-methyl-benzamide (compound IB-L1-1.17). 'H NMR (300 MHz, DMSO-d6) δ 1.38 (s, 9 H) 2.77 (d, 1=4.41 Hz, 3 H) 3.06 (s, 3 H) 3.77 (s, 3 H) 5.64 (dd, 1=7.72, 1.84 Hz, 1 H) 7.16 - 7.33 (m, 5 H) 7.43 (d, 1=2.21 Hz, 1 H) 7.73 (d, 1=7.72 Hz, l H) 7.84 (d, 1=8.46 Hz, 1 H) 8.37 (q, 1=4.41 Hz, 1 H) 10.00 (s, 1 H) 11.40 (d, 1=1.84 Hz, 1 H).

[001815] 2-{(E)-2-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-l-yl)-2-methoxy-phenyl]-vinyl}-N-(l,l-dioxo-tetrahydro-llambda*6*-thiophen-3-yl)-5-methanesulfonylamino-N-methyl-benzamide (compound IB-L1-1.18). 'H NMR (300 MHz, DMSO-d6) δ 1.37 (s, 9 H) 2.17 - 2.47 (m, 2 H) 2.70 (s, 3 H) 3.06 (s, 3 H) 3.15 - 3.31 (m, 2 H) 3.36 - 3.51 (m, 2 H) 3.77 (s, 3 H) 5.37 (dt, 1=17.74, 8.96 Hz, 1 H) 5.65 (dd, 1=7.91, 2.02 Hz, 1 H) 6.93 (d, 1=16.18 Hz, 1 H) 7.05 (d, 1=2.21 Hz, 1 H) 7.19 - 7.35 (m, 3 H) 7.50 (d, 1=2.57 Hz, 1 H) 7.76 (d, 1=8.09 Hz, 1II) 7.87 (d, 1=8.82 Hz, 1 H) 10.04 (s, 1 Η) 11.38 (d, 1=2.21 Hz, 1 H).

[001816] N-(4-{(E)-2-[3-tert-butyl-5-(5-chloro-2,4-dioxo-3,4-dihydro-2H-pyrimidin-l-yI)-2-methoxy-phenyl]-vinyl}-phenyl)-methanesulfonamide (Compound IB-L1-1.20). 'll NMR (300 MHz, DMSO-D6) δ ppm 11.31 (s, 1 H) 9.77 (s, 1 H) 7.53 (d, /=8.09 Hz, 1 H) 7.23 (d, ./=8.46 Hz, 2 H) 7.17 (d, /=2.57 Hz, 1 H) 7.06 (d,/=8.82 Hz, 2 H) 7.01 (d,/=2.57 Hz, 1 H) 6.53 - 6.71 (m, 2 H) 5.56 (d,/=7.72 Hz, 1 H) 3.81 (s, 3 H) 2.96 (s, 3 Η) 1.35 (s, 9 H) [001817] 2-{(E)-2-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-l-yl)-2-methoxy-phenyl]-vinyl}-5-methanesulfonylamino-benzamide (compound IB-L1-1.21). 'll NMR (300 MHz, DMSO-d6) δ 1.38 (s, 9 H) 3.07 (s, 3 H) 3.78 (s, 3 II) 5.64 (d, 1=7.72 Hz, 1 H) 7.18 - 7.34 (m, 5 H) 7.43 (d, 1=2.21 Hz, 1 H) 336 2014280939 24 Dec 2014 7.54 (s, 1 H) 7.73 (d, 1=7.72 Hz, 1 H) 7.84 (d, J=8.46 Hz, 1 H) 7.93 (s, 1 H).

[001818] N-(3-(azetidme-l-carbonyl)-4-{(E)-2-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-l-yl)-2-methoxy-phenyl]-vinyl}-phenyl)-methanesulfonamide (compound (compound IB-L1-1.22). 'H NMR (300 MHz, DMSO-d6) δ 1.38 (s, 9 H) 3.07 (s, 3 H) 3.78 (s, 3 H) 5.64 (d, 1=7.72 Hz, 1 H) 7.18 - 7.34 (m, 5 H) 7.43 (d, 1=2.21 Hz, 1 H) 7.54 (s, 1 H) 7.73 (d, J=7.72 Hz, 1 H) 7.84 (d, .1=8.46 Hz, 1 H) 7.93 (s, l H).

[001819] 2-{(E)-2-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-l-yl)-2-methoxy-phenyl]-vinyl}-5-methanesulfonylamino-N-(2-methoxy-ethyl)-N-methyl-benzamide (compound 1B-L1-1.24). H NMR (300 MHz, DMSO-d6) δ 1.40 (s, 9 H) 2.81 (s, 3 H) 3.07 (s, 3 H) 3.23 (s, 3 H) 3.29 (t, J=5.33 Hz, 1 H) 3.39 (t, J=4.96 Hz, 1 H) 3.62 (t, J=4.78 Hz, 2 H) 3.82 (s, 3 H) 5.68 (d, J=8.09 Hz, 1 H) 6.96 - 7.07 (m, 1 H) 7.09 - 7.17 (m, 1 H) 7.23 - 7.38 (m, 3 H) 7.49 (dd, 1=16.55, 2.57 Hz, 1 H) 7.71 - 7.76 (m, 1 H) 7.83 - 7.94 (m, 1 H).

[001820] N-(4-{(E)-2-[3 -tert-butyl-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-l-yl)-2-methoxy-phenyl]-vinyl}-3-isopropoxymethyl-phenyl)-methanesulfonamide (compound IB-L1-1.25). H NMR (300 MHz, DMSO-d6) δ 1.16 (d, J=5.88 Hz, 6 H) 1.38 (s, 9 H) 3.01 (s, 3 H) 3.69 (dt, J=12.13, 6.07 Hz, 1 H) 3.79 (s, 3 H) 4.59 (s, 2 H) 5.65 (dd, J=7.91, 2.02 Hz, 1 H) 7.13 - 7.29 (m, 4 H) 7.32 - 7.40 (m, 1 H) 7.59 (d, J=2.57 Hz, 1 H) 7.75 (d, 1=8.09 Hz, 2 H) 9.86 (s, 1 H) 11.43 (d, J=1.84 Hz, 1 H).

[001821] N-[4-{(E)-2-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-l-yl)-2-methoxy-phenyl]-vinyl}-3-(pyrrolidine-l -carbonyl)-phenyl]-methanesulfonamide (compound IB-L1-1.27). 'll NMR (300 MHz, DMSO-d6) δ 1.37 (s, 9 Η) 1.73 - 1.89 (m, 4 H) 3.03 - 3.12 (m, 5 H) 3.51 (t, J=6.80 Hz, 2 H) 3.76 (s, 3 H) 5.64 (dd, 1=7.91, 2.02 Hz, 1 H) 6.99 - 7.06 (m, 1 H) 7.08 (d, J=2.21 Hz, 1 H) 7.19 - 7.31 (m, 3 H) 7.46 (d, J=2.57 Hz, 1 H) 7.75 (d, J=8.09 Hz, 1 H) 7.82 (d, 1=8.82 Hz, 1 H) 10.01 (s, 1 Η) 11.41 (d, 1=2.21 Hz, 1 H).

[001822] N-[4-{(E)-2-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-l-yl)-2-methoxy-phenyl]-vinyl}-3-(3-hydroxy-azetidin-l-ylmethyl)-phenyl]-methanesulfonamide (compound IB-L1-1.29). 'H NMR(300 MHz, DMSO-d6) δ 1.38 (s, 9 H) 2.78 - 2.85 (m, 2 H) 2.99 (s, 3 H) 3.50 - 3.58 (m, 2 H) 3.71 (s, 2 H) 3.79 (s, 3 H) 4.19 (td, J=12.41, 6.07 Hz, 1 H) 5.29 (d, 1=6.25 Hz, 1 H) 5.66 (d, 1=8.09 Hz, 1 H) 7.10 - 7.18 (m, 2 H) 7.20 (t, 1=2.21 Hz, 2 H) 7.35 - 7.42 (m, 1 H) 7.63 (d, 1=2.57 Hz, 1 H) 7.69 (d, 1=8.46 Hz, 1 H) 7.76 (d, 1=7.72 Hz, 1 H) 9.78 (s, 1 Η) 11.42 (s, 1 H).

[001823] N-(4-{(E)-2-[3-tert-Butyl-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-l-yl)-2-methoxy-phenyl]-vinyl}-3-pyrrolidin-l-ylmethyl-phenyl)-methanesulfonamide (compound IB-L1-1.33), 'HNMR (500 MHz, DMSO-d6) δ 1.40 (s, 9 H) 1.72 - 1.95 (m, 4 H) 2.84 (s, 2 H) 2.88 - 2.98 (m, 2 H) 3.01 (s, 3 H) 3.81 (s, 3 H) 3.86 - 4.23 (m, 2 H) 5.63 (d, 1=7.81 Hz, 1 H) 7.17 (d, 1=15.63 Hz, 1 H) 7.21 - 7.28 (m, 2 H) 7.32 - 7.38 (m, 1 H) 7.47 (d, J=16.11 Hz, 1 H) 7.53 - 7.59 (m, 1 H) 7.61 (d, 1=7.81 Hz, 1 H) 7.70 (d, 1=6.35 337 2014280939 24 Dec 2014

Hz, 1 H) 9.42 (s, 1 H) 10.88 (s, 1 H).

[001824] N-(4-{(Z)-2-[3-tert-Bu1yl-5-(2,4-dioxo-3,4-dihydro-2H-pyrirnidin-1 -yl)-2-methoxy-phenyl]~ vinyl}-phenyl)-methanesulfonamide (compound IB-L1-1.34 *H NMR (300 MHz, DMSO-D6) δ ppm 11.31 (s, 1 H) 9.77 (s, 1 H) 7.53 (d, /=8.09 Hz, 1 H) 7.23 (d, /=8.46 Hz, 2 H) 7.17 (d, /=2.57 Hz, 1 H) 7.06 (d, /=8.82 Hz, 2 H) 7.01 (d,/=2.57 Hz, 1 H) 6.53 - 6.71 (m, 2 H) 5.56 (d, /=7.72 Hz, 1 H) 3.81 (s, 3 H) 2.96 (s, 3 H) 1.35(s, 9 H) [001825] N-(4-((3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-1 (2H)-yl)phenyl)elhynyl)phenyl> methanesulfonamide (compound IA-L2-1.1). H NMR (300 MHz, DMSO-d6) δ ppm 1.30 (s, 9 H) 2.72 (t, 1=6.43 Hz, 2 H) 3.06 (s, 3 H) 3.82 (t, 1=6.62 Hz, 2 H) 7.24 (d, 1=8.82 Hz, 2 H) 7.33 (s, 1 H) 7.39 (d, 1=1.47 Hz, 2 H) 7.54 (d, J=8.82 Hz,2H) 10.08 (s, 1 H) 10.40(8, 1 H) [001826] N-(4-((3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)phenyl)ethynyl)-3-methyl-phenyl)methanesulfonamide (compound IA-L2-1.2). *H NMR (300 MHz, DMSO-d6) δ ppm 1.30 (s, 9 H) 2.44 (s, 3 H) 2.72 (t, 1=6.62 Hz, 2 H) 3.05 (s, 3 H) 3.82 (t, 1=6.62 Hz, 2 H) 7.07 (dd, 1=8.46, 1.47 Hz, 1 H) 7.13 (s, 1 H) 7.33 (s, 1 H) 7.39 (d, 1=1.47 Hz, 2 H) 7.48 (d, 1=8.09 Hz, 1 H) 9.98 (s, 1 H) 10.40 (s, 1 H) [001827] l-(3-tert-butyl-4-methoxy-5-(phenylethynyl)phenyl)dihydropyrimidine-2,4(lH,3H)-dione (compound IA-L2-1.4). 'll NMR (300 MHz, DMSO-d6) δ ppm 1.36 (s, 9 H) 2.70 (t, /=6.62 Hz, 2 H) 3.78 (t, /=6.43 Hz, 2 H) 4.07 (s, 3 H) 7.27 (d, /=2.57 Hz, 1 H) 7.38 (d, /=2.57 Hz, 1 H) 7.41 - 7.49 (m, 3 H) 7.55 - 7.63 (m, 2 H) 10.37 (s, 1 H).

[001828] N-(3-((3-tert-butyI-5-(2,4-dioxotetrahydropyrimidin-.l(2H)-yl)-2-methoxyphenyl) ethynyl)phenyl)methanesulfonamide (compound IA-L2-1.7). *H NMR (300 MHz, DMSO-ds) δ ppm 1.36 (s, 9 H) 2.70 (t,/=6.62 Hz, 2 H) 3.04 (s, 3 H) 3.78 (t, /=6.62 Hz, 2 H) 4.06 (s, 3 H) 7.23 - 7.35 (m, 3 H) 7.35 - 7.46 (m, 3 H) 9.94 (s, 1 H) 10.37 (s, 1 H).

[001829] N-(4-((3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl) ethynyl)-phenyl)methanesulfonamide (compound IA-L2-1.8).1H NMR (300 MHz, DMSO-d6) δ ppm 1.35 (s, 9 H) 2.70 (t, /=6.62 Hz, 2 H) 3.06 (s, 3 H) 3.77 (t, /=6.62 Hz, 2 H) 4.05 (s, 3 H) 7.25 (dd, /=5.52, 2.94 Hz, 3 H) 7.35 (d, /=2.57 Hz, 1 H) 7.55 (d,/=8.46 Hz, 2 H) 10.09 (s, 1 H) 10.37 (s, 1 H).

[001830] N-(4-((3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl) ethynyl)-2-methylphenyl)methanesulfonamide (compound IA-L2-1.10). 'll NMR (300 MHz, DMSO-d6) δ 1.35 (s, 9 H) 2.32 (s, 3 H) 2.70 (t, 1=6.62 Hz, 2 H) 3.03 (s, 3 H) 3.78 (t, 1=6.62 Hz, 2 H) 4.06 (s, 3 H) 7.26 (d, 1=2.57 Hz, 1 H) 7.32 - 7.44 (m, 3 H) 7.48 (s, 1 H) 9.23 (s, 1 H) 10.37 (s, 1 H) [001831] N-(4-((3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl) ethynyl)-3-ethylphenyl)methanesulfonamide (compound LA-L2-l.il). 'H NMR (300 MHz, DMSO-d6) δ ppm 1.15- 1.28 (m, 3 Η) 1.36 (s, 9 H)2.70 (t,/=6.62 Hz, 2 H) 2.81 (q,/=7.72 Hz, 2 H) 3.05 (s, 3 H) 3.78 (t,/=6.62 338 2014280939 24 Dec 2014

Hz, 2 H) 4.04 (s, 3 H) 7.10 (dd, ./=8.27, 2.02 Hz, 1 H) 7.14 (s, 1 H) 7.25 (d, ./=2.57 Hz, 1 H) 7.35 (d, ./=2.21 Hz, 1 H) 7.50 (d, /=8.09 Hz, 1 H) 10.01 (s, 1 H) 10.36 (s, 1 H).

[001832] N-(4-((3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl) ethynyl)-3-fluorophenyl)methanesulfonamide (compound IA-L2-1.12). 'll NMR (300 MHz, DMSO-dg) δ ppm 1.35 (s, 9 H) 2.70 (t, /=6.62 Hz, 2 H) 3.13 (s, 3 H) 3.78 (t, /=6.62 Hz, 2 H) 4.05 (s, 3 H) 6.98 - 7.20 (m, 2 H) 7.28 (d, /=2.57 Hz, 1 H) 7.36 (d,/=2.57 Hz, 1 H)7.61 (t,/=8.27 Hz, 1 H) 10.37 (s, 2 H).

[001833] N-(4-((3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-1 (2H)-yl)-2-methoxyphenyl) ethynyl)-2-fluorophenyl)methanesulfonamide (compound 1A-L2-1.13). 'H NMR (300 MHz, DMSO-d6) δ ppm 1.35 (s, 9 H) 2.70 (t, J=6.62 Hz, 2 H) 3.10 (s, 3 H) 3.78 (t, J=6.62 Hz, 2 H) 4.05 (s, 3 H) 7.28 (d, J=2.57 Hz, 1 H) 7.38 (d, J=2.57 Hz, 1 H) 7.42 - 7.61 (m, 3 H) 9.89 (s, 1 H) 10.38 (s, 1 H).

[001834] N-(4-((3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl) ethynyl)-3-chlorophenyl)methanesulfonamide (compound IA-L2-1.14). 'll NMR (300 MHz, DMSO-d6) δ ppm 1.35 (s, 9 H) 2.70 (t, J=6.62 Hz, 2 H) 3.12 (s, 3 H) 3.78 (t, J=6.80 Hz, 2 H) 4.07 (s, 3 H) 7.21 (dd, J=8.46,2.21 Hz, 1 H) 7.28 (d, J=2.57 Hz, 1 H) 7.36 (dd, J=4.60, 2.39 Hz, 2 H) 7.67 (d, J=8.46 Hz, 1 H) 10.32 (s, 1 H) 10.37 (s, 1 H).

[001835] N-(4-((3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl) ethynyl)-2-chlorophenyl)methanesulfonamide (compound IA-L2-1.15). ’H NMR (300 MHz, DMSO-d6) δ ppm 1.35 (s, 9 H) 2.70 (t, J=6,62 Hz, 2 H) 3.10 (s, 3 H) 3.78 (t, J=6.62 Hz, 2 H) 4.06 (s, 3 H) 7.29 (d, J=2.94 Hz, 1 H) 7.39 (d, J=2.57 Hz, 1 H) 7.48 - 7.59 (m, 2 H) 7.75 (s, 1 H) 9.65 (s, 1 H) 10.38 (s, 1 H) [001836] N-(4-((3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl) ethynyl)-3-methoxyphenyl)methanesulfonamide (compound IA-L2-1.16). 'll NMR (300 MHz, DMSO-d6) δ ppm 1.35 (s, 9 H) 2.63 - 2.76 (m, 2 H) 3.08 (s, 3 H) 3.77 (t, J=6.80 Hz, 2 H) 3.82 (s, 3 H) 4.08 (s, 3 H) 6.79 -6.89 (m, 1 H) 6.91 (d, J=1.84 Hz, 1 H) 7.22 (d, J=2.57 Hz, 1 H) 7.30 (d, J=2.94 Hz, 1 H) 7.45 (d, J=8.46 Hz, 1 H) 10.06 (s, 1 H) 10.35 (s, 1 H).

[001837] N-(4-((3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl) ethynyl)-2-(trifluoromethoxy)phenyl)methanesulfonamide (compound 1A-L2-1.17), 'll NMR (300 MHz, DMSO-d6) δ ppm 1.35 (s, 9 H) 2.70 (t, J=6.62 Hz, 2 H) 3.13 (s, 3 H) 3.78 (t, J=6.62 Hz, 2 H) 4.05 (s, 3 H) 7.29 (d, J=2.57 Hz, 1 H) 7.40 (d, J=2.57 Hz, 1 H) 7.52 - 7.69 (m, 3 H) 10.06 (s, 1 H) 10.38 (s, 1 H).

[001838] N-(4-((3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl) ethynyl)-2-(trifluoromethyl)phenyl)methanesulfonamide (compound IA-L2-1.19). 'll NMR (300 MHz, DMSO-d6) δ ppm 1.35 (s, 9 H) 2.72 (d, J=6.62 Hz, 2 H) 3.09 (s, 3 H) 3.78 (s, 2 H) 4.06 (s, 3 H) 7.29 (s, 1 H) 7.41 (s, 1 H) 7.57 - 7.73 (m, 1 H) 7.80 - 7.94 (m, 2 H) 9.62 (s, 1 H) 10.38 (s, 1 H).

[001839] N-(4-((3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yi)-2-methoxyphenyl) ethynyl)-2-fluoro-5-methylphenyl)methanesulfonamide (compound IA-L2-1.20). ‘H NMR (300 MHz, DMSO-D6) δ 339 2014280939 24 Dec 2014 ppm 1.36 (s, 9 H) 2.45 (s, 3 H) 2.71 (t, 1=6.43 Hz, 2 H) 3.09 (s, 3 H) 3.78 (t, J=6.62 Hz, 2 H) 4.05 (s, 3 H) 7.28 (d, 1=2.57 Hz, 1 H) 7.36 (d, J=8.09 Hz, 1 H) 7.39 (d, J=2.57 Hz, 1 H) 7.47 (d, J=11.03 Hz, 1 H) 9.80 (s, 1 H) 10.37 (s, 1 H) [001840] N-(4-((3-tert-buty]-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl) ethynyl)-3-chloro-2-fluorophenyl)methanesulfonamide (compound IA-L2-1.21). 'H NMR (300 MHz, DMSO-d6) δ ppm 1.36 (s, 9 H) 2.71 (t, J=6.43 Hz, 2 H) 3.14 (s, 3 H) 3.78 (t, 1=6.62 Hz, 2 H) 4.08 (s, 3 H) 7.31 (d, J=2.94 Hz, 1 H) 7.39 - 7.46 (m, 1 H) 7.48 (d, J=7.72 Hz, 1 H) 7.51 - 7.61 (m, 1 H) 10.15 (s, 1 H) 10.38 (s, 1 H).

[001841] N-(4-((3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl) ethynyl)-2-fluoro-5-(trifluoromethyl)pheny[)methanesulfonamide (compound IA-L2-1.22). 'H NMR (300 MHz, DMSO-D6) δ ppm 1.35 (s, 9 H) 2.71 (t, J=6.62 Hz, 2 H) 3.17 (s, 3 H) 3.78 (t, J=6.43 Hz, 2 H) 4.03 (s, 3 H) 7.32 (d, 1=2.57 Hz, 1 H) 7.37 (d, J=2.21 Hz, 1 H) 7.83 (d, 1=7.72 Hz, 1 H) 7.88 (d, 1=10.66 Hz, 1 H) 10.27 (s, 1 H) 10.38 (s, 1 H) [001842] N-(6-((3-tert-butyi-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl) ethynyl)-5-methylpyridin-3-yl)methanesulfonamide (compound IA-L2-1.24). 'H NMR (300 MHz, DMSO-dé) δ ppm 1.36 (s, 9 H) 2.71 (t, J= 6.62 Hz, 2 H) 3.13 (s, 3 H) 3.79 (t, ./=6.80 Hz, 2 H) 4.07 (s, 3 H) 7.30 (d, ./=2.57 Hz, 1 H) 7.41 (d, ./=2.57 Hz, 1 H) 7.55 (s, 1 H) 8.29 (s, 1 H) 10.24 (s, 1 H) 10.38 (s, 1 H).

[001843J N-(5-((3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl) ethynyl)-pyridin-2-yl)methanesulfonamide 2,2,2-trifluoroacetate (compound IA-L2-1.26). 'H NMR (300 MHz, DMSO-d6) δ ppm 1.35 (s, 9 H) 2.70 (t, ./=6.62 Hz, 2 H) 3.78 (t, ./=6.80 Hz, 2 H) 4.05 (s, 3 H) 7.01 (d, ./=8.82 Hz, 1 H) 7.27 (d, ./=2.57 Hz, 1 H) 7.37 (d, ./=2.57 Hz, 1 H) 7.93 (dd, ./=8.82, 2.21 Hz, 1 H) 8.50 (s, 1 H) 10.37 (s, 1 H) 10.93 (s, 1 H).

[001844] N-(4-((3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl) ethynyl)-naphthalen-l-yl)methanesulfonamide (compound IA-L2-2.1). ]H NMR (300 MHz, DMSO-d6) δ ppm 1.39 (s, 9 H) 2.73 (t, 1=6.62 Hz, 2 H) 3.08 (s, 3 H) 3.82 (t, 1=6.62 Hz, 2 H) 4.13 (s, 3 H) 7.32 (d, 1=2.57 Hz, 1 H) 7.55 (d, 1=2.57 Hz, 1 H) 7.58 (d, 1=7.72 Hz, 1 H) 7.72 (m, 2 H) 7.87 (d, 1=7.72 Hz, 1 H) 8.35 (d, 1=8.82 Hz, 1 H) 8.41 (d, 1=8.09 Hz, 1 H) 9.99 (s, 1 H) 10.39 (s, 1 H).

[001845] N-(4-((3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl) ethynyl)-3-methylphenyl)methanesulfonamide (compound IB-L2-1.1). II NMR (300 MHz, DMSO-D6) δ ppm 1.36 (s, 9 H) 2.46 (s, 3 H) 3.05 (s, 3 H) 4.09 (s, 3 H) 5.64 (d, 1=7.72 Hz, 1 H) 7.09 (dd, 1=8.27,2.02 Hz, 1 H) 7.14 (s, 1 H) 7.31 (d, 1=2.57 Hz, 1 H) 7.51 (m, 2 H) 7.73 (d, 1=7.72 Hz, 1 H) 10.00 (s, 1 Η) 11.42 (s, 1 H) [001846] N-(4-((3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2H)-yl)-2-methoxyphenyl) ethynyl)-3-chlorophenyl)methanesulfonamide (compound IB-L2-1.2) H NMR (300 MHz, DMSO-D6) δ ppm 1.36 (s, 9 H) 3.12 (s, 3 H) 4.11 (s, 3 H) 5.65 (dd, 1=7.91, 2.02 Hz, 1 H) 7.22 (dd, 1=8.46, 2.21 Hz, 1 H) 7.34 (d, 340 2014280939 24 Dec 2014 J=2.57 Hz, l H) 7,36 (d, J=2.21 Hz, 1 H) 7.50 (d, J=2.57 Hz, 1 H) 7.68 (d, 1=8.82 Hz, 1 H) 7.74 (d, 1=8.09 Hz, 1 H) 10.33 (s, 1 II) 11.42 (d, J=1.84 Hz, 1 H) [001847] N-(4-((3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)~2-methoxyphenyl) ethynyl)-2-fluoro-5-methylphenyl)methanesulfonamide (compound IB-L2-1.3). ’H NMR (300 MHz, DMSO-D6) δ ppm 1.36 (s, 9 H) 2.45 (s, 3 H) 3.09 (s, 3 H) 4.09 (s, 3 H) 5.65 (dd, 1=7.91, 2.02 Hz, 1 H) 7.36 (m, 2 H) 7.48 (d, 1=10.66 Hz, 1 H) 7.53 (d, 1=2.57 Hz, 1 H) 7.74 (d, 1=7.72 Hz, 1 H) 9.81 (s, 1 Η) 11.43 (d, 1=1.84 Hz, 1 H) [001848] N-(4-((3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl) ethynyl)- 2,6-difluorophenyl)methanesulfonamide (compound EB-L2-1.4). 'H NMR (300 MHz, DMSO-D6) δ ppm 1.36 (s, 9 H) 3.10 (s, 3 H) 4.10 (s, 3 H) 5.66 (dd, 1=7.72, 2.21 Hz, 1 H) 7.37 (d, 1=2.57 Hz, 1 H) 7.46 -7.58 (m, 3 H) 7.74 (d, 1=8.09 Hz, 1 H) 9.74 (s, 1 Η) 11.44 (d, 1=1.84 Hz, 1 H) [001849] N-(4-((3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2H)-yl)-2-methoxyphenyI) ethynyl)-2-fluoro-5-(trifluoromethyl)phenyl)methanesulfonamide (compound IB-L2-1.5). 'H NMR (300 MHz, DMSO-D6) δ ppm 1.36 (s, 9 H) 3.17 (s, 3 H) 4.07 (s, 3 H) 5.66 (dd, 1=7.91,2.02 Hz, 1 H) 7.38 (d, 1=2.57 Hz, 1 H) 7.50 (d, 1=2.57 Hz, 1 H) 7.74 (d, 1=8.09 Hz, 1 H) 7.83 (d, 1=7,72 Hz, 1 H) 7.89 (d, 1=10.66 Hz, 1 H) 10.28 (s, 1 H) 11.43 (d, 1=1.84 Hz, 1 H) [001850] N-(4-((3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl) ethynyl)-3-hydroxyphenyl)fmethanesulfonamide (compound IB-L2-1.6). Π NMR (300 MHz, DMSO-ds) δ ppm 1.36 (s, 9 II) 3.04 (s, 3 H) 4.12 (s, 3 H) 5.64 (dd, /=7.72,2.21 Hz, 1 H) 6.68 (dd, /=8.46, 2.21 Hz, 1 H) 6.88 (d,/=1.84 Hz, 1 H) 7.26 (d,/=2.57 Hz, 1 H) 7.35 (d,/=8.46 Hz, 1 H) 7.41 (d,/=2.57 Hz, 1 H) 7.73 (d, /=7.72 Hz, 1 H) 9.97 (s, 1 H) 10.30 (s, 1 Η) 11.41 (d, /=2.21 Hz, 1 H).

[001851] methyl 2-((3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl)-ethynyI)-5-(methylsulfonamido)benzoate (compound 1B-L2-1.7). 'll NMR (300 MHz, DMSO-d6) δ ppm 1.37 (s, 9 H) 3.09 (s, 3 H) 3.88 (s, 3 H) 4.11 (s, 3 H) 5.65 (dd, 1=7.72, 2.21 Hz, 1 H) 7.32 (d, 1=2.57 Hz, 1 H) 7.46 (m, 2 H) 7.74 (in, 3 H) 10.30 (s, 1 H) 11.42 (d, 1=1.84 Hz, 1 H).

[001852] N-(6-((3-tert~butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl) ethynyl)-pyridin-3-yl)methanesulfonamide (compound IB-L2-1.8). 'll NMR (300 MHz, DMSO-df) δ ppm 1.36 (s, 9 H) 3.13 (s, 3 11)4.11 (s, 3 H) 5.65 (dd, /=7.91, 2.02 Hz, 1 H) 7.35 (d, /=2.57 Hz, 1 H) 7.53 (d, /=2.57 Hz, 1 H) 7.66 (d, /=1.47 Hz, 2 H) 7.75 (d, /=7.72 Hz, 1 H) 8.45 (s, 1 H) 10.33 (s, 1 Η) 11.43 (d, /=1.84 Hz, 1 H).

[001853] N-(5-((3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl) ethynyl)-pyrazin-2-yl)methanesulfonamide (compound 1B-L2-1.9). lH NMR (300 MHz, DMSO-d6) δ ppm 1.37 (s, 9II) 3.38 (s, 3 H) 4.12 (s, 3 H) 5.65 (dd, /=8.09, 2.21 Hz, 1 H) 7.38 (d, /=2.94 Hz, 1 H) 7.55 (d, /=2.57 Hz, 1 H) 7.75 (d, /=7.72 Hz, 1 H) 8.32 (s, 1 H) 8.62 (d, /=1.47 Hz, 1 Η) 11,43 (s, 2 H). 341 2014280939 24 Dec 2014 [001854] N-(3-tert-butyl-4-((3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy-phenyl)ethynyl)phenyl)methanesulfonamide (compound IB-L2-1.10). 'tl NMR (300 MHz, DMSO-d6) δ ppm 1,37 (s, 9 H) 1,49 (s, 9 H) 3.06 (s, 3 H) 4.08 (s, 3 H) 5.64 (d, /=7.72 Hz, 1 H) 7.13 (dd, /=8.27,2.02 Hz, 1 H) 7.30 (dd, /=6.80,2.39 Hz, 2 H) 7.43 (d, /=2.57 Hz, 1 H) 7.56 (d, /=8.09 Hz, 1 H) 7.74 (d, /=8.09 Hz, 1 H) 10.01 (s, 1 H) 11.41 (s, 1 H).

[001855] N-(4-((3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl) ethynyl)-3-(morpholine-4-carbonyl)phenyl)methanesulfonamide (compound IB-L2-l.il). 'H NMR (300 MHz, DMSO-ds) δ ppm 1.36 (s, 9 H) 3.11 (s, 3 H) 3.19 (t, J=4.92 Hz, 2 H) 3.50 (t, 1=4.95 Hz, 2 H) 3.65 (m, 4 H) 4.01 (s, 3 H) 5.65 (dd, J=7.91, 2.02 Hz, 1 H) 7.13 (d, J=1.84 Hz, 1 H) 7.29 (m, 2 H) 7.42 (d, 1=2.57 Hz, 1 H) 7.62 (d, 1=8.82 Hz, 1 H) 7.75 (d, 1=8.09 Hz, 1 H) 10.28 (s, 1 Η) 11.43 (d, 1=1.56 Hz, 1 H).

[001856] N-(2-((3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl) ethynyl)-5-(methylsulfonamido)phenyl)acetamide (compound IB-L2-1.12). 'H NMR (300 MHz, DMSO-d6) δ ppm 1.36 (s, 9 H) 2.10 (s, 3 H) 3.07 (s, 3 H) 4.08 (s, 3 H) 5.66 (dd, 1=7.72, 2.21 Hz, 1 H) 7.04 (dd, 1=8.46, 2.21 Hz, 1 H) 7.31 (d, 1=2.94 Hz, 1 H) 7.53 (m, 2 H) 7.67 (s, 1 H) 7.73 (d, 1=8.09 Hz, 1 H) 9.50 (s, 1 H) 10.13 (s, 1 Η) 11.44 (d, 1=2.21 Hz, 1 H).

[001857] N-(4-((5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-3-iodo-2-methoxyphenyl)ethynyl)-3-methy!phenyi)methanesulfonamide (compound IB-L2-1.15). ’H NMR (300 MHz, DMSO-d6) δ ppm 2.46 (s, 3 H) 3.06 (s, 3 H) 3.95 (s, 3 H) 5.65 (dd, 1=8.09, 1.47 Hz, 1 H) 7.09 (dd, 1=8.46, 2.19 Hz, 1 H)7.15 (d, 1=1.84 Hz, 1 H) 7.49 (d, 1=8.46 Hz, 1 H) 7.67 (d, 1=2.57 Hz, 1 H) 7.73 (d, 1=7.72 Hz, 1 H) 7.94 (d, 1=2.57 Hz, 1 H) 10.04 (s, 1 Η) 11.47 (d, 1=1.26 Hz, 1 H).

[001858] N-(4-((3-tert-buty 1-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2Ii)-yl)-2-methoxyphenyl) ethynyl)-naphthalen-1 -yl)methanesulfonamide (compound IB-L2-2.1). !H NMR (300 MHz, DMSO-d6) δ ppm 1.40 (s, 9 H) 3.08 (s, 3 H) 4.17 (s, 3 H) 5.67 (dd, 1=7.91,2.02 Hz, 1 H) 7.37 (d, 1=2.57 Hz, 1 H) 7.58 (d, 1=7.72 Hz, 1 H) 7.71 (m, 3 H) 7.78 (d, 1=8.09 Hz, 1 H) 7.88 (d, 1=7.72 Hz, 1 H) 8.35 (d, 1=8.46 Hz, 1 H) 8.42 (d, 1=8.09 Hz, 1 H) 10.00 (s, 1 Η) 11.45 (d, 1=1.84 Hz, 1 H).

[001859] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-1 (2H)-yl)-2-hydroxy-N-methyl-N-phenyl-benzamide (compound IA-L3-1.1) ]H NMR (300 MHz, DMSO-d6) δ 1.27 (s, 9 H) 2.53 - 2.61 (m, 5 H) 3.28 (t, 1=6.80 Hz, 2 H) 6.69 (d, 1=2.57 Hz, 1 H) 7.06 (d, 1=2.57 Hz, 1 H) 7.16 - 7.25 (m, 3 H) 7.26 - 7.34 (m, 2 H) 10.22 (s, 1 H) 10.32 (s, 1 H).

[001860] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxy-N-methyl-N-(4-(methyl-sulfonamido)phenyl)benzamide (compound IA-L3-1.2). ’ll NMR (300 MHz, DMSO-d6) δ 1.28 (s, 9 H) 2.57 (t, 1=6.62 Hz, 2 H) 2.95 (s, 3 H) 3.33 - 3.45 (m, 5 H) 6.68 (d, 1=1.10 Hz, 1 H) 7.08 (d, 1=8.82 Hz, 3 H) 7.14 - 7.19 (m, 2 H) 9.76 (s, 1 H) 10.21 (s, 1 H) 10.43 (s, 1 H).

[001861] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxy-N-phenylbenzamide 342 2014280939 24 Dec 2014 (compound IA-L3-1.3). 'H NMR (300 MHz, DMSO d6) δ 1.39 (s, 9II) 2.74 (t, J=6.80 Hz, 2 H) 3.79 (t, .1=6.62 Hz, 2 H) 7.20 (t, J=7.35 Hz, 1 H) 7.35 - 7.47 (m, 3 H) 7.64 (d, J=7.35 Hz, 2 H) 7.91 (d, J=2.21 Hz, 1 H) 10.39 (s, 1 H) 10.45 (s, 1 H) 13.27 (s, 1 H).

[001862] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxy-N-(4-(N-methyl methylsulfonamido)phenyl)benzamide (compound IA-L3-1.4). H NMR (300 MHz, DMSO-d6) δ ppm 1.39 (s, 9 H) 2.74 (t, ./=6.62 Hz, 2 H) 2.96 (s, 3 H) 3.24 (s, 3 H) 3.79 (t, J=6.62 Hz, 2 H) 7.38 - 7.49 (m, 3 H) 7.69 (d, 7=8.82 Hz, 2 H) 7.90 (d, 7=2.57 Hz, 1 H) 10.39 (s, 1 H) 10.51 (s, 1 H) 13.21 (s, 1 H).

[001863] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxy-N-(3-(methylsulfcn amido) phenyl)benzamide (compound IA-L3-1.5). *H NMR (300 MHz, DMSO-df,) δ 1.39 (s, 9 H) 2.74 (t, J=6,62 Hz, 2 H) 3.02 (s, 3 H) 3.79 (t, J=6.62 Hz, 2 H) 7.03 (d, J=7.72 Hz, 1 H) 7.30 - 7.47 (m, 3 H) 7.54 - 7.62 (m, 1 H) 7.90 (d, J=2.57 Hz, 1 H) 9.86 (s, 1 H) 10.39 (s, 1 H) 10.49 (s, 1 H) 13.20 (s, 1 H).

[001864] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxy-N-(4-(2-methyl propylsulfonamido)phenyl)benzamide (compound IA-L3-1.7). ’H NMR (300 MHz, DMSO-d(l) 6 1.00 (d, J=6.62 Hz, 6 H) 1.39 (s, 9 H) 2.14 (ddd, 1=19.76, 13.14, 6.80 Hz, 1 H) 2.73 (t, 1=6.62 Hz, 2 H) 2.98 (d, 1=6.25 Hz, 2 H) 3.78 (t, 1=6.62 Hz, 2 H) 7.22 (d, 1=8.82 Hz, 2 H) 7.40 (d, 1=2.21 Hz, 1 H) 7.59 (d, 1=8.82 Hz, 2 H) 7.89 (d, 1=2.21 Hz, 1 H) 9.80 (s, 1 H) 10.39 (s, 1 H) 10.43 (s, 1 H) 13.30 (s, 1 H).

[001865] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxy-N-(4-(2,2,2-trifluoro ethylsulfonamido)phenyl)benzamide (compound IA-L3-1.9). 'H NMR (300 MHz, DMSO-ds) δ 1.39 (s, 9 H) 2.73 (t, 1=6.62 Hz, 2 H) 3.78 (t, 1=6.43 Hz, 2 H) 4.52 (q, 1=9.44 Hz, 2 H) 7.25 (d, 1=8.82 Hz, 2 H) 7.40 (d, 1=1.84 Hz, 1 H) 7.62 (d, 1=8.82 Hz, 2 H) 7.89 (d, 1=2.21 Hz, 1 H) 10.39 (s, 1 H) 10.45 (d, 1=2.57 Hz, 2 H) 13.28 (s, 1 H).

[001866] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxy-N-(4-(phenylsulfon-amido)phenyl)benzamide (compound IA-L3-1.10). 'll NMR (300 MHz, DMSO-de) δ 1.37 (s, 9 H) 2.72 (t, 1=6.62 Hz, 2 H) 3.76 (t, 1=6.62 Hz, 2 H) 7.11 (d, 1=8.82 Hz, 2 H) 7.38 (d, 1=2.21 Hz, 1 H) 7.48 (d, 1=8.82 Hz, 2 H) 7.52 - 7.64 (m, 3 H) 7.76 (d, 1=6.62 Hz, 2 H) 7.83 (d, 1=2.21 Hz, 1 H) 10.29 (s, 1 H) 10.37 (d, 1=1.84 Hz, 2 H) 13.21 (s, 1 H).

[001867] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxy-N-(3-(methylsulfon-amidomethyl)phenyl)benzamide (compound IA-L3-l.il). 'll NMR (300 MHz, DMSO-de) δ 1.39 (s, 9 H) 2.74 (t, 1=6.62 Hz, 2 H) 2.89 (s, 3 H) 3.79 (t, 1=6.62 Hz, 2 H) 4.18 (d, 1=6.62 Hz, 2 H) 7,18 (d, 1=7.72 Hz, 1 H) 7.35 - 7.43 (m, 2 H) 7.57 - 7.66 (m, 3 H) 7.93 (d, 1=2.21 Hz, 1 H) 10.39 (s, 1 H) 10.49 (s, 1 H) 13.27 (s, 1 H).

[001868] 3 -tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxy-N-(4-(phenylmethyl-sulfonamido)phenyl)benzamide (compound IA-L3-1.12). 'll NMR (300 MHz, DMSO-d6) δ 1.39 (s, 9 H) 2.74 (t, 1=6.80 Hz, 2 H) 3.79 (t, 1=6.62 Hz, 2 H) 4.47 (s, 2 H) 7.22 (d, 1=8.82 Hz, 2 H) 7.26 - 7.33 (m, 2 343 2014280939 24 Dec 2014 Η) 7.34 - 7.44 (m, 4 Η) 7.60 (d, J=8.82 Hz, 2 H) 7.90 (d, J=1.10IIz, 1 H) 9.87 (s, 1 H) 10.39 (s, 1 H) 10.44 (s, 1H) 13.32 (s, 1 H).

[001869] 3 -tert-butyl-N-(4-(3,5 -dimethy lisoxazole-4-sulfonamido)phenyl)-5 -(2,4-d ioxotetrahydro-pyrimidin-l(2H)-yl)-2-hydroxybenzamide (compound IA-L3-1.13), 'HNMR (300 MHz, DMSO-d6) δ 1.38 (s, 9 H) 2.22 (s, 3 H) 2.44 (s, 3 H) 2.73 (t, J=6.62 Hz, 2 H) 3.77 (t, J=6.43 Hz, 2 H) 7.13 (d, J=8.82 Hz, 2 H) 7.40 (d, J=2.21 Hz, 1 H) 7.59 (d, J=8.82 Hz, 2 H) 7.87 (d, J 1.84 Hz, 1 H) 10.38 (s, 1 H) 10.40 (s, 1H) 10.45 (s, 1 H) 13.19 (s, 1 H).

[001870] 3-tert-butyl-5-(2,4-dioxotetrahydrapyrimidin-l(2H)-yl)-2-hydroxy-N-(4-(2-morpholino ethylsulfonamido)phenyl)benzamide (compound IA-L3-1.14). 'H NMR (300 MHz, DMSO-d6) δ 1.39 (s, 9 H) 2.25 - 2.37 (m, 4 H) 2.63 - 2.81 (m, 4 H) 3.20 - 3.29 (m, 2 H) 3.44 - 3.53 (m, 4 H) 3.78 (t, J=6.80 Hz, 2 H) 7.25 (d, J=8.82 Hz, 2 H) 7.40 (d, J=2.21 Hz, 1 H) 7.59 (d, J=9.19 Hz, 2 H) 7.89 (d, J=2.57 Hz, 1 H) 9.83 (s, 1 H) 10.39 (s, 1 H) 10.44 (s, 1 H) 13.30 (s, 1 H).

[001871] 2-(4-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxybenzamido) phenyl-acetic acid (compound IA-L3-1.15). !H NMR(300 MHz, DMSO-d6) δ 1.39 (s, 9 H) 2.73 (t, .1-6.62 Hz, 2 H) 3.57 (s, 2 H) 3.78 (t, J=6.80 Hz, 2 H) 7.28 (d, J=8.46 Hz, 2 H) 7.39 (d, J=0.74 Hz, 1 H) 7.58 (d, J=8.46 Hz, 2 H) 7.90 (s, 1 H) 10.38 (s, 1 H) 10.44 (s, 1 H) 12.34 (s, 1 H) 13.31 (s, 1 H).

[001872] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxy-N-(4-(N-methyl sulfamoylmethyl)phenyl)benzamide (compound IA-L3-1.16). 'H NMR (300 MHz, DMSO-d6) δ 2.50 (s, 9 H) 2.58 (d, J=5.15 Hz, 3 H) 2.74 (t, J-6.80 Hz, 2 H) 3.79 (t, 3=6.62 Hz, 2 H) 4.33 (s, 2 H) 6.95 (q, J=4,78 Hz, 1 H) 7.36 - 7.44 (m, 3 H) 7.66 (d, J=8.82 Hz, 2 H) 7.91 (d, J=2.21 Hz, 1 H) 10.39 (s, 1 H) 10.49 (s, 1 H) 13.25 (s, 1 H).

[001873] 3-tert-butyl-N-(4-(cyanomcthoxy)phenyl)-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxybenzamide (compound IA-L3-1.17). ]H NMR (300 MHz, DMSO-D6) δ ppm 1.39 (s, 9 H) 2.73 (t, J=6.62 Hz, 2 H) 3.79 (t, J=6,80 Hz, 2 H) 5.18 (s, 2 H) 7.08 (m, 2 H) 7.40 (d, J=2.57 Hz, 1 H) 7.60 (m, 2 H) 7.89 (d, J=2.21 Hz, 1 H) 10.39 (s, l H) 10.44 (s, 1 H) 13.33 (s, 1 H) J001874] N-(4-(2-amino-2-oxoethoxy)phenyl)-3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxybenzamide (compound IA-L3-1.18). Ή NMR (300 MHz, DMSO-D6) δ ppm 1.39 (s, 9 H) 2.73 (t, J=6.62 Hz, 2 H) 3.78 (t, J=6.80 Hz, 2 H) 4.43 (s, 2 H) 6.97 (m, 2 H) 7.40 (m, 2 H) 7.53 (m, 3 H) 7.89 (d, J=2.21 Hz, 1 H) 10.40 (m, 2 H) 13.41 (s, 1 H) [001875] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxy-N-(2-(methyl sulfonyl)phenyl)benzamide (compound IA-L3-1.20). 'H NMR (300 MHz, DMSO-d6) δ 1.39 (s, 9 H) 2.74 (t, 3=6.62 Hz, 2 H) 3.27 (s, 3 H) 3.78 (t, J=6.62 Hz, 2 H) 7.45 (d, J-1.47 Hz, 1 H) 7.57 - 7.66 (m, 1 H) 7.77 (d, J=1.84 Hz, 1 H) 7.81 - 7.89 (m, 2 H) 8.02 (d, J=7.72 Hz, 1 H) 10.40 (s, 1 H) 10.64 (s, 1 H) 12.99 (s, 1 H). 344 2014280939 24 Dec 2014 f001876] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxy-N-(4-(methyl sulfonyl)phenyl)benzamide (compound IA-L3-1.21). !H NMR (300 MHz, DMSO-d6) δ 1.40 (s, 9 H) 2.74 (t, 1=6.62 Hz, 2 H) 3.22 (s, 3 H) 3.79 (t, 1=6.80 Hz, 2 H) 7.44 (d, J=2.21 Hz, 1 H) 7.92 (d, 1=2.21 Hz, 1 H) 7.96 (s, 4 H) 10.41 (s, 1 H) 10.75 (s, 1 H) 12.89 (s, 1 H).

[001877] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxy-N-(2-sulfamoyl phenyl)benzamide (compound IA-L3-1.22). 'H NMR (300 MHz, DMSO-d6) δ 1.40 (s, 9 H) 2.74 (t, 1=6.62 Hz, 2 H) 3.78 (t, 1=6.62 Hz, 2 H) 7.39 - 7.49 (m, 2 H) 7.61 - 7.74 (m, 4 H) 7.93 (d, 1=8.09 Hz, 1 H) 8.01 (d, 1=8.09 Hz, 1 H) 10.39 (s, 1 H) 10.42 (s, 1 II) 12.93 (s, 1 Ii).

[001878] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy-N-phenylbenzamide (compound IA-L3-1.24). 'll NMR (300 MHz, DMSO-d6) δ 1.37 (s, 9 H) 2.71 (t, 1=6.80 Hz, 2 H) 3.70 -3.86 (m, 5 H) 7.10 (t, 1=7.35 Hz, 1 H) 7.24 - 7.44 (m, 4 H) 7.73 (d, 1=7.35 Hz, 2 H) 10.36 (s, 1 H) 10.39 (s, 1 H).

[001879] 3-tert-butyl-N-[4-(methanesulfonyl-methyl-amino)-pheny]]-2-methoxy-5-(3-methyl-2,4-dioxo-tetrahydro-pyrimidin-l-yl)-benzamide (compound IA-L3-1.25). 'H NMR (300 MHz, DMSO-D6) δ ppm 1.37 (s, 9 H) 2.84 (t, 1=6.80 Hz, 2 H) 2.94 (s, 3 H) 3.04 (s, 3 H) 3.22 (s, 3 H) 3.71 - 3.81 (m, 5 H) 7.30 (d, 1=2.57 Hz, 1 H) 7.35 (d, 1=2.57 Hz, 1 H) 7.39 (d, 1=8.82 Hz, 2 H) 7.75 (d, 1=8.82 Hz, 2 H) 10.51 (s, 1 H) [001880] 3-tert-butyl-2-methoxy-5-(3-methyl-2,4-dioxotetrahydropyrimidin-l(2H)-yl)-N-(4-(N-methylmethylsuIfonamido)phenyl)benzamide (compound IA-L3-1.26). 'H NMR (300 MHz, DMSO-d6) δ 1.37 (s, 9 H) 2.84 (t, 1=6.80 Hz, 2 H) 2.94 (s, 3 H) 3.04 (s, 3 H) 3.22 (s, 3 H) 3.71 - 3.81 (m, 5 H) 7.30 (d, 1=2.57 Hz, 1 H) 7.35 (d, 1=2.57 Hz, 1 H) 7.39 (d, 1=8.82 Hz, 2 H) 7.75 (d, 1=8.82 Hz, 2 H) 10.51 (s, 1 H).

[001881] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-N-(2-ethylphenyl)-2-methoxy benzamide (compound IA-L3-1.28).

[001882] 2-(4-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxybenzamido) phenyl)-acetic acid (compound IA-L3-1.30). 'H NMR (300 MHz, DMSQ-d6) δ 1.37 (s, 9 H) 2.71 (t, 1=6.62 Hz, 2 H) 3.53 (s, 2 H) 3.73 - 3.82 (m, 5 H) 7.23 (d, 1=8.46 Hz, 2 H) 7.28 (d, 1=2.57 Hz, 1 H) 7.33 (d, 1 H) 7.66 (d, 1=8.46 Hz, 2 II) 10.35 (s, 1 II) 10.37 (s, 1 H) 12.29 (s, 1 H).

[001883] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy-N-(4-(N-methyl sulfamoyl methyl)phenyl)benzamide (compound IA-L3-1.31). 'HNMR (300 MHz, DMSO-d6) δ 1.37 (s, 9 H) 2.58 (d, 1=4.78 Hz, 3 H) 2.71 (t, 1=6.62 Hz, 2 H) 3.72 - 3.84 (m, 5 H) 4.29 (s, 2 H) 6.89 (q, 1=4.78 Hz, 1 H) 7.29 (d, 1=2.57 Hz, 1 H) 7.31 - 7.40 (m, 3 H) 7.72 (d, 1=8.46 Hz, 2 H) 10.36 (s, 1 H) 10.46 (s, 1 H). [001884J 3-tert-butyl-5-(2,4-dioxo-tetrahydro-pyrimidin-l-yl)-2-methoxy-N-(4-trifluoromethyl-phenyl)-benzamide (compound IA-L3-1.32).

[001885] 3 -tert-butyl-5-(2,4-dioxotetrahydropyrimidin-1 (2H)-yl)-N-(4-hydroxyphenyl)-2-methoxybenzamide (compound IA-L3-1.33). lH NMR (300 MHz, DMSO-d6) δ ppm 1.37 (s, 9 H) 2.71 (t, 345 2014280939 24 Dec 2014 J=6.62 Hz, 2 H) 3.76 (s, 3 H) 3.76 - 3.82 (m, 2 H) 6.73 (d, J=8.82 Hz, 2 H) 7.25 (d, J=2.57 Hz, 1 H) 7.31 (d, J=2.57 Hz, 1 H) 7.50 (d, J=9.19 Hz, 2 II) 9.25 (s, 1 H) 10.11 (s, 1 H) 10.35 (s, 1 H).

[001886] 3-tert-butyl-5-(2,4-dioxo-tetrahydro-pyrimidin-l-yl)-2-methoxy-N-(2-methoxy-phenyl)-benzamide (compound IA-L3-1.34).

[001887] 3-tert-butyl-5-(2,4-dioxo-tetrahydro-pyrimidin-l-yl)-2-methoxy-N-(3-methoxy-phenyl)-benzamide (compound IA-L3-1.35).

[001888] 3-tert-butyl-5-(2,4-dioxo-tetrahydro-pyrimidin-l-yl)-2-methoxy-N-(4-methoxy-phenyl)-benzamide (compound IA-L3-1.36).

[001889] 3-lert-butyl-5-(2,4-dioxo-tetrahydro-pyrimidin-1 -yl)-N-(2-ethoxy-phenyl)-2-methoxy-benzamide (compound IA-L3-1.37).

[001890] 3-tert-butyl-N-(4-(cyanomethoxy)phenyl)-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxybenzamide (compound IA-L3-1.38). ’H NMR (300 MHz, DMSO-D6) δ ppm 1.37 (s, 9 H) 2.71 (t, J=6.62 Hz, 2 H) 3.76 (m, 5 H) 5.15 (s, 2 H) 7.07 (m, 2 H) 7.29 (d, J=2.94 Hz, 1 H) 7.33 (d, J=2.57 Hz, 1 H) 7.69 (m, 2 H) 10.35 (m, 2 H) [001891] N-(4-(2-amino-2-oxoethoxy)phenyi)-3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxybenzamide (compound IA-L3-1.39). Ή NMR (300 MHz, DMSO-D6) δ ppm 1.37 (s, 9 H) 2.71 (t, J=6.80 Hz, 2 H) 3.78 (m, 5 H) 4.40 (s, 2 H) 6.95 (m, 2II) 7.27 (d, J=2.57 Hz, 1 H) 7.32 (d, J=2.57 Hz, 1 H) 7.39 (s, l H) 7.51 (s, 1 H) 7.64 (m, 2 H) 10.26 (s, 1 H) 10.35 (s, 1 H) [001892] 3-tert-butyl-5-(2,4-dioxo-tetrahydro-pyrimidin-1 -yl)-2-methoxy-N-(4-trifluoromethoxy-pheny 1)-benzamide (compound IA-L3-1.40).

[001893] 4-(3-iert~butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxybenzamido)phenyl methanesulfonate (compound IA-L3-1.41). ‘H NMR (300 MHz, DMSO-d6) δ 1.37 (s, 9 H) 2.72 (t, J=6.62 Hz, 2 H) 3.43 (s, 3 H) 3.73 - 3.83 (m, 5 H) 7.30 (d, J=2.94 Hz, 1 H) 7.33 - 7.39 (m, 3 H) 7.82 (d, J=8.82 Hz, 2 H) 10.36 (s, 1 H) 10.58 (s, 1 H).

[001894] N-(4-acetylphenyl)-3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxybenzamide (compound IA-L3-1.42). 'H NMR (300 MHz, DMSO d6) δ ppm 1.38 (s, 9 H) 2.71 (t, J=6.62 Hz, 2 H) 3.75 (s, 3 II) 3.78 (t, 1=6,62 Hz, 2 H) 6.02 (s, 1 H) 6.55 (d, J=8.82 Hz, 1 H) 7.34 (dd, .1=11.77, 2.57 Hz, 2 H) 7.66 (d, 1=8.82 Hz, 1 H) 7.83 - 7.92 (m, 2 H) 7.92 - 8.04 (m, 2 H) 10.37 (s, 1 H) 10.75 (s, 1H).

[001895] ethyl 3-(4-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxybenzamido) phenyl)-3-oxopropanoate (compound IA-L3-1.43). *HNMR (300 MHz, DMSO d6) δ ppm 1.19 (t, J=7.17 Hz, 3 H) 1.38 (s, 9 H) 2.71 (t, J=6.62 Hz, 2 H) 3.61 - 3.83 (m, 5 II) 4.06 - 4.20 (m, 4 H) 7.35 (dd, J=12.13, 2.57 Hz, 2 H) 7.84-7.91 (m, 2 H) 7.96 - 8.06 (m, 2 H) 10.37 (s, 1 H) 10.80 (s, 1 H).

[001896] 3-tert-butyl-N-(3-carbamoyl-phenyl)-5-(2,4-dioxo-tetrahydro-pyrimidin-l-yl)-2-methoxy-346 2014280939 24 Dec 2014 benzamide (compound IA-L3-1.44).

[001897] 3-tert-butyl-5-(2,4-dioxo-tetrahydro-pyrimidin-1 -yl)-N-(4-fluoro-phenyl)-2-methoxy-benzamide (compound IA-L3-1.45).

[001898] 3-tert-butyl-N-(4-chloro-phenyI)-5-(2,4-dioxo-tetrahydro-pyrimidin-l-yl)-2-methoxy-benzamide (compound IA-L3-1.46).

[001899] N-(4-acetamidophenyl)-3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy-benzamide (compound IA-L3-1.47). 'HNMR (300 MHz, DMSO d6) δ 10.35 (s, 1 H), 10.31 (s, 1 H), 9.91 (s, 1 H), 7.59 - 7.72 (m, 2 H), 7.41 - 7.59 (m, 2 H), 7.33 (d, J=2.57 Hz, 1 H), 7.28 (d, J=2.94 Hz, 1 H). 3.58 - 3.93 (m, 5 H), 2.71 (t, J=6.62 Hz, 2 H), 2.03 (s, 3 H), 1.37 (s, 9 H).

[001900] 2-(4-(3-tert-butyl-5-(2,4-dioxotetrahydropyrirnidin-l(2H)-yl)-2-methoxybenzamido) phenyl-amino)-2-oxoethyl acetate (compound IA-L3-1.48). 'll NMR (300 MHz, DMSO d6) δ 10.35 (s, 2 H), 10.06 (s, 1 H), 7.64 - 7.76 (m, 2 H), 7.54 (d, J=9.19 Hz, 1 H), 7.33 (d, J=2.57 Hz, 1 H), 7.28 (d, 1=2.94 Hz, 1 H), 4.63 (s, 2 H), 3.60 - 3.90 (m, 5 H), 2.71 (t, J=6.62 Hz, 2 H), 2.12 (s, 3 H), 1.39 (s, 9 H).

[001901] Methyl 4-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l (2H)-yl)-2-methoxybenzamido) phenylcarbamate (compound IA-L3-1.49). 'H NMR (300 MHz, DMSO d6) δ 10.35 (s, 1 H), 10.28 (s, 1 H), 9.59 (s, 1 H), 7.62 (d, J=9.19 Hz, 2 H), 7.41 (d, J=8.82 Hz, 2 H), 7.32 (d, 1=2.94 Hz, 1 H), 7.27 (d, J=2.57 Hz, 1 H), 3.69 - 3.88 (m, 5 H), 3.66 (s, 3 H),2.71 (t, 1=6.80 Hz, 2 H), 1.37 (s, 9 H).

[001902] Tert-butyl 4-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxybenzamido)-phenylcarbarnate (compound IA-L3-1.50). 'll NMR (300 MHz, DMSO d6) δ 1.37 (s, 9 H) 1.47 (s, 9 H) 2.71 (t, 1=6.62 Hz, 2 H) 3.71 - 3.84 (m, 5 H) 7.27 (d, 1=2.57 Hz, 1 H) 7.32 (d, 1=2.94 Hz, 1 H) 7.40 (d, 1=8.82 Hz, 2 H) 7.59 (d, J=8.82 Hz, 2 H) 9.29 (s, 1II) 10.25 (s, 1 H) 10.35 (s, 1 H).

[001903] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy-N-(4-(2-methylpropyl-sulfonamido)phenyl)benzamide (compound IA-L3-1.52), 'H NMR (300 MHz, DMSO d6) δ 0.99 (d, 1=6.62 Hz, 6 11) 1.37 (s, 9 H) 2.03 - 2.25 (m, 1 H) 2.71 (t, 1=6.80 Hz, 2 H) 2.94 (d, 1=6.25 Hz, 2 H) 3.69 -3.84 (m, 5 H) 7.18 (d, 1=8.82 Hz, 2 H) 7.28 (d, 1=2.57 Hz, 1 H) 7.33 (d, 1=2.57 Hz, 1 H) 7.67 (d, 1=8.82 Hz, 2 H) 9.66 (s, 1 H) 10.36 (s, 1 H) 10.37 (s, 1 H).

[001904] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-N-(4-(2-hydroxyethylsulfonamido) phenyl)-2-methoxybenzamide (compound IA-L3-1.53). 'H NMR (300 MHz, DMSO-D6) δ 1.37 (s, 9 H) 2.71 (t, 1=6.80 Hz, 2 H) 3.19 (t, 1=6.80 Hz, 2 H) 3.69 - 3.86 (m, 7 H) 4.93 (t, 1=5.70 Hz, 1 H) 7.20 (d, 1=8.82 Hz, 2 H) 7.28 (d, 1=2.94 Hz, 1 H) 7.33 (d, 1=2.57 Hz, 1 H) 7.68 (d, 1=8.82 Hz, 2 H) 9.60 (s, 1 H) 10.36 (s, 1 H) 10.38 (s, 1 H) [001905] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)~2-methoxy-N-(4-(2-methoxyethyl sulfonamido)phenyl)benzamide (compound IA-L3-1.54). 'H NMR (300 MHz, DMSO d6) δ 1.37 (s, 9 H) 2.71 (t, 1=6.62 Hz, 2 H) 3.21 (s, 3 H) 3.25 - 3.31 (m, 2 H) 3.66 (t, 1=6.07 Hz, 2 H) 3.71 - 3.83 (m, 5 H) 347 2014280939 24 Dec 2014 7.19 (d, J=8.82 Hz, 2 H) 7.28 (d, J=2.57 Hz, 1 H) 7.33 (d, J=2.57 Hz, 1 H) 7.67 (d, J=8.82 Hz, 2 H) 9.67 (s, 1 H) 10.35 (s, 1 H) 10.37 (s, 1 H).

[001906] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy-N-(4-(2,2,2-trifluoro-ethyIsulfonamido)phenyl)benzamide (compound IA-L3-1.55). 'H NMR (300 MHz, DMSO d6) δ 1.37 (s, 9 H) 2.71 (t, J=6.62 Hz, 2 H) 3.71 - 3.85 (m, 5 H) 4.46 (q, J=9.93 Hz, 2 H) 7.20 (d, J=8.82 Hz, 2 H) 7.28 (d, J=2.57 Hz, 1 H) 7.33 (d, J=2.57 Hz, 1 H) 7.70 (d, J=8.82 Hz, 2 H) 10.32 (s, 1 Η) 10.36 (s, 1 H) 10.41 (s, 1 H).

[001907] N-(4-(2-(bis(2-hydroxyethyl)amino)ethylsulfonamido)phenyi)-3-tert-butyl-5-(2,4-dioxo-tetrahydropyrimidin-l(2H)-yl)~2-methoxybenzamide (compound IA-L3-1.56). ‘HNMR (300 MHz, DMSO d6) δ 1.37 (s, 9 H) 2.44 - 2.49 (m, 2 H) 2.71 (t, J=6.62 Hz, 2 H) 2.90 - 2.96 (m, 2 H) 3.18 (dd, J=9.01, 5.70 Hz, 2 H) 3.35 - 3.41 (m, 4 H) 3.73 - 3.81 (m, 5 H) 4.41 (s, 2 H) 7.20 (d, J=8.82 Hz, 2 H) 7.28 (d, J=2.57 Hz, 1 H) 7.33 (d, J=2.57 Hz, 1 H) 7.68 (d, J=9.19 Hz, 2 H) 9.65 (s, 1 H) 10.35 (s, 1 H) 10.38 (s, 1 H). 1001908] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy-N-(4-(phenylmethyl-sulfonamido)phenyl)benzamide (compound IA-L3-1.57). 'H NMR (300 MHz, DMSO-d6) δ 1.38 (s, 9 H) 2.72 (t, J=6.62 Hz, 2 H) 3.72 - 3.84 (m, 5 H) 4.43 (s, 2 H) 7.18 (d, J=8.82 Hz, 2 H) 7.25 - 7.41 (m, 7 H) 7.68 (d, J=8.82 Hz, 2 H) 9.75 (s, 1 H) 10.36 (s, 1 H) 10.38 (s, 1 H).

[001909] 3 -tert-buty 1-5 -(2,4-dioxotetrahydropyrimidin-1 (2H)-yl)-2-methoxy-N-(4-(2-morphol inoethy 1 sulfonamido)phenyl)benzamide (compound IA-L3-1.58). *H NMR (300 MHz, DMSO-d6) δ 1.37 (s, 9 H) 2.28 - 2.35 (m, 4 H) 2.63 - 2.75 (m, 4 H) 3.20 - 3.28 (m, 2 H) 3.46 - 3.54 (m, 4 H) 3.72 - 3.82 (m, 5 H) 7.20 (d, J=8.82 Hz, 2 H) 7.28 (d, J=2.57 Hz, 1 H) 7.33 (d, J=2.57 Hz, 1 H) 7.68 (d, J=8.82 Hz, 2 H) 9.70 (s, 1 H) 10.35 (s, 1 H) 10.37 (s, 1 IT).

[001910] 3-tert-butyl-N-[4-(3,5-dimethyl-isoxazole-4-sulfonylamino)-phenyl]-5-(2,4-dioxo-tetrahydro-pyrimidin-l-yl)-2-methoxy-benzamide (compound IA-L3-1.59). ’H NMR (300 MHz, DMSO-D6) δ ppm 1.38 (s, 9 H) 2.22 (s, 3 H) 2.44 (s, 3 H) 2.73 (t, J=6.62 Hz, 2 H) 3.77 (t, J=6.43 Hz, 2 H) 7.13 (d, J=8.82 Hz, 2 H) 7.40 (d, J=2.21 Hz, 1 H) 7.59 (d, J=8.82 Hz, 2 H) 7.87 (d, 1=1.84 Hz, 1 H) 10.38 (s, 1 H) 10.40 (s,lH) 10.45 (s, 1H) 13.19 (s, 1 H) 1001911] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy-N-(4-(plienylsulfonainido) phenyl)benzamide (compound IA-L3-1.60). 'll NMR (300 MHz, DMSO-d6) δ 1.35 (s, 9 H) 2.70 (t, J=6.62 Hz, 2 H) 3.71 (s, 3 H) 3.75 (t, J=6.62 Hz, 2 H) 7.05 (d, J=8.82 Hz, 2 H) 7.24 (d, J=2.57 Hz, 1 H) 7.31 (d, J=2.57 Hz, 1 H) 7.51 - 7.64 (m, 5 H) 7.70 - 7.80 (m, 2 H) 10.17 (s, 1 H) 10.31 (s, 1 H) 10.34 (s, 1 H). 1001912] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-1 (2H)-yl)-2-methoxy-N-(4-(N-methylmethyl sulfonamido)phenyl)benzamide (compound IA-L3-1.62). 'H NMR (300 MHz, DMSO-d6) δ ppm 1.37 (s, 348 2014280939 24 Dec 2014 9 Η) 2.71 (t, /= 6.62 Hz, 2 H) 2.94 (s, 3 H) 3.22 (s, 3 H) 3.73 - 3.84 (m, 5 H) 7.29 (d,/=2.57 Hz, 1 H) 7.34 (d, /=2.57 Hz, 1 H) 7.40 (d, ^8,82 Hz, 2 H) 7.75 (d, /=8.82 Hz, 2 H) 10.36 (s, 1 H) 10.50 (s, 1 H).

[001913] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-N-(4-(N-ethylmethylsulfonamido) phenyl)-2-methoxybenzamide (compound IA-L3-1.63). 1H NMR (300 MHz, DMSO d6) δ ppm 1.01 (t, J=6.99 Hz, 3 H) 1.38 (s, 9 H) 2.72 (t, J=6.62 Hz, 2 H) 2.97 (s, 3 H) 3.64 (d, J=7.35 Hz, 2 H) 3.74 - 3.83 (m, 5 H) 7.22 - 7.48 (m, 4 H) 7.77 (d, 1=8.82 Hz, 2 H) 10.36 (s, 1 H) 10.53 (s, 1 H).

[001914] (N-(4-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxybenzamido)phenyl) methylsulfonamido)methyl pivalate (compound IA-L3-1.65). *H NMR (300 MHz, DMSO-D6) δ ppm 1.19 (s, 9 Η) 1.38 (s, 9 H) 2.71 (t, J=6.62 Hz, 2 H) 3.17 (s, 3 H) 3.74 - 3.82 (m, 5 H) 5.56 (s, 2 H) 7.30 (d, J=2.57 Hz, 1 H) 7.35 (d, 1=2.57 Hz, 1 H) 7.41 (d, J=8.82 Hz, 2 H) 7.80 (d, J=8.82 Hz, 2 H) 10.36 (s, 1 H) 10.58 (s, 1H) [001915] 3 -tert-butyl-N-(4-(N-(cyclopropylmethyl)methylsulfonamido)phenyl)-5-(2,4-dioxotetrahydro pyrimidin-l(2H)-yl)-2-methoxybenzamide(compound IA-L3-1.66). lH NMR (300 MHz, DMSO-d6) δ ppm 0.09 (d, /=4.78 Hz, 2 H) 0.40 (d, /=7.72 Hz, 2 H) 0.84 (d, 1 H) 1.38 (s, 9 H) 2.72 (t, /=6.43 Hz, 2 H) 2.97 (s, 3 H) 3.47 (d, /=6.62 Hz, 2 H) 3.68 - 3.88 (m, 5 H) 7.19 - 7.54 (m, 4 H) 7.77 (d, /=8.82 Hz, 2 H) 10.36 (s, 1 H) 10.53 (s, 1 H).

[001916] 34ert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy-N-(4-(N-(4-methoxy-benzyl)methylsulfonamido)phenyl)benzamide (compound IA-L3-1.67). 'H NMR (300 MHz, DMSO-d6) δ ppm 1.36 (s, 9 H) 2.64 - 2.79 (m, 2 H) 3.06 (s, 3 H) 3.69 (s, 3 H) 3.76 (s, 3 H) 3.75 - 3.83 (m, 2 H) 4.75 (s, 2 H) 6.83 (d, J=8.46 Hz, 2 H) 7.16 (d, J=8.46 Hz, 2 H) 7.24 - 7.39 (m, 4 H) 7.65 (d, 1=8.82 Hz, 2 H) 10.35 (s, 1 H) 10.45 (s, 1 H).

[001917] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy-N-(4-(N-(methylsulfonyl) propionamido)phenyl)benzamide (compound ÏA-L3-1.70). 'H NMR (300 MHz, DMSO-D6) δ ppm 0.93 (t, 1=7.35 Hz, 3 H) 1.38 (s, 9 H) 2.12 (q, J=7.35 Hz, 2 H) 2.72 (t, J=6.62 Hz, 2 H) 3.52 (s, 3 H) 3.78 (m, 5 H) 7.31 (d, J=2.57 Hz, 1 H) 7.36 (d, 1=2.57 Hz, 1 H) 7.44 (d, J=8.46 Hz, 2 H) 7.83 (d, J=8.82 Hz, 2 H) 10.37 (s, 1 H) 10.64 (s, 1 H) [001918] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy-N-(4-(N-(methylsulfonyl) butyramido)phenyl)benzamide (compound IA-L3-1.71). 'H NMR (300 MHz, DMSO-D6) δ ppm 0.79 (t, 1=7.35 Hz, 3 H) 1.38 (s, 9 H) 1.48 (m, 2 H) 2.09 (t, J=7.17 Hz, 2 H) 2.72 (t, J=6.62 Hz, 2 H) 3.52 (s, 3 H) 3.78 (m, 5 H) 7.32 (d, 1=2.57 Hz, 1 H) 7.36 (d, 1=2.57 Hz, 1 H) 7.43 (d, 1=8.82 Hz, 2 H) 7.83 (d, 1=8.82 Hz, 2 H) 10.37 (s, 1 H) 10.65 (s, 1 H) [001919] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy-N-(4-(N-(methylsulfonyl) isobutyramido)phenyl)benzamide (compound IA-L3-1.72). 'H NMR (300 MHz, DMSO-D6) δ ppm 0.99 (d, 1=6.62 Hz, 6 Η) 1.38 (s, 9 H) 2.29 - 2.41 (m, 1 H) 2.72 (t, 1=6.62 Hz, 2 H) 3.51 (s, 3 H) 3.75 - 3.83 (m, 349 2014280939 24 Dec 2014 5 Η) 7.32 (d, J=2.57 Hz, 1 H) 7.36 (d, J=2.57 Hz, 1 H) 7.48 (d, 3=8.82 Hz, 2 H) 7.84 (d, J=8.82 Hz, 2II) 10.37 (s, 1 H) 10.66 (s, 1 H) [001920] Methyl 4-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-1 (2H)-yl)-2-methoxybenzamido) phenyl(methylsulfonyl)carbamate (compound 1A-L3-1.73). *H NMR (300 MHz, DMSO-D6) δ ppm 1.38 (s, 9 H) 2.72 (t, 3=6.62 Hz, 2 H) 3.56 (s, 3 H) 3.72 (s, 3 H) 3.74 - 3.84 (m, 5 H) 7.31 (d, J=2.57 Hz, 1 H) 7.35 (dd, J=5.70, 2.76 Hz, 3 H) 7.77 (d, 3=8.82 Hz, 2 H) 10.37 (s, 1 H) 10.58 (s, 1 H) [001921] Ethyl 4-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidm-l(2H)-yl)-2-methoxybenzamido)-phenyl(methylsulfonyl)carbamate (compound IA-L3-1.74). 'H NMR (300 MHz, DMSO-D6) δ ppm 1.16 (t, J=7.17 Hz, 3 H) 1.38 (s, 9 H) 2.71 (t, J=6.62 Hz, 2 H) 3.56 (s, 3 H) 3.73 - 3.84 (m, 5 H) 4.20 (q, J=6.99 Hz, 2 II) 7.26 - 7.41 (m, 4 H) 7.77 (d, J=8.82 Hz, 2 H) 10.37 (s, 1 H) 10.58 (s, 1 H) [001922] Isobutyl 4-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxybenzamido) phenyl(methylsulfonyl)carbamate (compound IA-L3-1.76). *H NMR (300 MHz, DMSO-D6) δ ppm 0.79 (d, J=6.99 Hz, 6 H) 1.38 (s, 9 H) 1.74- 1.92 (m, 1 H)2.71 (t, J=6.62 Hz, 2 H) 3.56 (s, 3 H) 3.73 - 3.83 (m, 5 H) 3.94 (d, J=6.62 Hz, 2 H) 7.29 - 7.41 (m, 4 H) 7.78 (d, 3=8.82 Hz, 2 H) 10.36 (s, 1 H) 10.58 (s, 1 H) [001923] 2-methoxyethyl 4-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-1 (2H)-yl)-2-methoxy benzamido)phenyl(methylsulfonyl)carbamate (compound IA-L3-1.77). 'H NMR (300 MHz, DMSO-D6) δ ppm 1.38 (s, 9 H) 2.71 (t, 3=6.62 Hz, 2 H) 3.19 (s, 3 H) 3.46 - 3.52 (m, 2 H) 3.57 (s, 3 H) 3.72 - 3.84 (m, 5 H) 4.28 (dd, J=5.52, 3.68 Hz, 2 H) 7.27 - 7.42 (m, 4 H) 7.78 (d, J=8.82 Hz, 2 H) 10.36 (s, 1 H) 10.58 (s, 1 H) [001924] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy-N-(4-(methylsulfonyl) phenyl)benzamide (compound IA-L3-1.78). *H NMR (300 MHz, DMSO-df,) δ 1.38 (s, 9 H) 2.72 (t, 3=6.62 Hz, 2 H) 3.19 (s, 3 H) 3.74 (s, 3 H) 3.78 (t, J=6.62 Hz, 2 H) 7.35 (dd, 2 H) 7.95 (dd, 4 H) 10.37 (s, 1 H) 10.86 (s, 1 H).

[001925] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy-N-(2-(methylsulfonyl) phenyl)benzamide (compound IA-L3-1.79). Ή NMR (300 MHz, DMSO-ds) δ 1.39 (s, 9 H) 2.72 (t, J=6.43 Hz, 2 H) 3.29 (s, 3 H) 3.77 - 3.85 (m, 5 H) 7.43 (d, J=2.57 Hz, 1 H) 7.45 - 7.49 (m, 1 H) 7.50 (d, 3=2.57 Hz, 1 H) 7.77 - 7.85 (m, 1 H) 7.95 (d, J=8.46 Hz, 1 H) 8.45 (d, J=8.46 Hz, 1 H) 10.39 (s, 2 H).

[001926] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy-N-(2-sulfamoylphenyl) benzamide (compound IA-L3-1.80). ]H NMR (300 MHz, DMSO-d6) δ 1.38 (s, 9 H) 2.72 (t, J=6.62 Hz, 2 H) 3.73 - 3.89 (m, 5 H) 7.34 (t, J=7.72 Hz, 1 H) 7.42 (d, J=2.94 Hz, 1 H) 7.49 (d, J=2.57 Hz, 1 H) 7.66 (t, 3=7.17 Hz, 1 H) 7.72 (s, 2 H) 7.91 (d, 3=8.09 Hz, 1 H) 8.48 (d, 3=8.09 Hz, 1 H) 10.31 (s, 1 H) 10.39 (s, 1 H).

[001927] 3-tert-butyl-5-(2,4-dioxo-tetrahydro-pyrimidin-l-yl)-N-(3-hydroxy-2-methyl-phenyl)-2-methoxy-benzamide (compound IA-L3-1.81). 350 2014280939 24 Dec 2014 [001928] 3-tert-butyl-5-(2,4-dioxo-tetrahydro-pyrimidin-l-yl)-N-(4-fluoro-2-methyl-phenyl)-2-methoxy-benzamide (compound IA-L3-1.82).

[001929] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy-N-(2-methyl-4-(methyl sulfonamido)phenyl)benzamide (compound IA-L3-1.83). H NMR (300 MHz, DMSO-D6) δ ppm 1.38 (s, 9 H) 2.26 (s, 3 H) 2.72 (t, 1=6.62 Hz, 2 H) 2.98 (s, 3 H) 3.79 (t, J=6.62 Hz, 2 H) 3.83 (s, 3 H) 7.04 (m, 2 H) 7.33 (m, 2 H) 7.47 (d, J=8.09 Hz, 1 H) 9.65 (s, 1 H) 9.78 (s, 1 H) 10.36 (s, 1 H) [001930] N-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)phenyl)-4-(methylsulfonamido) benzamide (compound IA-L3-1.84). ’H NMR (300 MHz, DMSO-D6) δ ppm 1.38 (s, 9 H) 2.72 (t, J=6.62 Hz, 2 H) 3.09 (s, 3 H) 3.79 (t, 1=6.62 Hz, 2 H) 3.84 (s, 3 H) 7.33 (d, .1=2.21 Hz, 1 H) 7.37 (d, J=2.57 Hz, 1 H) 7.55 (m, 2 H) 7.67 (d, J=8.82 Hz, 1 H) 10.03 (s, 1 H) 10.18 (s, 1 H) 10.38 (s, 1 H) [001931] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy-N-(2-methoxy-4-(methyl sulfonamido)phenyl)benzamidc (compound IA-L3-1.85). ‘H NMR (300 MHz, DMSO-d,,) δ 1.39 (s, 9 H) 2.68 - 2.76 (m, 2 H) 3.00 (s, 3 H) 3.75 - 3.87 (m, 8 H) 6.84 (dd, J=8.46, 2.21 Hz, 1 H) 6.94 (d, J=2.21 Hz, 1 H) 7.39 (d, J=2.94 Hz, 1 H) 7.47 (d, J=2.57 Hz, 1 H) 7.93 - 7.99 (m, 1 H) 9.59 (s, 1 H) 9.68 (s, 1 H) 10.37 (s, 1 H).

[001932] N-(5-acetylamino-2-methoxy-phenyl)-3-tert-butyl-5-(2,4-dioxo-tetrahydro-pyrimidin-l-yl)-2-methoxy-benzamide (compound IA-L3-1.86), [001933] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy-N-(4-(methylsulfon-amido)-3-nitrophenyl)benzamide (compound IA-L3-1.87). 'H NMR (300 MHz, DMSO-d6) δ 10.84 (s, 1 H) 10.37 (s, 1 H) 9.71 (s, 1 H) 8.52 (d, J=2.57 Hz, 1 H) 7.98 (dd, 1=9.01, 2.39 Hz, 1 H) 7.62 (d, 1=8.82 Hz, 1 H) 7.35 (dd, 1=12.50, 2.57 Hz, 2 H) 3.71 - 3.83 (m, 5 H) 3.11 (s, 3 H) 2.71 (t, 1=6.62 Hz, 2 H) 1.38 (s,9H).

[001934] butyric acid ({4-[3-tert-butyl-5-(3-butyryloxymethyl-2,4-dioxo-tetrahydro-pyrimidin-l-yl)-2-methoxy-benzoylaminoj-phenyl}-methanesulfonyl-amino)-methyl ester (compound IA-L3-1.88). 'H NMR (300 MHz, DMSO-D6) δ ppm 0.88 (m, 6 H) 1.38 (s, 9 H) 1.55 (m, 4 H) 2.26 (t, 1=7.17 Hz, 2 H) 2.39 (t, 1=7.17 Hz, 2 H) 2.95 (t, 1=6.62 Hz, 2 H) 3.14 (s, 3 H) 3.77 (s, 3 H) 3.81 (t, J=6.62 Hz, 2 H) 5.57 (s, 2 H) 5.68 (s, 2 H) 7.35 (d, 1=2.57 Hz, 1 H) 7.38 (d, 1=2.94 Hz, 1 H) 7.42 (d, 1=8.82 Hz, 2 H) 7.79 (d, 1=8.82 Hz, 2H) 10.60 (s, 1 H).

[001935] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxy-N-(4-(methylsulfonamido methyl)-3-sulfamoylthiophen-2-yl)benzamide (compound IA-L3-1.89). 'H NMR (300 MHz, DMSO-dfl) δ 1.40 (s, 9 H) 2.70 - 2.78 (m, 2 H) 2.97 (s, 3 H) 3.78 (t, 1=6.43 Hz, 2 H) 4.36 (d, 1=6.99 Hz, 2 H) 7.14 (s, 1 H) 7.42 (d, 1=2.21 Hz, 1 H) 7.47 (d, 1=2.21 Hz, 1 H) 7.60 (t, 1=6.43 Hz, l H) 7.82 (s, 2 H) 10.42 (s, 1 H) 11.43 (s, 1 H) 11.93 (s, 1 H).

[001936] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy-N-(4-(methylsulfonamide 351 2014280939 24 Dec 2014 methyl)-3-sulfamoylthiophen-2-yl)benzamide (compound IA-L3-1.90). lH NMR (300 MHz, DMSO-d(l) δ 1.40 (s, 9 H) 2.72 (t, J=6.62 Hz, 2 H) 2.97 (s, 3 H) 3.73 (s, 3 H) 3.80 (t, 1=6.80 Hz, 2 H) 4.36 (d, 1=5.52 Hz, 2 H) 7.06 (s, 1 H) 7.47 (d, 1=2.57 Hz, 1 H) 7.57 (t, J=6.43 Hz, 1 H 7.61 (d, J=2.57 Hz, 1 H) 7.70 (s, 2 H) 10.40 (s, 1 H) 11.56 (s, 1 H).

[001937] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxy-N-(4-(methylsulfonamido methyl)thiophen-2-yl)benzamide (compound IA-L3-1.91). 'H NMR (300 MHz, DMSO-d6) δ ppm 1.39 (s, 9 H) 2.74 (t, J=6.80 Hz, 2 H) 2.86 (s, 3 H) 3.79 (t, 1=6.62 Hz, 2 H) 4.10 (d, 1=6.25 Hz, 2 H) 6.98 (s, 1 H) 7.04 (d, 1=1.47 Hz, 1 H) 7.42 (d, 1=2.57 Hz, 1 H) 7.55 (t, 1=6.25 Hz, 1 H) 7.89 (d, 1=2.21 Hz, 1 H) 10.41 (s, 1 H) 11.68 (s, 1 H) 12.95 (s, 1 H).

[001938] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy-N-(4-(methylsulfonamido methyl)thiophen-2-yl)benzamide (compound 1A-L3-1.94). 'H NMR (300 MHz, DMSO-de) δ ppm 1.37 (s, 9 H) 2.71 (t, 1=6.80 Hz, 2 H) 2.85 (s, 3 H) 3.67 (s, 3 H) 3.78 (t, 1=6.62 Hz, 2 H) 4.07 (d, 1=5.88 Hz, 2 H) 6.82 (d, 1=1.84 Hz, 1 H) 6.87 (s, 1 H) 7.28 - 7.32 (m, 1 H) 7.36 (d, 1=2.57 Hz, 1 H) 7.49 (t, 1=6.25 Hz, 1 H) 10.37 (s, 1 Η) 11.59 (s, 1 H).

[001939] 3 -tert-butyl-5-(2,4-dioxotetrahydropyrimidin-1 (2H)-yI)-2-hydroxy-N-(4-((N-methylmethyl sulfonamido)methyl)thiophen-2-yl)benzamide (compound IA-L3-1.95). ’H NMR (300 MHz, DMSO-d6) δ ppm 1.39 (s, 9 H) 2.70 (s, 3 H) 2.74 (t, 1=6.80 Hz, 2 H) 2.92 (s, 3 H) 3.79 (t, 1=6.80 Hz, 2 H) 4.18 (s, 2 H) 7.01 (m, 2 H) 7.42 (d, 1=2.21 Hz, 1 H) 7.89 (d, 1=2,57 Hz, 1 H) 10.41 (s, 1 Η) 11.68 (s, 1 H) 12.92 (s, 1H).

[001940] tert-butyl (5-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxybenzamido) thiophen-3-yl)methyl(methylsulfonyl)carbamate (compound IA-L3-1.96). ’H NMR (300 MHz, DMSO-d6) δ ppm 1.37 (s, 9 H) 1.48 (s, 9 H) 2.71 (t, 1=6.62 Hz, 2 H) 3.30 (s, 3 H) 3.67 (s, 3 H) 3.78 (t, 1=6.62 Hz, 2 H) 4.66 (s, 2 H) 6.77 - 6.87 (m, 2 H) 7.30 (d, 1=2.57 Hz, 1 H) 7.36 (d, 1=2.57 Hz, 1 H) 10.37 (s, 1 H) 11.63 (s, 1H).

[001941] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy-N-(4-((N-methylmethyl sulfonamido)methyl)thiophen-2-yl)benzamide (compound IA-L3-1.97). 'H NMR (300 MHz, DMSO-d^) δ ppm 1.37 (s, 9 H) 2.70 (m, 5 H) 2.91 (s, 3 H) 3.68 (s, 3 H) 3.78 (t, 1=6.62 Hz, 2 H) 4.15 (s, 2 H) 6.80 (d, 1=1.47 Hz, 1 H) 6.94 (d, 1=1.47 Hz, 1 H)7.31 (d, 1=2.57 Hz, 1 H) 7.36 (d, 1=2.94 Hz, 1 H) 10.37 (s, 1 H) 11.59 (s, 1 H).

[001942] tert-butyl (5-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-1 (2H)-yl)-2-hydroxybenzamido) thiophen-3-yl)methyl(methylsulfonyl)carbamate (compound IA-L3-1.98). 'H NMR (300 MHz, DMSO-d6) δ ppm 1.39 (s, 9 H) 1.47 (s, 9 H) 2.74 (t, 1=6.80 Hz, 2 H) 3.35 (s, 3 H) 3.78 (t, 1=6.62 Hz, 2 H) 4.68 (s, 2 H) 6.96 (s, 1 H) 7.04 (d, 1=1.47 Hz, 1 H) 7.41 (d, 1=2.21 Hz, 1 H) 7.88 (d, 1=2.21 Hz, 1 H) 10.40 (s, 1 H) 11.70 (s, 1 H) 12.92 (s, 1 H). 352 2014280939 24 Dec 2014 [001943] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidm-l(2H)-yl)-2-methoxy-N-(6-(methylsulfonamido) pyridin-3-yl)benzamide (compound 1A-L3-1.99). 'H NMR (300 MHz, DMSO-dg) δ ppm 1.37 (s, 9 H) 2.71 (t, 3=6.62 Hz, 2 H) 3.28 (s, 3 H) 3.77 (m, 5 H) 7.01 (d, J=8.82 Hz, 1 H) 7.31 (d, 3=2.57 Hz, 1 H) 7.35 (d, J=2.57 Hz, 1 H) 8.07 (dd, J=8.82,2.57 Hz, 1 H) 8.61 (d, J=2.57 Hz, 1 H) 10.36 (s, 1 H) 10.49 (s, br, 1 H) 10.50 (s, 1 H).

[001944] N-(6-aminopyridm-3-y1)-3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy benzamide (compound IA-L3-1.100). ]H NMR (300 MHz, DMSO-d6) δ ppm 1.37 (s, 9 H) 2.71 (t, J=6.62 Hz, 2 H) 3.74 (s, 3 H) 3.78 (t, 3=6.62 Hz, 2 H) 7.06 (d, J=9.56 Hz, 1 H) 7.31 (d, J=2.57 Hz, 1 H) 7.37 (d, 3=2.57 Hz, 1 H) 7.99 (s, 2 H) 8.04 (dd, J=9.56,2.21 Hz, 1 H) 8.53 (d, 3=1.84 Hz, 1 H) 10.38 (s, 1 H) 10.67 (s, 1 H) 13.64 (s, 1 H).

[001945] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy-N-(5-(N-(methylsulfonyl) methylsulfonamido)pyridin-2-yl)benzamide (compound IA-L3-1.101). HNMR (300 MHz, DMSO-d6) δ ppm 1.38 (s, 9 H) 2.72 (t, J=6.62 Hz, 2 H) 3.58 (s, 6 H) 3.75 (s, 3 H) 3.80 (t, 3=6.62 Hz, 2 H) 7.36 (m, 2 H) 8.06 (dd, J=8.82, 2.57 Hz, 1 H) 8.30 (d, 3=8.82 Hz, 1 H) 8.51 (d, J=2.21 Hz, 1 H) 10.37 (s, 1 H) 11.10 (s, 1 H).

[001946] 3 -tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy-N-(5-(methylsulfonamido) pyridin~2-yl)benzamide (compound IA-L3-1.102).1 H NMR (300 MHz, DMSO-d6) δ ppm 1.37 (s, 9 H) 2.71 (t, J=6.62 Hz, 2 H) 3.02 (s, 3 H) 3.74 (s, 3 H) 3.79 (t, J=6.62 Hz, 2 H) 7.35 (m, 2 H) 7.71 (dd, J=8.82, 2.57 Hz, 1 H) 8.18 (m, 2 H) 9.81 (s, 1 H) 10.36 (s, 1 H) 10.74 (s, 1 H).

[001947] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy-N-((lr,4r)-4-(methylsulfon amido)cyclohexyl)benzamide (compound IA-L3-1.103). *H NMR (300 MHz, DMSO-d6) δ ppm 1.32 (d, 11 H) 1.91 (s, 2 H) 2.65 - 2.78 (m, 4 H) 2.91 (s, 3 H) 3.07 (s, 2 H) 3.39 (s, 2 H) 3.66 - 3.80 (m, 5 H) 7.03 (d, 3=7.35 Hz, 1 H) 7.12 (d, 3=2.57 Hz, 1 H) 7.25 (d, 3=2.57 Hz, 1 H) 8.19 (d, 3=8.09 Hz, 1 H) 10.32 (s, 1 H).

[001948] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxy-N-(thiazol-2-yl)benzamide (compound IA-L3-1.104). *H NMR (300 MHz, DMSO-d6) δ 1.56 - 1,68 (m, 9 H) 2.92 (t, 3=6.62 Hz, 2 H) 3.90 - 4.07 (m, 2 H) 7.27 - 7.70 (m, 2 H) 7.80 (d, 3=4.04 Hz, 1 H) 8.03 (s, 1 H) 10.51 (s, 1 H) 14.06 (d, 3=116.92 Hz, 1 H).

[001949] 3"iert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-N-(4-(methylsulfonamido)phenyl) benzamide (compound IA-L3-1.105). ’ll NMR (300 MHz, DMSO-d6) δ ppm 1.34 (s, 9 H) 2.74 (t, 7=6.62 Hz, 2 H) 2.96 (s, 3 H) 3.86 (t, J= 6.62 Hz, 2 H) 7.09 - 7.90 (m, 7 H) 9.62 (s, 1 H) 10.24 (s, 1 H) 10.43 (s, 1 H).

[001951] N-(4-aminophenyl)-3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-mcthoxy benzamide (compound IA-L3-1.107). *H NMR (300 MHz, DMSO-d6) δ 1.37 (s, 9 H) 2.71 (t, 3=6.62 Hz, 353 2014280939 24 Dec 2014 2 Η) 3.71 - 3.83 (m, 5 Η) 7.26 - 7.39 (m, 4 Η) 7.82 (d, J=8.82 Hz, 2 H) 9.95 (s, 1 H) 10.36 (s, 1 H) 10.57 (s, 1 H).

[001952] N-(4-(N-allylmethylsulfonamido)phenyl)-3-tert~butyl-5-(2,4-dioxotetrahydropyrimidin-l (2H)-yl)-2-methoxybenzamide (compound IA-L3-1.108). 'HNMR(300 MHz, DMSO-de) δ ppm 1.37 (s, 9 H) 2.71 (t, J=6.62 Hz, 2 H) 3.01 (s, 3 H) 3.70 - 3.83 (m, 5 H) 4.25 (d, J=5.88 Hz, 2 H) 5.00 - 5.24 (m, 2 H) 5.68 - 5.84 (m, 1 H) 7.29 (d, >2.57 Hz, 1 H) 7.30 - 7.41 (m, 3 H) 7.74 (d, >8.82 Hz, 2 H) 10.36 (s, 1 H) 10.51 (s, 1 H).

[001954] 5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-3-isopropyl-2-methoxy-N-(4-(methylsulfonamido) phenyl)benzamide (compound IA-L3-1.111). 'll NMR (500 MHz, DMSO-d6) δ ppm 1.22 (d, ./=6.71 Hz, 6 H) 2.72 (t, ./=6.71 Hz, 2 H) 2.95 (s, 3 H) 3.23 - 3.39 (m, 1 H) 3.75 (s, 3 H) 3.79 (t,./=6.71 Hz, 2 H) 7.19 (d, > 9.16 Hz, 2 H) 7.31 (d, ./=2.44 Hz, 1 H) 7.38 (d, ./=2.44 Hz, 1 H) 7.69 (d, ./=9.16 Hz, 2 H) 9.55 (s, 1 H) 10.29 (s, 1 H) 10.34 (s, 1H).

[001955] 5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-3-ethyl-2-methoxy-N-(4-(methylsulfonamido) phenyl)benzamide (compound IA-L3-1.112). 'H NMR (300 MHz, DMSO-de) δ ppm 1.20 (t, ./=7.35 Hz, 3 H) 2.60 - 2.78 (m, 4 H) 2.95 (s, 3 H) 3.69 - 3.84 (m, 5 H) 7.19 (d, ./=9,19 Hz, 2 H) 7.27 - 7.41 (m, 2 H) 7.69 (d, ./=8.82 Hz, 2 H) 9.59 (s, 1 H) 10.31 (s, 1 H) 10.38 (s, 1 H).

[001956] 5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-3-ethyl-2-hydroxy-N-(4-(methylsulfonamido) phenyl)benzamide (compound IA-L3-1.113). 1 FI NMR (300 MHz, DMSO-d6) δ ppm 1.17 (t, ./=7.54 Hz, 3 H) 2.54 - 2.66 (m, 2 H) 2.73 (t, > 6.62 Hz, 2 H) 2.99 (s, 3 H) 3.78 (t, ./=6.62 Hz, 2 H) 7.24 (d, >8.82 Hz, 2 H) 7.37 (d, >1.84 Hz, 1 H) 7.62 (d, >8.82 Hz, 2 H) 7.87 (d, >2.21 Hz, 1 H) 9.72 (s, 1 H) 10.40 (s, 1 H) 10.43 (s, 1 H) 12.70 (s, 1 H).

[001957] 5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxy-N-(4-(methylsulfonamido)phenyl) benzamide (compound IA-L3-1.114). 'H NMR (300 MHz, DMSO-d6) δ ppm 2.72 (t, >6.80 Hz, 2 H) 2.97 (s, 3 H) 3.76 (t, >6.80 Hz, 2 H) 6.99 (d, >8.82 Hz, 1 H) 7.22 (d, >9.19 Hz, 2 H) 7.40 (dd, >8.82, 2.57 Hz, 1 H) 7.65 (d, >8.82 Hz, 2 H) 7.87 (d, >2.57 Hz, 1 H) 9.66 (s, 1 H) 10.38 (d, >1.84 Hz, 2 H) 11.83 (s, 1 H).

[001958] 3-tert-butyl-5-(3-(2-(ethylamino)-2-oxoethyl)-2,4-dioxotetrahydropyrimidin-l(2H)-yl)-N-(4-(N-(2-(ethylamino)-2-oxoethyl)methylsulfonamido)phenyl)-2-methoxybenzamide (compound IA-L3-1.115).¾ NMR (300 MHz, DMSO-d6) δ ppm 0.92 - 1.04 (m, 6 Η) 1.37 (s, 9 H) 2.88 (t, >6.62 Hz, 2 H) 3.01 - 3.08 (m, 4 H) 3.09 (s, 3 H) 3.75 (s, 3 H) 3.81 (t, >6.62 Hz, 2 H) 4.22 (d, >5.52 Hz, 4 H) 7.30 (d, >2.57 Hz, 1 H) 7.31 - 7.37 (m, 1 H) 7.47 (d, >8.82 Hz, 2 H) 7.74 (d, >8.82 Hz, 2 H) 7.88 - 8.04 (m, 2 H) 10.53 (s, 1 H).

[001959] (3-(3-tert-butyl-4-methoxy-5-(4-(N-(pivaloyloxymethyl)methylsulfonamido)phenylcarbamoyl) phenyl)-2,6-dioxotetrahydropyrimidin-l(2H)-yl)methyl pivalate (compound IA-L3-1.116). 'll NMR (300 354 2014280939 24 Dec 2014 MHz, DMSO-ds) δ ppm 1.11 (s, 9 H) 1.19 (s, 9 H) 1.38 (s, 9 H) 2.95 (t, 1=6.62 Hz, 2 H) 3.17 (s, 3 H) 3.77 (s, 3 H) 3.81 (t, J=6.62 Hz, 2 H) 5.56 (s, 2 H) 5.67 (s, 2 H) 7.35 (d, 3=2.57 Hz, 1 H) 7.38 (d, J=2.57 Hz, 1 H) 7.41 (d, J=9.19 Hz, 2 H) 7.80 (d, 3=8.82 Hz, 2 H) 10.61 (s, 1 H).

[001960] 5-(3 -((1,3 -d ioxolan-2-yl)methy l)-2,4-dioxotetrahydropyrimidin-1 (2H)-yl)-3 -tert-butyl-2-methoxy-N-(4-(methylsulfonamido)phenyl)benzamide (compound IA-L3-1.117). ]H NMR (300 MHz, DMSO-d6) δ ppm 1.37 (s, 9 H) 2.87 (t, J=6.62 Hz, 2 H) 2.95 (s, 3 H) 3.78 (s, 3 H) 3.76 - 3.85 (m, 4 H) 3.87 - 3.96 (m, 4 H) 5.07 (t, 1=4.96 Hz, 1 H) 7.20 (d, 3=8.82 Hz, 2 H) 7.32 (dd, 3=13.97, 2.57 Hz, 2 H) 7.69 (d, 3=8.82 Hz, 2 H) 9.60 (s, 1 H) 10.40 (s, 1 H).

[001961] 5-(3-allyl-2,4-dioxotetrahydropyrimidin-l(2H)-yl)-N-(4-(N-allylmethylsulfonamido)phenyl)-3-tert-butyl-2-methoxybenzamide (compound IA-L3-1.118). *H NMR (300 MHz, DMSO-d6) δ ppm 1.37 (s, 9 H) 2.78 - 2.93 (m, 2 H) 3.01 (s, 3 H) 3.78 (s, 3 H) 3.76 - 3.85 (m, 2 H) 4.25 (d, 3=5.88 Hz, 4 H) 4.94 - 5.29 (m, 4 H) 5.67 - 5.96 (m, 1 H) 7.00 - 7.21 (m, 1 H) 7.31 (d, 3=2.57 Hz, 1 H) 7.35 - 7.42 (m, 3 H) 7.74 (d, 3=8.82 Hz, 2 H) 10.52 (s, 1 H).

[001962] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxy-N-(2-methoxy-4-(methyl sulfonamido)phenyl)benzamide (compound IA-L3-1.119). H NMR (300 MHz, DMSO-d6) δ 1.38 (s, 9 H) 2.73 (t, 3=6.62 Hz, 2 H) 3.05 (s, 3 H) 3.74 - 3.81 (m, 5 H) 6.84 (dd, 3=8.46, 2.21 Hz, 1 H) 6.95 (d, 3=2.21 Hz, 1 H) 7.30 (d, 3=8.46 Hz, 1 11) 7.39 (d, 3=2.21 Hz, 1 H) 7.89 (d, 3=2.57 Hz, 1 H) 9.82 (s, 1 H) 10.06 (s, 1 H) 10.37 (s, 1 H) 13.50 (s, 1 H).

[001963] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-1 (2H)-yl)-2-methoxy-N-(3 -(methylsulfonamido methyl)pheny!)benzamide (compound IA-L3-1.120). ’H NMR (300 MHz, DMSO-d6) δ 1.37 (s, 9 II) 2.71 (t, J=6.62 Hz, 2 H) 2.89 (s, 3 H) 3.69 - 3.88 (m, 5 H) 4.15 (d, 3=6.25 Hz, 2 H) 7.00 - 7.16 (m, 1 H) 7.26 - 7.40 (m, 3 H) 7.59 (t, 3=6.43 Hz, 1 H) 7.65 (d, 3=8.82 Hz, 1 H) 7.74 (s, 1 H) 10.36 (s, 1 H) 10.44 (s, 1 H).

[001964] 3-tert-butyl-N-(4-(2,5-dimethoxyphenylsulfonamido)phenyl)-5-(2,4-dioxotetrahydro-pyrimidin-l(2H)-yl)-2-methoxybenzamide (compound IA-L3-1.121). 1H NMR (300 MHz, DMSO d6) δ 1.35 (s, 9 H) 2.69 (t, 3=6.80 Hz, 2 H) 3.71 (s, 6 H) 3.75 (t, 3=6.62 Hz, 2 H) 3.85 (s, 3 H) 7.06 (d, 3=8.82 Hz, 2 H) 7.13 (s, 2 H) 7.22 (dd, 3=3.68, 2.21 Hz, 2 H) 7.31 (d, 3=2.57 Hz, 1 H) 7.53 (d, 3=8.82 Hz, 2 H) 9.87 (s, 1 H) 10.28 (s, 1 H) 10.34 (s, 1 H).

[001965] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-N-(4-(2-hydroxyethylsulfonamido) phenyl)-2-methoxybenzamide (compound 1A-L3-1.122). 'H NMR (300 MHz, DMSO-d6) δ 1.37 (s, 9 H) 2.71 (t, 3=6.80 Hz, 2 H) 3.19 (t, 3=6.80 Hz, 2 H) 3.69 - 3.86 (m, 7 H) 4.93 (t, 3=5.70 Hz, 1 H) 7.20 (d, 3=8.82 Hz, 2 H) 7.28 (d, 3=2.94 Hz, 1 H) 7.33 (d, 3=2.57 Hz, 1 H) 7.68 (d, 3=8.82 Hz, 2 H) 9.60 (s, 1 H) 10.36 (s, 1 H) 10.38 (s, 1 H).

[001966] (N-(4-(3-tert-butyI-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxybenzamido)pheny!) 355 2014280939 24 Dec 2014 methylsulfonamido)methyl butyrate (compound IA-L3-1.123). ’H NMR (300 MHz, DMSO-d6) δ 0.90 (t, J=7.54 Hz, 3 H) 1.38 (s, 9 H) 1.57 (m, 2 H) 2.39 (t, J=7.35 Hz, 2 H) 2.71 (t, J=6.62 Hz, 2 H) 3.14 (s, 3 H) 3.77 (m, 5 H) 5.57 (s, 2 H) 7.30 (d, J=2.57 Hz, 1 H) 7.35 (d, J=2.57 Hz, 1 H) 7.41 (d, J=8.82 Hz, 2 H) 7.79 (d, J=8.82 Hz, 2 H) 10.36 (s, 1 H) 10.57 (s, 1 H) [001967] 3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxy-N-(quinolin-6-yl) benzamide (compound IA-L3-2.1).’H NMR (300 MHz, DMSO-d6) δ 1.41 (s, 9 H) 2.75 (t, J=6.62 Hz, 2 H) 3.77 - 3.86 (m, 2 H) 7.45 (d, J=2.21 Hz, 1 H) 7.68 (dd, J=8.46, 4.41 Hz, 1 H) 7.98 (d, J=2.57 Hz, 1 H) 8.11 (s, 2 H) 8.44 (s, 1 H) 8.58 (d, J=8.46 Hz, 1 H) 8.96 (dd, £=4,41, 1.47 Hz, 1 H) 10.41 (s, 1 H) 10.81 (s, 1 H).

[001968] 3 -tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxy-N-(2-oxoindolin-5-yl) benzamide (compound IA-L3-2.2). *H NMR (300 MHz, DMSO-d6) δ 1.37 (s, 9 H) 2.71 (t, .)=6.62 Hz, 2 H) 3.50 (s, 2 H) 3.75 (s, 3 H) 3.77 (t, J=6.62 Hz, 2 H) 6.78 (d, J=8.46 Hz, 1 H) 7.26 (d, J=2.21 Hz, 1 H) 7.32 (d, J=2.57 Hz, 1 H) 7.48 (dd, J=8.46, 1.84 Hz, 1 H) 7.64 (s, 1 H) 10.24 (s, 1 H) 10.34 (s, 1 H) 10.35 (s, 1 H).

[001969] 3-tert-butyl-N-(2,2-dioxo-l,3-dihydrobenzo[c]thiophen-5-yl)-5-(2,4-dioxotetrahydropyrimidin-1 (2H)-yl)-2-methoxybenzamide (compound IA-L3-2.3). ’H NMR (300 MHz, DMSO-dc,) δ 1.37 (s, 9 H) 2.71 (t, JM6.43 Hz, 2 H) 3.70 - 3.85 (m, 5 H) 4.45 (s, 2 H) 4.53 (s, 2 H) 7.29 (d, J=2.S7 Hz, 1 H) 7.32 - 7.40 (m, 2 H) 7.62 (dd, J=8.27, 1.65 Hz, 1 H) 7.86 (s, 1 H) 10.36 (s, 1 H) 10.54 (s, 1 H).

[001970] 3-tert-buty 1-5 -(2,4-dioxotetrahydropyrimidin-l (2H)-yl)-2-methoxy-N-(2-oxo-l ,2,3,4-tetra hydroquinolin-6-yl)benzamide (compound IA-L3-2.4). ‘H NMR (300 MHz, DMSO-d6) δ 1.37 (s, 9 H) 2.44 (t, 2 H) 2.71 (t, J=6.62 Hz, 2 H) 2.86 (t, J=7.35 Hz, 2 H) 3.77 (t, 2 H) 3.75 (s, 3 H) 6.82 (d, J=8.46 Hz, 1 H) 7.26 (d, J=2.57 Hz, 1 H) 7.32 (d, J=2.57 Hz, 1 H) 7.45 (dd, J=8,46,2.21 Hz, 1 H) 7.57 (d, 1 H) 10.05 (s, 1 H) 10.24 (s, 1 H) 10.35 (s, 1 H).

[001971] 3-tert-butyl-N-(2,2-dioxo-l,3-dihydrobenzo[c]thiophen-5-yl)-5-(2,4-dioxotetrahydro pyrimidin-l(2H)-yl)-2-hydroxybenzamide (compound IA-L3-2.5).111 NMR (300 MHz, DMSO-d6) δ 1.39 (s, 9 H) 2.74 (t, J=6.80 Hz, 2 H) 3.79 (t, J=6.62 Hz, 2 H) 4.49 (s, 2 H) 4.55 (s, 2 H) 7.42 (dd, J=4.96, 2.76 Hz, 2 H) 7.59 (dd, J=8.27, 1.65 Hz, 1 H) 7.74 (s, 1 H) 7.90 (d, J=1.84 Hz, 1 H) 10.40 (s, 1 H) 10.54 (s, 1 H) 13.15 (s, 1 H).

[001972] 3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy-N-(4-(methylsulfon amido)phenyl)benzamide (compound IB-L3-1.1). 'H NMR (300 MHz, DMSO-d6) δ ppm 2.50 (s, 9 H) 2.94 (s, 3 H) 3.79 (s, 3 H) 5.66 (d, J=8,09 Hz, 1 H) 7.14 - 7.25 (m, 2 H) 7.39 (s, 2 H) 7.62 - 7.75 (m, 3 H) 9.60 (s, 1 H) 10.44 (s, 1 Η) 11.42 (s, 1 H).

[001973] 3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-hydroxy-N-(4-(methylsulfon-amide) phenyl)benzamide (compound IB-L3-1.2), 'll NMR (300 MHz, DMSO-d6) δ 1.40 (s, 9 H) 2.99 356 2014280939 24 Dec 2014 (s, 3 H) 5.70 (dd, J=7.72,2.21 Hz, 1 H) 7.24 (d, 3=8.82 Hz, 2 H) 7.46 (d, J=2.21 Hz, 1 H) 7.61 (d, J=8.82 Hz, 2 H) 7.76 (d, )=1.12 Hz, 1 H) 8.03 (d, 3=2.21 Hz, 1 H) 9.75 (s, 1 H) 10.45 (s, 1 Η) 11.48 (d, 3=2.21 Hz, 1 H) 13.52 (s, 1 H) [001974] 3-tert-butyl-2-methoxy-5-(6-methyl-2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-N-(4-(methyl sulfonamido)phenyl)benzamide (compound IB-L3-U). ’H NMR (300 MHz, DMSO-ch) δ ppm 1.37 (s, 9 H) 1.82 (s, 3 H) 2.96 (s, 3 H) 3.80 (s, 3 H) 5.63 (s, 1 H) 7.20 (d, 3=8.82 Hz, 2 H) 7.34 (s, 2 H) 7.69 (d, 3=8.82 Hz, 2 H) 9.60 (s, 1 H) 10.41 (s, 1 Η) 11.27 (s, 1 H).

[001975] 3-tert-butyl-2-hydroxy-5-(6-methyl-2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-N-(4-(methyl sulfonamido)phenyl)benzamide (compound IB-L3-1.4). 'H NMR (300 MHz, DMSOd6) δ ppm 1.39 (s, 9 H) 1.86 (s, 3 H) 2.99 (s, 3 H) 5.68 (s, 1 H) 7.24 (d, ./-8.82 Hz, 2 H) 7.40 (s, 1 H) 7.61 (d, .7=8.82 Hz, 2 H) 7.95 (s, 1 H) 9.74 (s, 1 H) 10.39 (s, 1 Η) 11.35 (s, 1 H) 13.57 (s, 1 H).

[001976] N-(3-tert-butyl-5-(2,4-dioxotetTahydropyrimidin-l(2H)-yl)phenyl)-4-(methylsulfonamido) benzamide (compound IA-L4-1.1), 'H NMR (300 MHz, DMSO-d6) δ 1.29 (s, 9 H) 2.72 (t, ./=6.62 Hz, 2 H) 3.09 (s, 3 H) 3.79 (t, /=6.62 Hz, 2 H) 7.08 (t, /=1.84 Hz, 1 H) 7.30 (d, /=8.82 Hz, 2 H) 7.67 (dd, /=6.99, 1.84 Hz, 2 H) 7.95 (d,/=8.82 Hz,2H) 10.16 (s, 1 H) 10.19 (s, 1 H) 10.35 (s, l H) [001977] N-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimid in-1 (2H)-yl)-2-hydroxyphenyl)benzamide (compound IA-L4-1.2). 'H NMR (300 MHz, DMSO-d6) δ 10.28 (s, 1 H) 10.17 (s, 1 H) 8.99 (s, 1 H) 8.04 (d, J=6.99 Hz, 2 H) 7.49 - 7.67 (m, 3 H) 7.22 (d, J=2.57 Hz, 1 H) 7.06 (d, J=2.57 Hz, 1 H) 3.73 (t, J=6.80 Hz, 2 H) 2.70 (t, J=6.80 Hz, 2 H) 1.40 (s, 9 H).

[001978] N-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxyphenyl)-4-(methylsulfon amido)benzamide (compound IA-L4-1.3). *H NMR (300 MHz, DMSO-dö) δ 10.29 (s, 1 H) 10.25 (br s, 1 H) 10.11 (s, 1 H) 9.02 (s, 1 H) 8.02 (d, 3=8.82 Hz, 2 H) 7.30 (d, J=8.82 Hz, 2 H) 7.19 (d, J=2.21 Hz, 1 H) 7.06 (d, J=2.57 Hz, 1 H) 3.73 (t, J=6.80 Hz, 2 H) 3.10 (s, 3 H) 2.71 (t, J=6.62 Hz, 2 II) 1.39 (s, 9 II).

[001979] N-(3-tert-butyl-5-(2,4-dioxotetrahydropyfimidin-l(2H)-yl)-2-hydroxyphenyl)-4-(methyl sulfonylmethyl)benzamide (compound IA-L4-1.4). 'H NMR (300 MHz, DMSO-dc) δ 1.40 (s, 9 II) 2.70 (t, J=6.62 Hz, 2 H) 2.95 (s, 3 H) 3.73 (t, J=6.80 Hz, 2 H) 4.61 (s, 2 II) 7.07 (d, J=2.57 Hz, 1 H) 7.21 (d, J=2.57 Hz, 1 H) 7.57 (d, J=8.46 Hz, 2 H) 8.05 (d, J=8.09 Hz, 2 H) 8.95 (s, 1 H) 10.16 (s, 1 H) 10.29 (s, 1 H).

[001980] N-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxyphenyl)-4-nitro benzamide (compound IA-L4-1.5). *H NMR (300 MHz, DMSO-d6) δ 10.28 (s, 1 H) 10.26 (s, 1 H) 8.91 (s, 1 H) 8.38 (d, J=8.82 Hz, 2 II) 8.26 (d, 3=9.20 Hz, 2 H) 7.19 (d, 3=2.57 Hz, 1 H) 7.09 (d, 3=2.57 Hz, 1 H) 3.73 (t, 3=6.62 Hz, 2 H) 2.70 (t, 3=6.80 Hz, 2 II) 1.40 (s, 9 H).

[001981] 4-ami no-N-(3-tert-butyl-5 -(2,4-dioxotetrahydropyrimidin-1 (2H)-yl)-2-hydroxyphenyl) benzamide (compound IA-L4-L6). 'H NMR (300 MHz, DMSO-dr,) δ 10.29 (s, 1II) 9.95 (s, 1 H) 9.46 (s, 357 2014280939 24 Dec 2014 1 Η) 7.79 (d, J=8.82 Hz, 2 H) 7.16 (d, J=2.57 Hz, 1 H) 7.03 (d, J=2.21 Hz, 1 H) 6.61 (d, J=8.46 Hz, 2 H) 5.90 (s, 2 H) 3.72 (t, J=6.80 Hz, 2 H) 2.70 (t, J=6.62 Hz, 2 H) 1.39 (s, 9 H).

[001982] N-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl)-N-methyl-4-(methylsulfonamido)benzamide (compound IA-L4-1.7). 'HNMR(300 MHz, DMSO-df,) δ 10.36 (s, 1 H) 9.81 (s, 1 H) 7.36 (d, 1=2.21 Hz, 1 H) 7.15 (d, J=8.46 Hz, 2 H) 7.05 (d, 1=2.21 Hz, 1 H) 6.92 (d, J=8.46 Hz, 2 H) 3.65 - 3.90 (m, 2 H) 3.41 (s, 3 H) 3.17 (d, J=5.52 Hz, 3 H) 2.88 (s, 3 H) 2.66 - 2.76 (m, 2 Η) 1.03 (s,9H).

[001983] N-(3-tert-butyl-5-(2,4-dioxoletrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl)benzamide (compound IA-L4-1.8).1H NMR (300 MHz, DMSO-d6) δ 10.33 (s, 1 H) 9.98 (s, 1 H) 8.00 - 8.07 (m, 2 H) 7.49 - 7.64 (m, 3 H) 7.38 (d, 1=2.57 Hz, 1 H) 7.13 (d, J=2.57 Hz, 1 H) 3.77 (t, J=6.62 Hz, 2 H) 3.72 (s, 3 H) 2.71 (t, J=6.62 Hz, 2 H) 1.37 (s, 9 H).

[001984] N-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl)-2-methoxy-4-(methylsulfonamido)benzamide (compound IA-L4-l.il). H NMR (300 MHz, DMSO-d6) δ 10.33 (s, 1 H) 10.31 (s, I H) 10.20 (s, 1 H) 8.21 (d, J=2.57 Hz, 1 H) 8.02 (d, J=8.82 Hz, 1 H) 7.01 - 7.07 (m, 2 H) 6.96 (dd, J=8.46, 1.84 Hz, 1 H) 4.03 - 4.07 (m, 3 H) 3.79 - 3.82 (m, 3 H) 3.76 (t, 1=6.80 Hz, 2H) 3.14 (s, 3 H) 2.71 (t, 1=6.62 Hz, 2 H) 1.39 (s, 9 H).

[001985] N-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl)-2-chloro-4-(methylsulfonamido)bcnzamide (compound IA-L4-1.12). 'H NMR (300 MHz, DMSO-de) δ 10.33 (s, 1 H) 10.23 (s, 1 H) 10.02 (s, 1 H) 7.52 - 7.65 (m, 2 H) 7.20 - 7.33 (m, 2 H) 7.09 (d, 1=2.57 Hz, 1 H) 3.71 - 3.82 (m, 5 H) 3.11 (s, 3 H) 2.71 (t, 1=6.62 Hz, 2 H) 1.35 (s, 9 H).

[001986] N-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl)-2-methoxy-4-(methylsulfonamido)benzamide (compound IB-L4-1.1). 'H NMR (300 MHz, DMSO-d6) δ 1.40 (s, 9 H) 3.14 (s, 3 H) 3.84 (s, 3 H) 4.06 (s, 3 H) 5.65 (dd, J=7.72, 2.21 Hz, 1 H) 6.96 (dd, 1=8.46, 1.84 Hz, 1 H) 7.04 (d, 1=1.84 Hz, 1 H) 7.09 (d, 1=2.94 Hz, 1 H) 7.71 (d, J=7.72 Hz, 1 H) 8.01 (d, 1=8.82 Hz, 1 H) 8.28 (d, 1=2.57 Hz, 1 H) 10.27 (s, 1 PI) 10.32 (s, 1 H) 11.41 (d, 1=2.21 Hz, 1 H).

[001987] {l-[3-tert-butyl-5-(2,4-dioxo-tetrahydro-pyrimidin-l-yl)-2-hydroxy-benzyl]-piperidin-4-yl}-carbamic acid tert-butyl ester (compound IA-L5-1-1.1), 'H NMR (300 MHz, CDC13) δ ppm 7.36 (s, 1 H) 7.03 (d, J= 2.94 Hz, 1 H) 6.77 (d, ./=2.57 Hz, 1 H) 4.43 (s, 1 H) 3.79 (t, ./=6.62 Hz, 2 H) 3.66 (s, 2 H) 3.44-3.61 (m, 1 H) 2.88-3.01 (m, 1 H) 2.81 (t, ./=6.62 Hz, 2 H) 2.22 (s, 2 Η) 1.98 (s, 2 H) 1.44 (s, 9 H) 1.39 (s, 9 H) 1.28-1.71 (m,2H) [001988] N-{l-[3-tert-butyl-5-(2,4-dioxo-tetrahydro-pyrimidin-l-yl)-2-hydroxy-benzyl]-piperidin-3-ylmethyl}-methanesulfonamide (compound IA-L5-1-1.2).1Η NMR (300 MHz, CDCI3) δ ppm 7.45 (s, 1 H) 7.03 (d, J= 2.57 Hz, 1 H) 6.78 (d, ./=2.21 Hz, 1 H) 4.37 (s, 1 H) 3.81 (t, ^=6.80 Hz, 2 H) 3.58-3.73 (m, 2 H) 3.07 (s, 2 H) 2.92 (s, 3 H) 2.81 (t, J= 6.62 Hz, 2 H) 1.72-1.95 (m, 4 H) 1.49-1.72 (m, 4 H) 1.39 (s, 9 358 2014280939 24 Dec 2014 Η) [001989] l-[3-tert-butyl-5-(2,4-dioxo-tetrahydro-pyrimidin-]-yl)-2-hydroxy-benzyl]-piperidine-3-carboxylic acid ethyl ester (compound IA-L5-1-1.3). 'H NMR (300 MHz, CDCI3) δ ppm 7.39 (s, I H) 7.03 (d, ./=2.57 Hz, 1 H) 6.78 (d, /= 2.57 Hz, 1 H) 4.09-4.22 (m, 2 H) 3.79 (t, /= 6.62 Hz, 2 H) 3.67 (s, 2 H) 3.05 (s, 1 H) 2.81 (t, ./=6.80 Hz, 2 H) 2.51-2.69 (m, 1 H) 2.38 (s, 1 H) 2.15 (s, 1 H) 1.88-2.07 (m, 1 H) 1.70-1.85 (m, 1 H) 1.46-1.69 (m, 3 H) 1.39 (s, 9 H) 1.21-1.30 (m, 3 H) [001990] l-[3-tert-butyl-4-hydroxy-5-(3-methyl-piperidin-l-ylmethyl)-phenyl]-dihydro-pyrimidine-2,4-dione; compound with trifluoroacetic acid (compound IA.-L5-1-1.4).

[001991] l-[3-tert-butyl-5-(2,4-dioxo-tetrahydro-pyrimidin-l-yl)-2-hydroxy-benzyl]-piperidine-4-carboxylic acid methyl ester (compound IA-L5-1-1.5). 'H NMR (300 MHz, CDC13) δ ppm 7.38 (s, 1 H) 7.03 (d, ./=2,57 Hz, 1 H) 6.77 (d, ./=2.57 Hz, 1 H) 3.79 (t, /=6.80 Hz, 2 H) 3.69 (s, 3 H) 3.66 (s, 2 H) 2.97 (s, 2 H) 2.80 (t, /=6.80 Hz, 2 H) 2.30-2.46 (m, 1 H) 2.17 (s, 2 Η) 1.91-2.03 (m, 2 H) 1.83 (s, 2 H) 1.39 (s, 9 H) [001992] l-[3-tert-butyl-4-hydroxy-5-((R)-3-hydroxy-piperidin-l-ylmethyl)-phenyl]-dihydro-pyrimidine-2,4-dione; compound with trifluoroacetic acid (compound IA-L5-1-1.6).

[001993] l-[3-tert-butyl-5-(2,4-dioxo-tetrahydro-pyrimidin-l-yl)-2-hydroxy-benzyl]-piperidme-3-carboxylic acid diethylamide, trifluoroacetic acid salt (compound IA-L5-1-1.7).

[001994] l-[3-tert-butyl-5-(2,4-dioxo-tetrahydro-pyrimidin-l-yl)-2-hydroxy-benzyl]-piperidine-3-carboxylic acid amide, trifluoroacetic acid salt (compound IA-L5-1-1.8).

[001995] 4-[3-tert-butyl-5-(2.4-dioxo-tetrahydro-pyrimidin-1 -yl)-2-hydroxy-benzyl]-piperazine-1 -carboxylic acid tert-butyl ester (compound IA-L5-1-1.10). 'HNMR (300 MHz, CDC13) δ ppm 7.37 (s, 1 H) 7.05 (d, /=2.57 Hz, 1 H) 6.80 (d, /=2.57 Hz, 1 H) 3.79 (t, /=6.62 Hz, 2 H) 3.69 (s, 2 H) 3.34-3.61 (m, 2 H) 2.81 (t, /=6.62 Hz, 2 H) 2.52 (s, 2 Η) 1.56 (s, 4 Η) 1.46 (s, 9 H) 1.39 (s, 9 H) [001996] N-{ 1 -[3-tert-butyl-5-(2,4-dioxo-tetrahydro-pyrimidm-1 -yl)-2-hydroxy-benzyl]-pyrrolidin-3-yl}-methanesulfonamide (compound IA-L5-l-l.il). 'H NMR (300 MHz, CDC13) δ ppm 7.48 (s, 1 H) 7.04 (d, /=2.57 Hz, 1 H) 6.81 (d, /=2.21 Hz, 1 H) 4.66 (s, 1 H) 4.04-4.17 (m, 2 H) 3.80 (t, /=6.62 Hz, 2 H) 2.96 (s, 3 H) 2.85-2.93 (m, 1 H) 2.82 (t, /=6.62 Hz, 2 H) 2.65-2.76 (m, 1 H) 2.50-2.64 (m, 1 H) 2.34-2.49 (m, 1 H) 1.73-1.89 (m, 1 H) 1.39 (s, 9 H) [001997] {1 - [3 -tert-butyl-5 -(2,4-dioxo-tetrahydro-pyrimidin-1 -yl)-2-hydroxy-benzy 1] -pyrrolidin-3 -y 1} -carbamic acid tert-butyl ester (compound IA-L5-1-1.12). 'H NMR (300 MHz, CDC13) δ ppm 7.38 (s, 1 H) 7.01-7.04 (m, 1 H) 6.77-6.80 (m, 1 H) 4.66-4.75 (m, 1 H) 4.16-4.27 (m, 1 H) 3.80 (t, 2 H) 3.68-3.87 (m, 2 H) 2.81 (t, 2 H) 2.26-2.96 (m, 5 H) 1.49-1.74 (m, 2 H) 1.43 (s, 9 H) 1.40 (s, 9 H) [001998] 1 -(3-tert-butyl-5-((2,6-dimethylmorpholino)methyl)-4-hydroxyphenyl)dihydro pyrimidine-2,4(1 H,3H)-dione 2,2,2-trifluoroacetate (compound IA-L5-1-1.13). 359 2014280939 24 Dec 2014 [001999] l-(3-tert-butyl-4-hydroxy-5-(morpholinomethyl)phenyl)dihydropyrimidine-2,4(lH,3H)-dione 2,2,2-trifluoroacetate (compound IA-L5-1-1.14).

[002000] 1 -(3 -tert-butyl-4-methoxy-5-(( 1 -methyl-1 H-indol-3 -yl)methyl)phenyl)dihydropyrimidine -2,4( 1 H,3H)-dione (compound IA-L5-1-2.1). 'H NMR (300MHz, DMSO-d6): δ 10.23 (s,lH), 7.48 (d, J=8.1Hz,lH), 7.38 (d, l=8.1Hz, 1H), 7.17 (m,1H), 7.08 (d, J=2.6Hz, 1H), 7.04 (s, 1H), 6.98 (m, 2H), 4.05 (s, 2H), 3.76 (s, 3H), 3.72 (s, 3H), 3.66 (t, J=6.6Hz, 1H), 2.62 (t, J=6.6Hz, 1H), 1.37 (s, 9H) [002001J N-(l-(3-tert~butyl~5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxybenzyl)-l,2,3,4-tetrahydroquinolin-6-yl)methanesulfonamide (compound IA-L5-1-2.2). 'H NMR (300 MHz, CDC13) δ 9.38 (s, 1 H) 7.46 (s, 1 H) 7.09 (d, 1=2.21 Hz, 1 H) 6.94 - 7.06 (m, 2 H) 6.91 (d, J=2.57 Hz, 1 H) 6.23 -6.31 (m, 1 H) 5.37 (d, J=6.99 Hz, 1 H) 3.77 - 3.89 (m, 3 H) 3.04 - 3.12 (m, 2 H) 2.97 (s, 3 H) 2.78 - 2.96 (m, 3 H) 1.94 - 2.04 (m, 2 H) 1.39 (s, 9 H).

[002002] N-(4-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)phenethyl)phenyl)methane sulfonamide (compound IA-L5-2-1.2). 'H NMR (300 MHz, DMSO-d6) δ 1.25 (s, 9 H) 2.69 (t, J=6,62 Hz, 2 H) 2.83 (s, 4 H) 2.91 (s, 3 H) 3.75 (t, 1=6.62 Hz, 2 H) 6.99 - 7.21 (m, 7 H) 9.60 (s, 1 H) 10.31 (s, 1 H).

[002003] methyl 2-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l (2H)-yl)-2-methoxyphen ethyl)-5-(methylsulfonamido)benzoate (compound IB-L5-2-1.1). 'H NMR (300 MHz, DMSO-d6) δ 1.34 (s, 9 H) 2.83 - 2.92 (m, 2 H) 2.96 (s, 3 H) 3.14 (dd, 1=10.30, 5.88 Hz, 2 H) 3.75 (s, 3 H) 3.83 (s, 3 H) 5.64 (d, J=7.72 Hz, 1 H) 7.13 (d, J=2.94 Hz, 1 H) 7.20 (d, J=2,57 Hz, 1 H) 7.28 - 7.36 (m, 2 H) 7.61 - 7.71 (m, 2 H) 9.88 (s, 1 H) 11.39 (s, 1 H) [002004] N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2II)-yl)-2-methoxyphenethyl)phenyl) methanesulfonamide (compound LB-L5-2-1.2). ’H NMR (300 MHz, DMSO-d6): δ 11.39 (s,lH), 9.60 (s,lH), 7.65 (d, J-8.1Hz,lH), 7.23(m,3H), 7.17(m,3H), 5.64(d,J=7.7Hz,lH), 3.77(s,3H), 2.93(s,3H), 2.88(bs,4H), 1.35(s,9H) [002005] N-(4-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxybenzyloxy)phenyl) methanesulfonamide (compound IA-L6-1.1), 'H NMR (300 MHz, DMSO-d6) δ ppm 1.36 (s, 9 H) 2.69 (t, J=6.62 Hz, 2 H) 2.89 (s, 3 H) 3.71 - 3.76 (m, 2 H) 3.78 (s, 3 H) 5.05 (s, 2 H) 6.96 - 7.12 (m, 2 H) 7.10 - 7.21 (m, 2 H) 7.23 (d, 1=2.94 Hz, 1 H) 7.32 (d, 1=2.57 Hz, 1 H) 9.39 (s, 1 H) 10.32 (s, 1 H).

[002006] l-(3-tert-butyl-5-((cyclohexyl(ethyl)amino)methyl)-4-hydroxyphenyl)dihydropyrimidine-2,4(lH,3H)-dione 2,2,2-trifluoroacetate (compound IA-L9-1.1).

[002007] 1 -(3-tert-buty!-5-((cyclohexyl(methyl)amino)methyl)-4-hydroxyphenyl)dihydro pyrimidine-2,4(1 H,3H)-dione 2,2,2-trifluoroacetate (compound IA-L9-1.2).

[002008] N-(4-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-hydroxybenzylamino)phenyl) methanesulfonamide (compound IA-L9-1.3). ‘H NMR (300 MHz, DMSO-d6) δ 1.37 (s, 9 H) 2.66 (t, 1=6.62 Hz, 2 H) 2.82 (s, 3 H) 3.65 (t, 1=6.62 Hz, 2 H) 4.24 (d, 1=5.15 Hz, 2 H) 6.10 (t, 1=5.52 Hz, 1 H) 360 2014280939 24 Dec 2014 6.64 (d, J=8.82 Hz, 2 H) 6.98 (d, J=8.82 Hz, 2 H) 7.03 (s, 2 H) 8.79 (s, 1 H) 9.04 (s, 1 H) 10.22 (s, 1 H).

[002009] N-(4-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxybenzylammo)phenyl) methanesulfonamide (compound IA-L9-1.4). 'H NMR (500 MHz, DMSO-ds) δ 1.36 (s, 9H), 2.65 (t, J=6,7 Hz, 2H), 2.80 (s, 3H), 3.68 (t, 6.7 Hz, 2H), 3.79 (s, 3H), 4.25 (d, J 5.5 Hz, 2H), 6.10 (m, 1H), 6.55 (d, J= 8.5 Hz, 2H), 6.94 (d, J= 8.5 Hz, 2H), 7.13 (d, J=2.5 Hz, 1H), 7.19 (d, J= 2.4 Hz, 1H), 8.92 (s, 1H), 10.23 (s, 1H).

[002010] N-(4-(2-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl)-2-oxoethyl)phenyl)methanesulfonamide (compound IA-L11-1.1).1H NMR (300 MHz, l)MSO-d6) δ 1.36 (s, 9 H) 2.70 (t, J=6.62 Hz, 2 H) 2.96 (s, 3 H) 3.64 (s, 3 H) 3.76 (t, J=6,62 Hz, 2 H) 4.27 (s, 2 H) 7.10 -7.26 (m, 4 H) 7.32 - 7.41 (m, 2 H) 9.67 (s, 1 H) 10.37 (s, 1 H).

[002011] N-(4-(2-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-2-methoxyphenyl)acetyl) phenyl)methanesulfonamide (compound IA-L12-1.1). ]H NMR (300 MHz, DMSO-d6) δ 1.33 (s, 9 H) 2.68 (t, J-6,62 Hz, 2 H) 3.12 (s, 3 H) 3.61 (s, 3 H) 3.72 (t, J=6.62 Hz, 2 H) 4.36 (s, 2 H) 7.01 (d, J=2.94 Hz, 1 H) 7.15 (d, J=2.57 Hz, 1 H) 7.29 (d, J=8.82 Hz, 2 H) 8.04 (d, J=8.82 Hz, 2 H) 10.29 (s, 1 H) 10.35 (s, 1 H).

[002012] The following compounds can be prepared utilizing the above discussion: TABLE Λ

361 2014280939 24 Dec 2014

IA-L2-L6

compound R5 substituent(s) IA-L3-1.23 -OH -2-OCH3- 362 compound R5 substituent(s) IA-L3-1.29 -OCH3 -4-C(H)2N(H)S(0)2CH3 IA-L3-1.61 -och3 O O IA-L3-1.68 -och3 -4-N[C(H)2C(H)=CH2] S(0)2CH3 IA-L3-1.75 -OCH3 -4-N[C(0)0C(H)2C(H)2CH3]S(0)2CH3 2014280939 24 Dec 2014 [002013] HCV Polymerase Inhibition Assay [002014] Either two-fold serial dilutions (fractional inhibition assay) or a narrower range of dilutions spanning the IC50 of the inhibitor (tight binding assay) of the inhibitors were incubated with 20mM Tris-C1 pH 7.4, 2mM MnCl2, ImM dithiothreitol, ImM ethylene diamine tetraacetic acid (EDTA), 60 to 125μΜ GTP and 20 to 50nM Δ21 NS5B (HCV Strain IB (BK, Genbank accession number M58335, or H77, Genbank accession number AF011751)) for 15min at room temperature. The reaction was initiated by the addition of 20μΜ CTP, 20μΜ ATP, ΙμΜ 3H-UTP (10mCi/umol), 5nM template RNA and 0.1 U/μΙ RNase inhibitor (RNasin, Promega), and allowed to proceed for 2 to 4h at room temperature. Reaction volume was 50μ1. The reaction was terminated by the addition of 1 volume of 4mM spermine in lOmM Tris-Cl pH 8.0, ImM EDTA. After incubation for at least 15 min at room temperature, the precipitated RNA was captured by filtering through a GF/B filter (Millipore) in a 96 well format. The filter plate was washed three times with 200μ1 each of 2mM spermine, lOmM Tris-Cl pH 8.0, ImM EDTA, and 2 times with ethanol. After air-drying, 30μ1 of Microscint 20 scintillation cocktail (Packard) was added to each well, and the retained cpm were determined by scintillation counting. IC50 values were calculated by a two-variable nonlinear regression equation using an uninhibited control and a fully inhibited control sample to determine the minimum and maximum for the curve. Tight-binding assays were performed on those compounds exhibiting IC50 values less than 0.005μΜ in the fractional inhibition assay in order to more precisely measure the IC50 values. Retained cpm were plotted vs. inhibitor concentration and fit to equation 1 using non-linear regression (ref. 1) to obtain the IC50 values:

Retained cpm=A [sqrt{(IC5o+It-Et)A2+4*IC5o*Et}-(IC5o+IrEt)] (eqn 1) where A=Vmax[S]/2(Km+[S]); It=totaI inhibitor concentration and Et=total active concentration of enzyme.

[002015] Ref. Morrison, J. F. and S. R. Stone. 1985. Approaches to the study and analysis of the 363 2014280939 24 Dec 2014 inhibition of enzymes by slow- and tight-binding inhibitors. Comments Mol. Cell. Biophys. 2: 347-368.

[002016] The sequence of the template RNA used was: 5-GGGCGAAUUG GGCCCUCUAG AUGCAUGCUC GAGCGGCCGC CAGUGUGAUG GAUAUCUGCA GAAUUCGCCC UUGGUGGCUC CAUCUUAGCC CUAGUCACGG CUAGCUGUGA AAGGUCCGUG AGCCGCUUGA CUGCAGAGAG UGCUGAUACU GGCCUCUCUG C AG A U C A AGUC-3' [002017] When tested by the above method, the compounds of this invention inhibit HCV polymerase 1A and/or IB. The legend in the table below is as follows: A — IC50 < O.OluM; B — 0.1uM> IC50> O.OluM; C--luM > IC50 > 0.1 uM; and D — IC5o > luM; ND-not determined.

Table KUn

compound la lb compound la lb IA-L0-1.1 A B IA-LO-1.2 B B IA-LO-1.3 C C IA-LO-1.4 B B IA-LO-1.5 C C IA-LO-1.6 B B IA-LO-1.7 D c IA-LO-1.8 C C IA-LO-1.9 B c IA-L0-1.10 D D IA-L0-l.il D D IB-L0-1.1 A A IB-LO-1.2 C C IB-LO-1.3 B B IB-LO-1.4 B B IB-LO-1.5 B B IB-LO-1.6 C C IB-LO-1.7 B B IB-LO-1.8 C C IB-LO-1.9 C C IB-L0-1.10 C C IA-LO-2.1 C C IA-LO-2.2 B B IA-LO-2.3 C C IA-LO-2.4 B B IA-LO-2.5 C c IA-LO-2.6 C C IA-LO-2.7 C c IA-LO-2.8 B B IA-LO-2.9 A A IA-L0-2.10 D D IB-LO-2.1 C C IB-L0-2.2 C C IB-LO-2.3 A A IB-LO-2.4 A A IB-LO-2.5 B B IB-LO-2.6 B B IB-LO-2.7 B B IB-LO-2.8 B B IB-LO-2.9 A A IB-L0-2.10 A B IB-LO-2.11 A A IB-LO-2,12 A B IB-LO-2.13 A B IB-LO-2.14 A A IB-LO-2.15 A B 364 2014280939 24 Dec 2014

compound la lb compound la lb IB-LO-2.16 A B IB-LO-2.17 A B IB-LO-2.18 A B IB-LO-2.19 A B IB-L0-2.20 A B IB-LO-2.21 B B IB-LO-2.22 B B ÏB-L0-2.23 B A IB-LO-2.24 B B IB-LO-2.25 B B 1B-L0-2.26 B B IB-LO-2.27 B B IB-LO-2.28 B B IB-LO-2.29 B B IB-L0-2.30 B B IB-LO-2.31 B B IB-LO-2.32 B B IB-LO-2.33 B B IB-LO-2.34 B B IB-LÖ-2.35 B B IB-LO-2.36 B C IB-LO-2.37 C C IB-LO-2.38 C B IB-LO-2.39 C C IB-L0-2.40 C C IB-LO-2.41 C C IB-LO-2.42 C C IB-LO-2.43 C C IB-LO-2.44 C C IB-LO-2.45 C C IB-LO-2.46 C C IB-LO-2.47 D D IB-LO-2.48 D D IB-LO-2.49 D D IB-L0-2.50 B B IB-LO-2.51 A B IB-LO-2.52 A B IB-LO-2.53 A B IB-LO-2.54 A B IB-LO-2.55 A B IB-LO-2.56 A B IB-LO-2.57 A B IB-LO-2.58 A B IB-LO-2.59 A B IB-L0-2.60 A B IB-LO-2.61 A B IB-LO-2.62 B B IB-LO-2.63 B B IB-LO-2.64 B B IB-LO-2.65 B A IB-LO-2.66 B B IB-LO-2.67 B B IB-LO-2.68 B B IB-LO-2.69 B B IB-L0-2.70 B C IB-LO-2.71 C C IB-LO-2.72 C C IB-LO-2.73 C C IB-LO-2.74 C C IB-LO-2.75 C D IB-LO-2.76 C D IB-LO-2.77 D D IB-LO-2.78 D D IB-LO-2.79 B B 365 2014280939 24 Dec 2014

compound la lb compound la lb IA-L1-1.3 A A IA-L1-1.4 A A IA-L1-1.5 A B IA-L1-1.6 A B IA-L1-1.9 A B IA-L1-1.10 B B IA-Ll-l.il B B IA-L1-1.12 C C IA-L1-1.13 C C IA-L1-1.14 D D IA-L1-1.16 A A IA-L1-1.17 B B IA-L 1-1.18 C C IA-L1-1.20 A B IA-L1-1.21 B B LA-L1-1.22 C C IA-L1-1.23 C C IA-L1-1.24 D D IA-L1-1.25 D D IA-L1-1.26 B B IA-L1-1.27 A B IB-L1-1.1 A A IB-L1-1.2 B B 1B-L1-1.4 A A IB-L1-1.5 A A IB-L1-1.6 A B IB-L1-1.7 A B IB-L1-1.8 A B IB-L1-1.9 A B IB-L1-1.10 A B IB-Ll-l.il A B IB-L1-1.12 A B IB-L1-1.13 A B IB-L1-1.14 A B IB-L1-1.15 A B IB-L1-1.16 A B IB-L1-1.17 A B IB-L1-1.18 A B IB-L1-1.19 A B IB-L1-1.20 A B IB-L1-1.21 A B IB-L1-1.22 B B IB-L1-1.23 B B IB-L1-1.24 B B IB-L1-1.25 B B IB-L1-1.26 B B IB-L1-1.27 B B IB-L1-1.28 B B IB-L1-1.29 B B IB-L1-1.30 B B IB-L1-1.31 B C IB-L1-1.32 C C IB-L1-1.33 C C IB-L1-1.34 D D IB-L1-1.45 A B IB-L1-1.46 B B IB-L1-1.47 B B IB-L1-1.48 B B IB-L1-1.49 B C IB-L1-1.50 B B IB-L1-1.51 B B IB-L1-1.52 C C IB-L1-1.53 D D IB-L1-1.55 D D 366 2014280939 24 Dec 2014

compound la lb compound la lb IA-L2-1.1 B A IA-L2-1.2 A A IA-L2-1.3 A A IA-L2-1.4 C C IA-L2-1.7 B B IA-L2-1.8 A A IA-L2-1.9 A A IA-L2-1.10 B B IA-L2-l.il A B IA-L2-1.12 A A IA-L2-1.13 A A IA-L2-1.14 A A IA-L2-1.15 B B IA-L2-1.16 A B IA-L2-1.17 B B IA-L2-1.18 A A IA-L2-1.19 C B IA-L2-1.20 A B IA-L2-1.21 A B IA-L2-1.22 B B IA-L2-1.23 C C IA-L2-1.24 A B IA-L2-1.25 A B IA-L2-1.26 B B IB-L2-1.1 A B IB-L2-1.2 A B IB-L2-1.3 A B IB-L2-1.4 B B IB-L2-1.5 B B IB-L2-1.6 A B IB-L2-1.7 A B IB-L2-1.8 A B IB-L2-1.9 C B IB-L2-1.10 A B IB-L2-l.il B B IB-L2-1.12 B B IB-L2-1.15 C C IA-L2-2.1 B B IB-L2-2.1 B B IA-L3-1.1 D D IA-L3-1.2 D B IA-L3-1.3 D C IA-L3-1.4 C B IA-L3-1.5 C B IA-L3-1.6 B A IA-L3-1.7 C B IA-L3-1.8 B B IA-L3-1.9 C B IA-L3-1.10 B B IA-L3-l.il D C IA-L3-1.12 C B IA-L3-1.13 C A IA-L3-L14 B A IA-L3-1.15 D C IA-L3-1.16 D B IA-L3-1.17 D ND IA-L3-1.18 D ND LA-L3-1.19 C B IA-L3-1.20 D B IA-L3-1.21 D C IA-L3-1.22 C B IA-L3-1.24 C C IA-L3-1.25 D D IA-L3-1.26 D D 367 2014280939 24 Dec 2014

compound la lb compound la lb IA-L3-1.27 c C IA-L3-1.28 ND ND IA-L3-1.30 D C IA-L3-1.31 D D IA-L3-1.32 ND ND IA-L3-1.33 D C IA-L3-1.34 ND ND IA-L3-1.35 ND ND IA-L3-1.36 ND ND IA-L3-1.37 ND ND IA-1,3-1.38 D C IA-L3-1.39 D C IA-L3-1.40 ND ND IA-L3-1.41 C D IA-L3-1.42 D D IA-L3-1.43 D D IA-L3-1.44 ND ND IA-L3-1.45 ND ND IA-L3-1.46 ND ND IA-L3-1.47 D D IA-L3-1.48 D D IA-L3-1.49 D D IA-L3-1.50 D D IA-L3-1.51 B B IA-L3-1.52 C C IA-L3-1.53 ND ND IA-L3-1.54 B C IA-L3-1.55 C C IA-L3-1.56 C C IA-L3-1.57 B C IA-L3-1.58 C C IA-L3-1.59 C B IA-L3-1.60 B B IA-L3-1.62 C C IA-L3-1.63 D D IA-L3-1.64 C D IA-L3-1.65 D D IA-L3-1.66 D D IA-L3-1.67 D D IA-L3-1.69 C C IA-L3-1.70 D D IA-L3-1.71 C D IA-L3-1.72 D D 1A-L3-1.73 D D IA-L3-1.74 D D IA-L3-1.76 D D IA-L3-1.77 D D IA-L3-1.78 D D IA-L3-1.79 D D IA-L3-1.80 D D IA-L3-1.81 ND ND IA-L3-1.82 ND ND IA-L3-1.83 B C IA-L3-1.84 C C IA-L3-1.85 C C IA-L3-1.86 ND ND IA-L3-1.87 D c IA-L3-1.88 D D IA-L3-1.89 B B IA-L3-1.90 B B IA-L3-1.91 B B IA-L3-1.94 C C IA-L3-1.95 C B IA-L3-1.96 C D 368 2014280939 24 Dec 2014

compound la lb compound la lb IA-L3-1.97 D D IA-L3-1.98 D C IA-L3-1.99 B C IA-L3-1.100 D C IA-L3-1.101 D D IA-L3-1.102 C C IA-L3-1.103 C D IA-L3-1.104 D C IA-L3-1.105 C B IA-L3-1.107 D D IA-L3-1.108 D D IA-L3-1.111 B C IA-L3-1.112 C C IA-L3-1.113 D D IA-L3-1.114 D D IA-L3-1.115 D D IA-L3-1.116 D D IA-L3-1.117 D D IA-L3-1.118 D D IA-L3-1.119 B A IA-L3-1.120 C C IA-L3-1.121 C C IA-L3-1.122 B B IA-L3-1.123 D D IB-L3-1.1 B B IB-L3-1.2 B A IB-L3-1.3 C D IB-L3-1.4 C B IA-L3-2.1 D C IA-L3-2.2 C C IA-L3-2.3 D D IA-L3-2.4 D D IA-L3-2.5 D C IA-L4-1.1 C C IA-L4-1.2 D D IA-L4-1.3 C C IA-L4-1.4 D D IA-L4-1.5 D D IA-L4-L6 D D IA-L4-1.7 C D IA-L4-1.8 D C IA-L4-1.9 B B IA-L4-1.10 D D IA-L4-l.il A B IA-L4-1.12 B B IB-L4-1.1 A B IA-L5-1-1.1 D D 1A-L5-1-1.2 D D IA-L5-1-1.3 D D IA-L5-1-1.4 D D IA-L5-1-1.5 D D IA-L5-1-1.6 D D IA-L5-1-1.7 D D IA-L5-1-1.8 D D IA-L5-1-1.10 D D IA-L5-l-l.il D D IA-L5-1-1.12 D D IA-L5-1-1.13 D D IA-L5-1-1.14 D D IA-L5-1-2.1 D D IA-L5-1-2.2 D D IA-L5-2-1.1 B B IA-L5-2-1.2 B B IB-L5-2-1.1 A B 369

compound la lb compound la lb IB-L5-2-1.2 B B IA-L6-U B C IA-L8-1.1 C C IA-L9-1.1 D D IA-L9-1.2 D D IA-L9-1.3 D D IA-L9-1.4 B C IA-L11-1.1 B B IA-L12-1.1 B B 2014280939 24 Dec 2014 [002018] HCV Polymerase Replicon Assay [002019] Two stable subgenomic replicon cell lines were used for compound characterization in cell culture: one derived from genotype la-H77 and one derived from genotype lb-Conl (obtained from Apath, LLC, St. Louis, MO). All replicon constructs were bicistronic subgenomic replicons similar to those described by Bartenschlager and coworkers (Lohmann et al., Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line, SCIENCE 285:110-3(1999)). The genotype la replicon construct contains NS3-NS5B coding region derived from the H77 strain of HCV (la-H77) (Blight et al., Efficient Replication of Hepatitis C Virus Genotype la RNAs in Cell Culture, J. VIROL. 77:3181-90 (2003)). The replicon also has a firefly luciferase reporter and a neomycin phosphotransferase (Neo) selectable marker. These two coding regions, separated by the FMDV 2a protease, comprise the first cistron of the bicistronic replicon construct, with the second cistron containing the NS3-NS5B coding region with addition of adaptive mutations E1202G, K1691R, K2040R and S2204I. The lb-Conl replicon construct is identical to the la-H77 replicon, except that the NS3-NS5B coding region was derived from the lb-Conl strain, and the adaptive mutations are E1202G, T12801 and S2204I. Replicon cell lines were maintained in Dulbecco’s modified Eagles medium (DMEM) containing 10% (v/v) fetal bovine serum (FBS), 100 IU/ml penicillin, 100mg/ml streptomycin (Invitrogen), and 200mg/ml G418 (Invitrogen).

[002020] The inhibitory effects of compounds on HCV replication were determined by measuring activity of the luciferase reporter gene. Briefly, replicon-containing cells were seeded into 96 well plates at a density of 5000 cells per well in lOOul DMEM containing 5% FBS. 16-24h later, the compounds were diluted in dimethyl sulfoxide (DMSO) to generate a 200x stock in a series of eight half-log dilutions. The dilution series was then further diluted 100-fold in the medium containing 5% FBS. Medium with the inhibitor was added to the overnight cell culture plates already containing lOOul of DMEM with 5% FBS. In assays measuring inhibitory activity in the presence of human plasma, the medium from the overnight cell culture plates was replaced with DMEM containing 40% human plasma and 5% FBS. The cells were incubated for three days in the tissue culture incubators and were then lysed for RNA extraction. For the luciferase assay, 30ul of Passive Lysis buffer (Promega) was added to each well, and then the plates were incubated for 15min with rocking to lyse the cells. Luciferin solution (50 to lOOul, Promega) was added to each well, and luciferase activity was measured with a Victor II 370 2014280939 24 Dec 2014 luminometer (Perkin-Elmer). The percent inhibition of HCV RNA replication was calculated for each compound concentration and the EC50 value was calculated using nonlinear regression curve fitting to the 4-parameter logistic equation and GraphPad Prism 4 software.

[002021] When tested by the above method, the compounds of this invention inhibit HCV polymerase 1A and/or IB. The legend in the table below is as follows: A -- EC50 < O.OluM; B — O.luM > ΕΟ50 > 0.01 uM;C- luM > EC50> O.luM; andD--EC50 > luM; ND-notdetermined.

TableECso

compound la lb compound la lb IA-LO-1.1 c A IA-LO-1.2 c B IA-L0-U c C IA-LO-1.4 c B IA-LO-1.5 D D IA-LO-1.6 c B 1A-L0-1.7 D D IA-L0-1.8 D D IA-L0-1.9 D C IA-L0-1.10 ND ND IA-L0-l.il ND ND IB-L0-1.1 B B IB-LO-1.2 D D IB-LO-1.3 C B IB-LO-1.4 C B IB-LO-1.5 B B IB-LO-1.6 D C IB-LO-1.7 D C IB-LO-1.8 D D IB-LO-1.9 D D IB-L0-1.10 D D IA-LO-2.1 D D IA-LO-2.2 C B IA-LO-2.3 C C IA-LO-2.4 D C 1A-L0-2.5 D D IA-LO-2.6 D D IA-LO-2.7 D C IA-LO-2.8 C B IA-LO-2.9 A A IA-L0-2.10 ND ND IB-LO-2.1 D C IB-L0-2.2 D D IB-LO-2.3 A A IB-L0-2.4 ND A IB-LO-2.5 B A IB-LO-2.6 C B IB-LO-2.7 C B IB-LO-2.8 ND B IB-LO-2.9 A A IB-L0-2.10 A A IB-LO-2.11 B A IB-L0-2.12 B A IB-LO-2.13 B A IB-L0-2.14 C B IB-LO-2,15 C B IB-L0-2.16 c A IB-LO-2.17 B A IB-LO-2.18 c B IB-LO-2.19 B B 371 2014280939 24 Dec 2014

compound la lb compound la lb IB-L0-2.20 c B IB-L0-2.21 c B IB-LO-2.22 c B IB-LO-2.23 c B IB-LO-2.24 B B IB-LO-2.25 c B IB-LO-2.26 D C IB-LO-2.27 c B IB-LO-2.28 D C IB-LO-2.29 c B IB-L0-2.30 C B IB-LO-2.31 c B IB-LO-2.32 C B IB-LO-2.33 c C IB-LO-2.34 D C IB-LO-2.35 D C IB-LO-2.36 C B IB-LO-2.37 D C IB-LO-2.38 D D IB-LO-2.39 D C IB-L0-2.40 D C IB-LO-2.41 c C IB-LO-2.42 C C IB-LO-2.43 D C IB-LO-2.44 D D IB-LO-2.45 D C IB-LO-2.46 ND ND IB-LO-2.47 ND ND IB-LO-2.48 ND ND IB-LO-2.49 ND ND IB-L0-2.50 C C IB-LO-2.51 B A IB-LO-2.52 B A IB-LO-2.53 B B IB-LO-2.54 B B IB-LO-2.55 B A IB-LO-2.56 C A IB-LO-2.57 C B IB-LO-2.58 B A IB-LO-2.59 C B IB-L0-2.60 C B IB-LO-2.61 C B IB-LO-2.62 C B IB-LO-2.63 C B IB-LO-2.64 C A IB-LO-2.65 C B IB-LO-2.66 C B IB-LO-2.67 C B IB-LO-2.68 D C IB-LO-2.69 C B IB-L0-2.70 D C IB-LO-2.71 C B IB-LO-2.72 D C IB-LO-2.73 C C IB-LO-2.74 D C IB-LO-2.75 D D IB-LO-2.76 ND ND IB-LO-2.77 ND ND IB-LO-2.78 ND ND IB-LO-2.79 C C IA-L1-1.3 B A IA-L1-1.4 A A IA-L1-1.5 B A IA-L1-1.6 B B 372 2014280939 24 Dec 2014

compound la lb compound la lb IA-L1-1.9 B A IA-L1-1.10 B B IA-Ll-l.il A A IA-L1-1.12 C C IA-L1-1.13 D C IA-L1-1.14 D D IA-L1-1.16 B B IA-L1-1.17 B B IA-L1-1.18 C C IA-L1-1.20 B B IA-L1-1.21 A A IA-L1-1.22 D C IA-L1-1.23 D D IA-L1-1.24 D D IA-L1-1.25 ND ND IA-L1-1.26 B B IA-L1-1.27 B A IB-L1-1.1 A A IB-L1-1.2 ND B IB-L1-1.4 B A IB-L1-1.5 B A IB-L1-1.6 A A IB-L1-1.7 A A IB-L1-1.8 B A IB-L1-1.9 B A IB-L1-1.10 A A IB-Ll-l.il B A IB-L1-1.12 B B IB-L1-1.13 B A IB-L1-1.14 B A IB-L1-1.15 A A IB-L1-1.16 C B IB-L1-1.17 B A IB-L1-1.18 B B IB-L1-1.19 B A IB-L1-1.20 B A IB-L1-1.21 B A IB-L1-1.22 B A IB-L1-1.23 C A IB-L1-1.24 B A IB-L1-1.25 B A IB-L1-1.26 B A IB-L1-1.27 B A IB-L1-1.28 A A IB-L1-1.29 C C IB-L1-1.30 C B IB-L1-1.31 D D IB-L1-1.32 C B IB-L1-1.33 C B IB-L1-1.34 B A IB-L1-1.45 B A IB-L1-1.46 C A IB-L1-1.47 C B IB-L1-1.48 C A IB-L1-1.49 D D IB-L1-1.50 C B IB-L1-1.51 D B IB-L1-1.52 D C IB-L1-1.53 ND ND IB-L1-1.55 ND ND IA-L2-1.1 C B IA-L2-1.2 B B IA-L2-1.3 B A IA-L2-1.4 C C 373 2014280939 24 Dec 2014

compound la lb compound la lb IA-L2-1.7 D C IA-L2-1.8 B A IA-L2-1.9 A A IA-L2-1.10 C B IA-L2-l.il A A IA-L2-1.12 B A IA-L2-1.13 C B IA-L2-1.14 A A IA-L2-1.15 C C IA-L2-1.16 B A IA-L2-1.17 c B IA-L2-1.18 B A IA-L2-1.19 D D IA-L2-1.20 B A IA-L2-1.21 B A IA-L2-1.22 C B IA-L2-1.23 D C IA-L2-1.24 C B IA-L2-1.25 C B IA-L2-1.26 B B IB-L2-1.1 A A IB-L2-1.2 ND A IB-L2-1.3 B A IB-L2-1.4 ND C IB-L2-1.5 C B IB-L2-1.6 B A IB-L2-1.7 ND A IB-L2-1.8 B A IB-L2-1.9 D ND 1B-L2-1.10 ND B IB-L2-l.il C B IB-L2-1.12 C B 1B-L2-1.15 D C IA-L2-2.1 C C IB-L2-2.1 C C IA-L3-1.1 ND ND IA-L3-1.2 D D IA-L3-1.3 D D IA-L3-1.4 D D IA-L3-1.5 D D IA-L3-1.6 C B IA-L3-1.7 D D IA-L3-1.8 D C IA-L3-1.9 D D IA-L3-1.10 C C 1A-L3-1.11 D D IA-L3-1.12 D D IA-L3-1.13 D D IA-L3-1.14 ND C ÏA-L3-1.15 D D IA-L3-1.16 D D IA-L3-1.17 D D IA-L3-1.18 D C IA-L3-1.19 D D IA-L3-1.20 D D IA-L3-1.21 D D IA-L3-1.22 D D IA-L3-1.24 D D IA-L3-1.25 ND ND IA-L3-1.26 ND ND IA-L3-1.27 D 'D IA-L3-1.28 ND ND IA-L3-1.30 D D IA-L3-1.31 D D 374 2014280939 24 Dec 2014

compound la lb compound la lb IA-L3-1.32 ND ND IA-L3-1.33 D D IA-I.3-1.34 ND ND IA-L3-1.35 ND ND IA-L3-1.36 ND ND IA-L3-1.37 ND ND IA-L3-1.38 D D IA-L3-1.39 D D IA-L3-1.40 ND ND IA-L3-1.41 D C IA-L3-1.42 ND ND IA-L3-1.43 ND ND IA-L3-1.44 ND ND IA-L3-1.45 ND ND IA-L3-1.46 ND ND IA-L3-1.47 ND ND IA-L3-1.48 ND ND IA-L3-1.49 ND ND IA-L3-1.50 ND ND IA-L3-1.51 C B IA-L3-1.52 D C IA-L3-1.53 ND ND IA-L3-1.54 ND B IA-L3-1.55 D D IA-L3-1.56 ND C IA-L3-1.57 C C IA-L3-1.58 ND C IA-L3-1.59 D D IA-L3-1.60 C B IA-L3-1.62 D C IA-L3-1.63 ND ND IA-L3-1.64 ND ND IA-L3-1.65 ND ND IA-L3-1.66 ND ND IA-L3-1.67 D C IA-L3-1.69 C B IA-L3-1.70 C B IA-L3-1.71 C B IA-L3-1.72 ND ND IA-L3-1.73 ND ND IA-L3-1.74 ND ND IA-L3-1.76 ND ND IA-L3-1.77 ND ND IA-L3-1.78 ND ND IA-L3-1.79 ND ND IA-L3-1.80 ND ND IA-L3-1.81 ND ND IA-L3-1.82 ND ND IA-L3-1.83 C C IA-L3-1.84 D D IA-L3-L85 C C IA-L3-1.86 ND ND IA-L3-1.87 ND D IA-L3-1.88 ND ND IA-L3-1.89 C B IA-L3-1.90 D C IA-L3-1.91 C C IA-L3-1.94 D C IA-L3-1.95 D D IA-L3-1.96 C D IA-L3-1.97 D D IA-L3-1.98 D C LA-L3-1.99 ND C IA-L3-1.100 ND D 375 2014280939 24 Dec 2014

compound la lb compound la lb IA-L3-1.101 ND ND IA-L3-1.102 ND C IA-L3-1.103 D D IA-L3-1.104 D D IA-L3-1.105 I) D IA-L3-1.107 D D IA-L3-1.108 ND ND IA-L3-1.111 ND C IA-L3-1.112 D C IA-L3-1.113 D D IA-L3-1.114 ND ND IA-L3-1.115 D D IA-L3-1.116 ND ND L4-L3-1.117 ND ND IA-L3-1.118 ND ND IA-L3-1.119 C B IA-L3-1.120 D D IA-L3-1.121 D C IA-L3-1.122 ND B IA-L3-1.123 C B IB-L3-1.1 C B IB-L3-1.2 C B IB-L3-1.3 ND C IB-L3-1.4 D D IA-L3-2.1 D D IA-L3-2.2 D D IA-L3-2.3 ND ND IA-L3-2.4 D D IA-L3-2.5 D D IA-L4-1.1 D D IA-L4-1.2 IA-L4-1.3 D D IA-L4-1.4 D D IA-L4-1.5 ND ND IA-L4-1.6 ND ND IA-L4-1.7 D D IA-L4-1.8 D C IA-L4-1.9 ND B IA-L4-1.10 ND ND IA-L4-l.il C B IA-L4-1.12 C C IB-L4-1.1 C B IA-L5-1-1.1 ND ND IA-L5-1-1.2 ND ND IA-L5-1-1.3 ND ND IA-L5-1-1.4 ND ND IA-L5-1-1.5 ND ND IA-L5-1-1.6 ND ND IA-L5-1-1.7 ND ND IA-L5-1-1.8 ND ND IA-L5-1-1.10 ND ND IA-L5-1-1.11 ND ND IA-L5-1-1.12 ND ND IA-L5-1-1.13 ND ND IA-L5-1-1.14 ND ND IA-L5-1-2.1 ND ND IA-L5-1-2.2 ND ND IA-L5-2-1.1 C B IA-L5-2-1.2 C C IB-L5-2-1.1 B A IB-L5-2-L2 C B IA-L6-1.1 C B IA-L8-1.1 c C IA-L9-L1 ND ND 376

compound la lb compound la lb IA-L9-1.2 ND ND IA-L9-1.3 ND ND IA-L9-1.4 D C IA-L11-1.1 C B IA-L12-1.1 C B *********** 2014280939 24 Dec 2014 [002022] All references (patent and non-patent) cited above are incorporated by reference into this patent application. The discussion of those references is intended merely to summarize the assertions made by their authors. No admission is made that any reference (or a portion of ay reference) is relevant prior art (or prior art at all). Applicants reserve the right to challenge the accuracy and pertinence of the cited references. 377

Claims (44)

1. Claims: 1. N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide or a solvate or hydrate thereof.
2. 2. Crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl) naphthalen-2-yl)methanesulfonamide.
3. 3. Crystalline solvate of N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl) naphthalen-2-yl)methanesulfonamide.
4. 4. Crystalline hydrate of N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl) naphthalen-2-yl)methanesulfonamide.
5. 5. A salt of N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl) naphthalen-2-yl)methanesulfonamide or a solvate or hydrate thereof.
6. 6. Crystalline salt of N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl) naphthalen-2-yl)methanesulfonamide.
7. 7. The salt of claim 5 or 6, wherein the salt is a sodium salt.
8. 8. The salt of any one of claims 5-7, wherein the salt is a monosodium salt.
9. 9. N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide, monosodium salt.
10. 10. Crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy- phenyl)naphthalen-2-yl)methanesulfonamide monosodium salt.
11. 11. The crystalline pattern B N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide monosodium salt of claim 10, wherein the salt has an X-ray powder diffraction pattern comprising at least three peaks selected from the group consisting of 5.4+0.2, 10.8+0.2, 14.4+0.2, 16.3+0.2, 17.0+0.2, 18.8+0.2, 19.2+0.2, 19.6+0.2, 21.6+0.2, 22.1+0.2, 23.7+0.2, 28.8+0.2, 29.1+0.2, and 31.8+0.2 degrees 2Θ.
12. 12. A pharmaceutical composition comprising the compound, or forms thereof, of any one of claims 1-11; and one or more excipients.
13. 13. The pharmaceutical composition of claim 12, wherein the pharmaceutical composition further comprises one or more additional therapeutic agents.
14. 14. The pharmaceutical composition of claim 13, wherein the one or more additional therapeutic agents are selected from the group consisting of interferon agents, ribavirin, HCV inhibitors, and anti-HIV agents.
15. 15. The pharmaceutical composition of claim 14, wherein the one or more additional therapeutic agents are selected from the group consisting of HCV inhibitors and anti-HIV agents.
16. 16. The pharmaceutical composition of claim 14, wherein the one or more additional therapeutic agents are selected from the group consisting of HCV protease inhibitors and anti-HIV agents.
17. 17. The pharmaceutical composition of claim 14, wherein the one or more additional therapeutic agents are selected from the group consisting of HCV inhibitors.
18. 18. The pharmaceutical composition of claim 14, wherein the additional therapeutic agent is ribavirin.
19. 19. A product comprising the compound, or forms thereof, of any one of claims 1-11, and one or more additional therapeutic agents selected from the group consisting of interferon agents, ribavirin, HCV inhibitors, and anti-HIV agents for simultaneous, sequential or both simultaneous and sequential use in inhibiting replication of a ribonucleic acid (RNA) virus.
20. 20. The product of claim 19, wherein the RNA virus is hepatitis C virus (HCV).
21. 21. A product comprising the compound, or forms thereof, of any one of claims 1-11, and one or more additional therapeutic agents selected from the group consisting of interferon agents, ribavirin, HCV inhibitors, and anti-HIV agents for simultaneous, sequential or both simultaneous and sequential use in treating hepatitis C in a mammal in need of such treatment.
22. 22. The product of any one of claims 19 to 21, wherein the one or more additional therapeutic agents are selected from the group consisting of HCV inhibitors and anti-HIV agents.
23. 23. The product of any one of claims 19 to 21, wherein the one or more additional therapeutic agents are selected from the group consisting of HCV protease inhibitors and anti-HIV agents.
24. 24. The product of any one of claims 19 to 21, wherein the one or more additional therapeutic agents are selected from the group consisting of HCV inhibitors.
25. 25. The product of any one of claims 19 to 21, wherein the additional therapeutic agent is ribavirin.
26. 26. A composition comprising a first therapeutic agent and one or more second therapeutic agent, wherein the first therapeutic agent comprises the compound, or forms thereof, of any one of claims 1-11, and the second therapeutic agent is selected from the group consisting of ribavirin, HCV inhibitor, HCV protease inhibitor, and HIV inhibitor.
27. 27. The composition of claim 26, further comprising one or more excipients.
28. 28. Use of the compound, or forms thereof, of any one of claims 1-11 in the manufacture of a medicament for inhibiting HCV polymerase.
29. 29. The use of claim 28, wherein said use further comprises one or more additional therapeutic agents.
30. 30. A method of inhibiting HCV polymerase, said method comprising administering a therapeutically effective amount of the compound, or forms thereof, of any one of claims 1-11, to a subject in need thereof.
31. 31. The method of claim 30, wherein the compound of any one of claims 1-11 is administered in combination with one or more additional therapeutic agents.
32. 32. The use or method of any one of claims 28 to 31, wherein the HCV polymerase is HCV genotype 1A polymerase.
33. 33. The use or method of any one of claims 28 to 31, wherein the HCV polymerase is HCV genotype IB polymerase.
34. 34. The use or method of any one of claims 28 to 31, wherein the HCV polymerase is encoded by NS5B gene.
35. 35. Use of the compound, or forms thereof, of any one of claims 1-11 in the manufacture of a medicament for inhibiting replication of HCV.
36. 36. The use of claim 35 wherein said use further comprises one or more additional therapeutic agents.
37. 37. A method of inhibiting replication of HCV, said method comprising administering a therapeutically effective amount of the compound, or forms thereof, of any one of claims 1-11, to a subject in need thereof.
38. 38. The method of claim 37, wherein the compound of any one of claims 1 to 11 is administered in combination with one or more additional therapeutic agents.
39. 39. The use or method of any one of claims 35 to 38, wherein the HCV is genotype 1 HCV.
40. 40. Use of the compound, or forms thereof, of any one of claims 1-11 in the manufacture of a medicament for treating hepatitis C in a subject.
41. 41. The use of claim 40, wherein said use further comprises one or more additional therapeutic agents.
42. 42. A method of treating hepatitis C, said method comprising administering a therapeutically effective amount of the compound, or forms thereof, of any one of claims 1-11, to a subject in need thereof.
43. 43. The method of claim 42 wherein the compound of any one of claim 1 to 11 is administered in combination with one or more additional therapeutic agents.
44. 44. The use or method of any one of claims 28 to 43, wherein said one or more additional therapeutic agents are selected from the group consisting of ribavirin, HCV inhibitor, HCV protease inhibitor, and HIV inhibitor.